ELEVATE
EXCHANGE PLANS
Denver Health Medical Plan Inc.™

Prior Authorization Approval Criteria

Effective Date: 10/01/2023
1. **Formulary Agents**
   Drug products that are listed in the Formulary as Prior Authorization (PA) require evaluation, per MedImpact Pharmacy and Therapeutics Committee guidelines, when the member presents a prescription to a network pharmacy. Each request will be reviewed on individual patient need. If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

2. **Non-Formulary Agents**
   Any product not found in the Formulary listing, or any Formulary updates published by MedImpact, shall be considered a Non-Formulary drug. Coverage for non-formulary agents may be applied for in advance. When a member gives a prescription order for a non-formulary drug to a pharmacist, the pharmacist will evaluate the patient’s drug history and contact the physician to determine if there is a legitimate medical need for a non-formulary drug. Each request will be reviewed on individual patient need. The following basic criteria are used:
   a. The use of Formulary Drug Products is contraindicated in the patient.
   b. The patient has failed an appropriate trial of Formulary or related agents.
   c. The choices available in the Drug Formulary are not suited for the present patient care need, and the drug selected is required for patient safety.
   d. The use of a Formulary drug may provoke an underlying condition, which would be detrimental to patient care.

   If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

3. **Obtaining Coverage**
   Coverage may be obtained by:
   a. Faxing a completed *Prior Authorization Request* to DHMP at (303) 602-2081.
   b. Contacting DHMP Pharmacy Department at (303) 602-2070 and providing all necessary information requested.

   Non-approved requests may be appealed. The prescriber must provide information to support the appeal on the basis of medical necessity.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of postmenopausal osteoporosis and meet ONE of the following criteria?
   - The patient has a high risk for fractures defined as ONE of the following:
     - History of osteoporotic (i.e., fragility, low trauma) fracture(s)
     - 2 or more risk factors for fracture (e.g., history of multiple recent low trauma fractures, BMD T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as Synarel [nafarelin])
     - No prior treatment for osteoporosis AND FRAX score ≥ 20% for any major fracture OR ≥ 3% for hip fracture
   - The patient is unable to use oral therapy (i.e., upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine)
   - The patient had a trial of, intolerance to, or a contraindication to a bisphosphonate (e.g., Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

   If yes, continue to #3.
   If no, continue to #2.

2. Is the request to increase bone density in a male patient with osteoporosis who meets ONE of the following criteria?
   - The patient is at high risk for fracture defined as ONE of the following:
     - History of osteoporotic fracture (e.g., fragility, low trauma)
     - Multiple risk factors for fracture (e.g., history of multiple recent low trauma fractures, BMD T-score less than or equal to -2.5, corticosteroid use, use of GnRH analogs such as Synarel [nafarelin])
   - The patient has failed or is intolerant to other available osteoporosis therapy (e.g., Forteo [teriparatide], Prolia [denosumab], Fosamax [alendronate], Actonel [risedronate])

   If yes, continue to #3.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
ABALOPARATIDE

GUIDELINES FOR USE (CONTINUED)

3. Has the patient received a total of 24 months cumulative treatment with any parathyroid hormone therapy (e.g., Tymlos [abaloparatide], Forteo [teriparatide])?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, approve up to 24 months cumulative lifetime treatment duration by HICL or GPI-10 with a quantity limit of #1.56mL per 30 days.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ABALOPARATIDE (Tymlos)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Postmenopausal osteoporosis (a type of bone condition)
   2. Increase bone density in a male patient with osteoporosis (a type of bone condition)

B. **If the request is for postmenopausal osteoporosis, approval also requires:**
   1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos [abaloparatide], Forteo [teriparatide])
   2. You meet ONE of the following (a, b, or c):
      a. You have high risk for fractures defined as ONE of the following:
         i. History of osteoporotic fracture(s) (broken bones) due to trauma (injury) or fragility (weakness)
         ii. Two or more risk factors for fracture such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, or use of GnRH (gonadotropin-releasing hormone) analogs such as Synarel (nafarelin)
         iii. No prior treatment for osteoporosis AND FRAX (Fracture Risk Assessment Tool) score greater than or equal to 20 percent for any major fracture OR greater than or equal to 3 percent for hip fracture
      b. You are unable to use oral therapy due to upper gastrointestinal (stomach and intestine) problems, you cannot tolerate oral medication, you have lower gastrointestinal problems (unable to absorb oral medications), you have trouble remembering to take oral medications or cannot plan to use an oral bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate]) with other oral medications in your daily routine
      c. You had a trial of, intolerance (side effect) to, or a contraindication (harmful for) to a bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

*(Denial text continued on next page)*
GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase bone density in a male patient with osteoporosis, approval also requires:
   1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos [abaloparatide], Forteo [teriparatide])
   2. You meet ONE of the following (a or b):
      a. You have high risk for fractures defined as ONE of the following:
         i. History of osteoporotic fracture (such as fragility [weakness] fracture, low trauma [injury] fracture)
         ii. Multiple risk factors for fracture (such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, use of GnRH [gonadotropin-releasing hormone] analogs such as Synarel [nafarelin])
      b. You have failed or are intolerant (side effect) to other available osteoporosis therapy (such as Forteo [teriparatide], Prolia [denosumab], Fosamax [alendronate], Actonel [risedronate])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tymlos.

REFERENCES
ABATACEPT - SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABATACEPT - SQ</td>
<td>ORENCIA - SQ</td>
<td>30289</td>
<td>41656</td>
<td>GPI-14</td>
<td>(6640001000D520)</td>
</tr>
<tr>
<td></td>
<td>ORENCIA</td>
<td>43389</td>
<td>43397</td>
<td>(6640001000E510)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CLICKJECT - SQ</td>
<td></td>
<td></td>
<td>(6640001000E515)</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** For requests for the IV dosage form of Orenicia, please see the Orenicia IV PA Guideline.

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   - The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

   **[NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months by GPID or GPI-14 as requested with the following quantity limits:
   - 125mg/mL syringe: #4mL per 28 days.
   - 125mg/mL ClickJect: #4mL per 28 days.

   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Actemra (tocilizumab), Xeljanz (tofacitinib IR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months by GPID or GPI-14 for all of the following:
   - 125mg/mL syringe: #4mL per 28 days.
   - 87.5mg/0.7mL syringe: #2.8mL per 28 days.
   - 50mg/0.4mL syringe: #1.6mL per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinoq (upadacitinib), Skyrizi (risankizumab-rzaa), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months by GPID or GPI-14 as requested with the following quantity limits:
   - 125mg/mL syringe: #4mL per 28 days.
   - 125mg/mL ClickJect: #4mL per 28 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ABATACEPT - SQ (Orencia - SQ) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   3. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Actemra (tocilizumab), Xeljanz IR (tofacitinib immediate release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinoq (upadacitinib), Skyrizi (risankizumab-rrzaa), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) or psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   - The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events
   
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 12 months by GPIID or GPI-14 as requested with the following quantity limits:
   - 125mg/mL syringe: #4mL per 28 days.
   - 125mg/mL ClickJect: #4mL per 28 days.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
ABATACEPT - SQ

RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Actemra (tocilizumab), Xeljanz (tofacitinib IR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 12 months by GPID or GPI-14 for all of the following:
   • 125mg/mL syringe: #4mL per 28 days.
   • 87.5mg/0.7mL syringe: #2.8mL per 28 days.
   • 50mg/0.4mL syringe: #1.6mL per 28 days.

If no, continue to #4.

4. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaxa), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 12 months by GPID or GPI-14 as requested with the following quantity limits:
   • 125mg/mL syringe: #4mL per 28 days.
   • 125mg/mL ClickJect: #4mL per 28 days.

If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ABATACEPT - SQ (Orencia - SQ)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   3. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Actemra (tocilizumab), Xeljanz IR (tofacitinib immediate release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

D. **If you have psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

*(Renewal denial text continued on next page)*
RENEWAL CRITERIA (CONTINUED)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orencia SQ.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 11/11
Client Approval: 07/23
P&T Approval: 04/23

Revised: 9/15/2023
GUIDELINES FOR USE

1. Does the patient have a diagnosis of early breast cancer and meet ALL of the following criteria?
   - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive
   - Verzenio will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor such as anastrozole, letrozole, exemestane) for adjuvant treatment
   - The patient is at high risk of recurrence

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, continue to #2.

2. Does the patient have advanced or metastatic breast cancer and meet ALL of the following criteria?
   - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Will Verzenio be used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) AND the patient meets the following criterion?
   - Verzenio will be used as initial endocrine-based therapy

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, continue to #4.

4. Will Verzenio be used in combination with fulvestrant AND the patient meets the following criterion?
   - The patient has experienced disease progression following endocrine therapy (e.g., anastrozole, letrozole, tamoxifen)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, continue to #5.

   **CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

5. Will Verzenio be used as monotherapy AND the patient meets the following criterion?
   - The patient has experienced disease progression following endocrine therapy (e.g., anastrozole, letrozole, tamoxifen) and prior chemotherapy in the metastatic setting

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ABEMACICLIB (Verzenio) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Early breast cancer (initial stage of breast cancer)
   2. Advanced or metastatic breast cancer (cancer that has progressed or has spread to other parts of the body)

B. If you have early breast cancer, approval also requires:
   1. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive (a type of protein)
   2. Verzenio will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor such as letrozole, anastrozole, exemestane) for adjuvant (add-on) treatment
   3. You are at high risk of recurrence (disease returning)

C. If you have advanced or metastatic breast cancer, approval also requires:
   1. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
   2. You meet ONE of the following:
      a. Verzenio will be used in combination with an aromatase inhibitor (such as letrozole, anastrozole, exemestane) as initial endocrine-based therapy
      b. Verzenio will be used in combination with fulvestrant, and you have had disease progression following endocrine therapy (such as letrozole, anastrozole, tamoxifen)
      c. Verzenio will be used as monotherapy (one drug), and you have had disease progression following endocrine therapy (such as letrozole, anastrozole, tamoxifen) and prior chemotherapy (drugs used to treat cancer) in the metastatic setting (cancer that has spread to other parts of the body)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ABEMACICLIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Verzenio.

REFERENCES
• Verzenio [Prescribing Information]. Indianapolis, IN. Eli Lilly and Company; March 2023.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/17
Commercial Effective: 07/01/23  Client Approval: 05/23
P&T Approval: 04/23
### GUIDELINES FOR USE

1. Does the patient have **ONE** of the following diagnoses?
   - Metastatic castration-resistant prostate cancer (mCRPC)
   - Metastatic high-risk castration-sensitive prostate cancer (mCSPC)
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Will the requested medication be used in combination with an oral corticosteroid (e.g., prednisone, prednisolone, methylprednisolone)?
   
   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
   - The patient had a bilateral orchiectomy
   - The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   - The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])
   
   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the patient concomitantly using a strong CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)?
   
   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit as follows:**
   - 250mg: #8 per day.
   - 500mg: #4 per day.

   If no, **approve for 12 months by GPID or GPI-14 with a quantity limit as follows:**
   - 250mg: #4 per day.
   - 500mg: #2 per day.

   **CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ABIRATERONE (Zytiga)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
   2. Metastatic high-risk castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and may respond to testosterone lowering treatment)

B. The requested medication will be used in combination with an oral corticosteroid (such as prednisone, prednisolone, methylprednisolone)

C. You meet ONE of the following:
   1. You had a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zytiga.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 08/01/23  
Created: 06/11  
Client Approval: 06/23  
P&T Approval: 07/23
ABIRATERONE SUBMICRONIZED

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABIRATERONE ACET, SUBMICRONIZED</td>
<td>YONSA</td>
<td>44946</td>
<td>GCN</td>
<td>Medispan (2140601025)</td>
<td>Exception/Other</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and meet ALL of the following criteria?
   • The requested medication will be used in combination with an oral corticosteroid (e.g., prednisone, prednisolone, methylprednisolone)
   • The patient had a trial of or contraindication to Zytiga (abiraterone acetate)

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   • The patient had a bilateral orchiectomy
   • The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   • The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

   If yes, continue to #3.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

3. Is the patient concomitantly using a strong CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.
   If no, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.

   CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ABIRATERONE SUBMICRONIZED (Yonsa)** requires the following rule(s) be met for approval:

A. You have metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)

B. The requested medication will be used in combination with an oral corticosteroid (such as prednisone, prednisolone, methylprednisolone)

C. You have tried or have a contraindication to (harmful for) Zytiga (abiraterone acetate)

D. You meet ONE of the following:
   1. You had a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Yonsa.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Client Approval: 06/23
P&T Approval: 07/23

Created: 03/23

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of refractory, moderate to severe atopic dermatitis and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
   - The patient has atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas
   - The patient has TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
   - The patient had a trial of or contraindication to ONE preferred agent: Dupixent (dupilumab), Rinvoq (upadacitinib)
   - Cibinqo will NOT be used concurrently with other systemic biologics (e.g., Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) for atopic dermatitis or other JAK inhibitors (e.g., Xeljanz [tofacitinib], topical Opzelura [ruxolitinib]) for any indication

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to TWO of the following?
   - High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate)
   - Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
   - Topical PDE-4 inhibitor (e.g., crisaborole)
   - Topical JAK inhibitor (e.g., ruxolitinib)
   - Phototherapy

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ABROCITINIB (Cibinqo) requires the following rule(s) be met for approval:
A. You have refractory, moderate to severe atopic dermatitis (a type of skin condition)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
D. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
F. You had a trial of or contraindication (harmful for) to TWO of the following:
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate)
   2. Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
   3. Topical PDE-4 inhibitor (Phosphodiesterase-4 Inhibitors such as crisaborole)
   4. Topical Janus kinase (JAK) inhibitor (Janus kinase inhibitor such as ruxolitinib)
   5. Phototherapy (light therapy)
G. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
H. You will NOT use Cibinqo concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-Idrm], Dupixent [dupilumab]) for atopic dermatitis or other Janus kinase (JAK) inhibitors (such as Xeljanz [tofacitinib], topical Opzelura [ruxolitinib]) for any indication

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ABROCITINIB

RENEWAL CRITERIA

1. Does the patient have a diagnosis of refractory, moderate to severe atopic dermatitis and meet ALL of the following criteria?
   - The patient has shown improvement while on therapy
   - The patient had a trial of or contraindication to ONE preferred agent: Dupixent (dupilumab), Rinvoq (upadacitinib)
   - Cibinqo will NOT be used concurrently with other systemic biologics (e.g., Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) for atopic dermatitis or other JAK inhibitors (e.g., Xeljanz [tofacitinib], topical Opzelura [ruxolitinib]) for any indication

If yes, approve for 12 months by HICL with a quantity limit of #1 per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ABROCITINIB (Cibinqo) requires the following rule(s) be met for renewal:
A. You have refractory, moderate to severe atopic dermatitis (a type of skin condition)
B. You have shown improvement while on therapy
C. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
D. You will NOT use Cibinqo concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) for atopic dermatitis or other Janus kinase (JAK) inhibitors (such as Xeljanz [tofacitinib], topical Opzelura [ruxolitinib]) for any indication

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cibinqo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/22
Commercial Effective: 10/01/23  Client Approval: 08/23  P&T Approval: 07/23

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
ACALABRUTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACALABRUTINIB</td>
<td>CALQUENCE</td>
<td>44607</td>
<td>GPI-10</td>
<td>(2153210300)</td>
<td></td>
</tr>
<tr>
<td>ACALABRUTINIB MALEATE</td>
<td>CALQUENCE</td>
<td>48182</td>
<td>GPI-10</td>
<td>(2153210350)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of mantle cell lymphoma (MCL) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received at least one prior therapy for mantle cell lymphoma
   - The patient had a trial of or contraindication to the preferred agent: Brukinsa (zanubrutinib)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) AND meet the following criterion?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to ONE of the following preferred agents: Brukinsa (zanubrutinib), Imbruvica (ibrutinib)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ACALABRUTINIB (Calquence) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Mantle cell lymphoma (MCL: a type of blood cancer)
   2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   3. Small lymphocytic lymphoma (SLL: a type of blood cancer)

B. **If you have mantle cell lymphoma, approval also requires:**
   1. You are 18 years of age or older
   2. You have received at least one prior therapy for mantle cell lymphoma
   3. You had a trial of or contraindication (harmful) to the preferred medication: Brukinsa (zanubrutinib)

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of or contraindication (harmful) to ONE of the following preferred medications: Brukinsa (zanubrutinib), Imbruvica (ibrutinib)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Calquence.

REFERENCES
• Calquence [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals; August 2022.
ACETAMINOPHEN DAILY LIMIT OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/other</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient taking a dose of the requested drug in an amount exceeding 4000mg of acetaminophen per day?

   If yes, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, continue to #2.

2. Is the requested medication being taken together with other acetaminophen containing product(s) and the combination will exceed 4000mg of acetaminophen per day?

   If yes, continue to #3.

   If no, **approve for ONE FILL count by GPID or GPl-14 for the requested medication and set override type MAXINGREDIENTDOSE to a value of “Y”**.

3. Will the patient discontinue the concurrent acetaminophen containing drug(s) that place the patient over 4000mg of acetaminophen per day?

   If yes, **approve for ONE FILL count by GPID or GPl-14 for the requested medication and set override type MAXINGREDIENTDOSE to a value of “Y”**.

   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ACETAMINOPHEN DAILY LIMIT OVERRIDE** will cause a denied claim for acetaminophen when the total daily dose acetaminophen exceeds 4000mg. The claim will also deny if the requested drug is being used at the same time with other acetaminophen containing product(s) and the combination exceeds 4000mg of acetaminophen per day limit.

**Approval requires the following rule be met:**

A. You will discontinue the other acetaminophen containing drug(s) that cause the daily acetaminophen dose to exceed 4000mg.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
ACETAMINOPHEN DAILY LIMIT OVERRIDE

RATIONALE
To ensure appropriate use of acetaminophen products and address overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. The maximum daily dose for an adult is 4000 mg. However, in some people, taking the maximum daily dose or more for an extended period of time can lead to serious liver damage.

A claim may reject at POS due to exceeding the acetaminophen daily limit as a result of concurrent use with other acetaminophen products. An approval is granted if the concurrent acetaminophen containing product will be discontinued. In some cases, the member’s history claim may have an incorrect day supply due to a pharmacy error. This will cause the new claim to reject at POS for exceeding the acetaminophen daily limit. This is addressed in question #2.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/01/20
Created: 12/18
Client Approval: 04/20
P&T Approval: 01/19
GUIDELINES FOR USE

1. Is the claim denying for an age limit, as noted in the POS reject message?

   If yes, continue to #2.
   If no, guideline does not apply.

2. Is the request for a cosmetic indication (e.g., melasma, photoaging, or wrinkles)?

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, continue to #3.

3. Has the patient had a trial of TWO low cost generic agents (e.g., Adapalene lotion, cream or gel, Tretinoin cream or gel, Adapalene/Benzoyl Peroxide gel)?

   If yes, approve the requested agent for 12 months by HICL or GPI-10.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ACNE AGE RESTRICTION OVERRIDE requires the following rule(s) be met for approval:
A. The request is for a non-cosmetic (not for appearance) diagnosis (such as melasma, photoaging, wrinkles)
B. You had a trial of TWO low cost generic medications (such as Adapalene lotion, cream or gel, Tretinoin cream or gel, Adapalene/Benzoyl Peroxide gel)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ACNE AGE RESTRICTION OVERRIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for agents in this guideline

REFERENCES
- Differin [Prescribing Information]. Dallas, TX: Galderma laboratories, L.P; April 2023.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 08/11
Client Approval: 08/23
P&T Approval: 07/23
ADAGRASIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAGRASIB</td>
<td>KRAZATI</td>
<td>48522</td>
<td>GPI-10</td>
<td>(2153241000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient's cancer has a KRAS G12C mutation as determined by an FDA-approved test
   • The patient has received at least one prior systemic therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **ADAGRASIB (Krazati)** requires the following rule(s) be met for approval:
   A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
   B. You are 18 years of age or older
   C. Your cancer has a KRAS G12C mutation (a type of abnormal gene) as determined by a Food and Drug Administration (FDA)-approved test
   D. You have received at least one prior systemic therapy

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Krazati.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A       Created: 01/23
Commercial Effective: 04/01/23  Client Approval: 02/23  P&T Approval: 01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, approve for 6 months by GPI-10 (6627001500) for Humira 40mg/0.4mL OR 40mg/0.8mL with a quantity limit of #2 per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, approve for 6 months by GPI-10 (6627001500) for all of the following:
   • Humira 10mg/0.2mL
   • Humira 10mg/0.1mL
   • Humira 20mg/0.4mL
   • Humira 20mg/0.2mL
   • Humira 40mg/0.8mL
   • Humira 40mg/0.4mL

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, approve for 6 months by GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, approve for 6 months by GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #6.
   If no, continue to #7.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Does the patient meet ONE of the following criteria?
   • The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and is switching to the requested drug
   • The patient has psoriasis covering 3% or more of body surface area (BSA)
   • The patient has psoriatic lesions affecting the hands, feet, genital area, or face

   If yes, approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:
   • Approve for 1 month for Humira 40mg/0.8mL Psoriasis Starter Package with a quantity of #4 pens OR for Humira Psoriasis Starter Package (contains one 80 mg/0.8 mL pen and two 40 mg/0.4 mL pens) with a quantity limit of #3 pens.
   • Approve for 5 months for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

7. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet ALL of the following criteria?
   • The patient is 6 years of age or older
   • Therapy is prescribed by or in consultation with a gastroenterologist
   • The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:
   • Approve for 1 month for Humira 40mg/0.8mL Crohn's Disease Starter Package with a quantity limit of #6 pens, OR for Humira 40mg/0.8mL Pediatric Crohn's Starter Package with quantity limit of either #3 syringes or #6 syringes, OR for Humira 80mg/0.8mL Pediatric Crohn's Disease Starter Package with a quantity limit of #3 syringes, OR for Humira Pediatric Crohn's Disease Starter Package (contains one 40mg/0.4mL syringe and one 80mg/0.8mL syringe) with a quantity limit of #2 syringes, OR for Humira 80 mg/0.8 mL Crohn's Disease Starter Package with a quantity limit of #3 pens.
   • Approve for 5 months for Humira 40mg/0.8mL, OR 40mg/0.4mL, OR 20mg/0.4mL, OR 20mg/0.2mL with a quantity limit of #2 per 28 days.

   If no, continue to #8.

CONTINUED ON NEXT PAGE
ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

8. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet ALL of the following criteria?
   • The patient is 5 years of age or older
   • Therapy is prescribed by or in consultation with a gastroenterologist
   • The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:
   • Approve for 1 month for ONE of the following as requested:
     o Humira 40mg/0.8mL Pen Ulcerative Colitis Starter Package: #6 pens.
     o Humira 80 mg/0.8 mL Ulcerative Colitis Starter Package: #3 pens.
     o Humira 80mg/0.8mL Pen Pediatric UC Starter Package: #4 pens.
     o Humira 40mg/0.8mL OR 40mg/0.4mL: #4 pens/syringes.
   • Approve for 5 months for ONE of the following as requested (enter a start date of 3 days before the end date of the first approval):
     o Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.
     o Humira 80mg/0.8mL: #2 per 28 days.
     o Humira 20mg/0.4mL OR 20mg/0.2mL: #4 per 28 days.

   If no, continue to #9.

9. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS) AND meet the following criterion?
   • The patient is 12 years of age or older

   If yes, approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:
   • Approve for 1 month for Humira 40mg/0.8mL Pen Starter Package for Hidradenitis Suppurativa (HS) with a quantity limit of #6 pens OR for Humira 80 mg/0.8 mL Hidradenitis Suppurativa Starter Package with a quantity limit of #3 pens.
   • Approve for 5 months for the requested agent as follows (enter a start date of 3 days before the end date of the first approval):
     o Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.
     o Humira 80mg/0.8mL: #2 per 28 days.

   If no, continue to #10.

CONTINUED ON NEXT PAGE
ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

10. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with an ophthalmologist
   • The patient does NOT have isolated anterior uveitis

If yes, approve for a total of 6 months by GPID or GPI-14 as follows:
   • For age 2 to 17 years, approve with a quantity limit of #2 per 28 for all of the following:
     o Humira 10mg/0.2mL
     o Humira 10mg/0.1mL
     o Humira 20mg/0.4mL
     o Humira 20mg/0.2mL
     o Humira 40mg/0.8mL
     o Humira 40mg/0.4mL
   • For age 18 years and above, please enter two authorizations as follows:
     o Approve for 1 month for Humira 40mg/0.8mL Uveitis Starter Package with a quantity limit of #4 pens OR for Humira Uveitis Starter Package (contains one 80 mg/0.8 mL pen and two 40 mg/0.4 mL pens) with a quantity limit of #3 pens.
     o Approve for 5 months for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ADALIMUMAB (Humira) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

(Initial denial text continued on next page)
ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
   1. You are 2 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

E. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
F. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3 percent or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the face, hands, feet, or genital area

G. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 6 years of age or older
   2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

H. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 5 years of age or older
   2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

I. If you have moderate to severe hidradenitis suppurativa, approval also requires:
   1. You are 12 years of age or older

J. If you have non-infectious intermediate, posterior and panuveitis, approval also requires:
   1. You are 2 years of age or older
   2. The medication is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
   3. You do not have isolated anterior uveitis (a different type of eye inflammation)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA)?

   If yes, continue to #2.
   If no, continue to #4.

2. Is the request for Humira 40mg dosed every other week and has the following criterion been met?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, continue to #3.

3. Is the request for Humira 40mg dosed every week OR Humira 80mg dosed every other week and have ALL of the following criteria been met?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   • The patient had a trial of at least a 3-month regimen of Humira 40mg dosed every other week

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:
   • Humira 40mg/0.8mL OR 40mg/0.4mL: #4 per 28 days.
   • Humira 80mg/0.8mL: #2 per 28 days.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

PAC NOTE: Please enter a proactive prior authorization for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL syringe/pen OR 40mg/0.4mL syringe/pen with a quantity limit of #2 syringes/pens per month.

CONTINUED ON NEXT PAGE
4. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for Humira 10mg/0.1mL, OR 10mg/0.2mL, OR 20mg/0.2mL, OR 20mg/0.4mL, OR 40mg/0.4mL, OR 40mg/0.8mL with a quantity limit of #2 per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, continue to #6.

6. Does the patient have a diagnosis of ankylosing spondylitis (AS) AND meet the following criterion?
   - The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, continue to #7.

7. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

   If no, continue to #8.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

8. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

   If yes, approve for 12 months by GPID or GPI-14 for Humira 40mg/0.8mL, OR 40mg/0.4mL, OR 20mg/0.4mL, OR 20mg/0.2mL with a quantity limit of #2 per 28 days.

   If no, continue to #9.

9. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   - Humira 40mg/0.8mL OR Humira 40mg/0.4mL: #4 per 28 days.
   - Humira 80mg/0.8mL: #2 per 28 days.
   - Humira 20mg/0.4mL OR Humira 20mg/0.2mL: #4 per 28 days.

   If no, continue to #10.

10. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS)?

    If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
    - Humira 40mg/0.8mL OR Humira 40mg/0.4mL: #4 per 28 days.
    - Humira 80mg/0.8mL: #2 per 28 days.

    If no, continue to #11.

11. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis AND meet the following criteria?

    The patient has not experienced treatment failure, defined as ONE of the following criteria:
    - Development of new inflammatory chorioretinal or retinal vascular lesions
    - A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade
    - A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best state achieved

    If yes, approve for 12 months by GPID or GPI-14 for Humira 10mg/0.1mL, OR 10mg/0.2mL, OR 20mg/0.2mL, OR 20mg/0.4mL, OR 40mg/0.8mL, OR 40mg/0.4mL with a quantity limit of #2 per 28 days.

    If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ADALIMUMAB (Humira) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. If you are requesting Humira 40mg weekly dosing OR Humira 80mg every other week dosing, we require you have tried at least a 3-month of Humira 40mg every other week

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

E. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

F. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

G. If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:

1. You have not experienced treatment failure, defined as ONE of the following:
   a. You have development of new inflammatory chorioretinal or retinal vascular lesions (eye tumors)
   b. A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on how bad eye inflammation is)
   c. A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best visual acuity achieved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Humira.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #3.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to a NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist
   • The patient had a trial of or contraindication to one or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #6.
   If no, continue to #7.

6. Does the patient meet ONE of the following criteria?
   • The patient was previously stable on another biologic (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cosentyx [secukinumab]) and is switching to the requested drug
   • The patient has psoriasis covering 3% or more of body surface area (BSA)
   • The patient has psoriatic lesions affecting the hands, feet, genital area, or face

   If yes, approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:
   • Approve for 1 month with a quantity limit of #4.
   • Approve for 5 months with a quantity limit of #2 per 28 days (enter a start date of 1 WEEK after the end date of the first approval).

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

7. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet **ALL** of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, **approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:**
   - **Approve for 1 month with a quantity limit of #6 per 28 days.**
   - **Approve for 5 months with a quantity limit of #2 per 28 days (enter a start date of 3 days before the end date of the first approval).**

   If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?
   - The patient is 5 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, **approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:**
   - **Approve for 1 month with a quantity limit of #8 per 28 days.**
   - **Approve for 5 months with a quantity limit of #4 per 28 days (enter a start date of 3 days before the end date of the first approval).**

   If no, continue to #9.

9. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS) **AND** meet the following criterion?
   - The patient is 12 years of age or older

   If yes, **approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:**
   - **Approve for 1 month with a quantity limit of #6 per 28 days.**
   - **Approve for 5 months with a quantity limit of #4 per 28 days (enter a start date of 3 days before the end date of the first approval).**

   If no, continue to #10.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

10. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with an ophthalmologist
   • The patient does NOT have isolated anterior uveitis

   If yes, approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:
   • Approve for 1 month with a quantity limit of #4.
   • Approve for 5 months with a quantity limit of #2 per 28 days (enter a start date of 1 WEEK after the end date of the first approval).
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ADALIMUMAB-ADBM (Cytezo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

E. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to a NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

F. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3 percent or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

*(Initial denial text continued on next page)*
INITIAL CRITERIA (CONTINUED)

G. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

H. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 5 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

I. If you have moderate to severe hidradenitis suppurativa, approval also requires:
   You are 12 years of age or older

J. If you have non-infectious intermediate, posterior and panuveitis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
   3. You do not have isolated anterior uveitis (a different type of eye inflammation)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA)?
   If yes, continue to #2.
   If no, continue to #4.

2. Is the request for Cyltezo 40mg dosed every other week AND has the following criterion been met?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #3.

3. Is the request for Cyltezo 40mg dosed every week OR 80mg dosed every other week and the patient meets ALL of the following criteria?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - The patient had a trial of at least a 3-month regimen of Cyltezo 40mg dosed every other week
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per 28 days.
   If no, do not approve. PAC NOTE: Please enter a proactive prior authorization for 12 months by GPID or GPI-10 for Cyltezo 40mg/0.8mL with a quantity limit of #2 per 28 days.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

4. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #5.

5. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #6.

CONTINUED ON NEXT PAGE
RENUEWAL CRITERIA (CONTINUED)

6. Does the patient have a diagnosis of ankylosing spondylitis (AS) AND meet the following criterion?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #7.

7. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   • The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
   If no, continue to #9.

9. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per 28 days.
   If no, continue to #10.

10. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS)?

    If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per 28 days.
    If no, continue to #11.

11. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis AND meet the following criteria?
    • The patient has not experienced treatment failure, defined as ONE of the following criteria:
      o Development of new inflammatory chorioretinal or retinal vascular lesions
      o A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade
      o A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best state achieved

    If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.
    If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ADALIMUMAB-ADBM (Cyltezo) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. If you are requesting Cyltezo 40mg weekly dosing OR Cyltezo 80mg every other week dosing, you have tried at least 3 months of Cyltezo 40mg every other week dosing

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

E. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

F. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
G. If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:
   1. You have not experienced treatment failure, defined as ONE of the following:
      a. You have development of new inflammatory chorioretinal or retinal vascular lesions
         (eye tumors)
      b. A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade
         (types of classifications on how bad eye inflammation is)
      c. A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to
         best visual acuity achieved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
your doctor to use a different medication or get us more information if it will allow us to approve
this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cyltezo
and Humira.

REFERENCES
• Cyltezo [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; May
  2023.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 07/03
Client Approval: 07/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, **approve for 6 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per 28 days.**
   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, **approve for 6 months by GPID for all strengths as follows:**
   - 10mg/0.2mL: #0.4mL per 28 days.
   - 20mg/0.4mL: #0.8mL per 28 days.
   - 40mg/0.8mL: #1.6mL per 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, **approve for 6 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per 28 days.**
   If no, continue to #4.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to a NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, approve for 6 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per 28 days.
   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist
   • The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #6.
   If no, continue to #7.

6. Does the patient meet ONE of the following criteria?
   • The patient was previously stable on another biologic (e.g., Humira [adalimumab], Cyltezo [adalimumab-adbm], Cosentyx [secukinumab]) and is switching to the requested drug
   • The patient has psoriasis covering 3% or more of body surface area (BSA)
   • The patient has psoriatic lesions affecting the hands, feet, genital area, or face

   If yes, approve for a total of 6 months by GPID for 40mg/0.8mL. Please enter two authorizations as follows:
   • Approve for 1 month with a quantity of #3.2mL.
   • Approve for 5 months with a quantity limit of #1.6mL per 28 days (enter a start date of 1 WEEK after the end date of the first approval).

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

7. Does the patient have a diagnosis of moderate to severe Crohn’s disease (CD) and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, approve for a total of 6 months by GPID. Please enter two authorizations as follows:
   - Approve for 1 month for 40mg/0.8mL with a quantity limit of #4.8mL per 28 days.
   - Approve for 5 months for all strengths as follows (enter a start date of 3 days before the end date of the first approval):
     - 20mg/0.4mL: #0.8mL per 28 days.
     - 40mg/0.8mL: #1.6mL per 28 days.

   If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet ALL of the following criteria?
   - The patient is 5 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, approve for a total of 6 months by GPID. Please enter two authorizations as follows:
   - Approve for 1 month for 40mg/0.8mL with a quantity limit of #6.4mL per 28 days.
   - Approve for 5 months for all strengths as follows (enter a start date of 3 days before the end date of the first approval):
     - 20mg/0.4mL: #1.6mL per 28 days.
     - 40mg/0.8mL: #3.2mL per 28 days.

   If no, continue to #9.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

9. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS) **AND** meet the following criterion?
   - The patient is 12 years of age or older

   If yes, **approve for a total of 6 months by GPID for 40mg/0.8mL. Please enter two authorizations as follows:**
   - Approve for 1 month with a quantity limit of #4.8mL per 28 days.
   - Approve for 5 months with a quantity limit of #3.2mL per 28 days (enter a start date of 3 days before the end date of the first approval).

   If no, continue to #10.

10. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis and meet **ALL** of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with an ophthalmologist
   - The patient does **NOT** have isolated anterior uveitis

   If yes, **approve for a total of 6 months by GPID. Please enter two authorizations as follows:**
   - Approve the requested strength for 1 month with a quantity of #3.2mL.
   - Approve for 5 months for all strengths as follows (enter a start date of 1 WEEK after the end date of the first approval):
     - 10mg/0.2mL: #0.4mL per 28 days.
     - 20mg/0.4mL: #0.8mL per 28 days.
     - 40mg/0.8mL: #1.6mL per 28 days.

   If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ADALIMUMAB-ATTO (Amjevita) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

*Initial denial text continued on next page*
INITIAL CRITERIA (CONTINUED)

**E. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You had a trial of or contraindication (harmful for) to a NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

**F. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
2. The medication is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
4. You meet ONE of the following:
   a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
   b. You have psoriasis covering 3 percent or more of body surface area (BSA)
   c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

**G. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 6 years of age or older
2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

**H. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 5 years of age or older
2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

**I. If you have moderate to severe hidradenitis suppurativa, approval also requires:**
1. You are 12 years of age or older

**J. If you have non-infectious intermediate, posterior and panuveitis, approval also requires:**
1. You are 2 years of age or older
2. The medication is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
3. You do not have isolated anterior uveitis (a different type of eye inflammation)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA)?
   - If yes, continue to #2.
   - If no, continue to #4.

2. Is the request for Amjevita 40mg dosed every other week and has the following criterion been met?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - If yes, approve for 12 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per 28 days.
   - If no, continue to #3.

3. Is the request for Amjevita 40mg dosed every week OR 80mg dosed every other week and the patient meets ALL of the following criteria?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - The patient had a trial of at least a 3-month regimen of Amjevita 40mg dosed every other week
   - If yes, approve for 12 months by GPID for 40mg/0.8mL with a quantity limit of #3.2mL per 28 days.
   - If no, do not approve.

   PAC NOTE: Please enter a proactive prior authorization for 12 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per 28 days.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

4. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - If yes, approve for 12 months by GPID for all strengths as follows:
     - 10mg/0.2mL: #0.4mL per 28 days.
     - 20mg/0.4mL: #0.8mL per 28 days.
     - 40mg/0.8mL: #1.6mL per 28 days.
   - If no, continue to #5.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count
     or swollen joint count while on therapy

   If yes, approve for 12 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per
   28 days.
   If no, continue to #6.

6. Does the patient have a diagnosis of ankylosing spondylitis (AS) AND meet the following criterion?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of
     1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

   If yes, approve for 12 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per
   28 days.
   If no, continue to #7.

7. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the
   following criterion?
   • The patient has achieved or maintained clear or minimal disease or a decrease in PASI
     (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

   If yes, approve for 12 months by GPID for 40mg/0.8mL with a quantity limit of #1.6mL per
   28 days.
   If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

   If yes, approve for 12 months by GPID for all strengths as follows:
   • 20mg/0.4mL: #0.8mL per 28 days.
   • 40mg/0.8mL: #1.6mL per 28 days.

   If no, continue to #9.

9. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

   If yes, approve for 12 months by GPID for all strengths as follows:
   • 20mg/0.4mL: #1.6mL per 28 days.
   • 40mg/0.8mL: #3.2mL per 28 days.

   If no, continue to #10.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

10. Does the patient have a diagnosis of moderate to severe hidradenitis suppurativa (HS)?

   If yes, approve for 12 months by GPID for 40mg/0.8mL with a quantity limit of #3.2mL per
   28 days.
   If no, continue to #11.

11. Does the patient have a diagnosis of non-infectious intermediate, posterior and panuveitis AND
    meet the following criteria?
    • The patient has not experienced treatment failure, defined as ONE of the following criteria:
      o Development of new inflammatory chorioretinal or retinal vascular lesions
      o A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade
      o A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best
        state achieved

    If yes, approve for 12 months by GPID for all strengths as follows:
      • 10mg/0.2mL: #0.4mL per 28 days.
      • 20mg/0.4mL: #0.8mL per 28 days.
      • 40mg/0.8mL: #1.6mL per 28 days.
    If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please
use these definitions if the particular text you need to use does not already have
definition(s) in it.

Our guideline named ADALIMUMAB-ATTO (Amjevita) requires the following rule(s) be met for
renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint
      condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. If you are requesting Amjevita 40mg weekly dosing OR Amjevita 80mg every other week dosing, we require you have tried at least a 3-month trial of Amjevita 40mg every other week

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

E. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

F. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

G. If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:
   1. You have not experienced treatment failure, defined as ONE of the following:
      a. You have development of new inflammatory chorioretinal or retinal vascular lesions (eye tumors)
      b. A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on how bad eye inflammation is)
      c. A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best visual acuity achieved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
adalimumab-atto

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Amjevita or Humira.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 07/23
Client Approval: 07/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic squamous non-small cell lung cancer (NSCLC) AND meet the following criterion?
   - The patient has disease progression after platinum-based chemotherapy (i.e., cisplatin, carboplatin, oxaliplatin)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient's tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test
   - Gilotrif will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva [erlotinib], Tagrisso [Osimertinib], Iressa [gefitinib])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AFATINIB (Gilotrif) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Metastatic squamous non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
   2. Metastatic non-small cell lung cancer (a different type of lung cancer that has spread to other parts of the body)
B. If you have metastatic squamous non-small cell lung cancer, approval also requires:
   1. Your disease has worsened after using platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
C. If you have metastatic non-small cell lung cancer, approval also requires:
   1. Your tumors have non-resistant epidermal growth factor receptor (EGFR: type of protein) mutations as shown by an FDA (Food and Drug Administration)-approved test
   2. You will NOT be using Gilotrif concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [Osimertinib], Iressa [gefitinib])

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gilotrif.

REFERENCES
- Gilotrif (afatinib) [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT. April 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/13
Commercial Effective: 07/01/22  Client Approval: 05/22  P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) AND meet the following criterion?
   • Patient is positive for anaplastic lymphoma kinase (ALK) fusion oncogene as detected by an FDA-approved test

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #240 per 30 days.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ALECTINIB (Alecensa) requires the following rules be met for approval:
   1. You have a diagnosis of metastatic non-small cell lung cancer (NSCLC; type of cancer that has spread)
   2. You are positive for anaplastic lymphoma kinase (ALK; gene mutation) fusion oncogene as detected by an FDA (Food and Drug Administration) -approved test

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Alcensa.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of house dust mite (HDM)-induced allergic rhinitis with or without conjunctivitis and meet ALL of the following criteria?
   - The patient is 12 to 65 years of age
   - The patient’s diagnosis is confirmed by in vitro testing for IgE antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts
   - Therapy is prescribed by or in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases
   - The patient has persistent symptoms of allergic rhinitis (defined as symptoms presenting at least 4 days a week or for at least 4 weeks)
   - The patient has moderate to severe symptoms of allergic rhinitis (including one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, impairment of school or work)
   - The patient has a current claim or prescription for auto-injectable epinephrine within the past 365 days

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra) requires the following rule(s) be met for approval:
A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by house dust mites, with or without conjunctivitis (type of inflammation of eye and eyelid)
B. You are 12 to 65 years of age
C. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
D. Your diagnosis is confirmed by in vitro testing (testing outside of your body in a tube) for IgE (Immunoglobulin E) antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts

(Initial denial text continued on next page)
ALLERGEN EXTRACT-HOUSE DUST MITE

INITIAL CRITERIA (CONTINUED)

E. You have persistent symptoms of allergic rhinitis (defined as symptoms presenting for at least 4 days a week or for at least 4 weeks)

F. You have moderate to severe symptoms of allergic rhinitis (including one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, impairment of school or work)

G. You have a current claim or prescription for auto-injectable epinephrine within the past 365 days

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra) requires the following rule is met for renewal:
   A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Odactra.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/18
Commercial Effective: 06/01/23  Client Approval: 05/23

P&T Approval: 07/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of grass pollen-induced allergic rhinitis that is confirmed by a positive skin prick test and/or a positive titer to specific IgE antibodies for any of the five grass (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens) species included in Oralair?
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Was Oralair prescribed by or given in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases?
   
   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include one or more of the following items: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)?
   
   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does patient have a current claim or prescription for auto-injectable epinephrine?
   
   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Is the patient between the ages of 5 and 17 years of age?

   If yes, approve for 12 months by GPID or GPI-14 for a quantity limit of #3 tablets of 100 IR for the first 2 days of therapy initiation and #1 tablet of 300 IR per day thereafter.
   APPROVAL TEXT: Renewal requires that the patient has experienced an improvement in signs and symptoms of allergic rhinitis from baseline.

   If no, continue to #6.

6. Is the patient between 18 and 65 years of age?

   If yes, approve for 12 months by GPID or GPI-10 for a quantity limit of #1 tablet (300 IR) per day.
   APPROVAL TEXT: Renewal requires that the patient has experienced an improvement in signs and symptoms of allergic rhinitis from baseline.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair) requires the following rule(s) be met for approval:
A. You have a diagnosis of allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
B. Your diagnosis is confirmed by a positive skin prick test and/or a positive titer (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for any of the five grass types included in Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens)
C. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
D. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
E. You have a current claim or prescription for auto-injectable epinephrine
F. You are between 5 and 65 years of age

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

   If yes, approve for 12 months by HICL or GPI-14 for a quantity limit of #1 tablet per day. If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair)** requires the following rules be met for renewal:
   A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Oralair.

 REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/01/20
Created: 05/14
Client Approval: 04/20
P&T Approval: 01/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of short ragweed pollen-induced allergic rhinitis and meet ALL of the following criteria?
   - The patient is between 5 and 65 years of age
   - Diagnosis is confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen
   - Therapy was prescribed by or given in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases
   - The patient has persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include one or more of the following items: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
   - The patient has a current claim or prescription for auto-injectable epinephrine

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.
If no, do not approve.
DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek)** requires the following rule(s) be met for approval:

A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by short ragweed pollen
B. You are between 5 and 65 years of age
C. Your diagnosis is confirmed by a positive skin test or in vitro testing (testing outside of your body in a tube) for pollen-specific IgE (Immunoglobulin E) antibodies for short ragweed pollen
D. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
F. You have a current claim or prescription for auto-injectable epinephrine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek) requires the following rule(s) be met for renewal:
A. You have experienced an improvement in signs and symptoms of allergic rhinitis from baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ragwitek.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/21
Created: 05/14
Client Approval: 05/21
P&T Approval: 07/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of grass pollen-induced allergic rhinitis and meet ALL of the following criteria?
   - The patient is between 5 and 65 years of age
   - Diagnosis is confirmed by a positive skin prick test and/or a positive titre to specific IgE antibodies for Timothy grass or cross-reactive grass pollens
   - Therapy is prescribed by or in consultation with an allergist, immunologist, or other physician experienced in the diagnosis and treatment of allergic diseases
   - The patient has persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
   - The patient has a current claim or prescription for auto-injectable epinephrine

If yes, approve for 12 months by GPID or GPI-14 for a quantity limit of #1 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek) requires the following rule(s) be met for approval:
A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
B. You are between 5 and 65 years of age
C. Your diagnosis is confirmed a positive skin prick test and/or a positive titre (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for Timothy grass or cross-reactive grass pollens
D. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN

INITIAL CRITERIA (CONTINUED)

E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)

F. You have a current claim or prescription for auto-injectable epinephrine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced an improvement in signs and symptoms of allergic rhinitis from baseline?

   If yes, **approve for 12 months by GPID or GPI-14 for a quantity limit of #1 per day.**

   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek)** requires the following rule be met for renewal:

   A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Grastek.

REFERENCES


CONTINUED ON NEXT PAGE
### Allergen Extract - Timothy Grass Pollen

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

- **Part D Effective:** N/A
- **Commercial Effective:** 01/01/22
- **Created:** 05/14
- **Client Approval:** 12/21
- **P&T Approval:** 01/18
ALPELISIB-PIQRAY

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPELISIB</td>
<td>PIQRAY</td>
<td>45761</td>
<td>GPI</td>
<td>GPI-10 (2153801000)</td>
<td>BRAND ≠ VIJOICE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ALL of the following criteria?
   - The patient is a postmenopausal female or a male
   - Piqray will be used in combination with Faslodex (fulvestrant)
   - The patient's breast cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative with PIK3CA-mutation as detected by an FDA-approved test
   - The patient has disease progression on or after an endocrine-based regimen

If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**
   - Piqray 300mg daily dose: #56 per 28 days.
   - Piqray 250mg daily dose: #56 per 28 days.
   - Piqray 200mg daily dose: #28 per 28 days.

If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ALPELISIB-PIQRAY** requires the following rule(s) be met for approval:
A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
B. You are a postmenopausal (after menopause) female or a male
C. Piqray will be used in combination with Faslodex (fulvestrant)
D. Your breast cancer is hormone receptor (HR: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with PIK3CA (type of gene)-mutation as detected by a Food and Drug Administration (FDA)-approved test
E. You have disease progression on or after an endocrine-based regimen (your disease has worsened after using a type of hormone therapy)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ALPELISIB-PIQRAY

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Piqray.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/09/22
Created: 08/19
Client Approval: 04/22
P&T Approval: 07/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of PIK3CA-related overgrowth spectrum (PROS) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - The patient has severe manifestations of PROS that require systemic therapy

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 50 mg daily dose: #28 per 28 days.
   - 125 mg daily dose: #28 per 28 days.
   - 250 mg daily dose: #56 per 28 days.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ALPELISIB - VIJOICE requires the following rule(s) be met for approval:
A. You have PIK3CA-related overgrowth spectrum (PROS: group of disorders that cause overgrowth of parts of the body due to mutations in a type of gene)
B. You are 2 years of age or older
C. You have severe manifestations of PROS that require systemic therapy (treatment that targets the entire body)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vijoice.

REFERENCES
- Vijoice [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals, Corp.; April 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 08/22
Client Approval: 09/22
P&T Approval: 07/22
** Please use the criteria for the specific drug requested **

**GUIDELINES FOR USE**

**GOCOVRI**

1. Does the patient have a diagnosis of Parkinson's disease and meet ALL of the following criteria?
   - The patient has dyskinesia
   - The patient is receiving levodopa-based therapy
   - The patient had a trial of generic amantadine capsules, tablets, or solution

   If yes, **approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:**
   - Gocovri 68.5mg: #1 per day.
   - Gocovri 137mg: #2 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of Parkinson's disease and meet ALL of the following criteria?
   - The patient is experiencing 'off' episodes
   - Therapy is given as an adjunctive treatment to levodopa/carbidopa therapy
   - The patient had a trial of generic amantadine capsules, tablets, or solution

   If yes, **approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:**
   - Gocovri 68.5mg: #1 per day.
   - Gocovri 137mg: #2 per day.

   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE - GOCOVRI (CONTINUED)

GOCOVRI DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AMANTADINE EXTENDED RELEASE (Gocovri)** requires the following rule(s) be met for approval:
A. You have Parkinson's disease (nervous system disorder that affects movement)
   B. **If you have dyskinesia (abnormal involuntary movements), approval also requires:**
      1. You are receiving levodopa-based therapy
      2. You have previously tried generic amantadine capsules, tablets, or solution
   C. **If you are experiencing 'off' episodes (when the medication stops working), approval also requires:**
      1. You are also receiving levodopa-carbidopa therapy
      2. You have previously tried generic amantadine capsules, tablets, or solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**OSMOLEX ER**

1. Does the patient have a diagnosis of Parkinson's disease?
   - If yes, continue to #3.
   - If no, continue to #2.

2. Is the request for the treatment of drug-induced extrapyramidal symptoms (EPS) AND the patient meets the following criterion?
   - The patient is 18 years of age or older
     - If yes, continue to #3.
     - If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
AMANTADINE EXTENDED RELEASE

GUIDELINES FOR USE - OSMOLEX ER (CONTINUED)

3. Does the patient meet ALL of the following criteria?
   • Therapy is prescribed by or given in consultation with a psychiatrist, neurologist, or geriatrician
   • The patient has had a trial of generic amantadine IR capsules, tablets, or solution

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with a quantity limit of #1 per day.
   If no, do not approve.

OSMOLEX ER DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AMANTADINE EXTENDED RELEASE (Osmolex ER) requires the following rule(s) be met for approval:
A. You have Parkinson's disease (nervous system disorder that affects movement) OR you are being treated for drug-induced extrapyramidal symptoms (group of movement disorders)
B. Therapy is prescribed by or given in consultation with a psychiatrist (mental disorder doctor), neurologist (nerve doctor), or geriatrician (doctor who treats elderly people)
C. You have previously tried generic amantadine immediate-release capsules, tablets or solution
D. If you are being treated for drug-induced extrapyramidal symptoms, approval also requires:
   1. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gocovri and Osmolex ER.

REFERENCES

CONTINUED ON NEXT PAGE
### AMANTADINE EXTENDED RELEASE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

- Part D Effective: N/A
- Created: 09/17
- Commercial Effective: 07/01/21
- Client Approval: 05/21
- P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient does not have idiopathic pulmonary fibrosis (IPF)

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does that patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) of greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) of greater than 2 Wood units

   If yes, approve for 12 months by HICL or GPI-10 for #1 per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named AMBRISENTAN (Letairis) requires the following rule(s) be met for approval:
   A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1)
   B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
   C. You do not have idiopathic pulmonary fibrosis (scarring of the lungs for an unknown reason) (Initial denial text continued on next page)

   CONTINUED ON NEXT PAGE
AMBRISENTAN

INITIAL CRITERIA (CONTINUED)

D. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:

1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1)?

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient remains stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

   If yes, approve for 12 months by HICL or GPI-10 for #1 per day.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **AMBRISENTAN (Letairis)** requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1)

B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

   *(Renewal denial text continued on next page)*

**CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Letairis.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/22
Commercial Effective: 07/01/23  Client Approval: 05/23  P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a neurologist or hematologist-oncologist
   - Diagnosis is confirmed by ALL of the following:
     Electrodiagnostic studies (e.g., reduced compound muscle action potential (CMAP)) and/or voltage-gated calcium channel (VGCC) antibody testing
     Clinical triad of muscle weakness, autonomic dysfunction, and decreased tendon reflexes

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Is the request for Firdapse and the patient meets the following criterion?
   - The patient is 6 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.
   If no, continue to #3.

3. Is the request for Ruzurgi?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #10 per day.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
AMIFAMPRIDINE

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AMIFAMPRIDINE (Firdapse, Ruzurgi) requires the following rule(s) be met for approval:
A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
B. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or hematologist-oncologist (a type of blood-cancer doctor)
C. Diagnosis is confirmed by ALL of the following:
   1. Electrodiagnostic studies and/or voltage-gated calcium channel (types of lab tests) antibody testing
   2. Three clinical symptoms of muscle weakness, autonomic dysfunction (nerve dysfunction), and decreased tendon reflexes
D. If you are requesting Firdapse, approval also requires:
   1. You are 6 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) AND meet the following criterion?
   • The patient has experienced improvement or stabilization in muscle weakness compared to baseline

If yes, approve for 12 months for the requested drug as follows:
   • Firdapse: Approve by HICL or GPI-10 with a quantity limit of #8 per day.
   • Ruzurgi: Approve by HICL or GPI-10 with a quantity limit of #10 per day.

If no, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AMIFAMPRIDINE (Firdapse, Ruzurgi) requires the following rule(s) be met for renewal:
A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
B. You have experienced improvement or stabilization in muscle weakness compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Firdapse and Ruzurgi.

REFERENCES
- Firdapse [Prescribing Information]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc; September 2022.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

1. Does the patient have a diagnosis of *Mycobacterium avium complex* (MAC) lung disease with limited or no alternative treatment options and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has **NOT** achieved negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen therapy
   - Arikayce will be used as part of a combination antibacterial drug regimen
   - Arikayce is being prescribed by or given in consultation with a pulmonologist or infectious disease specialist physician

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8.4mL (1 vial) per day.**

**APPROVAL TEXT:** Renewal requires that the patient has not had a positive MAC sputum culture after consecutive negative cultures and also has had improvement in symptoms. Additionally, for first renewal requests, approval requires documentation of at least one negative sputum culture for MAC by six months of Arikayce treatment. For second and subsequent renewal requests, approval requires documentation of at least three negative sputum cultures for MAC by 12 months of Arikayce treatment.

If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for approval:

- A. You have *Mycobacterium avium complex* (MAC – group of bacteria that cause serious infections) lung disease with limited or no alternative treatment options
- B. You are 18 years of age or older
- C. You have **NOT** achieved negative sputum cultures (mucus tests) after using multidrug background regimen therapy for at least 6 months in a row
- D. Arikayce will be used as part of a combination antibacterial drug regimen
- E. Arikayce is being prescribed by or given in consultation with a pulmonologist (lung doctor) or infectious disease specialist physician

*(Initial denial text continued on next page)*

CONTINUE ON NEXT PAGE
AMIKACIN LIPOSOMAL INHALATION

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for the first renewal of Arikayce for the treatment of patients with a diagnosis of Mycobacterium avium complex (MAC) lung disease and the patient meets ALL of the following criteria?
   - There is documentation of at least ONE negative sputum culture for MAC by 6 months of Arikayce treatment
   - The patient has NOT had a positive MAC sputum culture after consecutive negative cultures
   - The patient has had an improvement in symptoms

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8.4mL (1 vial) per day.**
   If no, continue to #2.

2. Is the request for the second or subsequent renewal of Arikayce for treatment of patients with a diagnosis of Mycobacterium avium complex (MAC) lung disease and the patient meets ALL of the following criteria?
   - There is documentation of at least THREE negative sputum cultures for MAC by 12 months of Arikayce treatment
   - The patient has NOT had a positive MAC sputum culture after consecutive negative cultures
   - The patient has had an improvement in symptoms

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8.4mL (1 vial) per day.**
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUE ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AMIKACIN LIPOSOMAL INHALATION (Arikayce) requires the following rule(s) be met for renewal:
A. You have Mycobacterium avium complex (MAC- group of bacteria that cause serious infections) lung disease
B. You have not had a positive Mycobacterium avium complex sputum culture (mucus test) after repeated negative cultures
C. You have experienced an improvement in symptoms
D. You meet ONE of the following:
   1. For first renewal requests, approval also requires documentation of at least ONE negative sputum culture (mucus test) for Mycobacterium avium complex by 6 months of Arikayce treatment
   2. For second or later renewal requests, approval also requires documentation of at least THREE negative sputum cultures (mucus test) for Mycobacterium avium complex by 12 months of Arikayce treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Arikayce.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/01/20

Created: 11/18
Client Approval: 04/20
P&T Approval: 10/18
GUIDELINES FOR USE

1. Is the patient unable to swallow oral amlodipine tablets at prescribed dose?
   
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of 10mL per day.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **AMLODIPINE SUSPENSION (Katerzia)** requires the following rule(s) be met for approval:
   A. You are unable to swallow oral amlodipine tablets at prescribed dose

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Katerzia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 04/01/20  
Created: 02/20  
Client Approval: 02/20  
P&T Approval: 01/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of both hypertension and osteoarthritis and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of amlodipine AND celecoxib
   - The patient has an adherence or other challenge which requires the use of the combination product over separate agents
   - Consensi will NOT be used together with any other calcium channel blocker agents (e.g. diltiazem, felodipine, verapamil)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day. If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **AMLODIPINE/CELECOXIB (Consensi)** requires the following rule(s) be met for approval:
   A. You have both hypertension (abnormal high blood pressure) and osteoarthritis (a type of arthritis that occurs when tissue at the ends of your bones wears down)
   B. You are 18 years of age or older
   C. You have previously tried amlodipine AND celecoxib
   D. You have an adherence or other challenge requiring the use of the combination product over separate agents
   E. You will NOT use Consensi together with any other calcium channel blocker agents (such as diltiazem, felodipine, verapamil)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
AMLODIPINE/CELECOXIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Consensi.

REFERENCES
- Consensi [Prescribing Information]. Hot Springs, AR: Burke Therapeutics, LLC; February 2017.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/20
Commercial Effective: 04/01/20  Client Approval: 02/20  P&T Approval: 01/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of narcolepsy AND meet the following criterion?
   - The patient is 6 years of age or older

   If yes, approve the requested strength for 12 months by GPID or GPI-14 with a quantity limit of #6 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of attention deficit disorder with hyperactivity and meet ALL of the following criteria?
   - The patient is 3 years of age or older
   - The patient had a previous trial of at least ONE of the following stimulant medications: mixed amphetamine salts (Adderall IR), methylphenidate (Ritalin IR), or dextroamphetamine (Dexedrine)

   If yes, approve the requested strength for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.
   If no, continue to #3.

3. Is the requested medication being used for weight loss or exogenous obesity?

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Are weight loss products (anti-obesity medications) a covered benefit?

   If yes, continue to #5.
   If no, guideline does not apply for plans that exclude treatment of obesity.

5. Is this an initial request (per MRF and claims history)?

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
6. Does the patient meet **ALL** of the following criteria?

   - The patient is 12 years of age or older
   - The patient had a previous trial of other weight loss medications (e.g., Contrave, Belviq, Qsymia, Xenical, phentermine, phendimetrazine, benzphetamine, diethylpropion)

   If yes, approve the requested strength for 12 weeks by G PID or GPI-14 with a quantity limit of #3 per day.
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it*

Our guideline named **AMPHETAMINE SULFATE (Evekeo)** requires the following rule(s) be met for approval:

**A.** You have **ONE** of the following diagnoses:
   1. Narcolepsy (condition where you suddenly fall asleep)
   2. Attention deficit disorder with hyperactivity (difficulty paying attention)
   3. Use for weight loss or exogenous obesity (overweight due to overeating)

**B.** If you have narcolepsy, approval also requires:
   1. You are 6 years of age or older

**C.** If you have attention deficit disorder with hyperactivity, approval also requires:
   1. You are 3 years of age or older
   2. You had a previous trial of at least ONE of the following stimulant medications: mixed amphetamine salts (Adderall immediate release), methylphenidate (Ritalin immediate release), dextroamphetamine (Dexedrine)

**D.** If the request is for weight loss or exogenous obesity, approval also requires:
   1. You are 12 years of age or older
   2. You had a previous trial of other weight loss medications such as Contrave, Belviq, Qsymia, Xenical, phentermine, phendimetrazine, benzphetamine, diethylpropion

**Note:** The approval of Evekeo for use as a short-term adjunct (add-on) in a regimen of weight reduction is for a maximum duration of 12 weeks

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
AMPHETAMINE SULFATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Evekeo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/15
Commercial Effective: 05/01/20  Client Approval: 04/20  P&T Approval: 07/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of attention deficit disorder with hyperactivity (ADHD) and meet ALL of the following criteria?
   - The patient is 6 to 17 years of age
   - The patient is unable to swallow amphetamine sulfate tablets
   - The patient had a trial of TWO of the following immediate-release stimulant medications: methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, dextroamphetamine-amphetamine

   If yes, approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:
   - 5 mg: #8 per day.
   - 10 mg: #4 per day.
   - 15 mg and 20 mg: #2 per day.

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AMPHETAMINE SULFATE ODT (Evekeo ODT) requires the following rule(s) be met for approval:
A. You have attention deficit disorder with hyperactivity (ADHD: difficulty paying attention)
B. You are 6 to 17 years of age
C. You are unable to swallow amphetamine sulfate tablets
D. You had a trial of TWO of the following immediate-release stimulant medications:
   - methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine,
   - dextroamphetamine-amphetamine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
AMPHETAMINE SULFATE ODT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Evekeo ODT.

REFERENCES
• Evekeo ODT [Prescribing Information]. Atlanta, GA: Arbor Pharmaceuticals LLC; September 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 11/22
Commercial Effective: 04/01/23  Client Approval: 02/23  P&T Approval: 10/22
**Please use the criteria for the specific drug requested**

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ANADROL-50

1. Does the patient have a diagnosis of anemia and meet ALL of the following criteria?
   - The anemia is caused by one of the following conditions: acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias, or Fanconi’s anemia
   - The patient does not have any of the following contraindications to anabolic steroid therapy:
     - Known or suspected carcinoma of the prostate or breast in male patients
     - Known or suspected carcinoma of the breast in females with hypercalcemia
     - Known or suspected nephrosis (the nephrotic phase of nephritis)
     - Known or suspected hypercalcemia
     - Severe hepatic dysfunction
   - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

   If yes, approve for 6 months by HICL or GPI-10.
   If no, continue to #2.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA - ANADROL-50 (CONTINUED)

2. Does the patient have a diagnosis of cachexia associated with AIDS and meet the following criteria?
   - The patient is on anti-retroviral therapy
   - The patient has a documented viral load (with date) of less than 200 copies per mL within the past 3 months
   - Therapy is prescribed by or given in consultation with a gastroenterologist, nutritional Support Specialist (SBS) or Infectious Disease specialist
   - The patient meets **ONE** of the following criteria:
     - The patient has 10% unintentional weight loss over 12 months
     - The patient has 7.5% unintentional weight loss over 6 months
     - The patient has 5% body cell mass (BCM) loss within 6 months
     - The patient has a body cell mass (BCM) of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
     - The patient has a body cell mass (BCM) of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
     - The patient has a BMI of less than 18.5 kg per meter squared
   - The patient does **not** have any of the following contraindications to anabolic steroid therapy:
     - Known or suspected carcinoma of the prostate or breast in male patients
     - Known or suspected carcinoma of the breast in females with hypercalcemia
     - Known or suspected nephrosis (the nephrotic phase of nephritis)
     - Known or suspected hypercalcemia
     - Severe hepatic dysfunction
   - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

If yes, **approve for 12 weeks by HICL or GPI-10.**
If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ANABOLIC STEROIDS (Anadrol-50)** requires the following rule(s) be met for approval:

A. You have anemia (lack of healthy red blood cells) or cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes

*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA - ANADROL-50 (CONTINUED)

C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:
   1. Known or suspected prostate or breast cancer in male patients
   2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
   3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
   4. Known or suspected hypercalcemia (high calcium levels)
   5. Severe hepatic (liver) dysfunction

D. **If you have anemia, approval also requires:**
   1. The anemia is caused by one of the following conditions: acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias, or Fanconi’s

E. **If you have cachexia associated with AIDS, approval also requires:**
   1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
   2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
   3. Therapy is prescribed by or given in recommendation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS), or infectious disease specialist
   4. You meet ONE of the following:
      a. You have 10% unintentional weight loss over 12 months
      b. You have 7.5% unintentional weight loss over 6 months
      c. You have 5% body cell mass (BCM) loss within 6 months
      d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
      e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
      f. You have a BMI of less than 18.5 kg per meter squared

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

OXANDRIN

1. Is the request for adjunctive therapy to promote weight gain and the patient meet ALL of the following criteria?
   - The patient’s weight loss is due to one of the following conditions: extensive surgery, chronic infections, or severe trauma
   - The patient does not have any of the following contraindications to anabolic steroid therapy:
     - Known or suspected carcinoma of the prostate or breast in male patients
     - Known or suspected carcinoma of the breast in females with hypercalcemia
     - Known or suspected nephrosis (the nephrotic phase of nephritis)
     - Known or suspected hypercalcemia
     - Severe hepatic dysfunction
   - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

   If yes, approve for 12 weeks by HICL or GPI-10.
   If no, continue to #2.

2. Is the request for adjunctive therapy to offset the protein catabolism associated with prolonged administration of corticosteroids and the patient meet ALL of the following criteria?
   - The patient does not have any of the following contraindications to anabolic steroid therapy:
     - Known or suspected carcinoma of the prostate or breast in male patients
     - Known or suspected carcinoma of the breast in females with hypercalcemia
     - Known or suspected nephrosis (the nephrotic phase of nephritis)
     - Known or suspected hypercalcemia
     - Severe hepatic dysfunction
   - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

   If yes, approve for 6 months by HICL or GPI-10.
   If no, continue to #3.

3. Is the request for the relief of the bone pain accompanying osteoporosis and the patient meet ALL of the following criteria?
   - The patient does not have any of the following contraindications to anabolic steroid therapy:
     - Known or suspected carcinoma of the prostate or breast in male patients
     - Known or suspected carcinoma of the breast in females with hypercalcemia
     - Known or suspected nephrosis (the nephrotic phase of nephritis)
     - Known or suspected hypercalcemia
     - Severe hepatic dysfunction
   - The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

   If yes, approve for 6 months by HICL or GPI-10.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
ANABOLIC STEROIDS

INITIAL CRITERIA - OXANDRIN (CONTINUED)

4. Does the patient have a diagnosis of cachexia associated with AIDS and meet ALL of the following criteria?
   • The patient is on anti-retroviral therapy
   • The patient has a documented viral load (with date) of less than 200 copies per mL within the past 3 months
   • Therapy is prescribed by or given in consultation with a gastroenterologist, nutritional support specialist (SBS) or Infectious disease specialist
   • The patient meets ONE of the following criteria:
     o The patient has 10% unintentional weight loss over 12 months,
     o The patient has 7.5% unintentional weight loss over 6 months
     o The patient has 5% body cell mass (BCM) loss within 6 months
     o The patient has a body cell mass (BCM) of less than 35% (men) and a body mass index (BMI) less than 27 kg per meter squared
     o The patient has a body cell mass (BCM) of less than 23% (women) of total body weight and a body mass index (BMI) less than 27 kg per meter squared
     o The patient has a BMI of less than 18.5 kg per meter squared
   • The patient does not have any of the following contraindications to anabolic steroid therapy:
     o Known or suspected carcinoma of the prostate or breast in male patients
     o Known or suspected carcinoma of the breast in females with hypercalcemia
     o Known or suspected nephrosis (the nephrotic phase of nephritis)
     o Known or suspected hypercalcemia
     o Severe hepatic dysfunction
   • The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

   If yes, approve for 12 weeks by HICL or GPI-10.
   If no, continue to #5.

5. Does the patient have a diagnosis of Turner’s Syndrome and meet ALL of the following criteria?
   • The patient does not have any of the following contraindications to anabolic steroid therapy:
     o Known or suspected carcinoma of the prostate or breast in male patients
     o Known or suspected carcinoma of the breast in females with hypercalcemia
     o Known or suspected nephrosis (the nephrotic phase of nephritis)
     o Known or suspected hypercalcemia
     o Severe hepatic dysfunction
   • The patient will be monitored for peliosis hepatis, liver cell tumors and blood lipid changes

   If yes, approve for 6 months by HICL or GPI-10.
   If no, do not approve.
   DENIAL TEXT: See Oxandrin initial denial text on the next page.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA - OXANDRIN (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ANABOLIC STEROIDS (Oxandrin)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Weight loss
   2. Protein catabolism (breakdown) caused by long-term use of corticosteroids
   3. Bone pain accompanying osteoporosis (weak and brittle bones)
   4. Cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
   5. Turner's Syndrome (disorder where female has one X chromosome)

B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes

C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:
   1. Known or suspected prostate or breast cancer in male patients
   2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
   3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
   4. Known or suspected hypercalcemia (high calcium levels)
   5. Severe hepatic (liver) dysfunction

D. **If you have weight loss, approval also requires:**
   1. Your weight loss is caused by extensive surgery, chronic infections, or severe trauma
   2. Medication is being used as add-on therapy to help weight gain

E. **If you have cachexia associated with AIDS, approval also requires:**
   1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
   2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
   3. Therapy is prescribed by or given in consultation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS) or infectious disease specialist
   4. You meet ONE of the following:
      a. You have 10% unintentional weight loss over 12 months
      b. You have 7.5% unintentional weight loss over 6 months
      c. You have 5% body cell mass (BCM) loss within 6 months
      d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
      e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
      f. You have a BMI of less than 18.5 kg per meter squared

*(Initial denial text continued on next page)*
INITIAL CRITERIA - OXANDRIN (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

(NOTE: For the diagnosis of anemia, weight loss, protein catabolism associated with prolonged administration of corticosteroids, bone pain accompanying osteoporosis, or Turner's Syndrome, please refer to the Initial Criteria section)

OXANDRIN and ANADROL-50

1. Is the request for cachexia associated with AIDS and the patient meet ALL of the following criteria?
   - The patient is on anti-retroviral therapy
   - The patient's viral load is less than 200 copies per mL within the past 3 months
   - The patient has responded to therapy as measured by at least a 10% increase in weight from baseline (current weight must have been measured within the last 4 weeks, document date of measurement)
   - The patient has not received more than 24 weeks of therapy in a calendar year

   If yes, approve for 12 weeks by HICL or GPI-10. (Note: therapy is limited to 24 weeks per calendar year.)
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ANABOLIC STEROIDS (Oxandrin and Anadrol-50) requires the following rule(s) be met for renewal:
   A. You have cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
   B. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
   C. Your viral load (amount of virus in your blood) is less than 200 copies per mL within the past 3 months
   D. You have a 10% increase in weight from baseline (current weight must have been measured within the last 4 weeks, document date of measurement)
   E. You have not received more than 24 weeks of therapy in a calendar year

   (Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED], We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Anadrol-50 and Oxandrin.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 05/15
Client Approval: 04/20
P&T Approval: 05/15
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for the treatment of coronavirus disease 2019 (COVID-19) in a hospitalized adult?
   
   If yes, do not approve. [NOTE: This indication is for hospital use only.]
   
   DENIAL TEXT: See initial denial text at the end of the guideline.
   
   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   
   If yes, continue to #3.
   If no, continue to #4.

3. Does the patient meet ONE of the following criteria?
   
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   • The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events
   
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]
   
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #0.67 mL per day.
   If no, do not approve.
   
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS) including Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and meet ALL of the following criteria?
   - The patient has genetic testing for gain-of-function mutations in the NLRP3 gene OR has inflammatory markers (i.e., elevated CRP, ESR, serum amyloid A protein (SAA) or S100 proteins)
   - The patient has TWO of the following: urticarial-like rash (neutrophilic dermatitis), cold-triggered episodes, sensorineural hearing loss, musculoskeletal symptoms, chronic aseptic meningitis, skeletal abnormalities
   - Kineret will NOT be used concurrently with other IL-1 inhibitors (e.g., Arcalyst [rilonacept], Ilaris [canakinumab])

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #5.

5. Does the patient have a diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) and meet ALL of the following criteria?
   - The patient has genetic testing for gain-of-function mutations in the IL1RN gene OR has inflammatory markers (i.e., elevated CRP, ESR)
   - The patient has ONE of the following: pustular psoriasis-like rashes, osteomyelitis, absence of bacterial osteomyelitis, nail changes (i.e., onychomadesis)
   - Kineret will NOT be used concurrently with other IL-1 inhibitors (e.g., Arcalyst [rilonacept], Ilaris [canakinumab])

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ANAKINRA (Kineret) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Cryopyrin-Associated Periodic Syndromes (CAPS) including Neonatal-Onset Multisystem Inflammatory Disease (NOMID: a type of immune disorder)
   3. Deficiency of Interleukin-1 Receptor Antagonist (DIRA: a type of immune system disorder)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. If you have Cryopyrin-Associated Periodic Syndromes including Neonatal-Onset Multisystem Inflammatory Disease, approval also requires:
   1. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *NLRP3* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: sign of inflammation], erythrocyte sedimentation rate [ESR: a type of blood test], serum amyloid A protein [SAA: a type of protein] or S100 proteins [a type of protein])
   2. You have TWO of the following: urticarial-like rash (neutrophilic dermatitis: a type of skin condition), cold-triggered episodes, sensorineural hearing loss (SNHL: a type of hearing loss), musculoskeletal symptoms (symptoms related to the skin and bones), chronic aseptic meningitis (inflammation of the brain and spinal cord), and skeletal (bone) abnormalities
   3. Kineret will NOT be used concurrently (at the same time) with other IL-1 inhibitors (such as Arcalyst [rilonacept], Ilaris [canakinumab])

D. If you have Deficiency of Interleukin-1 Receptor Antagonist, approval also requires:
   1. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *IL1RN* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: sign of inflammation], erythrocyte sedimentation rate [ESR: a type of blood test])
   2. You have ONE of the following: pustular psoriasis-like rashes (a type of skin condition), osteomyelitis (bone infection), absence of bacterial osteomyelitis, nail changes (onychomadesis: fungal infection of toenail)
   3. Kineret will NOT be used concurrently (at the same time) with other IL-1 inhibitors (such as Arcalyst [rilonacept], Ilaris [canakinumab])

E. NOTE: Kineret will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

NOTE: For the diagnoses of Cryopyrin-Associated Periodic Syndromes including Neonatal-Onset Multisystem Inflammatory Disease and Deficiency of Interleukin-1 Receptor Antagonist, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
   - The patient had a trial of or contraindication to **TWO** of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   - The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) **AND** the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

   **[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]**

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.67 mL per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ANAKINRA (Kineret)** requires the following rule(s) be met for renewal:
A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
C. You meet ONE of the following:
   1. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-ado)
   2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinoq [upadacitinib], Xeljanz [tofacitinib immediate release or extended release]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kineret.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 02/03
Client Approval: 08/23
P&T Approval: 07/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Are weight loss products (anti-obesity medications) a covered benefit?
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Is the request for Contrave for weight loss or weight management and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient meets ONE of the following criteria:
     o Body mass index (BMI) of 30 kg/m² or greater
     o BMI of 27 kg/m² or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)
   - Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

   If yes, approve for a total of 4 months by HICL or GPI-10 as follows:
   - FIRST APPROVAL: #78 for 30 days.
   - SECOND APPROVAL: #4 per day for 3 months with a start date of one day after the end date of the first approval.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Is the request for **Xenical (Orlistat)** for weight loss or weight management and the patient meets **ALL** of the following criteria?
   - The patient meets **ONE** of the following criteria:
     - Body mass index (BMI) of 30 kg/m\(^2\) or greater
     - BMI of 27 kg/m\(^2\) or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)
   - Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

   If yes, **approve for a total of 3 months by GPID or GPI-14 with a quantity limit of #3 per day**.

   If no, continue to #4.

4. Is the request for **Qsymia** for weight loss or weight management and the patient meets **ALL** of the following criteria?
   - Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program
   - The patient had a trial of or contraindication to the preferred agents: Saxenda AND Wegovy

   If yes, continue to #5.

   If no, continue to #7.

5. Is the patient 18 years of age or older and meets **ONE** of the following criteria?
   - Body mass index (BMI) of 30 kg/m\(^2\) or greater
   - BMI of 27 kg/m\(^2\) or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)

   If yes, **approve for all of the following strengths by GPID or GPI-14**:
   - 3.75/23mg: #1 per day for 2 weeks.
   - 7.5/46mg: #1 per day for 3 months with a start date of one day after the end date of the first authorization.

   If no, continue to #6.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Is the patient 12 to 17 years of age AND meets the following criterion?
   - The patient’s initial body mass index (BMI) is in the 95th percentile or greater for age and sex
   (See table below)

<table>
<thead>
<tr>
<th>Age (in years)</th>
<th>Male 95th Percentile BMI Value</th>
<th>Female 95th Percentile BMI Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>24.2</td>
<td>25.3</td>
</tr>
<tr>
<td>12.5</td>
<td>24.7</td>
<td>25.8</td>
</tr>
<tr>
<td>13</td>
<td>25.2</td>
<td>26.3</td>
</tr>
<tr>
<td>13.5</td>
<td>25.6</td>
<td>26.8</td>
</tr>
<tr>
<td>14</td>
<td>26.0</td>
<td>27.3</td>
</tr>
<tr>
<td>14.5</td>
<td>26.5</td>
<td>27.7</td>
</tr>
<tr>
<td>15</td>
<td>26.8</td>
<td>28.1</td>
</tr>
<tr>
<td>15.5</td>
<td>27.2</td>
<td>28.5</td>
</tr>
<tr>
<td>16</td>
<td>27.6</td>
<td>28.9</td>
</tr>
<tr>
<td>16.5</td>
<td>27.9</td>
<td>29.3</td>
</tr>
<tr>
<td>17</td>
<td>28.3</td>
<td>29.6</td>
</tr>
<tr>
<td>17.5</td>
<td>28.6</td>
<td>30.0</td>
</tr>
</tbody>
</table>

   If yes, approve for all of the following strengths by GPID or GPI-14:
   - 3.75/23mg: #1 per day for 2 weeks.
   - 7.5/46mg: #1 per day for 3 months with a start date of one day after the end date of the first authorization.

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

7. Is the request for Saxenda for weight loss or weight management and the patient meets ALL of the following criteria?
   - Saxenda will NOT be used concurrently with another GLP-1 receptor agonist (e.g., Victoza [liraglutide], Ozempic [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
   - Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

   If yes, continue to #8.
   If no, continue to #10.

   CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

8. Is the patient 18 years of age or older and meet ONE of the following criteria?
   • Body mass index (BMI) of 30 kg/m$^2$ or greater
   • BMI of 27 kg/m$^2$ or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)

   If yes, approve for 16 weeks by GPID or GPI-10 with a quantity limit of #0.5mL per day.
   If no, continue to #9.

9. Is the patient 12 to 17 years of age and meets ALL of the following criteria?
   • The patient’s body weight is greater than 60 kg
   • The patient’s initial BMI corresponds to 30 kg/m$^2$ or greater to that for adults (See table below)

   **BMI Cut-offs for Obesity in Patients 12 to 17 years that corresponds to 30 kg/m$^2$ in Adults**

<table>
<thead>
<tr>
<th>Age</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>26.02</td>
<td>26.67</td>
</tr>
<tr>
<td>12.5</td>
<td>26.43</td>
<td>27.24</td>
</tr>
<tr>
<td>13</td>
<td>26.84</td>
<td>27.76</td>
</tr>
<tr>
<td>13.5</td>
<td>27.25</td>
<td>28.20</td>
</tr>
<tr>
<td>14</td>
<td>27.63</td>
<td>28.57</td>
</tr>
<tr>
<td>14.5</td>
<td>27.98</td>
<td>28.87</td>
</tr>
<tr>
<td>15</td>
<td>28.30</td>
<td>29.11</td>
</tr>
<tr>
<td>15.5</td>
<td>28.60</td>
<td>29.29</td>
</tr>
<tr>
<td>16</td>
<td>28.88</td>
<td>29.43</td>
</tr>
<tr>
<td>16.5</td>
<td>29.14</td>
<td>29.56</td>
</tr>
<tr>
<td>17</td>
<td>29.41</td>
<td>29.69</td>
</tr>
<tr>
<td>17.5</td>
<td>29.70</td>
<td>29.84</td>
</tr>
</tbody>
</table>

   If yes, approve for 20 weeks by GPID or GPI-10 with a quantity limit of #0.5mL per day.
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

10. Is the request for **Wegovy** for weight loss or weight management and the patient meets ALL of the following criteria?
    • Evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program
    • Wegovy will NOT be used concurrently with another GLP-1 receptor agonist (e.g., Victoza [liraglutide], Ozempic [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])

    If yes, continue to #11.
    If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

11. Is the patient 18 years of age or older and meets ONE of the following criteria?
   • Body mass index (BMI) of 30 kg/m² or greater
   • BMI of 27 kg/m² or greater AND at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or hyperlipidemia)

   If yes, approve all of the following strengths for 29 weeks by GPID or GPI-14 with the following quantity limits:
   • 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL: #2mL per 28 days.
   • 1.7mg/0.75mL, 2.4mg/0.75mL: #3mL per 28 days.

   If no, continue to #12.

12. Is the patient 12 to 17 years of age AND meets the following criterion?
   • The patient has an initial BMI at the 95th percentile or greater standardized for age and sex
     (See table below)

   BMI Cut-offs for Obesity by Age and Sex

<table>
<thead>
<tr>
<th>Age (in years)</th>
<th>Male 95th Percentile BMI Value</th>
<th>Female 95th Percentile BMI Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>24.2</td>
<td>25.2</td>
</tr>
<tr>
<td>12.5</td>
<td>24.7</td>
<td>25.7</td>
</tr>
<tr>
<td>13</td>
<td>25.1</td>
<td>26.3</td>
</tr>
<tr>
<td>13.5</td>
<td>25.6</td>
<td>26.8</td>
</tr>
<tr>
<td>14</td>
<td>26.0</td>
<td>27.2</td>
</tr>
<tr>
<td>14.5</td>
<td>26.4</td>
<td>27.7</td>
</tr>
<tr>
<td>15</td>
<td>26.8</td>
<td>28.1</td>
</tr>
<tr>
<td>15.5</td>
<td>27.2</td>
<td>28.5</td>
</tr>
<tr>
<td>16</td>
<td>27.5</td>
<td>28.9</td>
</tr>
<tr>
<td>16.5</td>
<td>27.9</td>
<td>29.3</td>
</tr>
<tr>
<td>17</td>
<td>28.2</td>
<td>29.6</td>
</tr>
<tr>
<td>17.5</td>
<td>28.6</td>
<td>30.0</td>
</tr>
</tbody>
</table>

   If yes, approve all of the following strengths for 29 weeks by GPID or GPI-14 with the following quantity limits:
   • 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL: #2mL per 28 days.
   • 1.7mg/0.75mL, 2.4mg/0.75mL: #3mL per 28 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ANTI-OBEΣITΥ AGENTS (Contrave, Qsymia, Saxenda, Wegovy, Xenical [Orlistat]) requires the following rule(s) be met for approval:

A. The request is for weight loss OR weight loss management
B. You have evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program
C. If you are requesting Contrave, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus (a disorder with high blood sugar), or hyperlipidemia (high cholesterol)
D. If you are requesting Xenical [Orlistat], approval also requires you meet ONE of the following:
   1. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
   2. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus (a disorder with high blood sugar), or hyperlipidemia (high cholesterol)
E. If you are requesting Qsymia, approval also requires:
   1. You had a trial of or contraindication (harmful for) to the preferred medications: Saxenda AND Wegovy
   2. You are 18 years of age or older and meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus (a disorder with high blood sugar), or hyperlipidemia (high cholesterol)
   3. You are 12 to 17 years of age and meet the following:
      a. Your initial body mass index (BMI: a tool for evaluating body fat) is in the 95th percentile or greater for age and sex

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

F. If you are requesting Saxenda, approval also requires:
   1. You will NOT use Saxenda concurrently (at the same time) with a GLP-1 receptor agonist
      (a type of drug for type 2 diabetes such as Victoza [liraglutide], Ozempic [semaglutide],
      Byetta [exenatide], Bydureon [exenatide extended-release])
   2. You are 18 years of age or older and meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease)
      such as hypertension (high blood pressure), type 2 diabetes mellitus, or
      hyperlipidemia (high cholesterol)
   3. You are 12 to 17 years of age and meet the following:
      a. Body weight greater than 60 kg AND an initial BMI corresponding to 30 kg/m(2) for
         adults

G. If you are requesting Wegovy, approval also requires:
   1. You are 18 years of age or older and meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease)
      such as hypertension (high blood pressure), type 2 diabetes mellitus, or
      hyperlipidemia (high cholesterol)
   2. You are 12 to 17 years of age and meet the following:
      a. You have an initial body mass index (BMI: a tool for evaluating body fat) in the 95th
         percentile or greater standardized for age and sex
   3. You will NOT use Wegovy concurrently (at the same time) with a GLP-1 receptor agonist
      (a type of drug for type 2 diabetes such as Victoza [liraglutide], Ozempic [semaglutide],
      Byetta [exenatide], Bydureon [exenatide extended-release])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
your doctor to use a different medication or get us more information if it will allow us to approve
this request.

RENEWAL CRITERIA

1. Is the request for weight loss or weight management?
   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Is the request for Saxenda AND does the patient meet ONE of the following criteria?
   - The patient is 18 years of age or older AND has achieved or maintained at least 4% weight loss of baseline body weight after 16 weeks of treatment
   - The patient is 12 to 17 years of age AND has achieved or maintained at least 1% weight loss of baseline BMI after at least 12 weeks on the maximally tolerated dose

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #0.5mL per day.
   If no, continue to #3.

3. Is the request for Xenical (Orlistat) AND does the patient meet the following criterion?
   - The patient has achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #3 per day.
   If no, continue to #4.

4. Is the request for Contrave AND does the patient meet the following criterion?
   - The patient has achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment at the maintenance dose (two 8/90mg tablets twice daily)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #5.

5. Is the request for Wegovy and the patient meets ONE of the following criteria?
   - The patient is 18 years of age or older AND has achieved or maintained at least 5% weight loss of baseline body weight
   - The patient is 12 to 17 years of age AND has achieved or maintained at least 5% weight loss of baseline body mass index (BMI)

   If yes, approve all of the following strengths for 12 months by GPID or GPI-14 with the following quantity limits:
   - 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL: #2mL per 28 days.
   - 1.7mg/0.75mL, 2.4mg/0.75mL: #3mL per 28 days.

   If no, continue to #6.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

6. Is the request for **Qsymia 7.5/46mg AND** does the patient meet **ONE** of the following criteria?
   - The patient is 18 years of age or older AND has achieved or maintained at least 3% weight loss of baseline body weight after at least 3 months of treatment
   - The patient is 12 to 17 years of age AND has achieved or maintained at least 3% weight loss of baseline BMI after at least 3 months of treatment

   **If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   **If no, continue to #7.**

7. Is the request for dose escalation to **Qsymia 11.25/69mg** for 2 weeks, followed by **Qsymia 15/92mg**?

   **If yes, approve and enter two authorizations by GPID or GPI-14 as follows:**
   - 11.25/69mg: #1 per day for 2 weeks.
   - 15/92mg: #1 per day for 3 months with a start date of one day after the end date of the first authorization.

   **If no, continue to #8.**

8. Is the request for continuation of therapy after at least 12 weeks on **Qsymia 15/92mg AND** does the patient meet **ONE** of the following criteria?
   - The patient is 18 years of age or older AND has achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment
   - The patient is 12 to 17 years of age AND has achieved or maintained at least 5% weight loss of baseline BMI after 3 months of treatment

   **If yes, approve Qsymia 15/92mg for 12 months by GPID or GPI-14 for #1 per day.**
   **If no, do not approve. If the request is for Qsymia 15/92mg, please also enter a partial approval for ONE fill of Qsymia by HICL up to #4 total to taper dose in order to discontinue therapy.**

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ANTI-OBESITY AGENTS (Contrave, Qsymia, Saxenda, Wegovy, Xenical [Orlistat])** requires the following rule(s) be met for renewal:
A. The request is for weight loss OR weight loss management

*(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

B. If you are requesting Saxenda, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 4% weight loss of baseline body weight after 16 weeks of treatment
   2. You are 12 to 17 years of age AND have achieved or maintained at least 1% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after at least 12 weeks on the maximally tolerated dose

C. If you are requesting Xenical (Orlistat), renewal also requires:
   1. You have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment

D. If you are requesting Contrave, renewal also requires:
   1. You have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment at the maintenance dose (two 8/90mg tablets twice daily)

E. If you are requesting Wegovy, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 5% weight loss of baseline body weight
   2. You are 12 to 17 years of age AND have achieved or maintained at least 5% weight loss of baseline body mass index (BMI: a tool for evaluating body fat)

F. If you are requesting Qsymia 7.5/46mg, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 3% weight loss of baseline body weight after 3 months of treatment
   2. You are 12 to 17 years of age AND have achieved or maintained at least 3% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after at least 3 months of treatment

G. If you are requesting Qsymia 15/92mg, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment
   2. You are 12 to 17 years of age AND have achieved or maintained at least 5% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after 3 months of treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ANTI-OBESITY AGENTS

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for the requested Anti-Obesity agent.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/22/23
Created: 10/14
Client Approval: 05/23
P&T Approval: 04/23

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
**APALUTAMIDE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>APALUTAMIDE</td>
<td>ERLEADA</td>
<td>44773</td>
<td>GPI-10</td>
<td>(2140241000)</td>
<td></td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of metastatic castration-sensitive prostate cancer (mCSPC)?
   - If yes, continue to #3.
   - If no, continue to #2.

2. Does the patient have a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) **AND** meet the following criterion?
   - The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen [PSA] levels)
   - If yes, continue to #3.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
   - The patient previously received a bilateral orchiectomy
   - The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   - The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)
   - If yes, **approve for 12 months by GPID or GPI-14 with the following quantity limits:**
     - 60mg: #3 per day.
     - 240mg: #1 per day.
   - If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **APALUTAMIDE (Erleada)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy and has not spread to other parts of the body)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)

B. You meet ONE of the following:
   1. You previously received a bilateral orchietomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

C. **If you have a non-metastatic castration-resistant prostate cancer, approval also requires:**
   1. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA] levels)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have ONE of the following diagnoses?
   - Metastatic castration-sensitive prostate cancer (mCSPC)
   - Non-metastatic castration-resistant prostate cancer (nmCRPC)

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
2. Does the patient meet ONE of the following criteria?
   • The patient previously received a bilateral orchiectomy
   • The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   • The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

   If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   • 60mg: #3 per day.
   • 240mg: #1 per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named APALUTAMIDE (Erleada) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy but has not spread)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread and responds to hormone therapy)
B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
APALUTAMIDE

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Erleada.

REFERENCES

<table>
<thead>
<tr>
<th></th>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 05/18
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of advanced Parkinson's disease and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a neurologist
   - Apokyn will be used for the acute, intermittent treatment of hypomobility, OFF episodes associated with advanced Parkinson's disease
   - The physician has optimized drug therapy as evidenced by BOTH of the following:
     - Trial of or contraindication to TWO Parkinson disease agents from two different classes: dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (i.e., selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #60mL per month.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named APOMORPHINE (Apokyn) requires the following rule(s) be met for approval:
A. You have a diagnosis of advanced Parkinson's disease (a type of movement disorder)
B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
C. The requested medication will be used for acute, intermittent treatment of hypomobility (short and sudden episodes where you have decreased ability to move), OFF episodes associated with advanced Parkinson's disease
D. Your doctor has optimized your drug therapy as evidenced by BOTH of the following:
   1. Change in levodopa/carbidopa dosing strategy or formulation
   2. You have had a trial of or contraindication (harmful for) to TWO Parkinson disease agents from two different classes: dopamine agonist (ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (entacapone, tolcapone)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of advanced Parkinson’s disease AND meet the following criterion?
   - Patient has experienced improvement with motor fluctuations during OFF episodes with the use of Apokyn (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #60mL per month. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named APOMORPHINE (Apokyn) requires the following rule(s) be met for renewal:
A. You have a diagnosis of advanced Parkinson’s disease (a type of movement disorder)
B. You have had improvement with motor fluctuations during OFF episodes with the use of Apokyn (such as improvement in speech, facial expression, tremor [shaking] at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Apokyn.

REFERENCES
## APOMORPHINE - SL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOMORPHINE</td>
<td>KYNMOBI</td>
<td>01934</td>
<td></td>
<td>GPI-10 (7320301010)</td>
<td>BRAND = KYNMOBI</td>
</tr>
</tbody>
</table>

## GUIDELINES FOR USE

### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Parkinson's disease and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with a neurologist
   - The physician has optimized drug therapy as evidenced by **BOTH** of the following:
     - Change in levodopa/carbidopa dosing strategy or formulation
     - Trial of or contraindication to at least **TWO** Parkinson's agents from two different classes:
       - dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitor (MAO-I) (i.e., selegiline, rasagiline), or catechol-O-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)
   - Kynmobi is being used for the acute, intermittent treatment of 'OFF' episodes

If yes, **approve for 6 months for all strengths by GPIID or GPI-14 as follows:**
   - **Kynmobi Titration Kit**: no quantity limit.
   - **Kynmobi 10mg, 15mg, 20mg, 25mg and 30mg**: #5 per day.

**APPROVAL TEXT:** Renewal requires the patient had improvement with motor fluctuations during OFF episodes with the use of Kynmobi (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair).

If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **APOMORPHINE (Kynmobi)** requires the following rule(s) be met for approval:
A. You have Parkinson's disease (central nervous system disorder that affects movement, often including tremors)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a neurologist

*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

D. The physician has optimized drug therapy as evidenced by BOTH of the following:
   1. Change in levodopa/carbidopa dosing strategy or formulation
   2. Trial of or contraindication to at least two Parkinson's agents from two different classes:
      dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitor (MAO-I) (i.e., selegiline, rasagiline), or catechol-o-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)
E. The requested medication is being used for acute, intermittent treatment (sudden and periodic treatment) of 'OFF' episodes (when symptoms return due to your medication for Parkinson's disease wearing off)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Parkinson's disease AND meet the following criterion?
   • The patient had improvement with motor fluctuations during 'OFF' episodes with the use of Kynmobi (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

   If yes, approve for 12 months by GPID or GPI-14 for all of the following:
   • Kynmobi 10mg, 15mg, 20mg, 25mg and 30mg: #5 per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named APOMORPHINE (Kynmobi) requires the following rule(s) be met for renewal:
A. You have Parkinson's disease (central nervous system disorder that affects movement, often including tremors)
B. You had improvement with motor fluctuations during 'OFF' episodes (when symptoms return due to your medications for Parkinson's disease wearing off) with the use of Kynmobi (such as improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kynmobi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/20
Commercial Effective: 10/01/20  Client Approval: 08/20  P&T Approval: 07/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, enter approval(s) by GPID or GPI-14 as follows:
   • If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND
   • Approve for 6 months for #2 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of mild plaque psoriasis (PsO) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist
   • The patient had a trial of or contraindication to one conventional systemic agent (e.g., methotrexate, acitretin, cyclosporine) OR one conventional topical agent (e.g., PUVA, UVB, topical corticosteroids [e.g., betamethasone dipropionate, clobetasol propionate])

   If yes, continue to #3.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
APREMILAST

INITIAL CRITERIA (CONTINUED)

3. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
   - The patient has psoriasis covering 2% of body surface area (BSA)
   - The patient has a static Physician Global Assessment (sPGA) score of 2
   - The patient has a Psoriasis Area and Severity Index (PASI) score of 2 to 9

   If yes, enter approval(s) by GPID or GPI-14 as follows:
   - If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND
   - Approve for 6 months for #2 per day.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA, UVB, topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #5.
   If no, continue to #6.

5. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
   - The patient has psoriasis covering 3% or more of body surface area (BSA)
   - The patient has psoriatic lesions affecting the hands, feet, face, or genital area

   If yes, enter approval(s) by GPID or GPI-14 as follows:
   - If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND
   - Approve for 6 months for #2 per day.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Does the patient have a diagnosis of Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to ONE or more conservative treatments (e.g., colchicine, topical corticosteroid, oral corticosteroid)

If yes, enter approval(s) by GPID or GPI-14 as follows:
   - If the starter pack is requested for dosage titration, approve for 1 fill for either #1 Otezla Two Week Starter Pack (#27 tablets) OR for #1 Otezla 28-day Starter Pack (#55 tablets) AND
   - Approve for 6 months for #2 per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named APREMILAST (Otezla) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (a type of skin and joint condition)
   2. Plaque psoriasis (a type of skin condition)
   3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms

B. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

C. If you have mild plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication to (harmful for) one conventional (standard) systemic treatment that targets the entire body agent (such as methotrexate, acitretin, cyclosporine) OR one conventional topical agent (such as Phototherapy Ultraviolet Light A [PUVA], Ultraviolet Light B [UVB], topical corticosteroids [such as betamethasone dipropionate, clobetasol propionate])

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

4. You meet ONE of the following:
   a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
   b. You have psoriasis covering 2 percent of body surface area (BSA)
   c. You have a static Physician Global Assessment (Spga: a measure used to evaluate severity of your disease) score of 2
   d. You have a Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) score of 2 to 9

D. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of conventional (standard) therapies, such as Phototherapy Ultraviolet Light A (PUVA), Ultraviolet Light B (UVB), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, cyclosporine

4. You meet ONE of the following:
   a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
   b. You have psoriasis covering 3 percent or more of body surface area (BSA)
   c. You have psoriatic lesions (rashes) affecting your hands, feet, face, or genital area

E. If you have Behcet’s disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more conservative treatments such as colchicine, topical corticosteroid, oral corticosteroid

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
APREMILAST

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender or swollen joint count while on therapy

   If yes, approve for 12 months by HICL or GPI-10 for #2 per day.
   If no, continue to #2.

2. Does the patient have mild plaque psoriasis (PsO) AND meet the following criterion?
   - The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more OR a decrease in sPGA (static Physician Global Assessment) by at least a 2-point reduction from baseline

   If yes, approve for 12 months by HICL or GPI-10 for #2 per day.
   If no, continue to #3.

3. Does the patient have moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   - The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

   If yes, approve for 12 months by HICL or GPI-10 for #2 per day.
   If no, continue to #4.

4. Does the patient have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms AND meet the following criterion?
   - The patient has achieved or maintained clinical benefit compared to baseline (e.g., pain scores, number of ulcers)

   If yes, approve for 12 months by HICL or GPI-10 for #2 per day.
   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
APREMILAST RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named APREMILAST (Otezla) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (a type of skin and joint condition)
   2. Plaque psoriasis (a type of skin condition)
   3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms

B. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

C. If you have mild plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) of at least 50 percent or more OR a decrease in static Physician Global Assessment (Spga: a measure used to evaluate severity of your disease) by at least a 2-point reduction from baseline

D. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) of at least 50 percent or more

E. If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, renewal also requires:
   1. You have achieved or maintained clinical benefit compared to baseline such as an improvement in pain scores, number of ulcers

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
APREMILAST

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Otezla.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 04/14
Client Approval: 05/23
P&T Approval: 04/23
ARIPIPRAZOLE SENSOR TABS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIPIPRAZOLE TABLETS WITH SENSOR</td>
<td>ABILIFY MYCITE</td>
<td>24551</td>
<td>GCN</td>
<td>GPI-10</td>
<td>BRAND = ABILIFY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(5925001502,</td>
<td>MYCITE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5925001503)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of schizophrenia and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a psychiatrist
   - The patient has a medical necessity for tracking medication ingestion

   If yes, approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #1 kit per 30 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of major depressive disorder and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a psychiatrist
   - Abilify MyCite will be used as an adjunctive treatment
   - The patient has a medical necessity for tracking medication ingestion

   If yes, approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #1 kit per 30 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of bipolar I disorder and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a psychiatrist
   - The patient has a medical necessity for tracking medication ingestion

   If yes, continue to #4.

   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
ARIPIPRAZOLE SENSOR TABS

GUIDELINES FOR USE (CONTINUED)

4. Does the patient meet ONE of the following criteria?
   • The request is for acute treatment of manic and mixed episodes as monotherapy, OR as an
     adjunct to lithium or valproate
   • The request is for maintenance treatment as monotherapy, OR as an adjunct to lithium or
     valproate

   If yes, approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #1 kit
   per 30 days.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these
   definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ARIPIPRAZOLE SENSOR TABS (Abilify MyCite) requires the following
   rule(s) be met for approval:

   A. You have ONE of the following diagnoses:
      1. Schizophrenia (a type of mental health disorder)
      2. Bipolar I disorder (a type of mood disorder)
      3. Major depressive disorder (MDD: a type of mental health disorder)

   B. If you have schizophrenia, approval also requires:
      1. You are 18 years of age or older
      2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health
         doctor)
      3. You have a medical necessity for medication ingestion tracking

   C. If you have major depressive disorder, approval also requires:
      1. You are 18 years of age or older
      2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health
         doctor)
      3. Abilify MyCite will be used as an adjunctive (add-on) treatment
      4. You have a medical necessity for medication ingestion tracking

   D. If you have bipolar I disorder, approval also requires:
      1. You are 18 years of age or older
      2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health
         doctor)
      3. You have a medical necessity for medication ingestion tracking
      4. You meet ONE of the following:
         i. The request is for acute (short-term) treatment of manic and mixed episodes as
            monotherapy (used alone), OR as an adjunct (add-on) to lithium or valproate
         ii. The request is for maintenance treatment as monotherapy, OR as an adjunct to lithium
             or valproate

   (Denial text continued on the next page)
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Abilify MyCite.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/24/22
Created: 02/19
Client Approval: 10/22
P&T Approval: 01/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a mutational analysis prior to initiation AND Scemblix is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile (Please see header CML-5 of the current NCCN guidelines)

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Is the patient's cancer positive for the T315I mutation?

   If yes, approve Scemblix 40mg for 12 months by GPID or GPI-14 with a quantity limit of #10 per day.
   If no, continue to #3.

3. Has the patient been previously treated with at least TWO tyrosine kinase inhibitors (TKIs) (e.g., bosutinib, dasatinib, imatinib, nilotinib)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ASCIMINIB (Scemblix) requires the following rule(s) be met for approval:
   D. You have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: type of blood cancer) in chronic phase (CP)
   E. You are 18 years of age or older
   F. You had a mutational analysis prior to initiation of therapy AND Scemblix is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
   G. You meet ONE of the following:
      1. Your cancer has the T315I mutation (a type of abnormal gene)
      2. You have been previously treated with at least TWO tyrosine kinase inhibitors (TKIs), such as bosutinib, dasatinib, imatinib, nilotinib

   (Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Scemblix.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Created: 02/22

Commercial Effective: 04/01/22
Client Approval: 02/22
P&T Approval: 01/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) and meet ALL of the following criteria?
   - The patient is 1 month of age or older
   - The patient has developed hypersensitivity to E. coli-derived asparaginase
   - Rylaze will be used as a component of a multi-agent chemotherapeutic regimen

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ASPARAGINASE ERWINIA-RYWN (Rylaze) requires the following rule(s) be met for approval:
   A. You have acute lymphoblastic leukemia (ALL: type of blood cancer) or lymphoblastic lymphoma (LBL: type of cancer affecting the immune system)
   B. You are 1 month of age or older
   C. You have developed hypersensitivity to E.coli-derived asparaginase (you are allergic to an enzyme/protein that is from a type of bacteria)
   D. Rylaze will be used as a component of a multi-agent chemotherapeutic regimen

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rylaze.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is this a request for treatment of perinatal/infantile-onset hypophosphatasia (HPP)?
   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient have a documented diagnosis of perinatal/infantile-onset hypophosphatasia (HPP) and meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient was 6 months of age or younger at hypophosphatasia (HPP) onset
   - The patient is NOT currently receiving treatment with a bisphosphonate [e.g., Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].
   - The patient is positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meets at least **TWO** of the following criteria:
     - Serum alkaline phosphatase (ALP) level below that of normal range for patient age
     - Serum pyridoxal-5’-phosphate (PLP) levels elevated AND patient has not received vitamin B₆ supplementation in the previous week
     - Urine phosphoethanolamine (PEA) level above that of normal range for patient age
     - Radiographic evidence of hypophosphatasia (HPP) (e.g., flared and frayed metaphyses, osteopenia, widened growth plates, areas of radiolucency or sclerosis)
     - Presence of two or more of the following:
       - Rachitic chest deformity
       - Craniosynostosis (premature closure of skull bones)
       - Delay in skeletal growth resulting in delay of motor development
       - History of vitamin B₆ dependent seizures
       - Nephrocalcinosis or history of elevated serum calcium
       - History or presence of non-traumatic postnatal fracture and delayed fracture healing
   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is this a request for treatment of juvenile-onset hypophosphatasia (HPP)?
   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
ASFOTASE ALFA

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a documented diagnosis of juvenile-onset hypophosphatasia (HPP) and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient was 18 years of age or younger at hypophosphatasia (HPP) onset
   • The patient is NOT currently receiving treatment with a bisphosphonate [e.g., Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].
   • The patient is positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meets at least TWO of the following criteria:
     o Serum alkaline phosphatase (ALP) level below that of normal range for patient age
     o Serum pyridoxal-5'-phosphate (PLP) levels elevated AND patient has not received vitamin B₆ supplementation in the previous week
     o Urine phosphoethanolamine (PEA) level above that of normal range for patient age
     o Radiographic evidence of hypophosphatasia (HPP) (e.g., flared and frayed metaphyses, osteopenia, osteomalacia, widened growth plates, areas of radiolucency or sclerosis)
     o Presence of two or more of the following:
       ▪ Rachitic deformities (rachitic chest, bowed legs, knock-knees)
       ▪ Premature loss of primary teeth prior to 5 years of age
       ▪ Delay in skeletal growth resulting in delay of motor development
       ▪ History or presence of non-traumatic fractures or delayed fracture healing

   If yes, continue to #5.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

5. Does the patient meet ANY of the following criteria?
   • The patient’s serum calcium or phosphate level is below the normal range
   • The patient has a treatable form of rickets

   If yes, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline

   If no, approve for 6 months by HICL or GPI-10.
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ASFOTASE ALFA (Strensiq)** requires the following rules be met for approval:

A. You have a documented diagnosis of perinatal/infantile-onset hypophosphatasia (HPP: a type of genetic condition) or juvenile-onset hypophosphatasia (HPP).

B. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

C. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)]

D. **If you have perinatal/infantile-onset hypophosphatasia, approval also requires:**
   1. You were 6 months of age or younger at hypophosphatasia onset
   2. You are positive for a tissue non-specific alkaline phosphatase (a type of enzyme) (ALPL) gene mutation as confirmed by genetic testing OR you meet at least TWO of the following criteria:
      a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
      b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
      c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
      d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), widened growth plates, areas of radiolucency (ability to see through with x-rays/radiation) or sclerosis (hardening of an area)]
      e. Presence of two or more of the following:
         i. Rachitic chest deformity (chest bones are not normal)
         ii. Craniosynostosis (premature closure of skull bones)
         iii. Delay in skeletal growth resulting in delay of motor development
         iv. History of vitamin B6 dependent seizures
         v. Nephrocalcinosis (high calcium levels in kidney) or history of elevated serum calcium
         vi. History or presence of fracture after birth not due to injury or delayed fracture healing

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

E. If you have juvenile-onset hypophosphatasia, approval also requires:
   1. You were 18 years of age or younger at hypophosphatasia onset
   2. You are positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meet at least TWO of the following criteria:
      a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
      b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
      c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
      d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), osteomalacia (bone softening), widened growth plates, areas of radiolucency or sclerosis (hardening of an area)]
      e. Presence of two or more of the following:
         i. Rachitic deformities (rachitic chest, bowed legs, knock-knees)
         ii. Premature loss of primary teeth prior to 5 years of age
         iii. Delay in skeletal growth leading to motor development delay
         iv. History or presence of fracture after birth not due to injury or delayed fracture healing

Strensiq will not be approved if you meet any of the following:
   1. Your serum calcium or phosphate level is below the normal range
   2. You have a treatable form of rickets (softening and weakening of bones in children, usually due to low vitamin D)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ASFOTASE ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. During the last 6 months of treatment, has the patient experienced improvement in the skeletal characteristics of hypophosphatasia (HPP) (e.g., improvement of the irregularity of the provisional zone of calcification, physeal widening, metaphyseal flaring, radiolucencies, patchy osteosclerosis, ratio of mid-diaphyseal cortex to bone thickness, gracile bones, bone formation and fractures)?

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Is the patient currently receiving treatment with a bisphosphonate [e.g., Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)]?

   If yes, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

   If no, approve for 12 months by HICL or by GPI-10.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ASFOTASE ALFA (Strensiq) requires that the following rule(s) be met for renewal:

A. You have experienced improvement in the skeletal characteristics of hypophosphatasia (HPP: genetic disorder causing abnormal development of bones and teeth). Characteristics may include irregularity of the provisional zone of calcification (area on long bone for calcium build-up), physeal widening (area of bone that helps length growth), metaphyseal flaring (a narrow part of long bone grows), radiolucencies (ability to see with x-rays/radiation), patchy osteosclerosis (parts of abnormal hardening of bone), ratio of mid-diaphyseal cortex to bone thickness, gracile (slender) bones, bone formation and fractures.

B. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ASFOTASE ALFA

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Strensiq.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 07/01/22  
Created: 11/15  
Client Approval: 05/22  
P&T Approval: 04/22
1. Does the patient have a diagnosis of chronic coronary artery disease, (e.g., a history of MI or unstable angina), or a history of an ischemic stroke or transient ischemic attack (TIA)?

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT**: See the denial text at the end of guideline.

2. Does the patient meet the following criteria?
   - Patient has previously tried aspirin over-the-counter (OTC)
   - Durlaza is NOT being used for acute treatment of myocardial infarction or before percutaneous coronary intervention

   If yes, **approve for 12 months by GPID or GPI-10 for a quantity limit of #30 per 30 days**.
   If no, do not approve.

   **DENIAL TEXT**: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **ASPIRIN ER (Durlaza)** requires the following rules be met for approval:
   1. You have ONE of the following:
      a. Diagnosis of chronic coronary artery disease [damage or disease in the heart's major blood vessels; may include a history of myocardial infarction (heart attack) or unstable angina (chest pain when your heart doesn’t get enough oxygen)] OR
      b. History of an ischemic stroke or transient ischemic attack (arteries to your brain become narrowed or blocked, causing blood flow loss).
   2. You have previously tried aspirin over-the-counter (OTC)
   3. Durlaza is NOT being used for acute treatment (short term treatment) of myocardial infarction (heart attack) or before percutaneous coronary intervention (non-surgical procedure used to treat narrowing of the coronary arteries of the heart)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor.

   **CONTINUED ON NEXT PAGE**
ASPIRIN ER

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Durlaza.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 11/15
Client Approval: 04/20
P&T Approval: 11/15
GUIDELINES FOR USE

1. Does the patient require aspirin for secondary prevention of cardiovascular or cerebrovascular events and have **ONE** of the following diagnoses?
   - Ischemic stroke
   - Transient ischemia of the brain due to fibrin platelet emboli
   - Previous myocardial infarction
   - Unstable angina pectoris
   - Chronic stable angina pectoris
   - Previously undergone revascularization procedures (i.e., coronary artery bypass graft, percutaneous transluminal coronary angioplasty)
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a risk of developing aspirin associated gastrointestinal (GI) ulcers and meet **ALL** of the following criteria?
   - The patient is 55 years of age or older
   - Documented history of gastrointestinal (GI) ulcers

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried **ALL** of the following medications?
   - Aspirin over-the-counter (OTC)
   - Generic proton pump inhibitors (e.g., omeprazole, lansoprazole, pantoprazole, or rabeprazole)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
Our guideline named **ASPIRIN-OMEPRAZOLE (Yosprala)** requires the following rule(s) be met for approval:

A. The request is for secondary prevention of cardiovascular (related to heart and blood vessels) or cerebrovascular (related brain and blood vessels) events

B. You have ONE of the following:
   1. Ischemic stroke (arteries to your brain become narrowed or blocked, causing less blood flow)
   2. Transient ischemia of the brain due to fibrin platelet emboli (blood flow to your brain gets cut off for a short time due to temporary blockage)
   3. Previous myocardial infarction (heart attack)
   4. Unstable angina pectoris (chest pain when your heart doesn’t get enough oxygen)
   5. Chronic stable angina pectoris (chest pain when your heart doesn’t get enough oxygen)
   6. History of undergoing revascularization procedures (procedures that restore blood flow to heart such as coronary artery bypass graft, percutaneous transluminal coronary angioplasty)

C. You have a risk of developing aspirin associated gastrointestinal (GI) ulcers due to age (55 years or older) AND have a documented history of gastrointestinal (GI) ulcers

D. You have tried both aspirin over-the-counter (OTC) AND generic proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole, rabeprazole)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

### RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Yosprala.

### REFERENCES
ASPIRIN ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPIRIN</td>
<td>ASPIRIN, ASPIRIN EC, VARIOUS</td>
<td>161</td>
<td>16701</td>
<td>16713</td>
<td>16720</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GPI-14</td>
<td>(64100010000315, 64100010000510, 64100010000601, 64100010000605)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested aspirin agent AND does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?
   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the request for a generic agent?
   If yes, approve the requested agent for 12 months by GPID or GPI-14 at zero copay.
   If no, continue to #4.

4. Is the request for ONE of the following?
   • A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   • A multi-source brand (MSB) agent

   If yes, continue to #5.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet ONE of the following criteria?
   • Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
   • The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
   • The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

   If yes, approve the requested agent for 12 months by GPID or GPI-14 at zero copay. APPROVAL TEXT (applies to multi-source brand agents only): Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ASPIRIN ZERO COST SHARE OVERRIDE requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. A generic aspirin agent
   2. A single-source brand (SSB) aspirin agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) aspirin agent

B. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ASPIRIN ZERO COST SHARE OVERRIDE

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of aspirin for preventative use at zero copay. The override criteria allow patient access to all FDA-approved aspirin medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded aspirin medications.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of episodic migraines and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Qulipta is prescribed for the preventive treatment of migraines
   - Qulipta will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
   - The patient had a trial of or contraindication to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic migraines and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Qulipta is prescribed for the preventive treatment of migraines
   - Qulipta will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
   - The patient had a trial of or contraindication to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine, Botox [Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable]

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ATOGEPEANT (Qulipta)** requires the following rule(s) be met for approval:

A. You have migraines

B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
   1. You are 18 years of age or older
   2. Qulipta is prescribed for the preventive treatment of migraines
   3. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
   4. You have tried or have a contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine

C. **If you have chronic migraines (15 or more headache days per month), approval also requires:**
   1. You are 18 years of age or older
   2. Qulipta is prescribed for the preventive treatment of migraines
   3. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
   4. You have tried or have a contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine, Botox [Note: For Botox, previous trial of only National Drug Code (NDC) 00023-1145-01 or NDC 00023-3921-02 are allowable]

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Is the request for the preventive treatment of migraines AND does the patient meet the following criterion?
   • Qulipta will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
   • The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Qulipta therapy
   • The patient has experienced a reduction in migraine severity with Qulipta therapy
   • The patient has experienced a reduction in migraine duration with Qulipta therapy

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ATOGEPEANT (Qulipta)** requires the following rule(s) be met for renewal:

**A.** Qulipta is prescribed for the preventive treatment of migraines

**B.** You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention

**C.** You meet ONE of the following:
   1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Qulipta therapy
   2. You have experienced a reduction in migraine severity with Qulipta therapy
   3. You have experienced a reduction in migraine duration with Qulipta therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
ATOGEPANT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Qulipta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/21
Commercial Effective: 05/22/23  Client Approval: 05/23  P&T Approval: 01/23
1. Is the patient 18 years of age or older and the request is to reduce the risk of **ONE** of the following?  
   - Myocardial infarction (MI), stroke, revascularization procedures, or angina and the patient has multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD  
   - MI or stroke and the patient has type 2 diabetes mellitus and multiple risk factors for CHD but without clinically evident CHD  
   - Non-fatal MI, fatal or non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, or angina and the patient has clinically evident CHD  
   
   If yes, continue to #6.  
   If no, continue to #2.

2. Does the patient have a diagnosis of primary hyperlipidemia and meet **ALL** of the following criteria?  
   - The patient is 18 years of age or older  
   - Atorvaliq will be used in addition to diet  
   
   If yes, continue to #6.  
   If no, continue to #3.

3. Does the patient have a diagnosis of heterozygous familial hypercholesterolemia (HeFH) and meet **ALL** of the following criteria?  
   - The patient is 10 years of age or older  
   - Atorvaliq will be used in addition to diet  
   
   If yes, continue to #6.  
   If no, continue to #4.

4. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH) and meet **ALL** of the following criteria?  
   - The patient is 10 years of age or older  
   - Atorvaliq will be used in addition to other LDL-C lowering therapies (e.g., ezetimibe, fenofibrate) OR will be used alone if other LDL-C lowering therapies are unavailable  
   
   If yes, continue to #6.  
   If no, continue to #5.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of primary dysbetalipoproteinemia or hypertriglyceridemia and meet ALL of the following?
   - The patient is 18 years of age or older
   - Atorvaliq will be used in addition to diet

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet ALL of the following criteria?
   - The patient had a trial of or contraindication to generic atorvastatin tablets
   - The patient cannot swallow atorvastatin tablets AND had a trial of rosuvastatin (Ezallor) sprinkle capsule

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

7. Is the patient also requesting a zero-dollar cost share exception (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

   If yes, continue to #8.
   If no, approve for 12 months by GPID or GPI-14 with a quantity limit of #20 mL per day.

8. Is the patient between 40-75 years of age without a history of cardiovascular disease and has NOT used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on the patient's prescription claims profile or medical records?
   - Aspirin/dipyridamole (Aggrenox)
   - Clopidogrel (Plavix)
   - Dipyridamole
   - Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   - Prasugrel (Effient)
   - Praluent Pen
   - Repatha
   - Ticagrelor (Brilinta)
   - Ticlopidine
   - Vorapaxar sulfate (Zontivity)

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #5 mL per day.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ATORVASTATIN (Atorvaliq) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. To reduce the risk of one of the following and you are 18 years of age or older:
      i. Myocardial infarction (MI: heart attack), stroke, revascularization procedures (restoring blood flow to heart and other areas), or angina (chest pain) and you have multiple risk factors for coronary heart disease (CHD: heart arteries get blocked with fats and plaques) but without clinically evident CHD
      ii. MI or stroke and you have type 2 diabetes mellitus (a disorder with high blood sugar) and multiple risk factors for CHD but without clinically evident CHD
      iii. Non-fatal (not deadly) MI, fatal (deadly) or non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure (a type of heart failure), or angina and you have clinically evident CHD
   2. Primary hyperlipidemia (high level of fat in the blood due to genetic causes)
   3. Heterozygous familial hypercholesterolemia (HeFH: a type of inherited high cholesterol)
   4. Homozygous familial hypercholesterolemia (HoFH: a type of inherited high cholesterol)
   5. Primary dysbetalipoproteinemia (a condition leading to increased total cholesterol and triglyceride levels in the blood)
   6. Hypertriglyceridemia (high level of fat in the blood)
B. You had a trial of or contraindication (harmful for) to generic atorvastatin tablets
C. You cannot swallow atorvastatin tablets AND had a trial of rosuvastatin (Ezallor) sprinkle capsule
D. If you have primary hyperlipidemia, approval also requires:
   1. You are 18 years of age or older
   2. Atorvaliq will be used in addition to diet
E. If you have heterozygous familial hypercholesterolemia, approval also requires:
   1. You are 10 years of age or older
   2. Atorvaliq will be used in addition to diet
F. If you have homozygous familial hypercholesterolemia, approval also requires:
   1. You are 10 years of age or older
   2. Atorvaliq will be used in addition to other LDL-C lowering therapies (such as ezetimibe, fenofibrate) OR will be used alone if other LDL-C lowering therapies are unavailable

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

G. If you have dysbetalipoproteinemia or hypertriglyceridemia, approval also requires:
   1. You are 18 years of age or older
   2. Atorvaliq will be used in addition to diet

H. Requests for zero dollar cost share also requires that you are between 40-75 years of age without a history of cardiovascular disease (relating to heart and blood vessels) and you have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:
   1. Aspirin/dipyridamole (Aggrenox)
   2. Clopidogrel (Plavix)
   3. Dipyridamole
   4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   5. Prasugrel (Effient)
   6. Praluent Pen
   7. Repatha
   8. Ticagrelor (Brilinta)
   9. Ticlopidine
   10. Vorapaxar sulfate (Zontivity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Atorvaliq.

REFERENCES
AVACOPAN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVACOPAN</td>
<td>TAVNEOS</td>
<td>47626</td>
<td></td>
<td>GPI-10</td>
<td>(8580551000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or nephrologist
   - The patient is ANCA seropositive (anti-PR3 or anti-MPO)
   - Tavneos will be used as adjunctive therapy in combination with standard therapy including glucocorticoids (e.g., methylprednisolone, prednisone)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named AVACOPAN (Tavneos) requires the following rule(s) be met for approval:
   A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
   B. You are 18 years of age or older
   C. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
   D. You are ANCA seropositive for anti-PR3 or anti-MPO (a type of lab test)
   E. Tavneos will be used as adjunctive (add-on) therapy in combination with standard therapy including glucocorticoids (such as methylprednisolone, prednisone)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
AVACOPAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) AND meet the following criterion?
   • The patient continues to benefit from therapy (e.g., improvement of clinical manifestations, if renal vasculitis - improvement in eGFR and proteinuria values, reduction of corticosteroid dose without disease flares)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named AVACOPAN (Tavneos) requires the following rule(s) be met for renewal:
   A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
   B. You continue to benefit from the medication

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tavneos.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable or metastatic gastrointestinal stromal tumor (GIST) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL), AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #3.

3. Does the patient have a diagnosis of indolent systemic mastocytosis (ISM) AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AVAPRITINIB (Ayvakit) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic gastrointestinal stromal tumor (GIST: a type of digestive tumor that cannot be removed through surgery or has spread to other parts of the body)
   2. Advanced systemic mastocytosis (AdvSM: a type of blood disorder), including aggressive systemic mastocytosis (ASM: a type of blood disorder), systemic mastocytosis with an associated hematological neoplasm (SM-AHN: a type of blood disorder), or mast cell leukemia (MCL: a type of blood cancer)
   3. Indolent systemic mastocytosis (ISM: a type of blood disorder)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

B. **If you have unresectable or metastatic gastrointestinal stromal tumor, approval also requires:**
   1. You are 18 years of age or older
   2. You have a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations (a type of gene mutation)

C. **If you have advanced systemic mastocytosis, approval also requires:**
   1. You are 18 years of age or older

D. **If you have indolent systemic mastocytosis, approval also requires:**
   1. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ayvakit.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 05/20
Client Approval: 06/23
P&T Approval: 07/23
AVATROMBOPAG

Generic | Brand | HICL | GCN | Medi-Span | Exception/Other
---|---|---|---|---|---
AVATROMBOPAG MALEATE | DOPTELET | 44942 | | | 

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of thrombocytopenia and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a hematologist, gastroenterologist, hepatologist, immunologist, surgeon, or endocrinologist
   - The patient has chronic liver disease
   - The patient is scheduled to undergo a procedure 10 to 13 days following the initiation of Doptelet therapy
   - The patient has a platelet count of <50 x 10^9/L measured within the last 30 days
   - The patient is NOT receiving other thrombopoietin receptor agonist therapy (e.g., Promacta)

   If yes, **approve by HICL or GPI-10 for 1 fill with a quantity limit of #15.**
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a hematologist or immunologist
   - The patient had a trial of or contraindication to corticosteroids or immunoglobulins OR had an insufficient response to splenectomy

   If yes, **approve for 2 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
AVATROMBOPAG

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it

Our guideline named AVATROMBOPAG (Doptelet) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   a. Thrombocytopenia (a type of blood disorder)
   b. Chronic immune thrombocytopenia (immune system attacks your blood platelets)
B. If you have thrombocytopenia, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), gastroenterologist (doctor who treats digestive conditions), hepatologist (a type of liver doctor), immunologist (a type of immune system doctor), surgeon, or endocrinologist (a type of hormone doctor)
   3. You have chronic (long-term) liver disease
   4. You are scheduled to undergo a procedure 10 to 13 days after starting Doptelet therapy
   5. You have a platelet (type of blood cell that prevents bleeding) count of less than 50 x 10(9)/L measured within the last 30 days
   6. You are NOT receiving other thrombopoietin receptor agonist therapy such as Promacta
C. If you have chronic immune thrombocytopenia (cITP), approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or immunologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to corticosteroids or immunoglobulins OR you had an insufficient response to splenectomy (surgical removal of spleen did not work)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnosis of thrombocytopenia in chronic liver disease, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) AND meet the following criterion?
   - Patient had a clinical response to therapy as defined by an increase in platelet count to at least 50 x 10^9/L (at least 50,000 per microliter), compared to baseline.

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day. If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named AVATROMBOPAG (Doptelet) requires the following rule(s) be met for renewal:
   A. You have a diagnosis of chronic immune thrombocytopenia (immune system attacks your blood platelets)
   B. You had a clinical response to therapy as defined by an increase in platelet count to at least 50 x 10^9/L (at least 50,000 per microliter), compared to baseline.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Doptelet.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 08/18
Client Approval: 02/22
P&T Approval: 01/22
AXITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXITINIB</td>
<td>INLYTA</td>
<td>38446</td>
<td>GPI</td>
<td>GPI-10</td>
<td>(2133501300)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) and meet ONE of the following criteria?
   - The patient has tried at least ONE systemic therapy for the treatment of RCC [e.g., Nexavar (sorafenib), Torisel (temsirolimus), Sutent (sunitinib), Votrient (pazopanib), or Avastin (bevacizumab) in combination with interferon]
   - Inlyta will be used in combination with avelumab (Bavencio) as a first-line treatment
   - Inlyta will be used in combination with pembrolizumab (Keytruda) as a first-line treatment

If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   - Inlyta 1mg: #6 per day.
   - Inlyta 5mg: #4 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AXITINIB (Inlyta) requires the following rule(s) be met for approval:

A. You have advanced renal cell carcinoma (RCC; type of kidney cancer)
B. You also meet ONE of the following:
   1. You have tried at least ONE systemic therapy (treatment that spreads throughout the body) for the treatment of renal cell carcinoma such as Nexavar (sorafenib), Torisel (temsirolimus), Sutent (sunitinib), Votrient (pazopanib), or Avastin (bevacizumab) in combination with interferon
   2. Inlyta will be used in combination with avelumab (Bavencio) as a first-line treatment
   3. Inlyta will be used in combination with pembrolizumab (Keytruda) as a first-line treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
AXITINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Inlyta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/21
Created: 02/12
Client Approval: 03/21
P&T Approval: 07/20
AZACITIDINE

GUIDELINES FOR USE

1. Does the patient have a diagnosis of acute myeloid leukemia and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy
   • The patient is not able to complete intensive curative therapy

If yes, approve for 12 months for all strengths by GPID or GPI-14 with a quantity limit of #14 per 28 days.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named AZACITIDINE (Onureg) requires the following rule(s) be met for approval:
A. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many white blood cells)
B. You are 18 years of age or older
C. You have achieved first complete remission (CR: signs or symptoms of cancer have disappeared) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy (medications for cancer)
D. You are not able to complete intensive curative therapy (treatment to cure the disease)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Onureg.

REFERENCES
AZTREONAM INHALED

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZTREONAM</td>
<td>CAYSTON</td>
<td></td>
<td>28039</td>
<td>GPI-10</td>
<td>(1614001040)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of cystic fibrosis and meet ALL of the following criteria?
   - The patient is 7 years of age or older
   - The patient has a lung infection with a Gram negative species (such as *Pseudomonas aeruginosa*; not *Staphylococcus aureus* because it is not a Gram negative species)

   If yes, approve for 12 months by GPI-10 for 6 fills of #84 vials per 56 days.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **AZTREONAM INHALED** requires the following rule(s) be met for approval:
   A. You have a diagnosis of cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
   B. You are 7 years of age or older
   C. You have a lung infection with a Gram negative species such as *Pseudomonas aeruginosa*

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cayston.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 07/01/20  
Client Approval: 04/20  
P&T Approval: 05/12  
Created: 05/12  

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>BACLOFEN</td>
<td>OZOBAX, BACLOFEN</td>
<td>64209</td>
<td>GPI-14 (75100010002070)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BACLOFEN</td>
<td>FLEQSUUVY, BACLOFEN</td>
<td>51885</td>
<td>GPI-14 (75100010001825)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BACLOFEN</td>
<td>LYVISPAH</td>
<td>51638 51639 51652</td>
<td>GPI-14 (75100010003010), (75100010003020), (75100010003030)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

1. **Is the request for Ozobax (baclofen) and the patient meets ALL of the following criteria?**
   - The patient had a trial of or contraindication to generic baclofen tablets
   - The patient is unable to swallow generic baclofen tablets

   If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #80mL per day.**
   If no, continue to #2.

2. **Is the request for Fleqsuvy (baclofen) and the patient meets ALL of the following criteria?**
   - The patient had a trial of or contraindication to generic baclofen tablets
   - The patient is unable to swallow generic baclofen tablets

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day.**
   If no, continue to #3.

9. **Is the request for Lyvispah and the patient meets ALL of the following criteria?**
   - The patient had a trial of or contraindication to generic baclofen tablets
   - The patient is unable to swallow generic baclofen tablets

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
   - 5mg: #9 per day.
   - 10mg: #3 per day.
   - 20mg: #4 per day.

   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BACLOFEN (Ozobax, Fleqsuvy, Lyvispah) requires the following rule(s) be met for approval:
A. You have tried or have a contraindication (harmful for) to generic baclofen tablets
B. You are unable to swallow generic baclofen tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ozobax Fleqsuvy, and Lyvispah.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [Note: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #2.

2. Is the request for the treatment of coronavirus disease 2019 (COVID-19) in a hospitalized adult?
   If yes, do not approve. [NOTE: This indication is for hospital use only.]
   DENIAL TEXT: See initial denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient have a diagnosis of severe alopecia areata and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist
   • The patient has had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months
   • The patient is NOT utilizing other systemic biologics for alopecia areata or other JAK inhibitors for any indication (e.g., Xeljanz [tofacitinib], Rinvoq [upadacitinib])
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BARICITINIB (Olumiant) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Severe alopecia areata (a type of hair loss)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), AmJeffita (adalimumab-atto), Cyltezo (adalimumab-adbm)

C. If you have severe alopecia areata, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool) for more than 6 months
   4. You are NOT using other systemic biologics for alopecia areata or other JAK inhibitors for any indication (such as Xeljanz [tofacitinib], Rinoq [upadacitinib])


NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [Note: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of severe alopecia areata and meet ALL of the following criteria?
   - The patient has had improvement while on therapy (e.g., scalp hair coverage)
   - The patient is NOT utilizing other systemic biologics for alopecia areata or other JAK inhibitors for any indication (e.g., Xeljanz [tofacitinib], Rinvoq [upadacitinib])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BARICITINIB (Olumiant) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Severe alopecia areata (a type of hair loss)
B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
   2. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

*(Renewal denial text continued on next page)*
C. If you have severe alopecia areata, renewal also requires:
   1. You have had improvement while on therapy (such as scalp hair coverage)
   2. You are NOT using other systemic biologics for alopecia areata or other JAK inhibitors for any indication (such as Xeljanz [tofacitinib], Rinvoq [upadacitinib])

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Olumiant.

REFERENCES
- Olumiant [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; June 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 06/18
Commercial Effective: 08/28/23  Client Approval: 07/23  P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) (i.e., an isolate of M. tuberculosis that is resistant to at least isoniazid and rifampin) and meet ALL of the following criteria?
   - The patient meets ONE of the following:
     - The patient is 5 to less than 18 years of age AND weighs at least 15kg
     - The patient is 18 years of age or older
   - Sirturo will be used in combination with at least 3 other antibiotics

   If yes, approve for a total of 24 weeks by GPID or GPI-14 as follows:
   - FIRST APPROVAL: Approve for 4 weeks for the requested strength as follows:
     - Sirturo 20mg: #340 per 28 days.
     - Sirturo 100mg: #68 per 28 days.
   - SECOND APPROVAL: Approve for 20 weeks (total fill count 5) for the requested strength as follows:
     - Sirturo 20mg: #120 per 28 days.
     - Sirturo 100mg: #24 per 28 days.
     Please enter a start date of 3 WEEKS AFTER the START date of the first approval.

   If no, continue to #2.

2. Does the patient have a diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) (i.e., an isolate of M. tuberculosis that is resistant to at least isoniazid and rifampin) OR pulmonary extensively drug resistant tuberculosis (XDR-TB) (i.e., an isolate of M. tuberculosis that is resistant to at least isoniazid, rifampin, a fluoroquinolone, and an aminoglycoside) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Sirturo will be used in combination with pretomanid and linezolid

   If yes, approve for a total of 26 weeks for Sirturo 100mg by GPID or GPI-14 as follows:
   - FIRST APPROVAL: Approve for 4 weeks with a quantity limit of #68 per 28 days.
   - SECOND APPROVAL: Approve for 22 weeks (total fill count 6) with a quantity limit of #24 per 28 days. Please enter a start date of 3 WEEKS AFTER the START date of the first approval.

   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **BEDAQUILINE (Sirturo)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pulmonary multi-drug resistant tuberculosis (MDR-TB: tuberculosis bacteria in lungs does not respond to multiple drugs, including at least isoniazid and rifampin)
   2. Pulmonary extensively drug resistant tuberculosis (XDR-TB: tuberculosis bacteria is resistant to at least isoniazid, rifampin, a fluoroquinolone [type of antibiotic], and an aminoglycoside [a type of antibiotic])

B. **If you have pulmonary multi-drug resistant tuberculosis, approval also requires ONE of the following:**
   1. You are 5 years to less than 18 years of age AND weigh at least 15 kg (33 lbs), AND will be using Sirturo in combination with at least 3 other antibiotics
   2. You are 18 years of age, AND will be using Sirturo in combination with at least 3 other antibiotics
   3. You are 18 years of age, AND will be using Sirturo in combination with pretomanid and linezolid

C. **If you have pulmonary extensively drug resistant tuberculosis, approval also requires:**
   1. You are 18 years of age or older
   2. You will be using Sirturo in combination with pretomanid and linezolid

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sirturo.

REFERENCES
BELIMUMAB - SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELIMUMAB</td>
<td>BENLYSTA</td>
<td></td>
<td>43658</td>
<td>GPI-14 (9942201500D520, 9942201500E520)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>43661</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of systemic lupus erythematosus (SLE) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient is currently using corticosteroids, antimalarials, NSAIDs, or immunosuppressives

   If yes, approve for 6 months by GPID or GPI-14 for the requested product with a quantity limit of #4mL per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of lupus nephritis and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist or nephrologist
   • The patient is receiving standard therapy (e.g., steroids, antimalarials, NSAIDs, immunosuppressives)

   If yes, approve for a total of 6 months by GPID or GPI-14 for the requested product as follows:
   **FIRST APPROVAL:**
   • 200mg/mL: Approve for 1 month with a quantity limit of #8mL per 28 days.
   **SECOND APPROVAL:**
   • 200mg/mL: Approve for 5 months with a quantity limit of #4mL per 28 days (Please enter a start date 3 weeks after the start date of the first approval).

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BELIMUMAB - SQ (Benlysta)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Systemic lupus erythematosus (SLE: a type of immune condition)
   2. Lupus nephritis (LN: A type of immune condition that affects the kidneys)

B. **If you have systemic lupus erythematosus, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using corticosteroids, antimalarials (drugs that treat parasites), nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressives (drugs that weaken your immune system)

C. **If you have lupus nephritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
   3. You are receiving standard treatment (such as steroids, antimalarials, nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressives (drugs that weaken your immune system)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of systemic lupus erythematosus (SLE) AND meet the following criterion?
   - The patient has had clinical improvement while on Benlysta

   If yes, **approve for 12 months by G PID or GPI-14 for the requested product with a quantity limit of #4mL per 28 days.**

   If no, continue to #2.

CONTINUED ON NEXT PAGE
BELIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of lupus nephritis AND meet the following criterion?
   - The patient has had clinical improvement in renal response as compared to baseline laboratory values (i.e., eGFR or proteinuria) and/or clinical parameters (e.g., fluid retention, use of rescue drugs, glucocorticoid dose)

   If yes, approve for 12 months by GPID or GPI-14 for the requested product with a quantity limit of #4mL per 28 days.

   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named BELIMUMAB - SQ (Benlysta) requires the following rule(s) be met for renewal:

   A. You have ONE of the following diagnoses:
      1. Systemic lupus erythematosus (SLE: a type of immune condition)
      2. Lupus nephritis (LN: a type of immune condition that affects the kidneys)

   B. If you have systemic lupus erythematosus, renewal also requires:
      1. You have had clinical improvement while on Benlysta

   C. If you have lupus nephritis, renewal also requires:
      1. You have had clinical improvement in renal (kidney) response as compared to baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]), and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid dose)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Benlysta.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic graft-versus-host-disease (cGVHD) and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient had failure of at least two prior lines of systemic therapies

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BELUMOSUDIL (Rezurock) requires the following rule(s) be met for approval:
A. You have chronic graft-versus-host-disease (cGVHD: a long-term type of immune disorder)
B. You are 12 years of age or older
C. You had failure of at least two prior lines of systemic therapies (treatment that spreads throughout the body)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rezurock.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
GUIDELINES FOR USE

1. Does the patient have a diagnosis of von Hippel-Lindau (VHL) disease and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient requires therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET)
   • The patient does NOT require immediate surgery

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **BELZUTIFAN (Welireg)** requires the following rule(s) be met for approval:
   A. You have von Hippel-Lindau (VHL) disease (genetic disorder that causes tumors to grow in the body)
   B. You are 18 years of age or older
   C. You require therapy for associated renal cell carcinoma (RCC: a type of kidney cancer), central nervous system (CNS) hemangioblastomas (tumor in the brain or spinal cord), or pancreatic neuroendocrine tumors (pNET: tumor in the pancreas)
   D. You do NOT require immediate surgery

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Welireg.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - Therapy is prescribed by or in consultation with a physician specializing in pulmonary medicine or allergy medicine
   - The patient has a documented blood eosinophil level of at least 150 cells/mcL within the past 12 months
   - The patient is concurrently treated with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist [e.g., formoterol, salmeterol], long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline, or oral corticosteroid [e.g., prednisone])
   - Fasenra will NOT be used concurrently with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab]) when used for the treatment of asthma

   If yes, continue to #2.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.
INITIAL CRITERIA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?
   - The patient has experienced at least **ONE** asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months
   - The patient has experienced at least **ONE** serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months

   If yes, **approve for a total of 4 months by HICL or GPI-10 as follows:**
   - **FIRST APPROVAL:** approve for 2 months with a quantity limit of #1mL per 28 days.
   - **SECOND APPROVAL:** approve for 2 months with a quantity limit of #1mL per 56 days. (Start date is 1 week before the end of the first approval.)

   If no, continue to #3.

3. Does the patient have poor symptom control despite current therapy as evidenced by at least **THREE** of the following within the past 4 weeks?
   - Daytime asthma symptoms more than twice per week
   - Any night waking due to asthma
   - Use of a short-acting inhaled beta2-agonist reliever (SABA) [e.g., albuterol] for symptoms more than twice a week
   - Any activity limitation due to asthma

   If yes, **approve for a total of 4 months by HICL or GPI-10 as follows:**
   - **FIRST APPROVAL:** approve for 2 months with a quantity limit of #1mL per 28 days.
   - **SECOND APPROVAL:** approve for 2 months with a quantity limit of #1mL per 56 days. (Start date is 1 week before the end of the first approval.)

   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **BENRALIZUMAB (Fasenra)** requires the following rule(s) be met for approval:
A. You have severe asthma with an eosinophilic phenotype (type of lung condition with inflammation)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (lung/breathing) medicine or allergy medicine

*Initial denial text continued on next page*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mL within the past 12 months

E. You are being treated with a medium, high-dose, or a maximally tolerated dose of an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication which includes a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)

F. You meet ONE of the following:
   1. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      a. Daytime asthma symptoms more than twice a week
      b. Any night waking due to asthma
      c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice a week
      d. Any activity limitation due to asthma

G. You will NOT use Fasenra concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab]) when used for the treatment of asthma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient meet ALL of the following criteria?
   • The patient will continue to use an inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist [e.g., formoterol, salmeterol], a long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline, or oral corticosteroid [e.g., prednisone])
   • Fasenra will NOT be used concurrently with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab]) when used for the treatment of asthma

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient shown a clinical response as evidenced by ONE of the following criteria?
   • Reduction in asthma exacerbation from baseline
   • Decreased utilization of rescue medications
   • Increase in percent predicted FEV1 from pretreatment baseline
   • Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 56 days.
   If no, do not approve.
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **BENRALIZUMAB (Fasenra)** requires the following rule(s) be met for renewal:
   A. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, tiotropium, umeclidinium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or an oral corticosteroid (such as prednisone)
RENEWAL CRITERIA (CONTINUED)

B. You will NOT use Fasenra concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab]) when used for the treatment of asthma

C. You have shown a clinical response as evidenced by ONE of the following:
   1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   2. Decreased use of rescue medications (such as albuterol)
   3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Fasenra.

REFERENCES
• Fasenra [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceutical LP.; February 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/23
Created: 02/18
Client Approval: 05/23
P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • The diagnosis of HAE is confirmed via documentation of complement testing
   • Orladeyo is being used for prophylaxis against HAE attacks
   • Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   • The patient is NOT on concurrent treatment with an alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, Cinryze, danazol)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named BEROTRALSTAT (Orladeyo) requires the following rule(s) be met for approval:
   A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
   B. Your diagnosis is confirmed by documented complement testing (a type of blood test)
   C. You are 12 years of age or older
   D. Orladeyo is being used for prevention of hereditary angioedema attacks
   E. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor) or hematologist (blood doctor)
   F. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, Cinryze, danazol)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
   - The patient is NOT on concurrent treatment with an alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, Cinryze, danazol)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named BEROTRALSTAT (Orladeyo) requires the following rule(s) be met for renewal:
   A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
   B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
   C. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, Cinryze, danazol)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orladeyo.

REFERENCES

BETaine

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETaine</td>
<td>CYSTADANE, BETaine</td>
<td>12233</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(3090452000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of homocystinuria (including cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, and cobalamin cofactor metabolism (cbl) defect)?

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #20 grams per day.**
   
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BETaine (Cystadane)** requires the following rule(s) be met for approval:

A. You have homocystinuria (a type of genetic metabolic disorder), including cystathionine beta-synthase (CBS: a type of enzyme) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR: a type of enzyme) deficiency, and cobalamin cofactor metabolism (cbl: vitamin B12 that is required for enzyme activity) defect

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cystadane.

REFERENCES

- Cystadane [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases, Inc.; October 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Class: Commercial: 04/01/23  
Client Approval: 02/23  
P&T Approval: 04/22
GUIDELINES FOR USE

TARGRETIN (BEXAROTENE) CAPSULE

1. Does the patient have a diagnosis of cutaneous T-cell lymphoma (CTCL) AND meet the following criterion?
   The patient is refractory to at least one prior systemic therapy (e.g., gemcitabine, methotrexate, liposomal doxorubicin, bortezomib)

   If yes, approve for 12 months by GPID or GPI-10.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **BEXAROTENE (Targretin capsule)** requires the following rule(s) be met for approval:
   A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer)
   B. You are refractory (resistant) to at least one prior systemic therapy (therapy that spreads through the blood) such as gemcitabine, methotrexate, liposomal doxorubicin, or bortezomib

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

TARGRETIN (BEXAROTENE) GEL

1. Does the patient have a diagnosis of cutaneous T-cell lymphoma (CTCL) (stage IA or IB) and meet ONE of the following criteria?
   • The patient has refractory or persistent disease after other therapies
   • The patient has not tolerated other therapies

   If yes, approve for 12 months by GPID or GPI-10.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BEXAROTENE (Targretin gel) requires the following rule(s) to be met for approval:
A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer) (stage IA or IB)
B. You meet ONE of the following:
   1. You have refractory (resistant) or persistent disease after other therapies
   2. You have not tolerated other therapies

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Targretin.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet ALL of the following criteria?
   • The patient has BRAF V600E or V600K mutation as detected by an FDA-approved test
   • The medication will be used in combination with Braftovi (encorafenib)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named BINIMETINIB (Mektovi) requires the following rule(s) be met for approval:
   A. You have a diagnosis of unresectable (cannot completely remove by surgery) or metastatic (disease that has spread) melanoma (skin cancer)
   B. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by a Food and Drug Administration-approved test
   C. The medication will be used in combination with Braftovi (encorafenib)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mektovi.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1) and meet ALL of the following criteria?
   - The patient is 3 years of age or older
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   1. The patient does not have idiopathic pulmonary fibrosis (IPF)
   2. Tracleer (bosentan) will NOT be used concurrently with cyclosporine A or glyburide

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does that patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) of greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) of greater than 2 Wood units

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   - 62.5mg tablet: #2 per day.
   - 125mg tablet: #2 per day.
   - 32mg tablet for suspension: #4 per day.

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1: a way to classify the severity of disease)

B. You are 3 years of age and older

C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)

D. You do not have idiopathic pulmonary fibrosis (scarring of the lungs for an unknown reason)

E. Tracleer (bosentan) will NOT be used concurrently (at the same time) with cyclosporine A or glyburide

F. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:

1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1)?
   
   If yes, continue to #2.
   If no, do not approve.
   
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient using Tracleer (bosentan) concurrently with cyclosporine A or glyburide?
   
   If yes, do not approve.
   
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Is the patient between the ages of 3 and 17 years old and meets ONE of the following criteria?
   • The patient has demonstrated an improvement in pulmonary vascular resistance (PVR)
   • The patient has remained stable or shown improvement in exercise ability (e.g., 6-minute walk test, World Health Organization [WHO] functional class symptoms)

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • 62.5mg tablet: #2 per day.
   • 125mg tablet: #2 per day.
   • 32mg tablet for suspension: #4 per day.

   If no, continue to #4.

4. Is the patient 18 years of age or older and meets ONE of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient remains stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • 62.5mg tablet: #2 per day.
   • 125mg tablet: #2 per day.
   • 32mg tablet for suspension: #4 per day.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
BOSENTAN

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BOSENTAN (Tracleer) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1: a way to classify the severity of disease)
B. Tracleer (bosentan) will NOT be used concurrently (at the same time) with cyclosporine A or glyburide
C. If you are 3 to 17 years of age, renewal also requires ONE of the following:
1. You have demonstrated an improvement in pulmonary vascular resistance (a type of measurement for pulmonary arterial hypertension)
2. You have remained stable or shown improvement in exercise ability (such as the 6-minute walk test, World Health Organization [WHO] functional class symptoms) [way to classify how limited you are during physical activity]
D. If you are 18 years of age or older, renewal requires ONE of the following:
1. You have shown improvement from baseline in the 6-minute walk distance test
2. You remain stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tracleer.

REFERENCES
BOSUTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOSUTINIB</td>
<td>BOSULIF</td>
<td>39590</td>
<td>GPI-10 (2153181200)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a newly diagnosed, chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   - Bosulif 500mg: #1 per day.
   - Bosulif 400mg: #1 per day.
   - Bosulif 100mg: #3 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient previously tried or has a contraindication to other tyrosine kinase inhibitors [e.g., Gleevec (imatinib), Sprycel (dasatinib), Tasigna (nilotinib)]
   - The patient had a mutational analysis prior to initiation AND Bosulif is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile
     (Please see header CML-5 of the current NCCN guidelines)

   If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   - Bosulif 500mg: #1 per day.
   - Bosulif 400mg: #1 per day.
   - Bosulif 100mg: #3 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BOSUTINIB (Bosulif) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Newly diagnosed, chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML; a type of blood cancer)
   2. Chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia
B. You are 18 years of age or older

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

C. If you have chronic, accelerated, or blast phase Philadelphia chromosome-positive, approval also requires:
   1. You have previously tried or have a contraindication to (a medical reason why you cannot use) other tyrosine kinase inhibitors such as Gleevec (imatinib), Sprycel (dasatinib), Tasigna (nilotinib)
   2. You had a mutational analysis prior to initiation of therapy AND Bosulif is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Bosulif.

REFERENCES
## BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD PICOSULF/MAG OX/CITRIC AC</td>
<td>PREPOPIK, CLENPIQ</td>
<td>24291</td>
<td>4699200345</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BISACODYL/PEG/ELECTROLYTES</td>
<td>PEG-PREP</td>
<td>33281</td>
<td>4699200520</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG3350/SOD SULF,BICARB,CL/KCL</td>
<td>GAVILYTE-C, GAVILYTE-G, GOLYTELY COLYTE WITH FLAVOR PACKS, PEG 3350-ELECTROLYTES</td>
<td>34667</td>
<td>4699200530</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE/NAHCO3/KCL/PE</td>
<td>NULYTELY, GAVILYTE-N, PEG 3350-ELECTROLYTE</td>
<td>07981</td>
<td>4699200430</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG3350-SOD SUL-NACL-KCL-ASB-C</td>
<td>MOVIPREP, PLENVU, PEG3350-SOD SUL-NACL-KCL-ASB-C</td>
<td>34026</td>
<td>4699200630</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEG 3350/SOD SULF, CHLR/POT/MAG</td>
<td>SUFLAVE</td>
<td>49038</td>
<td>4699200538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM, POTASSIUM, MAG SULFATES</td>
<td>SUPREP</td>
<td>37152</td>
<td>4699200360</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOD SULF/POT CHLORIDE/MAG SULF</td>
<td>SUTAB</td>
<td>46967</td>
<td>4699200358</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOD PHOSPHATE MBAS/SOD PHOS,DI</td>
<td>OSMOPREP</td>
<td>21886</td>
<td>4610990212</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested bowel preparation agent **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

   - If yes, continue to #2.
   - If no, guideline does not apply.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?
   
   If yes, guideline does not apply.
   If no, continue to #3.

3. Does the patient meet ALL of the following criteria?
   • The patient is between 45 to 75 years of age
   • The request is for colorectal cancer screening

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for a generic agent?

   If yes, **approve for 12 months for the requested agent by HICL or GPI-10 at zero copay as follows:**
   If no fills in the past 365 days: Approve for 2 fills.
   If 2 or more fills in the past 365 days: Approve for 1 fill.

   If no, continue to #5.

5. Is the request for ONE of the following?
   • A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   • A multi-source brand (MSB) agent

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet **ONE** of the following criteria?
   - Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
   - The patient has tried or has a documented medical contraindication to **TWO** preferred medications (one if only one agent is available)
   - The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include additional follow-up colonoscopy required after a positive/abnormal screening test)

If yes, approve for 12 months for the requested agent by HICL or GPI-10 at zero copay as follows:
   - If **no** fills in the past 365 days: Approve for 2 fills.
   - If **2 or more** fills in the past 365 days: Approve for 1 fill.

**APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

**DENIAL TEXT:** Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for **ONE** of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. You are **45 to 75** years of age

C. The request is for colorectal cancer screening

D. **If the request is for a single-source brand or multi-source brand agent,** approval also requires you meet **ONE** of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to **TWO** preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include additional follow-up colonoscopy required after a positive/abnormal screening test)

*(Denial text continued on the next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for bowel preparation for colonoscopy agents listed.

This guideline applies to plans where the pharmacy benefit allows for coverage of bowel preparation for colonoscopy medications (used for colorectal cancer screening) at zero copay. The override criteria allow patient access to all FDA-approved bowel preparation for colonoscopy medications (if used for colorectal cancer screening) at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/14/23
Client Approval: 07/23
P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested AND does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?
   
   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the patient using the requested medication for prevention (risk reduction) of breast cancer AND meets the following criterion?
   - The patient is 35 years of age or older
   
   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Is the request for a generic agent?
   
   If yes, approve the requested agent for 12 months at zero copay as follows:
   • Anastrozole: Approve by HICL or GPI-10 with a quantity limit of #1 per day.
   • Exemestane: Approve by HICL or GPI-10 with a quantity limit of #1 per day.
   • Raloxifene: Approve by HICL or GPI-10 with no quantity limit.
   • Tamoxifen 10mg and 20mg: Approve both by GPID or GPI-14 (no quantity limit).
   
   If no, continue to #5.

CONTINUED ON NEXT PAGE
5. Is the request for **ONE** of the following?
   - A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   - A multi-source brand (MSB) agent

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?
   - Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
   - The patient has tried or has a documented medical contraindication to **TWO** preferred medications (one if only one agent is available)
   - The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may severity of side effects and ability to adhere to the appropriate use of the item or service)

   If yes, approve the requested agent for 12 months at zero copay as follows:
   - **Arimidex** (anastrozole): Approve by HICL with a quantity limit of **#1 per day**.
   - **Aromasin** (exemestane): Approve by HICL with a quantity limit of **#1 per day**.
   - **Evista** (raloxifene): Approve by HICL with no quantity limit.
   - **Tamoxifen** 10mg and 20mg: Approve by GPI or GPI-14 (no quantity limit).

   **APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:
A. The request is for **ONE** of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

   **(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

B. The requested medication is being used for prevention (risk reduction) of breast cancer
C. You are 35 years of age or older
D. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of medications for breast cancer prevention at zero copay. The override criteria allow patient access to all FDA-approved medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is Vyleesi (bremelanotide) a covered benefit?
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by ALL of the following criteria?
   • Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   • HSDD is NOT a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   • HSDD symptom causes marked distress or interpersonal difficulty

   If yes, continue to #3.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Does the patient meet ALL of the following criteria?
   • The patient is a premenopausal female
   • The patient is 18 years of age or older
   • The patient had a previous trial of or contraindication to bupropion
   • The patient is NOT currently using Addyi (fibanserin)

   If yes, approve for 8 weeks by HICL or GPI-10 with a quantity limit of #2.4mL per month.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BREMELANOTIDE (Vyleesi) requires the following rule(s) be met for approval:
A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder where you do not desire sexual activity), as defined by ALL of the following:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. HSDD is NOT a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
   3. HSDD symptom causes marked distress or interpersonal difficulty
B. You are a premenopausal female
C. You are 18 years of age or older
D. You had a previous trial of bupropion, unless there is a medical reason why you cannot (contraindication)
E. You are NOT currently using Addyi (flibanserin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by ALL of the following criteria?
   • Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   • HSDD is NOT a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   • HSDD symptom causes marked distress or interpersonal difficulty

   If yes, continue to #2.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet ALL of the following criteria?
   • The patient is a premenopausal female
   • The patient is NOT currently using Addyi (flibanserin)
   • The patient has demonstrated continued improvement in symptoms of HSDD/FSIAD (e.g., increased sexual desire, lessened distress)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2.4mL per month.**
If no, do not approve.

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BREMELANOTIDE (Vyleesi)** requires the following rule(s) be met for approval:

A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder [FSIAD] where you do not desire sexual activity), as defined by ALL of the following:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. HSDD is NOT a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
   3. HSDD symptom causes marked distress or interpersonal difficulty

B. You are a premenopausal female

C. You are NOT currently using Addyi (flibanserin)

D. You have experienced continued improvement in symptoms of HSDD/FSIAD such as increased sexual desire, lessened distress)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
### BREMELANOTIDE

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vyleesi.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 08/19
Client Approval: 04/20
P&T Approval: 07/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is positive for anaplastic lymphoma kinase (ALK) fusion oncogene as detected by an FDA-approved test

   If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   • Alunbrig 30mg: #120 per 30 days.
   • Alunbrig 90mg: #30 per 30 days.
   • Alunbrig 180mg: #30 per 30 days.
   • Alunbrig 90mg-180mg initiation pack: #30 per 30 days.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named BRIGATINIB (Alunbrig) requires the following rule(s) be met for approval:
   A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   B. You are 18 years of age or older
   C. You are positive for anaplastic lymphoma kinase (ALK) fusion oncogene (a type of gene mutation that causes a change in your DNA) as detected by a Food and Drug Administration (FDA)-approved test

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Alunbrig.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   - The patient has been counseled on and expresses understanding of the risk of suicidal ideation and behavior
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, approve for 6 months by entering TWO approvals by HICL or GPI-10 as follows:
   - FIRST APPROVAL: approve for 1 month with a quantity limit of #6mL.
   - SECOND APPROVAL: approve for 5 months with a quantity limit of #3mL per 28 days (Enter a start date that is 5 weeks AFTER the START date of the first approval).

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
BRODALUMAB

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BRODALUMAB (Siliq) requires the following rule(s) be met for approval:
A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
E. You had a trial of or contraindication (harmful for) to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
F. You have been counseled on and express an understanding of the risk of suicidal thoughts and behavior
G. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
BRODALUMAB RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
   - The patient has NOT developed or reported worsening depressive symptoms or suicidal ideation and behaviors
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3mL per 28 days.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BRODALUMAB (Siliq) requires the following rule(s) be met for renewal:
A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
B. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
C. You have NOT developed or reported worsening depressive symptoms or suicidal thoughts and behaviors while on treatment with Siliq (brodalumab)
D. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
BRODALUMAB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Siliq.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A        Created: 01/17
Commercial Effective: 08/28/23  Client Approval: 07/23  P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of mild to moderate active Crohn's Disease and meet ALL of the following criteria?
   - The patient is 8 years of age or older
   - The patient had a trial of generic budesonide 3mg capsules OR the patient cannot tolerate the pill burden associated with the generic product

   If yes, **approve for 6 months for all strengths by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of mild to moderate Crohn's Disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The requested medication is being used for the maintenance of clinical remission
   - The patient had a trial of generic budesonide 3mg capsules OR the patient cannot tolerate the pill burden associated with the generic product

   If yes, **approve for 6 months for all strengths by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **BUDESONIDE - ORTIKOS** requires the following rule(s) be met for approval:

A. You have mild to moderate Crohn’s Disease (a type of bowel disorder)
B. **If you have mild to moderate active Crohn's Disease, approval also requires:**
   1. You are 8 years of age or older
   2. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

**Denial text continued on the next page**

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If you have mild to moderate Crohn’s Disease, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication is being used for the maintenance of clinical remission (signs and symptoms of disease have either improved or disappeared)
   3. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ortikos.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 11/20
Commercial Effective: 01/17/22 Client Approval: 01/22
P&T Approval: 10/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a nephrologist
   • The patient's diagnosis is confirmed by a renal biopsy
   • The patient is currently on an ACE inhibitor (e.g., benazepril, lisinopril) or an ARB (e.g., losartan, valsartan) at maximum tolerated dose for at least three months OR has a contraindication to both
   • The patient has a progressively declining glomerular filtration rate (GFR) and/or worsening proteinuria (e.g., >1 gram protein/24-hour urine collection or UPCR [urine protein to creatinine ratio] ≥1 g/g)
   • The patient had a trial of or contraindication to one generic systemic corticosteroid therapy (e.g., oral prednisone, oral prednisolone)

If yes, approve for 9 months by GPIID or GPI-14 with a quantity limit of #4 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named BUDESONIDE - TARPEYO requires the following rule(s) be met for approval:
A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
D. Your diagnosis is confirmed by a renal biopsy (removal of cells or tissue from the kidney for examination)
E. You are currently on an angiotensin converting enzyme inhibitor (ACE-I: a type of drug used to protect kidneys such as benazepril, lisinopril, etc.) or an angiotensin receptor blocker (ARB: a type of drug used to protect kidneys such as losartan, valsartan, etc.) at maximum tolerated dose for at least three months OR have a contraindication (harmful for) to both

(Initial denial text continued on the next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

F. You have a progressively declining glomerular filtration rate (GFR: a tool for evaluating kidney function) and/or worsening proteinuria (such as greater than 1 gram protein in a 24-hour urine collection or greater than or equal to 1g/g urine protein to creatinine ratio [UPCR: test that measures the amount of protein in urine])

G. You had a trial of or contraindication to one generic systemic corticosteroid therapy (such as oral prednisone, oral prednisolone)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet ONE of the following criteria?
   • The patient has improved, or stable kidney function compared to baseline
   • The patient has had a reduction in proteinuria

   If yes, approve for 9 months by GPID or GPI-14 with a quantity limit of #4 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named BUDESONIDE - TARPEYO requires the following rule(s) be met for renewal:
   A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
   B. You have improved, or stable kidney function compared to baseline OR a reduction in proteinuria

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tarpeyo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 01/22
Commercial Effective: 01/17/22  Client Approval: 01/22  P&T Approval: 07/21
C1 ESTERASE INHIBITOR - BERINERT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1 ESTERASE INHIBITOR</td>
<td>BERINERT</td>
<td>18568</td>
<td>GPI-10 (8580202200)</td>
<td>FDB &amp; MEDI-SPAN: BRAND = BERINERT</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   - The patient’s diagnosis of HAE is confirmed via complement testing
   - Berinert is being used for acute attacks of hereditary angioedema
   - Berinert will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Ruconest, Firazyr, Kalbitor)

If yes, approve for 12 months by NDC.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named C1 ESTERASE INHIBITOR - BERINERT requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
C. Your diagnosis is confirmed by complement testing (a type of lab test)
D. Berinert is being used for acute (short term) attacks of hereditary angioedema
E. You will NOT be using Berinert concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Ruconest, Firazyr, Kalbitor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) AND meet the following criterion?
   • Berinert will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Ruconest, Firazyr, Kalbitor)

   If yes, approve for 12 months by NDC.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named C1 ESTERASE INHIBITOR - BERINERT requires the following rule(s) be met for renewal:
   A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
   B. You will NOT be using Berinert concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Ruconest, Firazyr, Kalbitor)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Berinert.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A    Created: 04/09
Commercial Effective: 11/01/22    Client Approval: 10/22    P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   - The patient's diagnosis of HAE is confirmed via documentation of complement testing
   - Cinryze is being used for prophylaxis against HAE attacks
   - Cinryze is NOT being used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, danazol)

If yes, approve for 12 months for all NDCs with a quantity limit of #40 vials per 28 days.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named C1 ESTERASE INHIBITOR - CINRYZE requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 6 years of age or older
C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
D. Your diagnosis is confirmed by documented complement testing (a type of lab test)
E. Cinryze is being used for prevention of hereditary angioedema attacks
F. You will not be using Cinryze concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, danazol)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
   - Cinryze will NOT be used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Haegarda, danazol)

If yes, approve for 12 months by NDC with a quantity limit of #40 vials per 28 days.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named C1 ESTERASE INHIBITOR - CINRYZE requires the following rule(s) be met for renewal:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
C. You will NOT be using Cinryze concurrently (at the same time) with alternative prophylactic (preventive) agent for HAE (such as Takhzyro, Haegarda, danazol)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cinryze.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 10/22
Client Approval: 10/22
P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet **ALL** of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   - The patient's diagnosis of HAE is confirmed via documentation of complement testing
   - Haegarda is being used for prophylaxis against HAE attacks
   - Haegarda will NOT be used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Cinryze, danazol)

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **C1 ESTERASE INHIBITOR - HAEGARDA** requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 6 years of age or older
C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
D. Your diagnosis of HAE is confirmed by documented complement testing (a type of lab test)
E. Haegarda is being used for prevention of hereditary angioedema attacks
F. You will not be using Haegarda concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Cinryze, danazol)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
   - Haegarda will NOT be used concurrently with alternative prophylactic agent for HAE (e.g., Takhzyro, Cinryze, danazol)

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named C1 ESTERASE INHIBITOR - HAEGARDA requires the following rule(s) be met for renewal:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
C. You will NOT be using Haegarda concurrently (at the same time) with alternative prophylactic (preventive) agent for HAE (such as Takhzyro, Cinryze, danazol)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Haegarda.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   - The patient's diagnosis of HAE is confirmed via complement testing
   - Ruconest is being used for acute attacks of hereditary angioedema
   - Ruconest will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Berinert, Firazyr, Kalbitor)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #8 vials per fill.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named C1 ESTERASE INHIBITOR - RUCONEST requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
C. Your diagnosis is confirmed by complement testing (a type of lab test)
D. Ruconest is being used for acute (short term) attacks of hereditary angioedema
E. You will NOT be using Ruconest concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Berinert, Firazyr, Kalbitor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) AND meet the following criterion?
   • Ruconest will NOT be used concurrently with alternative acute treatment for HAE attacks (e.g., Berinert, Firazyr, Kalbitor)

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #8 vials per fill.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **C1 ESTERASE INHIBITOR - RUCONEST** requires the following rule(s) be met for renewal:
   A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
   B. You will NOT be using Ruconest concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Berinert, Firazyr, Kalbitor)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ruconest.

REFERENCES
• Ruconest [Prescribing Information]. Raleigh, NC: Salix Pharmaceuticals; December 2019.
** Please use the criteria for the specific drug requested **

GUIDELINES FOR USE

COMETRIQ

1. Does the patient have a diagnosis of progressive, metastatic medullary thyroid cancer (MTC)?

   If yes, approve for 12 months by G PID or GPI-14 with a quantity limit of #112 per 28 days for the requested daily dose pack. (NOTE: Cometriq is available in three dosage packs each containing 7 days supply)
   - Cometriq 140mg daily dose pack.
   - Cometriq 100mg daily dose pack.
   - Cometriq 60mg daily dose pack.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CABOZANTINIB S-MALATE (Cometriq) requires the following rule be met for approval:
   A. You have progressive, metastatic medullary thyroid cancer (type of thyroid cancer that has spread)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
CABOMETYX

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) and meet ONE of the following criteria?
   - Cabometyx will be used as a single agent
   - Cabometyx will be used in combination with Opdivo (nivolumab) as first-line treatment (no prior treatment for advanced RCC)

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   - Cabometyx 60mg: #1 per day.
   - Cabometyx 40mg: #2 per day.
   - Cabometyx 20mg: #1 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of hepatocellular carcinoma (HCC) AND meet the following criterion?
   - The patient has previously been treated with Nexavar (sorafenib)

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   - Cabometyx 60mg: #1 per day.
   - Cabometyx 40mg: #2 per day.
   - Cabometyx 20mg: #1 per day.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE - CABOMETYX (CONTINUED)

3. Does the patient have a diagnosis of locally advanced or metastatic differentiated thyroid cancer (DTC) and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • The patient has disease progression following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy
   • The patient is radioactive iodine-refractory or ineligible

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   • Cabometyx 60mg: #1 per day.
   • Cabometyx 40mg: #2 per day.
   • Cabometyx 20mg: #1 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CABOZANTINIB S-MALATE (Cabometyx) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   2. Hepatocellular carcinoma (HCC: type of liver cancer)
   3. Locally advanced or metastatic differentiated thyroid cancer (DTC: type of thyroid cancer)

B. If you have advanced renal cell carcinoma, approval also requires ONE of the following:
   1. Cabometyx will be used as a single agent (used alone)
   2. Cabometyx will be used in combination with Opdivo (nivolumab) as first-line treatment (You have not received prior treatment for advanced renal cell carcinoma)

C. If you have hepatocellular carcinoma, approval also requires:
   1. You have previously been treated with Nexavar (sorafenib)

D. If you have locally advanced or metastatic differentiated thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. You have disease progression (disease has gotten worse) following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy (a type of cancer therapy)
   3. You are radioactive iodine-refractory (resistant to) or ineligible

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CABOZANTINIB S-MALATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cometriq or Cabometyx.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/04/21
Created: 01/13
Client Approval: 09/21
P&T Approval: 10/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Stage III colon cancer AND meet the following criterion?
   • The requested medication will be used as adjuvant treatment

   If yes, approve for 12 months by HICL or GPI-10 for 8 fills.
   If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced rectal cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication will be used as perioperative treatment
   • The requested medication will be used as part of chemoradiotherapy

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #3.

3. Does the patient have a diagnosis of unresectable or metastatic colorectal cancer?

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #4.

4. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ONE of the following criteria?
   • The requested medication will be used as a single agent, if an anthracycline- or taxane-containing chemotherapy is not indicated
   • The requested medication will be used in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #5.

5. Does the patient have a diagnosis of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication will be used as part of a combination chemotherapy regimen

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #6.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

6. Does the patient have a diagnosis of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has not received prior treatment for metastatic disease
   • The requested medication will be used as part of a combination regimen

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, continue to #7.

7. Does the patient have a diagnosis of pancreatic adenocarcinoma and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication will be used as adjuvant treatment
   • The requested medication will be used as part of a combination chemotherapy regimen

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CAPECITABINE (Xeloda)** requires the following rule(s) to be met for approval:

A. You have ONE of the following diagnoses:
   1. Stage III colon cancer (colon cancer that has spread to lymph nodes)
   2. Locally advanced rectal cancer (cancer that has spread from where it started to nearby tissue or lymph nodes)
   3. Unresectable (unable to remove by surgery) or metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)
   4. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   5. Unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer (a type of digestive system cancer that has spread to other parts of the body)
   6. HER2 (a type of protein)-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
   7. Pancreatic adenocarcinoma (a type of cancer of the pancreas)

B. **If you have Stage III colon cancer, approval also requires:**
   1. The requested medication will be used as adjuvant (add-on) treatment

   *Denial text continued on next page*

**CONTINUED ON NEXT PAGE**
CAPECITABINE

GUIDELINES FOR USE (CONTINUED)

C. If you have locally advanced rectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as perioperative (the time period before and after surgery) treatment
   3. The requested medication will be used as part of chemoradiotherapy (a type of cancer treatment)

D. If you have advanced or metastatic breast cancer, approval also requires ONE of the following:
   1. The requested medication will be used as a single agent (used alone), if an anthracycline (such as doxorubicin, daunorubicin)- or taxane (such as paclitaxel, docetaxel)-containing chemotherapy is not indicated
   2. The requested medication will be used in combination with docetaxel after disease progression (worsens) on prior anthracycline (such as doxorubicin, daunorubicin)-containing chemotherapy

E. If you have unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as part of a combination chemotherapy (drugs used to treat cancer) regimen

F. If you have HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You have not received prior treatment for metastatic disease
   3. The requested medication will be used as part of a combination regimen (such as with cisplatin, trastuzumab)

G. If you have pancreatic adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as adjuvant (add-on) treatment
   3. The requested medication will be used as part of a combination chemotherapy regimen (such as with gemcitabine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CAPECITABINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xeloda.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/23/23
Created: 02/13
Client Approval: 01/23
P&T Approval: 01/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a hematologist

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient experienced more than two recurrences of aTTP, while on Cablivi therapy (i.e., new drop in platelet count requiring repeat plasma exchange during 30 days post-plasma exchange therapy [PEX] and up to 28 days of extended therapy)?

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   If no, continue to #3.

3. Is the request for continuation of Cablivi therapy from inpatient (hospital) setting AND the patient meets the following criterion?
   • Cablivi was previously initiated as part of the FDA approved treatment regimen in combination with plasma exchange and immunosuppressive therapy within the inpatient setting

   If yes, approve for 1 month by HICL or GPI-10 for a maximum quantity of #30 vials.
   If no, continue to #4.

4. Is the request for continuation of Cablivi therapy from the initial 30 days treatment course (e.g., no break in therapy) and the patient meets ALL of the following criteria?
   • The patient is receiving immunosuppressive therapy
   • The patient is experiencing signs of persistent underlying disease (e.g., suppressed ADAMTS13 [a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13] activity level remain present)

   If yes, approve for 1 month by HICL or GPI-10 for a maximum quantity of #28 vials.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it*

Our guideline named **CAPLACIZUMAB-YHDP (Cablivi)** requires the following rule(s) be met for approval:

A. You have a diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP- a type of blood disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist)
D. You have NOT experienced more than two recurrences of acquired thrombotic thrombocytopenia purpura, while on Cablivi therapy. For example there’s a new drop in platelet count requiring repeat plasma exchange during 30 days post-plasma exchange therapy (process of replacing a liquid part of the blood) and up to 28 days of extended therapy
E. You also meet ONE of the following:
   1. Your request is for continuation of Cablivi therapy from inpatient (hospital) setting and you previously received plasma exchange and immunosuppressive therapy (treatment that weakens your immune system) within the inpatient setting
   2. Your request is for continuation of Cablivi therapy from the initial 30 days treatment course (no break in therapy) AND:
      a. You are receiving immunosuppressive therapy, and
      b. You are experiencing signs of persistent underlying disease (such as suppressed ADAMTS13 [a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13: type of blood clot disorder] activity level remain present)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cablivi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/19
Commercial Effective: 11/21/22  Client Approval: 11/22  P&T Approval: 04/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CAPMATINIB (Tabrecta) requires the following rule(s) be met for approval:
   A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   B. You are 18 years of age or older
   C. Your tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (an abnormal change in a gene that makes MET protein) as detected by an FDA-approved test

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tabrecta.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have neuropathic pain associated with ONE of the following conditions?
   - Postherpetic neuralgia (PHN)
   - Diabetic peripheral neuropathy (DPN) of the feet

   If yes, approve for 12 months by HICL or GPI-10 for 4 fills with a quantity limit of up to #4 patches per fill (maximum dose is 4 patches every 3 months).

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CAPSAICIN (Qutenza) requires the following rule be met for approval:

A. You have a diagnosis of neuropathic pain associated with ONE of the following conditions:
   - Postherpetic neuralgia (PHN) (painful condition that affects the nerve fibers and skin after having shingles)
   - Diabetic peripheral neuropathy (DPN) of the feet (numbness of the feet that is caused by diabetes)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Qutenza.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/24/20
Created: 05/10
Client Approval: 07/20
P&T Approval: 10/20
# CARBIDOPA-LEVODOPA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBIDOPA/LEVODOPA</td>
<td>DUOPA</td>
<td>37829</td>
<td>GPI-14</td>
<td>(73209902101820)</td>
<td></td>
</tr>
</tbody>
</table>

## GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced Parkinson’s disease?

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #100mL per day.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CARBIDOPA-LEVODOPA (Duopa) requires the following rule be met for approval:
   A. You have a diagnosis of advanced Parkinson's disease (nerve system disorder that affects movement)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

## RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Duopa.

## REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 05/15
Client Approval: 04/20
P&T Approval: 05/15
CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID</td>
<td>PLENITY</td>
<td>47522</td>
<td>GPI-10 (6120990306)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the request for weight management and the patient meets **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a body mass index (BMI) of 25 to 40 kg/m(2)
   - The requested medication will be used in conjunction with diet and exercise

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #168 per 28 days. If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID** (Plenity) requires the following rule(s) be met for approval:
   A. The request is for weight management
   B. You are 18 years of age or older
   C. You have a body mass index (BMI) of 25 to 40 kg/m(2)
   D. The requested medication will be used in conjunction (together) with diet and exercise

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Plenity.

REFERENCES

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of acute or chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency AND meet the following criterion?
   • NAGS gene mutation is confirmed by biochemical or genetic testing
     If yes, continue to #2.
     If no, continue to #4.

2. Is the request for generic carglumic acid?
   If yes, approve carglumic acid (generic only) by HICL or GPI-10 as follows:
   Acute HA due to NAGS deficiency: approve for 7 days.
   Chronic HA due to NAGS deficiency: approve for 6 months.
   If no, continue to #3.

3. Is the request for brand Carbaglu AND the patient meets the following criterion?
   • The patient had a trial of generic carglumic acid
     If yes, approve by HICL or GPI-10 as follows:
     Acute HA due to NAGS deficiency: approve for 7 days.
     Chronic HA due to NAGS deficiency: approve for 6 months.
     If no, do not approve.
     DENIAL TEXT: See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of acute hyperammonemia (HA) due to propionic acidemia (PA) AND meet following criterion?
   • The diagnosis is confirmed by the presence of elevated methylcitric acid and normal methylmalonic acid OR genetic testing confirming mutation in the PCCA or PCCB gene
     If yes, approve for 7 days by HICL or GPI-10.
     If no, continue to #5.
     DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of acute hyperammonemia (HA) due to methylmalonic acidemia (MMA) AND meet following criterion?
   - The diagnosis is confirmed by the presence of elevated methylmalonic acid, methylcitric acid OR genetic testing confirming mutation in the MMUT, MMA, MMAB or MMADHC genes

If yes, approve for 7 days by HICL or GPI-10.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CARGLUMIC ACID (Carbaglu) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Acute or chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency (short-term or long-term high ammonia blood levels due to a genetic disorder)
   2. Acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (short-term high ammonia blood levels due to a genetic disorder)

B. If you have acute or chronic hyperammonemia due to N-acetylglutamate synthase deficiency, approval also requires:
   1. Your N-acetylglutamate synthase gene mutation is confirmed by biochemical or genetic testing (types of lab test)
   2. Requests for brand Carbaglu requires a trial of generic carglumic acid

C. If you have acute hyperammonemia due to propionic acidemia, approval also requires:
   1. Your diagnosis is confirmed by the presence of elevated methylcitric acid and normal methylmalonic acid (substances that indicate presence of a disease) OR genetic testing confirming mutation in the PCCA or PCCB gene (types of abnormal genes)

D. If you have acute hyperammonemia due to methylmalonic acidemia, approval also requires:
   1. Your diagnosis is confirmed by the presence of elevated methylmalonic acid, methylcitric acid OR genetic testing confirming mutation in the MMUT, MMA, MMAB or MMADHC genes (types of abnormal genes)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CARGLUMIC ACID

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of acute hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency or acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency AND meet the following criterion?
   • The patient has clinical improvement or improved plasma (blood) ammonia levels

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CARGLUMIC ACID (Carbaglu) requires the following rule(s) be met for renewal:
   A. You have chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) (long-term high ammonia blood levels due to a genetic disorder)
   B. You have clinical improvement or improved plasma (blood) ammonia levels

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Carbaglu.

REFERENCES

• Carbaglu [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases, Inc.; August 2021.
GUIDELINES FOR USE

1. Is the request for the acute treatment of migraine and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of generic celecoxib AND OTC or generic aspirin, diclofenac, ibuprofen, or naproxen
   - The patient is unable to swallow pills (e.g., tablets or capsules)

If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #38.4 mL per 30 days.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CELECOXIB (Elyxyb) requires the following rule(s) be met for approval:
A. The request is for the acute (quick onset) treatment of migraines
B. You are 18 years of age or older
C. You had a trial of generic celecoxib AND over-the-counter (OTC) or generic aspirin, diclofenac, ibuprofen, or naproxen
D. You are unable to swallow pills (such as tablets or capsules)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Elyxyb.

REFERENCES
CENEGERMIN-BKBJ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CENEGERMIN-BKBJ</td>
<td>OXERVATE</td>
<td>45258</td>
<td></td>
<td>GPI-10</td>
<td>(8677002020)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of neurotrophic keratitis (NK) and meet ALL of the following criteria?
   - Therapy is prescribed by or given in consultation with an ophthalmologist
   - The patient has a medical history supportive of causative etiology for trigeminal nerve damage (e.g., herpes zoster infection, multiple sclerosis, diabetes, ocular surgical damage)
   - The patient has loss of corneal sensitivity, corneal epithelium changes, and/or loss of tear production
   - The patient is refractory to conservative management (i.e., artificial tears, ocular lubricants, topical antibiotics, therapeutic contact lenses)

If yes, approve for 8 weeks per lifetime by HICL or GPI-10 as follows:
   - If treatment is for 1 eye: #28 vials per 28 days for 2 fills.
   - If treatment is for 2 eyes: #56 vials per 28 days for 2 fills.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CENEGERMIN-BKBJ (Oxervate) requires the following rule(s) be met for approval:

A. You have a diagnosis of neurotrophic keratitis (an eye disease due to a damaged eye nerve)
B. Therapy is prescribed by or given in consultation with an ophthalmologist (eye doctor)
C. You have a medical history that supports a cause for trigeminal nerve damage (damage to a nerve in the head) such as herpes zoster infection (shingles virus), multiple sclerosis (disorder where immune system attacks nerves), diabetes, ocular surgical (eye surgery) damage
D. You have loss of corneal sensitivity, corneal epithelium changes, and/or loss of tear production
E. You are refractory (not fully responsive) to conservative management that includes artificial tears, ocular lubricants, topical antibiotics, therapeutic contact lenses

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use.
CENEGERMIN-BKBJ

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Oxervate.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/19
Commercial Effective: 09/04/20 Client Approval: 09/20 P&T Approval: 01/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of diabetes mellitus (type 1 or type 2) and meet ALL of the following criteria?
   - The patient is 21 years of age or older
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient follows a maintenance program of at least 3 injections of insulin per day
   - The patient has worked with the physician to adjust the dose of insulin for the past 6 months and has not met glucose goals
   - The patient requires bolus insulin dosing in increments of 2 units per bolus
   - The patient had a trial of ONE of the following preferred devices: Omnipod, Omnipod Dash, V-Go

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient on a multiple daily insulin injection regimen and meets ONE of the following criteria?
   - The patient's glycosylated hemoglobin level (HbA1c) is greater than 7%
   - The patient has a history of recurring hypoglycemia
   - The patient has wide fluctuations in blood glucose before mealtime
   - The patient experiences the dawn phenomenon with fasting blood glucose levels frequently exceeding 200 mg/dL
   - The patient has a history of severe glycemic excursions (i.e., sudden spikes in blood sugar levels)

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Is the request for more than 10 patches per month?

   If yes, continue to #4.
   If no, approve for 12 months for both agents as follows:
   • CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
   • CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.

4. Is the patient using more than more than 180 units of insulin per 72 hours?

   If yes, approve for 12 months for both agents as follows:
   • CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
   • CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] for the requested quantity per 30 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

[PAC NOTE: Enter proactive PAs for 12 months for both agents as follows:
   • CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
   • CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.]

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CEQUR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for approval:

A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
B. You are 21 years of age or older
C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
D. You follow a maintenance program of at least 3 injections of insulin per day
E. You have worked with the physician to adjust the dose of insulin for the past 6 months and have not met glucose (blood sugar) goals
F. You require bolus insulin dosing in increments of 2 units per bolus
G. You had a trial of ONE of the following preferred devices: Omnipod, Omnipod Dash, V-Go
H. If requesting more than 10 patches per month, then you must be using more than 180 units of insulin per 72 hours

(Initial denial text continued on next page)
CEQR SIMPLICITY INSULIN DEVICE

INITIAL CRITERIA (CONTINUED)

I. You are on a multiple daily insulin injection regimen and meet ONE of the following criteria:
   1. You have a glycosylated hemoglobin level (HbA1c: a type of lab test) greater than 7 percent
   2. You have a history of recurring hypoglycemia (low blood sugar)
   3. You have wide fluctuations (variations) in blood glucose before mealtime
   4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/dL
   5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of diabetes mellitus (type 1 or type 2) and meet ALL of the following criteria?
   • The patient has shown a positive response to therapy
   • The patient is adherent to physician follow-up visits

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Is the request for more than 10 patches per month?

   If yes, continue to #3.
   If no, approve 12 months for both as follows:
   • CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
   • CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.
RENEWAL CRITERIA (CONTINUED)

3. Is the patient using more than more than 180 units of insulin per 72 hours?

   If yes, approve 12 months for both as follows:
   - CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
   - CeQur Simplicity Patches: Approve by HICL or NDC [Medi-Span] for the requested quantity per 30 days.

   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

   [PAC NOTE: Enter proactive PAs for 12 months for both as follows:
   - CeQur Simplicity Inserter: Approve for 1 fill by NDC [FDB] or GPI-14.
   - CeQur Simplicity Patches: Approve HICL or NDC [Medi-Span] with a quantity limit of #10 per 30 days.]

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CEQUR SIMPLICITY INSULIN DEVICE requires the following rule(s) be met for renewal:
   A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
   B. You have shown a positive response to therapy
   C. You are adherent to your doctor follow-up visits
   D. If requesting more than 10 patches per month, you are using more than 180 units of insulin per 72 hours

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
CEQUR SIMPLICITY INSULIN DEVICE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for CeQur Simplicity.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/23
Created: 08/22
Client Approval: 02/23
P&T Approval: 07/22
CERITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERITINIB</td>
<td>ZYKADIA</td>
<td>41111</td>
<td>GPI</td>
<td>GPI-10 (2153051400)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CERITINIB (Zykadia) requires the following rule(s) be met for approval:
   A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread)
   B. You are 18 years of age or older
   C. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme) positive as confirmed by a Food and Drug Administration-approved test

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zykadia.

REFERENCE
CERTOLIZUMAB PEGOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERTOLIZUMAB PEGOL</td>
<td>CIMZIA</td>
<td>35554</td>
<td>GPI-10</td>
<td>(5250502010)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   - The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, approve for a total of 6 months. Please enter two authorizations by HICL or GPI-10 as follows:
   - FIRST APPROVAL: Approve for 1 month with a quantity limit of #3 kits.
   - SECOND APPROVAL: Approve for 5 months with a quantity limit of #1 kit per 28 days (Enter a start date that is 1 week AFTER the END date of the first approval).

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #4.
   If no, continue to #5.

4. Does the patient meet ONE of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, approve for a total of 6 months. Please enter two authorizations by HICL or GPI-10 as follows:
   - FIRST APPROVAL: Approve for 1 month with a quantity limit of #3 kits.
   - SECOND APPROVAL: Approve for 5 months with a quantity limit of #1 kit per 28 days

   (Enter a start date that is 1 week AFTER the END date of the first approval).

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

5. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, continue to #6.
   If no, continue to #7.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Does the patient meet ONE of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, approve for a total of 6 months. Please enter two authorizations by HICL or GPI-10 as follows:
   - **FIRST APPROVAL:** Approve for 1 month with a quantity limit of #3 kits.
   - **SECOND APPROVAL:** Approve for 5 months with a quantity limit of #1 kit per 28 days (Enter a start date that is 1 week AFTER the END date of the first approval).

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

7. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)

   If yes, continue to #8.
   If no, continue to #9.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

8. Does the patient meet **ONE** of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)
   [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, **approve for a total of 6 months.** Please enter two authorizations by HICL or GPI-10 as follows:
   - **FIRST APPROVAL:** Approve for 1 month with a quantity limit of #3 kits.
   - **SECOND APPROVAL:** Approve for 5 months with a quantity limit of #1 kit per 28 days (Enter a start date that is 3 weeks AFTER the END date of the first approval).

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

9. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #10.
   If no, continue to #11.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

10. Does the patient meet ONE of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 kits per 28 days.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

11. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, continue to #12.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

12. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cosentyx [secukinumab], Taltz [ixekizumab]) and is switching to the requested drug
   - The patient has C-reactive protein (CRP) levels above the upper limit of normal
   - The patient has sacroiliitis on magnetic resonance imaging (MRI)

   If yes, approve for a total of 6 months. Please enter two authorizations by HICL or GPI-10 as follows:
   - FIRST APPROVAL: Approve for 1 month with a quantity limit of #3 kits.
   - SECOND APPROVAL: Approve for 5 months with a quantity limit of #1 kit per 28 days (Enter a start date that is 1 week AFTER the END date of the first approval).

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CERTOLIZUMAB PEGOL (Cimzia) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Non-radiographic axial spondyloarthrits (nr-axSpA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Enbrel [etanercept], Humira [adalimumab]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial denial text continued on next page)
C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate release or extended release), Rinoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

E. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

G. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug such as (e.g., ibuprofen, naproxen, meloxicam)
   4. You have ONE of the following criteria:
      a. You were previously stable on another biologic (e.g., Cosentyx [secukinumab], Taltz [ixekizumab]) and you are switching to the requested drug
      b. You have C-reactive protein (CRP; a measure of how much inflammation you have) levels above the upper limit of normal
      c. You have sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CERTOLIZUMAB PEGOL

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) AND meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   • The patient is pregnant, breastfeeding, or trying to become pregnant
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   • The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit per 28 days.

   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #4.
   If no, continue to #5.

CONTINUED ON NEXT PAGE
CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

4. Does the patient meet ONE of the following criteria?
   • The patient is pregnant, breastfeeding, or trying to become pregnant
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzza), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit per 28 days.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

5. Does the patient have a diagnosis of ankylosing spondylitis (AS) AND meet the following criterion?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy
   If yes, continue to #6.
   If no, continue to #7.

6. Does the patient meet ONE of the following criteria?
   • The patient is pregnant, breastfeeding, or trying to become pregnant
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit per 28 days.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
7. Does the patient have non-radiographic axial spondyloarthritis (nr-axSpA) **AND** meet the following criterion?
   - The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit per 28 days.**

   If no, continue to #8.

8. Does the patient have a diagnosis of moderate to severe Crohn’s disease (CD) and meet **ONE** of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)
   [**NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.]

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 kit per 28 days.**

   If no, continue to #9.

9. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
   - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

   If yes, continue to #10.
   If no, do not approve.

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
10. Does the patient meet **ONE** of the following criteria?
   - The patient is pregnant, breastfeeding, or trying to become pregnant
   - The patient had a trial of or contraindication to **TWO** of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   
   **[NOTE:]** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify.

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 kits per 28 days.

If no, do not approve.

**RENEWAL DENIAL TEXT:** Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CERTOLIZUMAB PEGOL (Cimzia)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet **ONE** of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to **TWO** of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Enbrel [etanercept], Humira [adalimumab]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Renewal denial text continued on next page)
CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

D. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
   2. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

E. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more while on therapy
   2. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

F. If you have moderate to Crohn's disease, renewal also requires:
   1. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

(Renewal denial text continued on next page)
G. If you have non-radiographic axial spondyloarthritis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy

   NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cimzia.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 05/08
Client Approval: 07/23
P&T Approval: 04/23
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the requested medication being prescribed for the treatment of cerebrotendinous xanthomatosis (CTX)?
   
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 daily.
   If no, continue to #2.

2. Is the requested medication being prescribed for the treatment of radiolucent gallstones?
   
   If yes, continue to #3.
   If no, do not approve.
   
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Has the patient received previous chenodiol therapy with a total duration exceeding 24 months?
   
   If yes, do not approve.
   
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.
   If no, continue to #4.

4. Has the patient had a previous trial of or contraindication to ursodiol?
   
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #7 daily.
   If no, do not approve.
   
   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CHENODIOL (Chenodal)** requires the following rule(s) be met for approval:

A. You have radiolucent gallstones (hard deposits in your gall bladder that can barely be seen with x-rays) OR cerebrotendinous xanthomatosis (condition of missing an enzyme that changes cholesterol into a bile acid)

B. If you have radiolucent gallstones, approval also requires:
   1. You have tried ursodiol, unless there is a medical reason why you cannot (contraindication)
   2. You have not received previous chenodiol therapy for more than a total of 24 months

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the requested medication being used for radiolucent gallstones?

   If yes, continue to #2.
   If no, continue to #5.

2. Has the patient previously received a total duration of chenodiol therapy exceeding 24 months?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient have complete or no gallstone dissolution seen on imaging after 12 months of therapy?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #4.

4. Does the patient have partial gallstone dissolution seen on imaging after 12 months of therapy?

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #7 daily.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

5. Does the patient have a diagnosis of cerebrotendinous xanthomatosis (CTX) **AND** meet the following criterion?
   - The patient has experienced improvement in **ONE** of the following:
     - Normalization of elevated serum or urine bile alcohols
     - Normalization of elevated serum cholestanol levels
     - Improvement in neurologic and psychiatric symptoms (dementia, pyramidal tract and cerebellar signs)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 daily.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CHENODIOL (Chenodal) requires the following rule(s) be met for renewal:
A. You have radiolucent gallstones (hard deposits in your gall bladder that can barely be seen with x-rays) OR cerebrotendinous xanthomatosis (condition of missing an enzyme that changes cholesterol into a bile acid)
B. **If you have radiolucent gallstones, renewal also requires:**
   1. You have **NOT** had chenodiol therapy for more than a total of 24 months
   2. You do **NOT** have complete or no gallstone dissolution (disappearance) seen on imaging (such as oral cholecystograms or ultrasonograms) after 12 months of therapy
   3. You have partial gallstone dissolution seen on imaging (such as oral cholecystograms or ultrasonograms) after 12 months of therapy
C. **If you have cerebrotendinous xanthomatosis, renewal also requires you have experienced an improvement in** **ONE** of the following:
   1. Normalization of elevated serum or urine bile alcohols
   2. Normalization of elevated serum cholestanol levels
   3. Improvement in neurologic and psychiatric symptoms (dementia, pyramidal tract and cerebellar signs)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Chenodal.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption secondary to ONE of the following conditions?
   • Bile acid synthesis disorders
   • Peroxisomal disorders (i.e., Zellweger spectrum disorders)

If yes, **approve for 3 months by HICL or GPI-10.**
If no, do not approve.

**INITIAL DENIAL TEXT:**  *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for approval:
A. You show signs of liver disease, steatorrhea (excess fat in feces), or complications from your body not being able to absorb fat-soluble vitamins that occur from ONE of the following conditions:
   1. Bile acid synthesis disorders (your body has a problem making bile acid)
   2. Peroxisomal disorders (Zellweger spectrum disorders) (problems with a part of a cell that contains enzymes)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Did the patient experience improvement in liver function (as defined by at least **ONE** of the following criteria)?
   • ALT or AST values reduced to less than 50 U/L or baseline levels reduced by 80%
   • Total bilirubin values reduced to less than 1 mg/dL
   • No evidence of cholestasis on liver biopsy

If yes, **approve for 12 months by HICL or GPI-10.**
If no, do not approve.

**DENIAL TEXT:**  See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
CHOLIC ACID

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CHOLIC ACID (Cholbam) requires the following rule(s) be met for renewal:
A. You have experienced an improvement in your liver function as defined by at least ONE of the following criteria:
1. ALT (alanine aminotransferase) or AST (aspartate transaminase) (types of liver enzymes) values have been lowered to less than 50 U/L or baseline levels reduced by 80%
2. Total bilirubin values reduced to less than 1 mg/dL
3. No evidence of cholestasis (condition where bile cannot flow from liver) on liver biopsy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cholbam.

REFERENCES
• Cholbam [Prescribing Information]. Baltimore, MD: Asklepion Pharmaceuticals, LLC; March 2015.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 04/15
Commercial Effective: 07/01/20 Client Approval: 04/20 P&T Approval: 05/15
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve for 48 weeks by G PID or GPI-10.**

   **APPROVAL TEXT:** Renewal requires 1) physician attestation that the patient has demonstrated a clinical benefit compared to pre-treatment baseline, 2) the patient does not have lymphopenia, and 3) the patient has not received a total of two years of Mavenclad treatment (i.e., two treatment cycles divided into 2 yearly treatment courses).

   If no, do not approve.

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **CLADRIBINE (Mavenclad)** requires the following rule(s) be met for approval:

   A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.

   B. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) (e.g. relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.)?

   If yes, continue to #2.

   If no, do not approve.

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
CLADRIBINE

RENEWAL CRITERIA (CONTINUED)

2. Has the patient received a total of two years of Mavenclad treatment (i.e., two treatment cycles divided into 2 yearly treatment courses)?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient meet **ALL** of the following criteria?
   - The patient has demonstrated a clinical benefit compared to pre-treatment baseline
   - The patient does not have lymphopenia

   If yes, **approve for 48 weeks by GPID or GPI-10.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*
   Our guideline named **CLADRIBINE (Mavenclad)** requires the following rule(s) be met for renewal:
   A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
   B. You have demonstrated a clinical benefit compared to pre-treatment baseline (before you started therapy)
   C. You do not have lymphopenia (low amount of a type of white blood cell called lymphocyte)
   D. You have not received a total of two years of treatment with Mavenclad

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mavenclad.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 04/19
Commercial Effective: 07/01/20  Client Approval: 04/20
P&T Approval: 10/19

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of acne vulgaris and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • Therapy is prescribed by or given in consultation with a dermatologist
   • The patient had a trial of or contraindication to BOTH of the following:
     o ONE oral acne agent (e.g. oral antibiotics or oral isotretinoin)
     o TWO topical acne agents (e.g. topical retinoids, topical antibiotics, benzoyl peroxide)

   If yes, approve for 3 months by HICL or GPI-10 with a quantity limit of #60 grams (1 tube) per 30 days.
   APPROVAL TEXT: Renewal requires the patient had improvement of acne lesions.

   If no, do not approve.
   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CLASCOTERONE (Winlevi) requires the following rule(s) be met for approval:
   A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
   B. You are 12 years of age or older
   C. Therapy is prescribed by or given in consultation with a dermatologist (skin doctor)
   D. You have previously tried BOTH of the following unless there is a medical reason why you cannot (contraindication):
      1. ONE oral acne agent (such as oral antibiotics or oral isotretinoin)
      2. TWO topical acne agents (such as topical retinoids, topical antibiotics, benzoyl peroxide)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acne vulgaris AND meet the following criterion?
   • The patient had improvement of acne lesions

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #60 grams (1 tube) per 30 days.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named CLASCOTERONE (Winlevi) requires the following rule(s) be met for approval:
   A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
   B. You had improvement of acne lesions

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Winlevi.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/21
Created: 12/20
Client Approval: 12/20
P&T Approval: 10/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Lennox-Gastaut syndrome and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist
   - Sympazan will be used for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
   - The patient is unable to take tablets or suspension
   - The patient had a trial of or contraindication to generic/branded clobazam products (Onfi)

If yes, approve for 12 months by GPI-10 for all of the following strengths with a quantity limit of #2 per day:
   - 5mg film
   - 10mg film
   - 20mg film

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CLOBAZAM-SYMPAZAN requires the following rule(s) be met for approval:
A. You have Lennox-Gastaut Syndrome (a type of seizure disorder in young children)
B. You are 2 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
D. Sympazan will be used for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome
E. You are unable to take tablets or suspension
F. You had a trial of or contraindication (harmful for) to generic/branded clobazam products (Onfi)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CLOBAZAM-SYMPAZAN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sympazan.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 02/19
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's tumor has a BRAF V600E OR V600K mutation
   - Cobimetinib will be used in combination with vemurafenib (Zelboraf)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #63 per 28 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of histiocytic neoplasms and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Cobimetinib will be used as a single agent

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #63 per 28 days.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named COBIMETINIB (Cotellic) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (skin cancer that has spread or cannot be completely removed with surgery)
   2. Histiocytic neoplasms (a type of white blood cell disorder)
B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You are 18 years of age or older
   2. Your tumor has a BRAF V600E OR V600K mutation (a type of gene mutation)
   3. Cobimetinib will be used in combination with vemurafenib (Zelboraf)
C. If you have histiocytic neoplasms, approval also requires:
   1. You are 18 years of age or older
   2. Cobimetinib will be used as a single agent

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
COBIMETINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cotellic.

REFERENCES
- Cotellic [Prescribing Information]; San Francisco, CA: Genentech USA, Inc.; October 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/21/22
Created: 11/15
Client Approval: 11/22
P&T Approval: 01/23
COLLAGENASE TOPICAL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLLAGENASE</td>
<td>SANTYL</td>
<td>21190</td>
<td>GPI-14</td>
<td>(90700010004205)</td>
<td></td>
</tr>
<tr>
<td>CLOSTRIDIUM HIST.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic dermal ulcer(s) or severe burn(s) that require(s) debridement?

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the requested quantity for one tube (30 grams) or less?

   If yes, **approve by GPID or GPI-14 for one fill with a quantity limit of #30 grams.**
   If no, continue to #3.

3. Are BOTH of the following provided?
   - The patient's wound size (width/length)
   - The anticipated duration of therapy

   If yes, **approve by GPID or GPI-14 for one fill with a quantity limit based on the Santyl dosing calculator (https://santyl.com/hcp/dosing).**

   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **COLLAGENASE TOPICAL (Santyl)** requires the following rule(s) be met for approval:
   A. You have chronic dermal (skin) ulcer(s) or severe burn(s) that require(s) debridement (removal of damaged tissue from a wound)
   B. If the requested quantity is more than one tube (30 grams), approval also requires:
      1. The higher quantity is based on the size of your wound (width/length) and the anticipated duration of therapy, using the Santyl dosing calculator (https://santyl.com/hcp/dosing)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
COLLAGENASE TOPICAL

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Santyl.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 11/21
Client Approval: 02/22
P&T Approval: 10/21
**GUIDELINES FOR USE**

1. Does the patient meet **ONE** of the following criteria?
   - The patient is being treated with insulin (e.g., Humalog [insulin lispro], Lantus [insulin glargine])
   - The patient has a clinical need that cannot be managed with self-monitoring of blood glucose (SMBG) (e.g., frequent hypoglycemia, hypoglycemic unawareness, unable to achieve control of diabetes)
   - The patient is currently stable on the requested agent while covered by their current or previous health plan

   If yes, **approve the requested agent for 12 months by HICL or GPI-10 as follows:**
   - Dexcom G6: approve all of the following: Receiver, Transmitter, and Sensor.
   - FreeStyle Libre system: approve both Reader and Sensor.

   **NOTE TO PAC:** Override using the Step therapy edit only. Do not override any quantity limit without review. All other rejections will require clinical review.

   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

---

**CONTINUED ON NEXT PAGE**
DENIAL TEXT (Use G09): *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CGM STEP OVERRIDE** requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You are being treated with insulin (such as Humalog [insulin lispro], Lantus [insulin glargine])
   2. You have a clinical need that cannot be managed with self-monitoring of blood glucose
      (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes)
   3. You are currently stable on the requested agent

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for the related continuous glucose monitor.

REFERENCES

- Dexcom Continuous Glucose Monitoring Products. Dexcom, Inc. Available at: [https://www.dexcom.com/](https://www.dexcom.com/)

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 09/18/23
Created: 06/23
Client Approval: 09/23
P&T Approval: 04/23
### CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER</td>
<td>DEXCOM G4, DEXCOM G5</td>
<td>36756</td>
<td>GPI-10 (9720201202)</td>
<td>FDB &amp; Medi-Span: BRAND = DEXCOM G4%, DEXCOM G5%</td>
<td></td>
</tr>
<tr>
<td>BLOOD-GLUCOSE TRANSMITTER</td>
<td>DEXCOM G4, DEXCOM G5, EVERSENSE SMART TRANSMITTER, GUARDIAN CONNECT TRANSMITTER, GUARDIAN 4 TRANSMITTER, GUARDIAN LINK 3 TRANSMITTER</td>
<td>36760</td>
<td>GPI-10 (9720201206)</td>
<td>FDB &amp; Medi-Span: BRAND = DEXCOM G4%, DEXCOM G5%, EVERSENSE SMART TRANSMITTER, GUARDIAN CONNECT TRANSMITTER, GUARDIAN 4 TRANSMITTER, GUARDIAN LINK 3 TRANSMITTER</td>
<td></td>
</tr>
<tr>
<td>BLOOD-GLUCOSE SENSOR</td>
<td>DEXCOM G5-G4 SENSOR, DEXCOM G4 SENSOR, GUARDIAN SENSOR 3, GUARDIAN 4 GLUCOSE SENSOR</td>
<td>36696</td>
<td>GPI-10 (9720201204)</td>
<td>FDB &amp; Medi-Span: BRAND = DEXCOM G5-G4%, DEXCOM G4 SENSOR, GUARDIAN SENSOR 3, GUARDIAN 4 GLUCOSE SENSOR</td>
<td></td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

#### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of type 1, type 2, or gestational diabetes?

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

INITIAL CRITERIA (CONTINUED)

2. Does the patient meet ONE of the following criteria?
   • The patient is being treated with insulin (e.g., Humalog [insulin lispro], Lantus [insulin glargine])
   • The patient has a clinical need that cannot be managed with self-monitoring of blood glucose (SMBG) (e.g., frequent hypoglycemia, hypoglycemic unawareness, unable to achieve control of diabetes)

   If yes, continue to #3.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Is the request for Dexcom G4 or Dexcom G5 (i.e., meter, sensor, transmitter) AND the patient meets the following criterion?
   • The patient is 2 years of age or older

   If yes, continue to #7.
   If no, continue to #4.

4. Is the request for Guardian Connect (i.e., sensor, transmitter) AND the patient meets the following criterion?
   • The patient is 14 to 75 years of age

   If yes, continue to #7.
   If no, continue to #5.

5. Is the request for Guardian 4 (i.e., sensor, transmitter) or Guardian Link 3 Transmitter AND the patient meets the following criterion?
   • The patient is 7 years of age or older

   If yes, continue to #7.
   If no, continue to #6.

6. Is the request for Eversense Smart Transmitter AND the patient meets the following criterion?
   • The patient is 18 years of age or older

   If yes, continue to #7.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

INITIAL CRITERIA (CONTINUED)

7. Does the patient meet ONE of the following criteria?
   • The patient had a trial of or contraindication to Dexcom G6 or G7
   • The patient had a trial of or contraindication to Freestyle Libre
   • Dexcom G6, G7, and Freestyle Libre are not compatible with the patient's current insulin pump

If yes, approve the requested agent for 12 months by NDC as follows:
1. Dexcom G4: approve all of the following:
   • Receiver: #1 per 12 months.
   • Transmitter: #1 per 180 days.
   • Sensor: #4 per 28 days.
2. Dexcom G5: approve all of the following:
   • Receiver: #1 per 12 months.
   • Transmitter: #1 per 90 days.
   • Sensor: #4 per 28 days.
3. Guardian Connect: approve all of the following:
   • Transmitter: #1 per 12 months.
   • Sensor: #5 per 35 days.
4. Guardian 4: approve all of the following:
   • Transmitter: #1 per 12 months.
   • Sensor: #5 per 35 days.
5. Guardian Link 3 Transmitter: approve with a quantity limit of #1 per 12 months.
6. Eversense Smart Transmitter: approve with a quantity limit of #1 per 12 months.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CONTINUOUS GLUCOSE MONITORS - STAND-ALONE requires the following rule(s) be met for approval:
A. You have type 1, type 2, or gestational (during pregnancy) diabetes (too much sugar in your blood)
B. You had a trial of or contraindication (harmful for) to Dexcom G6, G7 or Freestyle Libre, OR all three products are not compatible with your current insulin pump
C. You meet ONE of the following:
   1. You are being treated with insulin (such as Humalog [insulin lispro], Lantus [insulin glargine])
   2. You have a clinical need that cannot be managed with self-monitoring of blood glucose (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you are requesting Dexcom G4 or Dexcom G5 system (meter, sensor, transmitter), approval also requires:
   1. You are 2 years of age or older

E. If you are requesting Guardian Connect (sensor, transmitter), approval also requires:
   1. You are 14 to 75 years of age

F. If you are requesting Guardian 4 (sensor, transmitter) or Guardian Link 3 Transmitter, approval also requires:
   1. You are 7 years of age or older

G. If you are requesting Eversense Smart Transmitter, approval also requires:
   1. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different product or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient continue to require continuous glucose monitoring?

If yes, approve the requested agent for 12 months by NDC as follows:

1. Dexcom G4: approve all of the following:
   - Receiver: #1 per 12 months
   - Transmitter: #1 per 180 days
   - Sensor: #4 per 28 days
2. Dexcom G5: approve all of the following:
   - Receiver: #1 per 12 months
   - Transmitter: #1 per 90 days
   - Sensor: #4 per 28 days
3. Guardian Connect: approve all of the following:
   - Transmitter: #1 per 12 months
   - Sensor: #5 per 35 days
4. Guardian 4: approve all of the following:
   - Transmitter: #1 per 12 months
   - Sensor: #5 per 35 days
5. Guardian Link 3 Transmitter: approve with a quantity limit of #1 per 12 months.
6. Eversense Smart Transmitter: approve with a quantity limit of #1 per 12 months.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CONTINUOUS GLUCOSE MONITORS – STAND-ALONE requires the following rule be met for renewal:
A. You continue to require continuous glucose monitoring

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CONTINUOUS GLUCOSE MONITORS – STAND-ALONE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for the related continuous glucose monitor.

REFERENCES
- Dexcom Continuous Glucose Monitoring Products. Dexcom, Inc. Available at: https://www.dexcom.com/
- Eversense Continuous Glucose Monitoring System. Senseonics, Inc. Available at: https://www.eversensediabetes.com/

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 02/18
Client Approval: 08/23
P&T Approval: 07/23
## CONTRACEPTIVE ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTRACEPTIVES, ORAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STC = 0248</td>
</tr>
<tr>
<td>CONTRACEPTIVES, TRANSDERMAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STC = 9495</td>
</tr>
<tr>
<td>CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC</td>
<td></td>
<td>GPI-2 (25)</td>
<td></td>
<td></td>
<td>STC = 9654</td>
</tr>
<tr>
<td>INTRA-UTERINE DEVICES (IUD'S)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STC = 4730</td>
</tr>
<tr>
<td>CONTRACEPTIVES, INJECTABLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STC = 4139</td>
</tr>
<tr>
<td>CONTRACEPTIVES, IMPLANTABLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STC = 3669</td>
</tr>
<tr>
<td>CONTRACEPTIVE, INTRAVAGINAL</td>
<td>GPI-10 (553001000)</td>
<td></td>
<td>STC = 0249</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIAPHRAGMS/CERVICAL CAP</td>
<td>GPI-10 (9740208000)</td>
<td></td>
<td>STC = 3322</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(9740181000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(9740201000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested contraceptive agent AND does the plan cover contraceptives at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does ANY of the following criteria apply?
   - The patient's plan has specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)
   - The request is for an agent with an excluded route of administration, such that the agent will be covered on the medical benefit
   
   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the request for a generic contraceptive agent?
   
   If yes, continue to #6.
   If no, continue to #4.

**CONTINUED ON NEXT PAGE**
GUIDELINE FOR USE (CONTINUED)

4. Is the request for ONE of the following?
   • A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
   • A multi-source brand (MSB) contraceptive agent

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet ONE of the following criteria?
   • Two preferred medications are medically inappropriate for the patient (alternatively, one if only one agent is available)
   • The patient has tried or has a documented medical contraindication to two preferred medications (alternatively, a trial of one if only one agent is available)
   • The prescriber provided documentation confirming that requested drug is considered as medically necessary (considerations may include severity of side effects, differences in permanence and reversibility of contraceptives, and ability to adhere to the appropriate use of the item or service)

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the requested medication also require step therapy? **(NOTE: Analyze the claim to determine if it also rejects for step therapy)**

   If yes, continue to #7.
   If no, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay. (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)**

   **APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

   **CONTINUED ON NEXT PAGE**
GUIDELINE FOR USE (CONTINUED)

7. Has the patient met the step therapy requirement? (NOTE: Analyze the claim to determine step therapy agents)

If yes, approve the requested agent for 12 months by GPID or GPI-14 at zero copay and also override the step restriction. (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)

APPROVAL TEXT (applicable to multi-source brand agents only): Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CONTRACEPTIVE ZERO COST SHARE OVERRIDE requires that the following rules be met for approval:

A. The request is for ONE of the following:
   1. A generic contraceptive agent
   2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) contraceptive agent

B. Approval may also require that you have tried preferred agent(s), unless you have a contraindication (harmful for). (NOTE TO REVIEWER: Provide the list of the preferred medication(s))

C. If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
CONTRACEPTIVE ZERO COST SHARE OVERRIDE

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of contraceptives at zero copay. The override criteria allow patient access to all FDA-approved contraceptive methods at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded contraceptives.

The MedImpact standard Zero Copay list currently offers coverage of all methods at zero cost share. The zero cost share list offers a variety of contraceptives. Covered methods (zero cost share) include 1) specified barrier contraceptives (condoms, diaphragms, cervical caps, and nonoxynol-9) 2) generic oral hormonal contraceptives under STC 0248, including generic emergency contraceptives and Ella 3) generic transdermal patch contraceptive (currently marketed by Mylan as Xulane) 4) Nuvaring vaginal ring 5) Intrauterine devices – levonorgestrel IUDs and copper IUDs 6) Depo-Provera injections and 7) Nexplanon implant devices. The majority of the contraceptives on the EHB Zero cost share list are generic agents, which promotes a cost-effective formulary.

The healthcare.gov website (https://www.healthcare.gov/coverage/birth-control-benefits/) currently recommends: All approved contraceptive methods prescribed by a woman’s doctor are covered, including:
Barrier methods (used during intercourse), like diaphragms and sponges
Hormonal methods, like birth control pills and vaginal rings
Implanted devices, like intrauterine devices (IUDs)
Emergency contraception, like Plan B® and Ella®
Sterilization procedures
Patient education and counseling

REFERENCES
• Birth control benefits; https://www.healthcare.gov/coverage/birth-control-benefits/
• FAQs about Affordable Care Act Implementation Part XII; http://www.dol.gov/ebsa/faqs/faq-aca12.html
• FAQ about Affordable Care Act Implementation (Part XXVI); http://www.dol.gov/ebsa/faqs/faq-aca26.html

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A        Created: 04/15
Commercial Effective: 07/01/22  Client Approval: 05/22  P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
CORTICOTROPIN

Generic    | Brand      | HICL | GCN       | Medi-Span         | Exception/Other
---        | ---        | ---  | ---       | ---               | ---
CORTICOTROPIN | ACTHAR,   | 02830 | GPI-10    | (3030001000)      | FDB: ROUTE = INJECTION
   CORTROPHIN     |           |      |           |                   |       

GUIDELINES FOR USE

1. Does the patient have a diagnosis of infantile spasms and meet the following criterion?
   • The patient is less than 2 years of age

   If yes, approve for 28 days by HICL or GPI-10 with a maximum of #8 vials (each 5mL vial contains 400 units).

   If no, continue to #2.

2. Is the request for any other indications other than infantile spasms?

   If yes, do not approve. See note and use denial text below.
   **Note:** Off-label guideline should not be used for Acthar because it hasn't demonstrated proven benefits in the other indications and has no proven advantage over synthetic steroids. Therefore, there isn't a pathway to approval for any other listed indications.

   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named CORTICOTROPIN (Acthar, Cortrophin) requires the following rule(s) be met for approval:
   A. You have infantile spasms (type of seizure disorder in young children)
   B. You are less than 2 years of age

   Acthar will not be approved for any other indications other than infantile spasms. Acthar has not demonstrated proven benefits or advantage over synthetic steroids in the treatment of other indications.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
CORTICOTROPIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Acthar.

REFERENCES
• Acthar Gel [Prescribing Information]. Bedminster, NJ: Mallinckrodt ARD LLC; April 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 11/07
Client Approval: 11/22
P&T Approval: 04/20
CRIZOTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRIZOTINIB</td>
<td>XALKORI</td>
<td>37916</td>
<td></td>
<td>GPI-10 (2153051700)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ONE** of the following criteria?
   - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
   - The patient's tumors are ROS1-positive as detected by an FDA-approved test

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) and meet **ALL** of the following criteria?
   - The patient is 1 year of age or older
   - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, continue to #3.

3. Does the patient have a diagnosis of unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) and meet **ALL** of the following criteria?
   - The patient is 1 year of age or older
   - The patient's tumors are anaplastic lymphoma kinase (ALK)-positive

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **CRIZOTINIB (Xalkori)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:
   1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   2. Relapsed (disease that has returned) or refractory (disease does not respond to treatment), systemic anaplastic large cell lymphoma (ALCL: type of blood cell cancer)
   3. Unresectable (unable to remove by surgery), recurrent, or refractory (disease does not respond to treatment) inflammatory myofibroblastic tumor (IMT: a rare type of tumor)

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
CRIZOTINIB

GUIDELINES FOR USE (CONTINUED)

B. If you have metastatic non-small cell lung cancer, approval also requires:
   1. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive or ROS1
      (a type of gene)-positive as detected by a Food and Drug Administration (FDA)-
      approved test

C. If you have relapsed or refractory systemic anaplastic large cell lymphoma, approval
   also requires:
   1. You are 1 year of age or older
   2. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

D. If you have unresectable, recurrent, or refractory inflammatory myofibroblastic tumor,
   approval also requires:
   1. You are 1 year of age or older
   2. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work
with your doctor to use a different medication or get us more information if it will allow us to
approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xalkori.

REFERENCE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 09/11
Commercial Effective: 08/29/22 Client Approval: 07/22
P&T Approval: 10/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of vernal keratoconjunctivitis AND meet the following criterion?
   - The patient had a trial of or contraindication to TWO ophthalmic dual-acting mast cell stabilizer/antihistamines (e.g., ketotifen) or mast cell stabilizers (e.g., cromolyn)

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #4 vials per day. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named CYCLOSPORINE (Verkazia) requires the following rule(s) be met for approval:
   A. You have vernal keratoconjunctivitis (allergic eye disease)
   B. You had a trial of or contraindication (harmful for) to TWO ophthalmic dual-acting mast cell stabilizer/antihistamines (such as ketotifen) or mast cell stabilizers (such as cromolyn)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Verkazia.

REFERENCES
### CYSTEAMINE BITARTRATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYSTEAMINE BITARTRATE</td>
<td>PROCYSBI</td>
<td>34656</td>
<td>47723</td>
<td>GPI-14</td>
<td>(56400030106520)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>34657</td>
<td>47724</td>
<td></td>
<td>(56400030106530)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(56400030103020)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(56400030103040)</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

1. Does the patient have a diagnosis of nephropathic cystinosis and meet **ALL** of the following criteria?
   - The patient is 1 year of age or older
   - The patient has previously tried an immediate-release formulation of cysteamine bitartrate such as Cystagon

   If yes, **approve for 12 months by GPIID or GPI-14 for all strengths.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **CYSTEAMINE BITARTRATE (Procysbi)** requires the following rule(s) be met for approval:
   A. You have nephropathic cystinosis (rare genetic, metabolic disease which results in an abnormal accumulation of a protein known as cysteine)
   B. You are 1 year of age or older
   C. You have previously tried an immediate-release formulation of cysteamine bitartrate such as Cystagon

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

### RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Procysbi.

### REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 08/13
Client Approval: 04/20
P&T Approval: 11/15
**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of cystinosis?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient require treatment for corneal cystine crystal accumulation or deposits?
   - If yes, approve the requested drug for 12 months by GPID or GPI-14 with a quantity limit as follows:
     - Cystaran: #60mL(4 bottles) per 28 days.
     - Cystadrops: #20mL (4 bottles) per 28 days.
   - If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **CYSTEAMINE HYDROCHLORIDE (Cystaran/Cystadrops)** requires the following rule(s) be met for approval:

**A.** You have cystinosis (a type of genetic disorder where a substance called cysteine builds up in body organs)
**B.** You require treatment for corneal cystine crystal accumulation or deposits (build up of cysteine in the eye)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
CYSTEAMINE HYDROCHLORIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cystaran/Cystadrops.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/13
Commercial Effective: 10/01/20  Client Approval: 09/20  P&T Approval: 05/13
GUIDELINES FOR USE

1. Is the request for the treatment of a venous thromboembolic event (VTE) AND the patient meets the following criterion?
   - The patient has been treated with a parenteral anticoagulation agent for at least 5 days
     
     If yes, continue to #3.
     If no, continue to #2.

2. Is the request to reduce the risk of venous thromboembolic event (VTE) recurrence AND the patient meets the following criterion?
   - The patient has been previously treated
     
     If yes, continue to #3.
     If no, do not approve.
     DENIAL TEXT: See the denial text at the end of guideline.

3. Does the patient meet ONE of the following criteria?
   - The patient is 3 months to 7 years of age
   - The patient is 8 to 11 years of age AND unable to swallow dabigatran (Pradaxa) capsule
     
     If yes, continue to #4.
     If no, do not approve.
     DENIAL TEXT: See the denial text at the end of guideline.

4. Has the patient had a trial of or contraindication to rivaroxaban (Xarelto) suspension?

   If yes, approve for 12 months for all strengths by GPID or GPI-14 with a quantity limit of #4 per day.

   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of guideline.

CONTINUED ON THE NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DABIGATRAN (Pradaxa) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. Treatment of a venous thromboembolic event (VTE: a type of blood clot disease in your veins)
   2. Reduce the risk of venous thromboembolic event recurrence (happening again)
B. You meet ONE of the following:
   1. You are 3 months to 7 years of age
   2. You are 8 to 11 years of age AND are unable to swallow dabigatran (Pradaxa) capsules
C. You have tried or have a contraindication (harmful for) to rivaroxaban (Xarelto) suspension
D. If the request is for the treatment of a venous thromboembolic event, approval also requires:
   1. You have been treated with parenteral anticoagulation agent (type of medication) for at least 5 days
E. If the request is to reduce the risk of venous thromboembolic event recurrence, approval also requires:
   1. You have been previously treated

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pradaxa.

REFERENCES
## GUIDELINES FOR USE

1. **Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ONE** of the following criteria?**
   - The patient has a BRAF V600E mutation as detected by an FDA-approved test AND the requested medication will be used as a single agent
   - The patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test AND the requested medication will be used in combination with Mekinist (trametinib)

   If yes, continue to #7.
   If no, continue to #2.

2. **Does the patient have a diagnosis of melanoma and meet **ALL** of the following criteria?**
   - The patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test
   - The requested medication has not previously been used for more than one year
   - The requested medication will be used in combination with Mekinist (trametinib) for adjuvant treatment
   - There is involvement of lymph node(s) following complete resection

   If yes, continue to #7.
   If no, continue to #3.

3. **Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?**
   - The patient has a BRAF V600E mutation as detected by an FDA-approved test
   - The requested medication will be used in combination with Mekinist (trametinib)

   If yes, continue to #7.
   If no, continue to #4.

4. **Does the patient have a diagnosis of locally advanced or metastatic anaplastic thyroid cancer (ATC) and meet **ALL** of the following criteria?**
   - The patient has a BRAF V600E mutation
   - The requested medication will be used in combination with Mekinist (trametinib)
   - The patient has no satisfactory locoregional treatment options available

   If yes, continue to #7.
   If no, continue to #5.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of unresectable or metastatic solid tumor and meet ALL of the following criteria?
   • The patient is 1 year of age or older
   • The patient has a BRAF V600E mutation
   • The requested medication will be used in combination with Mekinist (trametinib)
   • The patient’s disease has progressed following prior treatment and have no satisfactory alternative treatment options

   If yes, continue to #7.
   If no, continue to #6.

6. Does the patient have a diagnosis of low-grade glioma (LGG) and meet ALL of the following criteria?
   • The patient is 1 to 17 years of age
   • The patient has a BRAF V600E mutation
   • The requested medication will be used in combination with Mekinist (trametinib)
   • The patient requires systemic therapy

   If yes, continue to #7.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

7. Is the request for the capsule formulation?

   If yes, approve for 12 months by GPI-D or GPI-14 with a quantity limit of #4 per day.
   If no, continue to #8.

8. Is the request for the tablet for oral suspension AND the patient meets the following criterion?
   • The patient cannot swallow Tafinlar (dabrafenib) capsules

   If yes, approve for 12 months by GPI-D or GPI-14 with a quantity limit of #30 per day.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DABRAFENIB (Tafinlar) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (skin cancer that cannot be completely removed by surgery or has spread to other parts of the body)
   2. Melanoma (a type of skin cancer)
   3. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes, or it has spread to other parts of the body)
   5. Unresectable or metastatic solid tumor (tumor that cannot be completely removed by surgery or has spread to other parts of the body)
   6. Low-grade glioma (LGG: a type of brain cancer)

B. If you have unresectable or metastatic melanoma, approval also requires ONE of the following:
   1. You have a BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test AND the requested medication will be used as a single agent (by itself)
   2. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test AND the requested medication will be used in combination with Mekinist (trametinib)

C. If you have melanoma, approval also requires:
   1. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
   2. The requested medication has not previously been used for more than one year
   3. The requested medication will be used in combination with Mekinist (trametinib) for adjuvant (additional) treatment
   4. There is involvement of lymph node(s) following complete resection (removal by surgery)

D. If you have metastatic non-small cell lung cancer, approval also requires:
   1. You have a BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
   2. The requested medication will be used in combination with Mekinist (trametinib)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

E. If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:
   1. You have a BRAF V600E mutation (type of gene mutation)
   2. The requested medication will be used in combination with Mekinist (trametinib)
   3. You have no satisfactory locoregional (restricted to a localized region of the body) treatment options available

F. If you have an unresectable or metastatic solid tumor, approval also requires:
   1. You are 1 year of age or older
   2. You have a BRAF V600E mutation (type of gene mutation)
   3. The requested medication will be used in combination with Mekinist (trametinib)
   4. Your disease has progressed following prior treatment and have no satisfactory alternative treatment options

G. If you have low-grade glioma, approval also requires:
   1. You are 1 to 17 years of age
   2. You have a BRAF V600E mutation (type of gene mutation)
   3. The requested medication will be used in combination with Mekinist (trametinib)
   4. You require systemic therapy (treatment that targets the entire body)

H. If the request is for the tablet for oral suspension, approval also requires:
   1. You cannot swallow Tafinlar (dabrafenib) capsules

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tafinlar.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 06/13
Client Approval: 09/23
P&T Approval: 10/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of hepatitis C, genotype 1 or genotype 3 infection and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - There is evidence of current HCV infection and chronic HCV infection documented by at least **ONE** detectable HCV RNA level within the past 6 months
   - The patient is 1) without cirrhosis or 2) has decompensated cirrhosis or 3) post-liver transplant patient (with or without cirrhosis)
   - The request is for Daklinza in combination with Sovaldi

   **CLINICAL PHARMACIST:** Patient must also meet all criteria in Sovaldi guideline to be approvable for both agents. Review hepatitis C MRF and Sovaldi request to ensure patient meets criteria for both agents.

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
   - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
   - The patient is concurrently taking the following medications:
     - For Daklinza: amiodarone, carbamazepine, phenytoin, or rifampin **OR**
     - For Sovaldi: phenobarbital, oxcarbazepine, rifabutin, rifapentine, or tipranavir/ritonavir

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient meet **ONE** of the following?
   - The patient is decompensated cirrhosis (moderate or severe hepatitis impairment (Child-Pugh B or C))
   - The patient is post-liver transplant (with or without cirrhosis)

   If yes, continue to #4.
   If no, continue to #6.

   **CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

4. Is the request for triple therapy using Daklinza/Sovaldi WITH ribavirin?

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet **ONE** of the following criteria for the patient type?  
   **[NOTE: An individual who has completed a full course of therapy with Mavyret, Harvoni or Epclusa that did not achieve SVR will not be approved]**

   - Genotype 1, decompensated cirrhosis: short trial of Harvoni or Epclusa OR contraindication to Harvoni and Epclusa
   - Genotype 1, post-liver transplant: short trial of Harvoni or Mavyret OR contraindication to Harvoni and Mavyret
   - Genotype 3, decompensated cirrhosis short trial of or contraindication to Epclusa
   - Genotype 3, post-liver transplant WITHOUT cirrhosis: short trial of or contraindication to Mavyret
   - Genotype 3, post-liver transplant with compensated cirrhosis: short trial of Epclusa or Mavyret OR contraindication to Epclusa and Mavyret

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?  
   **[NOTE: An individual who has completed a full course of therapy with Mavyret, Harvoni or Epclusa that did not achieve SVR will not be approved]**

   - Genotype 1, without cirrhosis: treatment naïve or treatment experienced with a peginterferon and ribavirin regimen AND a short trial of Epclusa, Harvoni or Mavyret OR a contraindication Epclusa, Harvoni and Mavyret
   - Genotype 3, without cirrhosis: treatment naïve or treatment experienced with a peginterferon and ribavirin regimen AND a short trial of Epclusa or Mavyret OR a contraindication to Epclusa and Mavyret

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

DACLATASVIR

GUIDELINES FOR USE (CONTINUED)

7. Is the patient using any of the following moderate CYP3A inducers while taking Daklinza in combination with Sovaldi: rifapentine, bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcillin, or nevirapine?

CLINICAL PHARMACIST: Patient is on combination therapy with Sovaldi; please also review Sovaldi prior authorization guideline, member history, and hepatitis C MRF, if available to ensure appropriate length of approval and that the patient also meets approval for Sovaldi.

If yes, **approve Daklinza 90mg strength for 12 weeks by GPID or GPI-14 with a quantity limit of #1 tablet per day. (NOTE: 90mg tablet used for drug interactions listed above)**

If no, continue to #8.

8. Is the patient concurrently using any of the following with Daklinza?
   - HIV protease inhibitors (atazanavir with ritonavir, indinavir, nelfinavir, saquinavir)
   - A cobicistat-containing regimen (exception: darunavir/cobicistat does not require Daklinza 30mg dose), such as atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, or other cobicistat-containing regimen
   - Strong CYP3A inhibitors, such as clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, or voriconazole

If yes, **approve Daklinza 30mg strength for 12 weeks by GPID or GPI-14 with a quantity limit of #1 tablet per day. (NOTE: 30mg tablet used for drug interactions listed above)**

If no, **approve Daklinza 60mg strength for 12 weeks by GPID or GPI-14 with a quantity limit of #1 tablet per day.**

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **DACLATASVIR (Daklinza)** requires the following rule(s) be met for approval:
A. You have hepatitis C, with genotype 1 or genotype 3 infection
B. You are 18 years of age or older
C. You have documentation showing at least ONE detectable HCV (hepatitis C virus) RNA level (amount of virus in your blood) within the past 6 months as evidence of a current and chronic HCV infection.
D. You must be taking Daklinza in combination with Sovaldi, and must meet all required criteria for Sovaldi

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

E. For Genotype 1 infection approval also requires:
   1. **Patients without cirrhosis (liver scarring):**
      a. You are treatment naïve (never previously treated) or treatment experienced with a peginterferon and ribavirin regimen
      b. You have previously tried Epclusa, Harvoni or Mavyret required and you had adverse effects, intolerance early in therapy or contraindication to (medical reason why you cannot use) Epclusa, Harvoni and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
   2. **Patients with decompensated cirrhosis (you have symptoms related to liver scarring):**
      a. You have previously tried Epclusa or Harvoni and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Epclusa and Harvoni; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
      b. Concurrent (used at the same time with) ribavirin use required
   3. **Patients status post liver transplant:**
      a. You have previously tried Harvoni or Mavyret and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Harvoni and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
      b. Concurrent (used at the same time with) ribavirin use required

F. For Genotype 3 infection approval also requires:
   1. **Patients without cirrhosis:**
      a. You are treatment naïve (never previously treated) or treatment experienced with a peginterferon and ribavirin regimen
      b. You have previously tried Epclusa or Mavyret and you had adverse effect, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Epclusa and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
   2. **Patients with decompensated cirrhosis (Child-Pugh B or C; you have symptoms related to liver scarring):**
      a. You have previously tried Epclusa and you had adverse effect, intolerance early in therapy, or contraindication to (medical reason why you cannot use) therapy; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
      b. Concurrent (used at the same time with) ribavirin use required

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

3. **Post-liver transplant, without cirrhosis:**
   a. Previous trial of Mavyret required and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) therapy; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
   b. Concurrent (used at the same time with) ribavirin use required

4. **Post-liver transplant, with compensated cirrhosis**
   a. Previous trial of Epclusa or Mavyret required and you had adverse effects, intolerance early in therapy or contraindication to (medical reason why you cannot use) Epclusa and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
   b. Concurrent (used at the same time with) ribavirin use required

**Daklinza will not be approved if you meet ANY of the following:**
- You are using any of the following medications at the same time while on Daklinza: amiodarone, carbamazepine, phenytoin, or rifampin
- You are using any of the following medications at the same time while on Sovaldi: phenobarbital, oxcarbazepine, rifabutin, rifapentine, or tipranavir/ritonavir
- You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- You have compensated cirrhosis (Child-Pugh A; you have no symptoms related to liver damage) and are not status post liver transplant (you have not had a liver transplant)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Daklinza.

**REFERENCES**
## DACOMITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DACOMITINIB</td>
<td>VIZIMPRO</td>
<td>45283</td>
<td></td>
<td>GPI-10</td>
<td>(2136001900)</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet **ALL** of the following criteria?
   - The patient has epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
   - Vizimpro will be used as first-line treatment
   - Vizimpro will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva [erlotinib], Tagrisso [osimertinib], Iressa [gefitinib])

   **If yes,** approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   **If no,** do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **DACOMITINIB (Vizimpro)** requires the following rule(s) be met for approval:
   
   A. You have metastatic non-small cell lung cancer (type of cancer that has spread to other parts of the body)
   B. You have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
   C. Vizimpro will be used as first-line treatment
   D. You will NOT be using Vizimpro concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Iressa [gefitinib])

   Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
DACOMITINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vizimpro.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 11/18
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of multiple sclerosis (MS) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a neurologist
   • The patient has symptoms of a walking disability such as mild to moderate bilateral lower extremity weakness or unilateral weakness plus lower extremity or truncal ataxia

   If yes, approve for 3 months by HICL or GPI-10 for #2 tablets per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DALFAMPRIDINE (Ampyra) requires the following rule(s) be met for approval:
   A. You have multiple sclerosis (MS: a type of nerve disorder)
   B. You are 18 years of age or older
   C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   D. You have symptoms of a walking disability such as mild to moderate bilateral (both sides) lower extremity weakness or unilateral (one side) weakness plus lower extremity or truncal ataxia (impaired balance or coordination)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of multiple sclerosis (MS) AND meet the following criterion?
   • The patient has experienced or maintained at least a 15% improvement in walking ability

   If yes, approve for 12 months by HICL or GPI-10 for #2 tablets per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DALFAMPRIDINE (Ampyra) requires the following rule(s) be met for renewal:
   A. You have multiple sclerosis (MS: a type of nerve disorder)
   B. You have experienced or maintained at least a 15% improvement in walking ability

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ampyra.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/10
Commercial Effective: 08/29/22 Client Approval: 07/22 P&T Approval: 07/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet ALL of the following criteria?
   - The patient had a trial of the preferred agent: Retacrit
   - The patient has a hemoglobin level of less than 10g/dL

If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mcg/mL vial: #4mL per 28 days.
   - 40mcg/mL vial: #4mL per 28 days.
   - 60mcg/mL vial: #4mL per 28 days.
   - 100mcg/mL vial: #4mL per 28 days.
   - 200mcg/mL vial: #4mL per 28 days.
   - 300mcg/mL vial: #4mL per 28 days.
   - 10mcg/0.4mL syringe: #1.6mL per 28 days.
   - 25mcg/0.42mL syringe: #1.68mL per 28 days.
   - 40mcg/0.4mL syringe: #1.6mL per 28 days.
   - 60mcg/0.3mL syringe: #1.2mL per 28 days.
   - 100mcg/0.5mL syringe: #2mL per 28 days.
   - 150mcg/0.3mL syringe: #1.2mL per 28 days.
   - 200mcg/0.4mL syringe: #1.6mL per 28 days.
   - 300mcg/0.6mL syringe: #2.4mL per 28 days.
   - 500mcg/mL syringe: #4mL per 28 days.

If no, continue to #2.
DARBEPOETIN ALFA

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effect of concomitantly administered cancer chemotherapy and meet ALL of the following criteria?
   • The patient had a trial of the preferred agent: Retacrit
   • The patient has a hemoglobin level of less than 11g/dL OR the patient’s hemoglobin level has decreased at least 2g/dL below baseline level

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   • 25mcg/mL vial: #4mL per 28 days.
   • 40mcg/mL vial: #4mL per 28 days.
   • 60mcg/mL vial: #4mL per 28 days.
   • 100mcg/mL vial: #4mL per 28 days.
   • 200mcg/mL vial: #4mL per 28 days.
   • 300mcg/mL vial: #4mL per 28 days.
   • 10mcg/0.4mL syringe: #1.6mL per 28 days.
   • 25mcg/0.42mL syringe: #1.68mL per 28 days.
   • 40mcg/0.4mL syringe: #1.6mL per 28 days.
   • 60mcg/0.3mL syringe: #1.2mL per 28 days.
   • 100mcg/0.5mL syringe: #2mL per 28 days.
   • 150mcg/0.3mL syringe: #1.2mL per 28 days.
   • 200mcg/0.4mL syringe: #1.6mL per 28 days.
   • 300mcg/0.6mL syringe: #2.4mL per 28 days.
   • 500mcg/mL syringe: #4mL per 28 days.

   If no, continue to #3.
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa and meet ALL of the following criteria?
   - The patient had a trial of the preferred agent: Retacrit
   - The patient has a hemoglobin level of less than 10g/dL
   - The patient had a trial of or contraindication to ribavirin dose reduction

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:
   - 25mcg/mL vial: #4mL per 28 days.
   - 40mcg/mL vial: #4mL per 28 days.
   - 60mcg/mL vial: #4mL per 28 days.
   - 100mcg/mL vial: #4mL per 28 days.
   - 200mcg/mL vial: #4mL per 28 days.
   - 300mcg/mL vial: #4mL per 28 days.
   - 10mcg/0.4mL syringe: #1.6mL per 28 days.
   - 25mcg/0.42mL syringe: #1.68mL per 28 days.
   - 40mcg/0.4mL syringe: #1.6mL per 28 days.
   - 60mcg/0.3mL syringe: #1.2mL per 28 days.
   - 100mcg/0.5mL syringe: #2mL per 28 days.
   - 150mcg/0.3mL syringe: #1.2mL per 28 days.
   - 200mcg/0.4mL syringe: #1.6mL per 28 days.
   - 300mcg/0.6mL syringe: #2.4mL per 28 days.
   - 500mcg/mL syringe: #4mL per 28 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DARBEPOETIN ALFA (Aranesp) requires the following rule(s) be met for approval:

A. You have ONE of the following:
1. Anemia (low amount of healthy red blood cells) associated with chronic kidney disease
2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. **If you have anemia associated with chronic kidney disease, approval also requires:**
1. You have tried the preferred medication: Retacrit
2. You have a hemoglobin level (type of blood test) of less than 10g/dL

C. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires:**
1. You have tried the preferred medication: Retacrit
2. You have a hemoglobin level of less than 11g/dL OR your hemoglobin level has decreased at least 2g/dL below your baseline level

D. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
1. You have tried the preferred medication: Retacrit
2. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
3. You have a hemoglobin level of less than 10g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet ONE of the following criteria?
   - The patient has a hemoglobin level of less than 10g/dL if not on dialysis
   - The patient has a hemoglobin level of less than 11g/dL if on dialysis
   - The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and the dose is being reduced/interrupted to decrease the need for blood transfusions
   - The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and the dose is being reduced/interrupted to decrease the need for blood transfusions

If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mcg/mL vial: #4mL per 28 days.
   - 40mcg/mL vial: #4mL per 28 days.
   - 60mcg/mL vial: #4mL per 28 days.
   - 100mcg/mL vial: #4mL per 28 days.
   - 200mcg/mL vial: #4mL per 28 days.
   - 300mcg/mL vial: #4mL per 28 days.
   - 10mcg/0.4mL syringe: #1.6mL per 28 days.
   - 25mcg/0.42mL syringe: #1.68mL per 28 days.
   - 40mcg/0.4mL syringe: #1.6mL per 28 days.
   - 60mcg/0.3mL syringe: #1.2mL per 28 days.
   - 100mcg/0.5mL syringe: #2mL per 28 days.
   - 150mcg/0.3mL syringe: #1.2mL per 28 days.
   - 200mcg/0.4mL syringe: #1.6mL per 28 days.
   - 300mcg/0.6mL syringe: #2.4mL per 28 days.
   - 500mcg/mL syringe: #4mL per 28 days.

If no, continue to #2.

CONTINUED ON NEXT PAGE
2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy **AND** meet the following criterion?
   - The patient has a hemoglobin level between 10g/dL and 12g/dL

     If yes, **approve for 12 months by G PID or G PI-14 for the requested strength as follows:**
     - 25mcg/mL vial: #4mL per 28 days.
     - 40mcg/mL vial: #4mL per 28 days.
     - 60mcg/mL vial: #4mL per 28 days.
     - 100mcg/mL vial: #4mL per 28 days.
     - 200mcg/mL vial: #4mL per 28 days.
     - 300mcg/mL vial: #4mL per 28 days.
     - 10mcg/0.4mL syringe: #1.6mL per 28 days.
     - 25mcg/0.42mL syringe: #1.68mL per 28 days.
     - 40mcg/0.4mL syringe: #1.6mL per 28 days.
     - 60mcg/0.3mL syringe: #1.2mL per 28 days.
     - 100mcg/0.5mL syringe: #2mL per 28 days.
     - 150mcg/0.3mL syringe: #1.2mL per 28 days.
     - 200mcg/0.4mL syringe: #1.6mL per 28 days.
     - 300mcg/0.6mL syringe: #2.4mL per 28 days.
     - 500mcg/mL syringe: #4mL per 28 days.

     If no, continue to #3.

CONTINUED ON NEXT PAGE
3. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa AND meet the following criterion?
   • The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:
   • 25mcg/mL vial: #4mL per 28 days.
   • 40mcg/mL vial: #4mL per 28 days.
   • 60mcg/mL vial: #4mL per 28 days.
   • 100mcg/mL vial: #4mL per 28 days.
   • 200mcg/mL vial: #4mL per 28 days.
   • 300mcg/mL vial: #4mL per 28 days.
   • 10mcg/0.4mL syringe: #1.6mL per 28 days.
   • 25mcg/0.42mL syringe: #1.68mL per 28 days.
   • 40mcg/0.4mL syringe: #1.6mL per 28 days.
   • 60mcg/0.3mL syringe: #1.2mL per 28 days.
   • 100mcg/0.5mL syringe: #2mL per 28 days.
   • 150mcg/0.3mL syringe: #1.2mL per 28 days.
   • 200mcg/0.4mL syringe: #1.6mL per 28 days.
   • 300mcg/0.6mL syringe: #2.4mL per 28 days.
   • 500mcg/mL syringe: #4mL per 28 days.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DARBEPOETIN ALFA (Aranesp) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Anemia (low amount of healthy red blood cells) associated with chronic kidney disease
   2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
   2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
   3. Your hemoglobin has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   4. Your hemoglobin has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions.

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:
   1. You have a hemoglobin level between 10g/Dl and 12g/Dl

D. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Aranesp.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of insomnia and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has premature awakening and/or abnormal sleep onset delay lasting 30 minutes or longer, occurring 3 or more times weekly for the last month for acute insomnia or for at least 3 months for chronic insomnia
   - The patient has daytime impairment despite adequate time attempting to sleep and treatment of any treatable causes
   - The patient is NOT concurrently using Z hypnotics (e.g., eszopiclone, zaleplon, zolpidem) or benzodiazepines (e.g., estazolam, temazepam, triazolam) for sleep
   - The patient does NOT have narcolepsy
   - The patient had a trial of or contraindication to TWO generic insomnia medications (e.g., eszopiclone, zaleplon, zolpidem) AND Belsomra

If yes, approve for 3 months by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DARIDOREXANT (Quivibiq) requires the following rule(s) be met for approval:
A. You have insomnia (a type of sleep condition)
B. You are 18 years of age or older
C. You have premature awakening (waking up too early) and/or abnormal sleep onset delay (cannot fall asleep) lasting 30 minutes or longer, occurring 3 or more times weekly for the last month for acute (short-term) insomnia or for at least 3 months for chronic (long-term) insomnia
D. You have daytime impairment despite adequate time attempting to sleep and treatment of any treatable causes
E. You are NOT using Quivibiq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep
F. You do NOT have narcolepsy (a type of sleep condition)
G. You had a trial of or contraindication (harmful for) to TWO generic insomnia medications (such as eszopiclone, zaleplon, zolpidem) AND Belsomra

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of insomnia and meet ALL of the following criteria?
   - The patient has demonstrated improvement of insomnia symptoms but is not currently a candidate for discontinuation
   - The patient is NOT concurrently using Z hypnotics (e.g., eszopiclone, zaleplon, zolpidem) or benzodiazepines (e.g., estazolam, temazepam, triazolam) for sleep

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DARIDOREXANT (Quviviq) requires the following rule(s) be met for renewal:
   A. You have insomnia (a type of sleep condition)
   B. You have demonstrated improvement of insomnia symptoms but are not currently a candidate for discontinuation
   C. You are NOT using Quviviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
DARIDOREXANT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Quviviq.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 04/22
Commercial Effective: 05/09/22  Client Approval: 04/22  P&T Approval: 10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of non-metastatic castration resistant prostate cancer (nmCRPC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen [PSA] levels)

   If yes, continue to #3.
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) AND meet the following criterion?
   • The requested medication will be used in combination with docetaxel

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet ONE of the following criteria?
   • The patient previously received a bilateral orchiectomy
   • The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   • The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DAROLUTAMIDE (Nubeqa) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
C. If you have non-metastatic castration resistant prostate cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA: lab result that may indicate prostate cancer] levels)
D. If you have metastatic hormone-sensitive prostate cancer, approval also requires:
   1. The requested medication will be used in combination with docetaxel

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of non-metastatic castration resistant prostate cancer (nmCRPC)?
   If yes, continue to #3.
   If no, continue to #2.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of metastatic hormone-sensitive prostate cancer (mHSPC) AND meet the following criterion?
   • The requested medication will be used in combination with docetaxel

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
   • The patient previously received a bilateral orchiectomy
   • The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   • The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **DAROLUTAMIDE (Nubeqa)** requires the following rule(s) be met for renewal:

A. **You have ONE of the following diagnoses:**
   1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)

B. **You meet ONE of the following:**
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

C. **If you have metastatic hormone-sensitive prostate cancer, approval also requires:**
   1. The requested medication will be used in combination with docetaxel

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
DAROLUTAMIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nubeqa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 11/19
Commercial Effective: 01/01/23  Client Approval: 11/22  P&T Approval: 10/22
DASATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DASATINIB</td>
<td>SPRYCEL</td>
<td>33855</td>
<td>GCN</td>
<td>GPID-10 GPI-14</td>
<td>(2153182000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase and meet ONE of the following criteria?
   - The patient is 18 years of age or older AND is newly diagnosed
   - The patient is between 1 and 17 years of age

   If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:
   - SPRYCEL 20MG with a quantity limit of #3 per day.
   - SPRYCEL 50MG with a quantity limit of #1 per day.
   - SPRYCEL 70MG with a quantity limit of #1 per day.
   - SPRYCEL 80MG with a quantity limit of #1 per day.
   - SPRYCEL 100MG with a quantity limit of #1 per day.
   - SPRYCEL 140MG with a quantity limit #1 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is in chronic, accelerated, or myeloid or lymphoid blast phase
   - The patient has a resistance or intolerance to prior therapy including imatinib (Gleevec)
   - The patient had a mutational analysis prior to initiation AND Sprycel is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile (Please see header CML-5 of the current NCCN guidelines)

   If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:
   - SPRYCEL 20MG with a quantity limit of #3 per day.
   - SPRYCEL 50MG with a quantity limit of #1 per day.
   - SPRYCEL 70MG with a quantity limit of #1 per day.
   - SPRYCEL 80MG with a quantity limit of #1 per day.
   - SPRYCEL 100MG with a quantity limit of #1 per day.
   - SPRYCEL 140MG with a quantity limit #1 per day.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has a resistance or intolerance to prior therapy (e.g., imatinib (Gleevec), or nilotinib (Tasigna))

   If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:
   • SPRYCEL 20MG with a quantity limit of #3 per day.
   • SPRYCEL 50MG with a quantity limit of #1 per day.
   • SPRYCEL 70MG with a quantity limit of #1 per day.
   • SPRYCEL 80MG with a quantity limit of #1 per day.
   • SPRYCEL 100MG with a quantity limit of #1 per day.
   • SPRYCEL 140MG with a quantity limit #1 per day.

   If no, continue to #4.

4. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and meet ALL of the following criteria?
   • The patient is between 1 and 17 years of age
   • The patient is newly diagnosed
   • The patient is using Sprycel in combination with chemotherapy

   If yes, approve for all strengths for 12 months by GPID or GPI-14 as follows:
   • SPRYCEL 20MG with a quantity limit of #3 per day.
   • SPRYCEL 50MG with a quantity limit of #1 per day.
   • SPRYCEL 70MG with a quantity limit of #1 per day.
   • SPRYCEL 80MG with a quantity limit of #1 per day.
   • SPRYCEL 100MG with a quantity limit of #1 per day.
   • SPRYCEL 140MG with a quantity limit #1 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DASATINIB (Sprycel) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: a type of blood cancer) in chronic, accelerated, or myeloid or lymphoid blast phase
   2. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL: a type of blood cancer)

(Denial text continued on the next page)
GUIDELINES FOR USE (CONTINUED)

B. If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires ONE of the following:
   1. You are 18 years of age or older AND are newly diagnosed
   2. You are between 1 and 17 years of age

C. If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, accelerated phase, or myeloid or lymphoid blast phase, approval also requires:
   1. You are 18 years of age or older
   2. You have resistance or intolerance (side effect) to prior therapy including imatinib (Gleevec)
   3. You had a mutational analysis prior to initiation of therapy AND Sprycel is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

D. If you have Philadelphia chromosome-positive acute lymphoblastic leukemia, approval also requires ONE of the following:
   1. You are 18 years of age or older AND you have a resistance or intolerance (side effect) to prior therapy such as imatinib (Gleevec) or nilotinib (Tasigna)
   2. You are newly diagnosed, between 1 and 17 years of age, AND using Sprycel in combination with chemotherapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sprycel.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 05/12
Client Approval: 02/22
P&T Approval: 01/22
DECITABINE/CEDAZURIDINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DECITABINE/CEDAZURIDINE</td>
<td>INQOVI</td>
<td>46686</td>
<td></td>
<td>GPI-10 (2199000225)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of myelodysplastic syndromes (MDS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has ONE of the following International Prognostic Scoring System groups: intermediate-1, intermediate-2, or high-risk

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per 28 days. If no, continue to #2.

2. Does the patient have a diagnosis of chronic myelomonocytic leukemia (CMML) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per 28 days. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DECITABINE/CEDAZURIDINE (Inqovi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Myelodysplastic syndromes (MDS: type of blood cancer)
   2. Chronic myelomonocytic leukemia (CMML: rare form of blood cancer)

B. You are 18 years of age or older

C. If you have myelodysplastic syndromes (MDS), approval also requires:
   1. You meet ONE of the following International Prognostic Scoring System groups (scoring system used to predict the course of a patient's disease):
      a. Intermediate-1
      b. Intermediate-2
      c. High-risk

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
DECITABINE/CEDAZURIDINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Inqovi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/20
Commercial Effective: 01/01/21  Client Approval: 11/20  P&T Approval: 10/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request prescribed by or given in consultation with a hematologist or hematologist-oncologist?
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have a diagnosis of chronic iron overload due to blood transfusions?
   
   If yes, continue to #3.
   If no, continue to #4.

3. Does the patient meet **ALL** of the following criteria?
   
   - The patient is 2 years of age or older
   - The patient's serum ferritin levels are consistently greater than 1000mcg/L (at least 2 lab values in the previous 3 months)

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT)?
   
   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?
   - The patient is 10 years of age or older
   - The patient’s serum ferritin levels are consistently greater than 300mcg/L (at least 2 lab values in the previous 3 months)
   - The patient’s liver iron concentration (LIC) is at least 5mg Fe/g dry weight

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

6. Is the request for Exjade or Jadenu tablets?

   If yes, **approve Exjade or Jadenu tablets for all strengths of the requested drug for 6 months by GPID or GPI-14.**
   If no, continue to #7.

7. Is the request for Jadenu sprinkle packets **AND** the patient has tried a generic equivalent of Exjade or Jadenu tablets?

   If yes, **approve Jadenu Sprinkle for all strengths for 6 months by GPID or GPI-14.**
   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX)** requires the following rule(s) be met for approval:
A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)
B. The medication is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist/oncologist (tumor/cancer doctor)
C. **If you have chronic iron overload due to blood transfusions, approval also requires:**
   1. You are 2 years of age or older
   2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 1000mcg/L (we need at least 2 lab values taken within the previous 3 months)

*Initial denial text continued on next page*

CONTINUED ON NEXT PAGE
DEFERASIROX

INITIAL CRITERIA (CONTINUED)

D. If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), approval also requires:
1. You are 10 years of age or older
2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
3. Your liver iron concentration (LIC) is at least 5mg Fe/g dry weight or greater
E. Requests for Jadenu sprinkle packets require a trial of equivalent generic Exjade or Jadenu tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic iron overload due to blood transfusions AND meet the following criterion?
   • The patient's serum ferritin levels are consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)
   
   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT) and meet ONE of the following criteria?
   • The patient's serum ferritin levels are consistently greater than 300mcg/L (at least 2 lab values in the previous 3 months)
   • The patient's liver iron concentration (LIC) is at least 3mg Fe/g dry weight (Liver iron concentration supersedes serum ferritin level when both measurements are available)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DEFERASIROX

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX) requires the following rule(s) be met for renewal:

A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)

B. If you have chronic iron overload due to blood transfusions, renewal also requires:
   1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 500 mcg/L (we need at least 2 lab values taken within the previous 3 months)

C. If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), renewal also requires ONE of the following:
   1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300 mcg/L (we need at least 2 lab values taken within the previous 3 months)
   2. Your liver iron concentration (LIC) is at least 3mg Fe/g dry weight or greater

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Exjade and Jadenu.

REFERENCES
• Exjade [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.
DEFERIPRONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEFERIPRONE</td>
<td>FERRIPROX,</td>
<td>18544</td>
<td></td>
<td>GPI-10</td>
<td>(9310002800)</td>
</tr>
<tr>
<td></td>
<td>DEFERIPRONE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have ONE of the following diagnoses?
   - Transfusional iron overload due to thalassemia syndrome
   - Transfusional iron overload due to sickle cell disease or other anemias

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - Therapy is prescribed by or given in consultation with a hematologist or hematologist/oncologist
   - The patient had a trial of or contraindication to at least ONE of the following: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient experiencing intolerable toxicities, clinically significant adverse effects, has a contraindication to current chelators: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine), OR current chelation therapy is inadequate?

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient meet ONE of the following criteria?
   - The request is for Ferriprox (deferiprone) tablets **AND** the patient is 8 years of age or older
   - The request is for Ferriprox oral solution **AND** the patient is 3 years of age or older

   If yes, approve for 6 months for all strengths of the requested formulation by GPID or GPI-14.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEFERIPRONE (Ferriprox) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Transfusional iron overload due to a thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
   2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)
B. Therapy is prescribed by or given in consultation with a hematologist (a type of blood doctor) or hematologist/oncologist (a type of cancer doctor)
C. You have tried or have a contraindication (harmful for) to at least ONE of the following:
   Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
D. You meet ONE of the following:
   1. You are experiencing intolerable toxicities or clinically significant adverse effects or have a contraindication (harmful for) to current chelators (drugs that bind to iron): Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
   2. Current chelation therapy (therapy that lowers iron levels) with Exjade [deferasirox], Jadenu [deferasirox], or Desferal [deferoxamine]) is not working well enough
E. If the request is for Ferriprox (deferiprone) tablets, approval also requires:
   1. You are 8 years of age or older
F. If the request is for Ferriprox oral solution, approval also requires:
   1. You are 3 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have ONE of the following diagnoses?
   • Transfusional iron overload due to thalassemia syndrome
   • Transfusional iron overload due to a sickle cell disease or other anemias

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
2. Does the patient meet the following criterion?
   • The patient has serum ferritin levels consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)

   If yes, continue to #3.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

3. Does the patient meet ONE of the following criteria?
   • The request is for Ferriprox (deferiprone) tablets AND the patient is 8 years of age or older
   • The request is for Ferriprox oral solution AND the patient is 3 years of age or older

   If yes, approve for 12 months for all strengths of the requested formulation by GPID or GPI-14.
   If no, do not approve.
   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DEFERIPRONE (Ferriprox) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Transfusional iron overload due to thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
   2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)
B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay above 500mcg/L (at least 2 lab values in the previous 3 months)
C. If the request is for Ferriprox (deferiprone) tablets, approval also requires:
   1. You are 8 years of age or older
D. If the request is for Ferriprox oral solution, approval also requires:
   1. You are 3 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
DEFERIPRONE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ferriprox.

REFERENCES
• Ferriprox [Prescribing Information]. Weston, FL: ApoPharma USA, Inc.; April 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Client Approval: 02/22
P&T Approval: 01/22
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of chronic iron overload due to transfusion-dependent anemias and meet **ALL** of the following criteria?
   
   - The medication is prescribed by or given in consultation with a hematologist or hematologist-oncologist
   - The patient is 3 years of age or older
   - The patient has a serum ferritin levels that are consistently greater than 1000mcg/L (at least 2 lab values in the previous 3 months)

   If yes, **approve for 6 months by HICL or GPI-10.**
   If no, do not approve.

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **DEFEROXAMINE (Desferal)** requires the following rule(s) be met for approval:
   
   A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
   B. Therapy is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist-oncologist (tumor/cancer doctor)
   C. You are 3 years of age or older
   D. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 1000mcg/L (shown by at least 2 lab values in the previous 3 months)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic iron overload due to transfusion-dependent anemias and meet the following criterion?
   - The patient has a serum ferritin levels that are consistently greater than 500mcg/L (at least 2 lab values in the previous 3 months)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DEFEROXAMINE (Desferal) requires the following rules be met for renewal:
   A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
   B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 500mcg/L (at least 2 lab values in the previous 3 months)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Desferal.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 08/17
Commercial Effective: 04/17/23 Client Approval: 03/23 P&T Approval: 07/17
DEFLAZACORT

Guidelines for Use

Initial Criteria (Note: For Renewal Criteria See Below)

1. Does the patient have a diagnosis of Duchenne muscular dystrophy (DMD) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Documented genetic testing confirming Duchenne muscular dystrophy (DMD) diagnosis
   - Therapy is prescribed by or given in consultation with a neurologist specializing in treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center

   If yes, continue to #2.
   If no, do not approve.
   **Denial Text:** See the initial denial text at the end of the guideline.

2. Has the patient tried prednisone or prednisolone for at least 6 months?

   If yes, continue to #3.
   If no, do not approve.
   **Denial Text:** See the initial denial text at the end of the guideline.

3. Is the request for Emflaza due to lack of efficacy with prednisone or prednisolone and ALL of the following criteria are met?
   - Patient is not in Stage 1: pre-symptomatic phase
   - Steroid myopathy has been ruled out
   - Documented deterioration in ambulation, functional status, or pulmonary function while on prednisone or prednisolone, using standard measures over time, consistent with advancing disease (stage 2 or higher); Acceptable standard measures: [such as 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower’s maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA), pulmonary function (FVC, PFTs), upper limb strength (propelling a wheelchair 30 feet)]

   If yes, approve for 6 months by GPID or GPI-14 for all the following strengths with the following quantity limits:
   - 6mg tablet: #60 per 30 days
   - 18mg tablet: #30 per 30 days
   - 30mg tablet: #60 per 30 days
   - 36mg tablet: #60 per 30 days
   - 22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days

   If no, continue to #4.

**Continued on Next Page**
INITIAL CRITERIA (CONTINUED)

4. Is the patient experiencing an adverse consequence of prednisone or prednisolone and is the adverse consequence named or listed in the prescribing information adverse event profile of Emflaza?

   If yes, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.
   If no, continue to #5.

5. Has documentation of literature-based evidence been provided supporting the mitigating effect of Emflaza for the named adverse consequence?

   If yes, approve for 6 months by GPID or GPI-14 for all the following strengths with the following quantity limits:
   • 6mg tablet: #60 per 30 days
   • 18mg tablet: #30 per 30 days
   • 30mg tablet: #60 per 30 days
   • 36mg tablet: #60 per 30 days
   • 22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days

   If no, do not approve.
   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DEFLAZACORT (Emflaza) requires the following rules be met for approval:
   A. You have Duchenne muscular dystrophy (inherited muscular weakness that gets worse)
   B. You are 2 years of age or older
   C. You doctor confirms your diagnosis with genetic testing
   D. The drug is prescribed by or recommended by a neurologist (nerve system doctor) specializing in treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center

   (Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

E. You have tried prednisone or prednisolone for at least 6 months and meet one of the following:
   1. Prednisone or prednisolone did not work and you meet ALL of the following criteria:
      a. You are not in Stage 1: pre-symptomatic phase
      b. There is no steroid myopathy (muscle disease due to steroid)
      c. You have documentation that your disease is advanced— you cannot walk, cannot function, cannot breathe using standard measures over time, consistent with advancing disease (stage 2 or higher). Acceptable standard measures include: 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower’s maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA), pulmonary function (forced vital capacity, lung function tests), upper limb strength (propelling a wheelchair 30 feet)
   2. You had adverse side effects while on prednisone or prednisolone and there is documentation of literature-based evidence provided supporting Emflaza’s decreased effect for that side effect
      Note: Requests due to side effects while on prednisone or prednisolone that are named or listed in the prescribing information of Emflaza will not be approved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Duchenne muscular dystrophy (DMD) and is currently ambulatory?
   If yes, continue to #2.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Has the patient shown function, stabilization or improvement in a standard set of ambulatory or functional status measures since being on Emflaza that are being monitored, tracked, and documented consistently: Acceptable standard measures: [such as 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower’s maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA)]?

If yes, approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:
- 6mg tablet: #60 per 30 days
- 18mg tablet: #30 per 30 days
- 30mg tablet: #60 per 30 days
- 36mg tablet: #60 per 30 days
- 22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days

If no, do not approve. 
DENIAL TEXT: See the renewal denial text at the end of the guideline.

3. Is the patient non-ambulatory and has the patient maintained or demonstrated a less than expected decline in pulmonary function and/or upper limb strength assessed by standard measures since being on Emflaza, that are being monitored, tracked and documented consistently; Acceptable standard measures: pulmonary function (FVC, PFTs), upper limb strength measures (propelling a wheelchair 30 feet), Physician Global assessments (PGA)?

If yes, approve for 12 months by GPID or GPI-14 for all the following strengths with the following quantity limits:
- 6mg tablet: #60 per 30 days
- 18mg tablet: #30 per 30 days
- 30mg tablet: #60 per 30 days
- 36mg tablet: #60 per 30 days
- 22.75mg/mL oral suspension: #39mL (3 bottles) per 30 days

If no, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DEFLAZACORT

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **DEFLAZACORT (Emflaza)** requires the following rules be met for renewal:
A. You have Duchenne muscular dystrophy (inherited muscular weakness that worsens)
B. You meet ONE of the following criteria:
   i. **If you are currently ambulatory (can walk), renewal also requires:**
      a. You have shown function, stabilization or improvement in a standard set of ambulatory or functional status measures since being on Emflaza. These measures must be monitored, tracked, and documented consistently. Acceptable standard measures include: 6-minute walk distance, time to ascend/descend 4 stairs, rise from floor time (Gower's maneuver), 10-meter run/walk time, North Star Ambulatory Assessment, Physician Global Assessments
   ii. **If you are currently non-ambulatory (cannot walk), renewal also requires:**
      a. You have maintained or have a less than expected decrease in pulmonary (breathing) function and/or upper limb strength assessed by standard measures since being on Emflaza. These measures must be monitored, tracked, and documented consistently. Acceptable standard measures include: pulmonary function (force vital capacity, pulmonary function tests), upper limb strength measures (propelling a wheelchair 30 feet), Physician Global Assessments

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Emflaza.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/17
Commercial Effective: 07/01/20 Client Approval: 04/20
P&T Approval: 07/19
GUIDELINES FOR USE

1. Is therapy prescribed by or in consultation with an Infectious Disease (ID) specialist?

   If yes, approve as follows:
   - Acute bacterial skin or skin structure infection (ABSSSI): approve 450mg tablets for one fill by GID or GPI-14 with a quantity limit of #28 tablets per 14 days.
   - Community-acquired bacterial pneumonia (CABP): approve 450mg tablets for one fill by GID or GPI-14 with a quantity limit of #20 tablets per 10 days.
   - Other indications: approve 450mg tablets for one fill by GID or GPI-14 with a quantity limit of #28 tablets per 14 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of acute bacterial skin or skin structure infection (ABSSSI) and meet ALL of the following?
   - The patient is 18 years of age or older
   - The infection is caused by ONE of the following susceptible organisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, or Pseudomonas aeruginosa

   If yes, continue to #3.
   If no, continue to #6.

3. Is the requested medication being used for an animal or human bite, necrotizing fasciitis, diabetic foot infection, decubitis ulcer formation, myonecrosis or ecthyma gangrenosum?

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Has antimicrobial susceptibility testing been performed that meets ALL of the following criteria?
   • The results from the infection site culture indicate pathogenic organism(s) with resistance to ONE standard of care agent for acute bacterial skin or skin structure infection (ABSSSI) (e.g., sulfamethoxazole/trimethoprim, levofloxacin, clindamycin, cephalaxin, or vancomycin)
   • The results from the infection site culture indicate pathogenic organism(s) that are susceptible to delafloxacin

If yes, approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #28 tablets per 14 days.
If no, continue to #5.

5. Does the patient meet ALL of the following criteria?
   • Antimicrobial susceptibility results are unavailable
   • The patient has had a trial of or contraindication to ONE of the following agents:
     o Gram positive targeting antibiotic (e.g., linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin)
     o Penicillin antibiotic (e.g., amoxicillin)
     o Fluoroquinolone antibiotic (e.g., levofloxacin, ciprofloxacin, moxifloxacin)
     o Cephalosporin antibiotic (e.g., ceftriaxone, cephalaxin, cefazolin)

If yes, approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #28 tablets per 14 days.
If no, do not approve.
DENIAL TEXT: See the denial text at the end of the guideline.

6. Does the patient have a diagnosis of community-acquired bacterial pneumonia (CABP) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The infection is caused by any of the following susceptible microorganisms: Streptococcus pneumonia, Staphylococcus aureus (methicillin-susceptible [MSSA] isolates only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae

If yes, continue to #7.
If no, do not approve.
DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

7. Has antimicrobial susceptibility testing been performed that meets ALL of the following criteria?
   • The results from the infection site culture indicate pathogenic organism(s) with resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (CABP) (e.g., macrolide, doxycycline, alternative fluoroquinolone, beta-lactam, linezolid)
   • The results from the infection site culture indicate pathogenic organism(s) that are susceptible to delafloxacin

   If yes, approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #20 tablets per 10 days.
   If no, continue to #8.

8. Does the patient meet ALL of the following criteria?
   • Antimicrobial susceptibility results are unavailable
   • The patient had a trial of or contraindication to TWO standard of care agents for community-acquired bacterial pneumonia (CABP) (e.g., macrolide, doxycycline, alternative fluoroquinolone, beta-lactam, linezolid)

   If yes, approve 450mg tablets for one fill by GPID or GPI-14 with a quantity limit of #20 tablets per 10 days.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DELAFLOXACIN (Baxdela) requires the following rule(s) be met for approval:
A. You meet ONE of the following:
   1. The requested medication is prescribed by or in consultation with an infectious disease (ID) specialist
   2. You have an acute (serious and short-term) bacterial skin or skin structure infection (ABSSSI)
   3. You have community-acquired bacterial pneumonia (CABP: type of lung infection)

B. If you have an acute bacterial skin or skin structure infection, approval also requires:
   1. You are 18 years of age or older
   2. The infection is caused by any of the following bacteria: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa

(Denial text continued on next page)
DELAFLOXACIN

GUIDELINES FOR USE (CONTINUED)

3. You are not using the requested medication for an animal or human bite, necrotizing fasciitis (flesh eating disease), diabetic foot infection, decubitis ulcer formation (pressure/bed ulcer), myonecrosis (dead muscle tissue) or ecthyma gangrenosum.

4. You meet ONE of the following criteria:
   1. If antimicrobial susceptibility test is available (you have a test showing what drugs work on which bacteria of the infection site), we require the results of the test from the infection site show the bacteria is both a) resistant to ONE standard of care agent for acute bacterial skin or skin structure infection (such as sulfamethoxazole/trimethoprim, levofloxacin, clindamycin, cephalaxin, or vancomycin), AND b) delafloxacin will work against the bacteria.
   2. If antimicrobial susceptibility test is not available (you do not have a test showing what drugs work on which bacteria of the infection site), we require you had a trial or contraindication to (harmful for) ONE of the following agents: a penicillin (such as amoxicillin), a fluoroquinolone (such as levofloxacin, ciprofloxacin, moxifloxacin), a cephalosporin (such as ceftriaxone, cephalaxin, cefazolin), or a gram positive targeting antibiotic (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin).

C. If you have community-acquired bacterial pneumonia (CABP: type of lung infection), approval also requires:
   1. You are 18 years of age or older.
   2. The infection is caused by any of the following bacteria: Streptococcus pneumonia, Staphylococcus aureus (methicillin-resistant [MRSA] isolates only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, Chlamydia pneumoniae, Legionella pneumophila or Mycoplasma pneumoniae.

3. You meet ONE of the following criteria:
   1. If antimicrobial susceptibility test is available (you have a test showing what drugs work on which bacteria of the infection site), we require the results of the test from the infection site show the bacteria is both a) resistant to TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) AND b) delafloxacin will work against the bacteria.
   2. If antimicrobial susceptibility test is not available (you do not have a test showing what drugs work on which bacteria of the infection site), we require you had a trial or contraindication to (harmful for) TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
DELAFLOXACIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Baxdela.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 10/17
Client Approval: 07/23
P&T Approval: 01/20
GUIDELINES FOR USE

1. Is the request for Iprivask for the prevention (prophylaxis) of deep vein thrombosis (DVT) for a patient undergoing elective hip replacement surgery?

   If yes, approve for a total of 35 days of treatment. Enter two authorizations as follows:
   • Approve for 12 days by HICL or GPI-10 for #24 vials.
   • Also enter one fill for 23 days by HICL or GPI-10 for #46 vials with a start date of 7 days following the initial approval.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DESIRUDIN (Iprivask) requires that you are receiving Iprivask for the prevention of deep vein thrombosis (DVT; blood clot in a deep vein, usually in the legs) and you are undergoing elective hip replacement surgery.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Iprivask.

REFERENCES
• Iprivask [Prescribing Information]. Northbrook, IL: Marathon Pharmaceuticals; November 2014.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DESIRUDIN</td>
<td>IPRIVASK</td>
<td>19072</td>
<td></td>
<td>GPI-10</td>
<td>(8333403000)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 08/10
Commercial Effective: 07/01/20 Client Approval: 04/20
Commercial E effective: 07/01/20 P&T Approval: 11/13
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, face, or genital area
   - The patient had a trial of or contraindication to ONE conventional therapy (e.g., PUVA [Phototherapy Ultraviolet Light A], UVB [Ultraviolet Light B], topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, cyclosporine)
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1 per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEUCRACVACITINIB (Sotyktu) requires the following rule(s) be met for approval:
A. You have moderate to severe plaque psoriasis (a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, or genital area
E. You had a trial of or contraindication (harmful for) to ONE standard therapy (such as PUVA [Phototherapy Ultraviolet Light A], UVB [Ultraviolet Light B], topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, cyclosporine)

(Initial denial continued on next page)
INITIAL CRITERIA (CONTINUED)

F. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   • The patient has achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEUCRACVACITINIB (Sotyktu) requires the following rule(s) be met for renewal:
A. You have moderate to severe plaque psoriasis (a type of skin condition)
B. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating severity of psoriasis) of at least 50% or more while on therapy
C. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sotyktu.

REFERENCES
DEUTETRABENAZINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEUTETRABENAZINE</td>
<td>AUSTEDO,</td>
<td>44192</td>
<td>GPI-10</td>
<td>(6238003000)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUSTEDO XR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chorea (involuntary movements) associated with Huntington’s disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist or movement disorder specialist

   If yes, **approve for 12 months by GPID or GPI-14 for ALL of the following:**
   - 6-12-24mg XR titration kit: #42 per 28 days for 1 fill.
   - 6mg: #2 per day.
   - 9mg: #4 per day.
   - 12mg: #4 per day.
   - 6mg XR: #7 per day.
   - 12mg XR: #3 per day.
   - 24mg XR: #2 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe tardive dyskinesia (TD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's TD has been present for at least 3 months
   - Therapy is prescribed by or in consultation with a neurologist, movement disorder specialist, or psychiatrist
   - The patient has a prior history of using antipsychotic medications (e.g., aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if patient is 60 years of age or older) as documented in the prescription claims history

   If yes, **approve for 12 months by GPID or GPI-14 for ALL of the following:**
   - 6-12-24mg XR titration kit: #42 per 28 days for 1 fill.
   - 6mg: #2 per day.
   - 9mg: #4 per day.
   - 12mg: #4 per day.
   - 6mg XR: #7 per day.
   - 12mg XR: #3 per day.
   - 24mg XR: #2 per day.

   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEUTETRABENAZINE (Austedo) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Chorea (involuntary muscle movements) associated with Huntington's disease
   2. Moderate to severe tardive dyskinesia (uncontrolled body movements)
B. You are 18 years of age or older
C. If you have chorea associated with Huntington’s disease, approval also requires:
   1. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or movement disorder specialist
D. If you have moderate to severe tardive dyskinesia, approval also requires:
   1. Moderate to severe tardive dyskinesia (uncontrolled body movements) has been present for at least 3 months
   2. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor), movement disorder specialist, or psychiatrist (type of mental health doctor)
   3. You have a prior history of using antipsychotic medications (such as aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Austedo, Austedo XR.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of major depressive disorder (MDD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to Trintellix
   - The patient had a trial of or contraindication to any generic antidepressant indicated for the treatment of MDD (e.g., sertraline, duloxetine)

If yes, approve for 2 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEXTROMETHORPHAN-BUPROPION (Auvelity) requires the following rule(s) be met for approval:
A. You have major depressive disorder (MDD: a type of mental illness)
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to Trintellix
D. You had a trial of or contraindication (harmful for) to any generic antidepressant indicated for the treatment of major depressive disorder (such as sertraline, duloxetine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of major depressive disorder (MDD) AND meet the following criterion?
   - The patient has responded to therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **DEXTROMETHORPHAN-BUPROPION (Auvelity)** requires the following rule(s) be met for renewal:
   A. You have major depressive disorder (MDD: a type of mental illness)
   B. You have responded to therapy

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL

For further information, please refer to the Prescribing Information and/or Drug Monograph for Auvelity.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/22
Commercial Effective: 10/17/22  Client Approval: 10/22  P&T Approval: 07/21
GUIDELINES FOR USE

1. Does the patient have a diagnosis of pseudobulbar affect (PBA)?

   If yes, approve for 12 months by HICL or GPI-10 for #2 per day per month.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named DEXTROMETHORPHAN with QUINIDINE (Nuedexta) requires you have a pseudobulbar affect (sudden, uncontrollable laughter) for approval.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nuedexta.

REFERENCES

Library Commercial NSA
Yes Yes No

Part D Effective: N/A Created: 02/11
Commercial Effective: 07/01/20 Client Approval: 04/20 P&T Approval: 01/15
CSR NOTE: Requests for blood glucose (diabetic) test strips manufactured by Abbott (FreeStyle and Precision) will adjudicate at the point of service with no restrictions. Non-formulary test strips will require prior authorization.

GUIDELINES FOR USE

1. Has the patient tried one of the following preferred blood glucose (diabetic) meters and test strips by Abbott: FreeStyle or Precision?
   
   If yes, approve open-ended by GPID or GPI-14.
   If no, continue to #2.

2. Does the patient require the use of a non-preferred blood glucose test strip due to significant visual and/or cognitive impairment?
   
   If yes, approve open-ended by GPID or GPI-14.
   If no, continue to #3.

3. Is the prescriber requesting a non-preferred test strip due to a need for data management software? [Note: The preferred test strips include FreeStyle and Precision by Abbott]
   
   If yes, do not approve, and recommend the prescriber contact Abbott for data management software and a connection cable for the meter.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   
   If no, continue to #4.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Does the patient require the use of a non-preferred blood glucose test strip based on his/her use of another manufacturer's companion insulin pump?

If yes, **approve open-ended by GPID or GPI-14.**
If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **DIABETIC TEST STRIPS** requires ONE of following rules be met for approval:

A. You have tried ONE preferred blood glucose (diabetic) meter and test strips. The preferred meters and test strips are FreeStyle and Precision by Abbott
B. You require a non-preferred blood glucose test strip due to significant visual and/or cognitive impairment (problems with sight and/or memory and thinking)
C. You require a non-preferred blood glucose test strip because you use another manufacturer's companion insulin pump

Request for non-preferred test strips will not be approved if due to a need for data management software. Please note that data management software is available for the formulary test strip products. Please contact Abbott for data management software and a connection cable for the meter.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different product or get us more information if it will allow us to approve this request.

**RATIONALE**
The intent of this prior authorization is to encourage the use of cost-effective formulary preferred glucose testing strips before considering coverage of non-preferred alternatives.

**REFERENCES**
- Drug Facts and Comparisons (online version), Blood Glucose Meters. Available at [http://online.factsandcomparisons.com](http://online.factsandcomparisons.com).
DICHLORPHENAMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICHLORPHENAMIDE</td>
<td>KEVEYIS,</td>
<td>03642</td>
<td>GPI-10</td>
<td>(3710002000)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DICHLORPHENAMIDE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

4. Does the patient have a diagnosis of primary hypokalemic periodic paralysis and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has tried acetazolamide AND a potassium-sparing diuretic (i.e., spironolactone, triamterene)
   - Therapy is prescribed by or in consultation with a neurologist
   - The patient does not have hepatic insufficiency, pulmonary obstruction, or a health condition that warrants concurrent use of high-dose aspirin

   If yes, approve for two months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #2.

5. Does the patient have a diagnosis of primary hyperkalemic periodic paralysis or related variants and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has tried acetazolamide AND a thiazide diuretic (i.e., hydrochlorothiazide)
   - Therapy is prescribed by or in consultation with a neurologist
   - The patient does not have hepatic insufficiency, pulmonary obstruction, or a health condition that warrants concurrent use of high-dose aspirin

   If yes, approve for two months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DICHLORPHENAMIDE (Keveyis) requires the following rule(s) be met for approval:
A. You have a primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), or related variants
B. You are 18 years of age or older
C. The medication is prescribed by or in consultation with a neurologist (a type of brain doctor) (Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. You do not have hepatic insufficiency (liver failure), pulmonary obstruction (difficulty breathing due to blockage of airflow), or a health condition that requires you to use high-dose aspirin at the same time

E. **If you have primary hypokalemic periodic paralysis, approval also requires:**
   1. You have tried acetazolamide AND a potassium-sparing diuretic (spironolactone, triamterene)

F. **If you have primary hyperkalemic periodic paralysis or related variants, approval also requires:**
   1. You have tried acetazolamide AND a thiazide diuretic (hydrochlorothiazide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, or related variants **AND** meet the following criterion?
   - The patient has experienced at least two fewer attacks per week from their baseline

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **DICHLORPHENAMIDE (Keveyis)** requires the following rules be met for renewal:
   A. You have primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), or related variants
   B. You have experienced at least two fewer attacks per week from baseline (measurement before you started treatment)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
DICHLORPHENAMIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Keveyis.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 02/06/23
Created: 09/15
Client Approval: 01/23
P&T Approval: 11/15
DICLOFENAC TOPICAL GEL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM</td>
<td>SOLARAZE</td>
<td>86831</td>
<td>GPI-10</td>
<td>(9037403530)</td>
<td></td>
</tr>
<tr>
<td>DICLOFENAC SODIUM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of actinic keratosis and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a dermatologist or oncologist
   • The patient had a trial of or contraindication to topical fluorouracil (e.g., Efudex, Fluoroplex, Carac)

   If yes, approve for 3 months by GPID or GPI-10 with a quantity limit of #100 grams per 30 days.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DICLOFENAC TOPICAL GEL (Solaraze) requires the following rule(s) be met for approval:
   A. You have actinic keratosis (a type of skin condition)
   B. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor) or oncologist (a type of cancer doctor)
   C. You had a trial of or contraindication (harmful for) to topical fluorouracil (such as Efudex, Fluoroplex, Carac)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Solaraze.

REFERENCES

   • Solaraze [Prescribing Information]. PharmaDerm: Melville, NY; May 2016.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 10/22
Commercial Effective: 11/01/22 Client Approval: 10/22
P&T Approval: 01/22
DICLOFENAC TOPICAL SOLUTION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM</td>
<td>PENNSAID, DICLOFENAC SODIUM</td>
<td>35936</td>
<td>43213</td>
<td>GPI-14</td>
<td>(90210030302030)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of osteoarthritis of the knee(s) **AND** meet the following criterion?
   - The patient had a trial of diclofenac 1% gel **AND** diclofenac 1.5% drops

   If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #224 grams per 28 days.**

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **DICLOFENAC TOPICAL SOLUTION (Pennsaid)** requires the following rule(s) be met for approval:
A. You have osteoarthritis (a type of joint condition) of the knee(s)
B. You had a trial of diclofenac 1% gel **AND** diclofenac 1.5% drops

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pennsaid.

REFERENCES
- Pennsaid [Prescribing Information]. Lake Forest, IL: Horizon Pharma USA Inc.; January 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/22  Commercial Effective: 11/01/22  Client Approval: 10/22  P&T Approval: 01/22
DIGOXIN

GUIDELINES FOR USE

1. Does the patient have a diagnosis of heart failure?
   
   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.
   
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic atrial fibrillation AND meet the following criterion?
   
   - The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.
   
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DIGOXIN requires the following rule(s) be met for approval:
   
   A. You have ONE of the following diagnoses:
      
      1. Heart failure (a type of heart condition)
      2. Chronic atrial fibrillation (a type of heart condition)
   
   B. If you have chronic atrial fibrillation, approval also requires:
      
      1. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Lanoxin.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A

Commercial Effective: 07/01/22

Created: 05/22

Client Approval: 05/22

P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the request for generic dimethyl fumarate?

   If yes, approve generic dimethyl fumarate for 12 months by HICL or GPI-10 with a quantity limit of #2 per day and override ‘Generic Only’ field.
   If no, continue to #3.

3. Is the request for brand Tecfidera AND the patient meets the following criterion?
   - The patient had a previous trial of generic dimethyl fumarate

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.
   **DENIAL TEXT:** **Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

   Our guideline named DIMETHYL FUMARATE (Tecfidera) requires the following rules be met for approval:
   A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older
   C. If you are requesting brand Tecfidera, you must have previously tried generic dimethyl fumarate

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
DIMETHYL FUMARATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Review for Tecfidera.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/19/20
Created: 05/13
Client Approval: 10/20
P&T Approval: 01/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 capsules per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DIROXIMEL FUMARATE (Vumerity) requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease (symptoms return and go away) and active secondary progressive disease (advanced disease)
B. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vumerity.

REFERENCES
DONEPEZIL

GUIDELINES FOR USE

1. Does the patient have a diagnosis of dementia associated with Alzheimer’s disease and meet ALL of the following criteria?
   - The patient had a trial of or contraindication to TWO generic oral acetylcholinesterase inhibitors (e.g., donepezil, galantamine)
   - The patient had a trial of or contraindication to one generic acetylcholinesterase inhibitor patch (e.g., rivastigmine)

   If yes, approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #4 per 28 days.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DONEPEZIL (Adlarity) requires the following rule(s) be met for approval:
A. You have dementia (a type of memory disorder) associated with Alzheimer’s disease (a progressive brain disorder that slowly destroys memory and thinking skills)
B. You had a trial of or contraindication (harmful for) to TWO generic oral acetylcholinesterase inhibitors (such as donepezil, galantamine)
C. You had a trial of or contraindication (harmful for) to one generic acetylcholine inhibitor patch (such as rivastigmine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Adlarity.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of cystic fibrosis?
   
   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Is the request for once daily dosing (30 ampules per month)?
   
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #30 ampules per month.
   If no, continue to #3.

3. Has the patient tried once daily dosing (30 ampules per month per MRF or claims history)?
   
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #60 ampules per month.
   If no, do not approve. Enter a proactive authorization for 12 months by HICL or GPI-10 with a quantity limit of #30 ampules per month.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DORNASE ALFA (Pulmozyme) requires the following rule(s) be met for approval:
   A. You have cystic fibrosis (CF: an inherited disorder that damages lung and digestive system with fluid build up)
   B. If you are requesting twice daily dosing, we require that you have tried and failed once daily dosing

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
DORNASE ALFA

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pulmozyme.

REFERENCE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/12
Commercial Effective: 07/01/20  Client Approval: 04/20  P&T Approval: 05/12
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a documented diagnosis of neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy and meets ALL of the following criteria?
   - Patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with a neurologist or cardiologist
   - The patient had a previously had a trial of or contraindication to midodrine OR fludrocortisone

   If yes, continue to #2.
   If no, do not approve

   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the prescriber performed baseline blood pressure readings while the patient is sitting and also within minutes of standing from a supine (lying face up) position?

   If yes, continue to #3.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a documented decrease of at least 20mmHg in systolic blood pressure or 10mmHg diastolic blood pressure within 3 minutes after standing from a sitting position?

   If yes, continue to #4.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DROXIDOPA

INITIAL CRITERIA (CONTINUED)

4. Does the patient have persistent symptoms of neurogenic orthostatic hypotension, which include dizziness, lightheadedness, and the feeling of 'blacking out'?

If yes, **approve for 1 month by HICL or GPI-10 for #180 per 30 days.**

**APPROVAL TEXT:** Renewal requires a diagnosis of Neurogenic Orthostatic Hypotension (NOH) and that the patient meets ALL of the following criteria while on therapy with Northera:

- Patient has demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out
- Patient had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (laying face up) position

If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **DROXIDOPA (Northera)** requires the following rules be met for approval:

A. You have neurogenic orthostatic hypotension (a type of low blood pressure)
B. You are 18 years of age or older
C. You have a documented diagnosis of neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency (you are missing a type of enzyme), or non-diabetic autonomic neuropathy (nerve pain/damage)
D. You have previously tried midodrine OR fludrocortisone, unless there is a medical reason why you cannot (contraindication)
E. Theray is prescribed or given in consultation with a neurologist (nerve doctor) or cardiologist (heart doctor)
F. Your doctor performed baseline blood pressure readings while you are sitting and also within 3 minutes of standing from a supine (lying face up) position
G. You have a documented decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within 3 minutes after standing from a sitting position
H. You have persistent symptoms of neurogenic orthostatic hypotension which includes dizziness, lightheadedness, and the feeling of 'blacking out'

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of neurogenic orthostatic hypotension (NOH) and meets ALL of the following criteria?
   - The patient has demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like the patient may black out
   - The patient had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (lying face up) position

   If yes, approve for 3 months by HICL or GPI-10 for #180 per 30 days.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named DROXIDOPA (Northera) requires the following rule(s) be met for renewal:
   A. You have neurogenic orthostatic hypotension (NOH)
   B. You have demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like you may black out
   C. You had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (lying face up) position

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Northera.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have **ONE** of the following diagnoses?
   - Major depressive disorder
   - Diabetic peripheral neuropathy
   - Fibromyalgia
   - Chronic musculoskeletal pain

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of generic duloxetine
   - The patient cannot swallow duloxetine capsules

   If yes, approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:
   - 20 mg, 30 mg, 40 mg: #1 per day.
   - 60 mg: #2 per day.

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of generalized anxiety disorder and meet **ALL** of the following criteria?
   - The patient is 7 years of age or older
   - The patient had a trial of generic duloxetine
   - The patient cannot swallow duloxetine capsules

   If yes, approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:
   - 20 mg, 30 mg, 40 mg: #1 per day.
   - 60 mg: #2 per day.

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DULOXETINE (Drizalma Sprinkle) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Major depressive disorder (a type of mental illness)
   2. Generalized anxiety disorder (a type of mental illness)
   3. Diabetic peripheral neuropathy (a type of nerve damage caused by high blood sugar)
   4. Fibromyalgia (a type of pain disorder)
   5. Chronic musculoskeletal pain (severe pain relating to muscles and bones)

B. If you have major depressive disorder, diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of generic duloxetine
   3. You cannot swallow duloxetine capsules

C. If you have generalized anxiety disorder, approval also requires:
   1. You are 7 years of age or older
   2. You had a trial of generic duloxetine
   3. You cannot swallow duloxetine capsules

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Drizalma Sprinkle.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A          Created: 11/22
Commercial Effective: 04/01/23  Client Approval: 02/23  P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet ALL of the following criteria?
   - The patient is 6 months of age or older
   - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
   - The patient has TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
   - Dupixent will NOT be used concurrently with other systemic biologics (e.g., Adbry [tralokinumab-ldrm]) or any JAK inhibitors (e.g., Rinvoq [upadacitinib], topical Opzelura [ruxolitinib], Cibiqno [abrocitinib]) for the treatment of atopic dermatitis

   If yes, continue to #2.
   If no, continue to #4.

2. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Adbry [tralokinumab-ldrm]) and switching to the requested drug
   - The patient has atopic dermatitis involving at least 10% of body surface area (BSA)
   - The patient's atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas

   If yes, continue to #3.
   If no, do not approve.

DENIAL TEXT:  See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a trial of or contraindication to ONE of the following?
   • Topical corticosteroid (e.g., hydrocortisone, clobetasol, halobetasol propionate)
   • Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
   • Topical PDE-4 inhibitor [e.g., Eucrisa (crisaborole)]
   • Topical JAK inhibitor [e.g., Opzelura (ruxolitinib)]
   • Phototherapy

   If yes, enter TWO approvals by GPID or GPI-14 for the requested strength for a total of 6 months as follows:
   • FIRST APPROVAL: Approve with an end date of 1 month as follows:
     o 200mg/1.14mL: #4.56mL.
     o 300mg/2mL: #8mL.
   • SECOND APPROVAL: Approve for 5 months as follows (enter a start date of 1 week after the end of the first approval):
     o 200mg/1.14mL: #2.28mL per 28 days.
     o 300mg/2mL: #4mL per 28 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of moderate to severe asthma with an eosinophilic phenotype AND meet the following criterion?
   • The patient has a documented blood eosinophil level of 150 to 1500 cells/mcL within the past 12 months

   If yes, continue to #6.
   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe oral corticosteroid-dependent asthma?

   If yes, continue to #6.
   If no, continue to #9.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Does the patient meet **ALL** of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a physician specializing in pulmonary or allergy medicine
   - The patient is on concurrent treatment with medium, high-dose, or maximally tolerated inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide, etc.] AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [e.g., salmeterol, formoterol, etc.], long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton, etc.], theophylline)
   - Dupixent will NOT be used concurrently with Xolair (omalizumab) or an anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when these are used for the treatment of asthma

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

7. Does the patient meet **ONE** of the following criteria?
   - The patient experienced at least ONE asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
   - The patient has poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
     o Daytime asthma symptoms more than twice per week
     o Any night waking due to asthma
     o Short-acting inhaled beta2-agonist (SABA; e.g., albuterol) reliever for symptoms more than twice per week
     o Any activity limitation due to asthma

   If yes, continue to #8.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

8. Is the request for the 100 mg/0.67mL strength?

If yes, approve 100 mg/0.67mL by GPID or GPI-14 for 4 months with a quantity limit of #1.34mL per 28 days.

If no, enter TWO approvals by GPID or GPI-14 for the requested strength for a total of 4 months as follows:

- **FIRST APPROVAL**: Approve with an end date of 1 month as follows:
  - 200mg/1.14mL: #4.56mL.
  - 300mg/2mL: #8mL.
- **SECOND APPROVAL**: Approve for 3 months as follows (enter a start date of 1 week after the end of the first approval):
  - 200mg/1.14mL: #2.28mL per 28 days.
  - 300mg/2mL: #4mL per 28 days.

9. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an otolaryngologist, allergist, or immunologist
   - There is documentation of evidence of nasal polyps by direct examination, endoscopy, or sinus CT scan
   - The patient has inadequately controlled disease as determined by ONE of the following:
     - Use of systemic steroids in the past 2 years
     - Endoscopic sinus surgery
   - Dupixent will be used as add-on maintenance treatment (i.e., in conjunction with maintenance intranasal steroids)
   - The patient had a previous 90-day trial of ONE intranasal corticosteroid

If yes, approve 300mg/2mL for 6 months by GPID or GPI-14 with a quantity limit of #4mL per 28 days.

If no, continue to #10.

10. Does the patient have a diagnosis of eosinophilic esophagitis (EoE) and meet ONE of the following criteria?
   - The patient is 18 years of age or older
   - The patient is 12 to 17 years of age AND weighs at least 40kg

If yes, continue to #11.
If no, continue to #12.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

11. Does the patient meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a gastroenterologist, allergist, or immunologist
   • The patient's diagnosis is confirmed by an esophagastroduodenoscopy (EGD) with biopsy
   • The patient had a trial of or contraindication to dietary therapy
   • The patient had a trial of or contraindication to a proton pump inhibitor (e.g., omeprazole, lansoprazole, pantoprazole)

If yes, approve **300mg/2mL for 6 months by GPID or GPI-14 with a quantity limit of #8mL per 28 days.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

12. Does the patient have a diagnosis of prurigo nodularis (PN) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist, immunologist or allergist
   • The patient has chronic pruritis (i.e., itch lasting longer than 6 weeks), presence of multiple pruriginous lesions (localized or general), and a history or sign of a prolonged scratching behavior
   • The patient had a trial of or contraindication to ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (e.g., gabapentin, pregabalin), antidepressants (SNRI, SSRI, TCA), k-/mu-opioid receptor antagonists (e.g., naltrexone, butorphanol), thalidomide, topical corticosteroids, topical calcineurin inhibitors, topical calcipotriol, intralesional corticosteroids, phototherapy, methotrexate, cyclosporine, azathioprine

If yes, enter **TWO approvals by GPID or GPI-14 for the requested strength for a total of 6 months as follows:**
   • **FIRST APPROVAL:** Approve with an end date of 1 month as follows:
     300mg/2mL: #8mL
   • **SECOND APPROVAL:** Approve for 5 months as follows (enter a start date of 1 week after the end of the first approval):
     300mg/2mL: #4mL per 28 days.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DUPILUMAB (Dupixent) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Moderate to severe atopic dermatitis (a type of skin condition)
   2. Moderate to severe asthma
   3. Chronic rhinosinusitis with nasal polyposis (a type of long-term nasal condition)
   4. Eosinophilic esophagitis (a type of immune system disorder)
   5. Prurigo nodularis (a type of skin condition)

B. **If you have moderate to severe atopic dermatitis, approval also requires:**
   1. You are 6 months of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
   4. You had a trial of or contraindication (harmful for) to ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol, halobetasol propionate), topical calcineurin inhibitor [Elidel (pimecrolimus), Protopic (tacrolimus)], topical PDE-4 inhibitor [Eucrisa (crisaborole)], topical JAK inhibitor [Opzelura (ruxolitinib)], phototherapy (light therapy)
   5. You will NOT use Dupixent concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-Irdm]) or any JAK inhibitors (such as Rinoq [upadacitinib], topical Opzelura [ruxolitinib], Cibingo [abrocitinib]) for the treatment of atopic dermatitis
   6. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Adbry [tralokinumab-Irdm]) and switching to the requested drug
      b. You have atopic dermatitis involving at least 10 percent of body surface area (BSA)
      c. Your atopic dermatitis is affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe asthma, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/breathing) or allergy medicine
   3. You have an eosinophilic phenotype asthma (type of adult inflammatory asthma) with a documented blood eosinophil level of 150 to 1500 cells/mcL within the past 12 months OR you have oral corticosteroid-dependent asthma
   4. You are being treated at the same time with medium, high-dose, or maximally tolerated inhaled corticosteroid [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline
   5. You will NOT use Dupixent concurrently (at the same time) with Xolair (omalizumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when these are used for the treatment of asthma
   6. You meet ONE of the following:
      a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room (ER) visit within the past 12 months
      b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
         i. Daytime asthma symptoms more than twice per week
         ii. Any night waking due to asthma
         iii. Use of short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
         iv. Any activity limitation due to asthma

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have chronic rhinosinusitis with nasal polyposis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, throat doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. There is documentation of evidence of nasal polyps (non-cancerous growths) by direct examination, endoscopy (using a small camera) or sinus CT scan
   4. You have inadequately controlled disease as determined by ONE of the following:
      a. Use of systemic steroids in the past 2 years
      b. Endoscopic sinus surgery (using a small camera to help in surgery)
   5. Dupixent will be used as add-on maintenance treatment (in conjunction with maintenance intranasal steroids)
   6. You had a previous 90-day trial of ONE intranasal corticosteroid

E. If you have eosinophilic esophagitis, approval also requires:
   1. You meet ONE of the following:
      a. You are 18 years of age or older
      b. You are 12 to 17 years of age AND weigh at least 40 kilograms
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. Your diagnosis is confirmed by an esophagogastroduodenoscopy (EGD) with biopsy (a test that looks at the lining of your food pipe, stomach, and small intestine)
   4. You had a trial of or contraindication (harmful for) to dietary therapy
   5. You had a trial of or contraindication (harmful for) to a proton pump inhibitor (such as omeprazole, lansoprazole, pantoprazole)

F. If you have prurigo nodularis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (skin doctor), immunologist (type of immune system doctor), or allergist
   3. You have chronic pruritis (itch lasting longer than 6 weeks), presence of multiple pruriginous lesions (wounds), and a history or sign of a prolonged scratching behavior
   4. You had a trial of or contraindication (harmful for) to ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (e.g., gabapentin, pregabalin), antidepressants (serotonin-norepinephrine reuptake inhibitor [SNRI], selective serotonin reuptake inhibitor [SSRI], tricyclic antidepressant [TCA]), k-/mu-opioid receptor antagonists (e.g., naltrexone, butorphanol), thalidomide, topical corticosteroids, topical calcineurin inhibitors, topical calcipotriol, intralesional corticosteroids, phototherapy, methotrexate, cyclosporine, azathioprine

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet ALL of the following criteria?
   - The patient has shown improvement while on therapy
   - Dupixent will NOT be used concurrently with other systemic biologics (e.g., Adby [tralokinumab-ldrm]) or any JAK inhibitors (e.g., Rinvoq [upadacitinib], topical Opzelura [ruxolitinib], Cibin [abrocitinib]) for the treatment of atopic dermatitis

   If yes, approve for 12 months by GPI-14 for the requested strength as follows:
   - 200mg/1.14mL: #2.28mL per 28 days.
   - 300mg/2mL: #4mL per 28 days.

   If no, continue to #2.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe asthma and meet ALL of the following criteria?
   • The patient continues to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [such as salmeterol, formoterol, etc.], long-acting muscarinic antagonist [such as aclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [such as montelukast, zafirlukast, zileuton, etc.], theophylline)
   • The patient has shown a clinical response as evidenced by ONE of the following:
     o Reduction in asthma exacerbation from baseline
     o Decreased utilization of rescue medications
     o Increase in percent predicted FEV1 from pretreatment baseline
     o Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
   • Dupixent will NOT be used concurrently with Xolair (omalizumab) or an anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when these are used for the treatment of asthma

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   • 100mg/0.67mL: #1.34mL per 28 days.
   • 200mg/1.14mL: #2.28mL per 28 days.
   • 300mg/2mL: #4mL per 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) AND meet the following criterion?
   • The patient has shown clinical benefit compared to baseline (e.g., improvements in nasal congestion, sense of smell or size of polyps)

   If yes, approve 300mg/2mL for 12 months by GPID or GPI-14 with a quantity limit of #4mL per 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of eosinophilic esophagitis (EoE) AND meet the following criterion?
   • The patient has shown improvement while on therapy (e.g., symptom improvement or achieving histological remission defined as peak esophageal intraepithelial eosinophil count of less than or equal to 6 eos/hpf)

   If yes, approve 300mg/2mL for 12 months by GPID or GPI-14 with a quantity limit of #8mL per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of prurigo nodularis AND meet the following criterion?
   • The patient has had prurigo nodularis improvement (reduction) of pruritis or pruriginous lesions

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #4mL per 28 days.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DUPILUMAB (Dupixent) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe atopic dermatitis (a type of skin condition)
   2. Moderate to severe asthma
   3. Chronic rhinosinusitis with nasal polyposis (inflammation of nasal and sinus ways with small growths in the nose)
   4. Eosinophilic esophagitis (a type of immune system disorder)
   5. Prurigo nodularis (a type of skin condition)
B. If you have moderate to severe atopic dermatitis, renewal also requires:
   1. You have shown improvement while on therapy
   2. You will NOT use Dupixent concurrently (at the same time) with other systemic biologics (such as Adbyr [tralokinumab-lrdm]) or any JAK inhibitors (such as Rinvoq [upadacitinib], topical Opzelura [ruxolitinib], Cibinqo [abrocitinib]) for the treatment of atopic dermatitis

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
C. **If you have moderate to severe asthma, renewal also requires:**
   1. You will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [such as salmeterol, formoterol, etc.], long-acting muscarinic antagonist [such as aclidinium bromide, ipratropium, tiotropium, umeclidinium, etc.], a leukotriene receptor antagonist [such as montelukast, zafirlukast, zileuton, etc.], theophylline)
   2. You have shown a clinical response as evidenced by ONE of the following:
      a. Reduction in asthma exacerbation (worsening of symptoms) from baseline
      b. Decreased use of rescue medications
      c. Increase in percent predicted FEV1 (amount of air you can forcefully exhale) from pretreatment baseline
      d. Reduction in severity or frequency of asthma-related symptoms such as less wheezing, shortness of breath, coughing, etc.
   3. You will NOT use Dupixent concurrently (at the same time) with Xolair (omalizumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when these are used for the treatment of asthma

D. **If you have chronic rhinosinusitis with nasal polyposis, renewal also requires:**
   1. You have shown a clinical benefit compared to baseline (such as improvements in nasal congestion, sense of smell or size of polyps)

E. **If you have eosinophilic esophagitis, renewal also requires:**
   1. You have shown improvement while on therapy (such as symptom improvement or achieving histological remission defined as peak esophageal intraepithelial eosinophil count of less than or equal to 6 eos/hpf [a type of test that evaluates disease status])

F. **If you have prurigo nodularis, renewal also requires:**
   1. You have had prurigo nodularis improvement or reduction of pruritus (itching) or pruriginous lesions (wounds)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
DUPLUMAB

RATIONALE
For further information, refer to the Prescribing Information and/or Drug Monograph for Dupixent.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Created: 01/17
Commercial Effective: 07/01/23
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received at least two prior therapies for CLL or SLL

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **DUVELISIB (Copiktra)** requires the following rule(s) be met for approval:
   A. You have **ONE** of the following diagnoses:
      1. Relapsed or refractory chronic lymphocytic leukemia (CLL: a type of blood cancer that has returned after treatment or does not fully respond to treatment)
      2. Small lymphocytic lymphoma (SLL: a type of blood cancer)
   B. You are 18 years of age or older
   C. You have received at least two prior therapies for chronic lymphocytic leukemia or small lymphocytic lymphoma

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Copiktra.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 04/01/22  
Created: 11/18  
Client Approval: 03/22  
P&T Approval: 10/18
EDARAVONE ORAL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDARAVONE</td>
<td>RADICAVA ORS</td>
<td>52318</td>
<td>GPI-14 (74509030001820)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet ALL the following?
   - Therapy is prescribed by or in consultation with a neurologist or ALS specialist at an ALS Specialty Center or Care Clinic
   - The duration of patient’s disease (from onset of symptoms) is 3 years or less
   - The patient has a forced vital capacity (FVC) greater than 70%
   - The patient has mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, respiratory insufficiency
   - The patient has tried riluzole OR is currently taking riluzole

If yes, enter two approvals by GPID or GPI-14 for a total of 6 months as follows:
   - FIRST APPROVAL: Approve for 30 days with a quantity limit of #70mL per 28 days.
   - SECOND APPROVAL: Approve for 5 months with a quantity limit of #50mL per 28 days (Enter a start date of 2 days before the end of the first approval).

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EDARAVONE ORAL (Radicava ORS) requires the following rule(s) be met for approval:
A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist at an ALS Specialty Center or Care Clinic
C. You have had ALS (from onset of symptoms) for 3 years or less
D. You have a forced vital capacity (FVC: amount of air exhaled from lungs) of greater than 70 percent
E. You have tried riluzole OR are currently taking riluzole

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

F. You have mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R: a tool for evaluating functional status): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea (difficulty breathing), orthopnea (shortness of breath while lying down), respiratory insufficiency (a type of breathing condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet ALL of the following criteria?
   • The patient does not require invasive ventilation
   • The patient has improved baseline functional ability OR the patient has maintained a score of 2 or greater in all 12 items of the ALSFRS-R

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #50mL per 28 days.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EDARAVONE ORAL (Radicava ORS) requires the following rule(s) be met for renewal:
A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. You do not require invasive ventilation (inserting a breathing tube into your throat)
C. You have improved baseline functional ability OR you have maintained a score of 2 or greater in all 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Radicava ORS.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of onychomycosis (fungal infection) of the toenail(s) and meets the following criteria?
   - The patient previously tried or has a contraindication to oral terbinafine OR oral itraconazole AND ciclopirox topical solution
   - The patient has at least ONE of the following conditions:
     - The patient has diabetes, peripheral vascular disease (PVD), or immunosuppression
     - The patient has pain surrounding the nail or soft tissue involvement

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Are five or less toenails affected?

   If yes, approve for 48 weeks by HiCL or GPI-10 with a quantity limit of #4mL (1 bottle) per 30 days.
   If no, approve for 48 weeks by HiCL or GPI-10 with a quantity limit of #8mL (2 bottles) per 30 days.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named EFINACONAZOLE (Jublia) requires the following rule(s) be met for approval:
   You have onychomycosis of the toenail(s) (toenail fungus)
   A. You have previously tried the following unless contraindicated (a medical reason why you cannot use): ciclopirox topical solution AND either oral terbinafine OR oral itraconazole
   B. You have at least ONE of the following conditions:
      1. Diabetes, peripheral vascular disease (narrowed blood vessels reduce blood flow to the limbs), or immunosuppression (weakened immune system)
      2. Pain surrounding the nail or soft tissue involvement

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
EFINACONAZOLE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Jublia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 06/14
Client Approval: 04/20
P&T Approval: 01/17
ELAPEGADEMASE-LVLR

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) as manifested by ONE of the following?
   - Confirmatory genetic test
   - Suggestive laboratory findings (e.g. elevated deoxyadenosine nucleotide [dAXP] levels, lymphopenia) AND hallmark signs/symptoms (e.g. recurrent infections, failure to thrive, persistent diarrhea)

   If yes, continue to #2.
   If no, do not approve
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Is therapy prescribed by or given in consultation with an immunologist, hematologist/oncologist, or physician specializing in inherited metabolic disorders?

   If yes, continue to #3.
   If no, do not approve
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Does the patient meet ONE of the following criteria?
   - The patient has failed or is not a candidate for hematopoietic cell transplantation (HCT)
   - The requested medication will be used as a bridging therapy prior to planned hematopoietic cell transplant or gene therapy

   If yes, approve for 6 months by HICL or GPI-10.
   APPROVAL TEXT: Renewal requires 1) documentation of trough plasma ADA activity greater than or equal to 30 mmol/hr/L and trough dAXP levels less than 0.02 mmol/L, AND 2) improvement in/maintenance of immune function from baseline, and patient has not received successful hematopoietic cell transplant (HCT) or gene therapy.

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELAPEGADEMASE-LVLR (Revcovi) requires the following rule(s) be met for approval:
A. You have adenosine deaminase severe combined immune deficiency (type of inherited disorder that damages immune system) as shown by ONE of the following:
   1. Confirmatory generic test
   2. Suggestive laboratory findings such as elevated deoxyadenosine nucleotide levels or lymphopenia (not enough of a type of white blood cell) AND you have hallmark signs/symptoms such as recurrent infections, failure to thrive, persistent diarrhea
B. The requested medication is prescribed by or given in consultation with an immunologist (immune system doctor), hematologist/oncologist (blood/cancer doctor), or physician specializing in inherited metabolic disorders
C. You have failed or are not a candidate for hematopoietic cell transplant (blood cell transplant from bone marrow), OR the requested medication will be used as a bridging therapy prior to planned hematopoietic cell transplant or gene therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) and meet **ALL** of the following criteria?
   • Documentation of trough plasma ADA activity ≥30 mmol/hr/L AND trough dAXP levels <0.02 mmol/L
   • The patient has improvement in/maintenance of immune function from baseline (e.g. decrease in number and severity of infections), **AND** has not received successful hematopoietic cell transplant (HCT) or gene therapy

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELAPEGADEMASE-LVLR (Revcovi) requires the following rule(s) be met for renewal:
A. You have adenosine deaminase severe combined immune deficiency (type of inherited disorder that damages immune system)
B. You have documentation of trough plasma adenosine deaminase activity greater than or equal to 30 mmol/hr/L AND trough deoxyadenosine nucleotide levels less than 0.02 mmol/L
C. You have improvement in/maintenance of immune function from baseline (such as decrease in number and severity of infections), AND you have not received successful hematopoietic cell transplantation (HCT) or gene therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Revcovi.

REFERENCES
• Revcovi [Prescribing Information]. Gaithersburg, MD: Leadiant Biosciences Inc., October 2018.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 02/19
Client Approval: 04/20
P&T Approval: 01/19
EFLAPEGRASTIM-XNST

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFLAPEGRASTIM-XNST</td>
<td>ROLVEDON</td>
<td></td>
<td>48301</td>
<td>GPI-10 (8240151880)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a non-myeloid malignancy and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of neutropenia with fever
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EFLAPEGRASTIM-XNST (Rolvedon) requires the following rule(s) be met for approval:
A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
D. You are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of neutropenia (a type of blood condition) with fever
E. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
EFLAPEGRASITM-XNST

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rolvedon.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 10/22
Client Approval: 06/23
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ALL of the following criteria?
   - The patient's breast cancer is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative with estrogen receptor 1 gene (ESR1) mutation(s)
   - The patient has disease progression following endocrine therapy

If yes, approve for 12 months by GPID or GPI-14 for all strengths, with the following quantity limits:
   - 345 mg: #1 per day.
   - 86 mg: #3 per day.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELACESTRANT (Orserdu) requires the following rule(s) be met for approval:
A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
B. Your breast cancer is estrogen receptor (ER: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with estrogen receptor 1 (ESR1: a gene) mutation(s)
C. You have disease progression following endocrine therapy (disease has worsened after using a type of hormone therapy)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ELACESTRANT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orserdu.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23

Created: 05/23
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

2. Does the patient have a diagnosis of moderate to severe pain associated with endometriosis and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with an obstetrician/gynecologist
   • The diagnosis is confirmed via surgical or direct visualization (e.g., pelvic ultrasound) or histopathological confirmation (e.g., laparoscopy or laparotomy) in the last 10 years
   • Orilissa will NOT be used concurrently with another GnRH-modulating agent (e.g., Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Does the patient have normal liver function or mild hepatic impairment (Child-Pugh Class A)?

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   • 150mg: #1 per day.
   • 200mg: #2 per day.

   If no, continue to #3.

4. Does the patient have moderate hepatic impairment (Child-Pugh Class B)?

   If yes, approve 150mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELAGOLIX (Orilissa) requires the following rule(s) be met for approval:
A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
D. Your diagnosis of endometriosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
E. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])
F. Requests for Orilissa 200mg twice daily will only be approved if you have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient received ONE of the following regimens?
   - A 6-month course of Orilissa 200mg twice daily
   - A 6-month course of Orilissa 150mg once daily and the patient has moderate hepatic impairment (Child-Pugh Class B)
   - A 24-month course of Orilissa 150mg once daily and the patient has normal liver function or mild hepatic impairment (Child-Pugh Class A)

If yes, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline.

If no, continue to #2.
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of moderate to severe pain associated with endometriosis and meet ALL of the following criteria?

- The patient has had improvement of pain related to endometriosis while on therapy
- The patient has normal liver function or mild hepatic impairment (Child-Pugh Class A)
- Orilissa will NOT be used concurrently with another GnRH-modulating agent (e.g., Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])

If yes, approve 150mg for 18 months by GPID or GPI-14 with a quantity limit of #1 per day.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELAGOLIX (Orilissa) requires the following rule(s) be met for renewal:

A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
B. You have improvement of pain related to endometriosis while on therapy
C. You have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)
D. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])

Requests will not be approved if you meet ONE of the following:

A. You have received a 6-month course of Orilissa 200mg twice daily
B. You have received a 6-month course of Orilissa 150mg once daily and you have moderate hepatic (liver) impairment (Child-Pugh Class B)
C. You have received a 24-month course of Orilissa 150mg once daily and you have normal liver function or mild (liver) hepatic impairment (Child-Pugh Class A)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ELAGOLIX

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orilissa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/23
Created: 08/18
Client Approval: 05/23
P&T Approval: 04/22
ELBASVIR/GRAZOPREVIR

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C, with genotype 1 or genotype 4 AND meet the following criterion?
   - The patient is 12 years of age or older OR weighs at least 30kg
     
     If yes, continue to #2.
     If no, continue to #8.

2. Does the patient have an HCV RNA level within the past 6 months?
   
   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet at least ONE of the following criteria?
   - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
   - The patient has moderate or severe hepatitis impairment (Child-Pugh B or C)
   - The patient is currently taking any of the following medications: phenytoin, carbamazepine, rifampin, efavirenz (e.g., Atripla, Sustiva), atazanavir (e.g., Evotaz, Reyataz), darunavir (e.g., Prezcobix, Prezista), lopinavir, saquinavir, Aptivus (tipranavir), cyclosporine, nafcinilin, ketoconazole, modafinil, bosentan, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (e.g., Stribild, Genvoya), atorvastatin at doses higher than 20mg daily, rosuvastatin at doses greater than 10mg daily, Sovaldi (sofosbuvir; as a single agent), Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Does the patient meet **ONE** of the following criteria?
   - The patient has a contraindication to Epclusa (velpatasvir/sofosbuvir) AND Harvoni (ledipasvir/sofosbuvir)
   - The patient has failed a short trial with Epclusa (velpatasvir/sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) (e.g., inability to tolerate, adverse effect early in therapy); **(NOTE:** An individual who has completed a full course of therapy with Epclusa [velpatasvir/sofosbuvir] or Harvoni [ledipasvir/sofosbuvir] that did not achieve SVR will not be approved.)

   If yes, continue to #5.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet **ONE** of the following criteria?
   - Genotype 1a infection, treatment naïve, and NO baseline NS5A polymorphisms
   - Genotype 1a infection, previously treated with peginterferon/ribavirin, and NO baseline NS5A polymorphisms
   - Genotype 1b infection, treatment naive
   - Genotype 1b infection, previously treated with peginterferon/ribavirin
   - Genotype 4 infection, treatment naïve

   If yes, **approve for 12 weeks by HICL or GPI-10 for #1 per day.**
   If no, continue to #6.

6. Is the requested medication being used with ribavirin and the patient meets **ONE** of the following criteria?
   - Genotype 1a infection, previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (e.g., Victrelis [boceprevir], Incivek [telaprevir], Olysio [simeprevir]) plus peginterferon/ribavirin)
   - Genotype 1b infection, previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (e.g., Victrelis [boceprevir], Incivek [telaprevir], Olysio [simeprevir]) plus peginterferon/ribavirin)

   If yes, **approve for 12 weeks by HICL or GPI-10 for #1 per day.**
   If no, continue to #7.

   **CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

7. Is the requested medication being used with ribavirin and the patient meets ONE of the following criteria?
   - Genotype 1a infection, treatment naïve, and has baseline NS5A polymorphisms
   - Genotype 1a infection, previously treated with peginterferon/ribavirin, and has baseline NS5A polymorphisms
   - Genotype 4 infection, previously treated with peginterferon/ribavirin

   If yes, approve for 16 weeks by HICL or GPI-10 for #1 per day.
   If no, continue to #8.

8. Is the requested regimen recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment?

   If yes, approve as indicated per guidance in AASLD/IDSA.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline for ELBASVIR/GRAZOPREVIR (Zepatier) requires the following rule(s) be met for approval:
A. The requested regimen is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment
B. You have chronic hepatitis C (type of liver infection)
C. You have genotype 1 or genotype 4 hepatitis C
D. You are 12 years of age or older OR weigh at least 30kg
E. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
F. You have tried a short course of Epclusa (velpatasvir/sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) OR have a contraindication (harmful for) to both. Patients with previous failure of a full treatment of Epclusa (velpatasvir/sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) will not be approved
G. If you have genotype 1a infection, we require testing for baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)

(Denial text continued on next page)
Guidelines for Use (Continued)

H. Ribavirin use is required if you meet ANY of the following:
   1. You have genotype 1a or 1b infection and were previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (such as Victrelis [boceprevir], Incivek [telaprevir], Olysio [simeprevir]) plus peginterferon/ribavirin
   2. You have genotype 1a infection, are treatment naive, and have baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
   3. You have genotype 1a infection, were previously treated, and have baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
   4. You have genotype 4 infection and were previously treated

I. Treatment experienced patients will be approved per product labeling (previous failure of peginterferon/ribavirin for genotype 1a, 1b or 4; previous failure of HCV protease inhibitor triple therapy regimen for genotype 1a or 1b infection)

Zepatier will not be approved if you meet any of the following:

A. You are using any of the following interacting medications at the same time while on Zepatier (elbasvir/grazoprevir): phenytoin, carbamazepine, rifampin, efavirenz (such as Atripla, Sustiva), atazanavir (such as Evotaz, Reyataz), darunavir (such as PrezCISION, Prezista), lopinavir, saquinavir, Aptivus (tipranavir), cyclosporine, nafcillin, ketoconazole, modafinil, bosentan, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (such as Stribild, Genvoya), atorvastatin at doses higher than 20mg daily, rosuvastatin at doses greater than 10mg daily, Sovaldi (sofosbuvir), Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)

B. You have moderate or severe liver impairment (Child-Pugh B or C: type of liver condition)

C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

Continued on Next Page
ELBASVIR/GRAZOPREVIR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zepatier.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/16
Commercial Effective: 10/01/23  Client Approval: 08/23  P&T Approval: 07/23
ELAGOLIX/ESTRADIOL/NORETHINDRONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELAGOLIX AND ESTRADIOL AND NORETHINDRONE</td>
<td>ORIAHNN</td>
<td>46577</td>
<td>GPI-10 (2499350340)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Has the patient received a total of 24 months cumulative treatment with Oriahnn?
   - If yes, do not approve.
   - DENIAL TEXT: See the initial denial text at the end of the guideline.
   - If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and the patient meets ALL of following criteria?
   - The patient is 18 years of age or older
   - The patient is a premenopausal woman
   - Therapy is prescribed by or given in consultation with an OB/GYN

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.
   - APPROVAL TEXT: Renewal for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) requires the patient had improvement of heavy menstrual bleeding.

   If no, do not approve.
   - INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ELAGOLIX/ESTRADIOL/NORETHINDRONE (Oriahnn) requires the following rule(s) be met for approval:
   A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
   B. You are 18 years of age or older
   C. You are a premenopausal woman
   D. Therapy is prescribed by or given in consultation with an obstetrician or gynecologist (OB/GYN: doctor who specializes in women’s reproductive system)
   E. You have not received a total of 24 months cumulative treatment with Oriahnn

   (Initial denial text continued on next page)
INTIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient received a total of 24 months cumulative treatment with Oriahnn?

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.
   If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) **AND** the patient meets the following criterion?
   - The patient has had improvement of heavy menstrual bleeding

   If yes, **approve for 18 months (or up to 24 months cumulative lifetime treatment duration) by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, do not approve.
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ELAGOLIX/ESTRADIOL/NORETHISTERONE (Oriahnn)** requires the following rule(s) be met for renewal:
A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
B. You had improvement of heavy menstrual bleeding on therapy
C. You have not received a total of 24 months cumulative treatment with Oriahnn

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
ELAGOLIX/ESTRADIOL/NORETHINDRONE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Oriahnn.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/20
Commercial Effective: 01/01/21  Client Approval: 11/20  P&T Approval: 07/20
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of cystic fibrosis (CF) and meet **ALL** of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist or cystic fibrosis expert

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
   - There is documentation (e.g., chart note, lab result, diagnostic test result, etc.) that the patient has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
   - There is documentation (e.g., chart note, lab result, diagnostic test result, etc.) that the patient has at least one of the following mutations in the CFTR gene:

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Generic Code</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>3141del9</td>
<td>E822K</td>
<td>G1069R</td>
<td>L967S</td>
<td>R117L</td>
<td>S912L</td>
<td></td>
</tr>
<tr>
<td>546insCTA</td>
<td>F191V</td>
<td>G1244E</td>
<td>L997F</td>
<td>R117P</td>
<td>S945L</td>
<td></td>
</tr>
<tr>
<td>A46D</td>
<td>F311del</td>
<td>G1249R</td>
<td>L1077P</td>
<td>R170H</td>
<td>S977F</td>
<td></td>
</tr>
<tr>
<td>A120T</td>
<td>F311L</td>
<td>G1349D</td>
<td>L1324P</td>
<td>R258G</td>
<td>S1159F</td>
<td></td>
</tr>
<tr>
<td>A234D</td>
<td>F508C</td>
<td>H139R</td>
<td>L1335P</td>
<td>R334L</td>
<td>S1159P</td>
<td></td>
</tr>
<tr>
<td>A349V</td>
<td>F508C; S1251N</td>
<td>H199Y</td>
<td>L1480P</td>
<td>R334Q</td>
<td>S1251N</td>
<td></td>
</tr>
<tr>
<td>A455E</td>
<td>F508del</td>
<td>H939R</td>
<td>M152V</td>
<td>R347H</td>
<td>S1255P</td>
<td></td>
</tr>
<tr>
<td>A554E</td>
<td>F575Y</td>
<td>H1054D</td>
<td>M265R</td>
<td>R347L</td>
<td>T338I</td>
<td></td>
</tr>
<tr>
<td>A1006E</td>
<td>F1016S</td>
<td>H1085P</td>
<td>M952I</td>
<td>R347P</td>
<td>T1036N</td>
<td></td>
</tr>
<tr>
<td>A1067T</td>
<td>F1052V</td>
<td>H1085R</td>
<td>M952T</td>
<td>R352Q</td>
<td>T1053I</td>
<td></td>
</tr>
<tr>
<td>D110E</td>
<td>F1074L</td>
<td>H1375P</td>
<td>M1101K</td>
<td>R352W</td>
<td>V201M</td>
<td></td>
</tr>
<tr>
<td>D110H</td>
<td>F1099L</td>
<td>I148T</td>
<td>P5L</td>
<td>R553Q</td>
<td>V232D</td>
<td></td>
</tr>
<tr>
<td>D192G</td>
<td>G27R</td>
<td>I175V</td>
<td>P67L</td>
<td>R668C</td>
<td>V456A</td>
<td></td>
</tr>
<tr>
<td>D443Y</td>
<td>G85E</td>
<td>I336K</td>
<td>P205S</td>
<td>R751L</td>
<td>V456F</td>
<td></td>
</tr>
<tr>
<td>D443Y; G576A; R668C</td>
<td>G126D</td>
<td>I502T</td>
<td>P574H</td>
<td>R792G</td>
<td>V562I</td>
<td></td>
</tr>
<tr>
<td>D579G</td>
<td>G178E</td>
<td>I601F</td>
<td>Q98R</td>
<td>R933G</td>
<td>V754M</td>
<td></td>
</tr>
<tr>
<td>D614G</td>
<td>G178R</td>
<td>I618T</td>
<td>Q237E</td>
<td>R1066H</td>
<td>V1153E</td>
<td></td>
</tr>
<tr>
<td>D836Y</td>
<td>G194R</td>
<td>I807M</td>
<td>Q237H</td>
<td>R1070Q</td>
<td>V1240G</td>
<td></td>
</tr>
<tr>
<td>D924N</td>
<td>G194V</td>
<td>I980K</td>
<td>Q359R</td>
<td>R1070W</td>
<td>V1293G</td>
<td></td>
</tr>
<tr>
<td>D979V</td>
<td>G314E</td>
<td>I1027T</td>
<td>Q1291R</td>
<td>R1162L</td>
<td>W361R</td>
<td></td>
</tr>
</tbody>
</table>
If yes, approve for 24 weeks by GPID or GPI-14 for all of the formulations and strengths with the following quantity limits:

- 80-40-60mg granule packets: #2 per day.
- 100-50-75mg granule packets: #2 per day.
- 50-25-37.5mg tablets: #3 per day.
- 100-50-75mg tablets: #3 per day.

If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ELEXACAFOR/TEZACAFTOR/IVACAFTOR (Trikafta)** requires the following rule(s) be met for approval:

A. You have cystic fibrosis (a type of lung disorder)
B. You are 2 years of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (doctor who specializes in lungs) or cystic fibrosis expert
D. You meet ONE of the following:

1. There is documentation (such as chart notes, lab result, diagnostic test result) that you have at least one **F508del** mutation (an abnormal change in your gene) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2. There is documentation (such as chart notes, lab result, diagnostic test result) that you have at least one of the following mutations in the CFTR gene:

<table>
<thead>
<tr>
<th>Mutation 1</th>
<th>Mutation 2</th>
<th>Mutation 3</th>
<th>Mutation 4</th>
<th>Mutation 5</th>
<th>Mutation 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>3141del9</td>
<td>E822K</td>
<td>G1069R</td>
<td>L967S</td>
<td>R117L</td>
<td>S912L</td>
</tr>
<tr>
<td>546insCTA</td>
<td>F191V</td>
<td>G1244E</td>
<td>L997F</td>
<td>R117P</td>
<td>S945L</td>
</tr>
<tr>
<td>A46D</td>
<td>F311del</td>
<td>G1249R</td>
<td>L1077P</td>
<td>R170H</td>
<td>S977F</td>
</tr>
<tr>
<td>A120T</td>
<td>F311L</td>
<td>G1349D</td>
<td>L1324P</td>
<td>R258G</td>
<td>S1159F</td>
</tr>
<tr>
<td>A234D</td>
<td>F508C</td>
<td>H139R</td>
<td>L1335P</td>
<td>R334L</td>
<td>S1159P</td>
</tr>
<tr>
<td>A349V</td>
<td>F508C;</td>
<td>H199Y</td>
<td>L1480P</td>
<td>R334Q</td>
<td>S1251N</td>
</tr>
<tr>
<td>A455E</td>
<td>F508del</td>
<td>H939R</td>
<td>M152V</td>
<td>R347H</td>
<td>S1255P</td>
</tr>
</tbody>
</table>
Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status compared to baseline as shown by ONE of the following?
   - The patient has improved, maintained, or demonstrated less than expected decline in FEV1
   - The patient has improved, maintained, or demonstrated less than expected decline in BMI
   - The patient has experienced a reduction in rate of pulmonary exacerbations

   If yes, approve for lifetime by GPID or GPI-14 for all of the formulations and strengths with the following quantity limits:
   - 80-40-60mg granule packets: #2 per day.
   - 100-50-75mg granule packets: #2 per day.
   - 50-25-37.5mg tablets: #3 per day.
   - 100-50-75mg tablets: #3 per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (Trikafta) requires the following rule(s) be met for renewal:
A. You have cystic fibrosis (a type of lung disorder)
B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
   1. You have improved, maintained, or demonstrated less than expected decline in forced expiratory volume (FEV1: amount of air you can exhale in 1 second)
   2. You have improved, maintained, or demonstrated less than expected decline in body mass index (BMI: a tool for evaluating body fat)
   3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Trikafta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/15/23
Created: 02/20
Client Approval: 05/23
P&T Approval: 07/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of chronic immune (idiopathic) thrombocytopenia (cITP) and meet ALL of the following criteria?
   - The patient is 1 year of age or older
   - Therapy is prescribed by or given in consultation with a hematologist or immunologist
   - The patient had a trial of or contraindication to corticosteroids or immunoglobulins, or had an insufficient response to splenectomy

   If yes, continue to #2.
   If no, continue to #5.

2. Is the request for Promacta tablets?
   If yes, approve for 2 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg tablet: #1 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #1 per day.
   - Promacta 75mg tablet: #1 per day.
   APPROVAL TEXT: Renewal requires a clinical response, as defined by an increase in platelet count to at least 50X10(9)/L (at least 50,000 per microliter).

   If no, continue to #3.

3. Is the request for Promacta packets AND the patient is 12 years of age or less?
   If yes, approve for 2 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #1 per day.
   - Promacta 25mg packets: #3 per day.
   APPROVAL TEXT: Renewal requires a clinical response as defined by an increase in platelet count to at least 50X10(9)/L (at least 50,000 per microliter).

   If no, continue to #4.

CONTINUED ON NEXT PAGE
4. Is the request for Promacta packets and the patient meets ALL of the following criteria?
   • The patient is greater than 12 years of age
   • The patient had a trial of Promacta tablets
   • The patient has a medical need for powder packets

   If yes, **approve for 2 months by GPI-D or GPI-14 for all strengths as follows:**
   • Promacta 12.5mg packets: #1 per day.
   • Promacta 25mg packets: #3 per day.

   **APPROVAL TEXT:** Renewal requires a clinical response as defined by an increase in platelet count to at least 50X10(9)/L (at least 50,000 per microliter).

   If no, do not approve for Promacta packets. **Please enter proactive approvals for all strengths of Promacta tablets for 2 months by GPI-D or GPI-14 as follows:**
   • Promacta 12.5mg tablet: #1 per day.
   • Promacta 25mg tablet: #1 per day.
   • Promacta 50mg tablet: #1 per day.
   • Promacta 75mg tablet: #1 per day.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

5. Does the patient have a diagnosis of thrombocytopenia due to chronic hepatitis C AND meet the following criterion?
   • The patient's thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy

   If yes, continue to #6.
   If no, continue to #9.

6. Is the request for Promacta tablets?

   If yes, **approve for 12 months by GPI-D or GPI-14 for all strengths as follows:**
   • Promacta 12.5mg tablet: #1 per day.
   • Promacta 25mg tablet: #1 per day.
   • Promacta 50mg tablet: #2 per day.
   • Promacta 75mg tablet: #1 per day.

   If no, continue to #7.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

7. Is the request for Promacta packets **AND** the patient is 12 years of age or less?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #1 per day.
   - Promacta 25mg packets: #4 per day.

   If no, continue to #8.

8. Is the request for Promacta packets and the patient meets **ALL** of the following criteria?
   - The patient is greater than 12 years of age
   - The patient had a trial of Promacta tablets
   - The patient has a medical need for powder packets

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #1 per day.
   - Promacta 25mg packets: #4 per day.

   If no, do not approve for Promacta packets. Please enter proactive approvals for all strengths of Promacta tablets for 12 months by GPID or GPI-14 as follows:
   - Promacta 12.5mg tablet: #1 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #2 per day.
   - Promacta 75mg tablet: #1 per day.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

9. Does the patient have a diagnosis of severe aplastic anemia and meet **ALL** of the following criteria?
   - The patient is 2 years of age or older
   - Promacta will be used in combination with standard immunosuppressive therapy as first-line treatment

   If yes, continue to #10.
   If no, continue to #13.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

10. Is the request for Promacta tablets?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg tablet: #3 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #2 per day.
   - Promacta 75mg tablet: #2 per day.

   If no, continue to #11.

11. Is the request for Promacta packets AND the patient is 12 years of age or less?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #3 per day.
   - Promacta 25mg packets: #6 per day.

   If no, continue to #12.

12. Is the request for Promacta packets and the patient meets ALL of the following criteria?

   - The patient is greater than 12 years of age
   - The patient had a trial of Promacta tablets
   - The patient has a medical need for powder packets

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #3 per day.
   - Promacta 25mg packets: #6 per day.

   If no, do not approve for Promacta packets. Please enter proactive approvals for all strengths of Promacta tablets for 12 months by GPID or GPI-14 as follows:
   - Promacta 12.5mg tablet: #3 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #2 per day.
   - Promacta 75mg tablet: #2 per day.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

13. Does the patient have a diagnosis of severe aplastic anemia AND meet the following criterion?

   - The patient had an insufficient response to immunosuppressive therapy

   If yes, continue to #14.
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

14. Is the request for Promacta tablets?
   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg tablet: #1 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #2 per day.
   - Promacta 75mg tablet: #2 per day.
   If no, continue to #15.

15. Is the request for Promacta packets AND the patient is 12 years of age or less?
   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #1 per day.
   - Promacta 25mg packets: #6 per day.
   If no, continue to #16.

16. Is the request for Promacta packets and the patient meets ALL of the following criteria?
   - The patient is greater than 12 years of age
   - The patient had a trial of Promacta tablets
   - The patient has a medical need for powder packets
   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Promacta 12.5mg packets: #1 per day.
   - Promacta 25mg packets: #6 per day.
   If no, do not approve for Promacta packets. Please enter proactive approvals for all strengths of Promacta tablets for 12 months by GPID or GPI-14 as follows:
   - Promacta 12.5mg tablet: #1 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #2 per day.
   - Promacta 75mg tablet: #2 per day.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named ELTROMBOPAG (Promacta) requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Chronic immune (idiopathic) thrombocytopenia (low levels of the blood cells that prevent bleeding)
   2. Thrombocytopenia (low blood platelet count) due to chronic hepatitis C
   3. Severe aplastic anemia (type of blood disorder)

B. **If you are greater than 12 years of age and the request is for Promacta packets, approval also requires:**
   1. You previously had a trial of Promacta tablets
   2. You have a medical need for powder packets

C. **If you have chronic immune (idiopathic) thrombocytopenia, approval also requires:**
   1. You are 1 year of age or older
   2. You have tried corticosteroids or immunoglobulins, or did not have a good enough response to a splenectomy (removal of spleen) - unless there is a medical reason why you cannot (contraindication)
   3. The medication is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)

D. **If you have thrombocytopenia due to chronic hepatitis C, approval also requires:**
   1. Your thrombocytopenia does not allow you to start interferon-based therapy (type of drug for hepatitis) or limits your ability to maintain interferon-based therapy

E. **If you have severe aplastic anemia, approval also requires ONE of the following:**
   1. You are 2 years of age or older and Promacta will be used in combination with standard immunosuppressive therapy (treatment that prevents activity from your immune system) as first-line treatment
   2. You did not have a good enough response to immunosuppressive therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ELTROMBOPAG GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of thrombocytopenia due to chronic hepatitis C or severe aplastic anemia, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of chronic immune (idiopathic) thrombocytopenia (cITP), AND meet the following criterion?
   - The patient has a clinical response, as defined by an increase in platelet count to at least 50X10⁹/L (at least 50,000 per microliter)

   If yes, approve for 12 months by GPID or GPI-14 for all strengths and formulations as follows:
   - Promacta 12.5mg tablet: #1 per day.
   - Promacta 25mg tablet: #1 per day.
   - Promacta 50mg tablet: #1 per day.
   - Promacta 75mg tablet: #1 per day.
   - Promacta 12.5mg packets: #1 per day.
   - Promacta 25mg packets: #3 per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELTROMBOPAG (Promacta) requires the following rules be met for renewal:
A. You have chronic immune (idiopathic) thrombocytopenia (low levels of the blood cells that prevent bleeding)
B. You have a clinical response, as defined by an increase in platelet count to at least 50X10⁹/L (at least 50,000 per microliter)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Promacta.

REFERENCES
- Promacta [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/20/20
Created: 01/09
Client Approval: 04/20
P&T Approval: 07/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to Xifaxan (rifaximin) AND either tricyclic anti-depressants (e.g., amitriptyline, desipramine) OR dicyclomine

If yes, continue to #2.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELUXADOLINE (Viberzi) requires the following rule(s) be met for approval:
A. You have irritable bowel syndrome with diarrhea (an intestinal problem causing pain in the belly, gas, diarrhea, and constipation)
B. You are 18 years of age or older
C. The medication is prescribed by or given in consultation with a gastroenterologist (a doctor who specializes in conditions of the stomach, intestine and related organs)
D. You had a trial of Xifaxan (rifaximin) AND either tricyclic anti-depressants (such as amitriptyline, desipramine) OR dicyclomine, unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

2. Does the patient meet ANY of the following criteria?
   - Patient does not have a gallbladder
   - Patient is receiving concomitant OATP1B1 inhibitors (e.g., atazanavir, cyclosporine, eltrombopag, gemfibrozil, lopinavir, rifampin, ritonavir, saquinavir, tipranavir)
   - Patient has mild or moderate hepatic impairment
   - Patient is intolerant to Viberzi 100mg

   If yes, approve ELUXADOLINE 75MG for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.
   **APPROVAL TEXT:** Renewal requires that the patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale) and the patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

   If no, approve ELUXADOLINE 100MG for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.
   **APPROVAL TEXT:** Renewal requires that the patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale) and the patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

RENEWAL CRITERIA

1. Is the patient being treated for irritable bowel syndrome with diarrhea (IBS-D) and meets ALL of the following criteria?
   - Patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
   - Patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text on the next page.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ELUXADOLINE (Viberzi) requires the following rule(s) be met for renewal:
1. You have irritable bowel syndrome with diarrhea (an intestinal problem causing pain in the belly, gas, diarrhea, and constipation)
2. You had at least 30% decrease in abdominal pain (stomach pain) on a 0-10 point pain scale
3. You had at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Viberzi.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hemophilia A (congenital factor VIII deficiency) and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a hematologist
   • The requested medication will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for a patient **WITH** factor VIII inhibitors **AND** the patient meets the following criterion?
   • The patient has a history of a high titer of factor VIII inhibitor defined as at least 5 or more Bethesda units per milliliter

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, continue to #3.

3. Is the request for a patient **WITHOUT** factor VIII inhibitors?

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have moderate to severe hemophilia A, defined as less than 5% factor VIII activity compared to normal?

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, continue to #5.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

5. Does the patient have mild hemophilia A, defined as 5%-40% factor VIII activity compared to normal, and meet ONE of the following criteria?

- The patient has experienced severe, traumatic, or spontaneous bleeding episode(s) (may occur in joint or muscle)
- The patient has experienced a life-threatening bleed (e.g., intracranial hemorrhage [ICH])
- The patient has venous access difficulties impeding regular clotting factor infusions

If yes, approve for 12 months by HICL or GPI-10. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EMICIZUMAB-KXWH (Hemlibra) requires the following rule(s) be met for approval:

A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
C. The requested medication will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
D. If you have hemophilia A with factor VIII inhibitors (a type of protein), approval also requires:
   1. You have a history of a high titer (concentration) of factor VIII inhibitor defined as at least 5 or more Bethesda units per milliliter
E. If you have hemophilia A without factor VIII inhibitors (a type of protein), approval also requires ONE of the following criteria:
   1. You have moderate to severe hemophilia A, defined as less than 5% factor VIII activity compared to normal
   2. You have mild hemophilia A, defined as 5%-40% factor VIII activity compared to normal, and meet ONE of the following:
      a. You have experienced severe, traumatic, or spontaneous (sudden) bleeding episode(s) (may occur in joint or muscle)
      b. You have experienced a life-threatening bleed (for example intracranial hemorrhage [ICH: a type of bleeding in your head])
      c. It is difficult to access your veins which prevents or delays you in receiving regular clotting factor infusions

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hemophilia A (congenital factor VIII deficiency) AND meet the following criterion?
   • The patient has had clinical benefit compared to baseline

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named EMICIZUMAB-KXWH (Hemlibra) requires the following rule(s) be met for renewal:
   A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
   B. You had a clinical benefit after using the medication compared to baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Hemlibra.

REFERENCES
• Hemlibra [Prescribing Information]. Genentech, Inc.: South San Francisco, CA; June 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/18
Commercial Effective: 04/01/23 Client Approval: 02/23

P&T Approval: 01/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) AND meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is isocitrate dehydrogenase-2 (IDH2) mutation positive as detected by an FDA-approved diagnostic test

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ENASIDENIB (Idhifa) requires the following rule(s) be met for approval:

A. You have relapsed or refractory acute myeloid leukemia (a type of blood and bone marrow cancer that has returned after or is resistant to treatment)
B. You are 18 years of age or older
C. You are isocitrate dehydrogenase-2 (a type of enzyme) mutation positive as detected by an FDA (Food and Drug Administration)-approved diagnostic test

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Idhifa.

REFERENCES
• Idhifa [Prescribing Information]. Summit, NJ: Celgene Corporation; September 2019.
ENCORAFENIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENCORAFENIB</td>
<td>BRAFTOVI</td>
<td>45039</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(2153204000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet **ALL** of the following criteria?
   - The patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test
   - Braftovi will be used in combination with Mektovi (binimetinib)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic colorectal cancer (mCRC) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a BRAF V600E mutation as detected by an FDA-approved test
   - Braftovi will be used in combination with Erbitux (cetuximab)
   - The patient has previously received prior therapy

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ENCORAFENIB (Braftovi)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be completely removed with surgery or has spread to other parts of the body)
   2. Metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
   2. Braftovi will be used in combination with Mektovi (binimetinib)

C. If you have metastatic colorectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have a BRAF V600E mutation (types of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
   3. Braftovi will be used in combination with Erbitux (cetuximab)
   4. You have previously received treatment

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Braftovi.

REFERENCES
ENTRECTORINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENTRECTORINIB</td>
<td>ROZLYTREK</td>
<td>45952</td>
<td>GPI-10</td>
<td>(2153382000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has ROS1-positive tumors

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Rozlytrek 100mg: #5 per day.
   - Rozlytrek 200mg: #3 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of solid tumor and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The tumor has a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation
   - The tumor is metastatic or surgical resection is likely to result in severe morbidity
   - There are no satisfactory alternative treatments, or the patient has progressed following treatment

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Rozlytrek 100mg: #5 per day.
   - Rozlytrek 200mg: #3 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ENTRECTORINIB (Rozlytrek) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of body) OR a solid tumor
B. If you have metastatic non-small cell lung cancer (NSCLC), approval also requires:
   1. You are 18 years of age or older
   2. You have ROS1-positive tumors (you have a type of gene mutation)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
ENTRECTINIB

GUIDELINES FOR USE (CONTINUED)

C. If you have a solid tumor, approval also requires:
   1. You are 12 years of age or older
   2. The tumor has a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation (you have a type of gene mutation that doesn’t have any known resistance)
   3. The tumor is metastatic (has spread to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (disease)
   4. There are no satisfactory alternative treatments, or you have progressed (gotten worse) after treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rozlytrek.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 11/19
Client Approval: 04/20
P&T Approval: 10/19
ENZALUTAMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENZALUTAMIDE</td>
<td>XTANDI</td>
<td>39580</td>
<td></td>
<td>GPI-10 (2140243000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have ONE of the following diagnoses?
   - Metastatic castration-sensitive prostate cancer (mCSPC)
   - Metastatic castration-resistant prostate cancer (mCRPC)
   
   If yes, continue to #3.
   If no, continue to #2.

2. Does the patient have a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) AND meet the following criterion?
   - The patient has high risk prostate cancer (i.e., rapidly increasing prostate specific antigen levels)

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet ONE of the following criteria?
   - The patient previously received a bilateral orchiectomy
   - The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   - The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ENZALUTAMIDE (Xtandi) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
   3. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
C. If you have non-metastatic castration-resistant prostate cancer, approval also requires:
   1. You have a high-risk prostate cancer (rapidly increasing prostate specific antigen levels)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have ONE of the following diagnoses?
   • Metastatic or non-metastatic castration-resistant prostate cancer (CRPC)
   • Metastatic castration-sensitive prostate cancer (mCSPC)

If yes, continue to #2.
If no, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
2. Does the patient meet ONE of the following criteria?
   - The patient previously received a bilateral orchiectomy
   - The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   - The requested medication will be used concurrently with a gonadotropin releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin, degarelix)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **ENZALUTAMIDE (Xtandi)** requires the following rule(s) be met for renewal:
   A. You have ONE of the following diagnoses:
      1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
      2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
      3. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
   B. You meet ONE of the following:
      1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
      2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
      3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
ENZALUTAMIDE

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Xtandi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/12
Commercial Effective: 01/01/23  Client Approval: 11/22  P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet ALL of the following criteria?
   - The patient had a trial of the preferred agent: Retacrit
   - The patient has a hemoglobin level of less than 10g/dL

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   - Procrit 2,000U/mL: 12mL per 28 days.
   - Procrit 3,000U/mL: 12mL per 28 days.
   - Procrit 4,000U/mL: 12mL per 28 days.
   - Procrit 10,000U/mL: 12mL per 28 days.
   - Procrit 20,000U/mL: 12mL per 28 days.
   - Procrit 40,000U/mL: 4mL per 28 days.
   - Procrit 20,000U/2mL: 12mL per 28 days.
   - Epogen 2,000U/mL: 12mL per 28 days.
   - Epogen 3,000U/mL: 12mL per 28 days.
   - Epogen 4,000U/mL: 12mL per 28 days.
   - Epogen 10,000U/mL: 12mL per 28 days.
   - Epogen 20,000U/mL: 12mL per 28 days.
   - Epogen 20,000U/2mL: 12mL per 28 days.

   If no, continue to #2.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy and meet ALL of the following criteria?
   • The patient had a trial of the preferred agent: Retacrit
   • The patient has a hemoglobin level of less than 11g/dL OR the patient’s hemoglobin level has decreased at least 2g/dL below baseline level

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   • **Procrit 2,000U/mL**: #12mL per 28 days.
   • **Procrit 3,000U/mL**: #12mL per 28 days.
   • **Procrit 4,000U/mL**: #12mL per 28 days.
   • **Procrit 10,000U/mL**: #12mL per 28 days.
   • **Procrit 20,000U/mL**: #12mL per 28 days.
   • **Procrit 40,000U/mL**: #4mL per 28 days.
   • **Procrit 20,000U/2mL**: #12mL per 28 days.
   • **Epogen 2,000U/mL**: #12mL per 28 days.
   • **Epogen 3,000U/mL**: #12mL per 28 days.
   • **Epogen 4,000U/mL**: #12mL per 28 days.
   • **Epogen 10,000U/mL**: #12mL per 28 days.
   • **Epogen 20,000U/mL**: #12mL per 28 days.
   • **Epogen 20,000U/2mL**: #12mL per 28 days.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia related to zidovudine therapy and meet ALL of the following criteria?
   - The patient had a trial of the preferred agent: Retacrit
   - The patient has a hemoglobin level of less than 10g/dL

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   - Procrit 2,000U/mL: #12mL per 28 days.
   - Procrit 3,000U/mL: #12mL per 28 days.
   - Procrit 4,000U/mL: #12mL per 28 days.
   - Procrit 10,000U/mL: #12mL per 28 days.
   - Procrit 20,000U/mL: #12mL per 28 days.
   - Procrit 40,000U/mL: #4mL per 28 days.
   - Procrit 20,000U/2mL: #12mL per 28 days.
   - Epogen 2,000U/mL: #12mL per 28 days.
   - Epogen 3,000U/mL: #12mL per 28 days.
   - Epogen 4,000U/mL: #12mL per 28 days.
   - Epogen 10,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/2mL: #12mL per 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
INIONAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa and meet ALL of the following criteria?
   • The patient had a trial of the preferred agent: Retacrit
   • The patient has a hemoglobin level of less than 10g/dL
   • The patient had a trial of or contraindication to ribavirin dose reduction

If yes, approve for 6 months by GPID or GPI-14 for the requested agent as follows:
   • Procrit 2,000U/mL: #12mL per 28 days.
   • Procrit 3,000U/mL: #12mL per 28 days.
   • Procrit 4,000U/mL: #12mL per 28 days.
   • Procrit 10,000U/mL: #12mL per 28 days.
   • Procrit 20,000U/mL: #12mL per 28 days.
   • Procrit 40,000U/mL: #4mL per 28 days.
   • Procrit 20,000U/2mL: #12mL per 28 days.
   • Epogen 2,000U/mL: #12mL per 28 days.
   • Epogen 3,000U/mL: #12mL per 28 days.
   • Epogen 4,000U/mL: #12mL per 28 days.
   • Epogen 10,000U/mL: #12mL per 28 days.
   • Epogen 20,000U/mL: #12mL per 28 days.
   • Epogen 20,000U/2mL: #12mL per 28 days.

If no, continue to #5.
5. Is the patient undergoing elective, noncardiac, nonvascular surgery and meet \textbf{ALL} of the following criteria?
   - The patient had a trial of the preferred agent: Retacrit
   - The patient has a hemoglobin level of less than 13g/dL

If yes, approve for 1 month by GPID or GPI-14 for the requested agent as follows:
   - Procrit 2,000U/mL: #12mL per 28 days.
   - Procrit 3,000U/mL: #12mL per 28 days.
   - Procrit 4,000U/mL: #12mL per 28 days.
   - Procrit 10,000U/mL: #12mL per 28 days.
   - Procrit 20,000U/mL: #12mL per 28 days.
   - Procrit 40,000U/mL: #4mL per 28 days.
   - Procrit 20,000U/2mL: #12mL per 28 days.
   - Epogen 2,000U/mL: #12mL per 28 days.
   - Epogen 3,000U/mL: #12mL per 28 days.
   - Epogen 4,000U/mL: #12mL per 28 days.
   - Epogen 10,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/2mL: #12mL per 28 days.

If no, do not approve.

\textbf{DENIAL TEXT:} See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EPOETIN ALFA (Procrit, Epogen) requires the following rules be met for approval:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
   5. You are undergoing elective, noncardiac (not heart related), nonvascular surgery

B. If you have anemia associated with chronic kidney disease, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level (type of blood test) of less than 10g/Dl

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 11g/Dl OR your hemoglobin level has decreased at least 2g/Dl below your baseline level

D. If you have anemia related to zidovudine therapy, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 10g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
   3. You have a hemoglobin level of less than 10g/Dl

F. If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 13g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
EPOETIN ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and meet ONE of the following criteria?
   • The patient has a hemoglobin level of less than 10g/dL if not on dialysis
   • The patient has a hemoglobin level of less than 11g/dL if on dialysis
   • The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and the dose is being reduced/interrupted to decrease the need for blood transfusions
   • The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and the dose is being reduced/interrupted to decrease the need for blood transfusions

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   • Procrit 2,000U/mL: #12mL per 28 days.
   • Procrit 3,000U/mL: #12mL per 28 days.
   • Procrit 4,000U/mL: #12mL per 28 days.
   • Procrit 10,000U/mL: #12mL per 28 days.
   • Procrit 20,000U/mL: #12mL per 28 days.
   • Procrit 40,000U/mL: #4mL per 28 days.
   • Procrit 20,000U/2mL: #12mL per 28 days.
   • Epogen 2,000U/mL: #12mL per 28 days.
   • Epogen 3,000U/mL: #12mL per 28 days.
   • Epogen 4,000U/mL: #12mL per 28 days.
   • Epogen 10,000U/mL: #12mL per 28 days.
   • Epogen 20,000U/mL: #12mL per 28 days.
   • Epogen 20,000U/2mL: #12mL per 28 days.

   If no, continue to #2.

CONTINUED ON NEXT PAGE
2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy AND meet the following criterion?
   - The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   - Procrit 2,000U/mL: #12mL per 28 days.
   - Procrit 3,000U/mL: #12mL per 28 days.
   - Procrit 4,000U/mL: #12mL per 28 days.
   - Procrit 10,000U/mL: #12mL per 28 days.
   - Procrit 20,000U/mL: #12mL per 28 days.
   - Procrit 40,000U/mL: #4mL per 28 days.
   - Procrit 20,000U/2mL: #12mL per 28 days.
   - Epogen 2,000U/mL: #12mL per 28 days.
   - Epogen 3,000U/mL: #12mL per 28 days.
   - Epogen 4,000U/mL: #12mL per 28 days.
   - Epogen 10,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/2mL: #12mL per 28 days.

   If no, continue to #3.

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia related to zidovudine therapy AND meet the following criterion?
   • The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent as follows:
   • Procrit 2,000U/mL: #12mL per 28 days.
   • Procrit 3,000U/mL: #12mL per 28 days.
   • Procrit 4,000U/mL: #12mL per 28 days.
   • Procrit 10,000U/mL: #12mL per 28 days.
   • Procrit 20,000U/mL: #12mL per 28 days.
   • Procrit 40,000U/mL: #4mL per 28 days.
   • Procrit 20,000U/2mL: #12mL per 28 days.
   • Epogen 2,000U/mL: #12mL per 28 days.
   • Epogen 3,000U/mL: #12mL per 28 days.
   • Epogen 4,000U/mL: #12mL per 28 days.
   • Epogen 10,000U/mL: #12mL per 28 days.
   • Epogen 20,000U/mL: #12mL per 28 days.
   • Epogen 20,000U/2mL: #12mL per 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa AND meet the following criterion?
   - The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 6 months by GPID or GPI-14 for the requested agent as follows:
   - Procrit 2,000U/mL: #12mL per 28 days.
   - Procrit 3,000U/mL: #12mL per 28 days.
   - Procrit 4,000U/mL: #12mL per 28 days.
   - Procrit 10,000U/mL: #12mL per 28 days.
   - Procrit 20,000U/mL: #12mL per 28 days.
   - Procrit 40,000U/mL: #4mL per 28 days.
   - Procrit 20,000U/2mL: #12mL per 28 days.
   - Epogen 2,000U/mL: #12mL per 28 days.
   - Epogen 3,000U/mL: #12mL per 28 days.
   - Epogen 4,000U/mL: #12mL per 28 days.
   - Epogen 10,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/mL: #12mL per 28 days.
   - Epogen 20,000U/2mL: #12mL per 28 days.

   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EPOETIN ALFA (Procrit, Epogen) requires the following rule(s) be met for renewal:
A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
   2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
   3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL
D. If you have anemia related to zidovudine therapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL
E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
EPOETIN ALFA

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Procrit, Epogen.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/17/23
Created: 02/11
Client Approval: 03/23
P&T Approval: 01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) AND meet the following criterion?
   • The patient has a hemoglobin level of less than 10g/dL

      If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
      • 2,000U/mL: #12mL in 28 days.
      • 3,000U/mL: #12mL in 28 days.
      • 4,000U/mL: #12mL in 28 days.
      • 10,000U/mL: #12mL in 28 days.
      • 20,000U/mL: #12mL in 28 days.
      • 40,000U/mL: #4mL in 28 days.
      • 20,000U/2mL: #12mL in 28 days.

      If no, continue to #2.

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy and meet ONE of the following criteria?
   • The patient has a hemoglobin level of less than 11g/dL
   • The patient's hemoglobin level has decreased at least 2g/dL below baseline level

      If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
      • 2,000U/mL: #12mL in 28 days.
      • 3,000U/mL: #12mL in 28 days.
      • 4,000U/mL: #12mL in 28 days.
      • 10,000U/mL: #12mL in 28 days.
      • 20,000U/mL: #12mL in 28 days.
      • 40,000U/mL: #4mL in 28 days.
      • 20,000U/2mL: #12mL in 28 days.

      If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of anemia related to zidovudine therapy AND meet the following criterion?
   • The patient has a hemoglobin level of less than 10g/dL

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   • 2,000U/mL: #12mL in 28 days.
   • 3,000U/mL: #12mL in 28 days.
   • 4,000U/mL: #12mL in 28 days.
   • 10,000U/mL: #12mL in 28 days.
   • 20,000U/mL: #12mL in 28 days.
   • 40,000U/mL: #4mL in 28 days.
   • 20,000U/2mL: #12mL in 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa and meet ALL of the following criteria?
   • The patient has a hemoglobin level of less than 10g/dL
   • The patient had a trial of or contraindication to ribavirin dose reduction

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:
   • 2,000U/mL: #12mL in 28 days.
   • 3,000U/mL: #12mL in 28 days.
   • 4,000U/mL: #12mL in 28 days.
   • 10,000U/mL: #12mL in 28 days.
   • 20,000U/mL: #12mL in 28 days.
   • 40,000U/mL: #4mL in 28 days.
   • 20,000U/2mL: #12mL in 28 days.

   If no, continue to #5.

CONTINUED ON NEXT PAGE
EPOETIN ALFA-EPBX

INITIAL CRITERIA (CONTINUED)

5. Is the patient undergoing elective, noncardiac, nonvascular surgery AND meet the following criterion?
   • The patient has a hemoglobin level of less than 13g/dL

   If yes, approve for 1 month by GPID or GPI-14 for the requested strength as follows:
   • 2,000U/mL: #12mL in 28 days.
   • 3,000U/mL: #12mL in 28 days.
   • 4,000U/mL: #12mL in 28 days.
   • 10,000U/mL: #12mL in 28 days.
   • 20,000U/mL: #12mL in 28 days.
   • 40,000U/mL: #4mL in 28 days.
   • 20,000U/2mL: #12mL in 28 days.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EPOETIN ALFA-EPBX (Retacrit) requires the following rule(s) be met for approval:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
   5. You are undergoing elective, noncardiac (not heart related), nonvascular surgery

B. If you have anemia associated with chronic kidney disease, approval also requires:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL

C. If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires ONE of the following:
   1. You have a hemoglobin level of less than 11g/dL
   2. Your hemoglobin level has decreased at least 2g/dL below your baseline level

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. If you have anemia related to zidovudine therapy, approval also requires:
   1. You have a hemoglobin level of less than 10g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin
   plus an interferon alfa or peginterferon alfa, approval also requires:
   1. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
   2. You have a hemoglobin level of less than 10g/dL

F. If you are undergoing elective, noncardiac, nonvascular surgery, approval also
   requires:
   1. You have a hemoglobin level of less than 13g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
your doctor to use a different medication or get us more information if it will allow us to approve
this request.

RENEWAL CRITERIA

NOTE: Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the
Initial Criteria section.

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD) and
   meet ONE of the following criteria?
   • The patient has a hemoglobin level of less than 10g/dL if not on dialysis
   • The patient has a hemoglobin level of less than 11g/dL if on dialysis
   • The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and the dose is
     being reduced/interrupted to decrease the need for blood transfusions
   • The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and the dose is
     being reduced/interrupted to decrease the need for blood transfusions

If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:

   • 2,000U/mL: #12mL in 28 days.
   • 3,000U/mL: #12mL in 28 days.
   • 4,000U/mL: #12mL in 28 days.
   • 10,000U/mL: #12mL in 28 days.
   • 20,000U/mL: #12mL in 28 days.
   • 40,000U/mL: #4mL in 28 days.
   • 20,000U/2mL: #12mL in 28 days.

If no, continue to #2.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of anemia due to the effects of concomitantly administered cancer chemotherapy AND meet the following criterion?
   - The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 12 months by GPIP or GPI-14 for the requested strength as follows:
   - 2,000U/mL: #12mL in 28 days.
   - 3,000U/mL: #12mL in 28 days.
   - 4,000U/mL: #12mL in 28 days.
   - 10,000U/mL: #12mL in 28 days.
   - 20,000U/mL: #12mL in 28 days.
   - 40,000U/mL: #4mL in 28 days.
   - 20,000U/2mL: #12mL in 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of anemia related to zidovudine therapy AND meet the following criterion?
   - The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 12 months by GPIP or GPI-14 for the requested strength as follows:
   - 2,000U/mL: #12mL in 28 days.
   - 3,000U/mL: #12mL in 28 days.
   - 4,000U/mL: #12mL in 28 days.
   - 10,000U/mL: #12mL in 28 days.
   - 20,000U/mL: #12mL in 28 days.
   - 40,000U/mL: #4mL in 28 days.
   - 20,000U/2mL: #12mL in 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa AND meet the following criterion?
   • The patient has a hemoglobin level between 10g/dL and 12g/dL

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:
   • 2,000U/mL: #12mL in 28 days.
   • 3,000U/mL: #12mL in 28 days.
   • 4,000U/mL: #12mL in 28 days.
   • 10,000U/mL: #12mL in 28 days.
   • 20,000U/mL: #12mL in 28 days.
   • 40,000U/mL: #4mL in 28 days.
   • 20,000U/2mL: #12mL in 28 days.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EPOETIN ALFA-EPBX (Retacrit) requires the following rule(s) be met for renewal:
A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
   2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
   3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

D. If you have anemia related to zidovudine therapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Retacrit.

REFERENCES
ERDAFITINIB

GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic urothelial carcinoma (i.e., bladder cancer) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has susceptible fibroblast growth factor receptor (FGFR3 or FGFR2) genetic alterations as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have ONE of the following criteria?
   - The patient has progressed during or following at least one line of prior platinum-containing chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin)
   - The patient has progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin)

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Balversa 3mg tablet: #3 per day.
   - Balversa 4mg tablet: #2 per day.
   - Balversa 5mg tablet: #1 per day.

   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ERDAFITINIB (Balversa) requires the following rule(s) be met for approval:
A. You have locally advanced or metastatic urothelial carcinoma (type of bladder cancer that has spread)
B. You are 18 years of age or older
C. You have susceptible fibroblast growth factor receptor (FGFR3 or FGFR2) genetic alterations (abnormalities) as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

D. You meet ONE of the following:
   1. You have progressed (worsened disease) during or following at least one line of prior platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
   2. You have progressed within 12 months of neoadjuvant (treatment given before main therapy) or adjuvant (add-on) platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Balversa.

REFERENCES
- Balversa [Prescribing Information]. Horsham, PA: Janssen Products, LP; April 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 07/01/20  
Created: 04/19  
Client Approval: 04/20  
P&T Approval: 04/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of episodic migraines and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Aimovig is prescribed for the preventive treatment of migraines
   • Aimovig will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
   • The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1mL per 30 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic migraines and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Aimovig is prescribed for the preventive treatment of migraines
   • Aimovig will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
   • The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable]

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1mL per 30 days.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ERENUMAB-AOOE (Aimovig) requires the following rule(s) be met for approval:

A. You have migraines

B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Aimovig is prescribed for the preventive treatment of migraines
   3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Aimovig is prescribed for the preventive treatment of migraines
   3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable]

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Is Aimovig being prescribed for the preventive treatment of migraines **AND** does the patient meet the following criterion?
   - Aimovig will **NOT** be used concurrently with other CGRP inhibitors (e.g., Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
   - The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Aimovig therapy
   - The patient has experienced a reduction in migraine severity with Aimovig therapy
   - The patient has experienced a reduction in migraine duration with Aimovig therapy

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 30 days.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **ERENUMAB-AOOE (Aimovig)** requires the following rule(s) be met for renewal:
   A. Aimovig is being prescribed for preventive treatment of migraines.
   B. You will **NOT** use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
   C. You meet **ONE** of the following criteria:
      1. You have experienced less migraines or headache attacks by at least 2 days per month with Aimovig therapy
      2. You have experienced a lessening in migraine severity with Aimovig therapy
      3. You have experienced a lessening in migraine duration with Aimovig therapy

   Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
ERENUMAB-AOOE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Aimovig.

REFERENCE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 05/18
Client Approval: 06/23
P&T Approval: 01/22
GUIDELINES FOR USE

1. Is Migergot being used to abort or prevent vascular headaches (e.g., migraine, migraine variants, so-called 'histaminic cephalalgia') and the patient meets ALL of the following criteria?
   - The patient cannot swallow ergotamine/caffeine tablets
   - The patient had a trial of or contraindication to generic ergotamine/caffeine tablets AND two triptans (e.g., sumatriptan, rizatriptan)

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #24 per 30 days. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named ERGOTAMINE-CAFFEINE (Migergot) requires the following rule(s) be met for approval:
A. Migergot is being used to abort (stop) or prevent vascular headaches (such as migraines, migraine variants, so-called 'histaminic cephalalgia' [types of headaches])
B. You cannot swallow ergotamine/caffeine tablets
C. You had a trial of or contraindication (harmful for) to generic ergotamine/caffeine tablets AND two triptans (such as sumatriptan, rizatriptan)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Migergot.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective:04/01/23  Created: 11/22
Client Approval: 02/23       P&T Approval: 10/22
ERLOTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERLOTINIB HCL</td>
<td>TARCEVA, ERLOTINIB HCL</td>
<td>26745</td>
<td>GPI-10</td>
<td>(2136002510)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient’s tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
   - Tarceva (erlotinib) will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Gilotrif, Tagrisso, Iressa, Vizimpro)

   If yes, **approve for 12 months by GPID or GPI-14 as requested with the following quantity limits:**
   - 25mg: #2 per day.
   - 100mg: #2 per day.
   - 150mg: #3 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer and meet ALL of the following criteria?
   - The requested medication will be used in combination with gemcitabine
   - The medication will be used as a first line treatment

   If yes, **approve for 12 months by GPID or GPI-14 as requested with the following quantity limits:**
   - 25mg: #2 per day.
   - 100mg: #2 per day.
   - 150mg: #3 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ERLOTINIB (Tarceva)** requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
   2. Locally advanced, unresectable, or metastatic pancreatic cancer (pancreas cancer that has spread or cannot be completely removed by surgery)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. If you have metastatic non-small cell lung cancer, approval also requires:
   1. Your tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (types of gene mutations or permanent change in the DNA that makes up a gene) as detected by an FDA (Food and Drug Administration)-approved test
   2. You will NOT be using Tarceva (erlotinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Gilotrif, Tagrisso, Iressa, Vizimpro)

C. If you have locally advanced, unresectable, or metastatic pancreatic cancer, approval also requires:
   1. The requested medication will be used in combination with gemcitabine
   2. The medication will be used as a first line treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tarceva.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:
   • 25mg syringes: #4mL per 28 days.
   • 25mg vials: #8 vials OR #4mL per 28 days.
   • 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #2.

2. Does the patient have moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength as follows:
   • 25mg syringes: #4mL per 28 days.
   • 25mg vials: #8 vials OR #4mL per 28 days.
   • 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to **ONE DMARD** (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an **NSAID** (e.g., naproxen, ibuprofen, meloxicam)

   If yes, **approve for 6 months by GPID or GPI-14 for the requested strength as follows:**
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
   - The patient is 4 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to **ONE or more forms** of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #6.
   If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

6. Does the patient meet ONE of the following criteria?
   • The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and is switching to the requested drug
   • The patient has psoriasis covering 3% or more of body surface area (BSA)
   • The patient has psoriatic lesions affecting the hands, feet, genital area, or face

If yes, approve for a total of 6 months by GPID or GPI-14 and enter two approvals as follows:
   • FIRST APPROVAL: approve for 3 months for the requested strength:
     o 25mg syringes: #8mL per 28 days.
     o 25mg vials: #16 vials OR #8mL per 28 days.
     o 50mg syringes/cartridges: #8mL per 28 days.
   • SECOND APPROVAL: approve for the requested strength for the next 3 months:
     o 25mg syringes: #4mL per 28 days.
     o 25mg vials: #8 vials OR #4mL per 28 days.
     o 50mg syringes/cartridges: #4mL per 28 days.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ETANERCEPT (Enbrel) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial denial text continued on next page)
ETANERCEPT

INITIAL CRITERIA (CONTINUED)

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

E. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as naproxen, ibuprofen, meloxicam)

F. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 4 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested medication
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUARDIAN FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of ankylosing spondylitis (AS) AND meet the following criterion?
   - The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy
   
   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   - The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - 25mg syringes: #4mL per 28 days.
   - 25mg vials: #8 vials OR #4mL per 28 days.
   - 50mg syringes/cartridges: #4mL per 28 days.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ETANERCEPT (Enbrel) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

*(Renewal denial text continued on next page)*
RENEWAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

D. If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

E. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy.

F. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Enbrel.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 02/03
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have **ONE** of the following diagnoses?
   - Edema associated with congestive heart failure, cirrhosis of the liver, or renal disease (including nephrotic syndrome)
   - Ascites due to malignancy, idiopathic edema, or lymphedema

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to **TWO** generic loop diuretics (e.g., furosemide, bumetanide, torsemide)?

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ETHACRYNIC ACID (Edecrin)** requires the following rule(s) be met for approval:
A. You have **ONE** of the following diagnoses:
   1. Edema (swelling caused by fluid build-up in the body) associated with congestive heart failure (a type of heart condition), cirrhosis (liver damage), or renal disease (including nephrotic syndrome [a type of kidney disorder])
   2. Ascites (accumulation of fluid in the abdominal cavity) due to malignancy (cancer), idiopathic (unknown cause) edema, or lymphedema (swelling in an arm or leg due to build-up of lymph fluid)
B. You had a trial of or contraindication (harmful for) to **TWO** generic loop diuretics (such as furosemide, bumetanide, torsemide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
ETACRYNIC ACID

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Edecrin.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma (SEGA) and meet ALL of the following criteria?
   - The patient is 1 year of age or older
   - The patient’s diagnosis requires therapeutic intervention but cannot be curatively resected

   If yes, **approve for 12 months by GPID or GPI-14.**
   If no, continue to #2.

2. Does the patient have a diagnosis of tuberous sclerosis complex (TSC)-associated partial-onset seizures and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Afinitor Disperz will be used as adjunctive treatment

   If yes, **approve for 12 months by GPID or GPI-14.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **EVEROLIMUS (Afinitor Disperz)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated subependymal giant cell astrocytoma (SEGA: a type of brain tumor)
   2. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated partial-onset seizures

B. **If you have tuberous sclerosis complex (TSC)-subependymal giant cell astrocytoma (SEGA), approval also requires:**
   1. You are 1 year of age or older
   2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)

C. **If you have tuberous sclerosis complex (TSC)-associated partial-onset seizures, approval also requires:**
   1. You are 2 years of age or older
   2. Afinitor Disperz will be used as adjunctive (add-on) treatment

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Afinitor Disperz.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/23
Created: 03/23
Client Approval: 03/23
P&T Approval: 04/18
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced hormone receptor (HR)-positive, HER2-negative breast cancer and meet **ALL** of the following criteria?
   - The patient is a postmenopausal woman
   - Afinitor will be used in combination with exemestane
   - The patient has failed or has a contraindication to treatment with Femara (letrozole) or Arimidex (anastrozole)

   If yes, **approve for 12 months for the requested strength by GPID or GPI-14 as follows**:
   - 2.5mg: #1 per day.
   - 5mg: #1 per day.
   - 7.5mg: #2 per day.
   - 10mg: #2 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of progressive, neuroendocrine tumors (NET) with unresectable, locally advanced or metastatic disease **AND** meet the following criterion?
   - The patient is 18 years of age or older

   If yes, continue to #3.
   If no, continue to #4.

3. Does the patient meet **ONE** of the following?
   - The patient has a neuroendocrine tumors of pancreatic origin (PNET)
   - The patient has well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin

   If yes, **approve for 12 months for the requested strength by GPID or GPI-14 as follows**
   - 2.5mg: #1 per day.
   - 5mg: #1 per day.
   - 7.5mg: #2 per day.
   - 10mg: #2 per day.

   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

4. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months for the requested strength by GPID or GPI-14 as follows:
   • 2.5mg: #1 per day.
   • 5mg: #1 per day.
   • 7.5mg: #2 per day.
   • 10mg: #2 per day.

   If no, continue to #5.

5. Does the patient have a diagnosis of tuberous sclerosis complex (TSC)-associated renal angiomyolipoma and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient does not require immediate surgery

   If yes, approve for 12 months for the requested strength by GPID or GPI-14 as follows:
   • 2.5mg: #1 per day.
   • 5mg: #1 per day.
   • 7.5mg: #2 per day.
   • 10mg: #2 per day.

   If no, continue to #6.

6. Does the patient have a diagnosis of tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma (SEGA) and meet ALL of the following criteria?
   • The patient is 1 year of age or older
   • The patient's diagnosis requires therapeutic intervention but cannot be curatively resected

   If yes, approve for 12 months by GPID or GPI-14.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named EVEROLIMUS (Afinitor) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Advanced hormone receptor-positive (HR: a type of protein), human epidermal growth factor receptor 2 (HER2: a type of protein)-negative breast cancer
   2. Progressive, neuroendocrine tumors (NET: a rare type of tumor) with unresectable (unable to remove by surgery), locally advanced (cancer that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (cancer that has spread to other parts of the body)
   3. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   4. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated renal angiomyolipoma (type of kidney tumor)
   5. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated subependymal giant cell astrocytoma (SEGA: a type of brain tumor)

B. If you have advanced hormone receptor-positive, HER2-negative breast cancer, approval also requires:
   1. You are a postmenopausal woman
   2. Afinitor will be used in combination with Aromasin (exemestane)
   3. You have failed or have a contraindication (harmful for) to treatment with Femara (letrozole) or Arimidex (anastrozole)

C. If you have progressive, neuroendocrine tumors (NET) with unresectable, locally advanced or metastatic disease, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have neuroendocrine tumors of pancreatic origin (PNET: tumor in the pancreas)
      b. You have well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI: relates to the digestive system) or lung origin

D. If you have advanced renal cell carcinoma, approval also requires:
   1. You are 18 years of age or older

E. If you have tuberous sclerosis complex (TSC)-associated renal angiomyolipoma, approval also requires:
   1. You are 18 years of age or older
   2. You do not require immediate surgery

(Denial text continued on next page)
EVEROLIMUS-AFINITOR

GUIDELINES FOR USE (CONTINUED)

F. If you have tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma, approval also requires:
   1. You are 1 year of age or older
   2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Afinitor.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/23
Created: 05/11
Client Approval: 10/21
P&T Approval: 04/18
**EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXCLUDED DRUGS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*******Customer Service/PAC Alert**********
(For Internal Use Only)

**DO NOT OVERRIDE OR APPROVE WITHOUT SUBMITTING FOR PHARMACIST OR PHYSICIAN REVIEW.**

**GUIDELINES FOR USE**

1. Is the request for an excluded drug and the claim is rejecting with the error code **REJ-922**?
   - If yes, continue to #2.
   - If no, guideline does not apply.

2. Is the request for a glucose test strip or meter?
   - If yes, please refer to the corresponding guideline for further clinical review.
   - If no, continue to #3.

3. Is the requested drug being used for the treatment of an FDA-approved indication?
   - If yes, continue to #5.
   - If no, continue to #4.

4. If the drug is requested for a non-FDA approved indication, does the patient have a diagnosis for which the drug is considered safe and effective based on sound medical evidence found in peer-reviewed medical literature, accepted standards of medical practice, or in one of the following compendia?
   - American Hospital Formulary Service-Drug Information (AHFS-DI): Contains narrative text supporting use
   - Clinical Pharmacology: Contains narrative text supporting use
   - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium: Category 1 or 2A
   - Non-Formulary & Excluded Drug Exceptions Process
   - Truven Health Analytics Micromedex DrugDex: Class I, Class IIa, or Class IIb
   - Wolters Kluwer Lexi-Drugs: Use: Off-label rated as 'Evidence Level A' with a 'Strong' recommendation
   - If yes, continue to #5.
   - If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE (CONTINUED)

5. Is the requested drug under ANY of the following categories?
   • Protected class drugs (such as Anticonvulsants, Antidepressants, Antineoplastic, Antipsychotics, Antiretroviral, or Immunosuppressants) and the member is already stabilized, and discontinuation of therapy could lead to harm
   • The request is for a member who is stabilized on an Attention Deficit Hyperactivity Disorder or an Anti-mania (Bipolar Affective Disorder) drug prescribed by or given in consultation with a psychiatrist and discontinuation of therapy could lead to harm
   • The member is in the middle of completing an antibiotic or Hepatitis C treatment regimen

   If yes, approve the requested drug for 12 months by GPID or GPI-14. For requests for antibiotic or Hepatitis C drugs, please approve based on the duration of remaining therapy per AASLD (Hepatitis C) or the FDA approved duration.
   If no, continue to #6.

6. Does the requested drug have a corresponding clinical PA guideline on the standard commercial formulary?
   If yes, please refer to the corresponding guideline for further clinical review.
   If no, continue to #7.

7. Is the request for a combination product (e.g., Vimovo, Duexis) for which the individual components with the same route of administration are commercially available and covered by the plan?
   If yes, continue to #8.
   If no, continue to #9.

8. Have ALL of the following criteria been met?
   • The patient has tried and failed the individual components together, AND
   • The prescriber provided a medical rationale that the requested combination product would be safer and/or more efficacious than using the individual components together. Document the rationale in PA approval.

   If yes, continue to #11.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

9. Does the requested medication have clinically appropriate covered alternatives with the same active ingredient and same route of administration?
   Examples of possible alternatives:
   - Conzip: generic tramadol extended-release capsules or tablets
   - Zipsor: generic diclofenac DR tablets
   - Metformin ER gastric: trial of generic Glucophage XR
   - Onzetra Xsail: trial of sumatriptan nasal spray

   If yes, continue to #10.
   If no, continue to #11.

10. Has the patient had a previous trial of at least three covered alternatives with the same active ingredients and same route of administration (if available), OR does the patient have a documented intolerance or contraindication to those agents? Provide reason for therapeutic failure, intolerance or contraindication.

   If yes, continue to #11.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

11. Has the patient tried and failed at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested medication? Provide reasons for therapeutic failure.

   If yes, **approve the requested drug for 12 months by GPID or GPI-14**.
   If no, continue to #12.

12. Does the patient have a documented intolerance or contraindication to the agents identified in question #11? Provide reason for therapeutic failure, intolerance or contraindication.

   If yes, **approve the requested drug for 12 months by GPID or GPI-14**.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: Our guideline named EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA (reviewed for <insert drug name>) requires that ALL of the following rule(s) be met for approval:

A. The requested medication is being used for the treatment of ONE of the following:
   1. A Food and Drug Administration (FDA)-approved indication
   2. A medically accepted indication and it is considered safe and effective by approved compendia (medical references), peer-reviewed medical literature, or accepted standards of medical practice.

B. You meet one of the following criteria (1, 2, or 3):
   1. If the request is for a combination product and the individual components with the same route of administration are commercially available and are covered by your plan, you must meet the following (a, b, and c):
      a. You have previously tried <insert individual components> together
      b. Your doctor provided a medical rationale that the requested combination product would be safer and/or more efficacious than using the individual components together
      c. You have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents
   2. If the request is for a medication that has clinically appropriate covered alternative(s) with the same active ingredient and same route of administration, you must meet the following (a and b):
      a. You have previously tried at least three clinically appropriate covered alternatives with the same active ingredients and same route of administration (if available), including but not limited to <insert formulary agents>, OR there is a medical rationale why the covered alternatives cannot be tried.
      b. You have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents
   3. If the requested medication does NOT have clinically appropriate covered alternatives with the same active ingredient and same route of administration, you must have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents.

(Denial text continued on next page)

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
Page 512 of 1529
GUIDELINES FOR USE (CONTINUED)

A previous trial of <insert applicable drugs/therapies to this case> is noted but we do not have information showing that you have tried the above alternatives. Therefore, your request was not approved. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request. Note: The preferred alternatives may also require a prior authorization.

RATIONALE
To allow an exception for coverage of an excluded drug based on the following considerations:
- The drug is being requested for treatment of an FDA or medically supported indication.
- The patient cannot use covered products due to therapeutic failure, contraindication or intolerance as documented by their physician.
- Any applicable prior authorization clinical criteria for the excluded drug have been met.

FDA APPROVED INDICATIONS
See package insert for requested drug.

Part D Effective: N/A
Effective: 12/17/20
Created: 01/18
Client Approval: 12/20
P&T Approval: 10/19
GUIDELINES FOR USE

1. Is the request for the prevention of recurrent *Clostridioides difficile* infection (CDI) **AND** the patient meets the following criterion?
   - The patient is 18 years of age or older
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient previously received Vowst?
   
   If yes, continue to #4.
   If no, continue to #3.

3. Has the patient completed antibiotic treatment (e.g., vancomycin [Vancocin], fidaxomicin [Dificid]) for recurrent CDI (defined as at least 3 CDI episodes)?
   
   If yes, **approve for 30 days by HICL or GPI-10 for 1 fill with a quantity limit of #12 per 3 days.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet **ALL** of the following criteria?
   - The patient had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Vowst, **AND** a positive stool test for *C. difficile*
   - The patient has not previously received more than 1 treatment course of Vowst **AND** the start of that treatment course was at least 12 days and not more than 8 weeks prior
   
   If yes, **approve for 30 days by HICL or GPI-10 for 1 fill with a quantity limit of #12 per 3 days.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **Fecal Microbiota Capsule (Vowst)** requires the following rule(s) be met for approval:
A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* (C. difficile) infection (CDI: a bacterial infection)
B. You are 18 years of age or older
C. **If you have NOT previously received Vowst, approval also requires:**
   1. You have completed antibiotic (such as vancomycin [Vancocin], fidaxomicin [Dificid]) treatment for recurrent CDI (defined as at least 3 CDI episodes)
D. **If you have been previously treated with Vowst, approval also requires:**
   1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Vowst, AND a positive stool test for *C. difficile*
   2. You have not previously received more than 1 treatment course of Vowst AND the start of that treatment course was at least 12 days and not more than 8 weeks prior

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vowst.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/23
Created: 05/23
Client Approval: 05/23
P&T Approval: 04/23
## FECAL MICROBIOTA SUSPENSION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>FECAL MICROBIOTA, LIVE-JSLM</td>
<td>REBYOTA</td>
<td>48488</td>
<td>GCN</td>
<td>Medi-Span</td>
<td>Exception/Other</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GPI-10</td>
<td>(5252201030)</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

1. Is the request for the prevention of recurrent *Clostridioides difficile* infection (CDI) **AND** the patient meets the following criterion?
   - The patient is 18 years of age or older
     
     If yes, continue to #2.
     If no, do not approve.
     **DENIAL TEXT**: See the denial text at the end of the guideline.

2. Has the patient previously received Rebyota?
   
   If yes, continue to #4.
   If no, continue to #3.

3. Has the patient completed antibiotic treatment (e.g., vancomycin [Vancocin]) for recurrent CDI (defined as at least 3 CDI episodes) at least 24 hours prior?
   
   If yes, approve for 30 days by HICL or GPI-10 for 1 fill with a quantity limit of #150 mL.
   If no, do not approve.
   **DENIAL TEXT**: See the denial text at the end of the guideline.

4. Does the patient meet **ALL** of the following criteria?
   - The patient had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of first dose of Rebyota **AND** a positive stool test for *C. difficile*  
   - The patient has not previously received more than 1 dose of Rebyota **AND** that dose was at least 7 days and not more than 8 weeks prior
     
     If yes, approve for 30 days by HICL or GPI-10 for 1 fill with a quantity limit of #150 mL.
     If no, do not approve.
     **DENIAL TEXT**: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **FECAL MICROBIOTA SUSPENSION (Rebyota)** requires the following rule(s) be met for approval:

A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* 
   (C. difficile) infection (CDI: a bacterial infection)
B. You are 18 years of age or older

(**Denial text continued on next page**)
GUIDELINES FOR USE (CONTINUED)

C. If you have NOT previously received Rebyota, approval also requires:
   1. You have completed antibiotic (such as vancomycin [Vancocin]) treatment for recurrent CDI (defined as at least 3 CDI episodes) at least 24 hours prior

D. If you have been previously treated with Rebyota, approval also requires:
   1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Rebyota AND a positive stool test for C. difficile
   2. You have not previously received more than 1 dose of Rebyota AND that dose was at least 7 days and not more than 8 weeks prior

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rebyota.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytemia) myelofibrosis (MF) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient had a trial of or contraindication to Jakafi (ruxolitinib)

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #4 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FEDRATINIB (Inrebic) requires the following rule(s) be met for approval:
A. You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytemia) myelofibrosis (type of bone marrow cancer)
B. You are 18 years of age or older
C. You previously had a trial of or contraindication (medical reason why you cannot use) to Jakafi (ruxolitinib)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)?

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient shown symptom improvement by meeting ONE of the following criteria?
   - The patient has a spleen volume reduction of 35% or greater from baseline
   - The patient has a 50% or greater reduction in total symptom score (e.g., Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   - The patient has a 50% or greater reduction in palpable spleen length

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **FEDRATINIB (Inrebic)** requires the following rule(s) be met for renewal:

A. You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
B. You have shown symptom improvement by meeting ONE of the following:
   1. You have a spleen volume reduction of 35% or greater from baseline
   2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FEDRATINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Inrebic.

REFERENCES
• Inrebic [Prescribing Information]. Summit, NJ: Celgene Corporation; September 2020.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 11/19
Commercial Effective: 01/01/22  Client Approval: 11/21
P&T Approval: 10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist
   - The patient had a trial of or contraindication to TWO of the following: valproic acid derivative, clobazam, topiramate

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #11.8mL per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist
   - The patient had a trial of or contraindication to valproic acid or derivatives
   - The patient had a trial of or contraindication to TWO of the following: Epidiolex, rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #11.8mL per day.**
   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **FENFLURAMINE (Fintepla)** requires the following rule(s) be met for approval:

A. You have seizures associated with ONE of the following:
   1. Dravet syndrome (a rare type of seizure)
   2. Lennox-Gastaut syndrome (LGS: a type of seizure disorder in young children)

B. **If you have Dravet syndrome, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivative, clobazam, topiramate

*Initial denial text continued on next page*

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact.
MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
INITIAL CRITERIA (CONTINUED)

C. **If you have Lennox-Gastaut syndrome, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or given in consultation with a neurologist (a type of brain doctor)
   3. You had a trial of or contraindication (harmful for) to valproic acid or derivatives
   4. You had a trial of or contraindication (harmful for) to TWO of the following: Epidiolex, rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

**NOTE:** For the diagnosis of Lennox-Gastaut syndrome (LGS), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome **AND** meet the following criterion?
   - The patient has shown continued clinical benefit (e.g., reduction of seizures, reduced length of seizures, seizure control maintained)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #11.8mL per day.**
   If no, do not approve.

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **FENFLURAMINE (Fintepla)** requires the following rule(s) be met for approval:
A. You have seizures associated with Dravet syndrome (a rare type of seizure)
B. You have shown continued clinical benefit (such as reduction of seizures, reduced length of seizures, seizure control maintained) while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
FENFLURAMINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Fintepla.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 07/20
Client Approval: 05/22
P&T Approval: 04/22
FENTANYL NASAL SPRAY

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>FENTANYL CITRATE</td>
<td>LAZANDA</td>
<td></td>
<td>27648</td>
<td>29146</td>
<td>41539</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(65100025102050)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of cancer?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient on a maintenance dose of controlled release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)?
   - If yes, continue to #3.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried, or does the patient have a contraindication to at least 1 immediate-release oral pain agent (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these)?
   - If yes, continue to #5.
   - If no, continue to #4.

4. Does the patient have difficulty swallowing tablets or capsules?
   - If yes, continue to #5.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Has the patient tried, or does the patient have a contraindication to generic fentanyl citrate lozenge?
   - If yes, continue to #6.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

6. Has the patient tried, or does the patient have a contraindication to Abstral, or Fentora?

   If yes, **approve for 6 months by G PID or GPI-14 with a quantity limit of #15 per month.**
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these
definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **FENTANYL NASAL SPRAY (Lazanda)** requires the following rule(s) to be met for approval:
   A. You have a diagnosis of cancer-related pain
   B. You are currently taking a maintenance dose of a controlled-release pain medication (such as MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
   C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
   D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
   E. You had a trial of Abstral or Fentora (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lazanda.

**REFERENCES**
- Lazanda [Prescribing Information]. Northbrook, IL: West Therapeutic Development, LLC; October 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 08/11
Commercial Effective: 07/01/20 Client Approval: 04/20 P&T Approval: 11/14
GUIDELINES FOR USE

1. Does the patient have a diagnosis of cancer?

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient on a maintenance dose of controlled release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)?

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried or does the patient have a contraindication to at least one immediate-release oral pain agent (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these)?

   If yes, continue to #5.
   If no, continue to #4.

4. Does the patient have difficulty swallowing tablets or capsules?

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Has the patient tried or does the patient have a contraindication to generic fentanyl citrate lozenge?

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

6. Has the patient tried or does the patient have a contraindication to Abstral or Fentora?

   If yes, **approve for 6 months by GPID or GPI-12 with a quantity limit of #120 per month.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **FENTANYL SUBLINGUAL SPRAY (Subsys)** requires the following rule(s) be met for approval:
   A. You have cancer-related pain
   B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
   C. You had a trial of an oral immediate-release pain medication (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
   D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
   E. You had a trial of Abstral or Fentora, all of which may also require a prior authorization, unless there is a medical reason why you cannot (contraindication)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Subsys.

**REFERENCES**

FENTANYL TRANSDERMAL PATCH

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>FENTANYL</td>
<td>DURAGESIC, FENTANYL</td>
<td>24635</td>
<td>19200</td>
<td>37952</td>
<td>GPI-12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19201</td>
<td>37947</td>
<td>19202</td>
<td>(651000250086)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>37948</td>
<td>19203</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient meet the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose of another opioid)?
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT**: See the denial text at the end of the guideline.

2. Does the request form indicate that this medication will be used on an "as needed" or “PRN” basis?
   
   If yes, do not approve.
   **DENIAL TEXT**: See the denial text at the end of the guideline.
   If no, continue to #3.

3. Is the request for more than one strength of transdermal fentanyl patch OR does the patient have an active prior authorization(s) for a different strength of fentanyl patch?
   
   If yes, send to Clinical Pharmacist for review.
   If no, continue to #4.

4. Is the request for every 72 hours dosing?
   
   If yes, approve for 12 months by GPID or GPI-14 for the requested strength(s) with the following quantity limits:
   - FOR EVERY 72 HOUR DOSING (12, 25, 37.5, 50, 62.5, 75, 87.5mcg/hr): #10 patches per 30 days.
   - FOR 100mcg/hr: up to #20 patches per 30 days.
   (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR_RES).
   
   If no, continue to #5.

**CONTINUED ON NEXT PAGE**
5. Is the request for dosing every 48 hours?
   If yes, continue to #6.
   If no, send to Clinical Pharmacist for review.

6. Has the patient tried every 72 hours dosing?

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength(s) with the following quantity limits:
   - FOR EVERY 48 HOUR DOSING (12, 25, 37.5, 50, 62.5, 75, 87.5mcg/hr): #15 patches per 30 days.
   - FOR 100mcg/hr: up to #30 patches per 30 days.
   (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR_RES).

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named FENTANYL TRANSDERMAL PATCH (Duragesic) requires the following rule(s) be met for approval:
   A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose (equal pain-relieving dose) of another opioid
   B. The requested medication is not prescribed on an 'as needed' basis
   C. Requests for dosing every 48 hours requires a trial of transdermal (absorbed through the skin) fentanyl patch dosed every 72 hours

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
**FENTANYL TRANSDERMAL PATCH**

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Duragesic.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 02/03
Client Approval: 04/20
P&T Approval: 07/19
## Fentanyl Transmucosal Agents

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl Citrate</td>
<td>ACTIQ, ABSTRAL,</td>
<td>01747</td>
<td>GPI-10</td>
<td>(6510002510)</td>
<td>FDB &amp; Medi-Span: ROUTE = BUCCAL, SUBLINGUAL</td>
</tr>
<tr>
<td></td>
<td>FENTORA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Guidelines for Use

1. Does the patient have a diagnosis of cancer?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the patient on a maintenance dose of controlled release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)?
   - If yes, continue to #3.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient tried or does the patient have a contraindication to at least one immediate-release oral pain agent (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these)?
   - If yes, continue to #5.
   - If no, continue to #4.

4. Does the patient have difficulty swallowing tablets or capsules?
   - If yes, continue to #5.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the request for generic fentanyl citrate lozenge?
   - If yes, **approve for 6 months by GPID or GPI-14 for the requested strength with a quantity limit of #120 per month.**
   - If no, continue to #6.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

6. Has the patient tried or does the patient have a contraindication to generic fentanyl citrate lozenge?

If yes, approve for 6 months by GPID or GPI-14 for the requested strength with a quantity limit of #120 per month.
If no, do not approve.

DENIAL TEXT: “Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FENTANYL TRANSMUCOSAL AGENTS (Actiq, Fentora, Abstral) requires the following rule(s) be met for approval:
A. You have cancer-related pain
B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)
C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization) unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Actiq, Fentora, and Abstral.

REFERENCES
• Actiq [Prescribing Information]. North Wales, PA: Cephalon, Inc.; October 2019.
• Fentora [Prescribing Information]. North Wales, PA: Cephalon, Inc.; October 2019.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of iron deficiency and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to an OTC oral iron preparation (e.g., ferrous sulfate, ferrous gluconate, ferrous fumarate)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FERRIC MALTOL (Accrufer) requires the following rule(s) be met for approval:
A. You have iron deficiency (low iron levels)
B. You are 18 years of age or older
C. You had a trial of an over-the-counter (OTC) oral iron preparation (e.g., ferrous sulfate, ferrous gluconate, ferrous fumarate), unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Accrufer.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 07/21
Commercial Effective: 10/01/21 Client Approval: 08/21 P&T Approval: 07/21
GUIDELINES FOR USE

INITIAL CRITERIA (FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe menopausal vasomotor symptoms (VMS) and meet ALL of the following criteria?
   - The patient experiences 7 or more hot flashes per day
   - The patient had a trial of or contraindication to hormonal therapy (e.g., estradiol transdermal patch [Minivelle, Climara], oral conjugated estrogens [Premarin], micronized progesterone [Prometrium])

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named FEZOLINETANT (Veozah) requires the following rule(s) be met for approval:

A. You have moderate to severe menopausal vasomotor symptoms (VMS: a type of symptom related to menopause)
B. You experience 7 or more hot flashes per day
C. You had a trial of or contraindication (harmful for) to hormonal therapy (such as estradiol transdermal patch [Minivelle, Climara], oral conjugated estrogens [Premarin], micronized progesterone [Prometrium])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe menopausal vasomotor symptoms (VMS) and meet ALL of the following criteria?
   
   • The patient has a continued need for VMS treatment (i.e., persistently symptomatic with hot flashes)
   
   • The patient had a reduction in VMS frequency OR severity due to Veozah (fezolinetant) treatment

   If yes, approve for 12 months by HICL or GPI-10 with a quantity of #1 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named FEZOLINETANT (Veozah) requires the following rule(s) be met for renewal:
   
   A. You have moderate to severe menopausal vasomotor symptoms (VMS: a type of symptom related to menopause)
   
   B. You have a continued need for VMS treatment (you still experience persistent hot flashes)
   
   C. You had a reduction in VMS frequency OR severity due to Veozah (fezolinetant) treatment

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Veozah.

REFERENCES
GUIDELINES FOR USE

1. Does the patient meet **ONE** of the following criteria?
   - The patient has a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient has a diagnosis of acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
   - The patient has a non-myeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
   - The requested medication will be used for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
   - The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia
   - The requested medication will be used to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nivestym (filgrastim-aafi)

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FILGRASTIM (Neupogen) requires the following rule(s) be met for approval:
A. You meet ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Neupogen for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause)
   6. You will be using Neupogen to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)
B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FILGRASTIM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Neupogen.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Client Approval: 05/23
Created: 08/21
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient meet **ONE** of the following criteria?
   - The patient has a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient has a diagnosis of acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
   - The patient has a non-myeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
   - The requested medication will be used for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
   - The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia
   - The requested medication will be used to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is therapy prescribed by or in consultation with a hematologist or oncologist?

   If yes, **approve for 12 months by HICL or GPI-10**.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FILGRASTIM-AAFI (Nivestym) requires the following rule(s) be met for approval:
A. You meet ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Nivestym for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles or due to unknown cause)
   6. You will be using Nivestym to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)
B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FILGRASTIM-AAFI

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nivestym and Neupogen.

REFERENCES
- Nivestym [Prescribing Information]. Lake Forest, IL: Pfizer; April 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/22
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient meet **ONE** of the following criteria?
   - The patient has a nonmyeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient has acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
   - The patient has a nonmyeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
   - The requested medication will be used for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
   - The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia
   - The requested medication will be used to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nivestym (filgrastim-aafi)

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named FILGRASTIM-AYOW (Releuko) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. You have a nonmyeloid malignancy (a type of cancer) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a nonmyeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Releuko for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles, or due to unknown cause)
   6. You will be using Releuko to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)
B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FILGRASTIM-AYOW

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Releuko and Neupogen.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/22
Commercial Effective: 07/01/23  Client Approval: 05/23  P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient meet ONE of the following criteria?
   - The patient has a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient has a diagnosis of acute myeloid leukemia (AML) and is undergoing induction or consolidation chemotherapy treatment
   - The patient has a non-myeloid malignancy, is undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT), and is experiencing neutropenia and/or neutropenia-related clinical sequelae (e.g., febrile neutropenia)
   - The requested medication will be used for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
   - The patient has a diagnosis of congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia
   - The requested medication will be used to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nivestym (filgrastim-aafi)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
Our guideline named **FILGRASTIM-SNDZ (Zarxio)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever.
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body).
   3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever]).
   4. You will be using Zarxio for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood).
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause).
   6. You will be using Zarxio to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity).

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor).

C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
FILGRASTIM-SNDZ

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zarxio and Neupogen.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/22
Client Approval: 05/23
P&T Approval: 04/23
FINASTERIDE-TADALAFIL

GUIDELINES FOR USE

1. Has the patient received a 26-week course of Entadfi?

   If yes, do no approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, continue to #2.

2. Is the request for a male patient with a diagnosis of benign prostatic hyperplasia (BPH) who meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to TWO alpha blockers (e.g., terazosin, doxazosin, tamsulosin)
   - The patient had a trial of or contraindication to ONE 5-alpha-reductase inhibitor (e.g., finasteride, dutasteride)
   - The patient had a trial of or contraindication to tadalafil 2.5 mg or tadalafil 5 mg

   If yes, **approve for 26 weeks by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named FINASTERIDE-TADALAFIL (Entadfi) requires the following rule(s) be met for approval:
   A. You are male and have benign prostatic hyperplasia (BPH: a type of prostate condition)
   B. You are 18 years of age or older
   C. You had a trial of or contraindication (harmful for) to TWO alpha blockers (such as terazosin, doxazosin, tamsulosin)
   D. You had a trial of or contraindication (harmful for) to ONE 5-alpha-reductase inhibitor (such as finasteride, dutasteride)
   E. You had a trial of or contraindication (harmful for) to tadalafil 2.5 mg or tadalafil 5 mg

   Requests will not be approved if you have received a 26-week course of Entadfi.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
FINASTERIDE-TADALAFIL

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Entadfi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/29/22
Created: 08/22
Client Approval: 08/22
P&T Approval: 04/22
FINERENONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>FINERENONE</td>
<td>KERENDIA</td>
<td>47487</td>
<td></td>
<td>GPI-10 (3035403000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to BOTH of the following:
     - A sodium-glucose cotransport-2 (SGLT2) inhibitor (e.g., Farxiga, Invokana, Jardiance, Steglatro)
     - Spironolactone OR eplerenone

If yes, approve for 12 months by HICL or GPI-10 with a quantity of #1 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FINERENONE (Kerenda) requires the following rule(s) be met for approval:
A. You have chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
B. You are 18 years of age or older
C. You had a trial of or contraindication to (medical reason why you cannot use) BOTH of the following:
   1. A sodium-glucose cotransport-2 (SGLT2) inhibitor (such as Farxiga, Invokana, Jardiance, Steglatro)
   2. Spironolactone OR eplerenone

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FINERENONE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kerendia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/01/23
Created: 07/21
Client Approval: 03/23
P&T Approval: 04/21
GUIDELINES FOR USE

1. Does the patient have the diagnosis of a relapsing form of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease AND meet the following criterion?
   • The patient is 10 years of age or older

   If yes, continue to #2.
   If no, do not approve.  
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient have ANY of the following contraindications to Gilenya?
   • A recent (within past 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
   • A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker
   • A baseline QTC interval 500 msec or above
   • Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FINGOLIMOD (Gilenya) requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease
B. You are 10 years of age or older.
C. You do not have any of the following contraindications (medical reason why you cannot use) to Gilenya:
   1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker.
3. A baseline QTC interval 500 msec or above (a measure of the speed of electrical conduction in the heart).
4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gilenya.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, and meet **ALL** of the following criteria?
   - The patient is 10 years of age or older
   - The patient had a trial of fingolimod capsules
   - The patient is unable to swallow fingolimod capsules
   - The patient had a trial of or contraindication to ONE agent indicated for the treatment of MS

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have **ANY** of the following contraindications to Tascenso ODT?
   - A recent (within past 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
   - A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker
   - A baseline QTc interval of 500 msec or greater
   - Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

**CONTINUED ON NEXT PAGE**
FINGOLIMOD LAURYL SULFATE

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FINGOLIMOD LAURYL SULFATE (Tascenso ODT) requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (a type of nerve disorder), to include clinically isolated syndrome (a type of nerve disorder that occurs once), relapsing-remitting disease (symptoms or disease returns and goes away) and active secondary progressive disease (advanced disease)
B. You are 10 years of age or older
C. You had a trial of fingolimod capsules
D. You are unable to swallow fingolimod capsules
E. You had a trial of or contraindication (harmful for) to one other agent indicated for the treatment of multiple sclerosis
F. You do not have any of the following contraindications (harmful for) to Tascenso ODT:
   1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure
   2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker
   3. A baseline QTc interval of 500 msec or greater (a measure of the speed of electrical conduction in the heart)
   4. Current treatment with Class la (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FINGOLIMOD LAURYL SULFATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tascenso ODT.

REFERENCES
• Tascenso ODT [Prescribing Information]. San Jose, CA: Handa Neuroscience, LLC; December 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A		Created: 11/22
Commercial Effective: 01/16/23	Client Approval: 12/22	P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

1. Is Addyi (flibanserin) a covered benefit?

   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by ALL of the following criteria?
   - Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   - HSDD is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   - HSDD symptom cause marked distress or interpersonal difficulty

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Have ALL of the following criteria been met?
   - The patient is a premenopausal female
   - The patient is 18 years of age or older
   - The patient had a previous trial of or contraindication to bupropion
   - The patient is not currently using Vyleesi (bremelanotide)

   If yes, **approve for 8 weeks by HICL or GPI-10 with a quantity limit of #1 tablet per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
FLIBANSERIN

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FLIBANSERIN (Addyi) requires the following rule(s) be met for approval:
A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by ALL of the following criteria:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty
B. You are a premenopausal female
C. You are 18 years of age or older
D. You previously had a trial of bupropion, unless there is a medical reason why you cannot (contraindication)
E. You are not currently using Vyleesi (bremelanotide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) (also referred to as female sexual interest/arousal disorder [FSIAD] per DSM-5), as defined by ALL of the following criteria?
   • Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   • HSDD is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   • HSDD symptom cause marked distress or interpersonal difficulty

   If yes, continue to #2.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
FLIBANSERIN

RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet ALL of the following criteria?
   - The patient is a premenopausal female
   - The patient is not currently using Vyleesi
   - The patient has demonstrated continued improvement in symptoms of HSDD/FSIAD (e.g., increased sexual desire, lessened distress)?

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 tablet per day. If no, do not approve.

RENEWAL DENIAL TEXT: “Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline for FLIBANSERIN (Addyi) requires the following rule(s) be met for renewal:

A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by ALL of the following criteria:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty

B. You are a premenopausal female
C. You are 18 years of age or older
D. You are not currently using Vyleesi (bremelanotide)
E. You have demonstrated continued improvement in symptoms of hypoactive sexual desire disorder/female sexual interest and arousal disorder (such as increased sexual desire, lessened distress)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FLIBANSERIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Addyi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 09/15
Commercial Effective: 07/01/20 Client Approval: 04/20

P&T Approval: 07/19
FLUORIDE ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUORIDE (SODIUM)</td>
<td>SODIUM</td>
<td>7472</td>
<td>GPI-14</td>
<td>(79300020000505,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FLUORIDE,</td>
<td>7473</td>
<td>79300020000510,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LUDENT</td>
<td>7476</td>
<td>79300020000515,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FLUORIDE</td>
<td>7510</td>
<td>79300020002050</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7511</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7512</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested agent AND does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact’s Essential Health Benefit Tables)?

   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the patient 6 months to 6 years of age?

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the request for a generic agent?

   If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay.**
   If no, continue to #5.

5. Is the request for ONE of the following?
   - A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   - A multi-source brand (MSB) agent

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
6. Does the patient meet **ONE** of the following criteria?
   - Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
   - The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
   - The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, approve the requested agent for 12 months by GPID or GPI-14 at zero copay. **APPROVAL TEXT** (applies to multi-source brand agents only): Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve. **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **FLUORIDE ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for **ONE** of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. You are 6 months to 6 years of age

C. If the request is for a single-source brand or multi-source brand agent, approval also requires **ONE** of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
FLUORIDE ZERO COST SHARE OVERRIDE

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of fluoride at zero copay. The override criteria allow patient access to all FDA-approved fluoride medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
** Please use the criteria for the specific drug requested **

**GUIDELINE FOR USE**

**CARAC**

1. Does the patient have a diagnosis of actinic or solar keratosis of the face and anterior scalp AND meet the following criterion?
   - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

   If yes, **approve for 1 month by GPID or GPI-14.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **FLUOROURACIL CREAM (Carac)** requires the following rule(s) be met for approval:

A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the face and anterior (front) scalp

B. You have previously tried **TWO** generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**FLUOROPLEX**

1. Does the patient have a diagnosis of actinic or solar keratosis AND meet the following criterion?
   - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

   If yes, **approve for 1 month by GPID or GPI-14.**
   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FLUOROURACIL CREAM (Fluoroplex) requires the following rule(s) be met for approval:
A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure)
B. You have previously tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Carac or Fluoroplex.

REFERENCES
FOLIC ACID ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOLIC ACID</td>
<td>FOLIC ACID, VARIOUS</td>
<td>94783</td>
<td>94784</td>
<td>GPI-14 (82200010000305, 82200010000310)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested folic acid agent AND does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?
   
   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the request for a generic agent?
   
   If yes, approve the requested agent for 12 months by GPID or GPI-14 at zero copay.
   If no, continue to #4.

4. Is the request for ONE of the following?
   - A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   - A multi-source brand (MSB) agent

   If yes, continue to #5.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet ONE of the following criteria?
   - Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
   - The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
   - The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, approve the requested agent for 12 months by GPID or GPI-14 at zero copay.

APPROVAL TEXT (applies to multi-source brand agents only): Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FOLIC ACID ZERO COST SHARE OVERRIDE requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FOLIC ACID ZERO COST SHARE OVERRIDE

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of folic acid 0.4 mg and 0.8 mg tablets at zero copay. The override criteria allow patient access to all FDA-approved folic acid medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of molybdenum cofactor deficiency (MoCD) Type A?

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FOSDENOPTERIN (Nulibry) requires the following rule(s) be met for approval:
   A. You have molybdenum cofactor deficiency (MoCD) Type A (rare condition characterized by brain dysfunction)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nulibry.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or given in consultation with a hematologist or immunologist

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient received splenectomy?
   If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   **APPROVAL TEXT:** Renewal requires clinically significant prevention of bleeds while on therapy, attainment of platelet levels of 50-450 x 10^9/L, and proof of normal LFTs (liver function tests), total bilirubin, and ANC (absolute neutrophil count).

   If no, continue to #3.

3. Has the patient had a previous trial of or contraindication to TWO of the following treatments?
   • Corticosteroids
   • IVIG (intravenous immunoglobulin)
   • Rhogam
   • Rituxan (rituximab)
   • Thrombopoietin receptor agonist (i.e., Promacta (eltrombopag), Nplate (romiplostim))

   If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   **APPROVAL TEXT:** Renewal requires clinically significant prevention of bleeds while on therapy, attainment of platelet levels of 50-450 x 10^9/L, and proof of normal LFTs (liver function tests), total bilirubin, and ANC (absolute neutrophil count).

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text on the next page.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FOSTAMATINIB (Tavalisse) requires the following rule(s) be met for approval:
A. You have chronic immune thrombocytopenia (cITP; Low levels of the blood cells that prevent bleeding)
B. You are 18 years of age or older
C. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)
D. You had a splenectomy (surgical removal of spleen) OR a previous trial of or contraindication to (medical reason why you cannot use) at least TWO of the following treatments:
1. Corticosteroids
2. IVIG (intravenous immunoglobulin)
3. Rhogam
4. Rituxan (rituximab)
5. Thrombopoietin receptor agonist such as Promacta (eltrombopag), Nplate (romiplostim)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic immune thrombocytopenia (cITP) and meet ALL of the following criteria?
   • The patient has had clinically significant prevention of bleeds while on therapy
   • The patient's AST and ALT levels have remained under 3 times the upper limits of normal per reference range
   • The patient's total bilirubin level has remained under 2 times the upper limits of normal per reference range
   • The patient's ANC has remained within normal limits per reference range
   • The patient's platelets have attained a level between 50 and 450 x 10^9/L

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline on the next page.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FOSTAMATINIB (Tavalisse) requires the following rule(s) be met for renewal:
A. You have chronic immune thrombocytopenia (cITP; Low levels of the blood cells that prevent bleeding)
B. You had clinically significant prevention of bleeds while on therapy
C. Your AST (aspartate transaminase) and ALT (alanine transaminase) levels (types of liver enzymes) have remained under 3 times the upper limits of normal per reference range
D. Your total bilirubin level has remained under 2 times the upper limits of normal per reference range
E. Your absolute neutrophil count (ANC; a measure of the number of neutrophils which are a type of white blood cell) has remained within normal limits per reference range
F. Your platelets have reached a level between 50 and 450 x 10(9)/L

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tavalisse.

REFERENCES
• Tavalisse [Prescribing Information]. South San Francisco, CA. Rigel Pharmaceuticals, Inc. April 2018.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 08/18
Client Approval: 04/20
P&T Approval: 07/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) infection and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The requested medication will be used in combination with other antiretroviral(s)
   - The patient is treatment experienced
   - The patient has multidrug-resistant HIV-1 infection
   - The patient is failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations
   
   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FOSTEMSAVIR (Rukobia) requires the following rule(s) be met for approval:
A. You have human immunodeficiency virus type 1 (HIV-1) infection (a virus that attacks the body’s immune system and if untreated, can lead to AIDS [acquired immunodeficiency syndrome])
B. You are 18 years of age or older
C. The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)
D. You are treatment experienced (previously treated)
E. You have multidrug-resistant HIV-1 infection (your virus is resistant to more than one HIV medication)
F. You are failing your current antiretroviral regimen due to resistance, intolerance, or safety considerations

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rukobia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 07/20
Commercial Effective: 08/01/20  Client Approval: 07/20
P&T Approval: 07/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of episodic migraines and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Ajovy is prescribed for the preventive treatment of migraines
   • Ajovy will NOT be used concurrently with other CGRP inhibitors (e.g., Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   • The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
   • The patient had a trial of TWO of the following preferred agents: Aimovig, Emgality, Nurtec ODT, Qulipta

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1.5mL per 30 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of chronic migraines and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Ajovy is prescribed for the preventive treatment of migraines
   • Ajovy will NOT be used concurrently with other CGRP inhibitors (e.g., Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   • The patient had a trial of ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable]
   • The patient had a trial of TWO of the following preferred agents: Aimovig, Emgality, Nurtec ODT, Qulipta

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1.5mL per 30 days.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: “Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FREMANEZUMAB-VFRM (Ajovy) requires the following rule(s) be met for approval:
A. You have migraines
B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Ajovy is prescribed for the preventive treatment of migraines
   3. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
   5. You have tried TWO of the following: Aimovig, Emgality, Nurtec ODT, Qulipta
C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Ajovy is prescribed for the preventive treatment of migraines
   3. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]
   5. You have tried TWO of the following: Aimovig, Emgality, Nurtec ODT, Qulipta

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FREMANEZUMAB-VFRM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is Ajovy being prescribed for the preventive treatment of migraines AND does the patient meet the following criterion?
   • Ajovy will NOT be used concurrently with other CGRP inhibitors (e.g., Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   • The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Ajovy therapy
   • The patient has experienced a reduction in migraine severity with Ajovy therapy
   • The patient has experienced a reduction in migraine duration with Ajovy therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1.5mL per 30 days.

   If no, do not approve.
   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FREMANEZUMAB-VFRM (Ajovy) requires the following rule(s) be met for renewal:
A. Ajovy is prescribed for the preventive treatment of migraines
B. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Amovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
C. You meet ONE of the following:
   1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Ajovy therapy
   2. You have experienced a reduction in migraine severity with Ajovy therapy
   3. You have experienced a reduction in migraine duration with Ajovy therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FREMANEZUMAB-VFRM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ajovy.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 09/18
Client Approval: 02/22
P&T Approval: 01/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has been previously treated for unresectable, locally advanced or metastatic iCCA
   - The patient has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
   - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to the initiation of Lytgobi and at the recommended scheduled intervals

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named FUTIBATINIB (Lytgobi) requires the following rule(s) be met for approval:
A. You have unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) (a type of bile duct cancer inside the liver that is unable to be removed by surgery, has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)
B. You are 18 years of age or older
C. You have been previously treated for unresectable, locally advanced or metastatic iCCA
D. You have fibroblast growth factor receptor 2 (FGFR2: a type of protein) gene fusions or other rearrangements
E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting Lytgobi and at the recommended scheduled times

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
FUTIBATINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lytgoi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 11/22
Commercial Effective: 11/14/22  Client Approval: 11/22  P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of episodic migraines and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Emgality is prescribed for the preventive treatment of migraines
   - Emgality will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   - The patient had a trial of **ONE** of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

   If yes, **approve for a total of 6 months by entering TWO approvals as follows:**
   - **FIRST APPROVAL:** approve for 1 month by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #2mL per 30 days.
   - **SECOND APPROVAL:** approve for 5 months by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #1mL per 30 days. (Please enter a start date of 23 days AFTER the start date of the first approval).

   If no, continue to #2.

   CONTINUED ON NEXT PAGE
GALCANEZUMAB-GNLM

INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of chronic migraines and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Emgality is prescribed for the preventive treatment of migraines
   - Emgality will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Vyepti, Nurtec ODT, Quilpta) for migraine prevention
   - The patient had a trial of ONE of the following preventive migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]

   If yes, approve for a total of 6 months by entering TWO approvals as follows:
   - FIRST APPROVAL: approve for 1 month by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #2mL per 30 days.
   - SECOND APPROVAL: approve for 5 months by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #1mL per 30 days. (Please enter a start date of 23 days AFTER the start date of the first approval).

   If no, continue to #3.

3. Is the request for the treatment of episodic cluster headache AND does the patient meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 3 months by GPID or GPI-14 for Emgality 100mg/mL with a quantity limit of #3mL per 30 days.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named GALCANEZUMAB-GNLM (Emgality) requires the following rule(s) be met for approval:
   A. You have migraines or episodic cluster headaches (very painful headaches that occur in patterns)

   (Initial denial text continued on next page)

   CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Emgality is prescribed for the preventive treatment of migraines
   3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Emgality is prescribed for the preventive treatment of migraines
   3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]

D. If you have episodic cluster headaches, approval also requires:
   5. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is Emgality prescribed for the preventive treatment of migraines AND does the patient meet the following criterion?
   - Emgality will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention

   If yes, continue to #2.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient meet **ONE** of the following criteria?
   - The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month with Emgality therapy
   - The patient has experienced a reduction in migraine severity with Emgality therapy
   - The patient has experienced a reduction in migraine duration with Emgality therapy

   If yes, **approve for 12 months by GPID or GPI-14 for the requested Emgality 120mg/mL formulation with a quantity limit of #1mL per 30 days.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Is Emgality prescribed for the treatment of episodic cluster headache **AND** does the patient meet the following criterion?
   - The patient had improvement in episodic cluster headache frequency as compared to baseline

   If yes, **approve for 12 months by GPID or GPI-14 for Emgality 100mg/mL with a quantity limit of #3mL per 30 days.**
   If no, do not approve.
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   **Our guideline named GALCANEZUMAB-GNLM (Emgality) requires the following rule(s) be met for renewal:**
   - **A.** Emgality is being prescribed for preventive treatment of migraines OR for the treatment of episodic cluster headache (very painful headaches that occur in patterns)
   - **B.** **If you have migraines, renewal also requires:**
     1. You will **NOT** use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
     2. You meet **ONE** of the following:
        a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Emgality therapy
        b. You have experienced a reduction in migraine severity with Emgality therapy
        c. You have experienced a reduction in migraine duration with Emgality therapy
   - **C.** **If you have episodic cluster headaches, renewal also requires:**
     1. You had improvement in episodic cluster headache frequency as compared to baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
GALCANEZUMAB-GNLM

RATIONALE
For further information, please refer to the Prescribing information and/or Drug Monograph for Emgality.

REFERENCES
• Emgality [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; March 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 10/18
Commercial Effective: 04/01/22 Client Approval: 02/22 P&T Approval: 01/22
GANAXOLONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>GANAXOLONE</td>
<td>ZTALMY</td>
<td>47912</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(7260003300)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of seizures and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - The patient's seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #36 mL per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named GANAXOLONE (Ztalmy) requires the following rule(s) be met for approval:
   A. You have seizures
   B. You are 2 years of age or older
   C. Your seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD: a type of genetic disorder)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ztalmy.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient has tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
   - Iressa (gefitinib) will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva [erlotinib], Tagrisso [osimertinib], Gilotrif [afatinib], Vizimpro [dacomitinib])

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named Gefitinib (Iressa) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
B. Your tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (abnormal changes in a gene) as detected by an FDA (Food and Drug Administration)-approved test
C. You will NOT be using Iressa (gefitinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Gilotrif [afatinib], Vizimpro [dacomitinib])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Iressa.

REFERENCES
GILTERITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILTERITINIB</td>
<td>XOSPATA</td>
<td>45506</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(2153302020)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **GILTERITINIB (Xospata)** requires the following rule(s) be met for approval:
   A. You have relapsed or refractory acute myeloid leukemia (AML: type of white blood cell cancer)
   B. You are 18 years of age or older
   C. You have FMS-like tyrosine kinase 3 (type of gene) mutation (change in the DNA gene) as detected by a Food and Drug Administration-approved test

   Your doctor told us *[INSERT PT SPECIFIC INFO PROVIDED]*. We do not have information showing you *[INSERT UNMET CRITERIA]*. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xospata.

REFERENCES

- Xospata [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.; November 2018

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 03/19
Commercial Effective: 04/10/21  Client Approval: 03/21  P&T Approval: 01/19

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
GUIDELINES FOR USE

1. Does the patient have a diagnosis of newly-diagnosed acute myeloid leukemia (AML) AND meet the following criterion?
   - The requested medication will be used in combination with low-dose cytarabine

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   - The patient is 75 years of age or older
   - The patient has comorbidities that prevent use of intensive induction chemotherapy

   If yes, approve for 12 months by GPIID or GPI-14 for the requested strength with a quantity limit as follows:
   - Daurismo 25mg: #2 per day.
   - Daurismo 100mg: #1 per day.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GLASDEGIB (Daurismo) requires the following rule(s) be met for approval:
A. You have newly-diagnosed acute myeloid leukemia (AML: type of white blood cell cancer)
B. The requested medication will be used in combination with low-dose cytarabine
C. You are 75 years of age or older, OR you have comorbidities (having more than one disease) that prevents the use of intensive induction chemotherapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GLASDEGIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Daurismo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 01/19
Client Approval: 04/20
P&T Approval: 01/19
GLATIRAMER ACETATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLATIRAMER ACETATE</td>
<td>COPAXONE, GLATOPA, GLATIRAMER ACETATE</td>
<td>12810</td>
<td></td>
<td>GPI-10 (6240003010)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease **AND** meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**
   - 20mg/mL: #1mL per day.
   - 40mg/mL: #12mL per 28 days.

   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **GLATIRAMER ACETATE (Copaxone, Glatopa)** requires the following rule(s) be met for approval:
   1. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   2. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
GLATIRAMER ACETATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Copaxone and Glatopa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/21
Created: 02/14
Client Approval: 11/20
P&T Approval: 02/14
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 AND meet the following criterion?
   - The patient is 3 years of age or older
     If yes, continue to #2.
     If no, continue to #12.

2. Does the patient have an HCV RNA level within the past 6 months?
   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet at least ONE of the following criteria?
   - The patient has moderate or severe liver impairment (Child-Pugh B or C)
   - The patient is concurrently taking any of the following medications (alone or in combination): rifampin, atazanavir, carbamazepine, efavirenz, darunavir, lopinavir, ritonavir, atorvastatin, lovastatin, simvastatin, rosuvastatin (at doses greater than 10mg), cyclosporin (for patients requiring stable cyclosporin doses greater than 100mg/day), medications containing ethinyl estradiol, Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (velpatasvir/sofosbuvir/voxilaprevir), or Zepatier (elbasvir/grazoprevir)
   - The patient has prior failure of a direct-acting antiviral (DAA) regimen that contains a NS5A inhibitor AND a NS3/4A protease inhibitor (e.g., Viekira Pak [ombitasvir/paritaprevir/ritonavir/dasabuvir], Viekira XR [ombitasvir/paritaprevir/ritonavir/dasabuvir extended release], Technivie [ombitasvir/paritaprevir/ritonavir], Vosevi [sofosbuvir/velpatasvir/voxilaprevir], Zepatier [elbasvir/grazoprevir], or previous concurrent treatments containing a NS5A inhibitor AND NS3/4A protease inhibitor
   - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
     If yes, do not approve.
     **DENIAL TEXT:** See the denial text at the end of the guideline.
     If no, continue to #4.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

4. Has the patient previously received a full treatment of a regimen that contains a NS5A inhibitor (e.g., Harvoni [ledipasvir/sofosbuvir], Epclusa [velpatasvir/sofosbuvir], or Daklinza [daclatasvir]/Sovaldi [sofosbuvir] combination)?

   If yes, continue to #11.
   If no, continue to #5.

5. Has the patient failed a short trial of the preferred formulary agent or has a contraindication to therapy with the preferred formulary agent(s) as specified below?
   - For genotype 1, 4, 5, or 6 HCV infection: a short trial of Epclusa (sofosbuvir/velpatasvir) or Harvoni (ledipasvir/sofosbuvir) (e.g., adverse effect early in therapy to Harvoni [ledipasvir/sofosbuvir] or Epclusa [sofosbuvir/velpatasvir]) or contraindication to BOTH agents
   - For genotype 2 or 3 HCV infection: a short trial of Epclusa (sofosbuvir/velpatasvir) (e.g., adverse effect early in therapy to Epclusa [sofosbuvir/velpatasvir]) or contraindication to this agent

   If yes, continue to #6.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

6. Is the patient post kidney transplant or post-liver transplant and meet ONE of the following criteria?
   - Genotype 1 infection, treatment experienced (previous treatment with NS5A inhibitor) AND NS3/4A protease inhibitor naïve
   - Genotype 3 infection, treatment experienced (previous treatment with a regimen that contains interferon or peginterferon with ribavirin, and/or sofosbuvir)

   If yes, approve for 16 weeks for the requested strength by G PID or G PI-14 as follows:
      - 100mg-40mg tablet: #3 per day.
      - 50mg-20mg pellets: #5 per day.

   If no, continue to #7.

7. Is the patient post kidney transplant or post-liver transplant and meet ALL of the following criteria?
   - Treatment experienced or treatment naïve
   - Without cirrhosis or with compensated cirrhosis

   If yes, approve for 12 weeks for the requested strength by G PID or G PI-14 as follows:
      - 100mg-40mg tablet: #3 per day.
      - 50mg-20mg pellets: #5 per day.

   If no, continue to #8.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

8. Does the patient meet **ONE** of the following criteria?
   - Genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis and treatment naïve
   - Genotype 1, 2, 4, 5 or 6 infection without cirrhosis and treatment experienced (previous treatment failure with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir)

   If yes, **approve for 8 weeks for the requested strength by GPID or GPI-14 as follows:**
   - 100mg-40mg tablet: #3 per day.
   - 50mg-20mg pellets: #5 per day.

   If no, continue to #9.

9. Does the patient meet **ONE** of the following criteria?
   - Genotype 1, 2, 4, 5 or 6 infection with compensated cirrhosis and treatment experienced (previous treatment failure with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir)
   - Genotype 1 infection and treatment experienced (previous treatment with NS3/4A inhibitor [e.g., Victrelis (boceprevir), Incivek (telaprevir), Olysio (simeprevir)] AND is NS5A inhibitor naïve)

   If yes, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:**
   - 100mg-40mg tablet: #3 per day.
   - 50mg-20mg pellets: #5 per day.

   If no, continue to #10.

10. Does the patient have genotype 1, 2, 3, 4, 5 or 6 infection with compensated cirrhosis and treatment naïve?

    If yes, **approve for 8 weeks for the requested strength by GPID or GPI-14 as follows:**
    - 100mg-40mg tablet: #3 per day.
    - 50mg-20mg pellets: #5 per day.

    If no, continue to #11.

    CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

11. Does the patient meet ONE of the following criteria?
   • Genotype 1 infection and treatment experienced (previous treatment with NS5A inhibitor) AND is NS3/4A protease inhibitor naïve
   • Genotype 3 infection and treatment experienced (previous treatment failure with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir)

   If yes, approve for 16 weeks for the requested strength by GPID or GPI-14 as follows:
   • 100mg-40mg tablet: #3 per day.
   • 50mg-20mg pellets: #5 per day.

   If no, continue to #12.

12. Is the requested regimen recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment?

   If yes, approve as indicated per guidance in AASLD/IDSA.
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GLECAPREVIR/PIBRENTASVIR (Mavyret) requires the following rule(s) be met for approval:
A. The requested regimen is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment
B. You have chronic hepatitis C (type of liver inflammation), genotype 1, 2, 3, 4, 5, or 6
C. You are 3 years of age or older
D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
E. You have compensated cirrhosis (type of liver condition) or no cirrhosis (no liver damage) and meet ONE of the following:
   1. You are treatment naïve (never been treated) (genotype 1-6)
   2. You are treatment experienced with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir (genotype 1-6)
   3. You are treatment experienced with NS5A (nonstructural protein 5A) inhibitor or NS3/4A protease inhibitor (genotype 1)
   4. You had a kidney transplant or liver transplant and are treatment naïve or treatment experienced (genotype 1-6)

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

F. You had a short trial of a preferred formulary agent (you stopped because of intolerance or adverse effect early in therapy) or have a contraindication (harmful for) to therapy with the preferred formulary agent(s) as specified below unless you had prior NS5A (nonstructural protein 5A) inhibitor treatment:

1. If you have genotype 1, 4, 5, or 6 infection, you had a short trial of Epclusa (velpatasvir/sofosbuvir) or Harvoni (ledipasvir/sofosbuvir), or you have a contraindication (harmful for) to BOTH agents.

2. If you have genotype 2 or 3 infection, you had a short trial of Epclusa (velpatasvir/sofosbuvir) or you have a contraindication (harmful for) to this agent.

Mavyret will not be approved if you meet any of the following:

A. You are concurrently taking (alone or in combination): rifampin, atazanavir, carbamazepine, efavirenz, darunavir, lopinavir, ritonavir, atorvastatin, lovastatin, simvastatin, rosuvastatin (at doses greater than 10mg), cyclosporine (for patients requiring stable cyclosporine doses greater than 100mg/day), medications containing ethinyl estradiol, Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (velpatasvir/sofosbuvir/voxilaprevir) or Zepatie (elbasvir/grazoprevir).

B. You have moderate or severe liver impairment (Child-Pugh B or C).

C. You have prior failure of a direct-acting antiviral (DAA) regimen that contains NS5A inhibitor AND NS3/4A protease inhibitor (such as Technivie [ombitasvir/paritaprevir/ritonavir], Viekira [ombitasvir/paritaprevir/ritonavir/dasabuvir], Viekira XR [ombitasvir/paritaprevir/ritonavir/dasabuvir extended release], Vosevi [sofosbuvir/velpatasvir/voxilaprevir], Zepatie [elbasvir/grazoprevir]) or you had previous concurrent (used at the same time) treatments containing a NS5A inhibitor AND NS3/4A protease inhibitor.

D. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mavyret.

REFERENCES
- Mavyret [Prescribing Information]. North Chicago, IL: Abbvie; September 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/17
Commercial Effective: 10/01/23  Client Approval: 08/23  P&T Approval: 07/23
GLP-1 AGONIST

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIXISENATIDE</td>
<td>ADLYXIN</td>
<td>40782</td>
<td>GCN</td>
<td>GPI-10 (2717005600)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of type 2 diabetes and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of metformin (IR/ER), a sulfonylurea (e.g., glipizide, glimepiride), pioglitazone, or a preferred combination product containing any of the above agents (e.g., glipizide-metformin, pioglitazone-metformin)
   - The patient had a trial of a preferred GLP-1 agonist (e.g., Byetta, Bydureon, Victoza)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6mL per 28 days.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named GLP-1 AGONIST (Adlyxin) requires the following rule(s) be met for approval:
   A. You have type 2 diabetes (a disorder with high blood sugar)
   B. You are 18 years of age or older
   C. You had a trial of metformin (extended-release/immediate-release), a sulfonylurea (such as glipizide, glimepiride), pioglitazone, or a preferred combination product containing any of the above agents (such as glipizide-metformin, pioglitazone-metformin)
   D. You had a trial of a preferred GLP-1 agonist (such as Byetta, Bydureon, Victoza)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Adlyxin.

REFERENCES

GLP-1 STEP OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXENATIDE MICROSPHERES</td>
<td>BYDUREON,</td>
<td>38451</td>
<td>GPI-10</td>
<td>(2717002000)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BYDUREON BCISE,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BYDUREON PEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXENATIDE</td>
<td>BYETTA</td>
<td>32893</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIRZEPATIDE</td>
<td>MOUNJARO</td>
<td>48014</td>
<td>GPI-10</td>
<td>(2717308000)</td>
<td></td>
</tr>
<tr>
<td>SEMAGLUTIDE</td>
<td>OZEMPIC,</td>
<td>44675</td>
<td>GPI-10</td>
<td>(2717007000)</td>
<td>BRAND ≠ WEGOVY</td>
</tr>
<tr>
<td></td>
<td>RYBELSUS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DULAGLUTIDE</td>
<td>TRULICITY</td>
<td>41421</td>
<td>GPI-10</td>
<td>(2717001500)</td>
<td></td>
</tr>
<tr>
<td>LIRAGLUTIDE</td>
<td>VICTOZA</td>
<td>36436</td>
<td>GPI-10</td>
<td>(2717005000)</td>
<td>BRAND ≠ SAXENDA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of type 2 diabetes AND meet the following criterion?
   - The patient had a trial of:
     o metformin (IR/ER), OR
     o a sulfonylurea (e.g., glipizide, glimepiride), OR
     o pioglitazone, OR
     o any combination product containing any of the above agents (e.g., glipizide-metformin, pioglitazone-metformin)

   If yes, approve the requested agent for 12 months by HICL or GPI-10.
   NOTE TO PAC: Override using the Step therapy edit only. Do not override any quantity limit without review. All other rejections will require clinical review.

   If no, continue to #2.

2. Is the patient currently stable on the medication while covered by their current or previous health coverage for the diagnosis of Type 2 Diabetes?

   If yes, approve the requested agent for 12 months by HICL or GPI-10.
   NOTE TO PAC: Override using the Step therapy edit only. Do not override any quantity limit without review. All other rejections will require clinical review.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Is the patient currently stable on the medication while covered by their current or previous health coverage for the diagnosis of weight loss (Obesity)?

   If yes, do not approve. See denial text below.
   If no, do not approve. See denial text below.

DENIAL TEXT (Use G09): *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GLP-1 STEP OVERRIDE requires ALL of the following rules be met for approval:
A. You have type 2 diabetes (a disorder with high blood sugar) AND
B. You meet ONE of the following rules:
   1. You had a trial of metformin (extended-release/immediate-release), a sulfonylurea (such as glipizide, gimepiride), pioglitazone, or any combination product containing any of the above agents (such as glipizide-metformin, pioglitazone-metformin)
   2. You are currently stable on the medication

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza.

REFERENCES
- Mounjaro [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC, May 2022.
GLYCEROL PHENYLBUTYRATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCEROL PHENYLBUTYRATE</td>
<td>RAVICTI</td>
<td>39990</td>
<td></td>
<td>GPI-10</td>
<td>(3090803000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet ALL of the following criteria?
   - Documentation of confirmation of UCD via enzymatic, biochemical or genetic testing
   - The patient is 2 months of age or older
   - Ravicti will be used as adjunctive therapy along with dietary protein restriction
   - The disorder cannot be managed by dietary protein restriction and/or amino acid supplementation alone
   - The patient does NOT have a deficiency of N-acetylglutamate synthetase deficiency (NAGS) or acute hyperammonemia
   - The patient has tried or has a contraindication to Buphenyl (sodium phenylbutyrate)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #17.5mL per day. APPROVAL TEXT: Renewal requires the patient has clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity).

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GLYCEROL PHENYLBUTYRATE (Ravicti) requires the following rule(s) be met for approval:
A. You have a urea cycle disorder (genetic disorder that causes buildup of ammonia in blood)
B. Documentation of confirmation of urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
C. You are 2 months of age or older
D. Ravicti will be used as adjunctive (add-on) therapy along with dietary protein restriction
E. The disorder cannot be managed by dietary protein restriction and/or amino acid supplementation alone
F. The patient does NOT have a deficiency of N-acetylglutamate synthetase (type of enzyme) or acute hyperammonemia (short and sudden high ammonia levels)
G. You have previously tried Buphenyl (sodium phenylbutyrate), unless there is a medical reason why you cannot (contraindication)

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet the following criterion?
   • The patient had clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #17.5mL per day. If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named GLYCEROL PHENYLBUTYRATE (Ravicti) requires the following rule(s) be met for renewal:
   A. You have a urea cycle disorder (genetic disorder that causes buildup of ammonia in blood)
   B. You had clinical benefit from baseline (such as normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity).

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ravicti.

REFERENCES

• Ravicti [Prescribing Information]. Lake Forest, IL: Horizon Pharma USA, Inc; November 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/13
Commercial Effective: 07/01/20 Client Approval: 04/20 P&T Approval: 07/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of primary axillary hyperhidrosis and meet ALL of the following criteria?
   - The patient is 9 years of age or older
   - The patient had a trial of prescription strength aluminum chloride product (e.g., Drysol)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 packet per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GLYCOPHYRRONIUM TOPICAL (Qbrexza) requires the following rule(s) be met for approval:
A. You have primary axillary hyperhidrosis (excessive underarm sweating)
B. You are 9 years of age or older
C. You had a trial of a prescription strength aluminum chloride product such as Drysol

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Qbrexza.

REFERENCES
GOLIMUMAB - SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLIMUMAB - SQ</td>
<td>SIMPONI</td>
<td>22533</td>
<td>(6627004000D540)</td>
<td>GPI-14</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>22536</td>
<td>(6627004000E540)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>34697</td>
<td>(6627004000D520)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>35001</td>
<td>(6627004000E520)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to at least 3 months of treatment with **ONE** DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   - The patient is currently using or has a contraindication to methotrexate

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet **ONE** of the following criteria?
   - The patient had a trial of or contraindication to **TWO** of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   - The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

   **[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]**

   If yes, **approve for 6 months of the 50 mg prefilled SmartJect autoinjector or syringe by GPI-14 with a quantity limit of #0.5 mL per 28 days.**

   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months of the 50 mg prefilled SmartJect autoinjector or syringe by GPI-14 with a quantity limit of #0.5 mL per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe ankylosing spondylitis (AS) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months of the 50 mg prefilled SmartJect autoinjector or syringe by GPI-14 with a quantity limit of #0.5 mL per 28 days.

   If no, continue to #5.
INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
   - The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)  
     **[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]**

If yes, **approve for a total of 6 months by GPID or GPI-14 and enter two authorizations as follows:**
   - **FIRST APPROVAL:** Approve 1 month of the 100 mg/mL prefilled syringe OR SmartJect autoinjector with a quantity limit of #3 mL per 28 days.
   - **SECOND APPROVAL:** Approve 5 months of the 100 mg/mL prefilled syringe OR SmartJect autoinjector with a quantity limit of #1 mL per 28 days (Enter a start date that is 1 week AFTER the END date of the first approval).

If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You are currently using or have a contraindication (harmful for) to methotrexate
   5. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept] AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

D. **If you have moderate to severe ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
   4. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

*(Initial denial text continued on next page)*
INITIAL CRITERIA (CONTINUED)

E. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   • The patient is currently using or has a contraindication to methotrexate

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   • The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 12 months of the 50 mg prefilled SmartJect autoinjector or syringe by GPID or GPI-14 with a quantity limit of #0.5 mL per 28 days.

   If no, do not approve.

   DENIAL TEXT: See renewal denial text at the end of the guideline.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 12 months of the 50 mg prefilled SmartJect autoinjector or syringe by GPID or GPI-14 with a quantity limit of #0.5 mL per 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
4. Does the patient have a diagnosis of moderate to severe ankylosing spondylitis (AS) and meet ALL of the following criteria?
   - The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 12 months of the 50 mg prefilled SmartJect autoinjector or syringe by GPID or GPI-14 with a quantity limit of #0.5 mL per 28 days.

If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) AND meet the following criterion?
   - The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 12 months of the 100 mg prefilled SmartJect autoinjector or syringe by GPID or GPI-14 with a quantity limit of #1 mL per 28 days.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named GOLIMUMAB-SQ (Simponi) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

(Renewal denial text continued on next page)
GOLIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using or have a contraindication (harmful for) to methotrexate
   3. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release), Amjevita (adalimumab-atto), Cyletezo (adalimumab-adbm)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyletezo (adalimumab-adbm)

D. If you have moderate to severe ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (diagnostic test to determine the effectiveness of drug therapy) while on therapy
   2. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate-release or extended-release), Rinoq (upadacitinib), Taltz (ixekizumab), Amjevita (adalimumab-atto), Cyletezo (adalimumab-adbm)

E. If you have moderate to severe ulcerative colitis, renewal also requires:
   1. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyletezo (adalimumab-adbm)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GOLIMUMAB - SQ

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Simponi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 06/09
Commercial Effective: 08/28/23  Client Approval: 07/23  P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
   - The patient has psoriasis covering 3% or more of body surface area (BSA)
   - The patient has psoriatic lesions affecting the hands, feet, genital area, or face

   If yes, approve for 6 months by entering TWO approvals by HICL or GPI-10 as follows:
   - FIRST APPROVAL: approve for 1 month with a quantity limit of #1mL per 28 days.
   - SECOND APPROVAL: approve for 5 months with a quantity limit of #1mL per 56 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval)

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?

   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, **approve for 6 months by entering TWO approvals by HICL or GPI-10 as follows:**
   - FIRST APPROVAL: approve for 1 month with a quantity limit of #1mL per 28 days.
   - SECOND APPROVAL: approve for 5 months with a quantity limit of #1mL per 56 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval)

   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **GUSELKUMAB (Tremfya)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet **ONE** of the following criteria:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   • The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 56 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 56 days.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **GUSELKUMAB (Tremfya)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

C. **If you have psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tremfya.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 07/17
Client Approval: 05/23
P&T Approval: 04/23
HIGH CONCENTRATION OPIOID ORAL SOLUTIONS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORPHINE SULFATE</td>
<td>MORPHINE SULFATE</td>
<td>16063</td>
<td>GPI-14</td>
<td>(65100055102090)</td>
<td></td>
</tr>
<tr>
<td>OXYCODONE HCL</td>
<td>OXYCODONE HCL</td>
<td>16281</td>
<td>GPI-14</td>
<td>(65100075101320)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate?

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following?
   - The patient is enrolled in hospice
   - The patient is receiving palliative care or end-of-life care

   If yes, **approve the requested drug for a lifetime approval by GPID or GPI-14.**
   If no, continue to #3.

3. Does the patient meet **ALL** of the following criteria?
   - The patient has previous use of at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
   - The patient has trouble swallowing opioid tablets, capsules, or large volumes of liquid

   If yes, **approve the requested drug for 3 months by GPID or GPI-14.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **HIGH CONCENTRATION OPIOID ORAL SOLUTIONS (morphine sulfate, oxycodone hydrochloride)** requires the following rule(s) be met for approval:
A. You have pain severe enough to require opioid analgesic and for which alternative treatments are inadequate

*Denial text continued on next page*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. You meet ONE of the following:
   1. You are enrolled in hospice OR you are receiving palliative care or end-of-life care
   2. You meet ALL of the following:
      a. You have previous use of at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
      b. You have trouble swallowing opioid tablets, capsules, or large volumes of liquid

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Morphine Sulfate or Oxycodone Hydrochloride oral solution.

REFERENCES
HYDROCORTISONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCORTISONE</td>
<td>ALKINDI SPRINKLE</td>
<td>46547</td>
<td>GP1-14</td>
<td>(22100025006810)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>46548</td>
<td>(22100025006815)</td>
<td>(22100025006820)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>46549</td>
<td></td>
<td>(22100025006830)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>46551</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of adrenocortical insufficiency and meet **ALL** of the following criteria?
   - The patient is less than 18 years of age
   - The patient is unable to take the tablet formulation of hydrocortisone (e.g., need for lower strength, difficulty swallowing)

   If yes, **approve for 6 months for all strengths by GPID or GPI-14.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **HYDROCORTISONE (Alkindi Sprinkle)** requires the following rule(s) be met for approval:
   A. You have adrenocortical insufficiency (your body does not produce enough of certain hormones)
   B. You are less than 18 years of age
   C. You are unable to take the tablet form of hydrocortisone (for example you need a lower strength, or you have difficulty swallowing)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Alkindi Sprinkle.

REFERENCES

GUIDELINES FOR USE

1. Does the patient meet the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose of another opioid)?

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the request form indicate that this medication will be used on an "as needed" or "PRN" basis?

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, continue to #3.

3. Does the patient require a dosage of 16mg or less?

   If yes, **approve for 12 months by GPIID or GPI-14 for the requested agent (8mg, 12mg, 16mg) for #1 per day.** (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR_RES).

   If no, continue to #4.

4. Was this dosage recommended by a pain specialist?

   If yes, **approve for 12 months by GPIID or GPI-14 (32mg) for #2 per day.** (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR_RES).

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named HYDROMORPHONE ER (Exalgo) requires the following rule(s) be met for approval:
A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose (equal pain relieving dose) of another opioid
B. The requested medication is not prescribed on an as-needed basis
C. Dosages above 16mg require recommendation from a pain specialist

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Exalgo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 03/04/22
Created: 04/10
Client Approval: 02/22
P&T Approval: 07/19
GUIDELINES FOR USE

1. Is the request for the treatment of vulvovaginal candidiasis (VVC) and the patient meets ALL of the following criteria?
   - The patient is a post-menarchal female
   - The patient had a trial of or contraindication to oral fluconazole AND an intravaginal azole (e.g., terconazole cream)

   If yes, **approve for 30 days by HICL or GPI-10 for one fill with a quantity limit of #4.**
   If no, continue to #2.

2. Is the request for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) and the patient meets **ALL** of the following criteria?
   - The patient is a post-menarchal female
   - The patient had a trial of or contraindication to oral fluconazole (the patient had a breakthrough episode of VVC while taking fluconazole 150 mg weekly)
   - The patient is NOT currently on oteseconazole for RVVC

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient previously received Brexafemme?

   If yes, continue to #5.
   If no, continue to #4.

4. Has the patient had 3 or more episodes of VVC in the past 12 months?

   If yes, **approve for 6 months by HICL or GPI-10 for 6 fills total with a quantity limit of #4 per 30 days.**

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet ALL of the following criteria?
   - The patient has successfully completed a course of Brexafemme for prevention of RVVC
   - The patient is either being treated or has just completed treatment for a new recurrence of VVC

   If yes, approve for 6 months by HICL or GPI-10 for 6 fills total with a quantity limit of #4 per 30 days.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named IBREXAFUNGERP (Brexafemme) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Treatment of vulvovaginal candidiasis (VVC: vaginal yeast infection)
   2. Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC: repeated vaginal yeast infection)

B. If you are using Brexafemme for the treatment of vulvovaginal candidiasis, approval also requires:
   1. You are a post-menarchal (you have started having your period) female
   2. You have tried or have a contraindication to (harmful for) oral fluconazole AND an intravaginal azole (type of drug that is inserted into the vagina and used to treat yeast infections such as terconazole cream)

C. If you are using Brexafemme for the reduction in the incidence of recurrent vulvovaginal candidiasis, approval also requires:
   1. You are a post-menarchal (you have started having your period) female
   2. You have tried or have a contraindication to (harmful for) oral fluconazole (you had a breakthrough episode of VVC while taking fluconazole 150 mg weekly)
   3. You are NOT currently on oteseconazole for RVVC
   4. You meet ONE of the following:
      a. You have not previously received Brexafemme AND you had 3 or more episodes of RVVC in the past 12 months
      b. You have been previously treated with Brexafemme and meet ALL of the following:
         i. You have successfully completed a course of Brexafemme for prevention of RVVC
         ii. You are either being treated or have just completed treatment for a new recurrence of VVC

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
IBREXAFUNGERP

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Brexafermme.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/23
Created: 07/21
Client Approval: 02/23
P&T Approval: 07/21
IBRUTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBRUTINIB</td>
<td>IMBRUVICA</td>
<td>40745</td>
<td>GPI-10 (2153213300)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the request for Imbruvica (ibrutinib) 560 mg tablet?
   - If yes, do not approve. (Note: This strength does not have an FDA-approved indication.)
   - DENIAL TEXT: See the denial text at the end of the guideline.
   - If no, continue to #2.

2. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Waldenstrom's macroglobulinemia (WM) AND meet the following criterion?
   - The patient is 18 years of age or older
   - If yes, approve for 12 months by GPID or GPI-14 for all of the following:
     - 70 mg capsule: #1 per day.
     - 140 mg capsule: #2 per day.
     - 140 mg tablet: #1 per day.
     - 280 mg tablet: #1 per day.
     - 420 mg tablet: #1 per day.
     - 70 mg/mL oral suspension: #7.2 mL per day.
   - If no, continue to #3.

3. Does the patient have a diagnosis of chronic graft versus host disease (cGVHD) and meet ALL of the following criteria?
   - The patient is 1 year of age or older
   - The patient has failed one or more lines of systemic therapy (e.g., prednisone, prednisolone, methylprednisolone)
   - If yes, approve for 12 months by GPID or GPI-14 for all of the following:
     - 70 mg capsule: #1 per day.
     - 140 mg capsule: #2 per day.
     - 140 mg tablet: #1 per day.
     - 280 mg tablet: #1 per day.
     - 420 mg tablet: #1 per day.
     - 70 mg/mL oral suspension: #7.2 mL per day.
   - If no, do not approve.
   - DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **IBRUTINIB (Imbruvica)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   2. Small lymphocytic lymphoma (SLL: a type of blood cancer)
   3. Waldenstrom's macroglobulinemia (WM: a type of blood cancer)
   4. Chronic graft versus host disease (cGVHD: a type of immune disorder)

B. **If you have chronic lymphocytic leukemia, small lymphocytic lymphoma, or Waldenstrom's macroglobulinemia**, approval also requires:
   1. You are 18 years of age or older

C. **If you have chronic graft versus host disease**, approval also requires:
   1. You are 1 year of age or older
   2. You have failed one or more lines of systemic therapy (treatment spread through the blood, such as prednisone, prednisolone, methylprednisolone)

**Note:** Requests for Imbruvica (ibrutinib) 560mg tablet will not be approved. This strength does not have a Food and Drug Administration (FDA)-approved indication.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Imbruvica.

**REFERENCES**

GUIDELINES FOR USE

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   - The patient's diagnosis is confirmed via complement testing
   - The requested medication is being used for treatment of acute attacks of hereditary angioedema
   - The requested medication will NOT be used concurrently with other acute treatments for HAE attacks (e.g., Berinert, Ruconest, Kalbitor)

If yes, approve for 12 months by HICL or GPI-10, each fill of #18mL (6 syringes), up to 12 fills per year.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ICATIBANT (Firazyr, Sajazir) requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy doctor or immune system doctor) or hematologist (blood doctor)
D. Your diagnosis is confirmed by complement testing (a type of lab test)
E. The requested medication is being used for treatment of acute (sudden and severe) attacks of hereditary angioedema
F. The requested medication will NOT be used concurrently (at the same time) with other acute treatments for HAE attacks (such as Berinert, Ruconest, Kalbitor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ICATIBANT

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Firazyr and Sajazir.

REFERENCE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/22
Created: 09/11
Client Approval: 07/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed chronic lymphocytic leukemia (CLL) AND meet the following criterion?
   • Zydelig will be used in combination with rituximab

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   DENIAL TEXT:  *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named IDELALISIB (Zydelig) requires the following rule(s) be met for approval:
   A. You have relapsed chronic lymphocytic leukemia (CLL: a type of blood cancer)
   B. Zydelig will be used in combination with rituximab

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Zydelig.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A          Created: 08/14
Commercial Effective: 04/01/22  Client Approval: 02/22
                                  P&T Approval: 11/14
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) **AND** meet the following criterion?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
     
     If yes, continue to #2.
     If no, do not approve.
     **DENIAL TEXT:** See initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?
   - Mean pulmonary artery pressure (PAP) of greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) of greater than 2 Wood units
     
     If yes, continue to #3.
     If no, do not approve.
     **DENIAL TEXT:** See initial denial text at the end of the guideline.

3. Has the patient had a trial of or contraindication to **TWO** of the following agents from different drug classes?
   - Oral endothelin receptor antagonist (e.g., Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   - Oral phosphodiesterase-5 inhibitor (e.g., Revatio [sildenafil], Adcirca [tadalafil])
   - Oral cGMP stimulator (e.g., Adempas [riociguat])
   - IV/SQ prostacyclin (e.g., Flolan [epoprostenol], Remodulin [Treprostinil])
     
     If yes, **approve for 12 months by HICL or GPI-10.**
     If no, do not approve.
     **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ILOPROST (Ventavis)** requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)

C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

D. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
   1. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   2. Oral phosphodiesterase-5 inhibitor (such as Revatio [sildenafil], Adcirca [tadalafil])
   3. Oral cGMP stimulator (such as Adempas [riociguat])
   4. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [Treprostinil])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ONE of the following criteria?
   - The patient shown improvement from baseline in the 6-minute walk distance test
   - The patient remains stable from baseline in the 6-minute walk distance test AND the patient's WHO functional class remained stable or has improved

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ILOPROST (Ventavis) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable in the 6-minute walk distance test AND your World Health Organization functional class has remained stable or improved (WHO-FC: classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Ventavis.

REFERENCES
IMATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMATINIB MESYLATE</td>
<td>GLEEVEC, IMATINIB MESYLATE</td>
<td>22096</td>
<td></td>
<td>GPI-10 (2153183510)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have ONE of the following diagnoses?
   - Newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML) in chronic phase
   - Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy

   If yes, continue to #2.
   If no, continue to #3.

2. Has the patient received previous treatment with another tyrosine kinase inhibitor [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)]?

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

   If no, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
   - Gleevec 400mg: #2 per day.
   - Gleevec 100mg: #6 per day.

3. Does the patient have a diagnosis of relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
   - Gleevec 400mg: #1 per day.
   - Gleevec 100mg: #6 per day.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Does the patient have newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) AND meet the following criterion?
   • The requested medication will be used in combination with chemotherapy

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • Gleevec 400mg: #1 per day.
   • Gleevec 100mg: #6 per day.

   If no, continue to #5.

5. Does the patient have a diagnosis of a myelodysplastic/myeloproliferative disease associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve Gleevec 400mg for 12 months by GPID or GPI-14 with a quantity limit of #1 tablet per day.
   If no, continue to #6.

6. Does the patient have a diagnosis of aggressive systemic mastocytosis without D816V c-Kit mutation or with c-Kit mutational status unknown AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • Gleevec 400mg: #1 per day.
   • Gleevec 100mg: #3 per day.

   If no, continue to #7.

7. Does the patient have a diagnosis of hypereosinophilic syndrome and/or chronic eosinophilic leukemia AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • Gleevec 400mg: #1 per day.
   • Gleevec 100mg: #3 per day.

   If no, continue to #8.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

8. Does the patient have a diagnosis of unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans AND meet the following criterion?
   • The patient is 18 years of age or older

      If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
      • Gleevec 400mg: #2 per day.
      • Gleevec 100mg: #6 per day.

      If no, continue to #9.

9. Does the patient have a diagnosis of unresectable and/or metastatic malignant gastrointestinal stromal tumor (GIST) with a Kit (CD117) positive?

      If yes, continue to #11.
      If no, continue to #10.

10. Is the request for adjuvant treatment following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumor (GIST) AND the patient meets the following criterion?
    • The patient is 18 years of age or older

      If yes, continue to #11.
      If no, do not approve.
      DENIAL TEXT: See the denial text at the end of the guideline.

11. Is the request for Gleevec 400mg twice daily?

      If yes, continue to #12.
      If no, approve as follows:
      o For adjuvant GIST treatment: approve Gleevec 400mg for 36 months by GPID or GPI-14 with a quantity limit of #1 per day.
      o For unresectable and/or metastatic malignant GIST: approve Gleevec 400mg for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.

      CONTINUED ON NEXT PAGE
12. Has patient tried Gleevec 400mg once daily or does the patient have GIST tumor expressing a KIT exon 9 mutation?

If yes, approve as follows:
- For adjuvant GIST treatment: approve Gleevec 400mg for 36 months by GPID or GPI-14 with a quantity limit of #2 per day.
- For unresectable and/or metastatic malignant GIST: approve Gleevec 400mg for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.

If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named IMATINIB (Gleevec) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Newly diagnosed Philadelphia positive chronic myeloid leukemia (type of blood cell cancer that begins in bone marrow with an abnormal gene) in chronic phase
   2. Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy
   3. Relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer that has returned or did not respond to treatment)
   4. Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer)
   5. Myelodysplastic/myeloproliferative disease (a group of diseases where the bone marrow makes too many white blood cells) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
   6. Aggressive systemic mastocytosis (a type of cell accumulates in internal tissues and organs) without D816V c-Kit mutation or with c-Kit mutational status unknown
   7. Hypereosinophilic syndrome and/or chronic eosinophilic leukemia (type of inflammatory cancer)
   8. Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (type of rare skin tumor that cannot be completely removed by surgery or returns/ spreads)
   9. Unresectable and/or metastatic malignant gastrointestinal stromal tumor (tumor in stomach/intestines that spreads or cannot be removed by surgery) with a Kit (CD117) positive
   10. Adjuvant (add-on) treatment after complete gross resection (surgical removal) of Kit (CD117) positive gastrointestinal stromal tumor

**Continued on next page**
GUIDELINES FOR USE (CONTINUED)

B. If you are newly diagnosed with Philadelphia positive chronic myeloid leukemia in chronic phase, approval also requires:
   1. You have NOT received previous treatment with another tyrosine kinase inhibitor such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)

C. If you have Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, approval also requires:
   1. You have NOT received previous treatment with another tyrosine kinase inhibitor such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)

D. If you have relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:
   1. You are 18 years of age or older

E. If you have newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:
   1. The requested medication will be used in combination with chemotherapy

F. If you have myelodysplastic/myeloproliferative disease associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements, approval also requires:
   1. You are 18 years of age or older

G. If you have aggressive systemic mastocytosis without D816V c-Kit mutation or with c-Kit mutational status unknown, approval also requires:
   1. You are 18 years of age or older

H. If you have hypereosinophilic syndrome and/or chronic eosinophilic leukemia, approval also requires:
   1. You are 18 years of age or older

I. If you have unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans, approval also requires:
   1. You are 18 years of age or older

J. If the request is for adjuvant treatment following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumor (GIST), approval also requires:
   1. You are 18 years of age or older

K. If you have gastrointestinal stromal tumor, approval also requires:
   1. For request of Gleevec 400mg twice daily, approval requires a trial of Gleevec 400mg once daily OR a GIST tumor expressing a KIT exon 9 (type of gene) mutation (a permanent change in your DNA that make up your gene)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
IMATINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gleevec.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/21
Created: 11/11
Client Approval: 03/21
P&T Approval: 10/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of actinic keratosis (AK) of the full face or balding scalp and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient is immunocompetent
   - The patient had a trial of **TWO** generic topical agents indicated for AK (e.g., fluorouracil, imiquimod, diclofenac 3%)

   If yes, **approve the requested strength for 4 months by GPID or GPI-14 with the following quantity limits:**
   - 3.75% packet: #28 packets per 28 days.
   - 2.5% or 3.75% pump: #7.5g per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of external genital or perianal warts and meet **ALL** of the following criteria?
   - The patient is 12 years of age or older
   - The patient had a trial of or contraindication to generic imiquimod 5% topical cream

   If yes, **approve the requested strength for 2 months by GPID or GPI-14 with the following quantity limits:**
   - 3.75% packet: #28 packets per 28 days.
   - 2.5% or 3.75% pump: #7.5g per 28 days.

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **IMIQUIMOD (Zyclara)** requires the following rule(s) be met for approval:
A. You have **ONE** of the following diagnoses:
   1. Actinic keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the full face or balding scalp
   2. External genital or perianal (around the anus) warts

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. If you have actinic keratosis of the full face or balding scalp, approval also requires:
   1. You are 18 years of age or older
   2. You are immunocompetent (healthy immune system)
   3. You had a trial of TWO generic topical agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

C. If you have external genital or perianal warts, approval also requires:
   1. You are 12 years of age or older
   2. You have tried or have a contraindication (harmful for) to generic imiquimod 5% topical cream

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zyclara.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/12/23
Created: 08/97
Client Approval: 05/23
P&T Approval: 04/21
### IMMUNE GLOBULIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMMUNE GLOBULIN</td>
<td>BIVIGAM, CARIMUNE NF, NANOFILTERED, FLEBOGamma DIF, GAMASTAN S-D, GAMMAGARD S-D, GAMMAPLEX, PRIVIGEN, GAMMAGARD LIQUID, HIZENTRA</td>
<td>04202</td>
<td>41798</td>
<td>41995</td>
<td>GPI-10 (1910002020) (1910002010) (1910002000) (1910002030)</td>
</tr>
<tr>
<td>IMMUNE GLOB, GAM CAPRYLATE</td>
<td>GAMUNEX-C, GAMMAKED</td>
<td>25631</td>
<td></td>
<td></td>
<td>GPI-10 (1910002030)</td>
</tr>
<tr>
<td>IMMUNE GLOBULIN / MALTOSE</td>
<td>OCTAGAM</td>
<td>33220</td>
<td></td>
<td></td>
<td>GPI-10 (1910002010)</td>
</tr>
<tr>
<td>IGG/HYALURONIDASE, RECOMBINANT</td>
<td>HYQVIA</td>
<td>41391</td>
<td></td>
<td></td>
<td>GPI-10 (1999000235)</td>
</tr>
<tr>
<td>IMMUN GLOB (IGG)/GLY/IGA OV50</td>
<td>CUVITRU</td>
<td>41796</td>
<td></td>
<td></td>
<td>GPI-10 (1910002020)</td>
</tr>
<tr>
<td>IMMUN GLOB (IGG)-IFAS/GLYCINE</td>
<td>PANZYGIA</td>
<td>45354</td>
<td></td>
<td></td>
<td>GPI-10 (1910002060)</td>
</tr>
<tr>
<td>IMMUN GLOB (IGG)-HIPP/MALTOSE</td>
<td>CUTAQUIG</td>
<td>45734</td>
<td></td>
<td></td>
<td>GPI-10 (1910002057)</td>
</tr>
<tr>
<td>IMMUNE GLOBULIN (HUMAN)-KLHW</td>
<td>XEMBIFY</td>
<td>45891</td>
<td></td>
<td></td>
<td>GPI-10 (1910002064)</td>
</tr>
<tr>
<td>IMMUNE GLOBULIN (HUMAN)-SLRA</td>
<td>ASCENIV</td>
<td>46208</td>
<td></td>
<td></td>
<td>GPI-10 (1910002080)</td>
</tr>
</tbody>
</table>

This drug must be reviewed by a pharmacist.

**GUIDELINES FOR USE**

1. Is the request for use as a subcutaneous injection?
   - If yes, continue to #2.
   - If no, continue to #5.

CONTINUED ON NEXT PAGE
IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

2. Is the request for Hizentra and will be used for ONE of the following diagnoses?
   • Primary immunodeficiency disease (PID)
   • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

   If yes, approve for 12 months by GPIP or NDC (Medi-Span).
   If no, continue to #3.

3. Is the request for Gammagard Liquid, Cuvitru, Gamunex-C, Gammaked, Hyqvia, Cutaquig, or Xembify? (NOTE: Gammagard Liquid, Gamunex-C and Gammaked may be given via SC or IV route.)

   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Does the patient have a primary immunodeficiency disease (PID)?

   If yes, approve the requested agent for 12 months as follows:
   • Gammagard Liquid, Gamunex-C or Gammaked: Approve by NDC (FDB or Medi-Span).
   • Cuvitru: Approve by HICL or NDC (Medi-Span).
   • Hyqvia, Cutaquig, or Xembify: Approve by HICL or GPI-10.

   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

5. Is the request for use as an intravenous (IV) injection or intramuscular (IM) injection? (NOTE: Bivigam, Carimune NF Nanofiltered, Flebogamma, Gamastand S-D, Gammagard S-D, Gammaplex, Privigen, Octagam, Panzyga, and Asceniv are not self-administered (NSA) agents and may not be covered by some plans)

   If yes, continue to #6.
   If no, guideline does not apply.

6. Is the request for Cuvitru, Hizentra, Hyqvia or Xembify? (NOTE: Cuvitru, Hizentra, Hyqvia and Xembify are indicated only for SC route)

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, continue to #7.

CONTINUED ON NEXT PAGE
IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

7. Is the request for Asceniv and meet ALL of the following criteria?
   • The request is for primary immunodeficiency disease (PID)
   • The patient is 12 years of age or older
   • The patient has tried any other TWO immunoglobulin products (e.g., Panzyga, Bivigam, Flebotam, Octagam, Privigen)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #8.

8. Is the request for Gamastan S/D? (NOTE: Gamastan S/D is indicated for intramuscular use only)

   If yes, continue to #9.
   If no, continue to #10.

9. Is Gamastan S/D being used for hepatitis A, measles, varicella, or rubella prophylaxis, or passive immunization?

   If yes, approve for 12 months by GPID or GPI-10.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
10. Does the patient have ONE of the following diagnoses?

- Primary Immunodeficiency Disease (PID)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Multifocal Motor Neuropathy (MMN)
- Kawasaki Syndrome
- B-cell Chronic Lymphocytic Leukemia (CLL) with Hypogammaglobulinemia, Autoimmune Hemolytic Anemia (AIHA), Immune Thrombocytopenic Purpura (ITP), or pure Red Blood Cell Aplasia (PRCA)
- Guillain-Barre Syndrome (GBS)
- Myasthenia Gravis
- Autoimmune Graves’ Ophthalmopathy
- Cytomegalovirus-induced Pneumonitis related to a solid organ transplant
- Prevention of bacterial infection in an HIV-infected child
- Reduction of secondary infections in pediatric HIV infections
- Dermatomyositis or polymyositis
- Autoimmune uveitis (Birdshot retinochoroidopathy)
- Lambert-Eaton myasthenic syndrome
- IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy
- Stiff-man syndrome
- Neonatal sepsis
- Rotaviral enterocolitis
- Toxic shock syndrome
- Enteroviral meningoencephalitis
- Toxic Epidermal Necrolysis or Stevens-Johnson syndrome
- Autoimmune Mucocutaneous Blistering Disease (AMBD) (such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita)

If yes, approve the requested agent for 12 months as follows:

- Gammagard Liquid, Gamunex-C, Gammaked, Bivigam, Flebogamma DIF, Gammaplex, or Privigen: Approve by NDC (FDB or Medi-Span).
- Carimune NF Nanofiltered: Approve by GPID or GPI-14.
- Gammagard S-D: Approve by NDC (FDB) or GPI-14.
- Octagam: Approve by HICL or NDC (Medi-Span).
- Panzyga: Approve by HICL or GPI-10.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.
IMMUNE GLOBULIN

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named IMMUNE GLOBULIN requires the following rule(s) be met for approval:
A. For Gammagard Liquid, Gamunex-C, Gammaked, Blivigam, Carimune NF Nanofiltered, Flebogamma DIF, Gammagard S-D, Gammmaplex, Privigen, Octagam, or Panzyga for intravenous (IV) injection, approval requires you to have ONE of the following diagnoses:
   1. Primary Immunodeficiency Disease (genetic disease where your immune system is weak)
   2. Idiopathic Thrombocytopenic Purpura (Low levels of the blood cells that prevent bleeding)
   3. Chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)
   4. Multifocal Motor Neuropathy (nerve disorder with increasing muscle weakness and wasting)
   5. Kawasaki Syndrome (inflammation in the walls of blood vessels in the body)
   6. B-cell Chronic Lymphocytic Leukemia (blood and bone marrow cancer of immune cells) with Autoimmune Hemolytic Anemia (body destroys red blood cells more rapidly than it produces them), Immune Thrombocytopenic Purpura (decreased number of blood cells that prevent bleeding with increased easy bruising) OR Pure Red Cell Blood Aplasia (bone marrow stops making red blood cells)
   7. Guillain-Barre Syndrome (immune system attacks the nerves)
   8. Myasthenia Gravis (weakness and rapid fatigue of muscles under voluntary control)
   9. Autoimmune Graves' Ophthalmopathy (type of eye disease from having little to no thyroid)
   10. Cytomegalovirus-induced Pneumonitis related to a solid organ transplant (lung tissue inflammation) related to a solid organ transplant
   11. Prevention of bacterial infection in an HIV-infected child (human immunodeficiency virus)-infected child
   12. Reduction of secondary infections in pediatric HIV infections
   13. Dermatomyositis (inflammatory disease with muscle weakness and skin rash) or polymyositis (type of inflammatory muscle disease)
   14. Autoimmune uveitis (Birdshot retinochoroidopathy; inflammation of the middle layer of the eye)
   15. Lambert-Eaton myasthenic syndrome (nerve disease in which the immune system attacks the body's own tissues)
   16. IgM (Immunoglobulin M) anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy (type of nerve damage)
   17. Stiff-man syndrome (nerve disorder with increasing muscle stiffness (rigidity) and repeated episodes of painful muscle spasms)
   18. Neonatal sepsis (blood infection in infants)
   19. Rotaviral enterocolitis (severe diarrhea among infants and young children)
   20. Toxic shock syndrome (life-threatening complication of certain bacterial infections)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

21. Enteroviral meningoencephalitis (Inflammation of the brain and surrounding tissues caused by a virus)
22. Toxic Epidermal Necrolysis or Stevens-Johnson syndrome (both are types of serious skin bacterial infections)
23. Autoimmune Mucocutaneous Blistering Disease (group of serious skin conditions that start with blisters on the skin) such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita

B. For Asceniv, approval requires:
   1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)
   2. You are 12 years of age or older
   3. You have tried any other TWO immunoglobulin products

C. For Gamastan S-D, approval requires:
   1. You are using the requested drug for prophylaxis (prevention) or passive immunization (immune response where antibodies are obtained from outside the body) of hepatitis A, measles, varicella, or rubella

D. For Hizentra, approval requires:
   1. The medication is only for subcutaneous (under the skin) use
   2. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak) OR chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)

E. For Cuvitru, Hyqvia, Cutaquig, or Xembify, approval requires:
   • The medication is only for subcutaneous (under the skin) use
   • You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

F. For Gammagard Liquid, Gamunex-C, or Gammaked for subcutaneous use, approval requires:
   1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
IMMUNE GLOBULIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monographs for the drugs listed in this guideline.

REFERENCES
• Carimune NF [Prescribing Information]. CSL Behring LLC: Kankakee, IL. September 2013.
• Gammaphor 5% [Prescribing Information]. BPL Inc.: Durham, NC. December 2016.
• Gammaphor 10% [Prescribing Information]. BPL Inc.: Durham, NC. December 2016.
• Octagam 5% [Prescribing Information]. Octapharma USA Inc.: Hoboken, NJ. April 2015.
• Octagam 10% [Prescribing Information]. Octapharma USA Inc.: Hoboken, NJ. August 2015.
• Panzyga [Prescribing Information]. Octapharma USA Inc.: Hoboken, NJ. August 2018.
• Asceniv [Prescribing Information]. Boca Raton, FL: ADMA Biologics; April 2019.
• Xembify [Prescribing Information]. Research Triangle Park, NC: Grifols Therapeutics LLC; October 2019.
GUIDELINES FOR USE

1. Does the patient have **ONE** of the following diagnoses?
   - Moderate to severe rheumatoid arthritis (including acute flares of chronic disease)
   - Moderate to severe ankylosing spondylitis
   - Moderate to severe osteoarthritis
   - Acute painful shoulder (bursitis, tendinitis)
   - Acute gouty arthritis

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ALL** of the following criteria?
   - The patient had a trial of generic indomethacin capsules
   - The patient cannot swallow indomethacin capsules

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #40mL per day.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **INDOMETHACIN SUSPENSION** *(Indocin)* requires the following rule(s) be met for approval:
   A. You have ONE of following diagnoses:
      1. Moderate to severe rheumatoid arthritis (a type of joint condition)
      2. Moderate to severe ankylosing spondylitis (a type of joint condition)
      3. Moderate to severe osteoarthritis (a type of joint condition)
      4. Acute painful shoulder (such as bursitis, tendinitis)
      5. Acute gouty arthritis (a type of joint condition)

   B. You had a trial of generic indomethacin capsules

   C. You cannot swallow indomethacin capsules

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
INDOMETHACIN SUSPENSION

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Indocin.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/23
Created: 11/22
Client Approval: 02/23
P&T Approval: 10/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable locally advanced or metastatic cholangiocarcinoma and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has been previously treated for unresectable locally advanced or metastatic cholangiocarcinoma
   - The patient has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test
   - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to initiation of therapy and at the recommended scheduled intervals

If yes, **approve the requested dose pack for 12 months by GPID or GPI-14 with the following quantity limits:**

- 50mg: #42 per 28 days.
- 75mg: #63 per 28 days.
- 100mg: #21 per 28 days.
- 125mg: #42 per 28 days.

If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **INFIGRATINIB (Truseltiq)** requires the following rule(s) be met for approval:

A. You have unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has grown outside the organ but has not yet spread to other parts of the body and cannot be removed by surgery, or bile duct cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma
D. You have a fibroblast growth factor receptor 2 (FGFR2: type of protein) fusion or other rearrangement, as detected by a Food and Drug Administration (FDA)-approved test
E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

*(Denial text continued on next page)*
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Truseltiq.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 07/21
Client Approval: 11/22
P&T Approval: 10/22
**GUIDELINES FOR USE**

Do not approve requests for Picato gel.

*(NOTE: Picato discontinued due to safety concerns and increased risk of cancer.)*

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Picato.

Manufacturer provided FDA with notification of discontinuation in the manufacture of Picato. Discontinuation may be likely due to safety concerns; Picato is no longer authorized in the EU after concluding that Picato increases the risk of cancer.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/21
Created: 05/12
Client Approval: 08/21
P&T Approval: 04/21
INHALED INSULIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN REGULAR, HUMAN</td>
<td>AFREZZA</td>
<td>00768</td>
<td>GPI-10</td>
<td>(2710401000)</td>
<td>FDB &amp; Medi-Span:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ROUTE = INHALATION</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient meet any ONE of the following criteria?
   - Chronic lung disease (i.e., asthma or chronic obstructive pulmonary disease)
   - Active lung cancer
   - Currently in diabetic ketoacidosis
   - Patient who smokes or who has quit smoking within the past 6 months

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.
   If no, continue to #2.

2. Has baseline spirometry to measure FEV1 been performed?

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
INHALED INSULIN

INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis type 1 diabetes and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is concurrently using a long-acting insulin
   • The patient had a trial of a preferred formulary rapid acting insulin: Humalog

   If yes, approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:
   • Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   • Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   • Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   • Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.
   • Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.
   • Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   • Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   • Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   • Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.

   APPROVAL TEXT: Renewal requires a follow-up spirometry after 6 months of treatment and annually thereafter, and concurrent use of a long acting insulin. Renewal will not be provided for patients with a FEV1 that has declined 20% or more from baseline.

   If no, continue to #4.

   CONTINUED ON NEXT PAGE
INHALED INSULIN

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of type 2 diabetes and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of a preferred formulary rapid acting insulin: Humalog
   - The prescriber indicated that the patient is physically unable to or unwilling to administer injectable insulin

   If yes, **approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:**
   - Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.
   - Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.
   - Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.

   **APPROVAL TEXT:** Renewal requires a follow-up spirometry after 6 months of treatment and annually thereafter. Renewal will not be provided for patients with a FEV1 that has declined **20%** or more from baseline.

   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INHALED INSULIN (Afrezza) requires the following rule(s) be met for approval:
A. You have type 1 or type 2 diabetes
B. You are 18 years of age or older
C. You have a baseline spirometry (test to measure how well your lungs work) to measure FEV1 (forced expiratory volume)
D. If you have type 1 diabetes, approval also requires:
   1. You are using a long-acting insulin with the requested medication and that you have tried a formulary rapid acting insulin: Humalog
E. If you have type 2 diabetes, approval also requires:
   1. You tried a formulary rapid acting insulin: Humalog
   2. Your prescriber has indicated that you are physically unable or unwilling to use injectable insulin

Note: Afrezza will not be approved if you have any of the following conditions: chronic lung disease, active lung cancer, currently in diabetic ketoacidosis (condition where body breaks down fat too fast), or if you are currently smoking or who have quit smoking within the past 6 months

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of type 1 diabetes and currently on a long acting insulin?
   
   If yes, continue to #3.
   If no, continue to #2.

2. Does the patient have a diagnosis of type 2 diabetes?
   
   If yes, continue to #3.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
3. Was follow-up spirometry to measure FEV1 performed after 6 months of treatment and annually thereafter?

   If yes, continue to #4.
   If no, approve for 1 month by GPID or GPI-14 (to allow for follow-up spirometry evaluation) with the following quantity limits:
   - Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.
   - Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.
   - Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.

4. Has FEV1 declined 20% or more from baseline?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:
   - Afrezza 90-4 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-8 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-12 Unit Cartridges: #180 cartridges (2 kits) per 28 days.
   - Afrezza 90-4 Unit + 90-8 Unit Titration pack: #180 cartridges (1 kit) per 28 days.
   - Afrezza 90-8 Unit + 90-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.
   - Afrezza 30-4 Unit + 60-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-4 Unit + 30-8 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-8 Unit + 30-12 Unit Cartridges: #360 cartridges (4 kits) per 28 days.
   - Afrezza 60-4 Unit + 60-8 Unit + 60-12 Unit Cartridges: #180 cartridges (1 kit) per 28 days.

**CONTINUED ON NEXT PAGE**
INHALED INSULIN

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INHALED INSULIN (Afrezza) requires the following rule(s) be met for renewal:
A. You have type 1 or type 2 diabetes
B. You have documentation of follow up spirometry (test to measure how well your lungs work) to measure FEV1 (forced expiratory volume in one second) after 6 months of treatment and annually thereafter
C. Your FEV1 has NOT declined 20% or more from baseline
D. **If you have type 1 diabetes**, approval requires that you are using a long acting insulin at the same time with the requested medication

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Afrezza.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 02/15
Client Approval: 04/20
P&T Approval: 07/17
INOTERSEN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>INOTERSEN SODIUM</td>
<td>TEGSEDI</td>
<td>45353</td>
<td></td>
<td>GPI-10 (6270104010)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy and meet ALL the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, cardiologist, hATTR specialist, or medical geneticist
   - The patient has documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
     a. Biopsy of tissue/organ to confirm amyloid presence AND chemical typing to confirm presence of TTR protein
     b. DNA genetic sequencing to confirm hATTR mutation
   - The patient has FAP stage 1 or 2 OR up to PND stage llb polyneuropathy
   - The patient had a trial of or contraindication to the preferred agent: Amvuttra

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #6mL per 28 days. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INOTERSEN (Tegsedi) requires the following rule(s) be met for approval:
A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve pain/damage)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)
D. You have a documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
   1. Biopsy (surgical removal of a sample) of tissue/organ to confirm amyloid (abnormal protein that can build up in any tissue or organ) presence AND chemical typing to confirm presence of TTR (transhyretin) protein
   2. DNA genetic sequencing (lab test for genes) to confirm hATTR mutation
E. You have familial amyloidotic polyneuropathy (FAP) stage 1 or 2 OR up to polyneuropathy disability (PND) stage llb polyneuropathy
F. You had a trial of or contraindication (harmful for) to the preferred medication: Amvuttra

(Initial denial text continued on next page)
INTIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy AND meet the following criterion?
   • The patient has not progressed to FAP stage 3 OR PND stage IV polyneuropathy as evidenced by functional decline (e.g., wheelchair-bound, bedridden)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6mL per 28 days. If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named INOTERSEN (Tegsedi) requires the following rule(s) be met for renewal:
   A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve pain/damage)
   B. You have not progressed to familial amyloidotic polyneuropathy (FAP) stage 3 OR polyneuropathy disability (PND) stage IV polyneuropathy as shown by functional decline such as being wheelchair-bound or bedridden

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tegsedi.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 10/18
Client Approval: 09/22
P&T Approval: 07/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have **ONE** of the following diagnoses?
   - Hairy cell leukemia
   - Condylomata acuminata
   - AIDS-related Kaposi’s sarcoma
   - Chronic hepatitis B
   - Non-Hodgkin's lymphoma
   - Malignant melanoma
   - Chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally treated (within 1 year of diagnosis)
   - Follicular lymphoma
   - Angioblastoma
   - Carcinoid tumor
   - Chronic myeloid leukemia
   - Laryngeal papillomatosis
   - Multiple myeloma
   - Neoplasm of conjunctiva-neoplasm of cornea
   - Ovarian cancer
   - Polycythemia vera
   - Renal cell carcinoma
   - Skin cancer
   - Thrombocytosis
   - Vulvar vestibulitis

If yes, **approve by HICL or GPI-10 for 24 weeks (6 months)**.
If no, continue to #2.
INITIAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a gastroenterologist, infectious disease specialist or a physician specializing in the treatment of hepatitis (e.g., hepatologist)
   • The patient has a detectable pretreatment HCV RNA level/viral load of 50 IU/mL or higher
   • The requested medication will be used with ribavirin or the patient has a contraindication to ribavirin
   • The patient had a trial of or contraindication to peginterferon alfa-2a or peginterferon alfa-2b

If yes, approve by HICL or GPI-10 for 24 weeks (6 months).
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INTERFERON ALFA-2B (Intron A) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Chronic hepatitis C (type of liver inflammation)
   2. Hairy cell leukemia (bone marrow cancer that makes too many white blood cells)
   3. Condylomata acuminate (genital warts)
   4. AIDS (acquired immunodeficiency syndrome)-related Kaposi's sarcoma (cancer in those with weak immune system that causes tumors of lymph nodes/skin)
   5. Chronic hepatitis B (type of liver inflammation)
   6. Non-Hodgkin's lymphoma (cancer that starts in your lymphatic system- the disease-fighting network in the body)
   7. Malignant melanoma (serious type of skin cancer)
   8. Chronic phase, Philadelphia chromosome (type of abnormal gene) positive chronic myelogenous leukemia (type of blood cell cancer that starts in bone marrow) who are minimally treated (within 1 year of diagnosis)
   9. Follicular lymphoma (type of lymphatic system cancer)
   10. Angioblastoma (certain blood-vessel tumors of the brain)
   11. Carcinoid (cancer) tumor
   12. Chronic myeloid leukemia (type of cancer that starts in immature white blood cells)
   13. Laryngeal papillomatosis (tumors form along the pathways for breathing/digestion)

(Initial denial text continued on next page)
INTERFERON ALFA-2B

INITIAL CRITERIA (CONTINUED)

14. Multiple myeloma (plasma cell cancer)
15. Neoplasm of conjunctiva-neoplasm of cornea (eye tumors)
16. Ovarian cancer
17. Polycythemia vera (cancer where bone marrow makes too many red blood cells)
18. Renal cell carcinoma (type of kidney cancer)
19. Skin cancer, thrombocytosis (your body makes too many platelets)
20. Thrombocytosis (high level of platelets (cells that helps blood clot and stop bleeding) in your blood)
21. Vulvar vestibulitis (type of pain around the female sex organ called the vulva)

B. If you have chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
   2. You have a detectable pretreatment HCV (hepatitis C virus) RNA level/viral load (amount of virus in your blood) of 50 IU/mL or higher
   3. The requested medication will be used with ribavirin or you have a contraindication (harmful for)
   4. You had a trial of or contraindication (harmful for) to peginterferon alfa-2a or peginterferon alfa-2b

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic hepatitis C AND meet the following criterion?
   Therapy is prescribed by or in consultation with a gastroenterologist, infectious disease specialist or a physician specializing in the treatment of hepatitis (e.g., hepatologist)
   
   If yes, continue to #2.
   If no, approve by HICL or GPI-10 for 24 weeks (6 months).

2. Has the patient already received 24 weeks or more of interferon during this treatment?

   If yes, continue to #3.
   If no, approve by HICL or GPI-10 for 24 weeks (6 months).

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Is the patient's HCV RNA undetectable (less than 50 IU/mL) at 24 weeks?

   If yes, approve by HICL or GPI-10 for 24 weeks (6 months).
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named INTERFERON ALFA-2B (Intron A) requires the following rule(s) be met for renewal:
   A. The request is for continuation of current therapy or renewal with Intron A therapy
   B. **If you have chronic hepatitis C (type of liver inflammation), renewal also requires:**
      1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
      2. If you already received 24 weeks or more of interferon treatment, your HCV (hepatitis C virus) RNA level (amount of virus in your blood) is undetectable (less than 50 IU/mL) at 24 weeks

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Intron A.

**REFERENCES**

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 as follows:
   - Avonex: #1 kit per 28 days or 2mL (#4 syringes) per 28 days.
   - Avonex Pen: #1 pen injector kit per 28 days or 2mL (#4 syringes) per 28 days.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INTERFERON FOR MS - AVONEX requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
B. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Avonex.

REFERENCES
INTERFERON FOR MS - BETASERON

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERFERON</td>
<td>BETASERON</td>
<td>08537</td>
<td>GPI-10</td>
<td>(6240306050)</td>
<td>BRAND = BETASERON</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months for all NDCs or GPI-14 of Betaseron for #14 vials or kits per 28 days.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INTERFERON FOR MS - BETASERON requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
B. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Betaseron.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 10/22
Commercial Effective: 11/01/22 Client Approval: 10/22 P&T Approval: 01/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
INTERFERON FOR MS - EXTAVIA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERFERON</td>
<td>EXTAVIA</td>
<td>08537</td>
<td>GPI-10</td>
<td>(6240306050)</td>
<td>BRAND = EXTAVIA</td>
</tr>
<tr>
<td>BETA-1B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to any TWO of the following preferred agents for MS: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta
   (Please note: other multiple sclerosis agents may also require prior authorization)

   If yes, approve for 12 months for all NDCs or GPI-14 of Extavia for #14 vials or kits per 28 days.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named INTERFERON FOR MS - EXTAVIA requires the following rule(s) be met for approval:
   A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older
   C. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta
   (Please note: other multiple sclerosis medications may also require prior authorization)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
INTERFERON FOR MS - EXTAVIA

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Extavia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 10/22
Commercial Effective: 11/01/22 Client Approval: 10/22 P&T Approval: 01/20
INTERFERON FOR MS - PLEGRIDY

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEGINTERFERON BETA-1A</td>
<td>PLEGRIDY, PLEGRIDY PEN</td>
<td>41331</td>
<td></td>
<td>GPI-10 (6240307530)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 as follows:
   **INITIAL REQUESTS:**
   • FIRST APPROVAL: Plegridy injection starter pack: approve for 1 month with a quantity limit of 1mL (#2 prefilled pens or syringes).
   • SECOND APPROVAL: Plegridy Pen/Syringe: approve for 11 months (total approval duration of 12 months) with a quantity limit of 1mL (#2 125mcg prefilled pens or syringes) per 28 days. (Please enter start date of 3 weeks AFTER the START date of the first approval).

   **SUBSEQUENT REQUESTS:**
   • Plegridy Pen/Syringe: approve for 12 months with a quantity limit of 1mL (#2 125mcg prefilled pens or syringes) per 28 days.

   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named INTERFERON FOR MS - PLEGRIDY requires the following rule(s) be met for approval:
   A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
INTERFERON FOR MS - PLEGRIDY

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Plegridy.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/22
Commercial Effective: 11/01/22  Client Approval: 10/22  P&T Approval: 01/20
INTERFERON FOR MS - REBIF

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERFERON Beta- 1A/ALBUMIN</td>
<td>REBIF, REBIF REBIDOSE</td>
<td>23353</td>
<td>GPI-10 (6240306045)</td>
<td></td>
<td>FDB: BRAND = REBIF, REBIF REBIDOSE MED-SPAN: BRAND = REBIF REBIDOSE, REBIF REBIDOSE TITRATIONPACK, REBIF</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 as follows:
   **INITIAL REQUESTS:**
   - **FIRST APPROVAL:** Rebin Titration Pack/Rebin Rebidose Titration Pack: approve for 1 month with a quantity limit of 4.2mL (#12 syringes) per 28 days.
   - **SECOND APPROAL:** Rebin/Rebin Rebidose: approve for 11 months (total approval duration of 12 months) with a quantity limit of 6mL (#12 syringes) per 28 days. (Please enter start date of 3 weeks AFTER the START date of the first approval.)

   **SUBSEQUENT REQUESTS:**
   - Rebin/Rebin Rebidose: approve for 12 months with a quantity limit of 6mL (#12 syringes) per 28 days.

   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named INTERFERON FOR MS - REBIF requires the following rule(s) be met for approval:
   A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
INTERFERON FOR MS - REBIF

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rebif.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/22
Commercial Effective: 11/01/22  Client Approval: 10/22  P&T Approval: 01/20
INTERFERON GAMMA-1B, RECOMB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERFERON GAMMA-1B, RECOMB.</td>
<td>ACT IMMUNE</td>
<td>06068</td>
<td>GCN</td>
<td>GPI-10 (2170006070)</td>
<td>Exception/Other</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of chronic granulomatous disease (CGD) AND meet the following criterion?
   - The medication is prescribed by or given in consultation with a hematologist, infectious disease specialist, or immunologist

   If yes, approve for 6 months by HICL or GPI-10.
   APPROVAL TEXT: Renewal requires the following: 1) patient has demonstrated clinical benefit compared to baseline (e.g. reduction in frequency and severity of serious infections), and 2) patient has not received hematopoietic cell transplantation.

   If no, continue to #2.

2. Does the patient have a diagnosis of severe malignant osteopetrosis (SMO) AND meet the following criterion?
   - The medication is prescribed by or given in consultation with an endocrinologist

   If yes, approve for 6 months by HICL or GPI-10.
   APPROVAL TEXT: Renewal requires the following: 1) patient has demonstrated clinical benefit compared to baseline (e.g. reduction in frequency and severity of serious infections), and 2) patient has not received hematopoietic cell transplantation.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INTERFERON GAMMA-1B, RECOMB (Actimmune) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Chronic granulomatous disease (CGD: inherited immune system disorder that occurs when a type of white blood cells that usually helps your body fight infections does not work properly)
   2. Severe malignant osteopetrosis (SMO: a bone disease that makes bone abnormally thick and prone to breakage/fracture)

(Initial denial text continued on the next page)
INTERFERON GAMMA-1B, RECOMB

INITIAL CRITERIA (CONTINUED)

B. If you have chronic granulomatous disease, approval also requires:
   1. The medication is prescribed by or given in consultation with a hematologist (blood doctor), infectious disease specialist (doctor that specializes in treating infections), or immunologist (doctor that specializes in treating and managing allergies, asthma and immunologic disorders)

C. If you have severe malignant osteopetrosis, approval also requires:
   1. The medication is prescribed by or given in consultation with an endocrinologist (doctor that specializes in all things relating to our hormones)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO) and meet ALL of the following criteria?
   • The patient has demonstrated clinical benefit compared to baseline (e.g., reduction in frequency and severity of serious infections)
   • The patient has not received hematopoietic cell transplantation

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named INTERFERON GAMMA-1B, RECOMB (Actimmune) requires the following rules be met for renewal:

A. You have ONE of the following diagnoses:
   1. Chronic granulomatous disease (CGD: inherited immune system disorder that occurs when a type of white blood cells that usually helps your body fight infections does not work properly)
   2. Severe malignant osteopetrosis (SMO: a bone disease that makes bone abnormally thick and prone to breakage/fracture)

B. You have shown clinical (medical) benefit compared to baseline (such as reduction in frequency and severity of serious infections)

C. You have not received hematopoietic cell transplantation (transplant of stem cells from bone marrow, peripheral blood, or umbilical cord blood)

(Renewal denial text continued on the next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Actimmune.

REFERENCES
• Actimmune [Prescribing Information] Lake Forest, IL: Horizon Therapeutics USA, Inc., January 2020.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/05
Commercial Effective: 04/01/20  Client Approval: 02/20  P&T Approval: 01/20
ISAVUCONAZONIUM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISAVUCONAZONIUM</td>
<td>CRESEMBA</td>
<td></td>
<td>38095</td>
<td>GPI-14</td>
<td>(11407030100120)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is this request for continuation of therapy after the patient was started on Cresemba in the hospital?
   - If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #60 per 30 days.
   - If no, continue to #2.

2. Does the patient have a diagnosis of invasive aspergillosis and meet ALL of the following?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with an infectious disease specialist
   - The patient had a trial and failure of or contraindication to voriconazole
   - If yes, approve for 6 months by HICL or GPI-10 as follows:
     - INITIAL REQUESTS:
       - FIRST APPROVAL: approve for one fill with a quantity limit of #68 per 30 days.
       - SECOND APPROVAL: approve for 5 months with a quantity limit of #60 per 30 days.
     - SUBSEQUENT REQUESTS:
       - Approve for 6 months with a quantity limit of #60 per 30 days.
   - If no, continue to #3.

3. Does the patient have a diagnosis of invasive mucormycosis and meet ALL of the following?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with an infectious disease specialist
   - If yes, approve for 6 months by HICL or GPI-10 as follows:
     - INITIAL REQUESTS:
       - FIRST APPROVAL: approve for one fill with a quantity limit of #68 per 30 days.
       - SECOND APPROVAL: approve for 5 months with a quantity limit of #60 per 30 days.
     - SUBSEQUENT REQUESTS:
       - Approve for 6 months with a quantity limit of #60 per 30 days.
   - If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ISAVUCONAZONIUM (Cresemba) requires the following rule(s) be met for approval:
A. You meet ONE of the following:
   1. This is a request for continuation of therapy after you were started on Cresemba in the hospital
   2. You have invasive aspergillosis OR invasive mucormycosis (types of fungal infections)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an infectious disease specialist
D. If you have invasive aspergillosis, approval also requires:
   1. You had a trial and failure of or contraindication to (medical reason why you cannot use) voriconazole

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cresemba.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/21
Created: 05/21
Client Approval: 08/21
P&T Approval: 04/21
ISTRADEFYLLINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISTRADEFYLLINE</td>
<td>NOURIANZ</td>
<td>45994</td>
<td>GPI-10</td>
<td>(7340102500)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Parkinson's disease (PD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is experiencing 'OFF' episodes
   - Nourianz will be used concurrently with levodopa/carbidopa
   - The patient had a previous trial of, failure of, or contraindication to TWO Parkinson's agents from TWO different therapeutic classes: dopamine agonists (e.g., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (e.g., selegiline, rasagiline), or catechol-O-methyl transferase inhibitors (e.g., entacapone, tolcapone)

If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ISTRADEFYLLINE (Nourianz) requires the following rule(s) be met for approval:
A. You have Parkinson's disease (a nerve system disorder that affects movement)
B. You are 18 years of age or older
C. You are experiencing 'OFF' episodes (times when medication wears off and you have movement problems)
D. Nourianz will be used along with levodopa/carbidopa
E. You had a previous trial of or contraindication to (medical reason why you cannot use) TWO Parkinson's agents from TWO different drug classes:
   1. Dopamine agonists (such as ropinirole, pramipexole, rotigotine)
   2. Monoamine oxidase-inhibitors (such as selegiline, rasagiline)
   3. Catechol-O-methyl transferase inhibitors (such as entacapone, tolcapone)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ISTRADEFYLLINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nourianz.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A            Created: 11/19
Commercial Effective: 07/01/20    Client Approval: 04/20
                                      P&T Approval: 10/19
ITRACONAZOLE - TOLSURA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITRACONAZOLE</td>
<td>TOLSURA</td>
<td></td>
<td>45848</td>
<td>GPI-14</td>
<td>(11407035000113)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of ONE of the following types of fungal infections?
   - Blastomycosis, pulmonary and extrapulmonary
   - Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis
   - Aspergillosis, pulmonary and extrapulmonary, AND the patient is intolerant to or refractory to amphotericin B therapy

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with an infectious disease specialist
   - The patient had a previous trial of a generic itraconazole formulation
   - Tolsura is prescribed due to subclinical response to other formulations of itraconazole suspected to be due to poor bioavailability

   If yes, approve for a total of 12 months by GPID or GPI-14 as follows:
   INITIAL REQUESTS
   - FIRST APPROVAL: approve for 1 fill with a quantity limit of #126 per 30 days.
   - SECOND APPROVAL: approve for 11 months with a quantity limit of #120 per 30 days.

   SUBSEQUENT REQUESTS
   - Approve for 12 months with a quantity limit of #120 per 30 days.

   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named ITRACONAZOLE (Tolsura) requires the following rule(s) be met for approval:

A. You have ONE of the following fungal infections:
   1. Blastomycosis, pulmonary and extrapulmonary (type of fungal infection affecting in and outside of the lungs)
   2. Histoplasmosis (type of fungal infection), including chronic cavitary pulmonary (affecting the lungs) disease and disseminated, nonmeningeal (not affecting spinal cord and brain membranes) histoplasmosis
   3. Aspergillosis, pulmonary and extrapulmonary (type of fungal infection in and outside of the lungs), AND you are intolerant to or refractory to (not responsive to) amphotericin B therapy

B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an infectious disease specialist
D. You had a previous trial of a generic itraconazole formulation
E. Tolsura is prescribed because you had a poor clinical response to other formulations of itraconazole due to poor bioavailability (amount of drug in the body that has an effect)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tolsura.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 03/19
Commercial Effective: 07/01/21  Client Approval: 05/21  P&T Approval: 04/21
### GUIDELINES FOR USE

#### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of cystic fibrosis (CF) and meet **ALL** of the following criteria?
   - The patient is 1 month of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist or cystic fibrosis expert
   - The patient is **NOT** homozygous for the F508del mutation in the CFTR gene

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is there documentation (e.g., chart notes, lab results, diagnostic test results, etc.) that the patient has **ONE** of the following mutations in the CFTR gene?

<table>
<thead>
<tr>
<th>Mutation</th>
<th>F</th>
<th>I</th>
<th>R</th>
<th>S</th>
</tr>
</thead>
<tbody>
<tr>
<td>711+3A→G</td>
<td>F311del</td>
<td>I148T</td>
<td>R75Q</td>
<td>S589N</td>
</tr>
<tr>
<td>2789+5G→A</td>
<td>F311L</td>
<td>I175V</td>
<td>R117C</td>
<td>S737F</td>
</tr>
<tr>
<td>3272-26A→G</td>
<td>F508C</td>
<td>I807M</td>
<td>R117G</td>
<td>S945L</td>
</tr>
<tr>
<td>3849+10kbC→T</td>
<td>F508C; S1251N</td>
<td>I1027T</td>
<td>R117H</td>
<td>S977F</td>
</tr>
<tr>
<td>A120T</td>
<td>F1052V</td>
<td>I1139V</td>
<td>R117L</td>
<td>S1159F</td>
</tr>
<tr>
<td>A234D</td>
<td>F1074L</td>
<td>K1060T</td>
<td>R117P</td>
<td>S1159P</td>
</tr>
<tr>
<td>A349V</td>
<td>G178E</td>
<td>L206W</td>
<td>R170H</td>
<td>S1251N</td>
</tr>
<tr>
<td>A455E</td>
<td>G178R</td>
<td>L320V</td>
<td>R347H</td>
<td>S1255P</td>
</tr>
<tr>
<td>A1067T</td>
<td>G194R</td>
<td>L967S</td>
<td>R347L</td>
<td>T338I</td>
</tr>
<tr>
<td>D110E</td>
<td>G314E</td>
<td>L997F</td>
<td>R352Q</td>
<td>T103I</td>
</tr>
<tr>
<td>D110H</td>
<td>G551D</td>
<td>L1480P</td>
<td>R553Q</td>
<td>V232D</td>
</tr>
<tr>
<td>D192G</td>
<td>G551S</td>
<td>M152V</td>
<td>R668C</td>
<td>V562I</td>
</tr>
<tr>
<td>D579G</td>
<td>G576A</td>
<td>M952I</td>
<td>R792G</td>
<td>V754M</td>
</tr>
<tr>
<td>D924N</td>
<td>G970D</td>
<td>M952T</td>
<td>R933G</td>
<td>V1293G</td>
</tr>
<tr>
<td>D1152H</td>
<td>G1069R</td>
<td>P67L</td>
<td>R1070Q</td>
<td>W1282R</td>
</tr>
<tr>
<td>D1270N</td>
<td>G1244E</td>
<td>Q237E</td>
<td>R1070W</td>
<td>Y1014C</td>
</tr>
<tr>
<td>E56K</td>
<td>G1249R</td>
<td>Q237H</td>
<td>R1162L</td>
<td>Y1032C</td>
</tr>
<tr>
<td>E193K</td>
<td>G1349D</td>
<td>Q359R</td>
<td>R1283M</td>
<td></td>
</tr>
<tr>
<td>E822K</td>
<td>H939R</td>
<td>Q1291R</td>
<td>S549N</td>
<td></td>
</tr>
<tr>
<td>E831X</td>
<td>H1375P</td>
<td>R74W</td>
<td>S549R</td>
<td></td>
</tr>
</tbody>
</table>

*If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.*
*If no, do not approve.*

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **IVACAFTOR (Kalydeco)** requires the following rule(s) be met for approval:
A. You have cystic fibrosis (CF: a type of lung disorder)
B. You are 1 month of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (lung doctor) or cystic fibrosis expert
D. You are NOT homozygous (have two copies of the same gene) for the F508del mutation (an abnormal change) in the CFTR (cystic fibrosis transmembrane conductance regulator) gene
E. You have documentation (such as chart notes, lab results, diagnostic test results) of ONE of the following mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene:

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>711+3A→G</td>
<td>F311del</td>
<td>I148T</td>
<td>R75Q</td>
<td>S589N</td>
</tr>
<tr>
<td>2789+5G→A</td>
<td>F311L</td>
<td>I175V</td>
<td>R117C</td>
<td>S737F</td>
</tr>
<tr>
<td>3272-26A→G</td>
<td>F508C</td>
<td>I807M</td>
<td>R117G</td>
<td>S945L</td>
</tr>
<tr>
<td>3849+10kbC→T</td>
<td>F508C; S1251N</td>
<td>I11027T</td>
<td>R117H</td>
<td>S977F</td>
</tr>
<tr>
<td>A120T</td>
<td>F1052V</td>
<td>I1139V</td>
<td>R117L</td>
<td>S1159F</td>
</tr>
<tr>
<td>A234D</td>
<td>F1074L</td>
<td>L1060T</td>
<td>R117P</td>
<td>S1159P</td>
</tr>
<tr>
<td>A349V</td>
<td>G178E</td>
<td>L206W</td>
<td>R170H</td>
<td>S1251N</td>
</tr>
<tr>
<td>A455E</td>
<td>G178R</td>
<td>L320V</td>
<td>R347H</td>
<td>S1255P</td>
</tr>
<tr>
<td>A1067T</td>
<td>G194R</td>
<td>L967S</td>
<td>R347L</td>
<td>T338I</td>
</tr>
<tr>
<td>D110E</td>
<td>G314E</td>
<td>L997F</td>
<td>R352Q</td>
<td>T1053I</td>
</tr>
<tr>
<td>D110H</td>
<td>G551D</td>
<td>L1480P</td>
<td>R553Q</td>
<td>V232D</td>
</tr>
<tr>
<td>D192G</td>
<td>G551S</td>
<td>M152V</td>
<td>R668C</td>
<td>V562I</td>
</tr>
<tr>
<td>D579G</td>
<td>G576A</td>
<td>M952I</td>
<td>R792G</td>
<td>V754M</td>
</tr>
<tr>
<td>D924N</td>
<td>G970D</td>
<td>M952T</td>
<td>R933G</td>
<td>V1293G</td>
</tr>
<tr>
<td>D1152H</td>
<td>G1069R</td>
<td>P67L</td>
<td>R1070Q</td>
<td>W1282R</td>
</tr>
<tr>
<td>D1270N</td>
<td>G1244E</td>
<td>Q237E</td>
<td>R1070W</td>
<td>Y1014C</td>
</tr>
<tr>
<td>E56K</td>
<td>G1249R</td>
<td>Q237H</td>
<td>R1162L</td>
<td>Y1032C</td>
</tr>
<tr>
<td>E193K</td>
<td>G1349D</td>
<td>Q359R</td>
<td>R1283M</td>
<td></td>
</tr>
<tr>
<td>E822K</td>
<td>H939R</td>
<td>Q1291R</td>
<td>S549N</td>
<td></td>
</tr>
<tr>
<td>E831X</td>
<td>H1375P</td>
<td>R74W</td>
<td>S549R</td>
<td></td>
</tr>
</tbody>
</table>

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
IVACAFTOR

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status compared to baseline as shown by ONE of the following?
   - The patient has improved, maintained, or demonstrated a less than expected decline in FEV1
   - The patient has improved, maintained, or demonstrated a less than expected decline in BMI
   - The patient has experienced a reduction in rate of pulmonary exacerbations

   If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named IVACAFTOR (Kalydeco) requires the following rule(s) be met for renewal:
A. You have cystic fibrosis (CF: a type of lung disorder)
B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
   1. You have improved, maintained, or demonstrated a less than expected decline in forced expiratory volume (FEV1: amount of air you can exhale in 1 second)
   2. You have improved, maintained, or demonstrated a less than expected decline in body mass index (BMI: a tool for evaluating body fat)
   3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kalydeco.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a new diagnosis of acute myeloid leukemia (AML) and meet ALL of the following criteria?
   - The requested medication will be used in combination with azacitidine or as monotherapy
   - The patient's cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient is 75 years of age or older
   - The patient is 18 years of age or older AND has comorbidities that preclude the use of intensive induction chemotherapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #4.

4. Does the patient have a diagnosis of locally advanced or metastatic cholangiocarcinoma and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's cancer has an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
   - The patient's cancer has been previously treated

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named IVOSIDENIB (Tibsovo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Acute myeloid leukemia (AML: a type of blood cancer)
   2. Locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)

B. If you have a new diagnosis of acute myeloid leukemia, approval also requires:
   1. The requested medication will be used in combination with azacitidine or as monotherapy (one drug)
   2. Your cancer has a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
   3. You meet ONE of the following:
      a. You are 75 years of age or older
      b. You are 18 years of age or older AND have comorbidities (additional diseases) that prevent the use of intensive induction chemotherapy (start of a type of cancer treatment)

C. If you have relapsed or refractory acute myeloid leukemia, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test

D. If you have locally advanced or metastatic cholangiocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has an isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
   3. Your cancer has been previously treated

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
IVOSIDENIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tibsovo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 11/18
Commercial Effective: 07/18/22  Client Approval: 06/22  P&T Approval: 07/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of multiple myeloma and meet ALL of the following criteria?
   - Ninlaro (ixazomib) will be used in combination with lenalidomide and dexamethasone
   - The patient has received at least one prior therapy for the treatment of multiple myeloma such as bortezomib, carfilzomib, thalidomide, lenalidomide, melphalan or stem cell transplantation

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per 28 days.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named IXAZOMIB (Ninlaro) requires the following rule(s) be met for approval:
   A. You have multiple myeloma (plasma cell cancer)
   B. The requested medication will be used in combination with lenalidomide and dexamethasone
   C. You have received at least one prior therapy such as bortezomib, carfilzomib, thalidomide, lenalidomide, melphalan or stem cell transplantation

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ninlaro.

REFERENCES
IXEKIZUMAB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>IXEKIZUMAB</td>
<td>TALTZ</td>
<td>43193</td>
<td></td>
<td>GPI-10 (9025055400)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and is switching to the requested drug
   - The patient has psoriasis covering 3% or more of body surface area (BSA)
   - The patient has psoriatic lesions affecting the hands, feet, genital area, or face

   If yes, approve for a total of 6 months by HICL or GPI-10 as follows:
   - For patients who are 6 years to 17 years of age, enter TWO approvals:
     - FIRST APPROVAL: Approve for 1 month with a quantity limit of 2mL per 28 days.
     - SECOND APPROVAL: Approve for 5 months with a quantity limit of 1mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).
   - For patients who are 18 years of age or older, enter THREE approvals:
     - FIRST APPROVAL: Approve for 1 month with a quantity limit of 3mL per 28 days.
     - SECOND APPROVAL: Approve for 2 months with a quantity limit of 2mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).
     - THIRD APPROVAL: Approve for 3 months with a quantity limit of 1mL per 28 days (Start date is 1 WEEK BEFORE the END date of the second approval).

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #4.
   If no, continue to #5.

4. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?

   If yes, approve for a total of 6 months by HICL or GPI-10 as follows:
   • FIRST APPROVAL: Approve for 1 month with a quantity limit of 3mL per 28 days.
   • SECOND APPROVAL: Approve for 2 months with a quantity limit of 2mL per 28 days
     (Start date is 3 WEEKS AFTER the START date of the first approval).
   • THIRD APPROVAL: Approve for 3 months with a quantity limit of 1mL per 28 days
     (Start date is 1 WEEK BEFORE the END date of the second approval).

   If no, approve for a total of 6 months by HICL or GPI-10 as follows:
   • FIRST APPROVAL: Approve for 1 month with a quantity limit of 2mL per 28 days.
   • SECOND APPROVAL: Approve for 5 months with a quantity limit of 1mL per 28 days
     (Start date is 3 WEEKS AFTER the START date of the first approval).

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, approve for a total of 6 months by entering TWO approvals by HICL or GPI-10 as follows:
   - FIRST APPROVAL: Approve for 1 month with a quantity limit of 2mL per 28 days.
   - SECOND APPROVAL: Approve for 5 months with a quantity limit of 1mL per 28 days (Start date is 3 WEEKS AFTER the START date of the first approval).

   If no, continue to #6.

6. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, continue to #7.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

7. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cosentyx [secukinumab], Cimzia [certolizumab]) and is switching to the requested drug
   - The patient has C-reactive protein (CRP) levels above the upper limit of normal
   - The patient has sacroiliitis on magnetic resonance imaging (MRI)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named IXEKIZUMAB (Taltz) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

E. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cosentyx [secukinumab], Cimzia [certolizumab]) and are switching to the requested drug
      b. You have C-reactive protein (CRP; a measure of how much inflammation you have) levels above the upper limit of normal
      c. You have sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   • The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.
   If no, continue to #2.

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

B. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.
   If no, continue to #3.

C. Does the patient have a diagnosis of ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA) AND meet the following criterion?
   - The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of 1mL per 28 days.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named IXEKIZUMAB (Taltz) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have ankylosing spondylitis OR non-radiographic axial spondyloarthritis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

(Renewal denial text continued on next page)
IXEKIZUMAB

RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Taltz.

REFERENCES
- Taltz [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; September 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 04/16
Client Approval: 05/23
P&T Approval: 04/23
Please refer to CONTRACEPTIVE ZERO COST SHARE OVERRIDE section below if the request is also for zero copay override.

GUIDELINES FOR USE

1. Is the request for prevention of pregnancy in a female patient with reproductive potential and the patient meets ALL of the following criteria?
   • The patient is NOT concurrently using vaginal ring products (e.g., Annovera, Nuvaring)
   • The patient had a previous trial of or contraindication to two contraceptive agents (e.g., intrauterine device [Mirena, Kyleena, Liletta, Skyla, ParaGard], hormonal implant/injection/patch/oral products [Nexplanon, Depo-Provera, Xulane, etc.])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #60 grams per 30 days.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LACTIC ACID/CITRIC/POTASSIUM (Phexxi) requires the following rule(s) be met for approval:
   A. You are a female patient with reproductive potential using the requested medication for prevention of pregnancy
   B. You are not using vaginal ring products (such as Annovera or Nuvaring) together with Phexxi
   C. You had a previous trial of two contraceptive agents (such as an intrauterine device, hormonal implant, injection, patch, or oral products), unless there is a medical reason you cannot (contraindication)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

CONTRACEPTIVE ZERO COST SHARE OVERRIDE CRITERIA

6. Is the patient requesting a cost share exception for the requested contraceptive agent AND does the plan cover contraceptives at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact’s Essential Health Benefit Tables)?

   If yes, continue to #2.
   If no, guideline does not apply.

7. Do ANY of the following criteria apply?
   • The patient's plan has specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)
   • The request is for an agent with an excluded route of administration, such that the agent will be covered on the medical benefit

   If yes, guideline does not apply.
   If no, continue to #3.

8. Is the request for a generic agent?

   If yes, approve for 12 months by HICL or GPI-10 at zero copay.
   If no, continue to #4.

9. Is the request for ONE of the following?
   • A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
   • A multi-source brand (MSB) contraceptive agent

   If yes, continue to #5.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE - CONTRACEPTIVE ZERO COST SHARE OVERRIDE CRITERIA (CONTINUED)

10. Does the patient meet **ONE** of the following criteria?
   - Two preferred medications are medically inappropriate for the patient (alternatively, one if only one agent is available)
   - The patient has tried or has a documented medical contraindication to two preferred medications (alternatively, a trial of one if only one agent is available)
   - The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects, differences in permanence and reversibility of contraceptives, and ability to adhere to the appropriate use of the item or service)

If yes, **approve for 12 months by HICL or GPI-10 at zero copay.**
If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CONTRACEPTIVE ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

**A.** The request is for **ONE** of the following:
   1. A generic contraceptive agent
   2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) contraceptive agent

**B.** **If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires **ONE** of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Phexxi.

The Contraceptive Zero Cost Share Override criteria applies to plans where the pharmacy benefit allows for coverage of contraceptives at zero copay. The override criteria allow patient access to all FDA-approved contraceptive methods at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded contraceptives.

The MedImpact standard Zero Copay list currently offers coverage of all methods at zero cost share. The zero cost share list offers a variety of contraceptives. Covered methods (zero cost share) include 1) specified barrier contraceptives (condoms, diaphragms, cervical caps, and nonoxynol-9) 2) generic oral hormonal contraceptives under STC 0248, including generic emergency contraceptives and Ella 3) generic transdermal patch contraceptive (currently marketed by Mylan as Xulane) 4) Nuvaring vaginal ring 5) Intrauterine devices – levonorgestrel IUDs and copper IUDs 6) Depo-Provera injections, 7) Nexplanon implant devices, and 8) Intravaginal contraceptives. The majority of the contraceptives on the EHB Zero cost share list are generic agents, which promotes a cost-effective formula. The healthcare.gov website (https://www.healthcare.gov/coverage/birth-control-benefits/) currently recommends: All approved contraceptive methods prescribed by a woman’s doctor are covered, including:

- Barrier methods (used during intercourse), like diaphragms and sponges
- Hormonal methods, like birth control pills and vaginal rings
- Implanted devices, like intrauterine devices (IUDs)
- Emergency contraception, like Plan B® and Ella®
- Sterilization procedures
- Patient education and counseling

REFERENCES
- Birth control benefits; https://www.healthcare.gov/coverage/birth-control-benefits/
LANADELUMAB-FLYO

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LANADELUMAB-FLYO</td>
<td>TAKHZYRO</td>
<td>45177</td>
<td>GPI-10(8584204020)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with an allergist, immunologist or hematologist
   - The patient’s diagnosis of HAE is confirmed via documentation (e.g., chart note, lab result, diagnostic test result, etc.) of complement testing
   - Takhzyro is being used for prophylaxis against HAE attacks
   - The patient is NOT on concurrent treatment with alternative prophylactic agent for HAE (e.g., Cinryze, Haegarda, danazol, berotralstat)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL per 28 days.

   APPROVAL TEXT: Prescriber may consider a dosing interval of every 4 weeks if the patient is well-controlled for more than six months.

   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LANADELUMAB-FLYO (Takhzyro) requires the following rule(s) be met for approval:
   A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
   B. You are 2 years of age or older
   C. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor) or hematologist (blood doctor)
   D. Your diagnosis is confirmed by documentation (such as chart note, lab result, diagnostic test result) of complement testing (a type of blood test)
   E. Takhzyro is being used for prevention of hereditary angioedema attacks
   F. You will NOT be using Takhzyro concurrently (at the same time) with an alternative preventive agent for HAE (such as Cinryze, Haegarda, danazol, berotralstat)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LANADELUMAB-FLYO

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary angioedema (HAE) and meet ALL of the following criteria?
   - The patient has experienced improvement (i.e., reductions in attack frequency or attack severity) compared to baseline in HAE attacks
   - The patient is NOT on concurrent treatment with alternative prophylactic agent for HAE (e.g., Cinryze, Haegarda, danazol, berotralstat)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL per 28 days.
   APPROVAL TEXT: Prescriber may consider a dosing interval of every 4 weeks if the patient is well-controlled for more than six months.

   If no, do not approve.
   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LANADELUMAB-FLYO (Takhzyro) requires the following rule(s) be met for renewal:
   A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
   B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in hereditary angioedema attacks
   C. You will NOT be using Takhzyro concurrently (at the same time) with an alternative preventive agent for HAE (such as Cinryze, Haegarda, danazol, berotralstat)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
LANADELUMAB-FLYO

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Takhzyro.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/18
Commercial Effective: 04/10/23  Client Approval: 03/23  P&T Approval: 04/23
LAPATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAPATINIB DITOSYLATE</td>
<td>TYKERB, LAPATINIB</td>
<td>34541</td>
<td>GCN</td>
<td>GPI-10 (2153302610)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ALL of the following criteria?
   - The patient's breast cancer is human epidermal growth factor receptor 2 (HER2) positive
   - The requested medication will be used in combination with Xeloda (capecitabine)
   - The patient has received prior therapy with Herceptin (trastuzumab), an anthracycline (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin), AND a taxane (e.g., paclitaxel, docetaxel)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #5 per day**.
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic breast cancer and meet ALL of the following criteria?
   - The patient's breast cancer is human epidermal growth factor receptor 2 (HER2) positive
   - The patient's tumor is hormone receptor-positive
   - The requested medication will be used in combination with Femara (letrozole)
   - The patient is a postmenopausal woman

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day**.
   If no, do not approve.

**DENIAL TEXT:** Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LAPATINIB (Tykerb) requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of your body)
B. Your breast cancer is human epidermal growth factor receptor 2 (HER2: gene/protein in breast cancer) positive
C. **If you have advanced or metastatic breast cancer, approval also requires:**
   1. The requested medication will be used in combination with Xeloda (capecitabine)
   2. You have previously received treatment with Herceptin (trastuzumab), an anthracycline (such as daunorubicin, doxorubicin, epirubicin, idarubicin), AND a taxane (such as paclitaxel, docetaxel)
D. **If you have metastatic breast cancer, approval also requires:**
   1. Your tumor is hormone receptor-positive
   2. The requested medication will be used in combination with Femara (letrozole)
   3. You are a postmenopausal woman

(Denial text continued on the next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tykerb.

REFERENCES
- Tykerb [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A      Created: 04/10
Commercial Effective: 04/10/21 Commercial Client Approval: 03/21 P&T Approval: 08/13
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a solid tumor and meet ALL of the following criteria?
   - The tumor has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation
   - The tumor is metastatic or surgical resection is likely to result in severe morbidity
   - There are no satisfactory alternative treatments, or the patient has progressed following treatment

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

2. Is the request for Vitrakvi oral capsules?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Vitrakvi 25mg: #6 capsules per day.
   - Vitrakvi 100mg: #2 capsules per day.

   If no, continue to #3.

3. Is the request for Vitrakvi oral solution and the patient meets ONE of the following criteria?
   - The request is for a pediatric patient
   - The patient is unable to take Vitrakvi capsules due to difficulty swallowing or dysphagia
   - The patient has other medical need for the oral solution

   If yes, approve for 12 months by GPID or GPI-14 as follows:
   - Vitrakvi 20mg/mL oral solution: #10mL per day.

   If no, do not approve Vitrakvi oral suspension. Please enter a proactive PA for Vitrakvi capsules and approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Vitrakvi 25mg: #6 capsules per day.
   - Vitrakvi 100mg: #2 capsules per day.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LAROTRECTINIB (Vitrakvi) requires the following rule(s) be met for approval:
A. You have a solid tumor (abnormal mass of tissue that usually does not contain cysts or liquid)
B. Your tumor has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation (you have a type of enzyme that doesn't have a mutation)
C. Your tumor is metastatic (spreads to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (illness)
D. There are no satisfactory alternative treatments, or your tumor has gotten worse after treatment
E. Requests for Vitrakvi oral solution also require ONE of the following:
   1. You are a pediatric patient (less than 18 years of age)
   2. You are unable to take Vitrakvi capsules due to difficulty swallowing (or dysphagia)
   3. You have other medical need for the oral solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vitrakvi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A        Created: 03/19
Commercial Effective: 07/01/20  Client Approval: 04/20  P&T Approval: 01/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to **ONE** triptan (e.g., sumatriptan, rizatriptan)

   If yes, **approve for 6 months for the requested strength by GPID OR GPI-14 as follows:**
   - **50mg:** #8 per 30 days.
   - **100mg:** #8 per 30 days.

   **APPROVAL TEXT:** Renewal requires that the request is for acute treatment of migraines and the patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT]) OR the patient has experienced clinical improvement as defined by **ONE** of the following: 1) ability to function normally within 2 hours of dose, 2) headache pain disappears within 2 hours of dose, or 3) therapy works consistently in majority of migraine attacks.

   If no, **do not approve.**

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **LASMIDITAN (Reyvow)** requires the following rule(s) be met for approval:
   A. You are being treated for acute (quick onset) migraine
   B. You are 18 years of age or older
   C. You have previously tried **ONE** triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON THE NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets ONE of the following criteria?
   • The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
   • The patient has experienced clinical improvement as defined by ONE of the following:
     o Ability to function normally within 2 hours of dose
     o Headache pain disappears within 2 hours of dose
     o Therapy works consistently in majority of migraine attacks

If yes, approve for 12 months for the requested strength by GPI-14 as follows:
   • 50mg: #8 per 30 days.
   • 100mg: #8 per 30 days.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LASMIDITAN (Reyvow) requires the following rule(s) be met for renewal:
A. You are being treated for acute (quick onset) migraine
B. You meet ONE of the following:
   1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as Migraine Assessment of Current Therapy [MIGRAINE-ACT])
   2. You have experienced clinical improvement as defined by ONE of the following:
      a. Ability to function normally within 2 hours of dose
      b. Headache pain disappears within 2 hours of dose
      c. Treatment works consistently in majority of migraine attacks

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON THE NEXT PAGE
LASMIDITAN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Reyvow.

REFERENCES

- Reyvow [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC, January 2020.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/20
Commercial Effective: 12/12/20  Client Approval: 12/20  P&T Approval: 01/20
L-GLUTAMINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLUTAMINE</td>
<td>ENDARI</td>
<td></td>
<td>13365</td>
<td>GPI-10 (8280102000)</td>
<td>FDB: BRAND ≠ NUTRESTORE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of sickle cell disease (SCD) and meet ALL of the following criteria?
   - The medication is prescribed by or given in consultation with a hematologist
   - The patient had a trial of or contraindication to hydroxyurea

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient between the ages of 5 to 17 years old?

   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #180 packets per 30 days.
   **Approval Text:** Renewal requires that the patient has maintained or experienced a reduction in acute complications of sickle-cell disease (SCD) (e.g., number of sickle cell crises, hospitalizations, ACS).

   If no, continue to #3.

3. Is the patient 18 years of age or older and meets ONE of the following criteria?
   - The patient had at least 2 sickle cell crises in the past year (A sickle cell crises is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered narcotic or parenterally administered ketorolac, the occurrence of chest syndrome, priapism, or splenic sequestration)
   - The patient is having sickle-cell associated symptoms (e.g., pain or anemia) which are interfering with activities of daily living
   - The patient has a history of or has recurrent acute chest syndrome (ACS)

   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #180 packets per 30 days.
   **Approval Text:** Renewal requires that the patient has maintained or experienced a reduction in acute complications of sickle-cell disease (SCD) (e.g., number of sickle cell crises, hospitalizations, ACS).

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
L-GLUTAMINE

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named L-GLUTAMINE (ENDARI) requires the following rule(s) be met for approval:
A. You have sickle cell disease (type of red blood cell disorder)
B. You are 5 years of age or older
C. The medication is prescribed by or given in consultation with a hematologist (blood doctor specialist)
D. The patient had a trial of or contraindication to hydroxyurea
E. **If you are 18 years of age or older, approval also requires ONE of the following:**
   1. You had at least 2 sickle cell crises in the past year (A sickle cell crises is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered given into the vein, narcotic or parenterally administered ketorolac, the occurrence of chest syndrome, priapism (prolonged erection of penis), or splenic sequestration [suppressing of spleen])
   2. You are having sickle-cell associated symptoms such as pain or anemia (your blood doesn’t have enough healthy red blood cells and you’re tired) which are interfering with activities of daily living
   3. You have a history of or have recurrent acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of sickle cell disease **AND** meet the following criterion?
   • The patient has maintained or experienced a reduction in acute complications of sickle-cell disease (SCD) (e.g., number of sickle cell crises, hospitalizations, ACS)

   If yes, approve for lifetime by GPID or GPI-10 with a quantity limit of #180 packets per 30 days.
   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named L-GLUTAMINE (Endari) requires the following rule(s) be met for renewal:
A. You have sickle cell disease (type of red blood cell disorder)
B. You have maintained or experienced a reduction in acute complications of sickle-cell disease such as number of sickle cell crises, hospitalizations, acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Endari

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/20
Created: 09/17
Client Approval: 02/20
P&T Approval: 01/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C with genotype 1, genotype 4, genotype 5, or genotype 6 **AND** meet the following criterion?
   - The patient is 3 years of age or older
     
     If yes, continue to #2.
     If no, continue to #24.

2. Does the patient have an HCV RNA level within the past 6 months?
   
   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet at least **ONE** of the following criteria?
   - The patient is concurrently taking any of the following medications: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), rosuvastatin, Olysio (simeprevir), Sovaldi (sofosbuvir), Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir), Aptivus (tipranavir/ritonavir), Mavyret (pibrentasvir/glecaprevir), Epclusa (velpatasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)
   - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
     
     If yes, do not approve.
     **DENIAL TEXT:** See the denial text at the end of the guideline.
     If no, continue to #4.

4. Does the patient have decompensated cirrhosis?
   
   If yes, continue to #18.
   If no, continue to #5.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?
   - The patient is a liver transplant recipient
   - The patient does not have cirrhosis OR has compensated cirrhosis (Child-Pugh A)

   If yes, continue to #22.
   If no, continue to #6.

6. Is this request for treatment of genotype 4, 5, or 6?

   If yes, continue to #7.
   If no, continue to #8.

7. Is the request for Harvoni 45mg/200mg pellets **AND** the patient is unable to swallow tablets?

   If yes, **approve 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

   If no, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**
   - 90mg/400mg tablet: #1 per day.
   - 45mg/200mg tablet: #1 per day.
   - 33.75mg/150mg pellets: #1 per day.

8. Is the patient treatment naive?

   If yes, continue to #9.
   If no, continue to #14.

9. Does the patient have cirrhosis **OR** is this request for treatment of a pediatric patient?

   If yes, continue to #10.
   If no, continue to #11.

10. Is the request for Harvoni 45mg/200mg pellets **AND** the patient is unable to swallow tablets?

    If yes, **approve 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.**

    If no, **approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:**
    - 90mg/400mg tablet: #1 per day.
    - 45mg/200mg tablet: #1 per day.
    - 33.75mg/150mg pellets: #1 per day.
GUIDELINES FOR USE (CONTINUED)

11. Does the patient meet ALL of the following criteria?
   • Genotype 1 HCV infection
   • No cirrhosis
   • No HIV co-infection
   • Pre-treatment HCV RNA level < 6 million IU/mL

   If yes, continue to #12.
   If no, continue to #13.

12. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

   If yes, approve 45mg/200mg pellets for 8 weeks by GPID or GPI-14 with a quantity limit of #2 per day.

   If no, approve for 8 weeks by GPID or GPI-14 for the requested strength as follows:
   • 90/400mg tablet: #1 per day.
   • 45/200mg tablet: #1 per day.
   • 33.75/150mg pellets: #1 per day.

13. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

   If yes, approve 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.

   If no, approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:
   • 90/400mg tablet: #1 per day.
   • 45/200mg tablet: #1 per day.
   • 33.75/150mg pellets: #1 per day.

14. Has the patient received prior treatment (e.g., treatment-experienced patient) for hepatitis C with 1) peginterferon and ribavirin, or 2) triple therapy with HCV protease inhibitor, peginterferon and ribavirin, or 3) is the patient without cirrhosis with a prior non-NS5A inhibitor, sofosbuvir-containing regimen?

   If yes, continue to #15.
   If no, continue to #24.

15. Does the patient have cirrhosis?

   If yes, continue to #16.
   If no, continue to #17.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

16. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

If yes, approve 45mg/200mg pellets for 24 weeks by GPID or GPI-14 with a quantity limit of #2 per day.

If no, approve for 24 weeks by GPID or GPI-14 for the requested strength as follows:
- 90/400mg tablet: #1 per day.
- 45/200mg tablet: #1 per day.
- 33.75/150mg pellets: #1 per day.

17. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

If yes, approve 45mg/200mg pellets for 12 weeks by GPID or GPI-14 with a quantity limit of #2 per day.

If no, approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:
- 90/400mg tablet: #1 per day.
- 45/200mg tablet: #1 per day.
- 33.75/150mg pellets: #1 per day.

18. Is the requested medication being used with ribavirin?

If yes, continue to #19.
If no, continue to #24.

19. Has the patient previously failed a Sovaldi (sofosbuvir)-containing regimen?

If yes, continue to #20.
If no, continue to #21.

20. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

If yes, approve 45/200mg pellets for 24 weeks by GPID or GPI-14 with a quantity limit of #2 per day.

If no, approve for 24 weeks by GPID or GPI-14 for the requested strength as follows:
- 90/400mg tablet: #1 per day.
- 45/200mg tablet: #1 per day.
- 33.75/150mg pellets: #1 per day.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

21. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

   If yes, approve 45/200mg pellets for 12 weeks by G PID or G PI-14 with a quantity limit of #2 per day.

   If no, approve for 12 weeks by G PID or G PI-14 for the requested strength as follows:
   - 90/400mg tablet: #1 per day.
   - 45/200mg tablet: #1 per day.
   - 33.75/150mg pellets: #1 per day.

22. Is the requested medication being used with ribavirin?

   If yes, continue to #23.
   If no, continue to #24.

23. Is the request for 45mg/200mg pellets AND the patient is unable to swallow tablets?

   If yes, approve 45mg/200mg pellets for 12 weeks by G PID or G PI-14 with a quantity limit of #2 per day.

   If no, approve for 12 weeks by G PID or G PI-14 for the requested strength as follows:
   - 90mg/400mg tablet: #1 per day.
   - 45mg/200mg tablet: #1 per day.
   - 33.75mg/150mg pellets: #1 per day.

24. Is the requested regimen recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment?

   If yes, approve as indicated per guidance in AASLD/IDSA.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEDIPASVIR/SOFOSBUVIR (Harvoni) requires the following rule(s) be met for approval:
A. The requested regimen is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment
B. You have chronic hepatitis C (type of liver inflammation)
C. You have genotype 1, genotype 4, genotype 5, or genotype 6 hepatitis C
D. You are 3 years of age or older
E. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
F. If you are treatment-experienced (previously treated) with no cirrhosis (liver damage) and genotype 1, previous treatment should include one of the following: 1) peginterferon and ribavirin, 2) triple therapy with HCV protease inhibitor (type of drug to treat hepatitis C), peginterferon and ribavirin, or 3) a prior non-NS5A inhibitor (type of drug to treat hepatitis C), sofosbuvir-containing regimen
G. If you are treatment-experienced (previously treated) with compensated cirrhosis (type of liver condition) and genotype 1, previous treatment should include either 1) peginterferon and ribavirin, or 2) triple therapy with HCV protease inhibitor (type of drug to treat hepatitis C), peginterferon and ribavirin
H. If you have decompensated cirrhosis (type of liver condition) or are post-liver transplant (without cirrhosis or with compensated cirrhosis), approval also requires:
   1. You will be using a ribavirin-containing regimen
I. If the request is for Harvoni 45mg/200 mg pellets, approval also requires:
   1. You are unable to swallow tablets

Harvoni will not be approved if you meet ANY of the following:
A. You are using any of the following medications concurrently (at the same time) while on Harvoni: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), rosuvastatin, Olysio (simeprevir), Sovaldi (sofosbuvir), Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir), Aptivus (tipranavir/ritonavir), Mavyret (pibrentasvir/glecaprevir), Epclusa (velpatasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)
B. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LEDIPASVIR/SOFOSBUVIR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Harvoni (sofosbuvir/ledipasvir).

REFERENCES
• Harvoni [Prescribing Information]. Foster City, CA: Gilead Sciences; March 2020.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 11/14
Commercial Effective: 10/01/23 Client Approval: 08/23 P&T Approval: 07/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of community-acquired bacterial pneumonia (CABP) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Infection is caused by any of the following susceptible microorganisms: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae*

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

   If yes, approve Xenleta 600mg tablet for one fill by GPID or GPI-14 with a quantity limit of #10 per 5 days.
   If no, continue to #3.

3. Have antimicrobial susceptibility tests been performed that meet ALL of the following criteria?
   - The results from the infection site culture indicate pathogenic organism(s) with resistance to at least TWO standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)
   - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to Xenleta

   If yes, approve Xenleta 600mg tablet for one fill by GPID or GPI-14 with a quantity limit of #10 per 5 days.
   If no, continue to #4.

4. Does the patient meet ALL of the following criteria?
   - Antimicrobial susceptibility results are unavailable
   - The patient has had a trial of or contraindication to at least TWO standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)

   If yes, approve Xenleta 600mg tablet for one fill by GPID or GPI-14 with a quantity limit of #10 per 5 days.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEFAMULIN (Xenleta) requires the following rule(s) be met for approval:
A. You have community-acquired bacterial pneumonia (type of lung infection)
B. You are 18 years of age or older
C. The infection is caused by any of the following susceptible microorganisms (bacteria that the drug can kill): Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae
D. You meet ONE of the following criteria:
   1. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
   2. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with a) resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), AND b) susceptibility to Xenleta
   3. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of at least TWO standard of care agents (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) for community-acquired bacterial pneumonia, unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xenleta.

REFERENCES
LENACAPAVIR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENACAPAVIR</td>
<td>SUNLENCA</td>
<td>4855</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(1210155520)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is treatment-experienced
   - The patient's HIV-1 is multidrug resistant and has failed current antiretroviral regimen due to resistance, intolerance, or safety considerations

If yes, approve for 12 months by GPID or GPI-14 for all dosage forms as follows:
- 300mg tablet: #5 per 6 months.
- 463.5mg/1.5mL vial: #3 mL per 6 months.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LENACAPAVIR (Sunlenca) requires the following rule(s) be met for approval:
A. You have human immunodeficiency virus type 1 (HIV-1: a type of immune disorder)
B. You are 18 years of age or older
C. You are treatment-experienced
D. You have a multidrug resistant (not responding to treatment) HIV-1 infection and have failed your current antiretroviral regimen (HIV treatment) due to resistance, intolerance (side effects), or safety considerations

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LENACAPAVIR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sunlenca.

REFERENCES
• Sunlenca [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; December 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/23
Created: 01/23
Client Approval: 05/23
P&T Approval: 01/22
LENALIDOMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENALIDOMIDE</td>
<td>REVLIMID, LENALIDOMIDE</td>
<td>33412</td>
<td>GPI-10</td>
<td>(9939405000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient 18 years of age or older?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a diagnosis of multiple myeloma (MM)?
   - If yes, continue to #3.
   - If no, continue to #5.

3. Will Revlimid (lenalidomide) be used as induction treatment for multiple myeloma (MM)?
   - If yes, **approve for 12 months by HICL or GPI-10 for #21 every 28 days.**
   - If no, continue to #4.

4. Will Revlimid (lenalidomide) be used as maintenance treatment for multiple myeloma (MM)?
   - If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient have a diagnosis of anemia due to a myelodysplastic syndrome (MDS) **AND** meet the following criterion?
   - The patient's myelodysplastic syndrome (MDS) is associated with a deletion 5q abnormality
   - If yes, **approve for 12 months by HICL or GPI-10 for #1 per day.**
   - If no, continue to #6.

6. Does the patient have a diagnosis of mantle cell lymphoma (MCL) **AND** meet the following criterion?
   - The patient has relapsed or progressed after two prior therapies, one of which included Velcade (bortezomib)
   - If yes, **approve for 12 months by HICL or GPI-10 for #21 per 28 days.**
   - If no, continue to #7.

**CONTINUED ON NEXT PAGE**
LENALIDOMIDE

GUIDELINES FOR USE (CONTINUED)

7. Does the patient have a diagnosis of follicular lymphoma (FL) and meet ALL of the following criteria?
   • The patient has previously been treated for follicular lymphoma (FL)
   • The requested medication is being taken in combination with a rituximab product

   If yes, approve for 12 months by HICL or GPI-10 for #21 per 28 days for 12 fills.
   If no, continue to #8.

8. Does the patient have a diagnosis of marginal zone lymphoma (MZL) and meet ALL the following criterion?
   • The patient has previously been treated for marginal zone lymphoma (MZL)
   • The requested medication is being taken in combination with a rituximab product

   If yes, approve for 12 months by HICL or GPI-10 for #21 per 28 days for 12 fills.
   If no, do not approve.

DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LENALIDOMIDE (Revlimid) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Multiple myeloma (a type of blood cancer)
   2. Anemia due to a myelodysplastic syndrome (a type of blood cancer)
   3. Mantle cell lymphoma (a type of blood cell)
   4. Follicular lymphoma (a type of blood cancer)
   5. Marginal zone lymphoma (a type of blood cancer)

B. You are 18 years of age or older

C. If you have anemia due to a myelodysplastic syndrome, approval also requires:
   1. You have a deletion 5q (type of gene) abnormality

D. If you have mantle cell lymphoma, approval also requires:
   1. You have relapsed or progressed (disease has returned or worsened) after two prior therapies, one of which included Velcade (bortezomib) (Note: Velcade may be covered under the medical benefit and/or require prior authorization).

E. If you have follicular lymphoma, approval also requires:
   1. You have previously been treated for follicular lymphoma
   2. The requested medication is being taken in combination with a rituximab product (type of cancer drug)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

F. If you have marginal zone lymphoma, approval also requires:
   1. You have previously been treated for marginal zone lymphoma
   2. The requested medication is being taken in combination with a rituximab product

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Revlimid.

REFERENCES
LENIOLISIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENIOLISIB PHOSPHATE</td>
<td>JOENJA</td>
<td>48803</td>
<td></td>
<td>GPI-10</td>
<td>(9939154060)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of activated phosphoinositide 3-kinase delta (PI3Kdelta) syndrome (APDS) AND meet the following criterion?
   - The patient is 12 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named LENIOLISIB (Joenja) requires the following rule(s) be met for approval:
   A. You have activated phosphoinositide 3-kinase delta (PI3Kdelta) syndrome (APDS: a type of mutation that impacts the immune system)
   B. You are 12 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Joenja.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A                Created: 04/23
Commercial Effective: 07/01/23      Client Approval: 05/23

P&T Approval: 04/23
1. Does the patient have a diagnosis of differentiated thyroid cancer (DTC) and meet ALL of the following criteria; *(NOTE: Differentiated thyroid cancer (DTC) can be classified as papillary (PTC), follicular (FTC), or Hurthle cell)?*
   - The thyroid cancer is locally recurrent or metastatic
   - The thyroid cancer is progressive
   - The thyroid cancer is refractory to radioactive iodine therapy

   If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**
   - For a daily dose of 10mg, approve for 30 blisters per 30 days.
   - For a daily dose of 14mg, approve for 60 blisters per 30 days.
   - For a daily dose of 20mg, approve for 60 blisters per 30 days.
   - For a daily dose of 24mg, approve for 90 blisters per 30 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of advanced renal cell cancer (RCC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Lenvima will be used as a first-line treatment
   - Lenvima will be used in combination with pembrolizumab (Keytruda)

   If yes, **approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:**
   - For a daily dose of 8mg, approve for 60 blisters per 30 days.
   - For a daily dose of 10mg, approve for 30 blisters per 30 days.
   - For a daily dose of 14mg, approve for 60 blisters per 30 days.
   - For a daily dose of 20mg, approve for 60 blisters per 30 days.

   If no, continue to #3.

**CONTINUED ON NEXT PAGE**
3 Does the patient have a diagnosis of advanced renal cell cancer (RCC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Lenvima will be used in combination with everolimus
   • The patient has tried one anti-angiogenic therapy (e.g., Sutent [sunitinib], Votrient [pazopanib], Inlyta [axitinib], Nexavar [sorafenib])

   If yes, approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:
   • For a daily dose of 8mg, approve for 60 blisters per 30 days.
   • For a daily dose of 10mg, approve for 30 blisters per 30 days.
   • For a daily dose of 14mg, approve for 60 blisters per 30 days.
   • For a daily dose of 18mg, approve for 90 blisters per 30 days.

   If no, continue to #4.

4 Does the patient have a diagnosis of unresectable hepatocellular carcinoma (HCC) AND meet the following criterion?
   • Lenvima is being used as a first-line treatment

   If yes, approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:
   • For a dose of 4mg every other day, approve for 15 blisters per 30 days.
   • For a daily dose of 4mg, approve for 30 blisters per 30 days.
   • For a daily dose of 8mg, approve for 60 blisters per 30 days.
   • For a daily dose of 12mg, approve for 90 blisters per 30 days.

   If no, continue to #5.

CONTINUED ON NEXT PAGE
5 Does the patient have a diagnosis of advanced endometrial carcinoma (EC) and meet ALL of the following criteria?
   - Lenvima is used in combination with pembrolizumab (Keytruda)
   - The patient does not have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers
   - The patient has experienced disease progression following prior systemic therapy
   - The patient is not a candidate for curative surgery or radiation

If yes, approve for 12 months by GPID or GPI-14 based on the following daily dose requirements:
   - For a daily dose of 8mg, approve for 60 blisters per 30 days.
   - For a daily dose of 10mg, approve for 30 blisters per 30 days.
   - For a daily dose of 14mg, approve for 60 blisters per 30 days.
   - For a daily dose of 20mg, approve for 60 blisters per 30 days.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LENVATINIB (Lenvima) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Differentiated thyroid cancer (DTC: cancer cells look/act like normal thyroid cells)
   2. Advanced renal cell cancer (RCC: kidney cancer)
   3. Unresectable hepatocellular carcinoma (HCC: liver cancer that cannot be removed by surgery)
   4. Advanced endometrial carcinoma (EC: type of cancer that starts in the uterus)

B. If you have differentiated thyroid cancer (DTC), approval also requires:
   1. Your thyroid cancer is locally recurrent or metastatic (cancer that has spread to other parts of the body)
   2. Your thyroid cancer is progressive (getting worse)
   3. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

C. If you have advanced renal cell cancer (RCC), approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. Lenvima will be used as first-line treatment in combination with pembrolizumab (Keytruda)
      b. Lenvima is used in combination with everolimus AND you have tried one prior anti-angiogenic therapy (treatment that stop tumors from growing their own blood vessels, such as Sutent [sunitinib], Votrient [pazopanib], Inlyta [axitinib], Nexavar [sorafenib])

D. If you have unresectable hepatocellular carcinoma (HCC), approval also requires:
   1. Lenvima is being used as a first-line treatment

E. If you have advanced endometrial carcinoma (EC), approval also requires:
   1. Lenvima is used in combination with pembrolizumab (Keytruda)
   2. You do not have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers (characteristics that help determine what type of cancer you have and what treatment options there are for it)
   3. You have experienced disease progression following prior systemic therapy (disease has worsened after previous therapy)
   4. You are not a candidate for curative surgery or radiation

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lenvima.

REFERENCES
GUIDELINES FOR USE

1. Is the request for prophylaxis of cytomegalovirus (CMV) infection and disease in an allogeneic hematopoietic stem cell transplant (HSCT) recipient and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is a CMV-seropositive recipient [R+] of an allogeneic HSCT
   - Prevymis will be initiated between Day 0 and Day 28 post-transplant (before or after engraftment)

   If yes, continue to #2.
   If no, continue to #4.

2. Will the patient receive Prevymis beyond 100 days post-transplant?

   If yes, continue to #3.

   If no, approve for 100 days by GPID or GPI-14 for all strengths as follows:
   - 240mg tablet: #1 per day.
   - 480mg tablet: #1 per day.
   - 240mg/12mL vial: #12mL per day.
   - 480mg/24mL vial: #24mL per day.

3. Is the patient at risk for late CMV infection and disease, AND will not receive Prevymis beyond 200 days post-transplant?

   If yes, approve for 200 days by GPID or GPI-14 for all strengths as follows:
   - 240mg tablet: #1 per day.
   - 480mg tablet: #1 per day.
   - 240mg/12mL vial: #12mL per day.
   - 480mg/24mL vial: #24mL per day.

   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
4. Is the request for prophylaxis of cytomegalovirus (CMV) disease in a kidney transplant recipient and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is a kidney transplant recipient at high risk (i.e., donor is CMV seropositive, recipient is CMV seronegative [D+/R-])
   - Prevymis will be initiated between Day 0 and Day 7 post-transplant
   - The patient will not receive Prevymis beyond 200 days post-transplant

   If yes, approve for 200 days by GPID or GPI-14 for all strengths as follows:
   - 240mg tablet: #1 per day.
   - 480mg tablet: #1 per day.
   - 240mg/12mL vial: #12mL per day.
   - 480mg/24mL vial: #24mL per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LETERMOVIR (Prevymis) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. Prophylaxis (prevention) of cytomegalovirus (CMV: a type of virus) infection and disease in an allogeneic hematopoietic stem cell transplant (HSCT: cells transplanted from a matching donor) recipient
   2. Prophylaxis of cytomegalovirus (CMV) disease in a kidney transplant recipient

B. If the request is for prophylaxis of cytomegalovirus infection and disease in an allogeneic hematopoietic stem cell transplant recipient, approval also requires:
   1. You are 18 years of age or older
   2. You are a CMV-seropositive recipient [R positive] of an allogeneic HSCT
   3. Prevymis will be started between Day 0 and Day 28 post-transplant (before or after engraftment [a type of transplant])
   4. You meet ONE of the following:
      a. You are NOT at risk for late CMV infection and disease, AND you will not receive Prevymis beyond 100 days post (after)-transplant
      b. You are at risk for late CMV infection and disease, AND you will not receive Prevymis beyond 200 days post (after)-transplant

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If the request is for prophylaxis of cytomegalovirus disease in a kidney transplant recipient, approval also requires:
   1. You are 18 years of age or older
   2. You are a kidney transplant recipient at high risk (donor is CMV seropositive, recipient is CMV seronegative [D positive/R negative])
   3. Prevymis will be started between Day 0 and Day 7 post (after)-transplant
   4. You will not receive Prevymis beyond 200 days post-transplant

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Prevymis.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the requested medication being used for gender dysphoria?
   If yes, approve for 12 months by HICL or GPI-10 and override quantity limits.
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced prostate cancer?
   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #2 kits per 28 days.
   If no, continue to #3.

3. Is the request for a female patient who has a diagnosis of central precocious puberty (CPP) and meets ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a pediatric endocrinologist
   • The patient has elevated levels of follicle-stimulating hormone (FSH) (level > 4.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
   • The patient is younger than 8 years of age at the onset of CPP
   • There is documentation of pubertal staging using the Tanner scale for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)
   If yes, approve for 12 months by GPID or GPI-14.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Is the request for a male patient who has a diagnosis of central precocious puberty (CPP) and meets ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a pediatric endocrinologist
   • The patient has elevated levels of follicle-stimulating hormone (FSH) (level >5.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
   • The patient is younger than 9 years of age at the onset of CPP
   • There is documentation of pubertal staging using the Tanner scale for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

If yes, approve for 12 months by GPID or GPI-14.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEUPROLIDE requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)
   3. Central precocious puberty (CPP: early sexual development in girls and boys)
B. If you are female and have central precocious puberty, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 8 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)
C. If you are male and have central precocious puberty, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 9 years of age when your condition started

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
LEUPROLIDE

INITIAL CRITERIA (CONTINUED)

5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

NOTE: For the diagnoses of gender dysphoria or advanced prostate cancer, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of central precocious puberty (CPP) and meet ALL of the following criteria?
   - The Tanner scale staging at initial diagnosis of CPP has stabilized or regressed during three separate medical visits in the previous year
   - The patient has not reached the actual age which corresponds to their current pubertal age

If yes, approve for 12 months by GPI-14.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEUPROLIDE requires the following rule(s) be met for renewal:
A. You have central precocious puberty (CPP: early sexual development in girls and boys)
B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
C. You have not reached the actual age which corresponds to your current pubertal age

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LEUPROLIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Leuprolide.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 09/18
Commercial Effective: 01/23/23 Client Approval: 01/23
P&T Approval: 04/22
## LEUPROLIDE-ELIGARD

### GUIDELINES FOR USE

1. Is the requested medication being used for gender dysphoria?

   If yes, **approve for 12 months by HICL or GPI-10 and override quantity limits.**
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced prostate cancer?

   If yes, **approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:**
   - 7.5mg: #1 per month.
   - 22.5mg: #1 per 3 months.
   - 30mg: #1 per 4 months.
   - 45mg: #1 per 6 months.

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **LEUPROLIDE-ELIGARD** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
LEUPROLIDE-ELIGARD

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Eligard.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/18
Commercial Effective: 01/23/23  Client Approval: 01/23  P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of hypertension and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - The patient had a trial of or contraindication to TWO generic dihydropyridine calcium channel blockers (e.g., amlodipine, felodipine, nicardipine)
   - The patient had a trial of or contraindication to TWO other antihypertensive agents in another class (e.g., hydrochlorothiazide, lisinopril, losartan)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEVAMLODIPINE (Conjupri) requires the following rule(s) be met for approval:
A. You have hypertension (high blood pressure)
B. You are 6 years of age or older
C. You have tried or have a contraindication (harmful for) to TWO generic dihydropyridine calcium channel blockers (such as amlodipine, felodipine, nicardipine)
D. You have tried or have a contraindication (harmful for) to TWO other antihypertensive agents in another class (such as hydrochlorothiazide, lisinopril, losartan)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Conjupri.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of partial-onset seizures and meet ALL of the following criteria?
   - The patient is 4 years of age or older
   - The patient is unable to swallow levetiracetam tablets
   - The patient had a trial of levetiracetam oral solution

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 250mg: #4 per day.
   - 500mg: #4 per day.
   - 750mg: #4 per day.
   - 1000mg: #2 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of myoclonic seizures in juvenile myoclonic epilepsy and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - Spritam will be used as adjunctive therapy
   - The patient is unable to swallow levetiracetam tablets
   - The patient had a trial of levetiracetam oral solution

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 250mg: #4 per day
   - 500mg: #4 per day
   - 750mg: #4 per day
   - 1000mg: #2 per day

   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Does the patient have a diagnosis of primary generalized tonic-clonic seizures and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - Spritam will be used as adjunctive therapy
   - The patient is unable to swallow levetiracetam tablets
   - The patient had a trial of levetiracetam oral solution

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 250mg: #4 per day.
   - 500mg: #4 per day.
   - 750mg: #4 per day.
   - 1000mg: #2 per day.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEVETIRACETAM (Spritam) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Partial-onset seizures (type of seizure)
   2. Myoclonic seizures in juvenile myoclonic epilepsy (type of seizure in childhood)
   3. Primary generalized tonic-clonic seizures (type of seizure)

B. If you have partial-onset seizures, approval also requires:
   1. You are 4 years of age or older
   2. You are unable to swallow levetiracetam tablets
   3. You had a trial of levetiracetam oral solution

C. If you have myoclonic seizures in juvenile myoclonic epilepsy, approval also requires:
   1. You are 12 years of age or older
   2. Spritam will be used as adjunctive (add-on) therapy
   3. You are unable to swallow levetiracetam tablets
   4. You had a trial of levetiracetam oral solution

D. If you have primary generalized tonic-clonic seizures, approval also requires:
   1. You are 6 years of age or older
   2. Spritam will be used as adjunctive (add-on) therapy
   3. You are unable to swallow levetiracetam tablets
   4. You had a trial of levetiracetam oral solution

(Denial text continued on next page)
Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Spritam.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/23
Created: 11/22
Client Approval: 02/23
P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Parkinson's disease and meet ALL of the following criteria?
   - Inbrija is being used for intermittent treatment of OFF episodes associated with Parkinson's disease
   - The patient is currently being treated with carbidopa/levodopa
   - Therapy is prescribed by or given in consultation with a neurologist
   - The patient is NOT currently taking more than 1600mg of levodopa per day
   - The physician has optimized drug therapy as evidenced by BOTH of the following:
     - Change in levodopa/carbidopa dosing strategy or formulation
     - Trial of or contraindication to at least TWO Parkinson's disease agents from TWO different classes of the following: dopamine agonist (e.g., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (e.g., selegiline, rasagiline), catechol-o-methyl transferase (COMT) inhibitors (e.g., entacapone, tolcapone), adenosine receptor antagonist A2A (e.g., istradefylline)

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #10 capsules per day.

   APPROVAL TEXT: Renewal requires that the patient has experienced improvement with motor fluctuations during OFF episodes with the use of Inbrija (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LEVODOPA INHALATION (Inbrija) requires the following rule(s) be met for approval:
   A. You have Parkinson's disease (a nerve system disorder that affects movement)
   B. Inbrija is being used for intermittent treatment of OFF episodes (times when you have symptoms return due to medication wearing off) associated with Parkinson's disease
   C. You are currently being treated with carbidopa/levodopa
   D. The requested medication is prescribed by or given in consultation with a neurologist (nerve doctor)

   (Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

E. You are NOT currently taking more than 1600mg of levodopa per day

F. Your doctor has optimized drug therapy as evidenced by BOTH of the following:
   1. Change in levodopa/carbidopa dosing strategy or formulation
   2. Trial of or contraindication to (medical reason why you cannot use) at least TWO Parkinson's agents from TWO different classes of the following: dopamine agonist (such as ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (such as entacapone, tolcapone), adenosine receptor antagonist A2A (such as istradefylline)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Parkinson's disease AND meet the following criterion?
   • The patient had improvement with motor fluctuations during OFF episodes with the use of Inbrija (e.g., improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #10 capsules per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LEVODOPA INHALATION (Inbrija) requires the following rule(s) be met for renewal approval:
   A. You have Parkinson's disease (a nerve system disorder that affects movement)
   B. You had improvement with motor fluctuations during OFF episodes (times when you have symptoms return due to medication wearing off) with the use of Inbrija. Improvements can be in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
LEVODOPA

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Inbrija.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 05/19
Client Approval: 04/20
P&T Approval: 10/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Cushing’s syndrome and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient is not a candidate for surgery or surgery has not been curative
   • The patient has tried or has a contraindication to oral ketoconazole

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #8 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEVOKETOCONAZOLE (Recorlev) requires the following rule(s) be met for approval:
A. You have Cushing’s syndrome (a type of hormone disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
D. You are not a candidate for surgery or surgery has not been curative
E. You have tried or have a contraindication (harmful for) to oral ketoconazole

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Cushing’s syndrome and meet ALL of the following criteria?
   • The patient continues to have improvement of Cushing’s syndrome (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
   • The patient maintains tolerability to Recorlev

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LEVOKETOCONAZOLE (Recorlev) requires the following rule(s) be met for renewal:
A. You have Cushing’s syndrome (a type of hormone disorder)
B. You continue to have improvement of Cushing’s syndrome (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
C. You continue to tolerate treatment with Recorlev

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Recorlev.

REFERENCES

GUIDELINES FOR USE

1. Does the patient have a diagnosis of congenital or acquired hypothyroidism?
   
   If yes, continue to #3.
   
   If no, continue to #2.

2. Does the patient have a diagnosis of thyrotropin-dependent well-differentiated thyroid cancer AND meet the following criterion?
   
   • The requested medication will be used as an adjunct to surgery and radioiodine therapy
   
   If yes, continue to #3.
   
   If no, do not approve.
   
   DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient meet ALL of the following criteria?
   
   • The patient had a trial and failure of Thyquidity
   
   • The patient had a trial and failure of generic levothyroxine tablets
   
   • The patient is unable to swallow levothyroxine tablets or capsules

   If yes, approve for 12 months by GPID or GPI-14.
   
   If no, do not approve.
   
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LEVOHYROXINE-ERMEZA requires the following rule(s) be met for approval:
   
   A. You have ONE of the following diagnoses:
      
      1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
      
      2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
   
   B. You had a trial and failure (drug did not work) of Thyquidity
   
   C. You had a trial and failure (drug did not work) of generic levothyroxine tablets
   
   D. You are unable to swallow levothyroxine tablets or capsules
   
   E. If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:
      
      1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

   (Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ermeza.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of congenital or acquired hypothyroidism?
   - If yes, continue to #3.
   - If no, continue to #2.

2. Does the patient have a diagnosis of thyrotropin-dependent well-differentiated thyroid cancer AND meet the following criterion?
   - The requested medication is being used as an adjunct to surgery and radioiodine therapy
   - If yes, continue to #3.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - The patient had a trial and failure of generic levothyroxine tablets
   - There is documentation of rationale for not using generic levothyroxine tablets
   - If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.
   - If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **LEVOTHYROXINE-TIROSINT** requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
   2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
B. You are 6 years of age or older
C. You had a trial and failure (drug did not work) of generic levothyroxine tablets
D. There is documentation of rationale (reason) for not using generic levothyroxine tablets
E. If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:
   1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)
   **(Denial text continued on next page)**

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tirosint.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 07/21
Commercial Effective: 01/01/23  Client Approval: 12/22  P&T Approval: 10/21
### GUIDELINES FOR USE

1. Does the patient have a diagnosis of congenital or acquired hypothyroidism?
   - If yes, continue to #3.
   - If no, continue to #2.

4. Does the patient have a diagnosis of thyrotropin-dependent well-differentiated thyroid cancer AND meet the following criterion?
   - The requested medication is being used as an adjunct to surgery and radioiodine therapy
   - If yes, continue to #3.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Does the patient meet ALL of the following criteria?
   - The patient had a trial and failure of Thyquidity
   - The patient had a trial and failure of or contraindication to generic levothyroxine tablets
   - There is documentation of rationale for not using Thyquidity and generic levothyroxine tablets

   If yes, approve for 12 months by GPIID or GPI-14 with a quantity limit of #2mL per day.
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **LEVOTHYROXINE-TIROSINT-SOL** requires the following rule(s) be met for approval:

   **A.** You have ONE of the following diagnoses:
      1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
      2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
   **B.** You had a trial and failure (drug did not work) of Thyquidity
   **C.** You had a trial and failure (drug did not work) of or contraindication (harmful for) to generic levothyroxine tablets
   **D.** There is documentation of rationale (reason) for not using Thyquidity and generic levothyroxine tablets

   **(Denial text continued on the next page)**

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

E. If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:
   1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tirosint-Sol.

REFERENCES
GUIDELINES FOR USE

1. Is the requested medication being used to mitigate opioid withdrawal symptoms to facilitate abrupt opioid discontinuation and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is in a setting with close patient monitoring for a duration of Lucemyra (lofexidine) treatment not to exceed 18 days
   - Treatment with Lucemyra is being administered as part of an opioid discontinuation plan that includes other withdrawal symptom management medications (e.g., stool softeners, sleep aids) and psychosocial support is in place to help prevent relapse

If yes, approve for 1 fill by HICL or GPI-10 with a quantity limit of #264 per 18 days.
If no, do not approve.

DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline name LOFEXIDINE (Lucemyra) requires the following rule(s) be met for approval:
A. Lucemyra is being used to lessen opioid withdrawal symptoms to help abrupt opioid discontinuation
B. You are 18 years of age or older
C. You are in a setting with close patient monitoring of Lucemyra (lofexidine) treatment for a maximum of 18 days
D. Treatment with Lucemyra is being administered as part of an opioid discontinuation plan that includes other withdrawal symptom management medications (such as stool softeners, sleep aids) and psychosocial support is in place to help prevent relapse

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LOFEXIDINE

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Lucemyra.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 08/18
Client Approval: 04/20
P&T Approval: 07/18
GUIDELINES FOR USE

1. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH) as determined by meeting ONE of the following criteria?
   - Simon Broome diagnostic criteria (definite)
   - Dutch Lipid Network criteria with a score of at least 8
   - A clinical diagnosis based on a history of an untreated LDL-cholesterol level greater than 500 mg/dL, in combination with either:
     (1) xanthoma before 10 years of age OR
     (2) evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - The requested medication is prescribed by or given in consultation with a cardiologist, endocrinologist, or lipidologist
   - The patient has a LDL-cholesterol level greater than or equal to 70 mg/dL

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet ONE of the following criteria?
   - The patient has been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosvastatin 20-40 mg daily) for a duration of at least 8 weeks
   - The patient has been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given that the patient cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosvastatin 20-40 mg daily)

   If yes, continue to #4.
   If no, continue to #5.

4. Will the patient continue statin treatment as described above in combination with Juxtapid?

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
5. Does the patient meet ONE of the following criteria?
   • The patient has an absolute contraindication to statin therapy (e.g., active decompensated liver disease, nursing female, pregnancy or plans to become pregnant, hypersensitivity reaction)
   • The patient has complete statin intolerance as defined by severe and intolerable adverse effects (e.g., creatine kinase elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis, severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group) that have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin

   If yes, continue to #6.
   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet ONE of the following criteria?
   • The patient has had a previous trial of Repatha (evolocumab)
   • The patient lacks functioning LDL receptors

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • Juxtapid 5mg: #45 per 30 days.
   • Juxtapid 10mg: #30 per 30 days.
   • Juxtapid 20mg: #90 per 30 days.
   • Juxtapid 30mg: #90 per 30 days.
   • Juxtapid 40mg: #30 per 30 days.
   • Juxtapid 60mg: #30 per 30 days.

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **LOMITAPIDE (Juxtapid)** requires the following rule(s) be met for approval:
A. You have homozygous familial hypercholesterolemia (type of inherited high cholesterol)

( Denial text continued on next page )

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. Your diagnosis of homozygous familial hypercholesterolemia (type of inherited high cholesterol) was determined by meeting ONE of the following criteria:
   1. Simon Broome diagnostic criteria
   2. Dutch Lipid Network criteria with a score of at least 8
   3. A clinical diagnosis based on a history of an untreated LDL (low density lipoprotein) - cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma (condition where fatty growth develops under the skin) before 10 years of age OR (2) evidence of heterozygous familial hypercholesterolemia (type of inherited high cholesterol) in both parents

C. The requested medication is prescribed by or given in consultation with a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management doctor)

D. You have an LDL (low density lipoprotein) - cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated statin (drug used for cholesterol) treatment

E. You previously had a trial of Repatha (evolocumab) unless you do not have functional LDL (low density lipoprotein) receptors

F. **If you are statin tolerant, approval also requires:**
   1. You meet ONE of the following criteria:
      a. You have been taking a high-intensity statin (atorvastatin 40-80 mg daily, rosvastatin 20-40 mg daily) for a duration of at least 8 weeks
      b. You have been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given you cannot tolerate a high-intensity statin (atorvastatin 40-80 mg daily, rosvastatin 20-40 mg daily)
   2. You will continue statin (drug used for cholesterol) treatment in combination with Juxtapid

G. **If you are statin intolerant, approval also requires ONE of the following:**
   1. You have an absolute contraindication to (medical reason why you cannot use) statin therapy (drug used for cholesterol) such as active decompensated liver disease (you have symptoms related to liver damage), nursing female, pregnancy or plans to become pregnant, or hypersensitivity (allergic) reaction
   2. You have complete statin intolerance as defined by severe and intolerable adverse effects such as creatine kinase elevation (a measurement of how much muscle damage you have) greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (muscle breakdown), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group. These must have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
LOMITAPIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Juxtapid.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Client Approval: 04/20
P&T Approval: 04/18

Created: 01/13
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Hodgkin’s lymphoma?
   
   If yes, approve for 12 months by HICL or GPI-10.
   
   If no, continue to #2.

2. Does the patient have a diagnosis of primary and metastatic brain tumors AND meet the following criterion?
   
   - The patient has previously received appropriate surgical and/or radiotherapeutic procedures

   If yes, continue to #3.
   
   If no, do not approve.
   
   DENIAL TEXT: See the denial text at the end of the guideline.

3. Will the patient be using this medication as a part of the PCV regimen (procarbazine, lomustine, and vincristine)?

   If yes, approve for 12 months by HICL or GPI-10.
   
   If no, do not approve.
   
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LOMUSTINE (Gleostine) requires the following rule(s) be met for approval:
   
   A. You have ONE of the following diagnoses:
    1. Hodgkin’s lymphoma (type of immune system cancer)
    2. Primary and metastatic brain tumors (tumor that has spread to other parts of body)
   
   B. **If you have primary and metastatic brain tumors, approval also requires:**
    1. You have previously received appropriate surgical and/or radiotherapeutic procedures
    2. The requested medication will be used as a part of the PCV regimen (procarbazine, lomustine, and vincristine)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
LOMUSTINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gleostine.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 02/18
Client Approval: 11/22
P&T Approval: 01/18
GUIDELINES FOR USE

1. Is the patient 1 year of age or older AND meets the following criterion?
   • The patient has a body surface area (BSA) of 0.39m² or above

    If yes, continue to #2.
    If no, do not approve.
    DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient have a diagnosis of Hutchinson-Gilford progeria syndrome (HGPS)?

    If yes, approve for 12 months by HICL or GPI-10.
    If no, continue to #3.

3. Does the patient have a diagnosis of processing-deficient progeroid laminopathies with ONE of the following?
   • Heterozygous LMNA mutation with progerin-like protein accumulation
   • Homozygous or compound heterozygous ZMPSTE24 mutations

    If yes, approve for 12 months by HICL or GPI-10.
    If no, do not approve.
    DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LONAFARNIB (Zokinvy) requires the following rule(s) be met for approval:
A. You have Hutchinson-Gilford progeria syndrome (HGPS) OR processing-deficient progeroid laminopathies (rare genetic disorders that cause premature aging in children)
B. You are 1 year of age or older
C. You have a body surface area (BSA) of 0.39 meters squared or more
D. If you have processing-deficient progeroid laminopathies, approval also requires you have ONE of the following:
   1. Heterozygous LMNA (type of gene) mutation with progerin-like protein accumulation
   2. Homozygous or compound heterozygous ZMPSTE24 (type of gene) mutations

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LONAFARNIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zokinvy.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/21
Created: 02/21
Client Approval: 02/21
P&T Approval: 01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the requested medication being used for ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature (ISS)

   If yes, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.
   If no, continue to #2.

2. Does the patient have a diagnosis of growth failure due to inadequate secretion of endogenous growth hormone and meet ALL of the following criteria?
   - The patient is 1 year of age or older AND weighs at least 11.5kg
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient meets at least ONE of following criteria for short stature:
     - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     - Height velocity less than the 25th percentile for age
     - Documented low peak growth hormone (less than 10 ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for same age and gender

   If yes, approve for 12 months for all strengths by GPID or GPI-14 with the following quantity limits:
   - Skytrofa 3mg, 3.6mg, 4.3mg, 5.2mg, 6.3mg, 13.3mg: #1 cartridge per week.
   - Skytrofa 7.6mg, 9.1mg, 11mg: #2 cartridges per week.

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LONAPEGSOMATROPIN-TCGD (Skytrofa) requires the following rule(s) be met for approval:
A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
B. Skytrofa is not being used for the treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (ISS: a type of growth condition)
C. You are 1 year of age or older and weigh at least 11.5 kg
D. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
E. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
F. You meet at least ONE of the following criteria for short stature:
   1. Your height is at least 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
   2. Your height velocity is less than the 25th percentile for your age
   3. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) at least 2 standard deviations below the mean for your age and gender

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the requested medication being used for ANY of the following?
   • Athletic enhancement
   • Anti-aging purposes
   • Idiopathic short stature (ISS)

   If yes, do not approve.  
   DENIAL TEXT: See the renewal denial text at the end of the guideline.
   If no, continue to #2.

CONTINUED ON NEXT PAGE
2. Does the patient have a diagnosis of growth failure due to inadequate secretion of endogenous growth hormone and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient’s epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand OR the patient has not completed prepubertal growth)
   - The patient meets ONE of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients that are near terminal phase of puberty

If yes, approve for 12 months for all strengths by GPID or GPI-14 with the following quantity limits:
- Skytrofa 3mg, 3.6mg, 4.3mg, 5.2mg, 6.3mg, 13.3mg: #1 cartridge per week.
- Skytrofa 7.6mg, 9.1mg, 11mg: #2 cartridges per week.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LONAPEG SOMATROPIN-TCGD (Skytrofa) requires the following rule(s) be met for renewal:
A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
B. Skytrofa is not being used for the treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (ISS: a type of growth condition)
C. Therapy is prescribed by or given in consultation with an endocrinologist (a type of hormone doctor)
D. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
E. You meet ONE of the following:
   1. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
   2. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Skytrofa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective:11/01/21
Created: 10/21
Client Approval: 10/21
P&T Approval: 01/22
LORCASERIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>LORCASERIN HCL</td>
<td>BELVIQ,</td>
<td>40373</td>
<td>GPI-10</td>
<td>(6125655010)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Do not approve requests for Belviq or Belviq XR.

(NOTE: Safety concerns [increased risk of cancer] have prompted market withdrawal of Belviq and Belviq XR.)

RATIONALE

For further information, please refer to the prescribing information and/or drug monograph for Belviq/Belviq XR.

FDA requested removal from the market as Belviq/Belviq XR displayed an increased risk of cancer in a safety trial. Manufacturer complied with FDA request and product has been discontinued.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/21
Created: 01/13
Client Approval: 08/21
P&T Approval: 04/21
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient’s tumors are anaplastic lymphoma kinase (ALK) - positive as detected by an FDA-approved test

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • Lorbrena 25mg: #3 per day.
   • Lorbrena 100mg: #1 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LORLATINIB (Lorbrena) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. Your tumors are anaplastic lymphoma kinase (ALK: type of enzyme) - positive which is shown by an FDA (Federal and Drug Administration) approved test

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LORLATINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lorbrena.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/21
Created: 03/19
Client Approval: 03/21
P&T Approval: 04/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of dry eye disease AND meet the following criterion?
   • The patient had a trial of or contraindication to one generic loteprednol ophthalmic AND one non-loteprednol ophthalmic corticosteroid (e.g., fluorometholone, dexamethasone, prednisolone)

If yes, approve for 2 weeks by GPID or GPI-14 with a quantity limit of #8.3mL (1 bottle) per 14 days.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LOTEPRENDNOL (Eysuvis) requires the following rule(s) be met for approval:
A. You have dry eye disease
B. You previously tried one generic loteprednol ophthalmic product AND one non-loteprednol ophthalmic (eye) corticosteroid (such as fluorometholone, dexamethasone, prednisolone) unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Eysuvis.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

1. Does the patient have a diagnosis of cystic fibrosis (CF) and meet ALL of the following criteria?
   - The patient is 1 year of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist or CF expert
   - There is documentation that the patient is homozygous for the F508del-CFTR gene mutation

   If yes, approve by GPID or GPI-14 for 24 weeks for all of the formulations and strengths with the following quantity limits:
   - 75-94 mg granule packets: #2 per day.
   - 100-125 mg granule packets: #2 per day.
   - 150-188 mg granule packets: #2 per day.
   - 100-125 mg tablets: #4 per day.
   - 200-125 mg tablets: #4 per day.

   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named LUMACAFTOR-IVACAFTOR (Orkambi) requires the following rule(s) be met for approval:
   A. You have cystic fibrosis (a type of lung disorder)
   B. You are 1 year of age or older
   C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
   D. There is documentation that you are homozygous (have 2 copies of the same gene) for the F508del-CFTR (type of gene: cystic fibrosis transmembrane conductance regulator) mutation

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status as shown by ONE of the following?
   - The patient has improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume)
   - The patient has improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
   - The patient has experienced a reduction in rate of pulmonary exacerbations

If yes, approve by GPID or GPI-14 for lifetime for all of the formulations and strengths with the following quantity limits:
   - 75-94 mg granule packets: #2 per day.
   - 100-125 mg granule packets: #2 per day.
   - 150-188 mg granule packets: #2 per day.
   - 100-125 mg tablets: #4 per day.
   - 200-125 mg tablets: #4 per day.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LUMACAFTOR-IVACAFTOR (Orkambi) requires the following rule(s) be met for renewal:
A. You have cystic fibrosis (a type of lung disorder)
B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
   1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
   2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
   3. You have experienced a reduction in rate of pulmonary exacerbations (worsening in lung condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LUMACAFTOR-IVACAFTOR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orkambi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 07/15
Client Approval: 09/22
P&T Approval: 10/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of thrombocytopenia and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a hematologist, gastroenterologist, hepatologist, immunologist, endocrinologist, or surgeon
   • The patient has chronic liver disease
   • The patient is scheduled to undergo a procedure 8 to 14 days following initiation of Mulpleta (lusutrombopag) therapy
   • The patient has a platelet count of less than 50x10^9 cells/L measured within the last 30 days
   • The patient is not receiving other thrombopoietin receptor agonist therapy (e.g., avatrombopag, romiplostim, eltrombopag)

If yes, approve for 1 fill by HICL or GPI-10 with a quantity limit of #7 tablets.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named LUSUTROMBOPAG (Mulpleta) requires the following rule(s) be met for approval:
A. You have thrombocytopenia (a type of blood disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), gastroenterologist (a doctor who treats digestive conditions), hepatologist (a type of liver doctor), immunologist (a type of immune system doctor), endocrinologist (a type of hormone doctor), or surgeon
D. You have chronic liver disease
E. You are scheduled to undergo a procedure 8 to 14 days after starting Mulpleta (lusutrombopag) therapy
F. You have a platelet count of less than 50x10^9 cells/L measured within the last 30 days
G. You are not receiving other thrombopoietin receptor agonist therapy, such as avatrombopag, romiplostim, eltrombopag

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
LUSUTROMBOPAG

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mulpleta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 11/18
Client Approval: 02/22
P&T Approval: 01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1) and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a cardiologist or pulmonologist

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   • Mean pulmonary artery pressure (PAP) of greater than 20 mmHg
   • Pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg
   • Pulmonary vascular resistance (PVR) of greater than 2 Wood units

   If yes, approve for 12 months by HICL or GPI-10 for #1 per day.
   If no, do not approve.
   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MACITENTAN (Opsumit) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

(Initial denial text continued on next page)
MACITENTAN

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1)?

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient has remained stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class has improved or remained stable

   If yes, approve for 12 months by HICL or GPI-10 for #1 per day.
   If no, do not approve.
   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MACITENTAN (Opsumit) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
MACITENTAN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Opsumit.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/22
Client Approval: 05/23
P&T Approval: 04/23
MARALIXIBAT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>MARALIXIBAT CHLORIDE</td>
<td>LIVMARLI</td>
<td>47604</td>
<td>GPI-10</td>
<td>(5235005010)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of cholestatic pruritus associated with Alagille syndrome (ALGS) AND meet the following criterion?
   - The patient is 3 months of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3mL per day. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MARALIXIBAT (Livmarli) requires the following rule(s) be met for approval:
A. You have cholestatic pruritus (a type of skin condition) associated with Alagille syndrome (ALGS: a type of genetic disorder)
B. You are 3 months of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Livmarli.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/23
Created: 10/21
Client Approval: 03/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of post-transplant cytomegalovirus (CMV) infection and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • The patient is refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet

If yes, approve for 12 months by HICL or GPl-10 with a quantity limit of #4 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MARIBAVIR (Livtencity) requires the following rule(s) be met for approval:
A. You have a post-transplant cytomegalovirus (CMV) infection (a type of viral infection)
B. You are 12 years of age or older
C. You are refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Livtencity.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 12/21
Commercial Effective: 01/01/22 Client Approval: 12/21 P&T Approval: 10/21
GUARDIAN FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of symptomatic obstructive hypertrophic cardiomyopathy (HCM) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has New York Heart Association (NYHA) class II-III symptoms
   - The patient has a left ventricular outflow track (LVOT) gradient of 50 mmHg or higher
   - Therapy is prescribed by or in consultation with a cardiologist
   - The patient had a trial of or contraindication to beta-blockers (e.g., metoprolol, carvedilol) AND non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem)

If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MAVACAMTEN (Camzyos) requires the following rule(s) be met for approval:
A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
B. You are 18 years of age or older
C. You have New York Heart Association (NYHA) class II-III (classification system for heart failure) symptoms
D. You have a left ventricular outflow track gradient (a predictor of heart failure and cardiovascular death) of 50 mmHg or higher
E. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor)
F. You had a trial of or contraindication (harmful for) to beta-blockers (such as metoprolol, carvedilol) AND non-dihydropyridine calcium channel blockers (such as verapamil, diltiazem)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of symptomatic obstructive hypertrophic cardiomyopathy (HCM) AND meet the following criterion?
   • The patient has experienced continued clinical benefit (e.g., reduction of symptoms, NYHA classification improvement)

   If yes, approve for 12 months by HICL or GPI-10 with quantity limit of #1 per day. If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named MAVACMTEN (Camzyos) requires the following rule(s) be met for renewal:
   A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
   B. You have experienced continued clinical benefit (such as reduction of symptoms, NYHA classification improvement)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Camzyos.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Enterobius vermicularis (pinworm) infection and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • The patient had a trial of or contraindication to pyrantel pamoate (OTC)

   If yes, approve for 1 month by GPID or GPI-14 with a quantity limit of #2.
   If no, continue to #2.

2. Does the patient have a diagnosis of Trichuris trichiura (whipworm) or Ascaris lumbricoides (common roundworm) infection and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • There is documentation (e.g., chart notes, lab results, diagnostic test results) confirming the diagnosis of Trichuris trichiura (whipworm) or Ascaris lumbricoides (common roundworm) infection
   • The patient had a trial of or contraindication to albendazole (Albenza)

   If yes, approve for 1 month by GPID or GPI-14 with a quantity limit of #6.
   If no, continue to #3.

3. Does the patient have a diagnosis of Ancylostoma duodenale (common hookworm) or Necator americanus (American hookworm) infection and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • There is documentation (e.g., chart notes, lab results, diagnostic test results) confirming the diagnosis of Ancylostoma duodenale (common hookworm) or Necator americanus (American hookworm) infection
   • The patient had a trial of or contraindication to albendazole (Albenza) or pyrantel pamoate (OTC)

   If yes, approve for 1 month by GPID or GPI-14 with a quantity limit of #6.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MEBENDAZOLE (Emverm) requires the following rule(s) be met for approval:

A. You have a diagnosis of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), or Necator americanus (American hookworm) infection

B. You are 2 years of age or older

C. If you have Enterobius vermicularis (pinworm) infection, approval also requires:
   1. You had a trial of or contraindication (harmful for) to over-the-counter (OTC) pyrantel pamoate

D. If you have Trichuris trichiura (whipworm) or Ascaris lumbricoides (common roundworm) infection, approval also requires:
   1. There is documentation (such as chart notes, lab results, diagnostic test results) confirming your diagnosis of Trichuris trichiura (whipworm) or Ascaris lumbricoides (common roundworm) infection
   2. You had a trial of or contraindication (harmful for) to albendazole (Albenza)

E. If you have Ancylostoma duodenale (common hookworm) or Necator americanus (American hookworm) infection, approval also requires:
   1. There is documentation (such as chart notes, lab results, diagnostic test results) confirming your diagnosis of Ancylostoma duodenale (common hookworm) or Necator americanus (American hookworm) infection
   2. You had a trial of or contraindication (harmful for) to albendazole (Albenza) OR over-the-counter (OTC) pyrantel pamoate

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Emverm.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 09/11/23
Created: 03/16
Client Approval: 08/23
P&T Approval: 07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
MECAMYLAMINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>MECAMYLAMINE HCL</td>
<td>VECAMYL</td>
<td></td>
<td>1471</td>
<td>GPI-10</td>
<td>(3660002010)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of moderately severe to severe essential (or primary) hypertension or uncomplicated malignant hypertension?

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient tried or does the patient have a contraindication to three of the following: angiotensin converting enzyme (ACE) inhibitor or ACE-I combination, angiotensin receptor blocker (ARB) or ARB combination, Beta Blocker, or Calcium Channel Blocker?

   **PAC NOTE:** These drugs include: benazepril, benazepril-HCTZ, captopril, captopril-HCTZ, enalapril, enalapril-HCTZ, fosinopril, fosinopril-HCTZ, lisinopril, lisinopril-HCTZ, quinapril, ramipril, moexipril, moexipril-HCTZ, perindopril erbumine, quinapril, quinapril-HCTZ, trandolapril, trandolapril/verapamil, losartan, losartan-HCTZ, irbesartan, irbesartan-HCTZ, olmesartan, olmesartan-HCTZ, olmesartan-amlodipine-HCTZ, valsartan, valsartan-HCTZ, diltiazem HCL, diltiazem sustained release (generics only), verapamil, verapamil sustained release (generics only), atenolol, atenolol-chlorthalidone, bisoprolol, bisoprolol-HCTZ, carvedilol, metoprolol tartrate, nadolol, acebutolol, betaxolol, labetalol, metoprolol succinate, metoprolol-HCTZ, pindolol, propranolol, propranolol-HCTZ, sotalol, timolol maleate, or nebivolol.

   If yes, approve for 12 months by GPI-D or GPI-10.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MECAMYLAMINE HYDROCHLORIDE (Vecamyl) requires the following rule(s) be met for approval:
A. The requested medication will be used for the management of moderately severe to severe essential (or primary) hypertension or in uncomplicated cases of malignant hypertension
B. You have had a trial of at least three of the following, unless there is a medical reason why you cannot (contraindication): angiotensin converting enzyme inhibitor (ACE-I) or ACE-I combination, angiotensin receptor blocker (ARB) or ARB combination, Beta Blocker, or Calcium Channel Blocker, such as benazepril, benazepril-HCTZ, captopril, captopril-HCTZ, enalapril, enalapril-HCTZ, fosinopril, fosinopril-HCTZ, lisinopril, lisinopril-HCTZ, quinapril, ramipril, moexipril, moexipril-HCTZ, perindopril erbumine, quinapril, quinapril-HCTZ, trandolapril, trandolapril/verapamil, losartan, losartan-HCTZ, irbesartan, irbesartan-HCTZ, olmesartan, olmesartan-HCTZ, olmesartan-amlodipine-HCTZ, valsartan, valsartan-HCTZ, diltiazem HCL, diltiazem sustained release (generics only), verapamil, verapamil sustained release (generics only), atenolol, atenolol-chlorthalidone, bisoprolol, bisoprolol-HCTZ, carvedilol, metoprolol tartrate, nadolol, acebutolol, betaxolol, labetalol, metoprolol succinate, metoprolol-HCTZ, pindolol, propranolol, propranolol-HCTZ, sotalol, timolol maleate, or nebivolol.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vecamyl.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 05/13
Client Approval: 04/20
P&T Approval: 08/13
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have ONE of the following diagnoses?
   - Severe primary IGF-1 deficiency
   - Growth hormone (GH) gene deletion (not growth hormone-deficient short stature) AND have neutralizing antibodies to GH

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - The patient is 2 years to less than 18 years of age
   - The requested medication is prescribed by or given in consultation with a pediatric endocrinologist or a pediatric nephrologist
   - Height standard deviation score ≤ -3.0
   - Basal IGF-1 standard deviation score ≤ -3.0
   - Normal or elevated growth hormone (GH), [serum growth hormone level of ≥ 10ngm/mL to at least two stimuli (insulin, levodopa, arginine, clonidine, or glucagon)]
   - The patient’s epiphyses (bone growth plates) open (as confirmed by radiograph of the wrist and hand)

   If yes, approve by HICL or GPI-10 for 6 months up to a maximum dose of 9 vials per month.
   If no, do not approve.
   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **MECASERMIN (Increlex)** requires the following rule(s) be met for approval:
   A. You have ONE of the following diagnoses:
      1. Severe primary insulin growth-like factor 1 deficiency (IGF-1: hormone levels that promote normal bone and tissue growth and development are extremely low or undetectable in the blood)
      2. Growth hormone gene deletion (not growth hormone-deficient short stature) and developed neutralizing antibodies to growth hormone

   *(Initial denial text continued on the next page)*

**CONTINUED ON NEXT PAGE**
MECASERMIN

INITIAL CRITERIA (CONTINUED)

B. You are 2 years to less than 18 years of age
C. The requested medication is prescribed by or given in consultation with a pediatric endocrinologist (hormone doctor) or pediatric nephrologist (kidney doctor)
D. You have a height standard deviation score less than or equal to -3.0, basal IGF-1 (insulin growth-like factor 1) standard deviation score less than or equal to -3.0, and normal or elevated growth hormone [serum growth hormone level of greater than or equal to 10ngm/mL to at least 2 stimuli (insulin, levodopa, arginine, clonidine or glucagon)]
E. Your bone growth plates (epiphyses) are open (as confirmed by radiograph of the wrist and hand)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient shown a response in the first 6 months of IGF-1 therapy (i.e., increase in height, increase in height velocity)?

   If yes, approve by HICL or GPI-10 for 12 months up to a maximum dose of 9 vials per month.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MECASERMIN (Increlex) requires the following rule(s) be met for renewal:
A. You have shown a response in the first 6 months of insulin growth-like factor-1 (IGF-1) therapy (increase in height, increase in height velocity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
MECASERMIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph forIncrelex.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A      Created: 02/06
Commercial Effective: 04/01/20 Client Approval: 03/20      P&T Approval: 04/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCLs)?

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Has the patient tried prior skin-directed therapy (such as corticosteroids, carmustine, topical retinoids [Targretin, Tazorac], imiquimod, or local radiation therapy)?

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named MECHLORETHAMINE (Valchlor) requires the following rule(s) be met for approval:
   A. You have stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma (type of immune system cancer)
   B. You had prior skin-directed therapy such as corticosteroids, carmustine, topical retinoids (Targretin, Tazorac), imiquimod, or local radiation therapy

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Valchlor.

REFERENCES
MEPOLIZUMAB

Generic  Brand  HICL  GCN  Medi-Span  Exception/Other
MEPOLIZUMAB  NUCALA  42775  GCN  Medi-Span  GPI-10 (4460405500)

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet ALL of the following criteria?
   • The patient is 6 years of age or older
   • Therapy is prescribed by or in consultation with a physician specializing in pulmonary medicine or allergy medicine
   • The patient has a documented blood eosinophil level of at least 150 cells/mcL within the past 12 months
   • The patient is concurrently treated with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (ICS, e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist [e.g., formoterol, salmeterol], a long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline, or oral corticosteroid [e.g., prednisone])
   • Nucala will NOT be used concurrently with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL-5 biologic (e.g., Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

   If yes, continue to #2.
   If no, continue to #4.

2. Does the patient meet ONE of the following criteria?
   • The patient has experienced at least ONE asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months
   • The patient has experienced at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months

   If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks?
   - Daytime asthma symptoms more than twice per week
   - Any night waking due to asthma
   - Use of a short-acting inhaled beta2-agonist reliever (SABA, e.g., albuterol) for symptoms more than twice per week
   - Any activity limitation due to asthma

   If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an otolaryngologist or allergist/immunologist
   - Nucala will be used as add-on maintenance treatment
   - The patient had a 90-day trial of ONE intranasal corticosteroid (e.g., mometasone, fluticasone, beclomethasone)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 vials/syringes per 28 days.

   If no, continue to #6.

CONTINUED ON NEXT PAGE
MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

6. Does the patient have a diagnosis of hypereosinophilic syndrome (HES) and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient has had HES for 6 months or more without an identifiable non-hematologic secondary cause

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 vials/syringes per 28 days.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MEPOLIZUMAB (Nucala) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Severe asthma with an eosinophilic phenotype (type of lung condition with inflammation)
   2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus passages with small growths in the nose)
   3. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (inflammation of blood vessels with high levels of a type of white blood cell)
   4. Hypereosinophilic syndrome (HES) (a rare blood disorder)

B. If you have severe asthma with an eosinophilic phenotype, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/breathing) medicine or allergy medicine
   3. You have a documented blood eosinophil (type of white blood cell) level of at least 150 cells/mcL within the past 12 months
   4. You are being treated with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. You meet ONE of the following:
   a. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      i. Daytime asthma symptoms more than twice per week
      ii. Any night waking due to asthma
      iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      iv. Any activity limitation due to asthma

6. You will NOT use Nucala concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL-5 biologic (such as Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

C. If you have chronic rhinosinusitis with nasal polyps, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or allergist/immunologist (a type of allergy or immune system doctor)
   3. Nucala will be used as add-on maintenance treatment
   4. You had a 90-day trial of ONE intranasal corticosteroid (such as mometasone, fluticasone, beclomethasone)

D. If you have eosinophilic granulomatosis with polyangiitis, approval also requires:
   1. You are 18 years of age or older

E. If you have hypereosinophilic syndrome, approval also requires:
   1. You are 12 years of age or older
   2. You have had HES for 6 months or more without an identifiable non-hematologic (not present in the blood) secondary cause

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

NOTE: For the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) OR hypereosinophilic syndrome (HES), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of severe asthma with an eosinophilic phenotype and meet ALL of the following criteria?
   - The patient continues to use an inhaled corticosteroid (e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist [e.g., formoterol, salmeterol], a long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline, or oral corticosteroid [e.g., prednisone])
   - Nucala will NOT be used concurrently with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL-5 biologic (e.g., Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

   If yes, continue to #2. If no, continue to #3.

2. Has the patient shown a clinical response as evidenced by ONE of the following criteria?
   - Reduction in asthma exacerbation from baseline
   - Decreased utilization of rescue medications
   - Increase in percent predicted FEV1 from pretreatment baseline
   - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
MEPOLIZUMAB

RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) AND meet the following criterion?
   - The patient has had clinical benefit compared to baseline (e.g., improvements in nasal congestion, sense of smell or size of polyps)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 vial/syringe per 28 days.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MEPOLIZUMAB (Nucala) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Severe asthma with an eosinophilic phenotype (type of lung condition with inflammation)
   2. Chronic rhinosinusitis with nasal polyps (CRSwNP; inflammation of nasal and sinus ways with small growths in the nose)

B. **If you have severe asthma with an eosinophilic phenotype, renewal also requires:**
   1. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, tiotropium, umeclidinium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or an oral corticosteroid (such as prednisone)
   2. You will NOT use Nucala concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL-5 biologic (such as Cinqua [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma
   3. You have shown a clinical response as evidenced by ONE of the following:
      a. You have experienced a reduction in asthma exacerbation (worsening of symptoms) from baseline
      b. You have decreased use of rescue medications (such as albuterol)
      c. You have an increase in percent predicted FEV1 (amount of air you can forcefully exhale in one second) from pretreatment baseline (before starting Nucala)
      d. You have a reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

C. If you have chronic rhinosinusitis with nasal polyposis, renewal also requires:
   1. You have had a clinical benefit compared to baseline (before starting Nucala) (such as improvements in nasal congestion, sense of smell or size of polyps)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nucala.

REFERENCES
METHOXY PEG-EPOETIN BETA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>METHOXY PEG-EPOETIN BETA</td>
<td>MIRCERA</td>
<td>35005</td>
<td>GCN</td>
<td>GPI-10 (8240104010)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD)?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the patient 18 years of age or older and meets ALL of the following criteria?
   - The patient had a trial of the preferred agent: Retacrit
   - The patient has a hemoglobin level of less than 10g/dL
   - If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**
   - If no, continue to #3.

3. Is the patient between 5 and 17 years of age and meets ALL of the following criteria?
   - The patient is on hemodialysis
   - The patient is converting from another erythropoiesis-stimulating agent (ESA) (i.e., epoetin alfa, darbepoetin alfa) after the hemoglobin level has been stabilized with the ESA
   - If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**
   - If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named METHOXY PEG-EPOETIN BETA (Mircera) requires the following rule(s) be met for approval:
A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
B. **If you are 18 years of age or older, approval also requires:**
   1. You have tried the preferred medication: Retacrit
   2. You have a hemoglobin level (type of blood test) of less than 10g/dL
C. **If you are between 5 and 17 years of age, approval also requires:**
   1. You are on hemodialysis (process of removing excess water, toxins from the blood)
   2. You are changing from another erythropoiesis-stimulating agent (ESA; epoetin alfa, darbepoetin alfa) after the hemoglobin level has been stabilized with the ESA

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of anemia associated with chronic kidney disease (CKD)?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient 18 years of age or older and meets **ONE** of the following criteria?
   - The patient has a hemoglobin level of less than 11g/dL if on dialysis
   - The patient has a hemoglobin level that has reached 11g/dL (if on dialysis) and the dose is being reduced/interrupted to decrease the need for blood transfusions
   - The patient has a hemoglobin level of less than 10g/dL if not on dialysis
   - The patient has a hemoglobin level that has reached 10g/dL (if not on dialysis) and the dose is being reduced/interrupted to decrease the need for blood transfusions

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.**

   If no, continue to #3.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Is the patient between 5 and 17 years of age and meets ALL of the following criteria?
   • The patient is currently receiving dialysis treatment
   • The patient has a hemoglobin level of less than 11g/dL OR the patient has a hemoglobin level that has reached 11g/dL and the dose is being reduced/interrupted to decrease the need for blood transfusions

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #0.6mL per 28 days.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named METHOXY PEG-EPOETIN BETA (Mircera) requires the following rule(s) be met for renewal:

A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease

B. If you are 18 years of age or older, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 11g/dL if you are on dialysis (process of removing excess water, toxins from the blood)
   2. The patient has a hemoglobin level that has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   3. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis
   4. You have a hemoglobin level that has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions

C. If you are between 5 and 17 years of age, renewal also requires:
   1. You are currently receiving dialysis treatment (process of removing excess water, toxins from the blood)
   2. You have ONE of the following:
      a. A hemoglobin level (type of blood test) of less than 11g/dL
      b. A hemoglobin level that has reached 11g/dL and your dose is being reduced/interrupted to decrease the need for blood transfusions

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
METHOXY PEG-EPOETIN BETA

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mircera.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/17/23
Created: 02/11
Client Approval: 03/23
P&T Approval: 01/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
METHYLNALTREXONE

GUIDELINES FOR USE

1. Is the request for methylnaltrexone (Relistor) tablets or injection for a patient with constipation due to an opioid (such as morphine or methadone) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has chronic non-cancer pain (including chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation)
   - The patient has been taking opioids for at least four weeks
   - The patient has a previous trial of or contraindication to naloxegol (Movantik)

   If yes, approve for 12 months by G PID or GPI-14 for all of the following listed agents and quantity limits:
   - Relistor 12mg vial: #1 vial per day.
   - Relistor 12mg syringe: #1 syringe per day.
   - Relistor 150mg tablets: #3 tablets per day.

   If no, continue to #2.

2. Is the request for methylnaltrexone (Relistor) injection for a patient with constipation due to an opioid (such as morphine or methadone) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has advanced (terminal) illness or pain caused by active cancer who require opioid dosage escalation for palliative care

   If yes, approve Relistor injection for 6 months by G PID or GPI-14 with the following quantity limits:
   - Relistor 12 mg vial: #1 vial per day.
   - Relistor 12 mg syringe: #1 syringe per day.
   - Relistor 8 mg syringe: #1 syringe per day.

   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named METHYLNAUTREXONE (Relistor) requires the following rule(s) be met for approval:

A. You have opioid (type of pain medication)-induced constipation with chronic non-cancer pain, OR you have an advanced illness or pain caused by active cancer and you require opioid dosage increase for palliative care (treatment of symptoms)

B. You are 18 years of age or older

C. **If you have advanced (terminal) illness, or pain caused by active cancer and** you require opioid dosage increase for palliative care (treatment of symptoms), only Relistor injection may be approved

D. **If you have chronic non-cancer pain, approval also requires:**
   1. You have been taking opioids for at least four weeks
   2. You had a previous trial of naloxegol (Movantik), unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Relistor.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets **ONE** of the following criteria?
   - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
   - The patient has **AT LEAST ONE** of the following laboratory values confirming low testosterone levels:
     - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
     - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

   If yes, continue to #2.
   If no, continue to #5.

2. Is the patient 40 years of age or older?
   If yes, continue to #3.
   If no, continue to #4.

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?
   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Has the patient had a trial of or contraindication to **TWO** lower cost testosterone agents (e.g., testosterone cypionate, testosterone enanthate)?
   If yes, **approve the requested agent for 12 months by GPID or GPI-14 with a quantity limit of #5 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Is the request for a male patient with a diagnosis of delayed puberty not secondary to a pathological disorder AND meets the following criterion?
   • The patient had a trial of or contraindication to intramuscular testosterone enanthate

     If yes, approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #5 per day.

     If no, continue to #6.

6. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) AND the patient meets the following criterion?
   • The patient is 16 years of age or older

     If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

     If no, continue to #7.

7. Is the request for a female patient with a diagnosis of metastatic breast cancer AND meets the following criterion?
   • The patient had a trial of or contraindication to intramuscular testosterone enanthate

     If yes, approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #20 per day.

     If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named METHYLTESTOSTERONE (Testred, Android, Methitest) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Gender dysphoria (you identify yourself as a member of the opposite sex)
   4. Metastatic breast cancer (cancer spreading to other areas of body) in a female

(Initial denial text continues on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   3. You had a trial of or contraindication (harmful for) to TWO lower cost testosterone agents (such as intramuscular [injected into the muscle] testosterone cypionate, intramuscular testosterone enanthate)

C. **If you are a male with delayed puberty not secondary to a pathological disorder, approval also requires:**
   1. You had a trial of or contraindication (harmful for) to intramuscular (injected into the muscle) testosterone enanthate.

D. **If you have gender dysphoria, approval also requires:**
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
   2. You are 16 years of age or older

E. **If you are a female with metastatic breast cancer, approval also requires:**
   1. You had a trial of or contraindication (harmful for) intramuscular (injected into the muscle) testosterone enanthate.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ALL of the following criteria?
   • The patient has improved symptoms compared to baseline and tolerance to treatment
   • There is documentation (e.g., chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations compared to baseline
   • If the patient is 40 years of age or older, the patient’s prostate specific antigen (PSA) has been evaluated for prostate cancer screening

   If yes, approve the requested agent for 12 months by GPID or GPI-14 with a quantity limit of #5 per day.

   If no, continue to #2.

2. Is the request for a male patient with a diagnosis of delayed puberty not secondary to a pathological disorder?

   If yes, approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #5 per day.

   If no, continue to #3.

3. Is the request for a female patient with a diagnosis of metastatic breast cancer?

   If yes, approve the requested agent for lifetime by GPID or GPI-14 with a quantity limit of #20 per day.

   If no, continue to #4.

4. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

   If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
METHYLTESTOSTERONE

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named METHYLTESTOSTERONE (Testred, Android, Methitest) requires the following rule(s) be met for renewal:
You have ONE of the following diagnoses:
1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
3. Metastatic breast cancer (cancer spreading to other areas of body) in a female
4. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, renewal also requires:
1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, renewal also requires:
1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Testred, Android, and Methitest.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of acute and recurrent diabetic gastroparesis AND meet the following criterion?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to metoclopramide ODT

If yes, approve for 3 months by GPID or GPI-14 with a quantity limit of #9.8 mL (1 bottle) per 28 days.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named METOCLOPRAMIDE (Gimoti) requires the following rule(s) be met for approval:
A. You have acute (short duration) and recurrent (occurring repeatedly) diabetic gastroparesis (disorder that causes delayed emptying of food from the stomach)
B. You are 18 years of age or older
C. You have previously tried or have a contraindication (medical reason why you cannot take) to metoclopramide ODT (orally disintegrating tablet)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gimoti.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Created: 11/20
Commercial Effective: 01/01/21
Client Approval: 11/20
P&T Approval: 10/20
MIDOSTAURIN

GUIDELINES FOR USE

1. Does the patient have newly diagnosed acute myeloid leukemia (AML) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is FLT3 mutation-positive as detected by an FDA-approved diagnostic test
   - The requested medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation
   - The requested medication will not be used as a single-agent induction therapy for the treatment of patients with AML

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #56 per 28 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #224 per 28 days.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MIDOSTAURIN (Rydapt) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Newly diagnosed acute myeloid leukemia (AML: a type of blood cancer)
   2. Aggressive systemic mastocytosis (ASM: a type of blood disorder)
   3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN: type of blood cancer)
   4. Mast cell leukemia (MCL: type of blood cell cancer)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

B. If you have newly diagnosed acute myeloid leukemia, approval also requires:
   1. You are 18 years of age or older
   2. You are FLT3 (type of gene) mutation-positive as detected by a Food and Drug Administration (FDA)-approved diagnostic test
   3. The requested medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation (cancer drugs)
   4. The requested medication will not be used by itself to start treatment (single-agent induction therapy)

C. If you have aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia, approval also requires:
   1. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Rydapt.

REFERENCES
- Rydapt [Prescribing Information]. East Hanover, New Jersey: Novartis Pharmaceuticals; November 2021.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of endogenous Cushing's syndrome (CS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with an endocrinologist
   - Diagnosis is confirmed by ONE of the following:
     - 24-hour urine free cortisol (2 or more tests to confirm)
     - Overnight 1mg dexamethasone test
     - Late night salivary cortisol (2 or more tests to confirm)
   - The patient's hypercortisolism is not a result of chronic glucocorticoids
   - The patient also has a diagnosis of type 2 diabetes mellitus OR glucose intolerance
   - Patient has failed surgical treatment for Cushing's syndrome OR is not a candidate for surgery

If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #4 per day.

APPROVAL TEXT: Renewal for endogenous Cushing's syndrome requires that the patient continues to have improvement of glucose tolerance and/or stable glucose tolerance (e.g., reduced A1C, improved fasting glucose, etc.), tolerability to Korlym, and continues to not be a candidate for surgical treatment or has failed surgery.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MIFEPRISTONE (Korlym) requires the following rule(s) be met for approval:

A. You have endogenous Cushing's syndrome (CS: condition that occurs after having high levels of cortisol hormone in the body for a long time)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
D. Your diagnosis has been confirmed by ONE of the following:
   1. 24-hour urine free cortisol test (at least 2 or more tests to confirm)
   2. Overnight 1mg dexamethasone test
   3. Late night salivary cortisol (at least 2 or more tests to confirm)

(Initial denial text continued on the next page)
INITIAL CRITERIA (CONTINUED)

E. Your hypercortisolism (high levels of cortisol) is not a result of chronic glucocorticoids (class of drugs that consist of steroids)

F. You have type 2 diabetes mellitus (too much sugar in your blood) OR glucose intolerance (term for a group of conditions that result in elevated blood sugar)

G. You have failed surgical treatment for Cushing's syndrome OR you are not a candidate for surgery

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of endogenous Cushing's syndrome (CS) and meet ALL of the following criteria?
   - The patient continues to have improvement of glucose tolerance and/or stable glucose tolerance (e.g., reduced A1C, improved fasting glucose, etc.)
   - The patient continues to have tolerability to Korlym
   - The patient continues to not be a candidate for surgical treatment or has failed surgery

If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #4 per day. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MIFEPRISTONE (Korlym) requires the following rule(s) be met for renewal:

A. You have endogenous Cushing's syndrome (condition that occurs after having high levels of cortisol hormone in the body for a long time)

B. You continue to have improvement of glucose tolerance and/or stable glucose tolerance (such as reduced hemoglobin A1C [average amount of sugar in your blood over the last 2 to 3 months], improved fasting glucose)

C. You continue to tolerate Korlym

D. You are not a candidate for surgery or have failed surgery for Cushing's syndrome

(Renewal denial text continued on the next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Korlym.

REFERENCE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/20
Created: 04/12
Client Approval: 08/20
P&T Approval: 07/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Does the patient have a diagnosis of Fabry disease and meet ALL of the following criteria?

The patient is 18 years or older
Therapy is prescribed by or in consultation with a nephrologist, cardiologist, or specialist physician in genetics or inherited metabolic disorders
The patient has an amenable galactosidase alpha (GLA) gene variant based on in vitro assay data as interpreted by clinical genetics professional as pathogenic or likely pathogenic (i.e., patient does not have a benign amenable GLA variant)
Galafold will NOT be used concurrently with another Fabry disease therapy (e.g., Fabrazyme [agalsidase beta], Elfabrio [pegunigalsidase alfa-iwxj])
The patient is symptomatic OR has evidence of injury from GL-3 to the kidney, heart, or central nervous system recognized by laboratory, histological, or imaging findings (e.g., decreased GFR for age, persistent albuminuria, cerebral white matter lesions on brain MRI, cardiac fibrosis on contrast cardiac MRI)

If yes, continue to #2.
If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

Is the request for a female patient who meets the following criterion?
The patient has a galactosidase alpha (GLA) gene mutation via genetic testing

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #14 per 28 days.
If no, continue to #3.

Is the request for a male patient who meets ONE of the following criteria?
The patient has an alpha galactosidase A (a-Gal-A) deficiency as indicated by an enzyme assay
The patient has a galactosidase alpha (GLA) gene mutation via genetic testing

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #14 per 28 days.
If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MIGALASTAT (Galafold)** requires the following rule(s) be met for approval:

A. You have Fabry disease (a rare genetic disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor), cardiologist (heart doctor), or specialist in genetics or inherited metabolic disorders
D. You have an amenable (responsive) galactosidase alpha (GLA: a type of gene) gene variant based on in vitro assay data (data collected from lab test tubes or cultures) that is interpreted by clinical genetics professional as the cause of disease (pathogenic or likely pathogenic)
E. You will NOT use Galafold concurrently (taking at the same time) with another Fabry disease medication (such as Fabrazyme [agalsidase beta], Elfabrio [pegunigalsidase alfa-iwx])
F. You are symptomatic OR have evidence of injury from globotriaosylceramide (GL-3: a type of fat) to the kidney, heart, or central nervous system recognized by laboratory, histological, or imaging findings. Evidence of injury includes decreased GFR (measurement of how well your kidneys are working) for age, persistent albuminuria (buildup of a type of protein), cerebral white matter lesions on brain MRI (magnetic resonance imaging: a type of imaging lab), cardiac fibrosis (scarring of the heart) on contrast cardiac MRI
G. **If you are a female, approval also requires:**
   1. You have a galactosidase alpha (GLA: a type of gene) gene mutation via genetic testing
H. **If you are a male patient, approval also requires ONE of the following:**
   1. You do not have enough alpha galactosidase A (a-Gal-A: a type of protein) as indicated by an enzyme assay (a type of lab test)
   2. You have a galactosidase alpha (GLA: a type of gene) gene mutation via genetic testing

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
RENEWAL CRITERIA

1. Does the patient have a diagnosis of Fabry disease AND meet the following criterion?
   • Galafold will NOT be used concurrently with another Fabry disease therapy (e.g., Fabrazyme [agalsidase beta], Elfabrio [pegunigalsidase alfa-iwxj])

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Has the patient demonstrated improvement, maintenance, or stabilization in ONE of the following while on therapy?
   • Symptoms (e.g., pain, hypohidrosis/anhidrosis, exercise intolerance, GI symptoms, angiokeratomas, abnormal cornea, tinnitus/hearing loss)
   • Imaging (e.g., brain/cardiac MRI, DEXA, renal ultrasound)
   • Laboratory or histological testing (e.g., GL-3 in plasma/urine, renal biopsy)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #14 per 28 days.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MIGALASTAT (Galafold) requires the following rule(s) be met for renewal:
A. You have Fabry disease (rare genetic disease)
B. You will NOT use Galafold concurrently (taking at the same time) with another Fabry disease therapy (such as Fabrazyme [agalsidase beta], Elfabrio [pegunigalsidase alfa-iwxj])
C. You have demonstrated improvement, maintenance, or stabilization in ONE of the following while on therapy:
   1. Symptoms such as pain, hypohidrosis/anhidrosis (little to no sweat), exercise intolerance, gastrointestinal (GI) symptoms, angiokeratomas (dark red/purple raised spots), abnormal cornea, tinnitus (ringing in the ears), or hearing loss
   2. Imaging such as brain/cardiac MRI (magnetic resonance imaging: a type of imaging lab), DEXA (test to measure bone density), or renal (kidney) ultrasound
   3. Laboratory or histological (viewed by microscope) testing such as globotriaosylceramide (GL-3: a type of fat) in plasma/urine, renal biopsy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
MIGALASTAT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Galafold.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 11/18
Client Approval: 08/23
P&T Approval: 07/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of mild to moderate type 1 (non-neuronopathic) Gaucher disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The requested medication will be used as monotherapy
   - Enzyme replacement therapy is not a therapeutic option for this patient (e.g., due to allergy, hypersensitivity, or poor venous access)

   If yes, approve for up to 12 months by HICL or GPI-10 with a quantity limit of #90 per 30 days.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MIGLUSTAT (Zavesca) requires the following rule(s) be met for approval:
A. You have mild to moderate type 1 Gaucher disease (rare genetic disorder that affects organs and tissues)
B. You are 18 years of age or older
C. The requested medication will be used as monotherapy (used alone)
D. Enzyme replacement therapy is not a therapeutic option for this patient (due to allergy, hypersensitivity, or poor venous access)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zavesca.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Leishmaniasis and meet ALL of the following criteria?
   - The patient has ONE of the following types of infections:
     o Visceral leishmaniasis caused by *Leishmania donovani*
     o Cutaneous leishmaniasis caused by any of the following: *Leishmania braziliensis*, *Leishmania guyanensis*, or *Leishmania panamensis*
     o Mucosal leishmaniasis caused by *Leishmania braziliensis*
   - Leishmaniasis species is identified via ONE of the following CDC recommended tests:
     o Stained slides (using tissue from biopsy specimens, impression smears or dermal scrapings)
     o Culture medium
     o Polymerase chain reaction (PCR)
     o Serologic testing (e.g., rK39 Rapid Test)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline for MILTEFOSINE (Impavido) requires the following rule(s) be met for approval:

A. You have Leishmaniasis (type of parasite disease) with ONE of the following types of infection:
   1. Visceral leishmaniasis (affects your organs) caused by *Leishmania donovani* (type of parasite)
   2. Cutaneous leishmaniasis (affects your skin layers) caused by any of the following types of parasites:
      a. *Leishmania braziliensis*
      b. *Leishmania guyanensis*
      c. *Leishmania panamensis*
   3. Mucosal leishmaniasis (affects inside mouth, throat and nose) caused by *Leishmania braziliensis*

B. Species identification must be confirmed via ONE of the following CDC (Center for Disease Control and Prevention) recommended tests:
   1. Stained slides (using tissue from biopsy specimens, impression smears or dermal scrapings)
   2. Culture medium
   3. Polymerase chain reaction (lab method to make copies of genes)
   4. Serologic testing (testing your blood and body fluids such as rK39 Rapid Test)

*(Denial text continued on next page)*
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Impavido.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A    Created: 04/16
Commercial Effective: 11/01/21    Client Approval: 10/21
P&T Approval: 05/16
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: SEE RENEWAL CRITERIA BELOW)

1. Is this medication excluded from coverage?
   If yes, guideline does not apply.
   If no, continue to #2.

2. Does the patient have documentation of a confirmed diagnosis of periodontitis and meets ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or given in consultation with an oral health care professional
   • The patient has no history of minocycline or tetracycline sensitivity or allergy
   • The patient has no history of candidiasis or active oral candidiasis
   • The requested medication will be administered by an oral health care professional
   • The requested medication will be used as an adjunct to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
   • The requested medication is not being used for acutely abscessed periodontal pocket
   • The requested medication will not be used in an immunocompromised individual, such as those immunocompromised by any of the following conditions:
     o Uncontrolled diabetes mellitus
     o Chemotherapy
     o Radiation therapy
     o HIV infection
   • The requested medication is not being used in the regeneration of alveolar bone, either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants

If yes, approve for 3 months by HICL or GPI-10 for the quantity requested up to a maximum of 48 unit-dose cartridges.

If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MINOCYCLINE HCL MICROSPHERES (Arestin) requires the following rule(s) be met for approval:
A. You have documentation of confirmed periodontitis (inflammation and infection of the gums)
B. You are age 18 years or older
C. The medication is prescribed by or given in consultation with an oral health care professional
D. You do not have a history of minocycline or tetracycline sensitivity or allergy
E. You do not have a history of candidiasis (a type of fungal infection) or active oral candidiasis
F. The requested medication will be administered by an oral health professional
G. The requested medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
H. The requested medication is not being used for acutely abscessed periodontal pocket (not used for short-term and sudden infection with pus-filled pocket)
I. The medication is not being used in an immunocompromised individual (your immune system is weakened), such as those immunocompromised by any of the following conditions:
   1. Uncontrolled diabetes mellitus
   2. Chemotherapy
   3. Radiation therapy
   4. HIV (human immunodeficiency virus) infection
J. The medication is not being used in the regeneration of alveolar bone (bone that has tooth sockets), either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is this medication excluded from coverage?
   If yes, guideline does not apply.
   If no, continue to #2.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have documentation of a confirmed diagnosis of periodontitis and meets the following criteria?
   - The requested medication will be used as an adjunct to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing

   If yes, approve for 6 months by HICL or GPI-10 for the quantity requested up to a maximum of 48 unit-dose cartridges per 3 months.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MINOCYCLINE HCL MICROSPHERES (Arestin) requires the following rule(s) be met for renewal:
A. You have documentation of periodontitis (inflammation and infection of the gums)
B. The medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planning

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the prescribing information and/or drug monograph for Arestin.

REFERENCES
MIPOMERSEN SODIUM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIPOMERSEN SODIUM</td>
<td>KYNAMRO</td>
<td>40041</td>
<td></td>
<td>GPI-10</td>
<td>(3950004010)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the requested medication prescribed by or given in consultation with a cardiologist, endocrinologist, or lipidologist?
   
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   - The patient has been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks
   - The patient has been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given that the patient cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)

   If yes, continue to #3.
   If no, continue to #4.

3. Will the patient continue statin treatment as described above in combination with Kynamro?
   
   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet ONE of the following criteria?
   - The patient has an absolute contraindication to statin therapy (e.g., active decompensated liver disease, nursing female, pregnancy or plans to become pregnant, hypersensitivity reaction)
   - The patient has complete statin intolerance as defined by severe and intolerable adverse effects (e.g., creatine kinase elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis, severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group) that have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a LDL-cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated statin treatment?

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet **ONE** of the following criteria?
   - The patient has had a previous trial of Repatha (evolocumab)
   - The patient lacks functioning LDL receptors

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have a diagnosis of homozygous familial hypercholesterolemia (HoFH) as determined by meeting **ONE** of the following criteria?
   - Simon Broome diagnostic criteria (definite)
   - Dutch Lipid Network criteria with a score of at least 8
   - A clinical diagnosis based on a history of an untreated LDL-cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma before 10 years of age **OR** (2) evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL (4 syringes) per 28 days.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MIPOMERSEN SODIUM (Kynamro)** requires the following rule(s) be met for approval:

A. You have homozygous familial hypercholesterolemia (type of inherited high cholesterol) which was determined by meeting **ONE** of the following criteria:
   1. Simon Broome diagnostic criteria (definite)
   2. Dutch Lipid Network criteria with a score of at least 8
   3. A clinical diagnosis based on a history of an untreated LDL (low density lipoprotein)-cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma (fatty growths underneath the skin) before 10 years of age **OR** (2) evidence of heterozygous familial hypercholesterolemia (type of inherited high cholesterol) in both parents

B. The medication is prescribed by or recommended by a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management specialist)

C. You have an LDL (low density lipoprotein)-cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated drug treatment

D. You previously had a trial of Repatha (evolocumab) unless you do not have functional LDL (low density lipoprotein) receptors

E. **If you are statin tolerant, approval also requires:**
   1. You meet **ONE** of the following:
      i. You have been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks, **OR**
      ii. You have been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks and you cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)
   2. You will continue statin treatment in combination with Kynamro

F. **If you are statin intolerant, approval also requires **ONE OF THE FOLLOWING:**
   1. You have an absolute contraindication to (medical reason why you cannot use) statin therapy such as active decompensated liver disease (you have symptoms related to liver damage), nursing female, pregnancy or plans to become pregnant or hypersensitivity reaction
   2. You have complete statin intolerance as defined by severe and intolerable adverse effects such as creatine kinase elevation (a measure of how much muscle damage you have) greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (muscle breakdown), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group. These must have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kynamro.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Client Approval: 04/20
P&T Approval: 04/18
GUIDELINES FOR USE

1. Does the patient have a diagnosis of neurogenic detrusor overactivity (NDO) and meet ALL of the following criteria?
   • The patient is 3 years of age or older
   • The patient had a trial of or contraindication to ONE anticholinergic (e.g., oxybutynin, solifenacin)
   • The patient is unable to swallow Myrbetriq tablets

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per day. If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named MIRABEGRON SUSPENSION (Myrbetriq) requires the following rule(s) be met for approval:
   A. You have neurogenic detrusor overactivity (NDO: a type of bladder control condition)
   B. You are 3 years of age or older
   C. You had a trial of or contraindication (harmful for) to ONE anticholinergic (such as oxybutynin, solifenacin)
   D. You are unable to swallow Myrbetriq tablets

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Myrbetriq.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of hemolytic anemia and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has pyruvate kinase (PK) deficiency

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.**
If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for approval:
A. You have hemolytic anemia (a type of blood condition)
B. You are 18 years of age or older
C. You have pyruvate kinase (PK: a type of enzyme) deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED], We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hemolytic anemia with and meet ALL of the following criteria?
   - The patient has pyruvate kinase (PK) deficiency
   - The patient has had clinical benefit while on Pyrukynd

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
If no, do not approve.

**DENIAL TEXT:** See the renewal denial at the end of the guideline.

CONTINUED ON NEXT PAGE
MITAPIVAT

GUIDELINES FOR USE (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MITAPIVAT (Pyrukynd) requires the following rule(s) be met for renewal:
A. You have hemolytic anemia (a type of blood condition)
B. You have pyruvate kinase (PK: a type of enzyme) deficiency
C. You have had clinical benefit while on Pyrukynd

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pyrukynd.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 05/22
Commercial Effective: 07/01/22 Client Approval: 05/22
P&T Approval: 04/22
MOBOCERTINIB

GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test
   - The patient’s disease progressed on or after platinum-based chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MOBOCERTINIB (Exkivity) requires the following rule(s) be met for approval:
A. You have locally advanced or metastatic (cancer that has spread from where it started to nearby tissue or has spread to other parts of the body) non-small cell lung cancer (NSCLC: type of lung cancer)
B. You are 18 years of age or older
C. You have epidermal growth factor receptor (EGFR) exon 20 insertion mutations (type of gene mutation), as detected by a Food and Drug Administration (FDA)-approved test
D. Your disease progressed (disease has gotten worse) on or after platinum-based chemotherapy such as cisplatin, carboplatin, oxaliplatin

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Exkivity.

REFERENCES

CONTINUED ON NEXT PAGE
# MOBOCERTINIB

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

- **Part D Effective:** N/A
- **Commercial Effective:** 01/01/22
- **Created:** 11/21
- **Client Approval:** 11/21
- **P&T Approval:** 10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have non-self-administered (NSA) drug benefit coverage?
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Has the patient previously had 4 implants (2 per nostril) per lifetime?
   
   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient have a diagnosis of nasal polyps and meet **ALL** of the following criteria?
   
   • The patient is 18 years of age or older
   • Therapy is prescribed by or given in consultation with an otolaryngologist
   • The patient previously had ethmoid sinus surgery
   • The patient is a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
   • The patient had a previous 90-day trial of **ONE** intranasal corticosteroid (e.g., fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)
   
   If yes, approve for **12 months** by GPID or GPI-14 with a quantity limit of **2 implants (1 per nostril)**.
   **APPROVAL TEXT:** Renewal requires the patient has nasal polyps and has NOT had 4 implants (2 per nostril) per lifetime. In addition, the patient has ethmoid sinus polyps grade ≥ 1 on any side and does not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (grade 3 or 4).
   
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MOMETASONE IMPLANT (Sinuva) requires the following rule(s) be met for approval:
A. You have nasal polyps (small growths inside the nose)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an otolaryngologist (ear, nose and throat doctor)
D. You previously had ethmoid sinus surgery (process to remove blockage in your sinuses)
E. You are a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms (symptoms return and do not respond to surgery) of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
F. You previously had a 90-day trial of ONE intranasal corticosteroid (such as fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)
G. You have not received 4 implants (2 per nostril) in your lifetime

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient previously had 4 implants (2 per nostril) per lifetime?
   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #2.

2. Does the patient have a diagnosis of nasal polyps and meet ALL of the following criteria?
   • The patient has ethmoid sinus polyps grade ≥ 1 on any side
   • The patient does NOT have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (grade 3 or 4)

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of 2 implants (1 per nostril). (Note: maximum #4 implants [2 per nostril] allowed per lifetime.)
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named MOMETASONE IMPLANT (Sinuva) requires the following rule(s) be met for approval:
A. You have nasal polyps (small growths inside the nose)
B. You have ethmoid sinus polyps grade 1 or greater on any side
C. You do not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (scar tissue) (grade 3 or 4)
D. You have not previously received 4 implants (2 per nostril) in your lifetime

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sinuva.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A                Created: 05/18
Commercial Effective: 10/01/20        Client Approval: 08/20
                                      P&T Approval: 07/20
MONOMETHYL FUMARATE

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient had a trial of or contraindication to dimethyl fumarate AND ONE of the following agents: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta (Please note: other MS agents may also require prior authorization)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named MONOMETHYL FUMARATE (Bafiertam) requires the following rule(s) be met for approval:
   A. You have a relapsing form of multiple sclerosis (MS: immune system eats away at the protective covering of the nerves), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older
   C. You have previously tried or have a contraindication to (medical reason why you cannot take) dimethyl fumarate AND ONE of the following: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta (Please note: Other multiple sclerosis medications may also require prior authorization)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
MONOMETHYL FUMARATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Bafiertam.

REFERENCES
• Bafiertam [Prescribing Information]. High Point, NC: Banner Life Sciences LLC; May 2020.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A             Created: 11/20
Commercial Effective: 01/01/21    Client Approval: 11/20
                                  P&T Approval: 10/20
NAFARELIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAFARELIN ACETATE</td>
<td>SYNAREL</td>
<td>21103</td>
<td>GPI-10</td>
<td>(3008005510)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the requested medication being used for gender dysphoria?
   - If yes, **approve for 12 months by HICL or GPI-10 and override quantity limits.**
   - If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe pain associated with endometriosis and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The diagnosis is confirmed via surgical or direct visualization (e.g., pelvic ultrasound) OR histopathological confirmation (e.g., laparoscopy or laparotomy) in the last 10 years
   - Therapy is prescribed by or in consultation with an obstetrician/gynecologist
   - The patient had a trial of or contraindication to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (e.g., combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
   - The requested medication will NOT be used concurrently with another GnRH-modulating agent (e.g., elagolix, relugolix, Lupron Depot)
   - The patient has NOT received more than 6 months of treatment with Synarel per lifetime
   - If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #96mL per 6 months.**
   - If no, continue to #3.

3. Is the request for a female patient who has a diagnosis of central precocious puberty (CPP) and meets **ALL** of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a pediatric endocrinologist
   - The patient has elevated levels of follicle-stimulating hormone (FSH) (level >4.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
   - The patient is younger than 8 years of age at the onset of CPP
   - There is documentation of pubertal staging using the Tanner scale for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)
   - If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #32mL per month.**
   - If no, continue to #4.

CONTINUED ON NEXT PAGE
NAFARELIN

INITIAL CRITERIA (CONTINUED)

4. Is the request for a male patient who has a diagnosis of central precocious puberty (CPP) and meets ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a pediatric endocrinologist
   • The patient has elevated levels of follicle-stimulating hormone (FSH) (level >5.0 mIU/mL) and luteinizing hormone (LH) (level > 0.2 to 0.3 mIU/mL) at diagnosis
   • The patient is younger than 9 years of age at the onset of CPP
   • The patient has documentation of pubertal staging using the Tanner scale for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #32mL per month. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named NAFARELIN (Synarel) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   2. Moderate to severe pain from endometriosis (condition affecting the uterus)
   3. Central precocious puberty (CPP: early sexual development in girls and boys)

B. **If you have moderate to severe pain from endometriosis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
   3. Your diagnosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
   4. You have tried or have a contraindication (harmful for) to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (such as combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
   5. You are NOT using Synarel concurrently (at the same time) with another gonadotropin-releasing hormone (GnRH)-modulating agent (such as elagolix, relugolix, Lupron Depot)
   6. You have NOT received more than 6 months of treatment with Synarel per lifetime

*Initial denial text continued on next page*

CONTINUED ON NEXT PAGE
NAFARELIN

INITIAL CRITERIA (CONTINUED)

C. If you are female and have central precocious puberty, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 8 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

D. If you are male and have central precocious puberty, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 9 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
NAFARELIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of gender dysphoria or pain from endometriosis, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of central precocious puberty (CPP) and meet ALL of the following criteria?
   • The Tanner scale staging at initial diagnosis of CPP has stabilized or regressed during three separate medical visits in the previous year
   • The patient has not reached the actual age which corresponds to their current pubertal age

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #32mL per month.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named NAFARELIN (Synarel) requires the following rule(s) be met for renewal:
   A. You have central precocious puberty (CPP: early sexual development in girls and boys)
   B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
   C. You have not reached the actual age which corresponds to your current pubertal age

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Synarel.

REFERENCES

NERATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>NERATINIB</td>
<td>NERLYNX</td>
<td>44421</td>
<td></td>
<td>GPI-10</td>
<td>(2153303510)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of early stage (stage I-III) breast cancer and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a HER2-overexpressed/amplified (HER2-positive) tumor
   - The requested medication will be used as a single agent for extended adjuvant therapy following Herceptin- (trastuzumab-) based therapy
   - The medication is being requested within 2 years after completing last trastuzumab dose

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #180 per 30 days.**
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a HER2-overexpressed/amplified (HER2-positive) tumor
   - The requested medication will be used in combination with capecitabine
   - The patient has received two or more prior anti-HER2 based regimens in the metastatic setting

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #180 per 30 days.**
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NERATINIB (Nerlynx)** requires the following rule(s) be met for approval:
A. You have **ONE** of the following diagnoses:
   1. Early stage (stage I-III) breast cancer
   2. Advanced or metastatic breast cancer
B. **If you have early stage (stage I-III) breast cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
   3. The requested medication will be used as a single agent for extended adjuvant therapy following Herceptin- (trastuzumab-) based therapy
   4. The medication is being requested within 2 years of completing the last trastuzumab dose

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
C. **If you have advanced or metastatic breast cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
   3. The requested medication will be used in combination with capecitabine
   4. You have received two or more prior anti-HER2 based regimens in the metastatic setting

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

Rationale
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nerlynx.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/10/21
Created: 07/17
Client Approval: 03/21
P&T Approval: 04/20
GUIDELINES FOR USE

1. Does the patient have a newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase AND meet the following criterion?
   - The patient is 1 year of age or older

      If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
      If no, continue to #2.

2. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase or accelerated phase and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is resistant or intolerant to prior therapy that included imatinib (Gleevec)
   - The patient had a mutational analysis prior to initiation AND Tasigna is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile
      *(Please see header CML-5 of the current NCCN guidelines)*

      If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
      If no, continue to #3.

3. Does the patient have a diagnosis of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase or accelerated phase and meet ALL of the following criteria?
   - The patient is 1 to 17 years of age
   - The patient is resistant or intolerant to prior therapy with other tyrosine kinase inhibitors (TKI) [e.g., Gleevec (imatinib), Sprycel (dasatinib), Bosulif (bosutinib)]
   - The patient had a mutational analysis prior to initiation AND Tasigna is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile
      *(Please see header CML-5 of the current NCCN guidelines)*

      If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
      If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NILOTINIB (Tasigna)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML: a type of blood cell cancer) in chronic phase
   2. Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic or accelerated phase

B. If you have newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires:
   1. You are 1 year of age or older

C. If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase, approval also requires:
   1. If you are 18 years of age or older, you are resistant or intolerant to prior therapy including Gleevec (imatinib)
   2. If you are 1 to 17 years of age, you are resistant or intolerant to prior therapy with other tyrosine kinase inhibitors (TKI) such as Gleevec (imatinib), Sprycel (dasatinib), Bosulif (bosutinib)
   3. You had a mutational analysis prior to initiation of therapy AND Tasigna is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tasigna.

**REFERENCES**

GUIDELINES FOR USE

1. Does the patient have a history of subarachnoid hemorrhage (SAH) from a ruptured intracranial berry aneurysm within the past 21 days and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is unable to swallow nimodipine capsules

   If yes, **approve once for the requested strength by GPID or GPI-14 up to a maximum 21 day supply with the following quantity limits:**
   - Nyimalize 30mg/10mL: #120mL per day.
   - Nyimalize 60mg/20mL: #120mL per day.
   - Nyimalize 30mg/5mL: #60mL per day.
   - Nyimalize 60mg/10mL: #60mL per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NIMODIPINE SOLUTION (Nyimalize)** requires the following rule(s) be met for approval:
A. You have a history of subarachnoid hemorrhage (SAH: bleeding in the space surrounding your brain) from a ruptured intracranial berry aneurysm (an area of an artery wall in your brain ballooned and burst) within the past 21 days
B. You are 18 years of age or older
C. You are unable to swallow nimodipine oral capsules

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
NIMODIPINE SOLUTION

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nymalize.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/26/21
Created: 08/13
Client Approval: 07/21
P&T Approval: 07/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist
   - The patient has a usual interstitial pneumonitis (UIP) pattern as evidenced by high-resolution computed tomography (HRCT) alone or via a combination of surgical lung biopsy and HRCT
   - The patient does NOT have other known causes of interstitial lung disease (for example, connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis, systemic sclerosis, rheumatoid arthritis, radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus infection, viral hepatitis, or cancer)
   - The patient has a predicted forced vital capacity (FVC) of at least 50% at baseline

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and meet ALL of the following criteria?
   - The patient has a diagnosis of Systemic Sclerosis (SSc) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist or rheumatologist
   - The patient has at least 10% fibrosis on a chest high resolution computed tomography (HRCT)
   - The patient has a baseline forced vital capacity (FVC) of at least 40% of predicted value
   - The patient does NOT have other etiologies of interstitial lung disease (ILD) [e.g., heart failure/fluid overload, drug-induced lung toxicity (cyclophosphamide, methotrexate, ACE-inhibitors), recurrent aspiration (such as from GERD), pulmonary vascular disease, pulmonary edema, pneumonia, chronic pulmonary thromboembolism, alveolar hemorrhage or ILD caused by another rheumatic disease, such as mixed connective tissue disease (MCTD)]

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist or rheumatologist
   - The patient's lung function and respiratory symptoms OR chest imaging have worsened/progressed despite treatment with medications used in clinical practice for ILD (not attributable to comorbidities e.g., infection, heart failure)
   - The patient has ≥ 10% fibrosis on a chest high resolution computed tomography (HRCT) (e.g., defined as reticular abnormality with traction bronchiectasis with or without honeycombing)
   - The patient has a baseline forced vital capacity (FVC) at least 45% of predicted value

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named NINTEDANIB (Ofev) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
   2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
   3. Chronic fibrosing interstitial lung disease (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)
B. If you have idiopathic pulmonary fibrosis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
   3. You have a usual interstitial pneumonia pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy and HRCT
   4. You do NOT have other known causes of interstitial lung disease, such as connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (lung inflammation from inhaled substances), systemic sclerosis (an immune system disorder), rheumatoid arthritis (joint pain and inflammation), radiation, sarcoidosis (growth of inflammatory cells in the body), bronchiolitis obliterans organizing pneumonia (type of lung infection), human immunodeficiency virus infection, viral hepatitis (type of liver inflammation), or cancer
   5. You have a predicted forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 50 percent at baseline

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

C. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:
   1. You have systemic sclerosis (SSc) according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
   2. You are 18 years of age or older
   3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
   4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
   5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 40 percent of predicted value
   6. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure/fluid overload, drug-induced lung toxicity (cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)), recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease (MCTD)

D. If you have chronic fibrosing interstitial lung disease with progressive phenotype, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
   3. Your lung function and respiratory (breathing) symptoms OR chest imaging have worsened/progressed despite treatment with medications used in clinical practice for interstitial lung disease (not caused by comorbidities such as infection, heart failure)
   4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
   5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 45 percent of predicted value

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), or chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD) **AND** meet the following criterion?
   - The patient has experienced a clinically meaningful improvement or maintenance in annual rate of decline

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **NINTEDANIB (Ofev)** requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
   2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
   3. Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)
B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ofev.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Client Approval: 07/23
P&T Approval: 04/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is in complete or partial response to first-line platinum based-chemotherapy (e.g., cisplatin, carboplatin)
   • The requested medication will be used for maintenance treatment

      If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
      If no, continue to #2.

2. Does the patient have a diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is in complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin)
   • The requested medication will be used for maintenance treatment
   • The patient's cancer has deleterious or suspected deleterious germline BRCA-mutation (gBRCAmut) based on an FDA-approved companion diagnostic for Zejula
   • The requested medication will be used as monotherapy
   • The requested medication will be started no later than 8 weeks after the patient's most recent platinum-containing regimen
   • The patient has completed at least 2 or more lines of platinum-based chemotherapy (e.g., cisplatin, carboplatin)

      If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
      If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named NIRAPARIB (Zejula) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Advanced epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)
   2. Recurrent (returning) epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)

B. **If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You are in complete or partial response to first-line platinum based-chemotherapy (such as cisplatin, carboplatin)
   3. The requested medication will be used for maintenance treatment (treatment to prevent cancer from coming back after it has disappeared after initial therapy)

C. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You are in complete or partial response to platinum-based chemotherapy (such as cisplatin, carboplatin)
   3. The requested medication will be used for maintenance treatment (treatment to prevent cancer from coming back after it has disappeared after initial therapy)
   4. Your cancer has deleterious or suspected deleterious germline BRCA-mutation (gBRCAmut: a type of gene mutation [abnormal change]) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Zejula
   5. The requested medication will be used as monotherapy (used by itself for treatment)
   6. The requested medication is started no later than 8 weeks after your most recent platinum-containing regimen (such as cisplatin, carboplatin)
   7. You have completed at least two lines of platinum-based chemotherapy (such as cisplatin, carboplatin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
NIRAPARIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zejula.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 08/17
Client Approval: 08/23
P&T Approval: 07/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a documented diagnosis of hereditary tyrosinemia type 1 (HT-1) and meet ALL of the following criteria?
   - The patient has elevated urinary or plasma succinylacetone (SA) levels OR a mutation in the fumarylacetoacetate hydrolase (FAH) gene
   - Therapy is prescribed by or in consultation with a prescriber specializing in inherited metabolic diseases
   - The patient has been counseled on maintaining dietary restriction of tyrosine and phenylalanine

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Is the request for Nityr tablets; brand Orfadin 2mg, 5mg, 10 mg, 20 mg capsules; or Orfadin suspension AND the patient meets the following criterion?
   - The patient had a trial of or contraindication to generic nitisinone capsule

   If yes, **approve the requested drug for 6 months by GPID or GPI-14.**
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named NITISINONE (Orfadin, Nityr) requires the following rule(s) be met for approval:
A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
B. Your diagnosis is confirmed by elevated urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) OR a mutation in the fumarylacetoacetate hydrolase gene
C. Therapy is prescribed by or in consultation with a prescriber specializing in inherited metabolic diseases
D. You have been counseled on maintaining dietary restriction of tyrosine and phenylalanine
E. If you are requesting Nityr tablets; brand Orfadin 2mg, 5mg, 10 mg, 20 mg capsules; or Orfadin oral suspension, approval also requires:
   1. You have tried or have a contraindication (harmful for) to generic nitisinone capsules

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of hereditary tyrosinemia type 1 AND meet the following criterion?
   • The patients urinary or plasma succinylacetone (SA) levels have decreased from baseline while on treatment with nitisinone.

   If yes, approve for 12 months by GPIID or GPI-14 for all strengths of the requested formulation.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
NITISINONE

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named NITISINONE (Orfadin, Nityr) requires the following rule(s) be met for renewal:
A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
B. Your urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) have decreased from baseline while on treatment with nitisinone

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orfadin and Nityr.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 08/16
Commercial Effective: 04/17/23 Client Approval: 03/23
P&T Approval: 07/18
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of primary biliary cholangitis as confirmed by at least TWO of the following criteria?
   - An alkaline phosphatase level of at least 1.5 times the upper limit of normal
   - The presence of antimitochondrial antibodies at a titer of 1:40 or higher
   - Histologic evidence of non-suppurativa destructive cholangitis and destruction of interlobular bile ducts

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of guideline.

2. Does the patient meet ALL of the following criteria?
   - The patient is at least 18 years of age and older
   - The patient does not have cirrhosis OR has compensated cirrhosis with no evidence of portal hypertension
   - The medication is prescribed by or in consultation with a gastroenterologist or hepatologist
   - The requested agent will be used in combination with ursodeoxycholic acid (e.g., Ursodiol, Urso 250, Urso Forte) in adults with an inadequate response to ursodeoxycholic acid at a dosage of 13-15mg/kg/day for at least 1 year, OR as monotherapy in adults unable to tolerate ursodeoxycholic acid
   - The patient does not have complete biliary obstruction

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OBETICHOLIC ACID (Ocaliva) requires the following rule(s) be met for approval:

A. You have primary biliary cholangitis (type of liver disease), as confirmed by TWO of the following criteria:
   1. An alkaline phosphatase level (indicator of possible liver/gallbladder problems) of at least 1.5 times the upper limit of normal
   2. The presence of antimitochondrial antibodies (indicator of body attacking its own cells) at a titer (concentration) of 1:40 or higher
   3. Histologic evidence of non-suppurative destructive cholangitis and destruction of interlobular bile ducts (you have lab data that shows you have certain symptoms of liver disease)

B. You are 18 years of age and older

C. You do not have cirrhosis (liver damage) OR have compensated cirrhosis (a type of liver condition) with no evidence of portal hypertension (high blood pressure in the major vein that leads to the liver)

D. The medication is prescribed by or in consultation with a gastroenterologist (digestive system doctor) or hepatologist (liver doctor)

E. You meet ONE of the following:
   1. You have had an inadequate response to ursodeoxycholic acid (such as Ursodiol, Urso 250, Urso Forte) at a dosage of 13-15 mg/kg/day for at least 1 year and the requested medication will be used in combination with ursodeoxycholic acid
   2. You are unable to tolerate ursodeoxycholic acid and the requested medication will be used as monotherapy (only drug used for treatment)

F. You do not have complete biliary obstruction (blockage of bile ducts)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of primary biliary cholangitis and meets ALL of the following criteria?
   - The patient’s alkaline phosphatase levels are less than 1.67-times the upper limit of normal OR have decreased by at least 15% from baseline while on treatment with obeticholic acid
   - The patient has not developed complete biliary obstruction

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OBETICHOLIC ACID (Ocaliva) requires the following rule(s) be met for renewal:
A. You have primary biliary cholangitis (type of liver disease)
B. Your alkaline phosphatase levels (indicator of possible liver/gallbladder problems) are less than 1.67-times the upper limit of normal or have decreased by at least 15% from baseline while on treatment with obeticholic acid
C. You have not developed complete biliary obstruction (blockage of bile ducts)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ocaliva.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of acromegaly and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks
   • The patient had an inadequate response to surgery or radiotherapy, OR surgery or radiotherapy is not an option for this patient

   If yes, **approve the requested strength for 3 months by GPID or GPI-14 with the following quantity limit:**
   • 10 mg: #6 mL per 28 days.
   • 20 mg: #12 mL per 28 days.
   • 30 mg: #6 mL per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor and meet ALL of the following criterion?
   • The patient had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

   If yes, **approve for 2 months by HICL or GPI-12 with a quantity limit of #6 mL per 28 days.**
   If no, continue to #3.

3. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (VIPoma) and meet ALL of the following criterion?
   • The patient had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

   If yes, **approve for 2 months by HICL or GPI-12 with a quantity limit of #6 mL per 28 days.**
   If no, do not approve.

**DENIAL TEXT:** See initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OCTREOTIDE - IM (Sandostatin LAR Depot) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (a type of cancer that starts from hormone producing cells)
B. You had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks
C. **If you have acromegaly, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
   2. You had an inadequate response (drug did not work) to surgery or radiotherapy (radiation to treat cancer), OR surgery or radiotherapy is not an option for you

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acromegaly and meet ALL of the following criteria?
   • The patient has a reduction, normalization or maintenance of IGF-1 levels based on age and gender
   • The patient has shown an improvement or sustained remission of clinical symptoms of acromegaly

If yes, approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limit:
   • 10 mg: #6 mL per 28 days.
   • 20 mg: #12 mL per 28 days.
   • 30 mg: #6 mL per 28 days.

If no, continue to #2.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor AND meet the following criterion?
   • The patient has improvement or sustained remission of clinical symptoms

      If yes, approve for 12 months by HICL or GPI-12 with a quantity limit of #6 mL per 28 days.
      If no, continue to #3.

3. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (VIPoma) AND meet the following criterion?
   • The patient has improvement or sustained remission of clinical symptoms

      If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6 mL per 28 days.
      If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OCTREOTIDE - IM (Sandostatin LAR Depot) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (a type of cancer that starts from hormone producing cells)

B. If you have acromegaly, renewal also requires:
   1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
   2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

C. If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumor, renewal also requires:
   1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
OCTREOTIDE - IM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sandostatin LAR Depot.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/23
Created: 08/22
Client Approval: 02/23
P&T Approval: 07/22
**OCTREOTIDE - ORAL**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCTREOTIDE</td>
<td>MYCAPSSA</td>
<td></td>
<td>48334</td>
<td>GPI-14 (30170070106520)</td>
<td></td>
</tr>
<tr>
<td>ACETATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient has responded to and tolerated treatment with octreotide or lanreotide

   If yes, **approve for 3 months by GPID or GPI-14 with a quantity limit of #4 per day.**
   If no, **do not approve.**

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **OCTREOTIDE - ORAL (Mycapssa)** requires the following rule(s) be met for approval:
   A. You have acromegaly (a type of hormone disorder)
   B. Therapy is prescribed by or in consultation with an endocrinologist (doctor who specializes in hormones)
   C. You have responded to and tolerated treatment with octreotide or lanreotide

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
OCTREOTIDE - ORAL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
   - The patient has a reduction, normalization, or maintenance of IGF-1 levels based on age and gender
   - The patient has shown an improvement or sustained remission of clinical symptoms of acromegaly

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #4 per day.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT: **
   *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **OCTREOTIDE - ORAL (Mycapssa)** requires the following rule(s) be met for renewal:
   A. You have acromegaly (a type of hormone disorder)
   B. You have had a reduction, normalization, or maintenance of insulin-like growth factor 1 (IGF-1: a type of hormone) levels based on your age and gender
   C. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL

For further information, please refer to the Prescribing Information and/or Drug Monograph for Mycapssa.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 08/20
Client Approval: 09/22
P&T Approval: 07/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of acromegaly and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to ONE generic octreotide product (e.g., octreotide acetate)
   - The patient had an inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to ONE generic octreotide product (e.g., octreotide acetate)

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to ONE generic octreotide product (e.g., octreotide acetate)

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OCTREOTIDE - SQ (Bynfezia) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)

B. If you have acromegaly, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
   3. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)
   4. You had an inadequate response to or cannot be treated with ALL of the following:
      i. Surgical resection (removal by surgery)
      ii. Pituitary irradiation (radiation therapy directed at the pituitary)
      iii. Bromocriptine mesylate at maximally tolerated doses

C. If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)

D. If you have profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma), approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
OCTREOTIDE - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

4. Does the patient have a diagnosis of acromegaly and meet **ALL** of the following criteria?
   - The patient has a reduction, normalization or maintenance of IGF-1 levels based on age and gender
   - The patient has shown an improvement or sustained remission of clinical symptoms of acromegaly

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days**.
   If no, continue to #2.

5. Does the patient have a diagnosis of severe diarrhea and flushing episodes associated with metastatic carcinoid tumor **AND** meet the following criterion?
   - The patient has improvement or sustained remission of clinical symptoms

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days**.
   If no, continue to #3.

6. Does the patient have a diagnosis of profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma) **AND** meet the following criterion?
   - The patient has improvement or sustained remission of clinical symptoms

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #16.8mL per 28 days**.
   If no, do not approve.

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named OCTREOTIDE - SQ (Bynfezia) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)

*(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

B. If you have acromegaly, renewal also requires:
   1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
   2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

C. If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide tumor, renewal also requires:
   1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Bynfezia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 08/20
Client Approval: 09/22
P&T Approval: 07/22
DEVIXIBAT

GUIDELINES FOR USE

Does the patient have a diagnosis of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) AND meet the following criterion?
   The patient is 3 months of age or older

   If yes, approve for all strengths for 12 months by GPID or GPI-14 with the following quantity limits:
   200mcg pellets: #30 per day.
   400mcg capsule: #15 per day.
   600mcg pellets: #10 per day.
   1200mcg capsule: #5 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of cholestatic pruritus associated with Alagille syndrome (ALGS) AND meet the following criterion?
   The patient is 12 months of age or older

   If yes, approve for all strengths for 12 months by GPID or GPI-14 with the following quantity limits:
   200mcg pellets: #36 per day.
   400mcg capsule: #18 per day.
   600mcg pellets: #12 per day.
   1200mcg capsule: #6 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named DEVIXIBAT (Bylvay) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Pruritus (itching) associated with progressive familial intrahepatic cholestasis (PFIC: an inherited liver condition)
   2. Cholestatic pruritus (itching caused by liver disease) associated with Alagille syndrome (ALGS: a type of genetic disorder)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

B. If you have pruritus associated with progressive familial intrahepatic cholestasis, approval also requires:
   1. You are 3 months of age or older

C. If you have cholestatic pruritus associated with Alagille syndrome, approval also requires:
   1. You are 12 months of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Bylvay.

REFERENCES
OFATUMUMAB-SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OFATUMUMAB</td>
<td>KESIMPTA</td>
<td>48513</td>
<td>GPI-10 (6240506500)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, **AND** meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve the requested drug for a total of 12 months by GPID or GPI-10 as follows:**
   **INITIAL REQUEST:**
   - FIRST APPROVAL: Approve for 1 month with a quantity limit of #1.2mL per 28 days.
   - SECOND APPROVAL: Approve for 11 months with a quantity limit of #0.4mL per 28 days (Enter a start date 3 weeks AFTER THE START DATE of the first approval).
   **SUBSEQUENT/CONTINUATION REQUEST:**
   - Approve for 12 months with a quantity limit of #0.4mL per 28 days.

   If no, do not approve.
   **DENIAL TEXT:** **Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **OFATUMUMAB-SQ (Kesimpta)** requires the following rules be met for approval:
   A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
OFATUMUMAB-SQ

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kesimpta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/20
Commercial Effective: 01/01/21  Client Approval: 11/20
P&T Approval: 04/20
GUIDELINES FOR USE

1. Does the patient meet ONE of the following criteria?
   • The patient has a diagnosis of schizophrenia
   • The patient has a diagnosis of bipolar I disorder and meets ONE of the following:
     o Lybalvi is being used for acute treatment of manic or mixed episodes as monotherapy or as adjunct to lithium or valproate
     o Lybalvi is being used as maintenance monotherapy treatment

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a psychiatrist
   • The patient is at high risk for weight gain
   • The patient had a trial and failure of or contraindication to BOTH of the following:
     o TWO generic antipsychotics (e.g., aripiprazole, quetiapine, risperidone, etc.)
     o ONE of the following preferred brand agents: Vraylar, Latuda or Rexulti

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named OLANZAPINE/SAMIDORPHAN (Lybalvi) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Schizophrenia (type of mental health disorder)
   2. Bipolar I disorder (type of mood disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
D. You are at high risk for weight gain
E. You had a trial and failure of or contraindication (harmful for) to BOTH of the following:
   1. TWO generic antipsychotics (such as aripiprazole, quetiapine, risperidone)
   2. ONE of the following preferred brand agents: Vraylar, Latuda or Rexulti

*Denial text continued on next page*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

F. **If you have bipolar I disorder, approval also requires ONE of the following:**
   1. Lybalvi is being used for acute treatment of manic or mixed episodes as monotherapy or as adjunct to lithium or valproate
   2. Lybalvi is being used as maintenance monotherapy treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lybalvi.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/11/21
Created: 09/21
Client Approval: 09/21
P&T Approval: 10/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Lynparza will be used for maintenance treatment
   - The patient is in complete or partial response to first-line platinum-based chemotherapy (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)
   - The patient's diagnosis is confirmed by an FDA-approved companion diagnostic for Lynparza

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient's cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation
   - The patient's cancer is associated with a homologous recombination deficiency (HRD)-positive status as defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability, AND Lynparza will be used in combination with bevacizumab

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is in complete or partial response to their most recent platinum based-chemotherapy (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)
   - The patient has completed at least 2 or more lines of platinum-based chemotherapy (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)
   - Lynparza will be used as monotherapy for maintenance treatment

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Does the patient have a diagnosis of HER2-negative high risk early breast cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Lynparza will be used as adjuvant treatment
   • The patient's cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza
   • The patient has been treated with neoadjuvant or adjuvant chemotherapy (e.g., doxorubicin, paclitaxel)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #5.

5. Does the patient have a diagnosis of HER2-negative metastatic breast cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient's cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza
   • The patient has been treated with chemotherapy (e.g., doxorubicin, docetaxel) in the neoadjuvant, adjuvant, or metastatic setting

   If yes, continue to #6.
   If no, continue to #7.

6. Does the patient meet ONE of the following criteria?
   • The patient does not have hormone receptor (HR)-positive breast cancer
   • The patient has a hormone receptor (HR)-positive breast cancer and has been treated with a prior endocrine therapy or is considered inappropriate for endocrine therapy (e.g., tamoxifen, Arimidex [anastrozole])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
OLAPARIB

GUIDELINES FOR USE (CONTINUED)

7. Does the patient have a diagnosis of metastatic pancreatic adenocarcinoma and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Lynparza will be used for maintenance treatment
   • The patient's cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza
   • The patient's disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen (e.g., paclitaxel, docetaxel, cisplatin, carboplatin)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #8.

8. Does the patient have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, continue to #9.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

9. Does the patient meet BOTH of the following criteria?
   • The patient's cancer has a deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation as confirmed by an FDA-approved companion diagnostic for Lynparza
   • The patient's disease has progressed following prior treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga)

   If yes, continue to #11.
   If no, continue to #10.

10. Does the patient meet BOTH of the following criteria?
    • Lynparza will be used in combination with abiraterone (Yonsa, Zytiga) AND prednisone or prednisolone
    • The patient's cancer has a deleterious or suspected deleterious BRCA mutation (BRCAm) as confirmed by an FDA-approved companion diagnostic for Lynparza

    If yes, continue to #11.
    If no, do not approve.
    **DENIAL TEXT:** See the denial text at the end of the guideline.

    **CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

11. Does the patient meet ONE of the following criteria?
   - The patient previously had a bilateral orchiectomy
   - The patient has a castrate testosterone level (i.e., less than 50 ng/dL)
   - Lynparza will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OLAPARIB (Lynparza) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Recurrent (returning) or advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (types of reproductive system cancers)
   2. HER2 (a type of protein)-negative high risk early breast cancer (a type of breast cancer)
   3. HER2-negative metastatic breast cancer (a type of breast cancer that has spread to other parts of the body)
   4. Metastatic pancreatic adenocarcinoma (a type of pancreas cancer that has spread to other parts of the body)
   5. Homologous recombination repair (HRR) gene-mutated (type of mutation) metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
   6. BRCA-mutated (type of mutation) metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

B. If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
   1. You are 18 years of age or older
   2. Lynparza will be used for maintenance treatment
   3. You are in complete or partial response to first-line platinum-based chemotherapy (such as paclitaxel, docetaxel, cisplatin, carboplatin)
   4. Your diagnosis is confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
   5. You meet ONE of the following:
      a. Your cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation (a type of gene mutation)
      b. Your cancer is associated with a homologous recombination deficiency (HRD: type of gene mutation) positive status as defined by either a deleterious or suspected deleterious BRCA mutation (type of gene mutation), and/or genomic instability (high rate of gene mutation), AND Lynparza will be used in combination with bevacizumab

C. If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
   1. You are 18 years of age or older
   2. You are in complete or partial response to your most recent platinum-based chemotherapy (such as paclitaxel, docetaxel, cisplatin, carboplatin)
   3. You have completed at least two or more lines of platinum-based chemotherapy such as paclitaxel, docetaxel, cisplatin, carboplatin
   4. Lynparza will be used as monotherapy (used alone) for maintenance treatment

D. If you have HER2-negative high risk early breast cancer, approval also requires:
   1. You are 18 years of age or older
   2. Lynparza will be used as adjuvant (add-on) treatment
   3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
   4. You have been treated with neoadjuvant or adjuvant chemotherapy (cancer treatment given before main treatment or as add-on therapy such as doxorubicin, paclitaxel)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

E. If you have HER2-negative metastatic breast cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a deleterious or suspected deleterious germline BRCA mutation
      (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration
      (FDA)-approved companion diagnostic for Lynparza
   3. You have been treated with chemotherapy (such as doxorubicin, docetaxel) in the
      neoadjuvant (given before main treatment), adjuvant (add-on to main treatment), or
      metastatic setting (to treat disease that has spread to other parts of the body)
   4. You meet ONE of the following:
      a. You do not have hormone receptor (HR)-positive breast cancer
      b. You have hormone receptor (HR)-positive breast cancer and you have been treated
         with a prior endocrine (hormone) therapy (such as tamoxifen, Arimidex [anastrozole])
         or endocrine therapy is considered inappropriate for you

F. If you have metastatic pancreatic adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. Lynparza will be used for maintenance treatment
   3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation
      (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration
      (FDA)-approved companion diagnostic for Lynparza
   4. Your disease has not progressed on at least 16 weeks of a first-line platinum-based
      chemotherapy regimen (such as paclitaxel, docetaxel, cisplatin, carboplatin)

G. If you have homologous recombination repair gene-mutated metastatic castration-
   resistant prostate cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a deleterious or suspected deleterious germline or somatic homologous
      recombination repair (HRR) gene mutation (type of mutation) as confirmed by a Food
      and Drug Administration (FDA)-approved companion diagnostic for Lynparza
   3. Your disease has worsened following prior treatment with enzalutamide or abiraterone
   4. You meet ONE of the following:
      a. You previously had a bilateral orchiectomy (both testicles have been surgically
         removed)
      b. You have a castrate level of testosterone (your blood testosterone levels are less
         than 50 ng/dL)
      c. Lynparza will be used together with a gonadotropin-releasing hormone (GnRH)
         analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

H. If you have BRCA-mutated metastatic castration-resistant prostate cancer, approval also requires, approval also requires:
   1. You are 18 years of age or older
   2. Lynparza will be used in in combination with abiraterone (Yonsa or Zytiga) AND prednisone or prednisolone
   3. Your cancer has a deleterious or suspected deleterious BRCA mutation (BRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
   4. You meet ONE of the following:
      a. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
      b. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
      c. Lynparza will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lynparza.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory acute myeloid leukemia (AML) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **OLUTASIDENIB (Rezlidhia)** requires the following rule(s) be met for approval:
   A. You have relapsed or refractory acute myeloid leukemia (AML: a type of blood cancer that has returned or did not respond to treatment)
   B. You are 18 years of age or older
   C. You have a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: a type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rezlidhia.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic or accelerated phase chronic myeloid leukemia (CML) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a resistance or intolerance to TWO or more tyrosine kinase inhibitors (e.g., Gleevec, Sprycel, Tasigna, Bosulif, Iclusig)

If yes, approve for 12 months by HICL.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OMACETAXINE (Synribo) requires the following rule(s) be met for approval:
A. You have chronic or accelerated phase chronic myeloid leukemia (CML: type of blood cell cancer)
B. You are 18 years of age or older
C. You had a resistance or intolerance to TWO or more tyrosine kinase inhibitors (such as Gleevec, Sprycel, Tasigna, Bosulif, Iclusig)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Synribo.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of community-acquired bacterial pneumonia (CABP) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Infection is caused by any of the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydophila pneumoniae

   If yes, continue to #2.
   If no, continue to #5.

2. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

   If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #26 tablets per 13 days.**
   If no, continue to #3.

3. Have antimicrobial susceptibility tests been performed that meet ALL of the following criteria?
   - The results from the infection site culture indicate pathogenic organism(s) with resistance to at least TWO standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)
   - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to Nuzyra

   If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #26 tablets per 13 days.**
   If no, continue to #4.

4. Does the patient meet ALL of the following criteria?
   - Antimicrobial susceptibility results are unavailable
   - The patient has had a trial of or contraindication to at least TWO standard of care agents for CABP (e.g., azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)

   If yes, **approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #26 tablets per 13 days.**
   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
OMADACYCLINE

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of an acute bacterial skin or skin structure infection (ABSSSI) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Infection is caused by any of the following susceptible microorganisms: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus grp.* (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae*

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Is therapy prescribed by or given in consultation with an Infectious Disease (ID) specialist?

   If yes, approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #30 tablets per 14 days.
   If no, continue to #7.

7. Have antimicrobial susceptibility tests been performed that meet ALL of the following criteria?
   - The results from the infection site culture indicate pathogenic organism(s) with resistance to at least TWO standard of care agents for ABSSSI (e.g., linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalaxin, cefazolin)
   - The results from the infection site culture indicate pathogenic organism(s) with susceptibility to Nuzyra

   If yes, approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #30 tablets per 14 days.
   If no, continue to #8.

8. Does the patient meet ALL of the following criteria?
   - Antimicrobial susceptibility results are unavailable
   - The patient has had a trial of or contraindication to at least TWO standard of care agents for ABSSSI (e.g., linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalaxin, cefazolin)

   If yes, approve Nuzyra 150mg tablet for one fill by GPID or GPI-14 with a quantity limit of #30 tablets per 14 days.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OMADACYCLINE (Nuzyra) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Community-acquired bacterial pneumonia (CABP: type of lung infection)
   2. Acute (severe and sudden) bacterial skin or skin structure infection (ABSSSI)

B. If you have community-acquired bacterial pneumonia, approval also requires:
   1. You are 18 years of age or older
   2. The infection is caused by any of the following bacteria: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae
   3. You meet ONE of the following criteria:
      a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
      b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), AND 2) Nuzyra will work against the bacteria
      c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you have had a trial of or contraindication (medical reason why you cannot use) to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If you have acute bacterial skin or skin structure infection (ABSSSI), approval also requires:
   1. You are 18 years of age or older
   2. The infection is caused by any of the following bacteria: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus* grp. (Includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae*
   3. You meet ONE of the following criteria:
      a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
      b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalixin, cefazolin), AND 2) Nuzyra will work against the bacteria
      c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of or contraindication to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalixin, cefazolin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nuzyra.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 03/19
Commercial Effective: 07/01/20  Client Approval: 04/20  P&T Approval: 01/19
OMALIZUMAB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMALIZUMAB</td>
<td>XOLAIR</td>
<td>25399</td>
<td>GPI-10</td>
<td></td>
<td>(4460306000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have moderate to severe persistent asthma and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine
   - The patient has a positive skin prick or blood test (e.g., ELISA, FEIA) to a perennial aeroallergen
   - The patient has a documented baseline IgE serum level greater than or equal to 30 IU/mL
   - The patient is concurrently treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [e.g., salmeterol, formoterol], long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline, or oral corticosteroid [e.g., prednisone])
   - Xolair will NOT be used concurrently with Dupixent (dupilumab) or an anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

   If yes, continue to #2.
   If no, continue to #4.

2. Does the patient meet ONE of the following criteria?
   - The patient has experienced at least ONE asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months
   - The patient has experienced at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months

   If yes, approve for 4 months by GPID or GPI-14 for the requested product as follows:
   - Xolair 150mg vial: #6 vials per 28 days.
   - Xolair 75mg/0.5mL syringe: #5mL per 28 days.
   - Xolair 150mg/mL syringe: #5mL per 28 days.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

3. Does the patient have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks?
   - Daytime asthma symptoms more than twice per week
   - Any night waking due to asthma
   - Use of a short-acting inhaled beta2-agonist reliever (SABA) [e.g., albuterol] for symptoms more than twice per week
   - Any activity limitation due to asthma

   If yes, **approve for 4 months by GPIP or GPI-14 for the requested product as follows:**
   - Xolair 150mg vial: #6 vials per 28 days.
   - Xolair 75mg/0.5mL syringe: #5mL per 28 days.
   - Xolair 150mg/mL syringe: #5mL per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of nasal polyps and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an otolaryngologist or allergist/immunologist
   - Xolair will be used as add-on maintenance treatment
   - The patient had a previous 90-day trial of ONE intranasal corticosteroid (e.g., nasal mometasone)

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #8 per 28 days.**
   If no, continue to #5.

5. Does the patient have a diagnosis of chronic spontaneous urticaria (CSU; also called chronic idiopathic urticaria [CIU]) and meet **ALL** of the following criteria?
   - The patient is 12 years of age or older
   - Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine
   - The patient still experiences hives on most days of the week for at least 6 weeks
   - The patient has tried a high dose H1 antihistamine (e.g., four-fold dosing of Clarinex [desloratadine] or Xyzal [levocetirizine]) **AND** leukotriene antagonist (e.g., montelukast, zafirlukast) for at least 2 weeks

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.**
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OMALIZUMAB (Xolair) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe persistent asthma (a type of lung condition)
   2. Nasal polyps (small growths in the nose)
   3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
   3. You have a positive skin prick or blood test such as ELISA or FEIA (type of blood test to identify what you’re allergic to) to a perennial aeroallergen (airborne particles that cause allergies year-round)
   4. You have a documented baseline IgE (type of antibody that is produced by your immune system if you have an allergy) serum level greater than or equal to 30 IU/mL
   5. You are being treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotreine receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)
   6. You meet ONE of the following:
      a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
      b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
         i. Daytime asthma symptoms more than twice per week
         ii. Any night waking due to asthma
         iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
         iv. Any activity limitation due to asthma

7. You will NOT use Xolair concurrently (at the same time) with Dupixent (dupilumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqua [reslizumab], Fasenra [benralizumab]) when used for treatment of asthma

(Initial denial text continued on next page)
OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

C. If you have nasal polyps, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or an allergist/immunologist (a type of allergy or immune system doctor)
   3. Xolair will be used as add-on maintenance treatment
   4. You had a previous 90-day trial of ONE intranasal corticosteroid (such as nasal mometasone)

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), approval also requires:
   1. You are 12 years of age or older
   2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
   3. You still experience hives on most days of the week for at least 6 weeks
   4. You have tried a high dose H1 antihistamine (type of allergy medication such as four-fold dosing of Clarinex [desloratadine] or Xyzal [levocetirizine]) AND leukotriene antagonist (such as montelukast, zafirlukast, zileuton) for at least 2 weeks

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe persistent asthma and meet ALL of the following criteria?
   • The patient will continue to use an inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication (e.g., a long-acting inhaled beta2-agonist [e.g., formoterol, salmeterol], a long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline, or oral corticosteroid [e.g., prednisone])
   • Xolair will NOT be used concurrently with Dupixent (dupilumab) or an anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

If yes, continue to #2.
If no, continue to #3.

CONTINUED ON NEXT PAGE
OMALIZUMAB

RENEWAL CRITERIA (CONTINUED)

2. Has the patient shown a clinical response as evidenced by **ONE** of the following?
   - Reduction in asthma exacerbation from baseline
   - Decreased utilization of rescue medications
   - Increase in percent predicted FEV1 from pretreatment baseline
   - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

   If yes, **approve for 12 months by GPID or GPI-14 for the requested product as follows:**
   - Xolair 150mg vial: #6 vials per 28 days.
   - Xolair 75mg/0.5mL syringe: #5mL per 28 days.
   - Xolair 150mg/mL syringe: #5mL per 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of nasal polyps **AND** meet the following criterion?
   - The patient has had clinical benefit compared to baseline (e.g., improvements in nasal congestion, sense of smell, size of polyps)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per 28 days.**
   If no, continue to #4.

4. Does the patient have a diagnosis of chronic spontaneous urticaria (CSU; also called chronic idiopathic urticaria [CIU]) **AND** meet the following criterion?
   - Therapy is prescribed by or in consultation with an allergist or immunologist

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per 28 days.**
   If no, do not approve.

**DENIAL TEXT:**  See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
OMALIZUMAB

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OMALIZUMAB (Xolair) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe persistent asthma (a type of lung condition)
   2. Nasal polyps (small growths in the nose)
   3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, renewal also requires:
   1. You will continue to use an inhaled corticosteroid (ICS) [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, tiotropium, umeclidinium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)
   2. You will NOT use Xolair concurrently (at the same time) with Dupixent (dupilumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for treatment of asthma
   3. You have shown a clinical response as evidenced by ONE of the following:
      a. Reduction in asthma exacerbation (worsening of symptoms) from baseline
      b. Decreased use of rescue medications (such as albuterol)
      c. Increase in percent predicted FEV1 (amount of air you can forcefully exhale) from baseline before treatment
      d. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

C. If you have nasal polyps, renewal also requires:
   1. You have had a clinical benefit compared to baseline (before starting Xolair) (such as improvements in nasal congestion, sense of smell, size of polyps)

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), renewal also requires:
   1. Therapy is prescribed by or in consultation with an allergist or immunologist (immune system doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
OMALIZUMAB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xolair.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/03
Commercial Effective: 06/01/23  Client Approval: 05/232  P&T Approval: 04/22
OMAVELOXOLONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMAVELOXOLONE</td>
<td>SKYCLARYS</td>
<td>48741</td>
<td></td>
<td>GPI-10 (7413506000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Friedreich’s ataxia AND meet the following criterion?
   - The patient is 16 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named OMAVELOXOLONE (Skyclarys) requires the following rule(s) be met for approval:
   A. You have Friedreich’s ataxia (a type of nervous system and movement disorder)
   B. You are 16 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Skyclarys.

REFERENCES

GUIDELINES FOR USE

1. Does the patient have a diagnosis of hepatitis C, genotype 4 and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is treatment naïve or treatment experienced (previous treatment with peginterferon/ribavirin)

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient have one or more of the following conditions?
   • The patient is on hemodialysis
   • Moderate or severe liver impairment (Child-Pugh B or Child-Pugh C), or decompensated liver disease
   • A limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
   • Concurrent use with any of these medications (contraindicated or not recommended by the manufacturer): alfuzosin, carbamazepine, phenytoin, phenobarbital, rifampin, ergotamine, dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, NuvaRing, Ortho Evra or Xulane transdermal patch system), lovastatin, simvastatin, pimozide, efavirenz (Atripla, Sustiva), Revatio (sildenafil dose of 20mg and/or dosed TID for PAH), triazolam, oral midazolam, lopinavir/ritonavir, rilpivirine, salmeterol
   • Prior use (failure of a full course of therapy) or concurrent use of any HCV protease inhibitors including Olysio (simeprevir), Victrelis (boceprevir), or Incivek (telaprevir)
   • Prior use (failure of a full course of therapy) or concurrent use of any NS5B polymerase inhibitor including Sovaldi (sofosbuvir)
   • Prior use (failure of a full course of therapy) of concurrent use of any NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)
   • Prior use (short trial or failure of a full course of therapy) of Viekira Pak or Viekira XR

   If yes, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Does the patient have an HCV RNA level within the past 6 months?
   
   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient meet ONE of the following criteria?
   • Patient has a contraindication to therapy with Epclusa, Harvoni, **AND** Mavyret
   • Patient has previously failed a short trial with Epclusa, Harvoni or Mavyret (e.g., adverse effect early in therapy); **[NOTE:]** An individual who has completed a full course of therapy with Epclusa, Harvoni or Mavyret that did not achieve SVR will not be approved.

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the requested medication being used with ribavirin?
   
   If yes, **approve for 12 weeks by HICL or GPI-10 for #56 tablets (1 monthly carton) per 28 days.**
   (**NOTE:** Approval allows patients to complete a total maximum of 12 weeks of therapy.)
   
   If no, continue to #6.

6. Is the patient treatment naïve and without cirrhosis?
   
   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have an intolerance or contraindication to ribavirin?
   
   If yes, **approve for 12 weeks by HICL or GPI-10 for #56 tablets (1 monthly carton) per 28 days.**
   (**NOTE:** Approval allows patients to complete a total maximum of 12 weeks of therapy.)
   
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **OMBITASVIR/PARITAPREVIR/RITONAVIR (Technivie)** requires the following rule(s) be met for approval:

A. You have chronic hepatitis C, genotype 4 without cirrhosis (liver damage) or with compensated cirrhosis (you do not have symptoms related to liver damage; Child-Pugh A)

B. You are treatment naïve (never previously treated) or treatment experienced (previous treatment with peginterferon/ribavirin)

C. The requested medication will be used with ribavirin, unless you are treatment naïve without cirrhosis (you have never been previously treated and do not have liver damage) and you have an intolerance or contraindication to (medical reason why you cannot use) ribavirin

D. You are 18 years of age or older

E. You have previously failed a short trial of Harvoni or Epclusa or Mavyret. Reasons for failure may include adverse effect, intolerance to therapy, or contraindication to (medical reason why you cannot use) all 3 drugs **(NOTE: If you completed a full course of therapy with Mavyret and you did not achieve sustained virologic response [no virus can be detected in blood], the request will not be approved)**

F. You have an HCV RNA level (amount of virus in your blood) within the past 6 months

A total of 12 weeks of therapy will be approved.

The medication will NOT be approved for the following:

A. You are using any of the following medications at the same time while on Technivie: alfuzosin, carbamazepine, phenytoin, phenobarbital, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, NuvaRing, Ortho Evra or Xulane transdermal patch system), lovastatin, simvastatin, pimozide, efavirenz, Revatio, triazolam, oral midazolam, lopinavir/ritonavir, rilpivirine, or salmeterol

B. You have moderate or severe liver impairment (Child Pugh B or Child Pugh C)

C. You are on hemodialysis (process of purifying the blood of a person whose kidneys are not working normally)

D. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

**(Denial text continued on next page)**

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

E. You have previously used (failed a full course of therapy) or are currently using any of the following regimens:
   1. A nucleotide NS5B polymerase inhibitor (type of hepatitis C drug) including Sovaldi (sofosbuvir)
   2. A combination NS5B polymerase inhibitor/NS5A inhibitor (type of hepatitis C drug) including Harvoni (ledipasvir/sofosbuvir)
   3. Any HCV protease inhibitor including Olysio (simeprevir), Victrelis (boceprevir), and Incivek (telaprevir)
   4. Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir) or Viekira XR

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Technivie.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 08/15
Client Approval: 11/22
P&T Approval: 04/17
OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMBITASVIR/ PARITAPREVIR/ RITONAVIR/ DASABUVIR</td>
<td>VIEKIRA PAK, VIEKIRA XR</td>
<td>41644</td>
<td>GPI-10 (1235990460)</td>
<td>GPI-10</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient meet ONE of the following criteria?
   - The patient has a contraindication to therapy with Epclusa AND Harvoni
   - The patient has previously failed a short trial with Epclusa or Harvoni (e.g., adverse effect early in therapy); [NOTE: An individual who has completed a full course of therapy with Epclusa or Harvoni that did not achieve SVR will not be approved]

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have one or more of the following conditions?
   - Decompensated liver disease
   - Moderate liver impairment (Child-Pugh B) or severe liver impairment (Child-Pugh C)
   - A limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)
   - Patient is on hemodialysis
   - Concurrent use with any of these (contraindicated or not recommended by the manufacturer) medications: alfuzosin, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, Nuvaring, Ortho Evra or Xulane transdermal patch system), St. John’s Wort, lovastatin, simvastatin, pimozide, efavirenz, Revatio (sildenafil dose of 20mg and/or dosed TID for PAH), triazolam, oral midazolam, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, salmeterol
   - Prior use (failure of a full course of therapy) or concurrent use of any HCV protease inhibitors including Olysio (simeprevir), Victrelis (boceprevir), or Incivek (telaprevir)
   - Prior use (failure of a full course of therapy) or concurrent use of any NS5B polymerase inhibitor including Sovaldi (sofosbuvir)
   - Prior use (failure of a full course of therapy) of concurrent use of any NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Does the patient have an HCV RNA level within the past 6 months?
   
   If yes, continue to #4.
   If no, do not approve.
   
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Does the patient have a diagnosis of hepatitis C, genotype 1 and meet **ALL** of the following criteria?
   
   • The patient is 18 years of age or older
   • The patient is treatment naïve or treatment experienced (previous treatment with peginterferon/ribavirin)

   If yes, continue to #5.
   If no, do not approve.
   
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Is the requested medication being used with ribavirin; **(NOTE:** Ribavirin combination therapy with Viekira is approved for genotype 1a without cirrhosis, genotype 1a with cirrhosis, and for use in liver transplant patients.)?

   If yes, continue to #6.
   If no, continue to #12.

6. Is the patient a liver transplant recipient?

   If yes, **approve the requested strength for 24 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients who are liver transplant recipients to complete a total of 24 weeks of therapy):**
   
   • Viekira XR: #84 tablets (1 pack) per 28 days OR
   • Viekira Pak: #112 tablets (1 pack) per 28 days

   If no, continue to #7.

7. Does the patient have genotype 1a without cirrhosis?

   If yes, **approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1a without cirrhosis to complete a total maximum of 12 weeks of therapy):**
   
   • Viekira XR: #84 tablets (1 pack) per 28 days OR
   • Viekira Pak: #112 tablets (1 pack) per 28 days

   If no, continue to #8.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

8. Does the patient have genotype 1a with cirrhosis AND is treatment naïve?

   If yes, approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows treatment naïve patients with genotype 1a with cirrhosis to complete a total maximum of 12 weeks of therapy):
   • Viekira XR: #84 tablets (1 pack) per 28 days OR
   • Viekira Pak: #112 tablets (1 pack) per 28 days

   If no, continue to #9.

9. Does the patient have genotype 1a with cirrhosis and has received prior treatment (e.g., treatment-experienced patient) for hepatitis C with peginterferon and ribavirin; (NOTE: Approval not granted for patients with history of prior use of OR concurrent use of HCV protease inhibitors or HCV polymerase inhibitors: Olysio (simeprevir), Victrelis (boceprevir), Incivek (telaprevir), Sovaldi (sofosbuvir), or Harvoni (ledipasvir/sofosbuvir)?

   If yes, continue to #10.
   If no, continue to #12.

10. Is the patient a previous prior relapser or a prior partial responder?

    If yes, approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1a that are previous prior relapers or prior partial responders to complete a total of 12 weeks of therapy):
    • Viekira XR: #84 tablets (1 pack) per 28 days OR
    • Viekira Pak: #112 tablets (1 pack) per 28 days

    If no, continue to #11.

11. Is the patient a treatment-experienced patient and is a previous null responder?

    If yes, approve the requested strength for 24 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1a that are previous null responders to complete a total of 24 weeks of therapy):
    • Viekira XR: #84 tablets (1 pack) per 28 days OR
    • Viekira Pak: #112 tablets (1 pack) per 28 days

    If no, do not approve.

    DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
12. Does the patient have genotype 1b?

If yes, approve the requested strength for 12 weeks by GPID or GPI-14 with the following quantity limits (NOTE: Approval allows patients with genotype 1b to complete a total of 12 weeks of therapy):

- Viekira XR:  #84 tablets (1 pack) per 28 days OR
- Viekira Pak:  #112 tablets (1 pack) per 28 days

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OMBITASVIR/PARITAPREVIR/RITONAVIR/ DASABUVIR (Viekira Pak, Viekira XR) requires the following rule(s) be met for approval:
A. You have chronic hepatitis C, genotype 1 (a type of liver infection)
B. You are 18 years of age or older
C. You are treatment naïve (never previously treated) or treatment experienced (previous treatment with peginterferon/ribavirin)
D. You will be using ribavirin with the requested medication, unless you have genotype 1b
E. You have previously failed a short trial with Epclusa or Harvoni unless you have a medical reason why you cannot use (contraindication) BOTH drugs. Reasons for failure include adverse effect early in therapy, intolerance to therapy (NOTE: If you completed a full course of therapy with Epclusa or Harvoni and you did not achieve sustained virologic response [no virus can be detected in blood], the request will not be approved)
F. You have an HCV RNA level (amount of virus in the blood) within the past 6 months

(Denial text continued on the next page)
GUIDELINES FOR USE (CONTINUED)

The medication will not be approved for the following patients:

A. You are using any of the following medications at the same time while on Viekira: alfuzosin, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, Nuvaring, Ortho Evra or Xulane transdermal patch system), St. John’s Wort, lovastatin, simvastatin, pimozide, efavirenz, Revatio, triazolam, oral midazolam, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, or salmeterol

B. You have decompensated cirrhosis (symptoms related to liver damage)

C. You have moderate liver impairment (Child Pugh B) or severe liver impairment (Child Pugh C)

D. You are on hemodialysis (process of purifying the blood of a person whose kidneys are not working normally)

E. You have a limited life expectancy (less than 12 months) due to other conditions not related to the liver

F. You have previously used/failed a full course of therapy, or currently using any of the following regimens:
   1. A nucleotide NS5B polymerase inhibitor (type of hepatitis C drug) including Sovaldi (sofosbuvir)
   2. A combination NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)
   3. A hepatitis C virus protease inhibitor (type of hepatitis drug) including Olysio (simeprevir), Victrelis (boceprevir), and Incivek (telaprevir)

A total of 12 weeks of therapy will be approved except 24 weeks of therapy for 1) genotype 1a with cirrhosis if patient is treatment experienced, previous null responder or 2) a liver transplant recipient.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Viekira Pak/XR.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A     Created: 01/15
Commercial Effective: 01/01/23     Client Approval: 11/22
P&T Approval: 01/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Parkinson's disease and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient is experiencing “OFF” episodes
   • The patient is currently being treated with carbidopa/levodopa
   • The patient had a previous trial of, failure of, or contraindication to TWO Parkinson’s disease agents from TWO different classes of the following:
     o Dopamine agonist (e.g., ropinirole, pramipexole, rotigotine)
     o Monoamine oxidase-inhibitors (MAO-I) (e.g., selegiline, rasagiline)
     o Adenosine receptor antagonist A2A (e.g., istradefylline)
     o Catechol-O-methyltransferase (COMT) inhibitors (e.g., entacapone, tolcapone)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named OPICAPONE (Ongentys) requires the following rule(s) be met for approval:
   A. You have Parkinson's disease (PD: a nerve system disorder that affects movement)
   B. You are 18 years of age or older
   C. You are experiencing ‘OFF’ episodes (times when you have symptoms return due to medication wearing off)
   D. You are currently being treated with carbidopa/levodopa
   E. You have tried or failed or have a contraindication (medical reason why you cannot use) to TWO Parkinson's disease medications from TWO different classes of medications:
      1. Dopamine agonist (such as ropinirole, pramipexole, rotigotine)
      2. Monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline)
      3. Adenosine receptor antagonist A2A (such as istradefylline)
      4. Catechol-O-methyltransferase (COMT) inhibitors (such as entacapone, tolcapone)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
OPICAPONE

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ongentys.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/21
Created: 09/20
Client Approval: 11/20
P&T Approval: 10/20
OPIOID-ANTIPSYCHOTIC CONCURRENT USE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the claim rejecting with the following error code?
   - REJ-433-1205: OPIOID-ANTIPSYCHOTIC CONFLICT FOUND
     (H: DUR_CONCURRENT_USE)
     
     If yes, continue to #2.
     If no, guideline does not apply.

2. Does the patient meet at least ONE of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is in hospice care
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   - Patient has a diagnosis of sickle cell disease

     If yes, approve for 12 months by HICL or GPI-10 and set DUR_CONCURRENT_OVR to ‘OP_PSY’.
     If no, continue to #3.

3. Has the prescriber indicated that the concurrent use of an opioid and an antipsychotic medication is intended and clinically appropriate for the patient?
   [NOTE: Refer to the Medical Request Form (MRF) or chart notes if provided (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

     If yes, approve for 12 months by HICL or GPI-10 and set DUR_CONCURRENT_OVR to ‘OP_PSY’.
     If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON THE NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:
[NOTE: Enter proactive PAs for other UM overrides not including the Opioid-Antipsychotic Concurrent Use, if applicable.]

While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of an opioid drug and an antipsychotic drug together.

[Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID-ANTIPSYCHOTIC CONCURRENT USE allows an approval for use of an opioid with an antipsychotic medication (type of mental health drug) together when one of the following criteria is met:
A. You have active cancer
B. You are receiving palliative care or end-of-life care (care focused on treating symptoms of illness)
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms that the use of an opioid and an antipsychotic medication together is intended and clinically appropriate for you

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON THE NEXT PAGE
OPIOID-ANTIPSYCHOTIC CONCURRENT USE

RATIONALE
To mitigate the risk of overdose from dangerous combinations of antipsychotics and opioids while preserving patient access to drug regimens if deemed medically necessary.

In addition, align with the opioid restrictions from the SUPPORT Act. The SUPPORT Act is an acronym for the Congress HR 6 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. The rule identified six requirements that each State and Managed Care Entity must have in place by October 1, 2019. CMS defined the SUPPORT Act requirements as minimum Drug Utilization Review (DUR) standards for MMCPs and are listed below:

- Safety edits, as specified by the states, for subsequent opioid fills and maximum daily morphine milligram equivalent that exceed state-defined limitations
- Automated process that monitors when an individual is concurrently prescribed opioids and benzodiazepines or antipsychotics
- Monitoring antipsychotic prescribing for children
- Process that identifies potential fraud or abuse by enrolled individuals and pharmacies
- Report to the Secretary annually on state DUR activities
- Have in place managed care contracts that include these provisions

CMS noted that minimum standards may be expanded by the states or CMS in future rule making.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 03/01/21  
Created: 08/19

Client Approval: 02/21  
P&T Approval: 04/21
GUIDELINES FOR USE

1. Is the claim rejecting with the following error code?
   - **REJ- 433-1201: CLAIM CONFLICTS IN THERAPY WITH MEMBER HISTORY (H: DUR_CONCURRENT_USE)**
     
     If yes, continue to #2.
     If no, guideline does not apply.

2. Does the patient meet at least ONE of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is in hospice care
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   - Patient has a diagnosis of sickle cell disease
     
     If yes, **approve for 12 months by HICL or GPI-10 and set DUR_CONCURRENT_OVR to ‘OP_BZD’**.
     If no, continue to #3.

3. Has the prescriber provided attestation to proceed with the concurrent use of an opioid and a benzodiazepine for a clinically appropriate indication?
   
   If yes, **approve for 12 months by HICL or GPI-10 and set DUR_CONCURRENT_OVR to ‘OP_BZD’**.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONCLUDED ON THE NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:
While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of an opioid drug and a benzodiazepine drug together.

[Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID-BENZODIAZEPINE CONCURRENT USE allows for an approval of use of an opioid with a benzodiazepine together when ONE of the following criteria is met:
A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms (attests) to proceed with the concurrent use of an opioid and a benzodiazepine for a clinically appropriate indication

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

PARTIALLY APPROVED OPIOID TEXT:
Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT:
Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

CONTINUED ON THE NEXT PAGE
OPIOID-BENZODIAZEPINE CONCURRENT USE

RATIONALE
To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from the CMS 2019 Call Letter:
“We expect that Part D sponsors implement a concurrent opioid and benzodiazepine soft POS safety edit (which can be overridden by the pharmacist) to prompt additional safety review at the time of dispensing beginning in 2019.” CMS 2019 Call Letter, page 251
The claim will deny when there is concurrent use of benzodiazepines and opioids with any overlap in day supply. This can be overridden at POS or by a Prior Authorization. If the pharmacy does not submit the specified PPS codes, the claim should reject unless a prior approval is in place.
This guideline allows an approval for patients with one of the following conditions:
- Diagnosis of active cancer
- Receiving palliative care or end-of-life care
- Enrolled in hospice
- Resident of a long-term care facility or intermediate care for intellectually disabled
- Diagnosis of sickle cell disease
- Physician attestation that the prescriber is aware that the patient is concurrently receiving a benzodiazepine with an opioid(s) and would like to proceed with an opioid and benzodiazepine

REFERENCES
GUIDELINES FOR USE

1. Is the claim rejecting with ONE of the following error codes?
   - **REJ-433-1200 (DUR CONCURRENT USE): CLAIM CONFLICTS IN THERAPY WITH MEMBER HISTORY**
   - **REJ-1064 (DUR_DD_DENY): DRUG-DRUG INTERACTION FOUND**
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient meet at least ONE of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is in hospice care
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled

   If yes, approve for 12 months by HICL or GPI-10 with ONE of the following overrides:
   - For DUR_CONCURRENT_USE Rejection: Set DUR_CONCURRENT_OVR to ‘OP_BUP’
   - For DUR_DD_DENY Rejection: Set DUR_DD_DENY to ‘Y’ for Yes
   
   If the claim analysis continues to reject, follow the clinical coverage determination process.

   If no, continue to #3.

3. Has the prescriber provided attestation that the patient has discontinued or will be discontinuing opioid dependency treatment with buprenorphine or buprenorphine-containing agents and needs to resume chronic opioid treatment? *(NOTE: Consultation with an addiction medicine specialist is recommended)*

   If yes, approve for 4 months by HICL or GPI-10 with ONE of the following overrides:
   - For DUR_CONCURRENT_USE Rejection: Set DUR_CONCURRENT_OVR to ‘OP_BUP’
   - For DUR_DD_DENY Rejection: Set DUR_DD_DENY to ‘Y’ for Yes
   
   If the claim analysis continues to reject, follow the clinical coverage determination process.

   If no, continue to #4.

CONTINUED ON THE NEXT PAGE
4. Is the prescriber aware that the patient is currently receiving buprenorphine or buprenorphine-containing agents for treatment of opioid dependency and has provided attestation to proceed with opioid treatment for an acute, clinically appropriate indication? (NOTE: Consultation with an addiction medicine specialist is recommended)

If yes, approve for 30 days by HICL or GPI-10 with ONE of the following overrides:
- For DUR_CONCURRENT_USE Rejection: Set DUR_CONCURRENT_OVR to 'OP_BUP'
- For DUR_DD_DENY Rejection: Set DUR_DD_DENY to 'Y' for Yes

If the claim analysis continues to reject, follow the clinical coverage determination process.

If no, do not approve.

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT: While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of an opioid drug and a buprenorphine-containing drug together.

[Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID-BUPRENORPHINE CONCURRENT USE allows approval for use of an opioid with buprenorphine or a buprenorphine-containing agent together when ONE of the following rule(s) is met:
A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. Your doctor confirms (attests) that you have discontinued or will be discontinuing opioid dependency treatment with buprenorphine or buprenorphine-containing agents and you need to resume chronic opioid treatment. Consultation with an addiction medicine specialist is recommended.
F. Your doctor is aware that you are currently receiving buprenorphine or a buprenorphine-containing agent for treatment of opioid dependency and has confirmed to proceed with opioid treatment for an acute, clinically appropriate indication. Consultation with an addiction medicine specialist is recommended

(Denial text continued on next page)
GUIDELINES FOR USE

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

PARTIALLY APPROVED OPIOID TEXT:
Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT:
Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

RATIONALE
To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from CMS guidance. For further information, please refer to the Drug Monograph for Opioid-Buprenorphine Concurrent Use.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 03/01/21
Created: 12/18
Client Approval: 02/21
P&T Approval: 04/21
GUIDELINES FOR USE

1. Is the request for an opioid product equal to or exceeding the soft-stop threshold or hard-stop threshold as noted in the POS reject messaging?

   **NOTE:** Claims should stop for DUR_MAX_CUMUL_DOSE 2 edit with Soft_DENY_LIMIT= X or HARD_DENY_LIMIT= X (i.e., Cumulative morphine milligram equivalent of [patient’s current MME] = / exceeds threshold of [soft-stop threshold-mg MME or hard-stop threshold-mg MME]).

   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient meet at least ONE of the following criteria?
   • Patient has a diagnosis of active cancer
   • Patient is in hospice care
   • Patient is receiving palliative care or end-of-life care
   • Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   • Patient has a diagnosis of sickle cell disease

   If yes, **approve as follows:**
   • Approval duration should be for 12 months by HICL or GPI-10.
   • **NOTE:** Please enter a class override to override the MME cumulative dosing for the duration of 12 months.
   • If the claim rejects after analyzing, then follow the clinical coverage determination process.

   If no, continue to #3.

3. Is the prescriber aware of multiple prescribers for opioid prescriptions?

   If yes, continue to #4.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.
OPIOID CUMULATIVE DOSING OVERRIDE

GUIDELINES FOR USE (CONTINUED)

4. Have TWO of the following criteria been met?
   • There is documentation that the patient’s current level of opioid utilization is necessary and required for the level of pain management needed
   • Patient has been evaluated by a pain specialist, and/or the request is based on the recommendation of a pain specialist
   • Patient has a pain contract in place
   • Patient does not have a history of substance abuse or addiction
   • Provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

If yes, approve as follows:
   • Approval duration should be for 12 months by HICL or GPI-10.
   • NOTE: Please enter a class override to override the MME cumulative dosing for the duration of 12 months.
   • If the claim rejects after analyzing, then follow the clinical coverage determination process.

If no, do not approve.

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:

While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the amount of opiates prescribed and because your opiate amount exceeds or is equal to [enter soft stop threshold]-mg morphine milligram equivalent (MME) or [enter hard stop threshold]-mg morphine milligram equivalent (MME).

[Proceed to enter Denial Text below]

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

A claim for a pain medication will be denied when there are two or more providers prescribing opioid agents for a patient who is receiving a high quantity of these agents. Our guideline named **OPIOID CUMULATIVE DOSING OVERRIDE** will allow you to receive a higher quantity of an opioid medication if ONE of the following rules (A or B) is met:

A. You have ONE of the following conditions:
   1. You have active cancer
   2. You are receiving palliative care (treatment for comfort from symptoms) or end-of life care
   3. You are enrolled in a hospice
   4. You are a resident of a long-term care facility or intermediate care for intellectually disabled
   5. You have sickle cell disease (type of blood disorder)

B. Your prescriber is aware that there is more than one provider prescribing opiates for you, and you meet **TWO** of the following:
   1. You have documentation showing your current level of opioid use is necessary and required for your level of pain management needed
   2. You have been evaluated by a pain specialist, and/or the request is based on the recommendation of a pain specialist
   3. You have a pain contract in place
   4. You do not have a history of substance abuse or addiction
   5. Your provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record.

This safety edit allows for an override for an opioid product equal to or exceeding the **[enter soft stop threshold]-mg morphine milligram equivalent (MME)** or **[enter hard stop threshold]-mg morphine milligram equivalent (MME)**. Please consult your physician if you have any questions about this safety edit on prescription opioid medications and the requirements needed for you to obtain an approval for higher quantities of these agents.

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**PARTIALLY APPROVED OPIOID TEXT:**
Although we have entered a prior authorization for **<DRUG+QL/UM (if any)>** from **<DATE RANGE>**, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

*(Denial text continued on next page)*

---

**CONTINUED ON NEXT PAGE**
PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT: Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

RATIONALE
To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from the CMS 2019 Call Letter.

Prior authorization will be required for opioid prescriptions in excess of hard opioid edit. Soft opioid edit thresholds may be overridden by a dispensing pharmacist or provider/patient may request a coverage determination. This requirement should not apply to patients with active cancer, hospice patients, those receiving palliative or end of life care, residents of a long term facility or patients approved by case management or retrospective DUR Programming. Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease. Additional payment determination is required for patients identified as hospice. Soft-thresholds may also be overridden by the pharmacy via DUR PPS codes or as part of coverage determination process and by certain PPS codes. Hard-thresholds are overridable as part of the coverage determination process. The cumulative opioid edit minimizes false positives by accounting for known exceptions: 1) patients on hospice, have certain cancer diagnosis 2) overlapping dispensing dates for Rx refills and new Rx orders for continuing fills 3) high-dose opioid usage previously determined to be medically necessary (approved PAs, previous coverage determinations, case management) 4) no consecutive high-MME days’ criterion as it would not prevent beneficiaries from reaching high opioid doses.

CONTINUED ON NEXT PAGE
REFERENCES

- Announcement of Calendar Year (CY) 2017 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 09/16
Commercial Effective: 11/01/22 Client Approval: 09/22 P&T Approval: 04/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
OPIOID LONG-ACTING Duplicative Therapy

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/other</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the claim rejecting with the following error code?
   - **REJ-1045: THERAPEUTIC DUPLICATION DENIAL (DRUG_TD)**
     (The incoming claim for a long-acting (LA) opioid will reject when the patient is concurrently taking a different long-acting opioid [different HICL] from a different prescriber.)
     
     If yes, continue to #2.
     If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is in hospice care
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   - Patient has a diagnosis of sickle cell disease
     
     If yes, **approve for 12 months by HICL or GPI-10 and set DRUG_TD_OVR to ‘Y’ for Yes.**
     If no, continue to #3.

3. Is the prescriber aware that the patient is concurrently receiving more than one long-acting opioid therapy?
   
   If yes, **approve for 12 months by HICL or GPI-10 and set DRUG_TD_OVR to ‘Y’ for Yes.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUE ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:
While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of two long-acting opioid drugs together that are from different prescribers. [Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID LONG ACTING DUPLICATIVE THERAPY allows approval of the requested drug taken together with other long-acting opioid drug(s) from different prescribers when ONE of the following conditions are met:
A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms that they are aware that you are concurrently receiving more than one long-acting opioid medication

Please consult your physician if you have any questions about this prescription medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request

PARTIALLY APPROVED OPIOID TEXT:
Although we have entered a prior authorization for <DRUG+QL/UM (if any)> from <DATE RANGE>, your request has additional restrictions and criteria that you must meet as described above. You will be able to receive your medication once the additional criteria has been met and the restrictions have been removed.

PREVIOUSLY APPROVED OPIOID CLAIMS WITH NO PA, BUT NOW REJECTS DUE TO SAFETY EDIT TEXT:
Although you were previously approved for <DRUG> your new request now has additional safety restrictions that you must meet as described above. You will not be able to receive your medication until the newly added restrictions have been removed.

CONTINUED ON NEXT PAGE
RATIONAL
To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. In addition, align with the opioid restrictions from the CMS 2019 Call Letter:

“…we expect all Part D plan sponsors to implement a soft POS safety edit (which can be overridden by the pharmacist) for duplicative LA opioid therapy beginning in 2019, with or without a multiple prescriber criterion.” CMS 2019 Call Letter, page 252

Prior authorization will be required for Long Acting (LA) opioid prescriptions when an incoming claim for a long-acting opioid overlaps with another long acting opioid (different HICL) claim(s) from a different prescriber(s). The edit can be overridden by professional pharmacy professional service (PPS) code at POS or by a PA. This requirement does not apply to patients with a diagnosis of active cancer, patients receiving palliative care or end-of-life care, those enrolled in hospice or resident of a long-term care facility. Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease. This guideline also allows an override when there is physician attestation that the prescriber is aware that the patient is concurrently receiving long acting duplicative therapy and would like to proceed with treatment for a clinically appropriate indication.

REFERENCES
GUIDELINES FOR USE

1. Does the patient meet ALL of the following criteria?
   • The request is for an opioid product equal to or exceeding the soft-stop threshold or hard-stop threshold as noted in the POS reject messaging?
     NOTE: The following reject code(s) may also be present:
     • For Soft-Stop: REJ-88-1080
     • For Hard-Stop: REJ-88-1081

     If yes, continue to #2.
     If no, guideline does not apply.

2. Is the patient opioid-naive meaning they have not used an opioid drug(s) in the past 60 days (starting the day prior to the fill date of the incoming claim)?
   [NOTE: Please refer to the claims history in MedAcess, Medication Request Form (MRF) or chart notes (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

     If yes, continue to #3.
     If no, approve for one (1) month, for one (1) fill count by HICL or GPI-10 and set NAIVE_OP_HARD_LIMIT_OVR to ‘Y’ for Yes.

3. Does the patient meet at least ONE of the following criteria?
   • Patient has a diagnosis of active cancer
   • Patient is enrolled in hospice
   • Patient is receiving palliative care or end-of-life care
   • Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   • Patient has a diagnosis of sickle cell disease

     If yes, approve for 12 months by HICL or GPI-10 and set NAIVE_OP_HARD_LIMIT_OVR to ‘Y’ for Yes.
     If no, continue to #4.

CONTINUE ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Have BOTH of the following criteria been met?
   • The provider has indicated that the patient's current level of opioid utilization is necessary and required for the level of pain management needed
   • The provider has committed to monitoring the state's Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

   If yes, approve for one (1) month, for one (1) fill count by HICL or GPI-10 and set NAIVE_OP_HARDLIMIT_OVR to ‘Y’ for Yes.

   If no, do not approve.

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:
[NOTE: Enter proactive PAs for other UM overrides not including Opioid-Naive Cumulative Dosing, if applicable.]

While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because you are considered opioid naive (those who have not used opioid drugs within the past 60 days) and the opiate amount exceeds or is equal to [enter soft stop threshold]-mg morphine milligram equivalent (MME) or [enter hard stop threshold]-mg morphine milligram equivalent (MME). [Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID-NAIVE CUMULATIVE DOSING allows approval of a higher quantity of an opioid medication if at least ONE of the following conditions is met:
   • Diagnosis of active cancer
   • Receiving palliative care or end-of-life care (care focused on treating symptoms of illness)
   • Enrolled in hospice
   • Resident of a long-term care facility or intermediate care for intellectually disabled
   • Diagnosis of sickle cell disease (type of red blood cell disorder)
   • You are not opioid naive

If none of these conditions apply, BOTH of the following criteria must be met:
   • The provider has indicated that the patient's current level of opioid utilization is necessary and required for the level of pain management needed
   • The provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

Please consult your physician and/or your pharmacist to discuss your options or if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

CONTINUE ON NEXT PAGE
Rationale
To ensure appropriate use of opioids and address the prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens. The guideline is based on CDC dosage recommendations stated in the “Initial Opioid Prescribing at High Dosage” measures from the Pharmacy Quality Alliance (PQA) and Managed Medicaid program limits.

This requirement does not apply to patients with a diagnosis of active cancer, in palliative care, hospice patients, or patients living in a long-term care facility. Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease.

In addition, approval is granted if BOTH of the following conditions are met:
- The provider has indicated that the patient’s current level of opioid utilization is necessary and required for the level of pain management needed
- The provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

References

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 12/19
Client Approval: 09/22
P&T Approval: 04/21
OPIOID-NAIVE DAY SUPPLY LIMITATION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/other</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the claim rejecting with the following error code?
   - **REJ-1044: INITIAL FILL DAYS SUPPLY EXCEEDS LIMITS (DS-NAIVE)**

   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient meet at least **ONE** of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is enrolled in hospice
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   - Patient has a diagnosis of sickle cell disease
   - Patient is **NOT** opioid naive
     **(NOTE:** For new patients with no claims history, please refer to the MRF or MedAccess).

   If yes, **approve for one month, for one fill count by HICL or GPI-10 and set DS_NAIVE_OVR to ‘Y’ for Yes.**

   If no, continue to #3.

3. Has the prescriber provided attestation that the opioid medication with the requested day supply is the intended and medically necessary amount for the beneficiary?

   If yes, **approve for one month, for one fill count by HICL or GPI-10 and set DS_NAIVE_OVR to ‘Y’ for Yes.**

   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUE ON NEXT PAGE
OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT: While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the day supply you are requesting for this opioid medication.

[Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID-NAIVE DAY SUPPLY LIMITATION allows approval of the requested drug for a longer day supply when you meet at least ONE of the following conditions:

A. You have active cancer
B. You are enrolled in hospice
C. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of blood disorder)
F. You are NOT opioid naïve (you have been consistently using opioid pain medications)
G. Your doctor confirms (attests) that the prescribed dose of opioids with the requested day supply is intended and medically necessary

Please consult your doctor if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this medication.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
To ensure appropriate use of opioids and addressing prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens.

In addition, align with the opioid restrictions from the CMS 2019 Call Letter: “Beginning in 2019, we expect all Part D sponsors to implement a hard safety edit to limit initial opioid prescription fills for the treatment of acute pain to no more than a 7 days’ supply…” CMS 2019 Call Letter, page 237

CONTINUE ON NEXT PAGE
RATIONAL (CONTINUED)

Prior authorization will be required for opioid prescriptions with a longer day supply for opioid naive patients. This requirement does not apply to patients with a diagnosis of active cancer, patients receiving palliative care or end-of-life care, those enrolled in hospice or residents of a long-term care facility.

In addition, if the patient is determined to NOT be opioid naive during the coverage determination process, they are exempt from this safety edit. This exemption is based on the following guidance: “If during the coverage determination process, it becomes known that the patient is not opioid naive, he or she should be excluded from the opioid naive edit.” CMS Additional Guidance memo from October 23, 2018, page 8.

Following CMS guidance, patients with a diagnosis of sickle cell disease are also exempt from this restriction based on acute attacks and painful complications associated with the disease. This guideline also allows an override when there is attestation from the prescriber that the prescribed dose of opioids with the requested day supply is intended and medically necessary.

REFERENCES

### OPIOID NAIVE FILL LIMIT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

1. Is the claim rejecting with the following error code? **REJ-306-1066: THIS CLAIM EXCEEDS LIMIT OF 2 OPIOID FILLS IN 30 DAYS**
   
   **[NOTE]:** The incoming opioid analgesic claim will reject if an initially opioid-naive member exceeds two opioid fills regardless of day supply, for the same drug (HICL), within the past 30 days. In addition, the patient is considered opioid-naive if they have no history of an opioid analgesic drug(s) in the past 60 days (not counting same day claims).]
   
   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient meet at least ONE of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is in hospice care
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled
   - Patient has a diagnosis of sickle cell disease
   
   If yes, approve for 12 months by HICL or GPI-10 and set FILL_LIMIT_OVR to ‘Y’ for Yes.
   If no, continue to #3.

3. Has the prescriber indicated that the additional fill of the requested opioid analgesic medication is intended and clinically appropriate for the patient?
   
   **[NOTE]:** Refer to the Medical Request Form (MRF) or chart notes if provided (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.
   
   If yes, approve for 1 month, for one fill count by HICL or GPI-10 and set FILL_LIMIT_OVR to ‘Y’ for Yes.
   If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON THE NEXT PAGE**
OPIOID NAIVE FILL LIMIT

GUIDELINES FOR USE (CONTINUED)

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:
[NOTE: Enter proactive PAs for other UM overrides not including the Opioid Naive Fill Limit, if applicable.]

While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because you exceeded the fill limit of the requested opioid analgesic.

[Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID NAIVE FILL LIMIT allows an approval of the requested drug when it exceeds the fill limit for an initially opioid-naïve patient (those who have not used opioid drugs within the past 60 days) when ONE of the following conditions is met:
A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms that the additional fill of the requested opioid analgesic (pain-relieving) medication is intended and clinically appropriate for you

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON THE NEXT PAGE
OPID NAIVE FILL LIMIT

RATIONALE
To ensure appropriate use of opioids and to address prescription opioid overuse from a medication safety perspective while preserving patient access to medically necessary drug regimens.

In addition, the goal is to align with the opioid restrictions from the SUPPORT Act. The SUPPORT Act is an acronym for the Congress HR 6 - Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. The rule identified six requirements that each State and Managed Care Entity must have in place by October 1, 2019. CMS defined the SUPPORT Act requirements as minimum Drug Utilization Review (DUR) standards for MMCPs and they are listed below:

- Safety edits, as specified by the states, for subsequent opioid fills and maximum daily morphine milligram equivalent that exceed state-defined limitations
- Automated process that monitors when an individual is concurrently prescribed opioids and benzodiazepines or antipsychotics
- Monitoring antipsychotic prescribing for children
- Process that identifies potential fraud or abuse by enrolled individuals and pharmacies
- Report to the Secretary annually on state DUR activities
- Have in place managed care contracts that include these provisions

CMS noted that minimum standards may be expanded by the states or CMS in future rule making.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 03/01/21
Client Approval: 02/21
P&T Approval: 04/21

Created: 08/19
GUIDELINES FOR USE

1. Is the request for an opioid product equal to or exceeding the soft-stop threshold hard-stop threshold as noted in the POS reject messaging?

   NOTE: Claims should stop for DUR_MAX_SINGLE_DOSE edit with Soft_DENY_LIMIT = X or HARD_DENY_LIMIT = X (i.e., morphine milligram equivalent of [patient's current MME] = / exceeds threshold of [soft-stop threshold-mg MME or hard-stop threshold-mg MME]).

   If yes, continue to #2.
   If no, guideline does not apply.

2. Is the request for an opioid product less than or equal to the hard-stop threshold-1 MME?

   If yes, approve 12 months by HICL or GPI-10 up to hard-stop threshold-1 MME. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).
   If no, continue to #3.

3. Does the patient meet ANY of the following criteria?
   • Diagnosis of active cancer
   • Diagnosis of palliative care
   • Diagnosis of sickle cell disease
   • Patient is enrolled in hospice
   • Prescriber is a pain management specialist

   If yes, approve 12 months by HICL or GPI-10. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).
   If no, continue to #4.

4. Has the physician provided attestation that the requested high dose is considered medically necessary?

   If yes, continue to #5.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

5. Is the request for an opioid with an MME equal to or exceeding the hard-stop threshold and the prescriber has not indicated an opioid MME threshold value?

   If yes, approve for 12 months by HICL or GPI-10 up to 25% greater than the previously approved MME via the patient’s claim profile or physician attestation, up to 300 MME.
   (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).
   If no, continue to #6.

6. Did the physician indicate a maximum opioid threshold for the requested drug that is less than 300 MME?

   If yes, approve for 12 months by HICL or GPI-10 as requested up to 300 MME. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).
   If no, continue to #7.

7. Is the request for an opioid with an MME equal to or exceeding the maximum threshold (300 MME) for a patient who is currently stable on this MME?

   If yes, approve for 3 months by HICL or GPI-10. (NOTE: If the claim rejects after analyzing, follow the clinical prior authorization process).
   APROVAL TEXT: While your prior authorization for (enter requested drug) has been granted, your opiate amount is equal to or exceeds [300 morphine milligram equivalent (MME)] and is considered a high dose of opiate. Please consult with your pain management specialist regarding your treatment options.

   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named OPIOID SINGLE CLAIM DOSING AT POS allows for an override of an opioid product equal to or exceeding the soft-stop threshold of [enter soft stop threshold]-mg morphine milligram equivalent (MME) at the pharmacy or by a prior authorization. The hard-stop threshold of [enter hard stop threshold]-mg morphine milligram equivalent (MME) is not overdridable and requires a prior authorization.
   (Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

An override will be provided if ONE (A or B) of the following rule(s) are met:

A. You meet ONE of the following conditions:
   1. You have active cancer
   2. You are receiving treatment for palliative care (treatment for comfort from symptoms)
   3. You have sickle cell disease (type of blood disorder)
   4. You are enrolled in a hospice
   5. Your doctor is a pain management specialist

B. Your physician confirms that the requested high dose is considered medically necessary.
   1. If the requested dose is lower than 300 MME, your prescriber must provide a maximum opioid threshold. If your prescriber does not provide a maximum threshold and the request is for an opioid with an MME equal to or exceeding [enter hard-stop threshold]-mg morphine milligram equivalent (MME), the claim will be approved up to 25 percent greater than the previously approved MME.
   2. If the requested dose is equal to or greater than 300 MME, approval will be granted if you are stable on the dose.

Please consult your pain management specialist regarding your treatment options.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
To align with opioid restrictions required by several states and to prevent overutilization of opioids and increase safety.

This advanced POS intervention blocks an incoming claim when a single claim’s Morphine Milligram Equivalent (MME) is equal to or exceeds a specified hard-stop threshold (e.g. over 90 MME). The hard-stop is non-overridable except via prior authorization. The edit allows a soft stop on an incoming claim with an MME equal to or over a lower threshold (e.g. over 50 MME) that can be overridden by Pharmacy Professional Service (pps) codes at the point-of-sale (POS) or by prior authorization. Overriding the hard threshold for OSCDP will also override the OSCDP soft threshold, but does not affect Opioid Cumulative Dosing Program (OCDP).

This requirement does not apply to patients with a diagnosis of active cancer, sickle cell disease, in palliative care, hospice patients, or patients with a prescription from a pain management specialist.

CONTINUED ON NEXT PAGE
REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 06/18
Client Approval: 09/22
P&T Approval: 07/18
GUIDELINES FOR USE

1. Is the claim rejecting with the following error code?
   - **REJ- 433-1204: SOMA-OPIOID-BENZODIAZEPINE CONFLICT FOUND**
     (H: DUR_CONCURRENT_USE)
     
     If yes, continue to #2.
     If no, guideline does not apply.

2. Does the patient meet at least ONE of the following criteria?
   - Patient has a diagnosis of active cancer
   - Patient is in hospice care
   - Patient is receiving palliative care or end-of-life care
   - Patient is a resident of a long-term care facility or intermediate care for intellectually disabled

   If yes, approve for 12 months by HICL or GPI-10 and set DUR_CONCURRENT_OVR to ‘SOMA_OP_BZD’.
   If no, continue to #3.

3. Has the prescriber indicated that the concurrent use of an opioid with Soma (carisoprodol) and a benzodiazepine medication is intended and clinically appropriate for the patient?

   [NOTE: Refer to the Medical Request Form (MRF) or chart notes if provided (e.g., patient is stable on the requested drug, patient needs to continue use, etc.). The member cannot provide this information.]

   If yes, approve for one (1) month by HICL or GPI-10 and set DUR_CONCURRENT_OVR to ‘SOMA_OP_BZD’.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

   **CONTINUED ON THE NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

OPTIONAL OPERATIONAL DENIAL TEXT FOR APPROVAL OF CLINICAL UM, BUT DENIAL OF THE OPIOID SAFETY EDIT:
[NOTE: Enter proactive PAs for other UM overrides not including Opioid-Soma-Benzodiazepine Concurrent Use, if applicable.]
While your request for [enter approved UM] for [enter requested drug] has been granted, the drug has not been approved because of the use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together.

[Proceed to enter Denial Text below]

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE allows an approval for use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together when one of the following criteria is met:
A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. Your doctor confirms that the use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together is intended and clinically appropriate for you

Please consult your physician if you have any questions about this prescription pain medication and the requirements needed for you to obtain an approval for this agent.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON THE NEXT PAGE
OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE

RATIONALE
To mitigate the risk of the overdose from dangerous combinations of CNS depressants while preserving patient access to drug regimens if deemed medically necessary.
The Opioid-Benzodiazepine-Soma Concurrent Use at POS edit will identify and deny concurrent use of opioids, benzodiazepines, and carisoprodol when there is an overlap in day supply (for at least one drug from each ‘class’). This edit will reject the claim that creates the three-drug overlap.
The edit will have internal reject codes REJ-433-1204, and the following parameters:
1. Triple drug overlap = 1 day
2. Prescriber threshold = 1 prescriber
3. Exceptions =
   a) Cancer diagnosis (edit will lookback for presence of claims related to these diseases in the past 180 days to automatically exclude from the edit)
   b) Hospice or palliative care (edit will look for hospice attribute on claims to automatically exclude from the edit)
   c) Long Term Care residence (edit will look for patient residence code to automatically exclude from the edit)
Please note that sickle cell disease will not be included in the exception criteria. Although opioids and benzodiazepines can be used in managing pain crises, treatment guidelines do not mention skeletal muscle relaxants such as carisoprodol as a typical treatment modality.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 07/19
Commercial Effective: 03/01/21 Client Approval: 02/21 P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Cushing's disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an endocrinologist
   - Pituitary surgery is not an option or has not been curative for the patient
   - The patient had a trial of or contraindication to oral ketoconazole

If yes, approve for 6 months for all strengths by GPID or GPI-14 with the following quantity limits:
   - 1mg: #8 per day.
   - 5mg: #12 per day.
   - 10mg: #6 per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OSILODROSTAT (Isturisa) requires the following rule(s) be met for approval:
A. You have Cushing's disease (a type of hormone disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
D. Pituitary (major hormone gland) surgery is not an option or has not cured your condition
E. You had a trial of or contraindication (harmful for) to oral ketoconazole

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of Cushing's disease and meet ALL the following criteria?
   • The patient continues to have improvement of Cushing's disease (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
   • The patient maintains tolerability to Isturisa

   If yes, approve for 12 months for all strengths by GPID or GPI-14 with the following quantity limits:
   • 1mg: #8 per day.
   • 5mg: #12 per day.
   • 10mg: #6 per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OSILODROSTAT (Isturisa) requires the following rule(s) be met for renewal:
A. You have Cushing’s disease (a type hormone disorder)
B. You continue to have improvement of Cushing’s disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
C. You continue to tolerate treatment with Isturisa

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Isturisa.

REFERENCES
• Isturisa [Prescribing Information]. Lebanon, NJ: Recordati Rare Diseases, Inc.; March 2020.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 08/20
Client Approval: 06/23
P&T Approval: 07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
OSIMERTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSIMERTINIB MESYLATED</td>
<td>TAGRISSO</td>
<td>42803</td>
<td></td>
<td>GPI-10</td>
<td>(2136006820)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication is being used as adjuvant therapy after tumor resection
   • The patient is positive for an epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations and is confirmed by an FDA-approved test
   • Tagrisso will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva, Iressa, Gilotrif, Vizimpro)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Tagrisso will NOT be used concurrently with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Tarceva, Iressa, Gilotrif, Vizimpro)

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient's tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test **AND** Tagrisso will be used as first-line treatment?

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, continue to #4.

4. Does the patient's tumor have epidermal growth factor receptor (EGFR) T790M mutation, as detected by an FDA-approved test **AND** the patient meets the following criterion?
   • The patient’s disease has progressed while on or after epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor therapy (e.g., Tarceva, Iressa, or Gilotrif)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OSIMERTINIB (Tagrisso) requires the following rule(s) be met for approval:
A. You have non-small cell lung cancer (type of lung cancer)
B. You are 18 years of age or older
C. If you have non-small cell lung cancer, approval also requires:
   1. Tagrisso is being used as adjuvant therapy (add-on treatment) after tumor resection (surgical removal of a tumor)
   2. Your tumor is positive for an epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R (type of genes) mutations, as detected by an FDA-approved test
   3. You will NOT be using Tagrisso concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Iressa, Gilotrif, Vizimpro)
D. If you have metastatic non-small cell lung cancer (cancer that has spread throughout the body), approval also requires:
   1. You will NOT receiving another epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Iressa, Gilotrif, Vizimpro) together with Tagrisso
   2. You meet ONE of the following:
      a. Your tumor is positive for epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R (types of genes) mutations as confirmed by an FDA-approved test AND Tagrisso will be used as first-line treatment (initial treatment)
      b. Your tumor is positive for an epidermal growth factor receptor (EGFR) T790M (type of gene) mutation, as detected by an FDA (Food and Drug Administration)-approved test AND your disease has progressed (worsening of disease) while on or after EGFR tyrosine kinase-inhibitor therapy such as (Tarceva, Iressa, Gilotrif)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
OSIMERTINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tagrisso.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 11/15
Commercial Effective: 07/01/22 Client Approval: 05/22 P&T Approval: 04/22
**OTESECONAZOLE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>OTOSECONAZOLE</td>
<td>VIVJOA</td>
<td>47976</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(1140805000)</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

1. Is the request for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) and the patient meets **ALL** of the following criteria?
   - The patient is female
   - The patient is **NOT** of reproductive potential (defined as a biological female who is postmenopausal or has another reason for permanent infertility [e.g., tubal ligation, hysterectomy, salpingo-oophorectomy])
   - The patient is **NOT** currently on ibrexafungerp for RVVC

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Has the patient previously received Vivjoa?

   If yes, continue to #4.
   If no, continue to #3.

3. Has the patient had 3 or more episodes of VVC in the past 12 months?

   If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #18 per 12 weeks**.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Does the patient meet **ALL** of the following criteria?
   - The patient has successfully completed a course of Vivjoa for prevention of RVVC
   - The patient is either being treated or has just completed treatment for a new recurrence of VVC

   If yes, **approve for 3 months by HICL or GPI-10 with a quantity limit of #18 per 12 weeks**.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
OTESECONAZOLE

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OTESECONAZOLE (Vivjoa) requires the following rule(s) be met for approval:
A. You have recurrent vulvovaginal candidiasis (RVVC: a repeating vaginal fungal infection)
B. You are female
C. You are not able to reproduce, which means you are a biological female and are postmenopausal (after menopause) or you have another reason for permanent infertility (such as tubal ligation [having tubes tied], hysterectomy [removal of the uterus], salpingo-oophorectomy [removal of an ovary and its fallopian tube])
D. You are NOT currently on ibrexafungerp for RVVC
E. If you have not previously received Vivjoa, approval also requires:
   1. You had 3 or more episodes of RVVC in the past 12 months
F. If you have previously received Vivjoa, approval also requires:
   1. You have successfully completed a course of Vivjoa for prevention of RVVC
   2. You are either being treated or have just completed treatment for a new recurrence of VVC

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vivjoa.

REFERENCES
• Vivjoa [Prescribing Information]. Durham, NC: Mycovia Pharmaceuticals, Inc.; April 2022.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of blepharoptosis and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
   • The patient has been evaluated for surgical intervention
   • The patient had a trial of TWO ophthalmic alpha-adrenergic agonists (e.g., apraclonidine, tetrahydrozoline, naphazoline)

   If yes, approve for 3 months by HICL or GPI-10 with a quantity limit of #1 droperette per day.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OXYMETAZOLINE (Upneeq) requires the following rule(s) be met for approval:
A. You have blepharoptosis (drooping of the upper eyelid)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
D. You have been evaluated for surgical intervention
E. You had a trial of TWO ophthalmic alpha-adrenergic agonists (such as apraclonidine, tetrahydrozoline, naphazoline)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
OXYMETAZOLINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of blepharoptosis AND meet the following criterion?
   • The patient continues to have benefit from Upneeq

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 droperette per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named OXYMETAZOLINE (Upneeq) requires the following rule(s) be met for renewal:
   D. You have blepharoptosis (drooping of the upper eyelid)
   E. You continue to have benefit from Upneeq

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Upneeq.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 11/21
Client Approval: 02/22
P&T Approval: 10/21
OZANIMOD

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of ONE sphingosine-1-phosphate receptor modulator (e.g., Gilenya [fingolimod], Mayzent [Siponimod])
   - The patient had a trial of ONE agent indicated for the treatment of multiple sclerosis (e.g., Aubagio [teriflunomide], Tecfidera [dimethyl fumarate], Mavenclad [cladribine])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance programs do not qualify]

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: See the initial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OZANIMIOD (Zeposia) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. A relapsing form of multiple sclerosis (MS: type of nerve disorder) to include clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)
   2. Moderate to severe ulcerative colitis (UC: a type of digestive condition)
B. If you have a relapsing form of multiple sclerosis, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of ONE sphingosine-1-phosphate receptor modulator (such as Gilenya [ fingolimod], Mayzent [Siponimod])
   3. You had a trial of ONE agent indicated for the treatment of multiple sclerosis (such as Aubagio [teriflunomide], Tecfidera [dimethyl fumarate], Mavenclad [cladribine])
C. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, mesalamine
   4. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-abdm)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

NOTE: For the diagnosis of multiple sclerosis, please refer to the Initial Criteria section.

1. Does that patient have a diagnosis of moderate to severe ulcerative colitis (UC) AND meet the following criterion?
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named OZANIMIOD (Zeposia) requires the following rule(s) be met for renewal:
A. You have moderate to severe ulcerative colitis (UC: a type of digestive condition)
B. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zeposia.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has a platelet count below 50,000/uL

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PACRITINIB (Vonjo) requires the following rule(s) be met for approval:
A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocytopenia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
B. You are 18 years of age or older
C. You have a platelet count below 50,000/uL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis (MF)?

   If yes, continue to #2.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Has the patient shown symptom improvement by meeting ONE of the following criteria?
   • The patient has a spleen volume reduction of 35% or greater from baseline
   • The patient has a 50% or greater reduction in total symptom score (e.g., Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   • The patient has a 50% or greater reduction in palpable spleen length

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PACRITINIB (Vonjo) requires the following rule(s) be met for renewal:
   A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocythemia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
   B. You have shown symptom improvement by meeting ONE of the following:
      1. You have a spleen volume reduction of 35% or greater from baseline
      2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
      3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vonjo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 03/22
Client Approval:03/22
P&T Approval: 10/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ALL the following criteria?
   - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Will Ibrance be used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) AND the patient meets the following criterion?
   - The patient has NOT received prior endocrine-based therapy (e.g., letrozole, anastrozole, tamoxifen)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.
   If no, continue to #3.

3. Will Ibrance be used in combination with Faslodex (fulvestrant) AND the patient meets the following criterion?
   - The patient has experienced disease progression following endocrine therapy (e.g., letrozole, anastrozole, tamoxifen)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
PALBOCICLIB

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PALBOCICLIB (Ibrance) requires the following rule(s) be met for approval:
A. You have advanced or metastatic breast cancer (cancer that has worsened or has spread to other parts of the body)
B. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
C. You meet ONE of the following:
   1. Ibrance will be used in combination with an aromatase inhibitor (such as anastrozole, letrozole, exemestane) AND you have not received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen)
   2. Ibrance will be used in combination with Faslodex (fulvestrant) AND your disease has worsened after endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ibrance.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 05/15
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of multiple myeloma and meets ALL of the following criteria?
   - The patient has been treated with at least 2 prior regimens, including Velcade (bortezomib) and an immunomodulatory agent, such as Thalomid, Revlimid, or Pomalyst
   - The requested medication will be used concurrently with Velcade (bortezomib) and dexamethasone

   If yes, approve for 12 months by HICL or GPI-10 for #6 per 21 days with a fill count of 8 (8 cycles).

   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PANOBINOSTAT (Farydak) requires the following rule(s) be met for approval:
   A. You have multiple myeloma (cancer that forms in a type of white blood cell)
   B. You have been treated with at least 2 prior regimens including:
      1. Velcade (bortezomib)
      2. Immunomodulatory medication such as Thalomid, Revlimid, or Pomalyst. (These drugs adjust immune responses)
   C. The requested medication will be used in combination with Velcade (bortezomib) and dexamethasone

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Has the patient tolerated the first 8 cycles of therapy without any severe or medically significant toxicity?

   If yes, approve for 12 months by HICL or GPI-10 for #6 per 21 days with fill count of 8 (8 cycles).
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named PANOBINOSTAT (Farydak) requires the following rule(s) be met for renewal:
   A. You have tolerated the first 8 weeks of therapy without experiencing any severe or medically significant toxicity

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Farydak.

REFERENCES
• Farydak [Prescribing Information]. East Hanover, NJ: Novartis; September 2019.
PARATHYROID HORMONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARATHYROID HORMONE</td>
<td>NATPARA</td>
<td>34000</td>
<td></td>
<td>GPI-10 (3004405510)</td>
<td>ROUTE = SUBCUTANE.</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of hypocalcemia secondary to hypoparathyroidism and meets the following criteria?
   - Previous trial of activated vitamin D (calcitriol) and calcium
   - Patient’s hypoparathyroidism is not due to a calcium sensing receptor (CSR) mutation
   - Patient’s hypoparathyroidism is not considered acute post-surgical hypoparathyroidism (surgery in past 30 days)
   - Therapy is prescribed by or given in consultation with an endocrinologist

   If yes, approve for 12 months by HICL or GPI-10 for quantity of #2 cartridges per 28 days. If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline for PARATHYROID HORMONE requires the following rule(s) be met for approval:
   A. You have hypocalcemia secondary to hypoparathyroidism (low blood calcium due to low levels of a type of hormone)
   B. You have previously tried activated vitamin D (calcitriol) and calcium
   C. Your hypoparathyroidism (low levels of a type of hormone) is not due to a calcium sensing receptor (CSR) mutation (changes in your DNA that make up your gene)
   D. Your hypoparathyroidism is not considered acute post-surgical hypoparathyroidism (not sudden and severe due to surgery in past 30 days)
   E. Therapy is prescribed by or given in consultation with an endocrinologist (hormone specialist)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PARATHYROID HORMONE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Natpara.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 04/15
Client Approval: 04/20
P&T Approval: 05/15
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Cushing’s disease (CD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with an endocrinologist
   - The patient has undergone pituitary surgery or pituitary surgery is not an option for this patient
   - The patient had a trial of or contraindication to oral ketoconazole

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PASIREOTIDE (Signifor) requires the following rule(s) be met for approval:
A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotropic hormone [ACTH])
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
D. You have undergone pituitary (a major hormone gland) surgery OR pituitary surgery is not an option
E. You have previously tried oral ketoconazole, unless there is a medical reason you are cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PASIREOTIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Cushing’s disease (CD) and meet ALL of the following criteria?
   - The patient continues to have improvement of Cushing’s disease (e.g., clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
   - The patient maintains tolerability to Signifor

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PASIREOTIDE (Signifor) requires the following rule(s) be met for renewal:
   A. You have Cushing’s disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotropic hormone [ACTH])
   B. You continue to have improvement of Cushing’s disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
   C. You continue to tolerate treatment with Signifor

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL

For further information, please refer to the Prescribing Information and/or Drug Monograph for Signifor.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 10/01/20  
Created: 05/13  
Client Approval: 08/20  
P&T Approval: 07/20  

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Is the patient being treated for hyperkalemia AND meet the following criterion?
   • Therapy is prescribed by or given in consultation with a nephrologist or cardiologist

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   • The requested medication is being used as an emergency treatment for life-threatening hyperkalemia
   • The patient is currently receiving dialysis

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, continue to #3.

3. Has the patient attempted ONE of the following approaches in an effort to reduce the modifiable risks for hyperkalemia?
   • Limit to taking no more than one of the following drugs at any given time:
     o Angiotensin converting enzyme inhibitor (ACE-I)
     o Angiotensin receptor blocker (ARB)
   • Consideration of dose reduction of renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE-I's, ARB's, aldosterone antagonists)

   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Does the patient have an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² AND meet the following criterion?
   • The patient has tried loop diuretics (e.g., bumetanide, ethacrynic acid, furosemide, torsemide) for the treatment of hyperkalemia

   If yes, continue to #6.
   If no, continue to #5.

CONTINUED ON NEXT PAGE
5. Does the patient have an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m² or above and have tried ONE of the following for the treatment of hyperkalemia?
   - The patient has tried loop diuretic (e.g., bumetanide, ethacrynic acid, furosemide, torsemide)
   - The patient has tried thiazide diuretic (e.g., chlorothalidone, hydrochlorothiazide, metolazone)

   If yes, continue to #6.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Has the patient had a previous trial of Lokelma (sodium zirconium cyclosilicate)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #30 packets per 30 days.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PATIROMER (Veltassa) requires the following rule(s) be met for approval:
   A. You have hyperkalemia (high levels of potassium in blood)
   B. Therapy is prescribed by or given in consultation with a nephrologist (kidney doctor) or cardiologist (heart doctor)
   C. The requested medication is NOT being used as an emergency treatment for life-threatening hyperkalemia (high levels of potassium in blood)
   D. You are NOT currently receiving dialysis
   E. You have tried ONE of the following to lower the risks for hyperkalemia:
      1. Limit to taking no more than one of the following drugs at any given time:
         i. Angiotensin converting enzyme inhibitor (ACE-I such as lisinopril, benazepril)
         ii. Angiotensin receptor blocker (ARB such as valsartan, losartan)
      2. Lowering the dose of renin-angiotensin-aldosterone system (RAAS) inhibitors (such as ACE-I’s, ARB’s, aldosterone antagonists like spironolactone) has been considered
   F. **If your estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m(2), approval also requires:**
      1. You have tried to treat hyperkalemia with loop diuretics such as bumetanide, ethacrynic acid, furosemide, torsemide

   (Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

G. If your estimated glomerular filtration rate (eGFR) is 30 mL/min/1.73 m(2) or above approval also requires:
   1. You have tried to treat hyperkalemia with a loop diuretic such as bumetanide, ethacrynic acid, furosemide, torsemide, OR a thiazide diuretic such as chlorthalidone, hydrochlorothiazide, metolazone
   
H. You have previously tried Lokelma (sodium zirconium cyclosilicate)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Review for Veltassa.

REFERENCES

<table>
<thead>
<tr>
<th></th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Library</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>NSA</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 2/16
Commercial Effective: 07/01/20 Client Approval: 04/20
P&T Approval: 01/19
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced soft tissue sarcoma (STS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received prior chemotherapy (e.g., anthracycline treatment)
   - The patient does NOT have a diagnosis of adipocytic soft tissue sarcoma (STS) or gastrointestinal stromal tumors (GIST)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PAZOPANIB (Votrient) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
   2. Advanced soft tissue sarcoma (STS: cancer that starts in soft tissues like muscle, tendons, fat, lymph vessels, blood vessels, and nerves)
B. If you have advanced renal cell carcinoma, approval also requires:
   1. You are 18 years of age or older
C. If you have advanced soft tissue sarcoma, approval also requires:
   1. You are 18 years of age or older
   2. You have received prior chemotherapy (cancer treatment such as anthracycline treatment)
   3. You do NOT have adipocytic soft tissue sarcoma (type of cancer in fat cells) or gastrointestinal stromal tumors (GIST: type of cancer that starts in a type of cell in the digestive system)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PAZOPANIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Votrient.

REFERENCES
- Votrient [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A        Created: 05/11
Commercial Effective: 04/11/22 Client Approval: 03/22        P&T Approval: 08/16
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a peanut allergy and meet ALL of the following criteria?
   - The patient is 4 to 17 years of age
   - Therapy is prescribed by or in consultation with an allergist or immunologist
   - The patient has a clinical history of allergic reaction to peanuts
   - Palforzia will be used in conjunction with a peanut-avoidance diet
   - Palforzia will NOT be used concurrently with a peanut-specific immunotherapy (e.g., Viaskin Peanut)

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Has the patient completed a purposeful food challenge and has a documentation (e.g., chart notes, lab results, diagnostic test results, etc.) of ONE of the following criteria?
   - The patient tested positive on a skin prick test with a wheal diameter of at least 3 mm within the past 24 months
   - The patient has a peanut-specific immunoglobulin E level of at least 0.35 kUA/L within the past 24 months

   If yes, **approve for 12 months by GPID or GPI-14 for all of the following:**
   - 300 mg powder packet/sachet: #1 per day.
   - All other strengths: No quantity limit.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Has the patient NOT completed a purposeful food challenge and has a documentation (e.g., chart notes, lab results, diagnostic test results, etc.) of ONE of the following criteria?
   - The patient tested positive on a skin prick test with a wheal diameter of at least 8 mm within the past 24 months
   - The patient has a peanut-specific immunoglobulin E level of at least 14 kUA/L within the past 24 months

If yes, approve for 12 months by GPID or GPI-14 for all of the following:
300 mg powder packet/sachet: #1 per day.
All other strengths: No quantity limit.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEANUT ALLERGEN POWDER-DNFP (Palforzia) requires the following rule(s) be met for approval:
A. You have a peanut allergy
B. You are 4 to 17 years of age
C. Therapy is prescribed by or in consultation with an allergist (allergy doctor) or immunologist (immune system doctor)
D. You have a clinical history of an allergic reaction to peanuts
E. Palforzia will be used together with a peanut-avoidance diet
F. Palforzia will NOT be used concurrently (at the same time) with peanut-specific immunotherapy (such as Viaskin Peanut)
G. You meet ONE of the following:
   1. If you have completed a purposeful food challenge (a type of test): you have documentation (such as chart notes, lab results, diagnostic test results) of a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 3 mm within the past 24 months, OR you had a peanut-specific immunoglobulin E (IgE: a blood test that indicates an allergy to peanuts) level of at least 0.35 kUA/L within the past 24 months
   2. If you have NOT completed a purposeful food challenge: you have documentation (such as chart notes, lab results, diagnostic test results) of a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 8 mm within the past 24 months, OR you had a peanut-specific immunoglobulin E (IgE: a blood test that indicates an allergy to peanuts) level of at least 14 kUA/L within the past 24 months

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a peanut allergy and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with an allergist or immunologist
   • Palforzia will be used in conjunction with a peanut-avoidance diet
   • Palforzia will NOT be used concurrently with a peanut-specific immunotherapy (e.g., Viaskin Peanut)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient completed a purposeful food challenge?
   
   If yes, continue to #3.
   If no, continue to #4.

3. Does the patient have a documentation (e.g., chart notes, lab results, diagnostic test results, etc.) of a persistent peanut allergy and meets ONE of the following criteria?
   • The patient tested positive on a skin prick test with a wheal diameter of at least 3 mm within the past 24 months
   • The patient has a peanut-specific immunoglobulin E level of at least 0.35 kUA/L within the past 24 months

   If yes, approve for 12 months by GPID or GPI-14 for all of the following:
   300 mg powder packet/sachet: #1 per day.
   All other strengths: No quantity limit.

   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a documentation (e.g., chart notes, lab results, diagnostic test results, etc.) of a persistent peanut allergy and meets ONE of the following criteria?
   - The patient tested positive on a skin prick test with a wheal diameter of at least 8 mm within the past 24 months
   - The patient has a peanut-specific immunoglobulin E level of at least 14 kUA/L within the past 24 months

If yes, approve for 12 months by GPID or GPI-14 for all of the following:
300 mg powder packet/sachet: #1 per day.
All other strengths: No quantity limit.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEANUT ALLERGEN POWDER-DNFP (Palforzia) requires the following rule(s) be met for renewal:
A. You have an allergy to peanuts
B. Therapy is prescribed by or in consultation with an allergist (allergy doctor) or immunologist (immune system doctor)
C. Palforzia will be used together with a peanut-avoidance diet
D. Palforzia will NOT be used concurrently (at the same time) with peanut-specific immunotherapy (such as Viaskin Peanut)
E. You meet ONE of the following:
   1. If you have undergone a purposeful food challenge (a type of test): you have documentation (such as chart notes, lab results, diagnostic test results) of a persistent peanut allergy based on a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 3 mm, OR peanut-specific immunoglobulin E (IgE: a blood test that indicates an allergy to peanuts) level of at least 0.35 kUA/L within the past 24 months
   3. If you have NOT undergone a purposeful food challenge: you have documentation (such as chart notes, lab results, diagnostic test results) of a persistent peanut allergy based on a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 8 mm, OR you had a peanut-specific immunoglobulin E (IgE: a blood test that indicates an allergy to peanuts) level of at least 14 kUA/L within the past 24 months

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PEANUT ALLERGEN POWDER-DNFP

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Palforzia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/20
Commercial Effective: 08/01/23  Client Approval: 06/23  P&T Approval: 07/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or given in consultation with a hematologist
   • The patient has documented confirmation of PNH by flow cytometry demonstrating ALL of the following:
     o At least 2 different GPI-protein deficiencies (e.g., CD55, CD59) on at least 2 cell lineages (e.g., erythrocytes, granulocytes)
     o PNH granulocyte clone size of 10% or greater
   • The patient is NOT concurrently using C5 complement inhibitor therapy (e.g., Soliris, Ultomiris)
   • The patient has tried and failed Soliris or Ultomiris as evidenced by hemoglobin levels <10.5 g/dL directly following at least 3 months of stable dosing

If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #200mL per 30 days.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGCETACOPLAN (Empaveli) requires the following rule(s) be met for approval:
A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare disorder that causes red blood cells break)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist) (Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. You have documented confirmation of PNH by flow cytometry (type of measurement of physical and chemical qualities of cells) demonstrating ALL of the following:
   1. At least 2 different GPI-protein deficiencies (missing a certain type of protein such as CD55, CD59) on at least 2 cell lineages (types of cells such as erythrocytes, granulocytes)
   2. PNH granulocyte clone size of 10% or greater
E. You have tried and failed Soliris or Ultomiris as evidenced by hemoglobin (type of protein in red blood cells) levels less than 10.5 g/dL, directly following at least 3 months of stable dosing
F. You are not concurrently (at the same time) using C5 complement inhibitor therapy (such as Soliris, Ultomiris)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) and meet ALL of the following criteria?
   • The patient had a clinical benefit while on Empaveli (e.g., reduction in number of blood transfusions, improvement/stabilization of lactate dehydrogenase (LDH) or hemoglobin levels) compared to baseline (baseline defined as patient condition post treatment with Soliris or Ultomiris)
   • The patient is NOT concurrently using a C5 complement inhibitor therapy (e.g., Soliris, Ultomiris)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #200mL per 30 days.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGCETACOPLAN (Empaveli) requires the following rule(s) be met for renewal:
A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare disorder that causes red blood cells break)
(Re...
RENEWAL CRITERIA (CONTINUED)

B. You are not concurrently (at the same time) using a C5 complement inhibitor therapy (such as Soliris, Ultomiris)

C. You had a clinical benefit while on Empaveli (such as reduction in number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: type of enzyme] or hemoglobin levels [type of protein in red blood cells]) compared to baseline (baseline defined as your condition post treatment with Soliris or Ultomiris)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Empaveli.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/24/22
Created: 05/21
Client Approval: 10/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) AND does the patient meet the following criterion?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist

   If yes, continue to #4.
   If no, continue to #2.

2. Does the patient have a non-myeloid malignancy and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

   If yes, continue to #3.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Is the request for Neulasta Onpro kit AND the patient meets the following criterion?
   - The patient has a barrier to access (e.g., travel barriers, or the patient is unable to return to the clinic for Neulasta injections)

   If yes, **approve Neulasta Onpro for 12 months by GPID or GPI-14.**
   If no, continue to #4.

4. Has the patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)?

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGFILGRASTIM (Neulasta, Neulasta Onpro) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. You will be using Neulasta to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)
   2. You have a non-myeloid malignancy (cancer not affecting bone marrow)
B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You meet ONE of the following:
      a. The request is for Neulasta AND you had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)
      b. The request is for Neulasta Onpro AND you have a barrier to access (such as travel barriers, or you are unable to return to the clinic for Neulasta injections)
C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PEGFILGRASTIM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Neulasta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/21
Commercial Effective: 07/01/23  Client Approval: 05/23  P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a non-myeloid malignancy and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #2.

2. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) AND does the patient meet the following criterion?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGFILGRASTIM - APGF (NYVEPRIA) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Nyvepria to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PEGFILGRASTIM-APGF

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nyvepria and Neulasta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/22
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a non-myeloid malignancy and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #2.

2. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) and does the patient meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGFILGRASTIM - BMEZ (Ziextenzo) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Ziextenzo to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ziextenzo and Neulasta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/22
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a non-myeloid malignancy and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

2. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) and does the patient meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGFILGRASTIM - CBQV (Udenyca) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Udenyca to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Udenyca and Neulasta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/22
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a non-myeloid malignancy and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, continue to #2.

2. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) and does the patient meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGFILGRASTIM-FPGK (Stimufend) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Stimufend to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Stimufend and Neulasta.

REFERENCES
• Stimufend [Prescribing Information]. Lake Zurich, IL: Fresenius Kabi USA, LLC, September 2022.
GUIDELINES FOR USE

1. Does the patient have a non-myeloid malignancy and meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, continue to #2.

2. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) and does the patient meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **PEGFILGRASTIM - JMDB (Fulphila)** requires the following rule(s) be met for approval:
A. The request is for **ONE** of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Fulphila to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. **If you have a non-myeloid malignancy, approval also requires**:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

 *(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Fulphila and Neulasta.

REFERENCES
• Fulphila [Prescribing Information]. Zurich, Switzerland: Mylan GmbH; March 2021.
GUIDELINES FOR USE

1. Does the patient have a non-myeloid malignancy and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, continue to #2.

2. Is the request to increase survival in a patient acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome) and does the patient meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hematologist or oncologist
   - The patient had a trial of or contraindication to the preferred agent: Nyvepria (pegfilgrastim-apgf)

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named PEGFILGRASTIM-PBBK (Flyneta) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Flyneta to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. **If you have a non-myeloid malignancy, approval also requires:**
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred agent: Nyvepria (pegfilgrastim-apgf)

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred agent: Nyvepria (pegfilgrastim-apgf)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Fylnetra and Neulasta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A       Created: 10/22
Commercial Effective: 07/01/23      Client Approval: 05/23

P&T Approval: 04/23
GUIDELINES FOR USE

1. Is the patient currently taking the requested medication?
   
   If yes, continue to #2.
   If no, continue to #3.

2. Has the patient received 5 years of therapy with Sylatron?
   
   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, approve for 12 months by HICL or GPI-10.

3. Does the patient have a diagnosis of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection?
   
   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **PEG-INTERFERON ALFA-2B (Sylatron)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You are currently taking Sylatron and have NOT received 5 years of treatment with Sylatron
   2. You have melanoma (skin cancer) with the presence of cancer cells in your lymph nodes (microscopic or gross nodal involvement), within 84 days of surgical removal of the cancer

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
PEG-INTERFERON ALFA-2B

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sylatron.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/20
Created: 05/11
Commercial Effective: 10/01/20
Client Approval: 08/20
P&T Approval: 07/20
GUIDELINES FOR USE

1. Is the request for the treatment of chronic hepatitis C virus infection (HCV)?
   - If yes, do not approve.
     DENIAL TEXT: See the denial text at the end of the guideline.
   - If no, continue to #2.

2. Is the request for Pegasys?
   - If yes, continue to #3.
   - If no, do not approve.
     DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient have chronic hepatitis B AND meet the following criterion?
   - Therapy is prescribed by or in consultation with a gastroenterologist, infectious disease specialist, a physician specializing in the treatment of hepatitis (e.g., a hepatologist), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
   - If yes, continue to #4.
   - If no, do not approve.
     DENIAL TEXT: See the denial text at the end of the guideline.

4. Is the patient between 3 to 17 years of age and meet ALL of the following criteria?
   - The patient does NOT have cirrhosis
   - The patient has serum HBeAg-positive chronic hepatitis B
   - The patient has evidence of viral replication with elevated serum alanine aminotransferase (ALT)
   - If yes, approve for 24 weeks by HICL or GPI-10 with a quantity limit of #4 per 28 days.
   - If no, continue to #5.

CONTINUED ON NEXT PAGE
5. Is the patient 18 years of age or older and meet ALL of the following criteria?
   • The patient has serum HBeAg-positive or HBeAg-negative chronic hepatitis B
   • The patient has compensated liver disease with evidence of viral replication and liver inflammation

If yes, approve for 24 weeks by HICL or GPI-10 with a quantity limit of #4 per 28 days. If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGINTERFERON ALFA-2A or 2B (Pegasys, PegIntron) requires the following rule(s) be met for approval:
A. You have chronic hepatitis B (a type of liver infection)
B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive condition), infectious disease specialist (a doctor who specializes in the treatment of infections), a doctor specializing in the treatment of hepatitis such as a hepatologist (liver doctor), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
C. If you are between 3 to 17 years of age, approval also requires:
   1. You do NOT have cirrhosis (liver damage)
   2. Your blood test shows you have HBeAg (marker of active virus multiplying in the body)-positive chronic hepatitis B
   3. You have evidence of viral replication (virus is multiplying in the body) with elevated serum alanine aminotransferase (ALT: a type of liver enzyme test)
D. If you are 18 years of age or older, approval also requires:
   1. Your blood test shows you have HBeAg (marker of active virus multiplying in the body)-positive or HBeAg-negative chronic hepatitis B
   2. You have compensated liver disease (a type of liver condition) with evidence of viral replication and liver inflammation

Note: Pegasys and PegIntron will not be approved for the treatment of hepatitis C.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PEGINTERFERON ALFA 2A OR 2B

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pegasys/PegIntron.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/01/23
Created: 02/14
Client Approval: 04/23
P&T Approval: 01/17
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of phenylketonuria and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, as confirmed by a measurement in the last 30 days
   • The patient has had a trial of Kuvan (sapropterin)
   • The patient is not concurrently receiving Kuvan (sapropterin)

If yes, approve for 6 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • 2.5mg/0.5mL: #1mL (2 syringes) per 7 days.
   • 10mg/0.5mL: #0.5mL (1 syringe) per day.
   • 20mg/mL: #3mL (3 syringes) per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGVALIASE-PQPZ (Palynziq) requires the following rules be met for approval:
A. You have phenylketonuria (PKU: a type of birth defect that causes buildup of a chemical called phenylalanine)
B. You are 18 years of age or older
C. You have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, as confirmed by a measurement in the last 30 days
D. You have tried Kuvan (sapropterin)
E. You are NOT receiving Kuvan (sapropterin) at the same time as Palynziq (pegvaliase)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of phenylketonuria AND meet the following criterion?
   - The patient has demonstrated a reduction in phenylalanine levels, compared to baseline, by at least 20% or to a level below 600 micromol/L

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   - 2.5mg/0.5mL: #1mL (2 syringes) per 7 days.
   - 10mg/0.5mL: #0.5mL (1 syringe) per day.
   - 20mg/mL: #3mL (3 syringes) per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEGVALIASE-PQPZ (Palynziq) requires the following rules be met for renewal:
A. You have phenylketonuria (PKU: a type of birth defect that causes buildup of a chemical called phenylalanine)
B. Your phenylalanine levels have dropped by at least 20% from baseline or to a level under 600 micromol/L

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Palynziq.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable locally advanced or metastatic cholangiocarcinoma and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has been previously treated for unresectable locally advanced or metastatic cholangiocarcinoma
   - The patient has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
   - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to initiation of therapy and at the recommended scheduled intervals

   If yes, approve for 12 months by HICL or GPI-10 for #14 per 21 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a fibroblast growth factor receptor 1 (FGFR1) rearrangement
   - The patient will complete a comprehensive ophthalmological examination, including optical coherence tomography (OCT), prior to initiation of therapy and at the recommended scheduled intervals

   If yes, approve for 12 months by HICL or GPI-10 for #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PEMIGATINIB (Pemazyre) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread to nearby tissue and lymph nodes and cannot be removed by surgery, or it has spread to other parts of the body)
   2. Relapsed or refractory myeloid/lymphoid neoplasms (a type of blood cancer that has returned or did not respond to treatment)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

B. If you have unresectable locally advanced or metastatic cholangiocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma
   3. You have a fibroblast growth factor receptor 2 (FGFR2: a type of protein) fusion or other rearrangement as detected by a Food and Drug Administration (FDA)-approved test
   4. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

C. If you have relapsed or refractory myeloid/lymphoid neoplasms, approval also requires:
   1. You are 18 years of age or older
   2. You have a fibroblast growth factor receptor 1 (FGFR1: a type of protein) rearrangement
   3. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pemazyre.

REFERENCES
• Pemazyre [Prescribing Information]. Wilmington, DE: Incyte Corporation; August 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Created: 07/20
Commercial Effective: 01/01/23
Client Approval: 11/22
P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for D-Penamine and the patient has an active prior authorization approval for Depen?  
   [Note: D-Penamine is temporarily available to address a critical drug shortage of Depen. Patients previously approved for Depen will be allowed access without additional criteria during this shortage.]
   
   If yes, approve D-Penamine for 12 months by GPID or GPI-14 for the requested indication as follows:
   - Wilson’s Disease: #16 per day.
   - Active Rheumatoid Arthritis: #12 per day.
   - Cystinuria: #32 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of Wilson’s disease and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a hepatologist or gastroenterologist
   - The patient has a Leipzig score of 4 or greater
   - The patient is willing to follow a diet avoiding high copper foods (e.g., shellfish, nuts, chocolate, mushrooms, organ meat)

   If yes, continue to #3.
   If no, continue to #5.

3. Is the request for Depen or D-Penamine?

   If yes, approve for 12 months by GPID or GPI-14 for the requested drug as follows:
   - Depen: #8 per day.
   - D-Penamine: #16 per day.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Is the request for Cuprimine and the patient had a trial of or contraindication to Depen (penicillamine) or D-Penamine (penicillamine)?

   If yes, approve Cuprimine for 12 months by GPID or GPI-14 with a quantity limit of #8 per day.

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

5. Does the patient have a diagnosis of cystinuria and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a nephrologist
   - The patient has a daily cystine output that is greater than 300mg per 24 hours following urine cystine excretion testing
   - The patient has failed to respond to an adequate trial of or has a contraindication to conventional therapy which includes ALL of the following: increased fluid intake, modest reductions in sodium and protein intake, and urinary alkalinization

   If yes, continue to #6.
   If no, continue to #9.

6. Does the patient have nephrolithiasis and meet ONE of the following criteria?
   - The patient’s stone analysis shows a presence of cystine
   - The patient’s urinalysis shows pathognomonic hexagonal cystine crystals
   - The patient has a family history of cystinuria AND a positive cyanide-nitroprusside screening

   If yes, continue to #7.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

7. Is the request for Depen or D-Penamine?

   If yes, approve for 12 months by GPID or GPI-14 for the requested drug as follows:
   - Depen: #16 per day.
   - D-Penamine: #32 per day.

   If no, continue to #8.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

8. Is the request for Cuprimine and has the patient had a trial of or contraindication to Depen (penicillamine) or D-Penamine (penicillamine) AND Thiola (tiopronin)?

   If yes, approve Cuprimine for 12 months by GPID or GPI-14 with a quantity of #16 per day. If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

9. Does the patient have a diagnosis of active rheumatoid arthritis and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient does not have a history or other evidence of renal insufficiency
   • The patient has failed to respond to an adequate trial of at least 3 months of conventional therapy including at least ONE of the following DMARD (disease-modifying antirheumatic drug) agents: methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #10.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

10. Is the request for Depen or D-Penamine?

    If yes, approve for 12 months by GPID or GPI-14 for the requested drug as follows:
    • Depen: #6 per day.
    • D-Penamine: #12 per day.

    If no, continue to #11.

11. Is the request for Cuprimine and has the patient had a trial of or contraindication to Depen (penicillamine) or D-Penamine (penicillamine)?

    If yes, approve Cuprimine for 12 months by GPID or GPI-14 with a quantity of #6 per day.
    If no, do not approve.
    DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PENICILLAMINE (Cuprimine, Depen, D-Penamine) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   2. Cystinuria (a type of genetic metabolic disorder)
   3. Active rheumatoid arthritis (a type of joint condition)

B. If you have Wilson's disease, approval also requires:
   1. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
   2. You have a Leipzig score of 4 or greater (a type of diagnostic score)
   3. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
   4. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine)

C. If you have cystinuria, approval also requires:
   1. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
   2. You have a daily cystine output greater than 300mg per 24 hours after urine cystine excretion testing
   3. You have failed to respond to an adequate trial of or has a contraindication (harmful for) to conventional therapy which includes ALL of the following:
      a. Increased fluid intake
      b. Modest reductions in sodium and protein intake
      c. Urinary alkalization (a process that makes urine basic)
   4. You have nephrolithiasis (kidney stones) and ONE of the following:
      a. Your kidney stone analysis shows that there is a presence of cystine (an amino acid)
      b. Your urine analysis shows that there are hexagonal cystine crystals in your urine that are pathognomonic (signs relating to the disease)
      c. You have a family history of cystinuria and positive test results in the cyanide-nitroprusside screen (a test to determine the amount of cysteine in your body)
   5. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine) AND Thiola (tiopronin)

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
PENICILLAMINE

INITIAL CRITERIA (CONTINUED)

D. If you have active rheumatoid arthritis, approval requires:
   1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   2. You do not have a history or other evidence of renal insufficiency (kidney problems)
   3. You have failed to respond to an adequate trial of at least 3 months of conventional therapy including at least ONE of the following DMARD (disease-modifying antirheumatic drug) agents: methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine)

E. If you have an active prior authorization approval for Depen, D-Penamine will be approved without meeting additional criteria during the period of Depen shortage.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Wilson’s disease AND meet the following criterion?
   • The patient has achieved a free serum copper of less than 10 mcg/dL

   If yes, approve for lifetime by GPID or GPI-14 for the requested drug as follows:
   • Depen: #8 per day.
   • Cuprimine: #8 per day.
   • D-Penamine: #16 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of cystinuria AND meet the following criterion?
   • The patient has achieved a cystine excretion of less than 200 mg/day

   If yes, approve for lifetime by GPID or GPI-14 for the requested drug as follows:
   • Depen: #16 per day.
   • D-Penamine: #32 per day.
   • Cuprimine: #16 per day.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of active rheumatoid arthritis and meet ALL of the following criteria?
   - The patient does not have a history of or other evidence of renal insufficiency
   - The patient has experienced or maintained improvement in tender joint count or swollen joint count while on therapy compared to baseline

If yes, approve for lifetime by GPID or GPI-14 for the requested drug as follows:
   - Depen: #6 per day.
   - D-Penamine: #12 per day.
   - Cuprimine: #6 per day.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PENICILLAMINE (Cuprimine, Depen, D-Penamine) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   2. Cystinuria (a type of genetic metabolic disorder)
   3. Active rheumatoid arthritis (a type of joint condition)

B. If you have Wilson's disease, approval also requires:
   1. You have achieved a free serum copper of less than 10 mcg/dL

C. If you have cystinuria, approval also requires:
   1. You have achieved a cystine excretion of less than 200 mg/day

D. If you have active rheumatoid arthritis, approval also requires:
   1. You do not have a history of or other evidence of renal insufficiency (kidney problems)
   2. You have experienced or maintained improvement in tender joint count or swollen joint count while on therapy compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PENICILLAMINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cuprimine/Depen/Thiola EC.

REFERENCES
- FDA Website: Penicillamine (Depen) Titratable Tablets Drug Shortage. Available at: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Penicillamine%20(Depen)%20Titratable%20Tablets&st=c. Accessed on January 21, 2019

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/08/23
Created: 05/16
Client Approval: 04/23
P&T Approval: 10/22
PENTOSAN POLYSULFATE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of interstitial cystitis/bladder pain syndrome ongoing for at least six weeks?

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #3 per day.
   **APPROVAL TEXT:** Renewal requires that the patient has experienced clinical improvement from baseline secondary to treatment.

   If no, do not approve.
   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named PENTOSAN POLYSULFATE (Elmiron) requires the following rule(s) be met for approval:
   A. You have a diagnosis of interstitial cystitis/bladder (painful bladder condition) pain syndrome ongoing for at least six weeks

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Has the patient experienced clinical improvement from baseline secondary to treatment?

   If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PENTOSAN POLYSULFATE (Elmiron)** requires the following rule(s) be met for renewal:

A. You have experienced clinical improvement from baseline secondary to treatment.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Elmiron.

**REFERENCES**

- Elmiron [Prescribing Information]. Titusville, New Jersey: Janssen Pharmaceuticals, Inc. September 2018

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 04/01/20  
Created: 02/20  
Client Approval: 02/20  
P&T Approval: 01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of dry eye disease (DED) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
   - The patient has at least one positive diagnostic test (e.g., tear breakup time, tear film osmolarity, ocular surface staining, Schirmer test, etc.)
   - The patient had a trial of or contraindication to ONE ocular lubricant (e.g., carboxymethylcellulose [Refresh, Celluvisc, TheraTears, etc.], polyvinyl alcohol [LiquiTears, Refresh Classic, etc.], or wetting agent [Systane, Lacri-Lube, etc.])
   - The patient had a trial of or contraindication to BOTH of the following preferred agents: Restasis (cyclosporine ophthalmic emulsion) AND Xiidra (lifitegrast ophthalmic solution)

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #0.43 mL per day. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PERFLUOROHEXYLOCTANE (MIEBO) requires the following rule(s) be met for approval:

A. You have dry eye disease
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist or optometrist (types of eye doctor)
D. You have at least one positive diagnostic test (such as tear breakup time, tear film osmolarity, ocular surface staining, Schirmer test)
E. You had a trial of or contraindication (harmful for) to ONE ocular lubricant (such as carboxymethylcellulose [Refresh, Celluvisc, TheraTears], polyvinyl alcohol [LiquiTears, Refresh Classic], or wetting agent [Systane, Lacri-Lube])
F. You had a trial of or contraindication to (harmful for) BOTH of the following preferred medications: Restasis (cyclosporine eye drop) AND Xiidra (lifitegrast eye drop)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of dry eye disease (DED) AND meet the following criterion?
   • The patient has demonstrated improvement of dry eye disease

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #0.43 mL per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PERFLUOROHEXYLOCTANE (MIEBO) requires the following rule(s) be met for renewal:
   A. You have dry eye disease
   B. You have demonstrated improvement of dry eye disease

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Miebo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 08/01/23  
Created: 06/23  
Client Approval: 06/23  
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) and meet ALL of the following criteria?
   - TGCT is associated with severe morbidity or functional limitations
   - TGCT is NOT amenable to improvement with surgery
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PEXIDARTINIB (Turalio) requires the following rules be met for approval:
   A. You have symptomatic tenosynovial giant cell tumor (TGCT: type of non-cancerous growth in or around a joint causing tissue damage and reducing function)
   B. TGCT is associated with severe morbidity (disease) or functional limitations
   C. TGCT is NOT responsive to improvement with surgery
   D. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Turalio.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of pheochromocytoma and meet ALL of the following criteria?
   - The requested medication is used for the treatment of pheochromocytoma prior to pheochromocytoma resection/removal
   - Therapy is prescribed by or in consultation with an endocrinologist, an endocrine surgeon, or a hematologist - oncologist
   - The patient has had a previous trial of or contraindication to an alpha-1 selective adrenergic receptor blocker (e.g., doxazosin, terazosin, or prazosin)

If yes, approve for one fill by HICL or GPI-10 with a quantity limit of #10 capsules per day for 21 days.
If no, do not approve.

DENIAL TEXT: "Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PHENOXYBENZAMINE (Dibenzyline) requires the following rules be met for approval:
A. You have pheochromocytoma (tumor in your adrenal gland)
B. The requested drug is used to treat pheochromocytoma before pheochromocytoma surgery to remove the tumor
C. The requested drug is prescribed by an endocrinologist (hormone doctor), an endocrine surgeon (surgeon specializing in removal of glands such as adrenal glands), or a hematologist/oncologist (cancer doctor)
D. You must have tried an alpha-1 selective adrenergic receptor blocker (such as doxazosin, terazosin, or prazosin), unless there is a medical reason why you cannot (contraindication)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Dibenzyline.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 08/18
Client Approval: 04/20
P&T Approval: 07/18
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of presbyopia and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
   - The patient is not using corrective lenses OR corrective lenses are insufficient to completely correct patient's vision
   - The patient had a trial of or contraindication to generic pilocarpine ophthalmic solution

If yes, approve for 3 months by GPID or GPI-14 with a quantity limit of #10mL per 30 days.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PILOCARPINE (Vuity) requires the following rule(s) be met for approval:
A. You have presbyopia (not able to focus on nearby objects)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
D. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
E. You had a trial of or contraindication (harmful for) to generic pilocarpine ophthalmic (eye) solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
PILOCARPINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

2 Does the patient have a diagnosis of presbyopia and meet ALL of the following criteria?
   • The patient is not using corrective lenses OR corrective lenses are insufficient to completely correct patient’s vision
   • The patient continues to have benefit from Vuity

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per 30 days.

   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PILOCARPINE (Vuity) requires the following rule(s) be met for renewal:
   A. You have presbyopia (not able to focus on nearby objects)
   B. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
   C. You continue to have benefit from Vuity

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vuity.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Parkinson's disease psychosis and meets ALL of the following criteria?
   • Patient is 18 years of age or older
   • Medication is prescribed by or given in consultation with a physician specializing in one of the following areas: neurology, geriatric medicine, or behavioral health (such as psychiatrist)
     
     If yes, approve for 12 months by G PID or GPI-14 for the requested strength with the following quantity limits:
     • Nuplazid 34mg capsules: #30 capsules per 30 days.
     • Nuplazid 17mg tablets: #60 tablets per 30 days.
     • Nuplazid 10mg tablets: #30 tablets per 30 days.
     If no, do not approve.

     INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

     Our guideline named drug named PIMA VANSERIN (Nuplazid) requires you to meet the following rule(s) for approval:
     A. You have a diagnosis of psychosis associated with Parkinson's disease (a mental disorder that causes you to have false beliefs or to hear or see things that are not really there and is related to a movement disorder)
     B. You are at least 18 years old; and
     C. The drug is prescribed by a doctor specializing in one of the following areas: neurology (brain doctor), geriatric medicine (specialty that focuses on health care of elderly people), or behavioral health (such as a psychiatrist).

     Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

     CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. During the past 12 months of therapy, has the patient experienced an improvement in psychosis symptoms from baseline and demonstrates a continued need for treatment?

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   - Nuplazid 34mg capsules: #30 capsules per 30 days.
   - Nuplazid 17mg tablets: #60 tablets per 30 days.
   - Nuplazid 10mg tablets: #30 tablets per 30 days.

   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PIMAVNSERIN (Nuplazid) requires that you have experienced an improvement in psychosis symptoms (mental issues such as false beliefs or hearing or seeing things that are not really there) from baseline during the past 12 months of therapy and you show a continued need for treatment.

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Nuplazid.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 04/16
Commercial Effective: 07/01/20  Client Approval: 04/20  P&T Approval: 05/16
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a pulmonologist
   - The patient does NOT have other known causes of interstitial lung disease (e.g., connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis, systemic sclerosis, rheumatoid arthritis, radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia, human immunodeficiency virus (HIV) infection, viral hepatitis, or cancer)
   - The patient has a usual interstitial pneumonia (UIP) pattern as evidenced by high-resolution computed tomography (HRCT) alone or via a combination of surgical lung biopsy and HRCT
   - The patient has a predicted forced vital capacity (FVC) of at least 50% at baseline
   - The patient does NOT currently smoke cigarettes

   If yes, enter two authorizations for a total of 12 months as follows:  
   **FIRST APPROVAL:** Approve for 1 month by GPID or GPI-14 for all dosage strengths with the following quantity limits:
   - 267mg: #9 per day.
   - 534mg: #3 per day.
   - 801mg: #3 per day.
   **SECOND APPROVAL:** Approve for 11 months by HICL or GPI-10 with a quantity limit of #3 per day (enter a start date of 2 days before the end of the first approval).

   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PIRFENIDONE (Esbriet) requires the following rule(s) be met for approval:
A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. You do NOT have other known causes of interstitial lung disease. Other causes may include connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (type of lung infection), systemic sclerosis (chronic hardening and tightening of the skin and connective tissues), rheumatoid arthritis (a type of joint condition), radiation, sarcoidosis (a type of inflammatory disorder), bronchiolitis obliterans organizing pneumonia (infection affecting the small airways of the lung), human immunodeficiency virus infection (HIV: a type of immune disorder), viral hepatitis (a type of liver inflammation), or cancer

E. You have a usual interstitial pneumonia (type of lung infection) pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy (removal of cells or tissue from the body for examination) and HRCT

F. You have a predicted forced vital capacity (FVC: amount of air exhaled from lungs) of at least 50% at baseline

G. You do NOT currently smoke cigarettes

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of idiopathic pulmonary fibrosis (IPF) AND meet the following criterion?
   - The patient has experienced a clinically meaningful improvement or maintenance in annual rate of decline

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named PIRFENIDONE (Esbriet) requires the following rule(s) be met for renewal:
A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
PIRFENIDONE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Esbriet.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 02/15
Client Approval: 11/22
P&T Approval: 10/22
PIRTOBRUTINIB

GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory mantle cell lymphoma (MCL) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received at least TWO lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor (e.g., Imbruvica [ibrutinib], Calquence [acalabrutinib], Brukinsa [zanubrutinib])

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   - 50 mg: #3 per day.
   - 100 mg: #2 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PIRTOBRUTINIB (Jaypirca) requires the following rule(s) be met for approval:
A. You have relapsed or refractory mantle cell lymphoma (MCL: type of white blood cell cancer)
B. You are 18 years of age or older
C. You have previously received at least TWO lines of systemic therapy (treatment that targets the entire body) for mantle cell lymphoma, including a BTK inhibitor (Bruton’s tyrosine kinase inhibitors such as Imbruvica [ibrutinib], Calquence [acalabrutinib], Brukinsa [zanubrutinib])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Jaypirca.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy and narcolepsy is confirmed by ONE of the following criteria?
   - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
   - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
   - The patient has low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ALL of the following criteria?
   - The patient has excessive daytime sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
   - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - The patient had a trial of or contraindication to one generic typical stimulant (e.g., amphetamine sulfate, methylphenidate, etc.) AND solriamfetol, armodafinil, or modafinil

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of cataplexy with narcolepsy and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   • The patient has tried TWO of the following: venlafaxine, fluoxetine or a TCA (e.g., clomipramine, imipramine)

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PITOLISANT (Wakix) requires the following rule(s) be met for approval:
A. You have one of the following:
   1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
   2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)
B. If you have excessive daytime sleepiness with narcolepsy, approval also requires:
   1. You have narcolepsy that is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
   2. You have excessive daytime sleepiness (EDS) lasting for at least 3 months and Epworth Sleepiness Scale (type of sleepiness test) score of more than 10
   3. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   4. You had a trial of one generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.) AND solriamfetol, armodafinil, or modafinil, unless there is a medical reason why you cannot (contraindication)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

C. If you have cataplexy with narcolepsy, approval also requires:
   1. Wakix is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   2. You have tried TWO of the following: venlafaxine, fluoxetine, or a TCA (tricyclic antidepressant such as clomipramine, imipramine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy or cataplexy with narcolepsy and meet ONE of the following criteria?
   • The patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline
   • The patient has shown improvement in cataplexy symptoms compared to baseline
   • The patient has demonstrated improvement in sleep latency from baseline

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PITOLISANT (Wakix) requires the following rule(s) be met for renewal:
A. You have ONE of the following:
   1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
   2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)
B. You meet ONE of the following:
   1. You have demonstrated 25% or more improvement in Epworth Sleepiness Scale (type of sleepiness test) scores compared to baseline
   2. You have shown improvement in cataplexy (sudden and uncontrollable muscle weakness) symptoms compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep) from baseline

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Wakix.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 10/19
Commercial Effective: 01/01/23 Client Approval: 11/22
P&T Approval: 10/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of plasminogen deficiency type 1 (hypoplasminogenemia)?

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PLASMINOGEN (Ryplazim) requires the following rule(s) be met for approval:
   A. You have a diagnosis of plasminogen deficiency type 1 (hypoplasminogenemia: a type of genetic condition)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ryplazim.

REFERENCES
- Ryplazim [Prescribing Information]. Laval, Quebec, Canada: Prometic Bioproduction, Inc.; June 2021.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of multiple myeloma (MM) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The requested medication will be used in combination with dexamethasone
   - The patient has received at least two prior therapies including Revlimid (lenalidomide) and a proteasome inhibitor (e.g., Velcade [bortezomib], Kyprolis [carfilzomib], or Ninlaro [ixazomib])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.
   If no, continue to #2.

2. Does the patient have a diagnosis of Kaposi sarcoma (KS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient meets ONE of the following criteria:
     - The patient has AIDS-related Kaposi sarcoma after failing highly active antiretroviral therapy (HAART)
     - The patient is HIV-negative

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named POMALIDOMIDE (Pomalyst) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Multiple myeloma (MM: cancer that forms in your white blood cells)
   2. Kaposi sarcoma (KS: cancer that forms from the cells in your lymph or blood vessels)

B. If you have multiple myeloma, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication is used in combination with dexamethasone
   3. You have tried at least two drugs including Revlimid (lenalidomide) and a proteasome inhibitor (type of cancer drug such as Velcade [bortezomib], Kyprolis [carfilzomib], or Ninlaro [ixazomib])

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If you have Kaposi sarcoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failing highly active antiretroviral therapy (HAART: medications used to treat human immunodeficiency virus [HIV])
      b. You are human immunodeficiency virus (HIV)-negative

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Pomalyost.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 07/01/20  
Created: 02/13  
Client Approval: 06/20  
P&T Approval: 07/20
PONATINIB

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic myeloid leukemia (CML) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient had a mutational analysis prior to initiation AND Iclusig is appropriate per the NCCN guideline table for treatment recommendations based on BCR-ABL1 mutation profile (Please see header CML-5 of the current NCCN guidelines)

   If yes, continue to #2.
   If no, continue to #5.

2. Does the patient have T315I-positive CML (chronic phase, accelerated phase, or blast phase)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #3.

3. Does the patient have chronic phase (CP) chronic myeloid leukemia (CML) AND meet the following criterion?
   • The patient has a resistance or intolerance to at least TWO prior kinase inhibitors [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)]

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #4.

4. Does the patient have accelerated phase (AP) or blast phase (BP) chronic myeloid leukemia (CML) AND meet the following criterion?
   • There are no other kinase inhibitors [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
5. Does the patient have a diagnosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient meets ONE of the following:
     o The patient's cancer is positive for the T315I mutation
     o There are no other kinase inhibitors [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PONATINIB (Iclusig) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Chronic myeloid leukemia (CML: type of blood-cell cancer that begins in the bone marrow)
   2. Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer)
B. You are 18 years of age or older
C. If you have chronic myeloid leukemia, approval also requires:
   1. You had a mutational analysis prior to initiation of therapy AND Iclusig is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
   2. You meet ONE of the following:
      a. You have T315I-positive (a genetic mutation) CML (chronic phase, accelerated phase, or blast phase)
      b. You have chronic phase CML AND have a resistance to or are not able to safely use at least TWO prior kinase inhibitor treatments such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)
      c. You have accelerated phase or blast phase CML AND there are no other kinase inhibitors, such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib), that can be used for your disease
D. If you have Philadelphia chromosome positive acute lymphoblastic leukemia, approval also requires you meet ONE of the following:
   1. Your cancer is positive for the T315I mutation (a type of abnormal gene)
   2. There are no other kinase inhibitors [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

(Continued on next page)
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Iclusig.

REFERENCES

Library | Commercial | NSA
---|---|---
Yes | Yes | No

Part D Effective: N/A          Created: 01/13
Commercial Effective: 04/01/22  Client Approval: 02/22          P&T Approval: 04/21
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, AND meet the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial and failure of ONE sphingosine-1-phosphate receptor modulator (e.g., Gilenya, Mayzent) AND ONE other agent indicated for the treatment of MS

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PONESIMOD (Ponvory) requires the following rule(s) be met for approval:
   A. You have a relapsing form of multiple sclerosis (type of disease where body attacks its own nerves and symptoms return after treatment) to include clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)
   B. You are 18 years of age or older
   C. You had a trial of one sphingosine-1-phosphate receptor modulator (such as Gilenya or Mayzent) AND one other agent indicated for the treatment of multiple sclerosis (Please note: Other multiple sclerosis agents may also require prior authorization)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ponvory.

REFERENCES
POSACONAZOLE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>POSACONAZOLE</td>
<td>NOXAFIL, POSA</td>
<td>33461</td>
<td>GCN</td>
<td>GPI-10</td>
<td>ROUTE = ORAL</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the request for continuation of therapy after the patient was started on posaconazole in the hospital?
   
   If yes, **approve for 6 months by GPID or GPI-14.**
   If no, continue to #2.

2. Is the request for the treatment of invasive aspergillosis and the patient meets **ALL** of the following criteria?
   - The patient is 13 years of age or older
   - The request is for posaconazole (Noxafil) tablets
   
   If yes, **approve for 12 weeks by GPID or GPI-14.**
   If no, continue to #3.

3. Is the request for prophylaxis of invasive aspergillus or candida infections **AND** the patient meets the following criterion?
   - The patient is at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or has a hematologic malignancy with prolonged neutropenia from chemotherapy
   
   If yes, continue to #4.
   If no, continue to #7.

4. Is the request for posaconazole (Noxafil) tablets and the patient meets **ONE** of following criteria?
   - The patient is 18 years of age or older
   - The patient is 2 years of age or older **AND** weighs greater than 40 kg
   
   If yes, **approve for 6 months by GPID or GPI-14.**
   If no, continue to #5.

5. Is the request for posaconazole (Noxafil) oral suspension and the patient meets **ALL** of the following criteria?
   - The patient is 13 years of age or older
   - The patient is unable to swallow tablets
   
   If yes, **approve for 6 months by GPID or GPI-14.**
   If no, continue to #6.

CONTINUED ON NEXT PAGE
6. Is the request for posaconazole (Noxafil) PowderMix and the patient meets ALL of the following criteria?
   • The patient is 2 to less than 18 years of age AND weighs less than 40 kg
   • The patient is unable to swallow tablets

   If yes, approve for 6 months by GPID or GPI-14.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

7. Does the patient have a diagnosis of oropharyngeal candidiasis (OPC) and meet ALL of the following criteria?
   • The patient is 13 years of age or older
   • The patient had a trial of or contraindication to fluconazole OR itraconazole
   • The request is for posaconazole (Noxafil) oral suspension

   If yes, approve for 3 months by GPID or GPI-14.
   If no, continue to #8.

8. Does the patient have a diagnosis of esophageal candidiasis and meet ALL of the following criteria?
   • The patient is 13 years of age or older
   • The patient had a trial and failure of or contraindication to two of the following: fluconazole, itraconazole solution, or voriconazole

   If yes, approve for 3 months by GPID or GPI-14.
   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named POSACONAZOLE (Noxafil) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. Continuation of therapy after hospital discharge
   2. Treatment of invasive aspergillosis (type of fungal infection)
   3. Prophylaxis (prevention) of invasive aspergillus or candida infections (types of fungal infection)
   4. Oropharyngeal candidiasis (fungal infection of the throat)
   5. Esophageal candidiasis (fungal infection in the tube connecting the throat and stomach)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. **If the request is for treatment of invasive aspergillosis, approval also requires:**
   1. You are 13 years of age or older
   2. You are requesting Noxafil (posaconazole) tablets

C. **If the request is for prophylaxis of invasive aspergillus or candida infections, approval also requires:**
   1. You are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplantation (HSCT: bone marrow transplant) recipient with graft versus host disease (GVHD: a type of immune disorder) or you have hematologic malignancies (cancer affecting the blood) with prolonged neutropenia (low levels of a type of white blood cell) from chemotherapy (cancer treatment)
   2. If the request is for posaconazole (Noxafil) tablets, you meet ONE of the following:
      - You are 18 years of age or older
      - You are 2 years of age or older AND weigh greater than 40 kg
   3. If the request is for posaconazole (Noxafil) suspension, you meet ALL of the following:
      - You are 13 years of age or older
      - You are unable to swallow tablets
   4. If the request is for posaconazole (Noxafil) PowderMix, you meet the following:
      - You are 2 to 18 years of age AND weigh less than 40 kg
      - You are unable to swallow tablets

D. **If the request is for oropharyngeal candidiasis, approval also requires:**
   1. You are 13 years of age or older
   2. You had a trial of or contraindication (harmful for) to fluconazole OR itraconazole
   3. You are requesting Noxafil (posaconazole) oral suspension

E. **If the request is for esophageal candidiasis, approval also requires:**
   1. You are 13 years of age or older
   2. You had a trial and failure of or contraindication (harmful for) to TWO of the following: fluconazole, itraconazole solution, or voriconazole

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
POSACONAZOLE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Noxafil.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 11/07
Commercial Effective: 01/01/23  Client Approval: 11/22  P&T Approval: 10/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a RET fusion-positive tumor as detected by an FDA-approved test

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of advanced or metastatic thyroid cancer and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient has a RET fusion-positive tumor
   - The patient requires systemic therapy
   - The patient is radioactive iodine-refractory (if radioactive iodine is appropriate)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PRALSETINIB (Gavreto) requires the following rule(s) be met for approval:

A. You have ONE of the following:
   1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   2. Advanced or metastatic thyroid cancer (thyroid cancer that has spread to other parts of the body)

B. If you have metastatic non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have a rearranged during transfection (RET) fusion-positive (a type of gene mutation) tumor that has been detected by a Food and Drug Administration (FDA)-approved test

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
C. If you have advanced or metastatic thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. You have a rearranged during transfection (RET) fusion-positive (a type of gene
      mutation) tumor
   3. You need systemic therapy (treatment that targets the entire body)
   4. You have received treatment with radioactive iodine, and it did not work or is no longer
      working (if radioactive iodine is an appropriate treatment option)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
your doctor to use a different medication or get us more information if it will allow us to approve
this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Gavreto.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for an FDA approved indication and the patient meets ALL of the following criteria?
   - The patient had a previous trial of or contraindication to ONE of the following: generic prednisone, prednisolone, or methylprednisolone
   - The patient had a subclinical response or treatment failure of generic prednisone, prednisolone, or methylprednisolone

If yes, approve for 6 months by GPID or GPI-14 for the requested strength.

APPROVAL TEXT: Renewal requires the patient has a clinical benefit from using Rayos (e.g., improvement in inflammatory condition from baseline) and cannot be tapered off corticosteroid (i.e., Rayos).

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named PREDNISONE DELAYED-RELEASE TABS (Rayos) requires the following rule(s) be met for approval:
A. The request is for a Food and Drug Administration-approved indication
B. You had a previous trial of ONE of the following, unless there is a medical reason why you cannot (contraindication): generic prednisone, prednisolone, or methylprednisolone
C. You have had a subclinical response (not a full response) or treatment failure of generic prednisone, prednisolone, or methylprednisolone

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
REN EWAL CRITERIA

1. Is the request for an FDA approved indication and the patient meets ALL of the following criteria?
   • The patient has clinical benefit from using Rayos (e.g., improvement in inflammatory condition from baseline)
   • The patient cannot be tapered off corticosteroid (i.e., Rayos)

   If yes, approve for 6 months by GPID or GPI-14 for the requested strength.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named PREDNISONE DELAYED-RELEASE TABS (Rayos) requires the following rule(s) be met for renewal approval:
   A. The request is for a Food and Drug Administration-approved indication
   B. You have had a clinical benefit from using Rayos (such as improvement in inflammatory condition from baseline)
   C. You cannot be tapered off (slowly lowering the dose to stop use) corticosteroid (Rayos)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL E
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rayos.

REFERENCES
PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE</td>
<td>TRUVADA, EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE</td>
<td>2315</td>
<td>2</td>
<td>GPI-14 (12109902300320)</td>
<td></td>
</tr>
<tr>
<td>EMTRICITABINE/TENOFOVIR ALAFENAMIDE FUMARATE</td>
<td>DESCOVY</td>
<td>4095</td>
<td>3</td>
<td>GPI-14 (12109902290320)</td>
<td></td>
</tr>
<tr>
<td>TENOFOVIR DISOPROXIL FUMARATE</td>
<td>VIREAD, TENOFOVIR DISOPROXIL FUMARATE</td>
<td>1482</td>
<td>2</td>
<td>GPI-14 (12108570100320)</td>
<td></td>
</tr>
<tr>
<td>EMTRICITABINE</td>
<td>EMTRIVA, EMTRICITABINE</td>
<td>2001</td>
<td>9</td>
<td>GPI-14 (12106030000120)</td>
<td></td>
</tr>
<tr>
<td>CABOTEGRAVIR</td>
<td>APRENUDE</td>
<td>4727</td>
<td>0</td>
<td>GPI-10 (12103010000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested pre-exposure prophylaxis (PrEP) agent AND does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?
   
   If yes, continue to #2.
   
   If no, guideline does not apply.

2. Does the patient’s plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

   If yes, guideline does not apply.
   
   If no, continue to #3.

3. Does the patient meet ALL of the following criteria?
   
   • The requested agent is FDA-approved for PrEP or recommended by the CDC PrEP Guidelines
   
   • The requested agent is being used for PrEP regardless of HIV medication use history (e.g., patient has a history of post-exposure prophylaxis (PEP) medication use)

   If yes, continue to #4.
   
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023 Page 1049 of 1529
GUIDELINES FOR USE (CONTINUED)

4. Is the request for a generic agent?

If yes, approve for 12 months for the requested agent by GPID or GPI-14 at zero copay as follows:
- Emtricitabine/tenofovir disoproxil fumarate: #1 per day.
- Tenofovir disoproxil fumarate: #1 per day.
- Emtricitabine: #1 per day.

If no, continue to #5.

5. Is the request for ONE of the following?
- A single-source brand (SSB) PrEP agent that has no preferred generic agents or therapeutically equivalent products available
- A multi-source brand (MSB) agent

If yes, continue to #6.
If no, do not approve.
DENIAL TEXT: See the denial text at the end of the guideline.

6. Does the patient meet ONE of the following criteria?
- Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
- The patient has tried or has a documented medical contraindication to two preferred medications (one if only one agent is available)
- The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

If yes, approve for 12 months for the requested agent by GPID or GPI-14 at zero copay as follows:
- Truvada: #1 per day.
- Descovy: #1 per day.
- Viread: #1 per day.
- Emtriva: #1 per day.
- Apretude: #24mL per 12 months.

APPROVAL TEXT (applicable to multi-source brand agents only): Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

If no, do not approve.
DENIAL TEXT: See the denial text at the end of the guideline.
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. The requested medication is FDA (Food and Drug Administration)-approved for pre-exposure prophylaxis (PrEP) or recommended by the CDC (Centers for Disease Control and Prevention) PrEP Guidelines

C. You are using the medication for PrEP regardless of your human immunodeficiency virus (HIV) medication use history (such as you have a history of post-exposure prophylaxis medication use)

D. **If the request is for a single-source brand or multi-source brand medication, approval also requires you meet ONE of the following:**
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to appropriate use)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of pre-exposure prophylaxis (PrEP) medications at zero copay. The override criteria allow patient access to all FDA-approved PrEP medications at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded PrEP medications.

For further information, please refer to the Prescribing Information and/or Drug Monograph for Pre-Exposure Prophylaxis (PrEP) agents listed.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/20
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the patient being treated for acute toxoplasmosis AND meets the following criterion?
   - The medication is prescribed by or given in consultation with an infectious disease specialist

   If yes, approve for 6 weeks by GPID or GPI-10. Please enter two authorizations as follows:
   - Approve one fill for #8 per day.
   - Approve for 6 weeks with a quantity limit of #3 per day.

   APPROVAL TEXT: Renewal requires that the patient has persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging).

   If no, continue to #2.

2. Is the patient being treated for chronic maintenance of toxoplasmosis and meets ALL of the following criteria?
   - The patient is infected with human immunodeficiency virus (HIV)
   - The patient has successfully completed treatment for acute toxoplasmosis for at least 6 weeks treatment duration
   - The medication is prescribed by or given in consultation with an infectious disease specialist

   If yes, approve for 6 months by GPID or GPI-10 with a quantity limit of #2 per day.

   APPROVAL TEXT: Renewal requires that the patient's CD4 count is less than 200 cells/mm(3) and the patient is currently taking ART (anti-retroviral therapy).

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Is the patient being treated for primary prophylaxis of toxoplasmosis and meets ALL of the following criteria?
   - The patient is infected with human immunodeficiency virus (HIV)
   - The medication is prescribed by or given in consultation with an infectious disease specialist
   - The patient had a previous trial of or contraindication to Bactrim (SMX/TMP)
   - The patient is positive for Toxoplasma gondii IgG
   - The patient has a CD4 count of less than 100 cells/mm(3)

   If yes, approve for 6 months by GPID or GPI-10 with a quantity limit of #3 per day.
   **APPROVAL TEXT:** Renewal requires that the patient's CD4 count is less than 200 cells/mm(3) and the patient is currently taking ART (anti-retroviral therapy).

   If no, continue to #4.

4. Does the patient have a diagnosis of congenital toxoplasmosis AND meet the following criterion?
   - The medication is prescribed by or given in consultation with a neonatologist or pediatric infectious disease specialist

   If yes, approve for 12 months by GPID or GPI-10.
   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline for PYRIMETHAMINE (Daraprim) requires the following rule(s) be met for approval:
A. The request is ONE of the following:
   1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
   2. Chronic maintenance therapy for toxoplasmosis
   3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)
   4. Congenital toxoplasmosis (the infection was passed on to you as a baby from your mother)

B. If you are being treated for acute toxoplasmosis, approval also requires:
   1. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. If you are being treated for chronic maintenance for toxoplasmosis, approval also requires:
   1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
   2. You have successfully completed treatment for acute toxoplasmosis for at least 6 weeks treatment duration
   3. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)

D. If you are being treated for primary prophylaxis of toxoplasmosis, approval also requires:
   1. You are also infected with human immunodeficiency virus (HIV)
   2. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
   3. You had a previous trial of Bactrim (sulfamethoxazole and trimethoprim), unless there is a medication reason why cannot (contraindication)
   4. You tested positive for Toxoplasma gondii (a type of parasite) Immunoglobulins (IgG) (i.e., you had a current or past infection with Toxoplasma gondii)
   5. Your CD4 count (an indicator of how weak your immune system is) is less than 100 cells/mm(3)

E. If you have congenital toxoplasmosis, approval also requires:
   1. The medication is prescribed by or given in consultation with a neonatologist (doctor that specializes in sick and premature newborn infants) or pediatric (children and adolescents) infectious disease specialist

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

NOTE: For the diagnosis of congenital toxoplasmosis, please refer to Initial Criteria section.

1. Is the patient being treated for acute toxoplasmosis AND meets the following criterion?
   • The patient has persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging)

   If yes, approve for 6 weeks by GPID or GPI-10 with a quantity limit of #3 per day.
   If no, continue to #2.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

2. Is the patient being treated for chronic maintenance of toxoplasmosis OR primary prophylaxis of toxoplasmosis and meets ALL of the following criteria?
   • The patient is infected with human immunodeficiency virus (HIV)
   • The patient has a CD4 count of less than 200 cells/mm(3)
   • The patient is currently taking ART (anti-retroviral therapy)

   If yes, approve for 6 months by GPID or GPI-10 as follows:
   • Chronic maintenance of toxoplasmosis: #2 per day.
   • Primary prophylaxis of toxoplasmosis: #3 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline for PYRIMETHAMINE (Daraprim) requires the following rule(s) be met for renewal:
   A. The request is ONE of the following:
      1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
      2. Chronic maintenance therapy for toxoplasmosis
      3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)
   B. If you are being treated for acute toxoplasmosis, renewal also requires:
      1. You have persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging)
   C. If you are being treated for chronic maintenance of toxoplasmosis OR primary prophylaxis for toxoplasmosis, renewal also requires:
      1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
      2. Your CD4 count (an indicator of how weak your immune system is) is less than 200 cells/mm(3)
      3. You are currently taking ART (anti-retroviral therapy)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
PYRIMETHAMINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Daraprim.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A    Created: 10/15
Commercial Effective: 04/01/20    Client Approval: 02/20
P&T Approval: 01/20
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic angina and meet **ALL** the following criteria?
   - The patient had a trial of or contraindication to ranolazine ER tablets
   - The patient is unable to swallow ranolazine ER tablets
   - The patient had a trial of or contraindication to a nitrate (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

   If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**
   - 500mg: #2 per day.
   - 1000mg: #2 per day.

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **RANOLAZINE (Aspruzyo Sprinkle)** requires the following rule(s) be met for approval:
A. You have chronic angina (a type of heart condition)
B. You had a trial of or contraindication (harmful for) to ranolazine ER (extended release) tablets
C. You are unable to swallow ranolazine ER tablets
D. You had a trial of or contraindication (harmful for) to a nitrate (such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
RANOLAZINE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Aspruzyo Sprinkle.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/22
Commercial Effective: 10/01/22  Client Approval: 09/22

P&T Approval: 07/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic colorectal cancer (CRC) and meet ALL of the following criteria?
   - The patient has received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (e.g., FOLFOX, FOLFIRI, FOLFOXIRI, CapeOx, infusional 5-FU/LV, capecitabine)
   - The patient has received previous treatment with an anti-VEGF therapy (e.g., Avastin [bevacizumab], Zaltrap [ziv-afibercept])

   If yes, continue to #2.
   If no, continue to #4.

2. Is the colorectal cancer RAS wild-type (mutation negative)?

   If yes, continue to #3.
   If no, approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.

3. Has the patient received previous treatment with an anti-EGFR therapy (e.g., Erbitux [cetuximab], Vectibix [panitumumab])?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Does the patient have a diagnosis of locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST) AND meet the following criterion?
   - The patient has received previous treatment with Gleevec (imatinib) and Sutent (sunitinib)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.
   If no, continue to #5.

5. Does the patient have a diagnosis of hepatocellular carcinoma (HCC) AND meet the following criterion?
   - The patient has received previous treatment with Nexavar (sorafenib)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #84 per 28 days.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named REGORAFENIB (Stivarga) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (CRC: a type of digestive cancer that has spread to other parts of the body)
   2. Locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST: a type of digestive tumor that has spread from where it started to nearby tissue or lymph nodes, unable to remove by surgery, or has spread to other parts of the body)
   3. Hepatocellular carcinoma (HCC: a type of liver cancer)

B. If you have metastatic colorectal cancer, approval also requires:
   1. You had previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy such as FOLFOX, FOLFIRI, FOLFOXIRI, CapeOx, infusional 5-FU/LV, capecitabine
   2. You had previous treatment with an anti-VEGF therapy such as Avastin (bevacizumab), Zaltrap (ziv-aflibercept)
   3. If you have RAS wild-type (a type of unmutated gene) metastatic colorectal cancer, approval also requires you had previous treatment with an anti-EGFR therapy such as Erbitux (cetuximab), Vectibix (panitumumab)

C. If you have locally advanced, unresectable, or metastatic gastrointestinal stromal tumor, approval also requires:
   1. You had previous treatment with Gleevec (imatinib) and Sutent (sunitinib)

D. If you have hepatocellular carcinoma, approval also requires:
   1. You had previous treatment with Nexavar (sorafenib)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
REGORAFENIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Stivarga.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/12
Commercial Effective: 04/01/22  Client Approval: 03/22  P&T Approval: 07/17
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced prostate cancer AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for a total of 12 months as follows:

   FOR INITIAL REQUESTS:
   - FIRST APPROVAL: Approve for 1 month by HICL or GPI-10 with a quantity limit of #30 per 28 days.
   - SECOND APPROVAL: Approve for 11 months by HICL or GPI-10 with a quantity limit of #1 per day (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).

   FOR SUBSEQUENT/MAINTENANCE REQUESTS:
   - Approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named RELUGOLIX (Orgovyx) requires the following rule(s) be met for approval:
   A. You have advanced prostate cancer
   B. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orgovyx.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Has the patient received a total of 24 months cumulative treatment with Myfembree?
   
   If yes, do not approve.  
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.  
   If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and the patient meets **ALL** the following criteria?
   
   • The patient is 18 years of age or older  
   • The patient is a premenopausal woman  
   • Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN)
   
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.  
   If no, continue to #3.

3. Is the request for the management of moderate to severe pain associated with endometriosis and the patient meets **ALL** of the following criteria?
   
   • The patient is 18 years of age or older  
   • The patient is a premenopausal woman  
   • Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN)  
   • The patient's diagnosis is confirmed via surgical or direct visualization (e.g., pelvic ultrasound) or histopathological confirmation (e.g., laparoscopy or laparotomy) in the last 10 years  
   • Myfembree will NOT be used concurrently with another GnRH-modulating agent (e.g., Orilissa, Lupron Depot, Synarel)
   
   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.  
   If no, do not approve.  
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
   2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)
B. If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), approval also requires:
   1. You are 18 years of age or older
   2. You are a premenopausal (before menopause) woman
   3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
   4. You have not received a total of 24 months cumulative (total) treatment with Myfembree
C. If the request is for management of moderate to severe pain associated with endometriosis, approval also requires:
   1. You are 18 years of age or older
   2. You are a premenopausal (before menopause) woman
   3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
   4. Your diagnosis of endometriosis is confirmed via surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
   5. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
   6. You have not received a total of 24 months cumulative (total) treatment with Myfembree

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Has the patient received a total of 24 months cumulative treatment with Myfembree?
   
   If yes, do not approve.
   
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   
   If no, continue to #2.

2. Is the request for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) **AND** the patient meets the following criterion?
   
   • The patient has had improvement of heavy menstrual bleeding
   
   If yes, approve for 18 months (or up to 24 months cumulative lifetime treatment duration) by HICL or GPI-10 with a quantity limit of #1 per day.
   
   If no, continue to #3.

3. Is the request for the management of moderate to severe pain associated with endometriosis and the patient meets ALL of the following criteria?
   
   • The patient has had improvement in pain related to endometriosis
   • Myfembree will NOT be used concurrently with another GnRH-modulating agent (e.g., Orilissa, Lupron Depot, Synarel)
   
   If yes, approve for 18 months (or up to 24 months cumulative lifetime treatment duration) by HICL or GPI-10 with a quantity limit of #1 per day.
   
   If no, do not approve.
   
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree)** requires the following rule(s) be met for renewal:
   
   A. The request is for ONE of the following:
      
      1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
      2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)

   *(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

B. If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), renewal also requires:
   1. You had improvement of heavy menstrual bleeding on therapy
   2. You have not received a total of 24 months cumulative (total) treatment with Myfembree

C. If the request is for management of moderate to severe pain associated with endometriosis, renewal also requires:
   1. You have had improvement in pain related to endometriosis while on therapy
   2. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
   3. You have not received a total of 24 months cumulative (total) treatment with Myfembree

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Myfembree.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 06/21
Commercial Effective: 09/12/22  Client Approval: 08/22  P&T Approval: 04/22
1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ALL of the following criteria?
   - The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

   If yes, continue to #2.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline

2. Will Kisqali be used in combination with an aromatase inhibitor (e.g., anastrozole, exemestane, letrozole) AND the patient meets the following criterion?
   - The patient has NOT received prior endocrine-based therapy (e.g., letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer
   - The patient had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths as follows:**
   - 200mg: #0.75 per day.
   - 400mg: #1.5 per day.
   - 600mg: #2.25 per day.

   If no, continue to #3.

3. Will Kisqali be used in combination with Faslodex (fulvestrant) AND the patient is a male or a postmenopausal female?

   If yes, continue to #4.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
4. Does the patient meet **ONE** of the following criteria?
   - The patient has **NOT** received prior endocrine-based therapy (e.g., letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer
   - The patient has experienced disease progression on endocrine therapy AND had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

   **If yes,** **approve for 12 months by GPID or GPI-14 for all strengths as follows:**
   - 200mg: #0.75 per day.
   - 400mg: #1.5 per day.
   - 600mg: #2.25 per day.

   **If no,** do not approve.

**DENIAL TEXT:**  *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **RIBOCICLIB (Kisqali)** requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of the body)

B. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)

C. **If you are requesting Kisqali in combination with an aromatase inhibitor (such as anastrozole, exemestane, letrozole), approval also requires:**
   1. You have **NOT** received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer
   2. You had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

D. **If you are requesting Kisqali in combination with (Faslodex) fulvestrant, approval also requires:**
   1. You are a male or a postmenopausal (after menopause) female
   2. You meet **ONE** of the following:
      a. You have **NOT** received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer
      b. You have experienced disease progression (your condition worsened) on endocrine (hormone) therapy AND you had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
RIBOCICLIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kisqali.

REFERENCES
- Kisqali [Prescribing Information]. East Hanover, NJ. Novartis; October 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 07/01/23  
Created: 05/17  
Client Approval: 05/23  
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet ALL of the following criteria?
   • The patient's cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative
   • The patient has NOT received prior endocrine-based therapy (e.g., letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer (e.g., letrozole, anastrozole, tamoxifen)
   • The patient had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   • 200mg-2.5mg: #1.75 per day.
   • 400mg-2.5mg: #2.5 per day.
   • 600mg-2.5mg: #3.25 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RIBOCICLIB-LETROZOLE (Kisqali/Femara Co-Pack) requires the following rule(s) be met for approval:
A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of the body)
B. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
C. You have NOT received prior endocrine (hormone)-based therapy for advanced or metastatic breast cancer (such as letrozole, anastrozole, tamoxifen)
D. You had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RIBOCICLIB-LETROZOLE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kisqali/Femara Co-Pack.

REFERENCES
• Kisqali/Femara Co-Pack [Prescribing Information]. East Hanover, NJ. Novartis; October 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 03/23
Client Approval: 05/23
P&T Approval: 04/23
RIFAXIMIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIFAXIMIN</td>
<td>XIFAXAN</td>
<td>28530</td>
<td>93749</td>
<td>GPI-14 (16000049000340)</td>
<td></td>
</tr>
</tbody>
</table>

** Please use the criteria for the specific drug requested **

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

XIFAXAN 550MG TABLETS

1. Is the patient being treated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a hepatologist
   - The patient had a trial of lactulose or is currently on lactulose monotherapy

   If yes, approve for 12 months for Xifaxan 550mg by GPID or GPI-14 with a quantity limit of #2 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to tricyclic anti-depressants or dicyclomine

   If yes, approve for 8 weeks for Xifaxan 550mg by GPID or GPI-14 for 1 fill of #42.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA - XIFAXAN 550MG TABLETS (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named Rifaximin (Xifaxan 550 mg tablets) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Reduction of risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence
   2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)

B. For reduction in risk of overt hepatic encephalopathy recurrence, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor)
   3. You have previously tried lactulose or you are currently taking lactulose monotherapy (drug used alone for treatment)

C. If you have irritable bowel syndrome with diarrhea, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to tricyclic anti-depressants (such as amitriptyline, nortriptyline, etc.) or dicyclomine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

XIFAXAN 200MG TABLETS

1. Does the patient have a diagnosis of travelers' diarrhea (TD) and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • The patient had a trial of or contraindication to oral azithromycin, ciprofloxacin, ofloxacin, or levofloxacin

   If yes, approve for 3 days for Xifaxan 200mg by GPID or GPI-14 for 1 fill of #9.
   If no, continue to #2.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA - XIFAXAN 200MG TABLETS (CONTINUED)

2. Is the request for the treatment of overt hepatic encephalopathy (HE) AND the patient meets the following criterion?
   - The requested medication will be used in combination with lactulose
     If yes, approve for 10 days for Xifaxan 200mg by GPID or GPI-14 with a quantity limit of #6 per day.
     If no, continue to #3.

3. Does the patient have a diagnosis of Clostridium difficile infection (CDI) and meet ALL of the following criteria?
   - The patient has had at least one previous occurrence of Clostridium difficile infection
   - The requested medication will be used in combination with vancomycin
   - Therapy is prescribed by or in consultation with an infectious disease specialist
     If yes, approve for 20 days for Xifaxan 200mg by GPID or GPI-14 with a quantity limit of #6 per day.
     If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RIFAXIMIN (Xifaxan 200 mg tablets) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Travelers' diarrhea
   2. Clostridium difficile infection (a type of bacterial infection)
   3. Treatment of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage)

B. If you have traveler's diarrhea, approval also requires:
   1. You are 12 years of age or older
   2. You had a trial of or contraindication (harmful for) to oral azithromycin, ciprofloxacin, ofloxacin, or levofloxacin

C. For the treatment of overt hepatic encephalopathy, approval also requires:
   1. The requested medication will be used in combination with lactulose

D. If you have Clostridium difficile infection, approval also requires:
   1. You had at least one previous occurrence of Clostridium difficile infection
   2. The requested medication will be used in combination with vancomycin
   3. Therapy is prescribed by or in consultation with an infectious disease specialist (a doctor who specializes in the treatment of infections)

(Initial Xifaxan 200mg tablets denial text continued on next page)
INITIAL CRITERIA - XIFAXAN 200MG TABLETS (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for renewal of Xifaxan 550mg tablet?

   If yes, continue to #2.
   If no, please refer to initial criteria above for Xifaxan 200mg request.

2. Is the patient being treated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence?

   If yes, approve for 12 months for Xifaxan 550mg by GPID or GPI-14 with a quantity limit of #2 per day.
   If no, continue to 3.

3. Does the patient have a diagnosis of irritable bowel syndrome with diarrhea (IBS-D) and meet ALL of the following criteria?
   • At least 6 weeks have passed since the last treatment course of rifaximin
   • Patient has experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
   • Patient has experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

   If yes, approve for 12 months for Xifaxan 550mg by GPID or GPI-14 for up to 2 fills of #42 each fill, separated by at least 8 weeks (total of 2 fills in 12 months).

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RIFAXIMIN (Xifaxan 550 mg tablets) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Reduction of risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence
   2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)

B. If you have irritable bowel syndrome with diarrhea, renewal also requires:
   1. At least 6 weeks have passed since your last treatment course of rifaximin
   2. You have experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
   3. You have experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information for Xifaxan.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient has genetic testing for gain-of-function mutations in the *NLRP3* gene OR has inflammatory markers (i.e., elevated CRP, ESR, serum amyloid A protein (SAA) or S100 proteins)
   - The patient has TWO of the following: urticarial-like rash (neutrophilic dermatitis), cold-triggered episodes, sensorineural hearing loss, musculoskeletal symptoms, chronic aseptic meningitis, skeletal abnormalities
   - Arcalyst will NOT be used concurrently with other IL-1 inhibitors (e.g., Ilaris [canakinumab], Kineret [anakinra])

   If yes, enter TWO approvals by HICL or GPI-10 as follows:
   **FIRST APPROVAL:**
   - Approve for 1 month with a quantity limit of #5 per 28 days.

   **SECOND APPROVAL:**
   - Approve for lifetime with a quantity limit of #4 per 28 days (enter a start date of 3 days BEFORE the END of the first approval).

   If no, continue to #2.

2. Does the patient have a diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) and meet ALL of the following criteria?
   - The patient has genetic testing for gain-of-function mutations in the *IL1RN* gene OR has inflammatory markers (i.e., elevated CRP, ESR)
   - The patient has ONE of the following: pustular psoriasis-like rashes, osteomyelitis, absence of bacterial osteomyelitis, nail changes (i.e., onychomadesis)
   - Arcalyst will NOT be used concurrently with other IL-1 inhibitors (e.g., Ilaris [canakinumab], Kineret [anakinra])

   If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #8 per 28 days.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Is the request for the treatment or reduction in risk of recurrent pericarditis (RP) and the patient meets ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient had an episode of acute pericarditis
   - The patient has been symptom-free for an interval of 4 to 6 weeks
   - The patient has TWO of the following: chest pain consistent with pericarditis, pericardial friction rub, ECG showing diffuse ST-segment elevation or PR-segment depression, and new or worsening pericardial effusion
   - The patient had a trial of or contraindication to two NSAIDs (e.g., ibuprofen, indomethacin) AND colchicine
   - Arcalyst will NOT be used concurrently with other IL-1 inhibitors (e.g., Ilaris [canakinumab], Kineret [anakinra])

If yes, approve for 12 months by HICL or GPI-10 as follows:

INITIAL REQUESTS:
FIRST APPROVAL:
   - Approve for 1 month with a quantity limit of #5 per 28 days.
SECOND APPROVAL:
   - Approve for 11 months with a quantity limit of #4 per 28 days (enter a start date of 3 days BEFORE the END of the first approval).

SUBSEQUENT REQUESTS:
Approve for 12 months with a quantity limit of #4 per 28 days.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RILONACEPT (Arcalyst) requires the following rule(s) be met for approval:
A. You meet ONE of the following:
   1. You have Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS: an inherited inflammatory disorder that is triggered with cold) or Muckle-Wells Syndrome (MWS: a disorder characterized by periodic episodes of skin rash, fever, and joint pain)
   2. You have Deficiency of Interleukin-1 Receptor Antagonist (DIRA: a type of immune system disorder)
   3. Arcalyst will be used for the treatment or reduction in risk of recurrent pericarditis (RP: a type of heart condition that returns)

(Denial text continued on next page)
GUIDELINE FOR USE (CONTINUED)

B If you have Cryopyrin-Associated Periodic Syndromes including Familial Cold Autoinflammatory Syndrome or Muckle-Wells Syndrome, approval also requires:

1. You are 12 years of age or older
2. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the NLRP3 gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: sign of inflammation], erythrocyte sedimentation rate [ESR: a type of blood test], serum amyloid A protein [SAA: a type of protein] or S100 proteins [a type of protein])
3. You have TWO of the following: urticarial-like rash (neutrophilic dermatitis: a type of skin condition), cold-triggered episodes, sensorineural hearing loss (SNHL: a type of hearing loss), musculoskeletal symptoms (symptoms related to the skin and bones), chronic aseptic meningitis (inflammation of the brain and spinal cord), and skeletal (bone) abnormalities
4. Arcalyst will NOT be used concurrently (at the same time) with other IL-1 inhibitors (such as Ilaris [canakinumab], Kineret [anakinra])

C. If you have Deficiency of Interleukin-1 Receptor Antagonist, approval also requires:

1. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the IL1RN gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: sign of inflammation], erythrocyte sedimentation rate [ESR: a type of blood test])
2. You have ONE of the following: pustular psoriasis-like rashes (a type of skin condition), osteomyelitis (bone infection), absence of bacterial osteomyelitis, nail changes (onychomadesis: fungal infection of toenail)
3. Arcalyst will NOT be used concurrently (at the same time) with other IL-1 inhibitors (such as Ilaris [canakinumab], Kineret [anakinra])

D. If the request is for the treatment or reduction in risk of recurrent pericarditis, approval also requires:

1. You are 12 years of age or older
2. You had an episode of acute pericarditis (a type of short-term heart condition)
3. You have been symptom-free for 4 to 6 weeks
4. You have TWO of the following: chest pain consistent with pericarditis, pericardial friction rub (a type of heart condition), electrocardiogram (ECG: a type of lab test) showing diffuse ST-segment elevation or PR-segment depression (an abnormal heart test), and new or worsening pericardial effusion (a type of heart condition)
5. You had a trial of or contraindication to (harmful for) two NSAIDS (non-steroidal anti-inflammatory drugs such as ibuprofen, indomethacin) AND colchicine
6. Arcalyst will NOT be used concurrently with other IL-1 inhibitors (such as Ilaris [canakinumab], Kineret [anakinra])

(Denial text continued on next page)
GUIDELINE FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Arcalyst.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 08/23
Client Approval: 08/23
P&T Approval: 07/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has had a trial of riluzole tablets
   - The patient is unable to take riluzole tablet formulation

If yes, approve for 12 months by GPI-14 with the following quantity limits:
   - Exservan: #2 per day.
   - Tiglutik: #20mL per day.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RILUZOLE (Exservan, Tiglutik) requires the following rule(s) be met for approval:
A. You have amyotrophic lateral sclerosis (ALS: nervous system disease that weakens muscles and affects physical function)
B. You are 18 years of age or older
C. You have tried riluzole tablets
D. You are unable to take riluzole tablet formulation

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Exservan or Tiglutik.

REFERENCES

CONTINUED ON NEXT PAGE
<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 06/01/21  
Created: 11/18  
Client Approval: 05/21  
P&T Approval: 01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for the acute treatment of migraine and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to ONE triptan (e.g., sumatriptan, rizatriptan)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #18 per 30 days.
   If no, continue to #2.

2. Is the request for the preventive treatment of episodic migraines and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - Nurtec ODT will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
   - The patient had a trial of or contraindication to ONE of the following preventative migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RIMEGEPANT (Nurtec ODT) requires the following rule(s) be met for approval:
A. The request is for ONE of the following:
   1. Treatment of acute (quick onset) migraine
   2. Preventive treatment of episodic migraines
B. You are 18 years of age or older
C. If the request is for the treatment of acute migraine, approval also requires:
   1. You had a trial of or contraindication (harmful for) to ONE triptan (such as sumatriptan, rizatriptan)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If the request is for the preventive treatment of episodic migraines, approval also requires:
   1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
   2. You had a trial of or contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets ONE of the following criteria?
   - The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
   - The patient has experienced clinical improvement as defined by ONE of the following:
     o Ability to function normally within 2 hours of dose
     o Headache pain disappears within 2 hours of dose
     o Therapy works consistently in majority of migraine attacks

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #18 per 30 days. If no, continue to #2.

2. Is the request for the preventive treatment of episodic migraines AND does the patient meet the following criterion?
   - Nurtec ODT will NOT be used concurrently with other CGRP inhibitors (e.g., Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention

   If yes, continue to #3. If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
3. Does the patient meet **ONE** of the following criteria?
   - The patient has experienced a reduction in migraine or headache frequency of at least 2 days per month
   - The patient has experienced a reduction in migraine severity
   - The patient has experienced a reduction in migraine duration

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **RIMEGEPANT (Nurtec ODT)** requires the following rule(s) be met for renewal:
   A. **The request is for ONE of the following:**
      1. Treatment of acute (quick onset) migraine
      2. Preventive treatment of episodic migraines
   B. **If the request is for treatment of acute migraine, renewal also requires ONE of the following:**
      1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
      2. You have experienced clinical improvement as defined by ONE of the following:
         a. Ability to function normally within 2 hours of dose
         b. Headache pain disappears within 2 hours of dose
         c. Treatment works consistently in majority of migraine attacks
   C. **If the request is for the preventive treatment of episodic migraines, renewal also requires:**
      1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
      2. You meet **ONE** of the following:
         a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month
         b. You experienced a reduction in migraine severity
         c. You experienced a reduction in migraine duration

   **(Renewal denial text continued on next page)**

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nurtec ODT.

REFERENCES
- Nurtec ODT [Prescribing Information]. New Haven, CT: Biohaven Pharmaceuticals Inc; December 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 03/20
Client Approval: 02/22
P&T Approval: 01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient is NOT concurrently taking nitrates or nitric oxide donors (e.g., amyl nitrate), phosphodiesterase inhibitors (e.g., Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (e.g., dipyridamole, theophylline)

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Does the patient have a diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient has persistent or recurrent disease after surgical treatment OR the patient is not a candidate for surgery or has inoperable CTEPH
   - The patient has NYHA-WHO Functional Class II to IV symptoms
   - The patient is NOT concurrently taking nitrates or nitric oxide donors (e.g., amyl nitrate), phosphodiesterase inhibitors (e.g., Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (e.g., dipyridamole, theophylline)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RIOCIGUAT (Adempas) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: form of high blood pressure affecting the lungs caused by blood clots) World Health Organization (WHO: Group 4: a way to classify the severity of disease)
   2. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects the arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. If you have pulmonary arterial hypertension, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   3. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   4. You are not concurrently taking nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

C. If you have chronic thromboembolic pulmonary hypertension, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   3. You have persistent or recurrent disease after surgical treatment (it continues to exist or returns after surgery) OR you are not a candidate for surgery or have inoperable chronic thromboembolic pulmonary hypertension
   4. You have NYHA-WHO Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
   5. You are not concurrently taking nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

(Initial denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have one of the following diagnoses?
   • Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO (World Health Organization) Group 4)
   • Pulmonary arterial hypertension (PAH) (WHO Group 1)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the patient concurrently taking nitrate or nitric oxide donors (e.g., amyl nitrate), phosphodiesterase inhibitors (e.g., Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (e.g., dipyridamole, theophylline)?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient meet **ONE** of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient remains stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization (WHO) functional class

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **RIOCIGUAT (Adempas)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: form of high blood pressure affecting the lungs caused by blood clots) World Health Organization (WHO Group 4: a way to classify the severity of disease)
   2. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You are not concurrently (at the same time) taking nitrate or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

C. You show improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Adempas.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 07/01/23  
Created: 11/13  
Client Approval: 05/23  
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced gastrointestinal stromal tumor (GIST) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has received prior treatment with 3 or more kinase inhibitors (e.g. sunitinib, avapritinib, regorafenib), including imatinib

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named RIPRETINIB (Qinlock) requires ALL of the following rule(s) be met for approval:
   A. You have advanced gastrointestinal stromal tumor (GIST: a type of cancer in your digestive tract)
   B. You are 18 years of age or older
   C. You have received prior treatment with 3 or more kinase inhibitors (class of drugs), including imatinib

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Qinlock.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to one or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and is switching to the requested drug
   - The patient has psoriasis covering 3% or more of body surface area (BSA)
   - The patient has psoriatic lesions affecting the hands, feet, face, or genital area

   If yes, approve the requested strength and dosage form for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:
   **FIRST APPROVAL:**
   - 150mg/1.66mL Kit: Approve for 1 month with a quantity limit of #1 kit (2 syringes) per 28 days.
   - 150mg/mL pen/syringe: Approve for 1 month with a quantity limit of #1mL per 28 days.

   **SECOND APPROVAL:**
   - 150mg/1.66mL Kit: Approve for 5 months with a quantity limit of #1 kit (2 syringes) per 84 days (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).
   - 150mg/mL pen/syringe: Approve for 5 months with a quantity limit of #1mL per 84 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).

   If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, approve the requested strength and dosage form for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:
   **FIRST APPROVAL:**
   • 150mg/1.66mL Kit: Approve for 1 month with a quantity limit of #1 kit (2 syringes) per 28 days.
   • 150mg/mL pen/syringe: Approve for 1 month with a quantity limit of #1mL per 28 days.
   **SECOND APPROVAL:**
   • 150mg/1.66mL Kit: Approve for 5 months with a quantity limit of #1 kit (2 syringes) per 84 days (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).
   • 150mg/mL pen/syringe: Approve for 5 months with a quantity limit of #1mL per 84 days. (Please enter a start date of 3 WEEKS AFTER the START date of the first approval).

   If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a gastroenterologist
   • The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (e.g., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
RISANKIZUMAB-RZAA

INITIAL CRITERIA (CONTINUED)

5. Is the prescriber requesting an intravenous infusion induction dose of Skyrizi 600mg/10mL?

If yes, approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:

FIRST APPROVAL:
- 600mg/10mL: Approve for 3 months with a quantity limit of #10mL per 28 days.

SECOND APPROVAL (approve the requested strength):
- 180mg/1.2mL: Approve for 3 months with a quantity limit of #1.2 mL per 56 days
  (Please enter start date of 11 WEEKS AFTER the START date of the first approval).
- 360mg/2.4mL: Approve for 3 months with a quantity limit of #2.4 mL per 56 days
  (Please enter start date of 11 WEEKS AFTER the START date of the first approval).

If no, approve a maintenance dose for 6 months by GPID or GPI-14 for the requested strength as follows:
- 180mg/1.2mL: #1.2mL per 56 days.
- 360mg/2.4mL: #2.4mL per 56 days.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RISANKIZUMAB-RZAA (Skyrizi) requires the following rules be met for approval:
A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to one or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. If you have moderate to severe Crohn's disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   • The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

   If yes, approve the requested strength and dosage form for 12 months by GPID or GPI-14 with the following quantity limits:
   • 150mg/1.66mL Kit: #1 kit (2 syringes) per 84 days.
   • 150mg/mL pen/syringe: #1mL per 84 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve the requested strength and dosage form for 12 months by GPID or GPI-14 with the following quantity limits:
   • 150mg/1.66mL Kit: #1 kit (2 syringes) per 84 days.
   • 150mg/mL pen/syringe: #1mL per 84 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   • 180mg/1.2mL: #1.2mL per 56 days.
   • 360mg/2.4mL: #2.4mL per 56 days.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RISANKIZUMAB-RZAA (Skyrizi) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

C. If you have psoriatic arthritis, renewal also requires:
   1. You experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Skyrizi.

REFERENCES
• Skyrizi [Prescribing Information]. North Chicago, IL: AbbVie, Inc.; December 2022.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of spinal muscular atrophy (SMA) and meet ALL of the following criteria?
   • Diagnosis of spinal muscular atrophy (SMA) is confirmed by documentation of gene mutation analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1) gene (e.g., homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [i.e., deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
   • Therapy is prescribed by or given in consultation with a neuromuscular specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Is the patient presymptomatic AND meets the following criterion?
   • There is documentation of up to (i.e., no more than) three copies of survival motor neuron 2 (SMN2) based on newborn screening

   If yes, approve for 12 months by HICL or GPI-10 for #240mL per 30 days.

   APPROVAL TEXT: Renewal requires that the patient has improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline, OR in other muscle function.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Is the patient symptomatic and meets ALL of the following criteria?
   - The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
   - There is documentation of a baseline motor function assessment by a neuromuscular specialist or SMA specialist
   - For patients who have received prior gene therapy: the patient had less than expected clinical benefit with gene therapy

If yes, approve for 12 months by HICL or GPI-10 for #240mL per 30 days.

APPROVAL TEXT: Renewal requires that the patient has improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline, OR in other muscle function.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RISDIPLAM (Evrysdi) requires the following rule(s) be met for approval:

A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
B. Your diagnosis of spinal muscular atrophy (SMA) is confirmed by documentation of a gene mutation analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1: type of protein in spinal cord) gene (such as homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
C. The requested medication is prescribed by or given in consultation with a neuromuscular (nerve and muscle) specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center
D. If you are presymptomatic (symptoms have not yet appeared), approval also requires:
   1. There is documentation showing you have up to three copies of survival motor neuron 2 (SMN2: type of protein in spinal cord) based on screening done when you were a newborn
E. If you are symptomatic (symptoms have appeared), approval also requires:
   1. The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
   2. There is documentation showing you had a baseline motor function assessment by a neuromuscular (nerve and muscle) specialist or SMA specialist
   3. If you previously had gene therapy, you had less than expected clinical benefit (Initial denial text continued on the next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

2. Does the patient have a diagnosis of spinal muscular atrophy (SMA) and meet ONE of the following criteria?
   - The patient has improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline (e.g., HINE, HFMSE, CHOP-INTEND)
   - The patient has improved, maintained, or demonstrated less than expected decline in other muscle function (e.g., pulmonary)

   If yes, approve for 12 months by HICL or GPI-10 for #240mL per 30 days.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named RISDIPLAM (Evrysdi) requires the following rule(s) be met for renewal:
   A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
   B. You meet ONE of the following:
      1. You have improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline. Some types of motor assessment tests include Hammersmith Infant Neurological Examination (HINE), Hammersmith Functional Motor Scale - Expanded (HFMSE) and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
      2. You have improved, maintained, or demonstrated less than expected decline in other muscle function such as pulmonary (lung/breathing) function

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RISDIPLAM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Evrysdi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 09/07/20
Created: 08/20
Client Approval: 08/20
P&T Approval: 04/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of severe alopecia areata and meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient has had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months
   - The patient is **NOT** utilizing other systemic biologics for alopecia areata or other JAK inhibitors for any indication (e.g., Xeljanz [tofacitinib IR or XR], Rinvoq [upadacitinib])

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient had a trial of or contraindication to **TWO** of the following (from different categories)?
   - Intralesional corticosteroid (e.g., triamcinolone acetonide)
   - Topical corticosteroid (e.g., fluocinolone acetonide, betamethasone dipropionate, clobetasol propionate)
   - Minoxidil (e.g., minoxidil 5% solution)
   - Short contact Anthralin
   - Topical immunotherapy (e.g., squaric acid dibutylester [SADBE], diphencyprone [DPCP])
   - Systemic treatment (e.g., psoralen plus UV-A [PUVA], cyclosporine, methotrexate, steroids such as prednisone)

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient 12 to 17 years of age?

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day**.
   If no, continue to #4.

4. Is the patient 18 years of age or older **AND** meet the following criterion?
   - The patient had a trial of or contraindication to the preferred agent: Olumiant (baricitinib)

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day**.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RITLECITINIB (Litfulo) requires the following rule(s) be met for approval:
A. You have severe alopecia areata (a type of hair loss)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool) for more than 6 months
E. You are NOT using other systemic biologics for alopecia areata or other JAK (Janus kinase) inhibitors for any indication (such as Xeljanz [tofacitinib immediate-release or extended-release], Rinvoq [upadacitinib])
F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
   1. Intralesional corticosteroid (such as triamcinolone acetonide)
   2. Topical corticosteroid (such as fluocinolone acetonide, betamethasone dipropionate, clobetasol propionate)
   3. Minoxidil (such as minoxidil 5% solution)
   4. Short contact Anthralin
   5. Topical immunotherapy (such as squaric acid dibutylester [SADBE], diphencyprone [DPCP])
   6. Systemic treatment (such as psoralen plus UV-A [PUVA], cyclosporine, methotrexate, steroids such as prednisone)
G. If you are 18 years of age or older, approval also requires:
   1. You have tried or have a contraindication (harmful for) to the preferred medication: Olumiant (baricitinib)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENUEWAL CRITERIA

1. Does the patient have a diagnosis of severe alopecia areata and meet ALL of the following criteria?
   • The patient has had improvement while on therapy (e.g., scalp hair coverage)
   • The patient is NOT utilizing other systemic biologics for alopecia areata or other JAK inhibitors for any indication (e.g., Xeljanz [tofacitinib IR or ER], Rinvoq [upadacitinib])

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Is the patient 12 to 17 years of age?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, continue to #3.

3. Is the patient 18 years of age or older AND meet the following criterion?
   • The patient had a trial of or contraindication to the preferred agent: Olumiant (baricitinib)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named RITLECITINIB (Litfulo) requires the following rule(s) be met for renewal:
   A. You have severe alopecia areata (a type of hair loss)
   B. You are 12 years of age or older
   C. You have had improvement while on therapy (such as scalp hair coverage)
   D. You are NOT using other systemic biologics for alopecia areata or other JAK (Janus kinase) inhibitors for any indication (such as Xeljanz [tofacitinib immediate-release or extended-release], Rinvoq [upadacitinib])
   E. If you are 18 years of age or older, approval also requires:
      1. You had a trial of or contraindication (harmful for) to the preferred medication: Olumiant (baricitinib)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
RITLECITINIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Litfulo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A

Commercial Effective: 08/14/23

Created: 07/23

Client Approval: 08/23

P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of plaque psoriasis and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist
   • The patient has psoriasis covering 2% to 20% of body surface area (BSA) (excluding scalp, palms, and soles)
   • The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Has the patient had a trial of or contraindication to TWO of the following (from different categories)?
   • High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
   • Topical vitamin D analog (e.g., calcipotriene cream, calcitriol ointment)
   • Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
   • Topical retinoid (e.g., tazarotene cream/gel)
   • Anthralin

   If yes, approve for 2 months by GPID or GPI-10.
   If no, do not approve.
   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ROFLUMILAST (Zoryve) requires the following rule(s) be met for approval:
   A. You have plaque psoriasis (a type of skin condition)
   B. You are 12 years of age or older
   C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   *(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. You have psoriasis covering 2% to 20% of body surface area (BSA) (excluding scalp, palms, and soles)
E. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
   2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
   3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
   4. Topical retinoid (such as tazarotene cream/gel)
   5. Anthralin

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of plaque psoriasis and meet ALL of the following criteria?
   • The patient has achieved or maintained clear or minimal disease
   • The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

   If yes, approve for 12 months by GPID or GPI-10.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ROFLUMILAST (Zoryve) requires the following rule(s) be met for renewal:
   A. You have plaque psoriasis (a type of skin condition)
   B. You have achieved or maintained clear or minimal disease
   C. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

   (Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zoryve.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of polycythemia vera AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2mL per 28 days.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ROPEGINTERFERON ALFA-2B-NJFT (Besremi) requires the following rule(s) be met for approval:
   A. You have polycythemia vera (a type of blood cancer)
   B. You are 18 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Besremi.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's cancer has a deleterious BRCA mutation (germline and/or somatic)
   - The patient is in complete or partial response to platinum-based chemotherapy
   - The requested medication will be used for maintenance treatment

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's cancer has a deleterious BRCA mutation (germline and/or somatic) based on an FDA-approved companion diagnostic for Rubraca
   - The patient has been treated with an androgen receptor-directed therapy and a taxane-based chemotherapy

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet ONE of the following criteria?
   - The patient previously had a bilateral orchiectomy
   - The patient has a castrate level of testosterone (i.e., < 50 ng/dL)
   - The requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin, histrelin)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **RUCAPARIB (Rubraca)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (types of reproductive system cancers that has returned)
   2. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)

B. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
   1. You are 18 years of age or older
   2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life)
   3. You are in complete or partial response to platinum-based chemotherapy (a type of therapy to treat cancer)
   4. The requested medication will be used for maintenance treatment

C. **If you have metastatic castration-resistant prostate cancer, approval also requires:**
   1. You are 18 years of age or older
   2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Rubraca
   3. You have been treated with an androgen receptor-directed therapy and a taxane-based chemotherapy (types of therapy to treat cancer)
   4. You meet ONE of the following:
      a. You previously received a bilateral orchiectomy (removal of testicles)
      b. You have a castrate level of testosterone (blood testosterone levels are less than 50 ng/dL)
      c. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
RUCAPARIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Rubraca.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Created: 12/16
Commercial Effective: 01/23/23
Client Approval: 01/23
P&T Approval: 01/23
RUXOLITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>RUXOLITINIB PHOSPHATE</td>
<td>JAKAFI</td>
<td>38202</td>
<td>GPI-10 (2153756020)</td>
<td>ROUTE ≠ TOPICAL</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytemia myelofibrosis AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 6 months by GPID or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of polycythemia vera and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has had a trial of or contraindication to hydroxyurea

   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #3.

3. Does the patient have a diagnosis of steroid-refractory acute graft-versus-host disease AND meet the following criterion?
   • The patient is 12 years of age or older

   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.
   If no, continue to #4.

4. Does the patient have a diagnosis of chronic graft-versus-host disease and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • The patient has had a failure of one or two lines of systemic therapy

   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RUXOLITINIB (Jakafi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Intermediate or high-risk myelofibrosis, (type of bone marrow cancer such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis)
   2. Polycythemia vera (a type of blood cancer)
   3. Steroid-refractory acute graft-versus-host disease (a type of short-term immune disorder that did not respond to a type of treatment)
   4. Chronic graft-versus-host disease (a type of long-term immune disorder)

B. If you have intermediate or high-risk myelofibrosis, such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, approval also requires:
   1. You are 18 years of age or older

C. If you have polycythemia vera, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of hydroxyurea, unless you have a contraindication (harmful for)

D. If you have steroid-refractory acute graft-versus-host disease, approval also requires:
   1. You are 12 years of age or older

E. If you have chronic graft-versus-host disease, approval also requires:
   1. You are 12 years of age or older
   2. You had a failure of one or two lines of systemic therapy (treatment that targets the entire body)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RUXOLITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of polycythemia vera, acute graft-versus-host disease, or chronic graft-versus-host disease, please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytemia myelofibrosis?
   
   If yes, continue to #2.
   If no, do not approve.
   
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Has the patient shown symptom improvement by meeting ONE of the following criteria?
   • The patient has a 50% or greater reduction in total symptom score (e.g., Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   • The patient has a 50% or greater reduction in palpable spleen length
   • The patient has a spleen volume reduction of 35% or greater from baseline
   
   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.
   
   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named RUXOLITINIB (Jakafi) requires the following rule(s) be met for renewal:
A. You have intermediate or high-risk myelofibrosis, (type of bone marrow cancer such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytemia myelofibrosis)
B. You have shown symptom improvement by meeting ONE of the following:
   1. You have a 50 percent or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   2. You have a 50 percent or greater reduction in palpable (can be felt by external examination) spleen length
   3. You have a spleen volume reduction of 35 percent or greater from baseline

( Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Jakafi.

REFERENCES
- Jakafi [Prescribing Information]. Wilmington, DE. Incyte Corporation; September 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 01/01/22  
Created: 12/11  
Client Approval: 11/21  
P&T Approval: 10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of mild to moderate atopic dermatitis and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient is NOT immunocompromised
   - The patient had a trial of or contraindication to a topical corticosteroid (e.g., halobetasol, triamcinolone, fluocinonide) OR a topical non-steroidal immunomodulating agent (e.g., pimecrolimus, tacrolimus)

   If yes, continue to #2.
   If no, continue to #3.

2. Will Opzelura be used concurrently with ANY of the following?
   - Other non-steroid topicals (e.g., pimecrolimus, tacrolimus, Eucrisa)
   - Systemic therapeutic biologics (e.g., Dupixent, Adbry)
   - Other JAK inhibitors (e.g., Rinoq, Cibinqo)
   - Potent immunosuppressants (e.g., azathioprine, cyclosporine)

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial at the end of the guideline.

   If no, approve for 3 months by G PID or GPI-10 with a quantity limit of #60 grams per 30 days.

3. Does the patient have a diagnosis of nonsegmental vitiligo and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient has depigmented areas covering 10% or less of total body surface area
   - The patient had a trial of or contraindication to a topical corticosteroid (e.g., halobetasol, triamcinolone, fluocinonide) OR a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus)

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text on the next page.

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

4. Will Opzelura be used concurrently with ANY of the following?
   - Other non-steroid topicals (e.g., pimecrolimus, tacrolimus, Eucrisa)
   - Systemic therapeutic biologics (e.g., Dupixent, Adbry)
   - Other JAK inhibitors (e.g., Rinvoq, Cibinqo)
   - Potent immunosuppressants (e.g., azathioprine, cyclosporine)

If yes, do not approve.
If no, approve for 6 months by GPID or GPI-10 with a quantity limit of ##60 grams per 30
days.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use
these definitions if the particular text you need to use does not already have definition(s)
in it.

Our guideline named RUXOLITINIB TOPICAL (Opzelura) requires the following rule(s) be met
for approval:
A. You have ONE of the following diagnoses:
   1. Mild to moderate atopic dermatitis (a type of skin condition)
   2. Nonsegmental vitiligo (a type of skin condition)
B. If you have mild to moderate atopic dermatitis, approval also requires:
   1. You are 12 years of age or older
   2. You are NOT immunocompromised (low immune system)
   3. You had a trial of or contraindication (harmful for) to a topical corticosteroid (such as
      halobetasol, triamcinolone, fluocinonide) OR a topical non-steroidal immunomodulating
      agent (such as pimecrolimus, tacrolimus)
   4. You are NOT using Opzelura together with ANY of the following:
      a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
      b. Systemic therapeutic biologics (such as Dupixent, Adbry)
      c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
      d. Potent immunosuppressants (such as azathioprine, cyclosporine)

(Initial denial text continued on next page)
RUXOLITINIB TOPICAL

INITIAL CRITERIA (CONTINUED)

C. If you have nonsegmental vitiligo, approval also requires:
   1. You are 12 years of age or older
   2. You have depigmented (lightening of the skin) areas covering 10 percent or less of total body surface area
   3. You had a trial of or contraindication (harmful for) to a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) OR a topical calcineurin inhibitor (such as pimecrolimus, tacrolimus)
   4. You are NOT using Opzelura together with ANY of the following:
      a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
      b. Systemic therapeutic biologics (such as Dupixent, Adbry)
      c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
      d. Potent immunosuppressants (such as azathioprine, cyclosporine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of mild to moderate atopic dermatitis AND meet the following criterion?
   - The patient has experienced or maintained improvement in pruritus, relapsing-remitting dermatitis, or facial/interdigital involvement

   If yes, continue to #3.
   If no, continue to #2.

2. Does the patient have a diagnosis of nonsegmental vitiligo AND meet the following criterion?
   - The patient has experienced or maintained clinically meaningful regimentation

   If yes, continue to #3.
   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RUXOLITINIB TOPICAL

RENEWAL CRITERIA (CONTINUED)

3. Will Opzelura be used concurrently with ANY of the following?
   - Other non-steroid topicals (e.g., pimecrolimus, tacrolimus, Eucrisa)
   - Systemic therapeutic biologics (e.g., Dupixent, Adbry)
   - Other JAK inhibitors (e.g., Rinvoq, Cibinqo)
   - Potent immunosuppressants (e.g., azathioprine, cyclosporine)

   If yes, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

   If no, approve for 12 months by GPID or GPI-10 with a quantity limit of #60 grams per 30 days.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named RUXOLITINIB TOPICAL (Opzelura) requires the following rule(s) be met for renewal:

   A. You have ONE of the following diagnoses:
      1. Mild to moderate atopic dermatitis (a type of skin condition)
      2. Nonsegmental vitiligo (a type of skin condition)

   B. If you have mild to moderate atopic dermatitis, renewal also requires:
      1. You have experienced or maintained improvement in pruritus (itchiness), relapsing-remitting (disease returns and goes away) dermatitis, or facial/interdigital (between the fingers or toes) involvement
      2. You are NOT using Opzelura together with ANY of the following:
         a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
         b. Systemic therapeutic biologics (such as Dupixent, Adbry)
         c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
         d. Potent immunosuppressants (such as azathioprine, cyclosporine)

   C. If you have nonsegmental vitiligo, renewal also requires:
      1. You have experienced or maintained clinically meaningful regimentation (recoloration of the skin after loss in color)
      2. You are NOT using Opzelura together with ANY of the following:
         a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
         b. Systemic therapeutic biologics (such as Dupixent, Adbry)
         c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
         d. Potent immunosuppressants (such as azathioprine, cyclosporine)

   (Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Opzelura.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 09/21
Commercial Effective: 01/01/23 Client Approval: 11/22
P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a gastroenterologist or medical geneticist
   - The patient’s diagnosis is confirmed by ONE of the following:
     - Small bowel biopsy
     - Sucrose breath test
     - Genetic test

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SACROSIDASE (Sucraid) requires the following rule be met for approval:
A. You have a genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions) or medical geneticist (doctor who treats gene disorders)
C. Your diagnosis is confirmed by ONE of the following:
   1. Small bowel biopsy (removal of cells or tissue from the body for examination)
   2. Sucrose breath test
   3. Genetic test

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID) AND meet the following criterion?
   • The patient has experienced or maintained improvement on treatment

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SACROSIDASE (Sucraid) requires the following rule(s) be met for renewal:
   A. You have a genetically determined sucrase deficiency which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
   B. You have experienced or maintained improvement on treatment

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sucraid.

REFERENCES
• Sucraid [Prescriber Information]. Vero Beach, FL: QOL Medical, LLC.; August 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 05/12
Client Approval: 05/22
P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Therapy is prescribed by or given in consultation with a hematologist or oncologist?

   If yes, approve by HICL or GPI-10 for 3 months or requested duration of treatment up to 1 year.
   If no, continue to #2.

2. Is the request for ONE of the following indications?
   • To shorten time to neutrophil recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy in a patient with acute myeloid leukemia (AML) AND the patient is 55 years of age or older
   • For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis, the patient is undergoing autologous transplantation AND the patient is 18 years of age or older
   • For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation, in patients with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma AND the patient is 2 years of age or older
   • For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation from HLA-matched related donors AND the patient is 2 years of age or older
   • For the treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation AND the patient is 2 years of age or older
   • To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])

   If yes, approve by HICL or GPI-10 for 3 months or requested duration of treatment up to 1 year.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SARGRAMOSTIM (Leukine) requires the following rule(s) be met for approval:
   A. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor), OR you meet ONE of the following:
      1. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer) and are using the requested medication to shorten time to neutrophil (a type of white blood cell) recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy AND you are 55 years of age or older

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

2. You are undergoing autologous transplantation (your own blood-forming stem cells are collected) and using the requested medication for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis (to collect blood sample and separate white blood cells in a lab test) AND you are 18 years of age or older

3. You have non-Hodgkin's lymphoma (NHL: type of cancer), acute lymphoblastic leukemia (ALL: type of white blood cell cancer) or Hodgkin's lymphoma (type of cancer) and are using the requested medication for the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation (to help your blood and bone marrow recover) AND you are 2 years of age or older

4. The requested medication is being used for the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation from HLA-matched related donors (to help your blood and bone marrow recover after using a lab test to match you to the correct donors) AND you are 2 years of age or older

5. The requested medication is being used for the treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation AND you are 2 years of age or older

6. You are acutely exposed to myelosuppressive doses (doses that suppress bone marrow activity) of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]) and using the requested medication to increase your survival

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Leukine.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 02/03
Client Approval: 04/20
P&T Approval: 04/18

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following?
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   • The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #2.28mL per 28 days.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Does the patient have a diagnosis of polymyalgia rheumatica (PMR) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2.28mL per 28 days.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SARILUMAB (Kevzara) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Polymyalgia rheumatica (PMR: an inflammatory disorder causing muscle pain and stiffness)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib] due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have polymyalgia rheumatica, approval also requires:
   1. You are 18 years of age or older
   2. You had an inadequate response (drug did not work) to corticosteroids or cannot tolerate a corticosteroid taper

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

NOTE: For the diagnosis of polymyalgia rheumatica, please refer to the initial criteria section.

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) **AND** meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following?
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib IR or XR), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   - The patient has tried a TNF inhibitor (e.g., Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (e.g., Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality, malignancies, and serious cardiovascular events
     **[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]**

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2.28mL per 28 days**.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SARILUMAB (Kevzara) requires the following rule(s) be met for renewal:
A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.
C. You meet ONE of the following:
   1. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kevzara.

REFERENCE
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or given in consultation with a neurologist
   • Diagnosis is confirmed by a positive serologic test for anti-aquaporin-4 (AQP4) antibodies
   • The patient is NOT concurrently using rituximab, inebilizumab or eculizumab

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have ONE of the following core clinical characteristics?
   • Optic neuritis
   • Acute myelitis
   • Area postrema syndrome
   • Acute brainstem syndrome
   • Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
   • Symptomatic cerebral syndrome with NMOSD-typical brain lesions

   If yes, approve for a total of 12 months by HICL or GPI-10 as follows:
   • FIRST APPROVAL: Approve for 30 days with a quantity limit of #2mL per 28 days.
   • SECOND APPROVAL: Approve for 11 months with a quantity limit of #1mL per 28 days (Enter a start date 2 days before the end date of the first approval).

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SATRALIZUMAB-MWGE (ENSPRYNG) requires the following rule(s) be met for approval:
A. You have neuromyelitis optica spectrum disorder (NMOSD: a rare immune system disease that affects the central nervous system and causes inflammation in the optic nerve and spinal cord)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a neurologist (doctor who specializes in the brain, spinal cord, and nerves)
D. Your diagnosis is confirmed by a positive serologic (blood) test for anti-aquaporin-4 (AQP4: type of protein) antibodies
E. You are not concurrently (at the same time) using rituximab, inebilizumab, or eculizumab
F. You have at least ONE of the following core clinical characteristics:
   1. Optic neuritis (inflammation that damages an eye nerve)
   2. Acute myelitis (sudden and severe inflammation of the spinal cord)
   3. Area postrema syndrome (attacks of uncontrollable nausea, vomiting, or hiccups)
   4. Acute brainstem syndrome (problems with vision, hearing, swallowing and muscle weakness in the head)
   5. Symptomatic narcolepsy (sudden attacks of sleep) or acute diencephalic clinical syndrome (rare disorder caused by a tumor above the brainstem) with NMOSD-typical diencephalic MRI lesions
   6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and meet ALL of the following criteria?
   - The patient had a reduction in relapse frequency from baseline
   - The patient is NOT concurrently using rituximab, inebilizumab or eculizumab

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1mL per 28 days.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **SATRALIZUMAB-MWGE (ENSPRYNG)** requires the following rule(s) be met for renewal:
   A. You have neuromyelitis optica spectrum disorder (NMOSD: a rare disorder that affects the central nervous system and causes inflammation in the optic nerve and spinal cord)
   B. You had a reduction in relapse frequency from baseline
   C. You are not concurrently (at the same time) using rituximab, inebilizumab, or eculizumab

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **RATIONALE**
   For further information, please refer to the Prescribing Information and/or Drug Monograph for Enspryng.

   **REFERENCES**
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) without psoriatic arthritis involvement and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient has psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions affecting the hands, feet, genital area, or face
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #2.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

2. Does the patient meet ONE of the following criteria?
   - The patient is 6 to 17 years of age AND had a trial of or contraindication to THREE of the preferred agents: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)
   - The patient is 18 years of age or older AND had a trial of or contraindication to FOUR of the following preferred agents: Taltz (ixekizumab), Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve the requested strength and dosage form by NDC for a total of 6 months as follows:

FIRST APPROVAL
- 75mg every week dosing: Approve for 1 month with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only)
- 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
- 300mg every week dosing: Approve for 1 month with a quantity limit of #8mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only)

SECOND APPROVAL
- 75mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)
- 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)
- 300mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   • The patient had a trial of or a contraindication to ONE DMARD (disease-modifying anti-rheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #4.
   If no, continue to #7.

4. Does the patient meet ONE of the following criteria?
   • The patient is 2 to 5 years of age
   • The patient is 6 to 17 years of age AND had a trial of or contraindication to the preferred agent: Stelara (ustekinumab)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve the requested strength and dosage form by NDC for a total of 6 months as follows:
   **FIRST APPROVAL**
   • 75mg every week dosing: Approve for 1 month with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only)
   • 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
   **SECOND APPROVAL**
   • 75mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)
   • 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

   If no, continue to #5.

5. Is the patient 18 years of age or older AND meet the following criterion?
   • The patient had a trial of or contraindication to THREE of the following preferred agents: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzza), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, continue to #6.
   If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

6. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?  (Note: For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis.)

If yes, approve the requested strength and dosage form by NDC for a total of 6 months as follows:

FIRST APPROVAL
- 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
- 300mg every week dosing: Approve for 1 month with a quantity limit of #8mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only)

SECOND APPROVAL
- 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)
- 300mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

If no, continue to #8.

7. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Taltz (ixekizumab), Xeljanz (tofacitinib IR or XR), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, continue to #8.
If no, continue to #13.

8. Does the patient require a loading dose?

If yes, continue to #9.
If no, continue to #11.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

9. Is the request for a maintenance dosage of 300mg?

   If yes, continue to #10.
   If no, approve the 150mg dosage by NDC for a total of 6 months as follows:
   
   **FIRST APPROVAL**
   - 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
   
   **SECOND APPROVAL**
   - 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

10. Has the patient tried the 150mg maintenance dosing schedule **AND** continues to have active ankylosing spondylitis or active psoriatic arthritis?

   If yes, approve by NDC for a total of 6 months as follows:
   
   **FIRST APPROVAL**
   - 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
   
   **SECOND APPROVAL**
   - 300mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

   If no, do not approve.
   
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   
   **PAC NOTE:** Enter proactive PAs for the 150mg dosage by NDC for a total of 6 months as follows:
   
   **FIRST APPROVAL**
   - 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
   
   **SECOND APPROVAL**
   - 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

11. Is the request for a maintenance dosage of 300mg?
   If yes, continue to #12.
   If no, approve the 150mg dosage by NDC for 6 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only).

12. Has the patient tried the 150mg maintenance dosing schedule AND continues to have active ankylosing spondylitis or active psoriatic arthritis?
   If yes, approve the 300mg dosage by NDC for 6 months with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only).
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.
   PAC NOTE: Enter a proactive PA for the 150mg maintenance dosage by NDC for 6 months with a quantity limit of #1mL per 28 days. Enter NDC 00078-0639-68 or 00078-0639-97 only.

13. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
   • The patient meets ONE of the following objective signs of inflammation:
     • C-reactive protein (CRP) levels above the upper limit of normal
     • Sacroiliitis on magnetic resonance imaging (MRI)
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Taltz (ixekizumab), Cimzia (certolizumab), Rinvoq (upadacitinib) [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

       If yes, continue to #14.
       If no, continue to #16.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

14. Is the request for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) with a loading dose?

   If yes, approve the requested strength and dosage form by NDC for a total of 6 months as follows:
   **FIRST APPROVAL**
   • 150mg every week dosing: Approve for 1 month with a quantity of #4mL per 28 days.
     (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
   **SECOND APPROVAL**
   • 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

   If no, continue to #15.

15. Is the request for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) without a loading dose?

   If yes, approve the requested strength and dosage form by NDC for a total of 6 months as follows:
   • 150mg every 4 weeks dosing: #1mL per 28 days (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

16. Does the patient have a diagnosis of enthesitis-related arthritis (ERA) and meet ALL of the following criteria?
   • The patient is 4 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam), sulfasalazine, OR methotrexate

   If yes, approve the requested strength and dosage form by NDC for a total of 6 months as follow:
   **FIRST APPROVAL**
   • 75mg every week dosing: Approve for 1 month with a quantity limit of #2mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only.)
   • 150mg every week dosing: Approve for 1 month with a quantity limit of #4mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only.)

   **SECOND APPROVAL**
   • 75mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)
   • 150mg every 4 weeks dosing: Approve for 5 months with a quantity limit of #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only. Start date is 3 DAYS BEFORE the END date of the first approval.)

   If no, do not approve.

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **SECUKINUMAB (Cosentyx)** requires the following rule(s) be met for approval:
   A. You have ONE of the following diagnoses:
      1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
      2. Psoriatic arthritis (PsA: a type of skin and joint condition)
      3. Ankylosing spondylitis (AS: a type of joint condition)
      4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
      5. Enthesitis-related arthritis (ERA: a type of joint condition)
   
   *(Initial denial text continued on next page)*

   **CONTINUED ON NEXT PAGE**
B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You had a trial of or contraindication (harmful) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You meet ONE of the following:
      a. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to THREE of the preferred medications: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)
      b. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to FOUR of the following preferred medications: Taltz (ixekizumab), Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying anti-rheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, sulfasalazine
   4. Request for 300mg dosage in psoriatic arthritis without coexisting plaque psoriasis requires you have tried the 150mg maintenance dosing schedule AND continue to have active psoriatic arthritis
   5. You meet ONE of the following:
      a. You are 2 to 5 years of age
      b. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to the preferred medication: Stelara (ustekinumab)
      c. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to THREE of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz IR/XR (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzza), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam)
   4. Request for 300mg dosage requires you have tried the 150mg maintenance dosage schedule AND continue to have active ankylosing spondylitis
   5. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Taltz (ixekizumab), Xeljanz IR/XR (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

E. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam)
   4. You have ONE of the following signs of inflammation:
      a. C-reactive protein (CRP: a measure of how much inflammation you have) levels above the upper limit of normal
      b. Sacroilitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)
   5. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Taltz (ixekizumab), Cimzia (certolizumab), Rinvoq (upadacitinib)

F. If you have enthesitis-related arthritis, approval also requires:
   1. You are 4 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam), sulfasalazine, OR methotrexate

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SECUKINUMAB

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) AND meet the following criterion?
   • The patient has achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

If yes, continue to #2.
If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   • The patient is 6 to 17 years of age AND had a trial of or contraindication to THREE of the preferred agents: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)
   • The patient is 18 years of age or older AND had a trial of or contraindication to FOUR of the following preferred agents: Taltz (ixekizumab), Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Otezla (apremilast), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve the requested strength and dosage form by NDC for 12 months with the following quantity limits:
   • 75mg every 4 weeks dosing: #0.5mL per 28 days (PAC NOTE: Enter NDC 00078-1056-97 only).
   • 150mg every 4 weeks dosing: #1mL per 28 days (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only).
   • 300mg every 4 weeks dosing: #2mL per 28 days (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only).

If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #4.
   If no, continue to #5

4. Does the patient meet ONE of the following criteria?
   - The patient is 2 to 5 years of age
   - The patient is 6 to 17 years of age AND had a trial of or contraindication to the preferred agent: Stelara (ustekinumab)
   - The patient is 18 years of age or older AND had a trial of or contraindication to THREE of the following preferred agents: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib IR or XR), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve the requested strength and dosage form by NDC for 12 months with the following quantity limits:
   - 150mg every 4 weeks dosing: #1mL per 28 days (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only).
   - 300mg every 4 weeks dosing: #2mL per 28 days (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only).

   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Enbrel (etanercept), Humira (adalimumab), Taltz (ixeikizumab), Xeljanz (tocafitinib IR or XR), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve the requested strength and dosage form by NDC for 12 months with the following quantity limits:
   • 150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)
   • 300mg every 4 weeks dosing: #2mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-41 or 00078-0639-98 or 00078-1070-68 only)

   If no, continue to #6.

6. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet ALL of the following criteria?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Taltz (ixeikizumab), Cimzia (certolizumab), Rinvoq (upadacitinib) [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve the requested dosage form by NDC for 12 months with the following quantity limit:
   • 150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only)

   If no, continue to #7.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

7. Does the patient have a diagnosis of enthesitis-related arthritis (ERA) AND meet the following criterion?
   • The patient has experienced or maintained an improvement in global assessment of disease activity, functional ability, number of joints with active arthritis, OR number of joints with limited range of motion

   If yes, approve the requested strength and dosage form by NDC for 12 months with the following quantity limits:
   • 75mg every 4 weeks dosing: #0.5mL per 28 days. (PAC NOTE: Enter NDC 00078-1056-97 only).
   • 150mg every 4 weeks dosing: #1mL per 28 days. (PAC NOTE: Enter NDC 00078-0639-68 or 00078-0639-97 only).

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SECUKINUMAB (Cosentyx) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
   5. Enthesitis-related arthritis (ERA: a type of joint condition)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more while on therapy
   2. You meet ONE of the following:
      a. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to THREE of the preferred medications: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)
      b. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to FOUR of the following preferred medications: Taltz (ixekizumab), Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

(Renewal denial text continued on next page)
C. **If you have psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet ONE of the following:
      a. You are 2 to 5 years of age
      b. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to the preferred medication: Stelara (ustekinumab)
      c. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to THREE of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzza), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

D. **If you have ankylosing spondylitis, renewal also requires:**
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
   2. You had a trial or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Taltz (ixekizumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm)

E. **If you have non-radiographic axial spondyloarthritis, renewal also requires:**
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
   2. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Taltz (ixekizumab), Cimzia (certolizumab), Rinvoq (upadacitinib)

F. **If you have enthesitis-related arthritis, renewal also requires:**
   1. You have experienced or maintained an improvement in global assessment of disease activity, functional ability, number of joints with active arthritis, OR number of joints with limited range of motion

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SECUKINUMAB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cosentyx.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 02/15
Client Approval: 07/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) AND meet the following criterion?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?
   - Mean pulmonary artery pressure (PAP) of greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) of less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) of greater than 2 Wood units

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

3. Has the patient had a trial of or contraindication to TWO of the following agents from different drug classes?
   - Oral endothelin receptor antagonist (e.g., Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   - Oral phosphodiesterase-5 inhibitor (e.g., Revatio [sildenafil], Adcirca [tadalafil])
   - Oral cGMP stimulator (e.g., Adempas [riociguat])
   - IV/SQ prostacyclin (e.g., Flolan [epoprostenol], Remodulin [Treprostinil])

   If yes, approve for 12 months by GPID or GPI-14 as follows (enter both approvals):
   - FIRST APPROVAL: approve Uptravi 200-800 Titration pack with a quantity limit of #200 per 28 days for 1 fill.
   - SECOND APPROVAL: approve the requested strength as follows:
     - 200mcg tablet: #8 per day.
     - 400mcg, 600mcg, 800mcg, 1,000mcg, 1,200mcg, 1,400mcg, 1,600mcg tablet: #2 per day.
     - 1,800mcg vial: #2 per day.

   (NOTE: Uptravi vial is a non-self-administered [NSA] agent and may not be covered by some plans.)

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SELEXIPAG (Uptravi) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
   1. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   2. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
   3. Oral cGMP stimulator (such as Adempas [riociguat])
   4. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ONE of the following criteria?
   • The patient shown improvement from baseline in the 6-minute walk distance test
   • The patient remains stable from baseline in the 6-minute walk distance test AND the patients WHO functional class remained stable or has improved

   If yes, approve for 12 months by GPIID or GPI-14 for the requested strength with the following quantity limits:
   • 200mcg tablet: #8 per day.
   • 400mcg, 600mcg, 800mcg, 1,000mcg, 1,200mcg, 1,400mcg, 1,600mcg tablet: #2 per day.
   • 1,800mcg vial: #2 per day.
   (NOTE: Uptravi vial is a non-self-administered [NSA] agent and may not be covered by some plans.)

   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SELEXIPAG (Uptravi) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization (WHO) functional class (classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Uptravi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 01/16
Commercial Effective: 07/01/23  Client Approval: 05/23  P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of multiple myeloma (MM) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication will be used in combination with bortezomib (Velcade) AND dexamethasone
   • The patient has received at least one prior therapy

   If yes, approve all of the following for 12 months by GPID or GPI-14:
   • 40 mg once weekly dose: #4 per 28 days.
   • 60 mg once weekly dose: #4 per 28 days.
   • 80 mg once weekly dose: #8 per 28 days.
   • 100 mg once weekly dose: #8 per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory multiple myeloma (RRMM) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication will be used in combination with dexamethasone
   • The patient has received at least four prior therapies for the treatment of RRMM
   • The patient's RRMM is refractory to ALL of the following:
     o Two proteasome inhibitors (e.g., bortezomib [Velcade], carfilzomib [Kyprolis])
     o Two immunomodulatory agents (e.g., lenalidomide [Revlimid], pomalidomide [Pomalyst])
     o One anti-CD38 monoclonal antibody (e.g., daratumumab [Darzalex])

   If yes, approve all of the following for 12 months by GPID or GPI-14:
   • 60 mg once weekly dose: #4 per 28 days.
   • 80 mg once weekly: #8 per 28 days.
   • 100 mg once weekly dose: #8 per 28 days.
   • 80 mg twice weekly (160 mg total per week) dose: #32 per 28 days.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
SELINEXOR

GUIDELINES FOR USE (CONTINUED)

3. Does the patient have a diagnosis of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received at least two lines of systemic therapy

   If yes, approve all of the following for 12 months by GID or GPI-14:
   - 40 mg once weekly dose: #4 per 28 days.
   - 60 mg once weekly dose: #4 per 28 days.
   - 40 mg twice weekly (80 mg total per week) dose: #8 per 28 days.
   - 60 mg twice weekly (120 mg total per week) dose: #24 per 28 days.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SELINEXOR (Xpovio) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Multiple myeloma (MM: a type of blood cancer)
   2. Relapsed or refractory multiple myeloma (RRMM: a type of blood cancer that returned or did not respond to treatment)
   3. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL: a type of blood cancer), including DLBCL arising from follicular lymphoma
B. You are 18 years of age or older
C. If you have multiple myeloma, approval also requires:
   1. The requested medication will be used in combination with bortezomib (Velcade) and dexamethasone
   2. You have received at least one therapy before Xpovio
D. If you have relapsed or refractory multiple myeloma, approval also requires:
   1. The requested medication will be used in combination with dexamethasone
   2. You have received at least four prior therapies for the treatment of RRMM
   3. Your RRMM is refractory (non-responsive) to ALL of the following:
      a. Two proteasome inhibitors (such as bortezomib [Velcade], carfilzomib [Kyprolis])
      b. Two immunomodulatory agents (such as lenalidomide [Revlimid], pomalidomide [Pomalyt])
      c. One anti-CD38 monoclonal antibody (such as daratumumab [Darzalex])

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
E. If you have relapsed or refractory diffuse large B-cell lymphoma, approval also requires:
   1. You have received at least two lines of systemic therapy (treatment that spreads throughout the body)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xpovio.

REFERENCES
SELPERCATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SELPERCATINIB</td>
<td>RETEVMO</td>
<td>46525</td>
<td></td>
<td>GPI-10 (2153577900)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's cancer has a RET gene fusion, as detected by an FDA-approved test

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 40mg: #6 per day.
   - 80mg: #4 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of advanced or metastatic medullary thyroid cancer (MTC) and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient's cancer has a RET-mutation, as detected by an FDA-approved test
   - The patient requires systemic therapy

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 40mg: #6 per day.
   - 80mg: #4 per day.

   If no, continue to #3.

3. Does the patient have a diagnosis of advanced or metastatic thyroid cancer and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - The patient's cancer has a RET gene fusion, as detected by an FDA-approved test
   - The patient requires systemic therapy
   - The thyroid cancer is refractory to radioactive iodine therapy (if radioactive iodine is appropriate)

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 40mg: #6 per day.
   - 80mg: #4 per day.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Does the patient have a diagnosis of locally advanced or metastatic solid tumors and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's tumor has a RET gene fusion
   - The tumor has progressed on or following prior systemic treatment OR the patient has no satisfactory alternative treatment options

If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - 40mg: #6 per day.
   - 80mg: #4 per day.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SELPERCATINIB (Retevmo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)
   2. Advanced or metastatic medullary thyroid cancer (a type of thyroid cancer that has progressed or has spread to other parts of the body)
   3. Advanced or metastatic thyroid cancer (thyroid cancer that has progressed or has spread to other parts of the body)
   4. Locally advanced or metastatic solid tumors (abnormal mass that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)

B. If you have locally advanced or metastatic non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a rearranged during transfection (RET: type of gene) gene fusion, as detected by a Food and Drug Administration (FDA) approved test

C. If you have advanced or metastatic medullary thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. Your cancer has a rearranged during transfection (RET: type of gene) mutation, as detected by a Food and Drug Administration (FDA) approved test
   3. You require systemic therapy (treatment that travels through the entire body)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

D. **If you have advanced or metastatic thyroid cancer, approval also requires:**
   1. You are 12 years of age or older
   2. You require systemic therapy (treatment that travels through the entire body)
   3. Your cancer has a rearranged during transfection (*RET*: type of gene) gene fusion, as detected by a Food and Drug Administration (FDA) approved test
   4. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy, if radioactive iodine is appropriate

E. **If you have locally advanced or metastatic solid tumors, approval also requires:**
   1. You are 18 years of age or older
   2. Your tumor has a rearranged during transfection (*RET*: type of gene) gene fusion
   3. Your tumor has progressed on or following prior systemic treatment OR you have no satisfactory alternative treatment options

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Retevmo.

**REFERENCES**
- Retevmo [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; September 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 10/17/22  
Created: 07/20  
Client Approval: 09/22  
P&T Approval: 10/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of neurofibromatosis type 1 (NF1) and meet ALL of the following criteria?
   - The patient is 2 to 17 years of age
   - The patient has symptomatic, inoperable plexiform neurofibromas (PN)

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   - Koselugo 10mg: #10 per day.
   - Koselugo 25mg: #4 per day.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SELUMETINIB (Koselugo) requires the following rule(s) be met for approval:
   A. You have neurofibromatosis type 1 (NF1: a genetic disorder that causes light brown skin spots and non-cancerous tumors to form on nerve tissue)
   B. You are 2 to 17 years of age
   C. You have symptomatic, inoperable (not treatable by surgery) plexiform neurofibromas (PN: tumors that grow from nerves anywhere in the body)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Koselugo.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for chronic weight management in obesity, and does the patient meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - The patient's obesity is due to ONE of the following deficiencies:
     - Pro-opiomelanocortin (POMC)
     - Proprotein convertase subtilisin/kexin type 1 (PCSK1)
     - Leptin receptor (LEPR)
   - Confirmed genetic testing demonstrates variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)

   If yes, approve for 16 weeks by HICL or GPI-10 with a quantity limit of #0.3 mL per day.

   If no, continue to #2.

2. Is the request for chronic weight management in obesity, and does the patient meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - The patient's obesity is due to Bardet-Biedl syndrome (BBS)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #0.3 mL per day.
   If no, do not approve.

   DENIAL TEXT:  See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
SETMELANOTIDE

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SETMELANOTIDE (Imcivree) requires the following rule(s) be met for approval:

A. The request is for chronic weight management
B. You are 6 years of age or older
C. You have a diagnosis of obesity (a condition where you have higher than normal body fat) that is caused by ONE of the following:
   1. Bardet-Biedl syndrome (BBS: a genetic disorder)
   2. A deficiency in ONE of the following:
      a. Pro-opiomelanocortin (POMC: type of gene)
      b. Proprotein convertase subtilisin/kexin type 1 (PCSK1: type of gene)
      c. Leptin receptor (LEPR: type of gene)
D. If your obesity is caused by a POMC, PCSK1, or LEPR deficiency, approval also requires:
   1. Confirmed genetic testing shows variants (changes) in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic (causing disease), likely pathogenic, or of uncertain significance (VUS)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Is the request for chronic weight management in obesity caused by a deficiency in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR), and the patient meets ONE of the following criteria?
   - The patient is 18 years of age or older AND has lost at least 5% of baseline body weight
   - The patient is 6 to 17 years of age AND has lost at least 5% of baseline body mass index (BMI)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #0.3 mL per day. If no, continue to #2.

2. Is the request for chronic weight management in obesity caused by Bardet-Biedl syndrome, and the patient meets ONE of the following criteria?
   - The patient is 18 years of age or older AND has lost at least 5% of baseline body weight
   - The patient is 6 to 17 years of age AND has lost at least 5% of baseline body mass index (BMI)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #0.3 mL per day. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SETMELANOTIDE (Imcivree) requires the following rule(s) be met for approval:
A. You have a diagnosis of obesity (a condition where you have higher than normal body fat) that is caused by ONE of the following:
   1. Bardet-Biedl syndrome (BBS: a genetic disorder)
   2. A deficiency in ONE of the following:
      a. Pro-opiomelanocortin (POMC: type of gene)
      b. Proprotein convertase subtilisin/kexin type 1 (PCSK1: type of gene)
      c. Leptin receptor (LEPR: type of gene)
B. You meet ONE of the following:
   1. You are 18 years of age or older AND have lost at least 5% of your baseline body weight
   2. You are 6 to 17 years of age AND have lost at least 5% of your baseline body mass index (BMI: a tool for evaluating body fat)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SETMELANOTIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Imcivree.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 02/21
Client Approval: 06/23
P&T Approval: 01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #37.5mL per day.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SILDENAFIL IV (Revatio) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
D. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
E. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
F. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL the following criteria?
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   - The patient has shown improvement from baseline in the 6-minute walk distance test OR remains stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, approve for 12 months by G PID or GPI-14 with a quantity limit of #37.5mL per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SILDENAFIL IV (Revatio) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
D. You have shown improvement from baseline in the 6-minute walk distance test, OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SILDENAFIL IV

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Revatio.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 01/08
Client Approval: 05/23
P&T Approval: 04/23
SILDENAFIL SUSPENSION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SILDENAFIL CITRATE</td>
<td>REVATIO, LIQREV, SILDENAFIL CITRATE</td>
<td>33186</td>
<td>54078</td>
<td>GPI-14 (40143060102020, 40143060101825)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) and meet ALL of the following criteria?
   - The patient is 1 to 17 years of age
   - The request is for Revatio (sildenafil) suspension
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (e.g., nitroglycerin, isosorbide mononitrate)
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   - The patient is unable to swallow pills and has tried crushed sildenafil tablets

If yes, continue to #2.
If no, continue to #3.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #14.93mL per day.
If no, do not approve.
DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient is **NOT** concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (e.g., nitroglycerin, isosorbide mononitrate)
   - The patient is **NOT** concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with **ALL** of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

5. Is the request for **Revatio (sildenafil)** suspension **AND** the patient meets the following criterion?
   - The patient is unable to swallow pills and has tried crushed sildenafil tablets

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #26.13mL per day.**
   If no, continue to #6.

6. Is the request for **Liqrev** suspension and the patient meets **ALL** of the following criteria?
   - The patient is unable to swallow Revatio (sildenafil) tablet
   - The patient had a trial of generic sildenafil powder for suspension

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #8.13mL per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SILDENAFIL SUSPENSION (Revatio, Liqrev) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. If you are 1 to 17 years of age, approval also requires:
   1. You are requesting Revatio (sildenafil) suspension
   2. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
   3. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
   4. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   5. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   6. You are unable to swallow pills AND you have tried crushed sildenafil tablets

C. If you are 18 years of age or older, approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   3. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   4. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

5. If you are requesting Revatio (sildenafil) suspension, you are unable to swallow pills AND you have tried crushed sildenafil tablets
6. If you are requesting Liqrev suspension, you are unable to swallow Revatio (sildenafil) tablet AND you have tried generic sildenafil powder for suspension

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) and meet ALL of the following criteria?
   - The patient is 1 to 17 years old
   - The request is for Revatio (sildenafil) suspension
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (e.g., nitroglycerin, isosorbide mononitrate)
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient has shown improvement from baseline in 6-minute walk distance test
   - The patient remains stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class (WHO-FC)
   - The patient cannot perform exercise testing and is stable or improving on treatment

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #14.93mL per day.
   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (e.g., nitroglycerin, isosorbide mononitrate)
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   - The patient has shown improvement from baseline in the 6-minute walk distance test OR remains stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, approve for 12 months by GPID or GPI-14 for the requested agent with the following quantity limits:
- Revatio (sildenafil): #26.13mL per day.
- Liqrev (sildenafil): #8.13mL per day.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SILDENAFIL SUSPENSION (Revatio, Liqrev) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
B. If you are 1 to 17 years of age, approval also requires:
   1. You are requesting Revatio (sildenafil) suspension
   2. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   3. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   4. You meet ONE of the following criteria:
      a. You have shown improvement from baseline in the 6-minute walk distance test
      b. You remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)
      c. You cannot perform exercise testing and are stable or improving on treatment

(Renewal denial text continued on next page)
C. **If you are 18 years of age or older, approval also requires:**
   1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   3. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Revatio and Liqrev.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/12/23
Created: 01/08
Client Approval: 05/23
P&T Approval: 04/23
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) and meet ALL of the following criteria?
   • The patient is 1 to 17 years of age
   • Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   • The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   • The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   • Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   • Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   • Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #6 per day.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

3. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   • The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   • The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
4. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #12 per day.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SILDENAFIL TABLET (Revatio) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You are 1 year of age or older
C. If you are 18 years of age or older, approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   3. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   4. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. **If you are 1 to 17 years of age or older, approval also requires:**
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
   3. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   4. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group I) and meet ALL of the following criteria?
   - The patient is 1 to 17 years old
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   - The patient has shown improvement from baseline in the 6-minute walk distance test
   - The patient remains stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class
   - The patient cannot perform exercise testing and is stable or improving on treatment

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #6 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL the following criteria?
   - The patient is 18 years of age or older
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   - The patient has shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #12 per day.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SILDENAFIL TABLET (Revatio) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
B. You are 1 year of age or older
C. **If you are 18 years of age or older, approval also requires:**
   1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   3. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

*(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

D. If you are 1 to 17 years of age, approval also requires:
   1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   3. You meet ONE of the following criteria:
      a. You have shown improvement from baseline in the 6-minute walk distance test
      b. You remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)
      c. You cannot perform exercise testing and are stable or improving on treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Revatio.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1 and meet ALL of the following?
   - The patient is 18 years of age or older
   - The patient has a recent HCV infection documented by one detectable HCV RNA level within the past 6 months

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Has the patient completed a prior full course of therapy with 1) any HCV protease inhibitor [for example, telaprevir (Incivek), simeprevir (Olysio), or boceprevir (Victrelis)] OR 2) regimen containing an NS5A inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen) and has not achieved a sustained virologic response (SVR)?

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   If no, continue to #3.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

3. Does the patient meet ONE of the following criteria?
   • The patient has decompensated or compensated cirrhosis
   • The patient has limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
   • The requested medication is being used with ribavirin AND peginterferon alfa
   • The patient is taking any of the following medications that are not recommended for concurrent use with Olysio:
     o Amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
     o Any of the following HIV medications:
       ▪ A cobicistat-containing medication (e.g., Stribild or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, PrezcoBix, Tybost)
       ▪ An HIV protease inhibitor (e.g., atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, darunavir/ritonavir)
       ▪ Delavirdine, etravirine, nevirapine, or efavirenz

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.
   If no, continue to #4.

4. Is the request for a combination regimen with Sovaldi plus Olysio for 12 weeks?
   
   If yes, continue to #5.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

5. Does the patient meet ONE of the following?
   • The patient has contraindications to Epclusa, Harvoni and Mavyret
   • The patient has previously failed a short trial with Epclusa, Harvoni or Mavyret (e.g., inability to tolerate, adverse effect early in therapy); [NOTE: An individual who has completed a full course of therapy with Epclusa, Harvoni or Mavyret that did not achieve SVR will not be approved]

   If yes, continue to #6.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet ONE of the following?
   • The patient is treatment naïve
   • The patient is treatment experienced with prior treatment with peginterferon/ribavirin

   If yes, approve for the requested strengths for 12 weeks by HICL or GPI-10 for #1 per day.

   CLINICAL PHARMACISTS: Please review Sovaldi prior authorization guideline, member history, and hepatitis C MRF if available to ensure appropriate length of approval.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SIMEPREVIR (Olysio) requires the following rule(s) be met for approval:

A. You have chronic hepatitis C, genotype 1 (type of liver inflammation)
B. You are 18 years of age or older
C. You must have documentation of a recent hepatitis c virus infection by at least one detectable HCV RNA level (amount of virus in your blood) within the past 6 months
D. You will be using Olysio with Sovaldi taken at the same time
E. You have previously failed a short trial of Harvoni, Mavyret or Epclusa and stopped due to reasons such as adverse effect or intolerance early in therapy, unless there is a medical reason why you cannot (contraindication) take all 3 agents. The medication will not be approved for an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response)
F. You are treatment naïve (never previously treated) or treatment-experienced with prior treatment with peginterferon/ribavirin

Olysio will not be approved for the following patients:

A. You have failed a full course of treatment with 1) any HCV protease inhibitor (for example, simeprevir [Olysio], telaprevir [Incivek] or boceprevir [Victrelis]) OR 2) a regimen containing an NSSA inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen)
B. You have compensated cirrhosis (no symptoms related to liver damage) or decompensated cirrhosis (you have symptoms related to liver damage)
C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
D. You are using Olysio with ribavirin and peginterferon alfa

*Denial text continued on next page*
GUIDELINES FOR USE (CONTINUED)

E. You are taking any of the following medications that are not recommended for concurrent use with Olysio:
   1. Amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin, clarithromycin, telithromycin,itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
   2. Any cobicistat-containing medication (such as Stribild or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, Prezobix, Tybost)
   3. Delavirdine, etravirine, nevirapine, or efavirenz
   4. Any HIV protease inhibitor (such as atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, darunavir/ritonavir)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Olysio.

REFERENCES
GUIDELINES FOR USE

1. Has the patient been taking the requested medication for at least 12 months?

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, do not approve.

   **DENIAL TEXT:** "Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **SIMVASTATIN 80 (VYTORIN, ZOCOR)** requires the following rule(s) be met for approval:
   A. You have been taking the medication for at least 12 months

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vytorin and Zocor.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
### GUIDELINES FOR USE

1. **Does the patient meet ALL of the following criteria?**
   - Previous trial of or contraindication to simvastatin tablets
   - Prescriber documentation that the patient has dysphagia, difficulty swallowing tablets, or has a feeding tube (e.g., G-tube or J-tube)

   If yes, continue to #2.
   If no, do not approve
   
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. **Is the patient also requesting a zero dollar cost share exception (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?**

   If yes, continue to #3.
   If no, **approve for 12 months by GPID or GPI-14 with the following quantity limits (NOTE: Override the PA edit only, no change in copay):**
   - Flolipid 20mg/5mL: 150mL (#1 bottle) per 30 days.
   - Flolipid 40mg/5mL: 150mL (#1 bottle) per 30 days.

   **CONTINUED ON NEXT PAGE**

---

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMVASTATIN</td>
<td>FLOLIPID</td>
<td></td>
<td>41189</td>
<td>GPI-14</td>
<td>(39400075001810)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>41192</td>
<td></td>
<td>(39400075001820)</td>
</tr>
</tbody>
</table>
GUIDELINES FOR USE (CONTINUED)

3. Is the patient between 40-75 years of age without a history of cardiovascular disease and has NOT used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on the patient’s prescription claims profile or medical records?
   - Aspirin/dipyridamole (Aggrenox)
   - Clopidogrel (Plavix)
   - Dipyridamole
   - Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   - Prasugrel (Effient)
   - Praluent Pen
   - Repatha
   - Ticagrelor (Brilinta)
   - Ticlopidine
   - Vorapaxar sulfate (Zontivity)

   If yes, approve for 12 months by GPID or GPI-14 at zero cost share with the following quantity limits (NOTE: Override the PA edit and update the copay amount field with ZERO copay):
   - Flolipid 20mg/5mL: 150mL (#1 bottle) per 30 days.
   - Flolipid 40mg/5mL: 150mL (#1 bottle) per 30 days.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SIMVASTATIN ORAL SUSPENSION (Flolipid) requires the following rule(s) be met for approval:
   A. You had a previous trial of simvastatin tablets, unless there is a medical reason why you cannot (contraindication)
   B. Your prescriber provides documentation showing that you have dysphagia (general swallowing difficulties), difficulty swallowing tablets, or a feeding tube such as a G-tube or J-tube

   (Denial text continued on next page)

   CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. Requests for zero dollar cost share also requires that you are between 40-75 years of age without a history of cardiovascular disease (relating to heart and blood vessels) and you have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:

1. Aspirin/dipyridamole (Aggrenox)
2. Clopidogrel (Plavix)
3. Dipyridamole
4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
5. Prasugrel (Effient)
6. Praluent Pen
7. Repatha
8. Ticagrelor (Brilinta)
9. Ticlopidine
10. Vorapaxar sulfate (Zontivity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Flolipid.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 03/18
Client Approval: 04/20
P&T Approval: 01/18
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, continue to #2.
   If no, do not approve

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have a CYP2C9 *1/*1, *1/*2, or *2/*2 genotype?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Mayzent 0.25mg starter pack for 2 mg maintenance dose: #12 tablets (1 pack) per fill.
   - Mayzent 2mg: #1 per day.

   If yes, continue to #3.

3. Does the patient have a CYP2C9 *1/*3 or *2/*3 genotype?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   - Mayzent 0.25mg starter pack for 1 mg maintenance dose: #7 tablets (1 pack) per fill.
   - Mayzent 0.25mg: #4 per day.
   - Mayzent 1mg: #1 per day.

   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SIPONIMOD (Mayzent) requires the following rule(s) be met for approval:
A. You have relapsing forms of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (symptoms occur once), relapsing-remitting disease (symptoms return and go away), or active secondary progressive disease (advanced disease)
B. You are 18 years of age or older
C. You have CYP2C9 (type of enzyme) *1/*1, *1/*2, *2/*2, *1/*3, or *2/*3 genotype

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease and meet ALL of the following criteria?
   • The patient has demonstrated a clinical benefit compared to pre-treatment baseline
   • The patient does not have lymphopenia

   If yes, continue to #2.
   If no, do not approve

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Does the patient have a CYP2C9 *1/*1, *1/*2, or *2/*2 genotype?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   • Mayzent 0.25mg starter pack for 2 mg maintenance dose: #12 tablets (1 pack) per fill.
   • Mayzent 2mg: #1 per day.

   If no, continue to #3.

3. Does the patient have a CYP2C9 *1/*3 or *2/*3 genotype?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   • Mayzent 0.25mg starter pack for 1 mg maintenance dose: #7 tablets (1 pack) per fill.
   • Mayzent 0.25mg: #4 per day.
   • Mayzent 1mg: #1 per day.

   If no, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SIPONIMOD (Mayzent) requires the following rule(s) be met for renewal:
A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (symptoms occur once), relapsing-remitting disease (symptoms return and go away), or active secondary progressive disease (advanced disease)
B. You have demonstrated a clinical benefit compared to pre-treatment baseline
C. You do not have lymphopenia (low levels of a type of white blood cell)
D. You have CYP2C9 (type of enzyme) *1/*1, *1/*2, *2/*2, *1/*3, or *2/*3 genotype

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mayzent.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/11/22
Created: 04/19
Client Approval: 03/22
P&T Approval: 10/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of facial angiofibroma associated with tuberous sclerosis AND meet the following criterion?
   • The patient is 6 years of age or older

   If yes, **approve for 12 weeks by GPID or GPI-10**.
   If no, do not approve.

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **SIROLIMUS TOPICAL (Hyftor)** requires the following rule(s) be met for approval:
   A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)
   B. You are 6 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of facial angiofibroma associated with tuberous sclerosis?

   If yes, **approve for 12 months by GPID or GPI-10**.
   If no, do not approve.

   **DENIAL TEXT:** See the renewal denial at the end of the guideline.
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SIROLIMUS TOPICAL (Hyftor) requires the following rule(s) be met for renewal:
A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Hyftor.

REFERENCES
• Hyftor [Prescribing Information]. Bethesda, MD: Nobelpharma America, LLC.; March 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/29/22
Created: 08/22
Client Approval: 08/22
P&T Approval: 07/22
SMOKING CESSATION ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUPROPION HCL</td>
<td>ZYBAN, BUROPION HCL SR</td>
<td>27901</td>
<td></td>
<td>GPI-10</td>
<td>(6210000210)</td>
</tr>
<tr>
<td>VARENICLINE TARTRATE</td>
<td>CHANTIX, VARENICLINE TARTRATE</td>
<td>27046</td>
<td>27047</td>
<td>GPI-10</td>
<td>(6210008020)</td>
</tr>
<tr>
<td>NICOTINE</td>
<td>NICOTROL, NICOTROL NS, NICOTINE PATCH, NICODERM CQ, NTS, NICOTINE</td>
<td>06249</td>
<td></td>
<td>GPI-10</td>
<td>(6210000500)</td>
</tr>
<tr>
<td>NICOTINE POLACRILEX</td>
<td>NICOTINE GUM, NICOTINE LOZENGE, NICORETTE, VARIOUS</td>
<td>0249</td>
<td></td>
<td>GPI-14</td>
<td>(6210001000)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested smoking cessation agent AND does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

   If yes, continue to #2.
   If no, guideline does not apply.

2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?

   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the patient 18 years of age or older?

   If yes, continue to #4.
   If no, do not approve.

   **DENIAL TEXT:** See the denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
SMOKING CESSIONATION ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

4. Is the request for a generic agent?

   If yes, continue to #7.
   If no, continue to #5.

5. Is the request for ONE of the following?
   • A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   • A multi-source brand (MSB) agent

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

6. Does the patient meet ONE of the following criteria?
   • Two preferred medications are medically inappropriate for the patient (one if only one agent is available)
   • The patient has tried or has a documented medical contraindication to TWO preferred medications (one if only one agent is available)
   • The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the requested medication also require step therapy? (**NOTE:** Analyze the claim to determine if it also rejects for step therapy)

   If yes, continue to #8.
   If no, **APPROVE the requested agent for 12 months by GPID or GPI-14 at zero copay.** (**Note:** If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)
   **APPROVAL TEXT (applies to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

**CONTINUED ON NEXT PAGE**
8. Has the patient met the step therapy requirement? (NOTE: Analyze the claim to determine step therapy agents)

   If yes, **approve the requested agent for 12 months by GPID or GPI-14 at zero copay and also override the step restriction.** (Note: If the claim also rejects for exceeds quantity limit, please review for a quantity limit exception)

   **APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **SMOKING CESSATION ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:
   
   A. Your request is for ONE of the following:
      1. A generic agent
      2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
      3. A multi-source brand (MSB) agent
   
   B. You are 18 years of age or older
   
   C. Approval may also require that you have tried preferred agent(s), unless you have a contraindication (harmful for). (NOTE TO REVIEWER: Provide the list of the preferred medication(s))
   
   D. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
      1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
      2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
      3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
SMOKING CESSION ZERO COST SHARE OVERRIDE

RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of smoking cessation medication at zero co-pay. The override criteria allow patient access to all FDA-approved smoking cessation medications at zero co-pay by waiving the applicable cost-sharing for branded or non-preferred branded medications.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/22
Commercial Effective: 07/01/22  Client Approval: 05/22  P&T Approval: 04/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?
   - If yes, do not approve.
   - **DENIAL TEXT:** See the initial denial text at the end of the guideline.
   - If no, continue to #2.

2. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and the diagnosis is confirmed by **ALL** of the following criteria?
   - The patient does not have cataplexy
   - The patient has a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram is 15 minutes or less
   - The patient has 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy in association with a sleep log
   - The patient has had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND the patient has experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months
   - If yes, continue to #3.
   - If no, continue to #4.

3. Does the patient meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - The patient had a trial and failure of or contraindication to armodafinil OR modafinil
   - If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**
   - If no, do not approve.
   - **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of cataplexy in narcolepsy and meet ALL of the following criteria?
   • The patient is 7 years of age or older
   • Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   • The patient has tried TWO of the following: venlafaxine, fluoxetine, or a TCA (e.g., amitriptyline, clomipramine, imipramine)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.
   If no, continue to #5.

5. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) in narcolepsy and the narcolepsy diagnosis is confirmed by ONE of the following criteria?
   • The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND two or more early-onset REM sleep periods (SOREMPs)
   • The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one or more early-onset REM sleep periods (SOREMPs) AND additionally one early-onset SOREMP (within approx. 15 minutes or less) on a polysomnography the night preceding the MSLT, with the polysomnography has ruled out non-narcolepsy causes of EDS
     [Note to pharmacist: Multiple Sleep Latency Test (MSLT) is a guideline-supported instrument for assessing the severity and likelihood of narcolepsy, which consists of five 20-minute nap periods spread throughout a single test day at 2-hour intervals]
   • The patient has low Orexin/Hypocretin levels on CSF assay

   If yes, continue to #6.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Does the patient meet ALL of the following criteria?
   - The patient is 7 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - The patient has EDS persisting for 3 months or more and an Epworth Sleepiness Scale (ESS) score greater than 10
   - The patient meets ONE of the following:
     - The patient is 7 to 17 years of age AND had a trial and failure of or contraindication to one generic stimulant indicated for EDS in narcolepsy (e.g., amphetamine, dextroamphetamine, or methylphenidate)
     - The patient is 18 years of age or older AND had a trial and failure of or contraindication to one agent from EACH of the following categories:
       - Generic typical stimulant (e.g., amphetamine sulfate, dextroamphetamine, methylphenidate)
       - Armodafinil OR modafinil

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Idiopathic hypersomnia (IH: a type of sleep disorder)
   2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
   3. Excessive daytime sleepiness (EDS) in narcolepsy (a type of sleep disorder)
B. You are not concurrently on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

C. If you have idiopathic hypersomnia, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. Your diagnosis is confirmed by ALL of the following:
      a. You do not have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
      b. You have a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
      c. You have 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
      d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months
   4. You tried and failed or have a contraindication (harmful for) to armodafinil OR modafinil

D. If you have cataplexy in narcolepsy, approval also requires:
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have tried TWO of the following: venlafaxine, fluoxetine, or tricyclic anti-depressants (such as amitriptyline, clomipramine, imipramine)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

E. **If you have excessive daytime sleepiness in narcolepsy, approval also requires:**
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have EDS persisting for 3 or more months and an Epworth Sleepiness Scale (tool to measure your sleepiness) score of more than 10
   4. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
   5. If you are 7 to 17 years old, you tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine, dextroamphetamine, or methylphenidate)
   6. If you are 18 years or older, you tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
      a. Generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.)
      b. Armodafinil OR modafinil

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [ zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of narcolepsy and meet **ONE** of the following criteria?
   - The patient has demonstrated improvement of cataplexy symptoms compared to baseline
   - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
   - The patient has demonstrated improvement in sleep latency from baseline

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**
   If no, continue to #3.

3. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and meet **ONE** of the following criteria?
   - The patient has demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
   - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**
   If no, do not approve.

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:
   1. Narcolepsy (uncontrollable daytime sleepiness)
   2. Idiopathic hypersomnia (IH: a type of sleep disorder)

B. You are not concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

C. **If you have narcolepsy, renewal also requires you meet **ONE** of the following:**
   1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
   2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)

*(Renewal denial text continued on next page)*
RENEWAL CRITERIA (CONTINUED)

D. If you have idiopathic hypersomnia, renewal also requires you meet ONE of the following:
   1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
   2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xywav.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 11/20
Client Approval: 11/22
P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [ zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?
   
   If yes, do not approve.
   
   DENIAL TEXT: See the initial denial text at the end of the guideline.
   
   If no, continue to #2.

2. Does the patient have a diagnosis of cataplexy in narcolepsy and meet ALL of the following criteria?
   
   • The patient is 7 years of age or older
   • Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   • The patient had a trial of TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), TCA (tricyclic antidepressant, e.g., amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])
   • The patient had a trial of generic sodium oxybate

   If yes, approve for 6 months by GPIID or GPI-14 with a quantity limit of #1 per day.
   If no, continue to #3.

3. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) in narcolepsy and the narcolepsy diagnosis is confirmed by ONE of the following criteria?
   
   • The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND two or more early-onset REM sleep periods (SOREMPs)
   • The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one or more early-onset REM sleep periods (SOREMPS) AND additionally one early-onset SOREMP (within approx. 15 minutes or less) on a polysomnography the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of EDS
   
   [Note to pharmacist: Multiple Sleep Latency Test (MSLT) is a guideline-supported instrument for assessing the severity and likelihood of narcolepsy, which consists of five 20-minute nap periods spread throughout a single test day at 2-hour intervals]
   • The patient has low Orexin/Hypocretin levels on CSF assay

   If yes, continue to #4.
   If no, do not approve.
   
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Does the patient meet **ALL** of the following criteria?
   - The patient is 7 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - The patient has excessive daytime sleepiness (EDS) persisting for 3 or more months
   - The patient has an Epworth Sleepiness Scale (ESS) score of more than 10
   - The patient had a trial, failure, or contraindication to generic sodium oxybate

   If yes, continue to #5.
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

5. Is the patient 7 to 17 years of age **AND** meets the following criterion?
   A. The patient had a trial, failure, or contraindication to a generic typical stimulant (e.g., amphetamine [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])

   If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, continue to #6.

6. Is the patient 18 years of age or older **AND** meets the following criterion?
   A. The patient had a trial, failure, or contraindication to one agent from EACH of the following categories:
      - Generic typical stimulant (e.g., amphetamine [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
      - Armodafinil (Nuvigil) OR modafinil (Provigil)

   If yes, **approve for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, do not approve.

   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SODIUM OXYBATE (LUMRYZ) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
   2. Excessive daytime sleepiness (EDS) in narcolepsy (sleep disorder)
B. You are NOT concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
C. If you have cataplexy in narcolepsy, approval also requires:
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You had a trial of generic sodium oxybate
   4. You had a trial of TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), TCA (tricyclic antidepressant, such as amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])
D. If you have excessive daytime sleepiness (EDS) in narcolepsy, approval also requires:
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test (MLST) showing both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night before the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. You have excessive daytime sleepiness (EDS) persisting for 3 or more months
5. You have an Epworth Sleepiness Scale (ESS: questionnaire used to assess daytime sleepiness) score of more than 10
6. You had a trial, failure (drug did not work), or contraindication (harmful for) to generic sodium oxybate
7. If you are 7 to 17 years old, you had a trial, failure (drug did not work), or contraindication (harmful for) to a generic typical stimulant (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
8. If you are 18 years or older, you had a trial, failure (drug did not work), or contraindication (harmful for) to one agent from EACH of the following categories:
   a. Generic typical stimulant (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], or methylphenidate [Ritalin])
   b. Armodafinil (Nuvigil) or modafinil (Provigil)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have a diagnosis of narcolepsy and meet **ONE** of the following criteria?
   - The patient has demonstrated improvement of cataplexy symptoms compared to baseline
   - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
   - The patient has demonstrated improvement in sleep latency from baseline

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SODIUM OXYBATE (LUMRYZ) requires the following rule(s) be met for renewal:

A. You have narcolepsy (uncontrollable daytime sleepiness)
B. You are NOT concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
C. You meet ONE of the following:
   1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
   2. You have maintained improvement in Epworth Sleepiness Scale (ESS: questionnaire used to assess daytime sleepiness) scores by at least 25% compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lumryz.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 05/23
Client Approval: 08/23
P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and the diagnosis is confirmed by ALL of the following criteria?
   - The patient does NOT have cataplexy
   - The patient has a Multiple Sleep Latency Test (MSLT) showing less than two sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram is 15 minutes or less
   - The patient has one or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy in association with a sleep log
   - The patient has had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND the patient has experienced daily periods of an irrepressible need to sleep or daytime lapses into sleep for at least 3 months

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - Xyrem (sodium oxybate) will NOT be used concurrently with a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Restoril [temazepam])
   - The patient had a trial and failure of or contraindication to armodafinil (Nuvigil) OR modafinil (Provigil)

   If yes, continue to #8.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of cataplexy in narcolepsy and meet ALL of the following criteria?
   • The patient is 7 years of age or older
   • Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   • Xyrem (sodium oxybate) will NOT be used concurrently with a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Restoril [temazepam])
   • The patient has tried TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), a TCA (tricyclic antidepressant, e.g., amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #18mL per day.
   If no, continue to #4.

4. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) in narcolepsy and the narcolepsy diagnosis is confirmed by ONE of the following criteria?
   • The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND two or more early-onset REM sleep periods (SOREMPs)
   • The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one or more early-onset REM sleep periods (SOREMPs) AND additionally one early-onset SOREM (within approx. 15 minutes or less) on a polysomnography the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of EDS
   [Note to pharmacist: Multiple Sleep Latency Test (MSLT) is a guideline-supported instrument for assessing the severity and likelihood of narcolepsy, which consists of five 20-minute nap periods spread throughout a single test day at 2-hour intervals]
   • The patient has low orexin/hypocretin levels on CSF assay

   If yes, continue to #5.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Does the patient meet **ALL** of the following criteria?
   - The patient is 7 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - The patient has EDS persisting for 3 or more months
   - The patient has an Epworth Sleepiness Scale (ESS) score of more than 10
   - Xyrem (sodium oxybate) will **NOT** be used concurrently with a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Restoril [temazepam])

   If yes, continue to #6.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

6. Is the patient 7 to 17 years of age **AND** meet the following criterion?
   - The patient had a trial and failure of or contraindication to one generic stimulant indicated for excessive daytime sleepiness (EDS) in narcolepsy (e.g., amphetamine sulfate [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])

   If yes, continue to #8.
   If no, continue to #7.

7. Is the patient 18 years of age or older **AND** meet the following criterion?
   - The patient had a trial and failure of or contraindication to one agent from EACH of the following categories:
     - **Generic typical stimulant** (e.g., amphetamine sulfate [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
     - Armodafinil (Nuvigil) **OR** modafinil (Provigil)

   If yes, continue to #8.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

8. Is the request for generic sodium oxybate?

   If yes, **approve for 6 months for generic only by GPIID or GPII-14 with a quantity limit of #18mL per day.**

   If no, continue to #9.

**CONTINUED ON NEXT PAGE**
9. Is the request for brand Xyrem AND the patient meets the following criterion?
   • The patient had a trial and failure of or contraindication to generic sodium oxybate

   If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #18mL per day.
   If no, do not approve. (NOTE: Please enter a proactive PA for 6 months for generic sodium oxybate by GPID or GPI-14 with a quantity limit of #18mL per day.)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SODIUM OXYBATE (Xyrem) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Idiopathic hypersomnia (IH: a type of sleep disorder)
   2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
   3. Excessive daytime sleepiness (EDS) in narcolepsy (sleep disorder)
B. Xyrem (sodium oxybate) will NOT be used concurrently (at the same time) with a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta (eszopiclone), Ambien (zolpidem), or Restoril (temazepam)
C. If you have idiopathic hypersomnia, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. Your diagnosis is confirmed by ALL of the following:
      a. You do NOT have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
      b. You have a Multiple Sleep Latency Test (MSLT) showing less than two sleep-onset REM (rapid eye movement) sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
      c. You have one or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
      d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of an irrepressible need to sleep or daytime lapses into sleep for at least 3 months

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

4. You have tried and failed or have a contraindication (harmful for) to armodafinil (Nuvigil) OR modafinil (Provigil)
5. If you are requesting brand Xyrem, you have tried and failed or have a contraindication (harmful for) to generic sodium oxybate

D. **If you have cataplexy in narcolepsy, approval also requires:**
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have tried TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), a tricyclic anti-depressant (such as amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])

E. **If you have excessive daytime sleepiness in narcolepsy, approval also requires:**
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have EDS persisting for 3 or more months
   4. You have an Epworth Sleepiness Scale (tool to measure sleepiness) score of more than 10
   5. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND two or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test showing an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing low levels of a chemical that help with staying awake)
   6. If you are 7 to 17 years old, you have tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], or methylphenidate [Ritalin])
   7. If you are 18 years or older, you have tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
      a. Generic typical stimulant (such as amphetamine sulfate [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
      b. Armodafinil (Nuvigil) OR modafinil (Provigil)
      c. If you are requesting brand Xyrem, you have tried and failed or have a contraindication (harmful for) to generic sodium oxybate

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of narcolepsy AND meet the following criterion?
   • Xyrem (sodium oxybate) will NOT be used concurrently with a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Restoril [temazepam])
     
     If yes, continue to #2.
     
     If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   • The patient has demonstrated improvement of cataplexy symptoms compared to baseline
   • The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
   • The patient has demonstrated improvement in sleep latency from baseline
     
     If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #18mL per day.
     
     If no, do not approve.
     
     DENIAL TEXT: See the renewal denial text at the end of the guideline.

3. Does the patient have a diagnosis of idiopathic hypersomnia (IH) AND meet the following criterion?
   • Xyrem (sodium oxybate) will NOT be used concurrently with a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Restoril [temazepam])
     
     If yes, continue to #4.
     
     If no, do not approve.
     
     DENIAL TEXT: See the renewal denial text at the end of the guideline.

4. Does the patient meet ONE of the following criteria?
   • The patient has demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
   • The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
     
     If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #18mL per day.
     
     If no, do not approve.
     
     DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SODIUM OXYBATE (Xyrem) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   5. Narcolepsy (uncontrollable daytime sleepiness)
   6. Idiopathic hypersomnia (IH: a type of sleep disorder)
B. Xyrem (sodium oxybate) will NOT be used concurrently (at the same time) with a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], or Restoril [temazepam]
C. If you have narcolepsy, renewal also requires ONE of the following:
   a. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
   b. You have maintained improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
   c. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep)
D. If you have idiopathic hypersomnia, renewal also requires ONE of the following:
   1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
   2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xyrem.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 06/12/23  
Created: 11/13  
Client Approval: 05/23  
P&T Approval: 10/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) and meet ALL of the following criteria?
   • There is documentation (e.g., chart notes, lab results, diagnostic test results, etc.) of confirmation of UCD via enzymatic, biochemical or genetic testing
   • The requested medication will be used as adjunctive therapy along with dietary protein restriction
   • The patient cannot be managed by dietary protein restriction or amino acid supplementation alone

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Is the request for Buphenyl (sodium phenylbutyrate)?

   If yes, approve the requested formulation for 12 months by GPID or GPI-14 with the following quantity limits:
   • Buphenyl tablets: #40 per day.
   • Buphenyl powder: #25 grams per day.

   If no, continue to #3.

3. Is the request for Pheburane, and the patient meets ALL of the following criteria?
   • The patient had a trial of or contraindication to generic sodium phenylbutyrate powder
   • The patient is unable to swallow Buphenyl (sodium phenylbutyrate) tablet

   If yes, approve Pheburane for 12 months by GPID or GPI-14 with a quantity limit of #20 grams per day.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Is the request for Olpruva, and the patient meets ALL of the following criteria?
   • The patient had a trial of or contraindication to generic sodium phenylbutyrate powder
   • The patient is unable to swallow Buphenyl (sodium phenylbutyrate) tablet

If yes, approve the requested strength of Olpruva for 12 months by GPID or GPI-14 as follows:
   • 2 grams: #12 per day.
   • 3 grams: #12 per day.
   • 4 grams: #15 per day.
   • 5 grams: #12 per day.
   • 6 grams: #9 per day.
   • 6.67 grams: #9 per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SODIUM PHENYL BUTYRATE (Buphenyl, Pheburane, Olpruva) requires the following rule(s) be met for approval:
A. You have a urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
B. There is documentation (such as chart notes, lab results, diagnostic test results) confirming you have a urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
C. The requested medication will be used as adjunctive (add-on) therapy along with dietary protein restriction
D. Your condition cannot be managed by dietary protein restriction or amino acid supplementation alone
E. If your request is for Pheburane or Olpruva, approval also requires:
   1. You have tried or have a contraindication (harmful for) to generic sodium phenylbutyrate powder
   2. You are unable to swallow Buphenyl (sodium phenylbutyrate) tablet

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
RENEWAL CRITERIA

1. Does the patient have a diagnosis of a urea cycle disorder (UCD) AND meet the following criterion?  
   • The patient has experienced a clinical benefit from baseline (e.g., normal fasting glutamine, low-normal fasting ammonia levels, mental status clarity)

   If yes, continue to #2.  
   If no, do not approve.  

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Is the request for Buphenyl or Pheburane?

   If yes, **approve the requested medication for 12 months by GPID or GPI-14 as follows:**
   • Buphenyl tablet: #40 per day.  
   • Buphenyl powder: #25 grams per day.  
   • Pheburane: #20 grams per day.

   If no, continue to #3.

3. Is the request for Olpruva?

   If yes, **approve the requested strength of Olpruva for 12 months by GPID or GPI-14 as follows:**
   • 2 grams: #12 per day.  
   • 3 grams: #12 per day.  
   • 4 grams: #15 per day.  
   • 5 grams: #12 per day.  
   • 6 grams: #9 per day.  
   • 6.67 grams: #9 per day.

   If no, do not approve.  

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SODIUM PHENYL BUTYRATE (Buphenyl, Pheburane, Olpruva) requires the following rule(s) be met for renewal:
A. You have a urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
B. You have experienced a clinical benefit from baseline (for example you have normal fasting glutamine levels, low-normal fasting ammonia levels, mental status clarity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Buphenyl, Olpruva, or Pheburane.

REFERENCES
- Buphenyl [Prescribing Information]. Deerfield, IL: Horizon Therapeutics USA, Inc.; April 2023.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/19
Commercial Effective: 08/01/23 Client Approval: 06/23  P&T Approval: 07/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet ALL the following?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist or ALS specialist or being seen at an ALS Specialty Center or Care Clinic

   If yes, approve for a total of 6 months by HICL or GPI-10. Please enter two authorizations as follows:
   - FIRST APPROVAL: Approve for 21 days with a quantity limit of #1 per day.
   - SECOND APPROVAL: Approve for the remaining days with a quantity limit of #2 per day.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOD PHENYL BUTYRATE- TAURURSODIOL (Relyvrio) requires the following rule(s) be met for approval:
A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist or being seen at an ALS Specialty Center or Care Clinic

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of amyotrophic lateral sclerosis (ALS) and meet ALL of the following criteria?
   • The patient does not require invasive ventilation
   • The patient has improved or maintained baseline functional ability measured by functional assessments (e.g., Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS])

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day. If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio) requires the following rule(s) be met for renewal:
   A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
   B. You do not require invasive ventilation (inserting a breathing tube into your throat)
   C. You have improved or maintained baseline functional ability measured by functional assessments (e.g., Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS: a tool for evaluating functional status])

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Relyvrio.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/24/22
Created: 10/22
Client Approval: 10/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C and meet **ONE** of the following criteria?
   - The patient is 18 years of age or older with genotype 1 or 3
   - The patient is 3 to 17 years old with genotype 2 or 3

   If yes, continue to #2.
   If no, continue to #22.

2. Does the patient meet at least **ONE** of the following criteria?
   - The patient has severe renal impairment (estimated glomerular filtration rate (GFR) less than 30 mL/min/1.73m2), end stage renal disease, or requires dialysis
   - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
   - The patient is concurrently taking any of the following medications: carbamazepine, phenytoin, phenobarbital, oxicarbazine, rifampin, rifabutin, Priftin (rifapentine), Aptivus (tipranavir/ritonavir), Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (velpatasvir/sofosbuvir/voxilaprevir), or Zepatier (elbasvir/grazoprevir)
   - The patient is using the requested medication with a direct acting antiviral (e.g., Olysio [simeprevir] or Daklinza [daclatasvir]) AND is concurrently taking amiodarone

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.
   If no, continue to #3.

3. Does the patient have an HCV RNA level within the past 6 months?

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Is the patient younger than 18 years of age?

   If yes, continue to #18.
   If no, continue to #5.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

5. Does the patient meet **ALL** of the following?
   - The patient is treatment naïve OR treatment experienced (prior treatment with peginterferon/ribavirin)
   - The patient is without cirrhosis OR has decompensated cirrhosis OR is post-liver transplant (with or without cirrhosis)

   If yes, continue to #6.
   If no, continue to #22.

6. Does the patient have a trial of or contraindication to the preferred formulary agent based on their genotype?
   - For genotype 1 HCV infection: a short trial of Epclusa (velpatasvir/sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) or contraindication to BOTH agents
   - For genotype 3 HCV infection: a short trial of or contraindication to Epclusa (velpatasvir/sofosbuvir)

   **(NOTE:** An individual who has completed a full course of therapy with the preferred agent that did not achieve a sustained virologic response (SVR will not be approved)

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

7. Does the patient have decompensated cirrhosis?
   - If yes, continue to #13.
   - If no, continue to #8.

8. Is the requested medication being used with ribavirin OR peginterferon alfa and ribavirin?
   - If yes, continue to #22.
   - If no, continue to #9.

9. Is the requested medication being used in combination with Daklinza (daclatasvir)?
   **CLINICAL PHARMACISTS:** The patient must also meet all criteria in Daklinza (daclatasvir) guideline to be approvable for both agents. Review the hepatitis C MRF and Daklinza request to ensure that the patient meets criteria for both agents.
   - If yes, continue to #14.
   - If no, continue to #10.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

10. Does the patient have a genotype 1 hepatitis C infection AND meet the following criterion?
   - The requested medication is being used in combination with Olysio (simeprevir)
     
     If yes, continue to #11.
     If no, continue to #22.

11. Does the patient meet ONE of the following?
   - The patient has cirrhosis
   - The patient completed a full course of therapy with ONE of the following:
     - Any HCV protease inhibitor [for example, Incivek (telaprevir), Olysio (simeprevir), or Victrelis (boceprevir)] and has not achieved a sustained virologic response (SVR)
     - A regimen containing NS5A inhibitor [e.g., Harvoni (ledipasvir/sofosbuvir), Epclusa (velpatasvir/sofosbuvir), Technivie (ombitasvir-paritaprevir-ritonavir), Viekira Pak or Viekira XR (ombitasvir-paritaprevir-ritonavir), Zepatier (grazoprevir), or Daklinza (daclatasvir)-containing regimen]

     If yes, continue to #22.
     If no, continue to #12.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

12. Is the patient concurrently using the requested medication and Olysio (simeprevir) with ANY of the following medications?
   - Carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
   - An HIV medication: delavirdine, etravirine, nevirapine, or efavirenz
   - A Cobicistat-containing medication [e.g., Stribild or Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir), Evotaz (atazanavir/cobicistat), Prezinc (darunavir/cobicistat), Tybost (cobicistat)]
   - An HIV protease inhibitor (e.g., atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, Aptivus [tipranavir], ritonavir, darunavir/ritonavir)

   If yes, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

   If no, approve for 12 weeks for the requested strength by GID or GPI-14 as follows:
   - 400mg tablets: #1 per day.
   - 200mg pellets: #2 per day.
   (NOTE: Regimen approved for genotype 1 patient without cirrhosis: Olysio (simeprevir) and Sovaldi for 12 weeks)
   CLINICAL PHARMACISTS: The patient must also meet all of the criteria in the Olysio (simeprevir) guideline to be approved for both agents. Review the hepatitis C MRF and Olysio (simeprevir) request to ensure that the patient meets criteria for both agents.

13. Is the requested medication being used in combination with Daklinza (daclatasvir)?
   CLINICAL PHARMACISTS: The patient must also meet all criteria in the Daklinza (daclatasvir) guideline to be approved for both agents. Review the hepatitis C MRF and Daklinza (daclatasvir) request to ensure the patient meets criteria for both agents.

   If yes, continue to #14.
   If no, continue to #22.

CONTINUED ON NEXT PAGE
14. Is the patient concurrently using the requested medication and Daklinza (daclatasvir) with ANY of the following medications: amiodarone, carbamazepine, phenytoin, rifampin, or Priftin (rifapentine)?

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, continue to #15.

15. Does the patient have compensated cirrhosis?

   If yes, continue to #22.
   If no, continue to #16.

16. Does the patient have decompensated cirrhosis or is post-liver transplant?

   If yes, continue to #17.
   If no, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:** (Sovaldi in combination with Daklinza)
   • 400mg tablets: #1 per day.
   • 200mg pellets: #2 per day.
   **CLINICAL PHARMACISTS:** The patient must also meet all criteria in the Daklinza (daclatasvir) guideline to be approved for both agents. Review the hepatitis C MRF and Daklinza (daclatasvir) request to ensure the patient meets criteria for both agents.

17. Is the patient using a regimen of Daklinza and Sovaldi (sofosbuvir) **WITH** ribavirin?

   If yes, **approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:** (Sovaldi in combination with Daklinza and ribavirin)
   • 400mg tablets: #1 per day.
   • 200mg pellets: #2 per day.
   **CLINICAL PHARMACISTS:** The patient must also meet all criteria in Daklinza guideline to be approvable for both agents. Review hepatitis C MRF and Daklinza request to ensure patient meets criteria for both agents.

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

18. Does the patient have genotype 2 infection AND compensated cirrhosis (Child-Pugh A) or is without cirrhosis?

   If yes, continue to #19.
   If no, continue to #20.

19. Is the requested medication being used with ribavirin?

   If yes, approve for 12 weeks for the requested strength by GPID or GPI-14 as follows:
   • 400mg tablets: #1 per day.
   • 200mg tablets: #1 per day.
   • 200mg pellets: #2 per day.
   • 150mg pellets: #1 per day.

   If no, continue to #22.

20. Does the patient have genotype 3 infection AND compensated cirrhosis (Child-Pugh A) or is without cirrhosis?

   If yes, continue to #21.
   If no, continue to #22.

21. Is the requested medication being used with ribavirin?

   If yes, approve for 24 weeks for the requested strength by GPID or GPI-14 as follows:
   • 400mg tablets: #1 per day.
   • 200mg tablets: #1 per day.
   • 200mg pellets: #2 per day.
   • 150mg pellets: #1 per day.

   If no, continue to #22.

22. Is the requested regimen recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment?

   If yes, approve as indicated per guidance in AASLD/IDSA.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SOFOSBUVIR (Sovaldi)** requires the following rule(s) be met for approval:

A. The requested regimen is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment

B. You have chronic hepatitis C (type of liver inflammation)

C. You are 18 years of age or older with genotype 1 or 3, OR you are 3 to 17 years old with genotype 2 or 3

D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months

E. **If you are an adult patient (18 years of age or older), approval also requires:**
   1. You are treatment naive (never previously treated) or treatment experienced (prior treatment with peginterferon/ribavirin)
   2. You will be using Sovaldi with Olysio (simeprevir) (genotype 1 only) or Daklinza (daclatasvir) (genotype 1 or 3 only)
   3. You had a short trial of therapy with the following preferred formulary medication(s). If you completed a full course of therapy but did not achieve a sustained virologic response (SVR), you will not be approved to receive the requested medication.
      a. If you have genotype 1 infection, you had a short trial of Epclusa (velpatasvir/sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) or you have a contraindication (harmful for) to BOTH agents
      b. If you have genotype 3 infection, you had a short trial of Epclusa (velpatasvir/sofosbuvir) or you have a contraindication (harmful for) to this agent

F. **If you are a pediatric patient (under 18 years of age), approval also requires:**
   1. The request must meet the Food and Drug Administration (FDA)-approved indication [treatment naive (never previously treated) or treatment experienced patient with compensated cirrhosis (no symptoms related to liver damage) (Child-Pugh A) or without cirrhosis (liver scarring)]
   2. You will be using Sovaldi together with ribavirin (genotypes 2 and 3)

*(Denial text continued on next page)*
GUIDELINES FOR USE (CONTINUED)

G. **Sovaldi will not be approved if you meet any of the following:**
   1. You have severe renal (kidney) impairment (glomerular filtration rate less than 30 mL/min/1.73m²), end stage renal disease and/or those requiring dialysis
   2. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
   3. You are an adult with compensated cirrhosis (type of liver condition)
   4. You are using any of the following medications at the same time while on Sovaldi: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), Aptivus (tipranavir)/ritonavir, Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (velpatasvir/sofosbuvir/voxilaprevir), or Zepatier (elbasvir/grazoprevir)
   5. You are using Sovaldi with another direct acting antiviral (such as Olysio [simeprevir] or Daklinza [daclatasvir]) AND are on concurrent amiodarone
   6. You are 18 years of age or older and are taking Sovaldi with ribavirin OR peginterferon alfa and ribavirin

H. **If the request is for Sovaldi and Olysio (simeprevir), approval also requires:**
   1. You are 18 years of age or older
   2. You have genotype 1 hepatitis C (type of liver inflammation)
   3. You do not have cirrhosis (liver scarring)
   4. You have not previously failed a full course of therapy with ONE of the following:
      a. Any hepatitis C virus protease inhibitor (type of hepatitis C drug such as Incivek [telaprevir], Olysio [simeprevir], or Victrelis [boceprevir])
      b. A regimen containing NS5A inhibitor (type of hepatitis medication such as Harvoni (ledipasvir/sofosbuvir), Epclusa (velpatasvir/sofosbuvir), Technivie (ombitasvir-paritaprevir-ritonavir), Viekira Pak or Viekira XR (ombitasvir-paritaprevir-ritonavir), Zepatier (grazoprevir), or Daklinza (daclatasvir)-containing regimen)

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

I. You will not use the requested medication together with any of the following medications as they are contraindicated (harmful for) or not recommended by the manufacturer:
   1. Carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
   2. Any of the following human immunodeficiency virus (HIV) medications: delavirdine, etravirine, nevirapine, or efavirenz
   3. A cobicistat-containing medication such as Stribild or Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir), Evotaz (atazanavir/cobicistat), Prezcobix (darunavir/cobicistat), or Tybost (cobicistat)
   4. A human immunodeficiency virus (HIV) protease inhibitor such as atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, Aptivus (tipranavir), ritonavir, or darunavir/ritonavir

J. If the request is for Sovaldi with Daklinza (daclatasvir), approval also requires:
   1. You are 18 years of age or older
   2. You have genotype 1 or 3 hepatitis C (type of liver inflammation)
   3. You will not be using the requested medication together with any of the following medications because they are contraindicated (medical reason why you cannot use a drug) or not recommended by the manufacturer): amiodarone, carbamazepine, phenytoin, rifampin, or Priftin (rifapentine)
   4. You will be taking ribavirin together with Sovaldi and Daklinza if you have decompensated cirrhosis (type of liver condition) or you are post-liver transplant

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RATIOALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sovaldi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 01/14
Client Approval: 08/23
P&T Approval: 04/22
SOFOSBUVIR/VELPATASVIR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOFOSBUVIR/VELPATASVIR</td>
<td>EPCLUSA, SOFOSBUVIR-VELPATASVIR</td>
<td>43561</td>
<td>GPI-10</td>
<td>(1235990265)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 AND meet the following criterion?
   - The patient is 3 years of age or older

   If yes, continue to #2.
   If no, continue to #6.

2. Does the patient have an HCV RNA level within the past 6 months?

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet at least ONE of the following criteria?
   - The patient is currently taking any of the following medications: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), efavirenz-containing HIV regimens, rosuvastatin at doses above 10mg, Aptivus (tipranavir)/ritonavir, topotecan, Sovaldi (sofosbuvir, as a single agent), Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), Mavyret (pibrentasvir/glecaprevir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)
   - The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

   If yes, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   If no, continue to #4.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

4. Does the patient have decompensated cirrhosis AND the requested medication will be used with ribavirin?

   If yes, approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:
   • 400mg-100mg tablets: #1 per day.
   • 200mg-50mg tablets: #1 per day.
   • 200mg-50mg pellets: #2 per day.
   • 150mg-37.5mg pellets: #1 per day.

   If no, continue to #5.

5. Does the patient meet ONE of the following criteria?
   • Treatment naïve and genotype 1-6 infection
   • Treatment experienced, genotype 1-6 infection, with prior treatment with one of the following: 1) peginterferon/ribavirin or 2) NS3 protease inhibitor triple therapy (Olysio [simeprevir], Incivek [telaprevir] or Victrelis [boceprevir] with peginterferon/ribavirin)
   • Treatment experienced, genotype 1b or genotype 2 infection, with previous treatment with Sovaldi (sofosbuvir)-containing regimen (e.g., Sovaldi [sofosbuvir]/ribavirin with or without peginterferon or Sovaldi [sofosbuvir]/Olysio [simeprevir]) that does not include an NS5A inhibitor

   If yes, approve for 12 weeks by GPID or GPI-14 for the requested strength as follows:
   • 400mg-100mg tablets: #1 per day.
   • 200mg-50mg tablets: #1 per day.
   • 200mg-50mg pellets: #2 per day.
   • 150mg-37.5mg pellets: #1 per day.

   If no, continue to #6.

8. Is the requested regimen recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment?

   If yes, approve as indicated per guidance in AASLD/IDSA.
   If no, do not approve.

   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SOFOSBUVIR/VELPATASVIR (Epclusa)** requires the following rule(s) be met for approval:

A. The requested regimen is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment
B. You have chronic hepatitis C (type of liver inflammation) with genotype 1, 2, 3, 4, 5, or 6
C. You are 3 years of age or older
D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
E. **If you have decompensated cirrhosis (type of liver condition), approval also requires:**
   1. The requested medication will be used with ribavirin
F. **If you do not have cirrhosis (liver damage) OR you have compensated cirrhosis (type of liver condition), approval also requires** ONE of the following:
   1. You are treatment naive (never previously treated)
   2. You are treatment experienced (have previously been treated) with peginterferon/ribavirin or NS3 protease inhibitor triple therapy (type of hepatitis drug such as Olysio [simeprevir], Incivek [telaprevir] or Victrelis [boceprevir] with peginterferon/ribavirin)
   3. You have genotype 1b or genotype 2 infection AND you are treatment experienced with a Sovaldi (sofosbuvir)-containing regimen that does not include an NSSA inhibitor (type of hepatitis drug) such as Sovaldi (sofosbuvir)/ribavirin with or without peginterferon or Sovaldi (sofosbuvir)/Olysio (simeprevir)

**Epclusa will not be approved if you meet any of the following:**

A. You are using any of the following medications with the requested agent: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin (rifapentine), efavirenz-containing HIV (human immunodeficiency virus) regimens, rosuvastatin at doses above 10mg, Aptivus (tipranavir)/ritonavir, topotecan, Sovaldi (sofosbuvir, as a single agent), Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), Mavyret (pibrentasvir/glecaprevir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)
B. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
SOFOBUVIR/VELPATASVIR

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Epclusa.

REFERENCES
• Epclusa [Prescribing Information]. Foster City, CA: Gilead Sciences; April 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 07/16
Commercial Effective: 10/01/23  Client Approval: 08/23  P&T Approval: 07/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic hepatitis C, genotype 1, 2, 3, 4, 5, or 6 AND meet the following criterion?
   • The patient is 18 years of age or older

      If yes, continue to #2.
      If no, continue to #5.

2. Does the patient have an HCV RNA level within the past 6 months?

      If yes, continue to #3.
      If no, do not approve.
      DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient meet at least ONE of the following criteria?
   • The patient is concurrently taking any of the following medications: amiodarone, rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, Priftin (rifapentine), HIV regimen containing atazanavir, lopinavir, Aptivus (tipranavir)/ritonavir, or efavirenz, rosuvastatin, Livalo/Zypitamag (pitavastatin), pravastatin (at doses above 40mg), cyclosporine, methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, sulfasalazine, topotecan, Sovaldi (sofosbuvir; as a single agent), Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), or Mavyret (pibrentasvir/glecaprevir)
   • The patient has moderate or severe hepatic impairment (Child-Pugh B or C)
   • The patient has a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (e.g., physician attestation)

      If yes, do not approve.
      DENIAL TEXT: See the denial text at the end of the guideline.

      If no, continue to #4.

CONTINUED ON NEXT PAGE
4. Does the patient meet **ONE** of the following criteria?
   - Genotype 1-6, treatment experienced and previously failed a full course of therapy with DAA regimen that includes NS5A inhibitor [e.g., Harvoni (ledipasvir/sofosbuvir), Epclusa (elbasvir/grazoprevir), Technivie (ombitasvir/paritaprevir/ritonavir), Viekira Pak or Viekira XR (dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir), Daklinza (daclatasvir)/Sovaldi (sofosbuvir) combination]
   - Genotype 1a or 3, treatment experienced and previously failed a full course of therapy with DAA regimen that includes sofosbuvir without NS5A inhibitor [e.g., Sovaldi (sofosbuvir)/ribavirin, Sovaldi (sofosbuvir)/peginterferon/ribavirin, Olysio (simeprevir)/Sovaldi (sofosbuvir) (or other HCV protease inhibitor in combination with Sovaldi (sofosbuvir)]

   If yes, **approve for 12 weeks by HICL or GPI-10 for #1 per day.**
   If no, continue to #5.

5. Is the requested regimen recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment?

   If yes, **approve as indicated per guidance in AASLD/IDSA.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SOFOBUVIR/VELPATASVIR/VOXILAPREVIR (Vosevi)** requires the following rule(s) be met for approval:

A. The requested regimen is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment
B. You have chronic hepatitis C (type of liver inflammation)
C. You are 18 years of age or older
D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months

*Denial text continued on next page*
E. You meet ONE of the following:
   1. You have genotype 1, 2, 3, 4, 5, or 6 and previously failed a full course of therapy with a
direct-acting antiviral (DAA) regimen that includes NS5A inhibitor [class of hepatitis C
drug such as Harvoni (ledipasvir/sofosbuvir), Epclusa (elbasvir/grazoprevir), Technivie
(ombitasvir/paritaprevir/ritonavir), Viekira Pak or Viekira XR
dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir), Daklinza
daclatasvir)/Sovaldi (sofosbuvir) combination]
   2. You have genotype 1a or genotype 3 and previously failed a full course of therapy with
DAA regimen that includes sofosbuvir without NS5A inhibitor [class of hepatitis C drug
such as Sovaldi (sofosbuvir)/ribavirin, Sovaldi (sofosbuvir)/peginterferon/ribavirin, Olysio
(simeprevir)/Sovaldi (sofosbuvir) (or other hepatitis C virus protease inhibitor in
combination with Sovaldi)]

**Vosevi will not be approved if you meet any of the following:**
A. You are using the requested agent concurrently (at the same time) with any of the following
medications: amiodarone, rifampin, carbamazepine, phenytoin, phenobarbital,
oxcarbazepine, rifabutin, Priftin (rifapentine), HIV (human immunodeficiency virus) regimen
containing atazanavir, lopinavir, Aptivus (tipranavir/ritonavir, or efavirenz, rosuvastatin,
Livalo or Zypitamag (pitavastatin), pravastatin (at doses above 40mg), cyclosporine,
metothrexate, mitoxantrone, imatinib, irinotecan, lapatinib, sulfasalazine, topotecan, Sovaldi
(sofosbuvir, as a single agent), Epclusa (velpatasvir/sofosbuvir), Harvoni
(ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), or Mavyret (pibrentasvir/glecaprevir)
B. You have moderate or severe hepatic (liver) impairment (Child-Pugh B or C)
C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid
conditions (having two or more diseases at the same time)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
your doctor to use a different medication or get us more information if it will allow us to approve
this request.

**CONTINUED ON NEXT PAGE**
RATIONAL
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vosevi.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 08/17
Client Approval: 08/23
P&T Approval: 07/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of neurogenic detrusor overactivity and meet **ALL** of the following criteria?
   - The patient is 2 years of age or older
   - The patient had a trial of or contraindication to **TWO** of the following:
     - Anticholinergics (e.g., oxybutynin)
     - Beta-3 agonists (e.g., mirabegron)
   - The patient is unable to swallow oral solifenacin tablets

   If yes, **approve for 12 months by GPIID or GPI-14 with a quantity limit of #10mL per day.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **SOLIFENACIN SUSPENSION (Vesicare LS)** requires the following rule(s) be met for approval:
   A. You have neurogenic detrusor overactivity (type of bladder dysfunction)
   B. You are 2 years of age or older
   C. You had a trial of or contraindication (harmful for) to **TWO** of the following:
      1. Anticholinergics (such as oxybutynin)
      2. Beta-3 agonists (such as mirabegron)
   D. You are unable to swallow oral solifenacin tablets

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vesicare LS.

REFERENCES
SOLRIAMFETOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOLRIAMFETOL</td>
<td>SUNOSI</td>
<td>45666</td>
<td></td>
<td>GPI-10</td>
<td>(6137007020)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy AND the narcolepsy is confirmed by ONE of the following criteria?
   - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
   - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
   - The patient has low orexin (aka hypocretin) levels on a cerebrospinal fluid (CSF) assay

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ALL of the following criteria?
   - Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
   - Therapy is prescribed by or given in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
   - The patient had a trial of or contraindication to one amphetamine derivative (e.g., amphetamine sulfate, methylphenidate, etc.) AND modafinil or armodafinil

   If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   **APPROVAL TEXT:** Renewal requires the patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline.

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with obstructive sleep apnea (OSA) AND that OSA is confirmed by ONE of the following criteria?
   - Polysomnography
   - Home sleep apnea testing devices
   - Hospital-based bedside monitoring

   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

4. Does the patient meet ALL of the following criteria?
   - Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
   - The patient had a trial of or contraindication to modafinil or armodafinil
   - The patient is on ongoing treatment to address the obstructive causes of OSA, for at least one month since initiation, and has been counseled on weight-loss intervention (if BMI > 30)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #1 per day.
   APPROVAL TEXT: Renewal requires the patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline.

   If no, do not approve.
   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SOLRIAMFETOL (Sunosi) requires the following rule(s) be met for approval:
   A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).

   (Initial denial text continued on the next page)
INITIAL CRITERIA (CONTINUED)

B. If you have excessive daytime sleepiness (EDS) with narcolepsy, approval also requires:
   1. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      i. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND two (2) or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
      ii. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND one (1) early-onset rapid eye movement (REM) sleep test period (SOREMP) AND one (1) SOREMP (within about 15 minutes) on a sleep study (polysomnography) the night before the MSLT, with the sleep study ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
      iii. You have low orexin levels on a cerebrospinal fluid (CSF) assay (a test to determine the amount of a type of chemical for wakefulness in your brain)
   2. You have had Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
   3. Therapy is prescribed by or given in consultation with a neurologist (brain doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   4. You have tried one amphetamine derivative (e.g., amphetamine sulfate, methylphenidate, etc.) AND modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)

C. If you have excessive daytime sleepiness (EDS) with obstructive sleep apnea (OSA), approval also require:
   1. Your diagnosis of OSA is confirmed by a sleep study (polysomnography), home sleep apnea testing devices, or hospital-based bedside monitoring
   2. You have had Excessive Daytime Sleepiness (EDS) for at least 3 months and your Epworth Sleepiness Scale (ESS) score is more than 10
   3. You have tried modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)
   4. You have been on a treatment for the obstructive causes of OSA, for at least one month since initiation, and you have been counseled on weight-loss intervention [if your BMI (Body Mass Index: a measure of body fat based on height and weight) is greater than 30]

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOLRIAMFETOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) with narcolepsy or obstructive sleep apnea (OSA) AND meet the following criterion?
   • The patient has demonstrated 25% or more improvement in Epworth Sleepiness Scale (ESS) scores compared to baseline

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #30 per 30 days.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SOLRIAMFETOL (Sunosi) requires the following rule(s) be met for renewal:
   A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).
   B. You have sustained improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   RATIONALE
   For further information, please refer to the Prescribing Information and/or Drug Monograph for Sunosi.

   REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the requested medication being used for ANY of the following?
   • Athletic enhancement
   • Anti-aging purposes
   • Idiopathic short stature (ISS)

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have a diagnosis of growth failure due to inadequate secretion of endogenous growth hormone (GH) and meet ALL of the following criteria?
   • The patient is 3 to 17 years of age
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient has open epiphyses (as confirmed by radiograph of the wrist and hand)

   If yes, continue to #3.

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Does the patient meet ONE of following criteria?
   • The patient's height is at least 2 standard deviations (SD) below the mean height for normal children of the same age and gender
   • The patient has a height velocity that is less than 25th percentile for age
   • The patient has a low peak growth hormone (less than 10 ng/mL) on two GH stimulation tests, OR has an insulin-like growth factor 1 (IGF-1) that is at least 2 SD below the mean for same age and gender

   If yes, approve for 12 months by HICL or GPI-10.

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROGON-GHLA (Ngenla) requires the following rule(s) be met for approval:
A. You have growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone
B. You are 3 to 17 years of age
C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
D. You have open epiphyses (end part of long bone) as confirmed by a radiograph (type of imaging test) of the wrist and hand
E. You meet at ONE of the following criteria:
   1. Your height is at least 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
   2. Your height velocity is less than the 25th percentile for your age
   3. You have low peak growth hormone levels (less than 10 ng/mL) on two GH (growth hormone) stimulation tests, OR an insulin-like growth factor 1 (IGF-1) level at least 2 standard deviations below the mean for your age and gender
F. Request for Ngenla will NOT be approved for athletic enhancement, anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOMATROGON-GLHA

RENEWAL CRITERIA

1. Is the requested medication being used for **ANY** of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature (ISS)

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.
   If no, continue to #2.

2. Does the patient have a diagnosis of growth failure due to inadequate secretion of endogenous growth hormone (GH) and meet **ALL** of the following criteria?
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient has open epiphyses (as confirmed by radiograph of the wrist and hand), OR the patient has not completed prepubertal growth

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
   - The patient has an annual growth velocity of at least 2 cm compared with what was observed from the previous year
   - The patient is near the terminal phase of puberty and has an annual growth velocity of at least 1 cm compared with what was observed from the previous year

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROGON-GHLA (Ngenla) requires the following rule(s) be met for renewal:
A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
B. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
C. You have open epiphyses (end part of long bone) as confirmed by radiograph (type of imaging test) of the wrist and hand, OR you have not completed prepubertal growth
D. You meet ONE of the following:
   1. Your annual growth velocity (rate of growth) is at least 2 cm compared with what was observed from the previous year
   2. Your annual growth velocity is at least 1 cm compared with what was observed from the previous year if you are near the terminal (final) phase of puberty
E. Renewal request for Ngenla will NOT be approved for athletic enhancement, anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ngenla.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 09/01/23
Created: 08/23
Client Approval: 08/23
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient meets at least ONE of the following criteria for short stature:
     - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     - Height velocity less than the 25th percentile for age
     - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   **For growth failure associated with Turner syndrome, approval requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

For growth failure due to Prader-Willi syndrome (PWS), approval requires ALL of the following:
- Confirmed genetic diagnosis of PWS
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin

For growth failure in children born small for gestational age (SGA), approval requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For adult growth hormone deficiency, approval requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Genotropin) requires the following rule(s) be met for approval:
A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure associated with Turner syndrome (TS: a type of gene condition)
   3. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause of short height)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have growth failure associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. If you have growth failure due to Prader-Willi syndrome (PWS), approval also requires:
   1. You have a confirmed genetic diagnosis of Prader-Willi syndrome
   2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin

E. If you have growth failure and are a child born small for gestational age (SGA), approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph of the wrist and hand
   4. You had no catch-up growth by age 2 years
   5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

(Initial denial text continued on next page)
F. **If you have adult growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Is the request for treatment of **ANY** of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   - The patient meets **ONE** of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

   *(Renewal criteria continued on next page)*

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

For short stature associated with Turner syndrome, renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or
  patient has not reached 50th percentile for patient's predicted adult height

For growth failure due to Prader-Willi syndrome (PWS), renewal requires ALL of the
following:
- Therapy is prescribed by or in consultation with an endocrinologist
- Improvement in body composition

For growth failure in children born small for gestational age (SGA), renewal requires ALL of
the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or
  patient has not reached 50th percentile for patient's predicted adult height

For adult growth hormone deficiency, renewal requires:
- Therapy is prescribed by or in consultation with an endocrinologist

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Genotropin) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD)
   2. Growth failure associated with Turner syndrome (type of genetic disorder where you are
      missing a X chromosome)
   3. Growth failure due to Prader-Willi syndrome (PWS: genetic disorder that causes obesity,
      intellectual disability, and short height)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause of short height)

(Renewal denial text continued on next page)
B. **If you have pediatric growth hormone deficiency, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. **If you have short stature associated with Turner syndrome, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

D. **If you have growth failure due to Prader-Willi syndrome, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have experienced improvement in body composition

E. **If you have growth failure and are a child born small for gestational age, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. **If you have adult growth hormone deficiency, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOMATROPIN - GENOTROPIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Genotropin.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  
Commercial Effective: 11/01/22  
Created: 10/22  
Client Approval: 10/22  
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:**
   Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - Patient meets at least ONE of the following criteria for short stature:
     - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     - Height velocity less than the 25th percentile for age
     - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   **For short stature associated with Turner syndrome, approval requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

   **For short stature or growth failure in children with SHOX deficiency, approval requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

   *(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
For growth failure in children born small for gestational age (SGA), approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 to 4 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For adult growth hormone deficiency, approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, approve for 12 months by GPIID or GPI-14 for all strengths.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Humatrope) requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause for short height)

(Initial denial text continued on next page)
B. If you have pediatric growth hormone deficiency, approval also requires:
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
4. You meet at least ONE of the following criteria for short stature:
   a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
   b. Your height velocity is less than the 25th percentile for age
   c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have short stature associated with Turner syndrome, approval also requires:
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. If you have short stature or growth failure in short stature homeobox-containing gene deficiency, approval also requires:
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you have growth failure and are a child born small for gestational age, approval also requires:
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
5. You had no catch-up growth by age 2 to 4 years

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

F. **If you have adult growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   - The patient meets **ONE** of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

   *(Renewal criteria continued on next page)*

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

For short stature associated with Turner syndrome, renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For short stature or growth failure in children with SHOX deficiency, renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For growth failure in children born small for gestational age (SGA), renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For adult growth hormone deficiency, renewal requires:
- Therapy is prescribed by or in consultation with an endocrinologist

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Humatrope) requires the following rule(s) be met for renewal:
A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause for short height)

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

D. If you have short stature or growth failure in children with SHOX deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOMATROPIN - HUMATROPE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Humatrope.

REFERENCES
• Humatrope [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; October 2019.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 10/22
Client Approval: 10/22
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   
   DENIAL TEXT: See the initial denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   
   For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient meets at least ONE of the following criteria for short stature:
     - Patient's height greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     - Height velocity less than the 25th percentile for age
     - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   For short stature associated with Turner syndrome, approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

   For short stature associated with Noonan syndrome, approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

For short stature in pediatric patients born small for gestational age (SGA), approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Patient with no catch-up growth by age 2 to 4 years
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For adult growth hormone deficiency, approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, Surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

For growth failure due to Prader-Willi syndrome (PWS), approval requires ALL of the following:

- Confirmed genetic diagnosis of PWS
- Therapy is prescribed by or in consultation with an endocrinologist

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Norditropin Flexpro) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature associated with Noonan syndrome (a type of gene condition)
   4. Short stature born small for gestational age (SGA) in a pediatric patient
   5. Adult growth hormone deficiency
   6. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

B. **If you have pediatric growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. **If you have short stature associated with Turner syndrome, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. **If you have short stature associated with Noonan syndrome, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. **If you are a child with short stature born small for gestational age, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. You had no catch-up growth by age 2 to 4 years
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

F. **If you have adult growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

G. If you have growth failure due to Prader-Willi syndrome, approval also requires:
   1. You have confirmed genetic diagnosis of Prader-Willi syndrome
   2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of ANY of the following?
   • Athletic enhancement
   • Anti-aging purposes
   • Idiopathic short stature

   If yes, do not approve.

   DENIAL TEXT: See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient’s epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   • The patient meets ONE of the following:
     o Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     o Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

   **For short stature associated with Noonan syndrome, renewal requires ALL of the following:**
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   • Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient’s predicted adult height

   *(Renewal criteria continued on next page)*

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

For short stature associated with Turner syndrome, renewal requires ALL of the following:
• Therapy is prescribed by or in consultation with an endocrinologist
• The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
• Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For short stature in pediatric patients born small for gestational age (SGA), renewal requires ALL of the following:
• Therapy is prescribed by or in consultation with an endocrinologist
• The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
• Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For adult growth hormone deficiency, renewal requires:
• Therapy is prescribed by or in consultation with an endocrinologist

For growth failure due to Prader-Willi syndrome (PWS), renewal requires ALL of the following:
• Therapy is prescribed by or in consultation with an endocrinologist
• Improvement in body composition

If yes, approve for 12 months by GPID or GPI-14 for all strengths. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Norditropin Flexpro) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD)
   2. Short stature associated with Turner syndrome (type of genetic disorder where you are missing a X chromosome)
   3. Short stature associated with Noonan syndrome (a type of genetic disorder causing abnormal body development)
   4. Short stature born small for gestational age (SGA) in a pediatric patient
   5. Adult growth hormone deficiency
   6. Growth failure due to Prader-Willi syndrome (PWS: genetic disorder that causes obesity, intellectual disability, and short height)

This medication will not be approved for treatment of ANY of the following conditions:
1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause for short height)

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

B. **If you have pediatric growth hormone deficiency, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are **NOT** closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth
   3. You meet **ONE** of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. **If you have short stature associated with Noonan syndrome, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are **NOT** closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

D. **If you have short stature associated with Turner syndrome, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are **NOT** closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. **If you are a child with short stature born small for gestational age, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are **NOT** closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. **If you have adult growth hormone deficiency, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

G. **If you have growth failure due to Prader-Willi syndrome, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had improvement in body composition

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOMATROPIN - NORDITROPIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Norditropin.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Client Approval: 10/22
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient meets at least ONE of the following criteria for short stature:
     o The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     o Height velocity less than the 25th percentile for age
     o Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   For growth failure secondary to chronic kidney disease (CKD), approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with a nephrologist
   - The patient has NOT undergone a renal transplantation
   - The patient's height or growth velocity is greater than or equal to 2 standard deviations (SD) below the mean for normal children of the same age and gender

   (Initial criteria continued on next page)
INITIAL CRITERIA CONTINUED)

For short stature associated with Turner syndrome, approval requires ALL of the following:
• Therapy is prescribed by or in consultation with an endocrinologist
• The patient had a trial of or contraindication to the preferred agent: Norditropin
• The patient’s epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
• The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For adult growth hormone deficiency, approval requires ALL of the following:
• Therapy is prescribed by or in consultation with an endocrinologist
• The patient had a trial of or contraindication to the preferred agent: Norditropin
• The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypohipuitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

INITIAL DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Nutropin AQ Nuspin) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure secondary to chronic kidney disease (CKD)
   3. Short stature associated with Turner syndrome (TS: a type of gene condition)
   4. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

(Initial denial text continued on next page)
 INITIAL CRITERIA (CONTINUED)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

If you have growth failure secondary to chronic kidney disease, approval also requires:
   1. You have NOT undergone a renal (kidney) transplantation
   2. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
   3. Your height or growth velocity is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. If you have short stature associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   - The patient meets ONE of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year for patients who are near the terminal phase of puberty

   **For growth failure secondary to chronic kidney disease (CKD), renewal requires ALL of the following:**
   - The patient has not undergone a renal transplantation
   - Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

   **For short stature associated with Turner syndrome, renewal requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

   **For adult growth hormone deficiency, renewal requires:**
   - Therapy is prescribed by or in consultation with an endocrinologist

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Nutropin AQ Nuspin) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure secondary to chronic kidney disease (CKD)
   3. Short stature associated with Turner syndrome (TS: a type of gene condition)
   4. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have growth failure secondary to chronic kidney disease, renewal also requires:
   1. You have not had a renal (kidney) transplantation
   2. Your growth velocity is 2 cm or more compared with what was observed from the previous year or you have not reached 50th percentile for your predicted adult height

D. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

(Renewal denial text continued on next page)
RENWWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Nutropin AQ.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 10/22
Commercial Effective: 11/01/22 Client Approval: 10/22
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient meets at least ONE of the following criteria for short stature:
     o Patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     o Height velocity less than the 25th percentile for age
     o Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   For growth failure due to Prader-Willi syndrome (PWS), approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - Confirmed genetic diagnosis of PWS
   - The patient had a trial of or contraindication to the preferred agent: Norditropin

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
For growth failure in children born small for gestational age (SGA), approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- Patient with no catch-up growth by age 2 years
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For growth failure associated with Turner syndrome, approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For adult growth hormone deficiency, approval requires ALL of the following:

- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, approve for 12 months by GPID or GPI-14 for all strengths. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Omnitrope) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
   3. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

This medication will not be approved for treatment of ANY of the following conditions:
1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (unknown cause of short height)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have growth failure due to Prader-Willi syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have confirmed genetic diagnosis of Prader-Willi Syndrome
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin

D. If you have growth failure and are a child born small for gestational age, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had no catch-up growth by age 2 years
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   4. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you have growth failure associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

F. **If you have adult growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   - The patient meets ONE of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year in patients who are near the terminal phase of puberty

   *(Renewal criteria continued on next page)*

   **CONTINUED ON NEXT PAGE*
RENEWAL CRITERIA (CONTINUED)

For growth failure due to Prader-Willi syndrome (PWS), renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- Improvement in body composition

For growth failure in children born small for gestational age (SGA), renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patients predicted adult height

For growth failure associated with Turner syndrome, renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For adult growth hormone deficiency, renewal requires:
- Therapy is prescribed by or in consultation with an endocrinologist

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Omnitrope) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
   3. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have growth failure due to Prader-Willi syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have experienced improvement in body composition

D. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have growth failure associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
**RATIONAL**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Omnitrope.

**REFERENCES**


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22

Created: 10/22
Client Approval: 10/22

P&T Approval: 04/21
SOMATROPIN - SAIZEN

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.
   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?
   For pediatric growth hormone deficiency (GHD), approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   - The patient meets at least ONE of the following criteria for short stature:
     - Patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     - Height velocity is less than the 25th percentile for age
     - Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   For adult growth hormone deficiency, approval requires ALL of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient had a trial of or contraindication to the preferred agent: Norditropin
   - The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

   If yes, approve for 12 months by GPID or GPI-14 for all strengths.
   If no, do not approve.
   DENIAL TEXT: See the initial denial at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Saizen) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      Your height velocity is less than the 25th percentile for your age
      You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

1. Is the request for treatment of **ANY** of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?
   
   For **pediatric growth hormone deficiency (GHD)**, renewal requires **ALL** of the following:
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient’s epiphyses are **NOT** closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   - The patient meets **ONE** of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year in patients who are near the terminal phase of puberty

   For **adult growth hormone deficiency**, renewal requires:
   - Therapy is prescribed by or in consultation with an endocrinologist

   If yes, approve for **12 months** by GPID or GPI-14 for all strengths.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **SOMATROPIN (Saizen)** requires the following rule(s) be met for renewal:
   A. You have **ONE** of the following diagnoses:
      1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
      2. Adult growth hormone deficiency

   This medication will not be approved for treatment of **ANY** of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

   **(Renewal denial text continued on next page)**

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

B. **If you have pediatric growth hormone deficiency, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. **If you have adult growth hormone deficiency, renewal also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Saizen

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A                Created: 10/22
Commercial Effective: 11/01/22       Client Approval: 10/22
                                      P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a patient with a diagnosis of HIV wasting/cachexia who meets ALL of the following criteria?
   • The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
   • Therapy is prescribed by or in consultation with ONE of the following specialists: gastroenterologist, nutritional support specialist, or infectious disease specialist
   • The patient is on HIV anti-retroviral therapy
   • The patient has inadequate response to previous therapy (i.e., exercise training, nutritional supplements, appetite stimulants, or anabolic steroids)
   • The patient has an inadequate response to previous pharmacological therapy including one of the following: cyproheptadine, Marinol (dronabinol), or Megace (megestrol acetate)
   • Alternative causes of wasting have been ruled out; alternative causes include:
     o Altered metabolism (from metabolic and hormonal abnormalities) including testosterone deficiency or peripheral growth hormone resistance
     o Diarrhea
     o Inadequate energy (caloric) intake
     o Malignancies
     o Opportunistic infections
   • The patient meets ONE of the following criteria for weight loss:
     o 10% unintentional weight loss over 12 months
     o 7.5% unintentional weight loss over 6 months
     o 5% body cell mass (BCM) loss within 6 months
     o BCM less than 35% (men) AND a body mass index (BMI) less than 27 kg per meter squared
     o BCM less than 23% (women) of total body weight AND a body mass index (BMI) less than 27 kg per meter squared
     o BMI less than 18.5 kg per meter squared

If yes, continue to #2.
If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

2. Is the patient hypogonadal as defined by **ONE** of the following?
   - Total serum testosterone level of less than 300ng/dL (10.4 nmol/L)
   - A low total serum testosterone level as indicated by a lab result, with a reference range, obtained within 90 days
   - A free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

   If yes, continue to #3.
   If no, **approve for 12 weeks by GPID or GPI-14 for all strengths.**

3. For patients who are hypogonadal, does the patient meet the following criterion?
   - The patient has tried testosterone therapy (e.g., testosterone cypionate, AndroGel, Androderm, Axiron, Delatestryl, Fortesta, Striant, Testim, Testopel, Vogelxo, Natesto)

   If yes, **approve for 12 weeks by GPID or GPI-14 for all strengths.**
   If no, do not approve.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SOMATROPIN (Serostim)** requires the following rule(s) be met for approval:

A. You have HIV (human immunodeficiency virus) wasting/cachexia (extreme weight loss and muscle loss)
B. The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), nutritional support specialist OR infectious disease specialist (doctor who specializes in the treatment of infections)
D. You are on HIV (human immunodeficiency virus) anti-retroviral therapy
E. You have had an inadequate response to previous therapy such as exercise training, nutritional supplements, appetite stimulants or anabolic steroids
F. You have had an inadequate response to previous pharmacological (drug) therapy including one of the following: cyproheptadine, Marinol (dronabinol), or Megace (megestrol acetate)

*(Initial denial text continued on next page)*

**CONTINUED ON NEXT PAGE**
G. Alternative causes of wasting have been ruled out. Alternative causes may include:
   1. Altered metabolism (from metabolic and hormonal abnormalities) including testosterone deficiency or peripheral growth hormone resistance
   2. Diarrhea
   3. Inadequate energy (caloric) intake
   4. Malignancies (tumors)
   5. Opportunistic infections (an infection that can occur because of a weakened immune system)

H. You meet ONE of the following criteria for weight loss:
   1. 10% unintentional weight loss over 12 months
   2. 7.5% unintentional weight loss over 6 months
   3. 5% body cell mass (BCM) loss within 6 months
   4. BCM less than 35% (men) and a body mass index (BMI) less than 27 kg per meter squared
   5. BCM less than 23% (women) of total body weight and a body mass index (BMI) less than 27 kg per meter squared
   6. BMI less than 18.5 kg per meter squared

I. If you are hypogonadal (you have low testosterone levels), approval also requires:
   1. You meet one of the following criteria for low testosterone:
      a. Total serum testosterone level of less than 300ng/dL (10.4nmol/L)
      b. A low total serum testosterone level as indicated by a lab result, with a reference range, obtained within 90 days
      c. A free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   2. You have tried testosterone therapy (examples include testosterone cypionate, AndroGel, Androderm, Axiron, Delatestryl, Fortesta, Striant, Testim, Testopel, Vogelxo, Natesto)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Has the patient received more than 24 weeks of therapy within the plan year?

   If yes, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Is the request for a patient with HIV wasting/cachexia who meets ALL of the following criteria?
   - The requested agent is NOT prescribed for athletic enhancement or anti-aging purposes
   - The patient has shown clinical benefit in muscle mass and weight as indicated by a 10% or greater increase in weight or BCM from baseline (**Note:** Current and baseline weight must be documented including dates of measurement)
   - The patient is on HIV anti-retroviral therapy

   If yes, **approve for 12 weeks by GPID or GPI-14 for all strengths.**
   If no, do not approve.
   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **SOMATROPIN (Serostim)** requires the following rule(s) be met for renewal:
   A. You have HIV (human immunodeficiency virus) wasting/cachexia (severe muscle and weight loss)
   B. You have NOT received more than 24 weeks of therapy within the plan year
   C. The requested agent is NOT prescribed for athletic enhancement or anti-aging purposes
   D. You have shown clinical benefit in muscle mass and weight as indicated by at least a 10 percent increase in weight or BCM (body cell mass) from baseline (**Note:** current and baseline weight must be documented including dates of measurement)
   E. You are on HIV anti-retroviral therapy

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
SOMATROPIN - SEROSTIM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Serostim.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 10/22
Client Approval: 11/22
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for treatment of ANY of the following?
   • Athletic enhancement
   • Anti-aging purposes
   • Idiopathic short stature

   If yes, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.
   If no, continue to #2.

2. Does the patient have ONE of the following diagnoses and meet the associated criteria?

   **For pediatric growth hormone deficiency (GHD) approval requires ALL of the following:**
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient had a trial of or contraindication to the preferred agent: Norditropin
   • The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   • The patient meets at least ONE of the following criteria for short stature:
     o The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender
     o Height velocity is less than the 25th percentile for age
     o Documented low peak growth hormone (less than 10ng/mL) on two GH stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 SD below the mean for age and gender

   **For short stature associated with Turner syndrome, approval requires ALL of the following:**
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient had a trial of or contraindication to the preferred agent: Norditropin
   • The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   • The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

   **For short stature in children born small for gestational age (SGA), approval requires ALL of the following:**
   • Therapy is prescribed by or in consultation with an endocrinologist
   • The patient had a trial of or contraindication to the preferred agent: Norditropin
   • The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
   • Patient with no catch-up growth by age 2 to 4 years
   • The patient's height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

   (Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

For short stature or growth failure in children with SHOX deficiency, approval requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient’s epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- The patient’s height is greater than or equal to 2 standard deviations (SD) below the mean height for normal children of the same age and gender

For adult growth hormone deficiency, approval requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient had a trial of or contraindication to the preferred agent: Norditropin
- The patient has growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases, hypothalamic disease, surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

If yes, approve for 12 months by GPID or GPI-14 for all strengths.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SOMATROPIN (Zomacton)** requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature in children born small for gestational age (SGA)
   4. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of **ANY** of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

*(Initial denial text continued on next page)*
INITIAL CRITERIA (CONTINUED)

B. **If you have pediatric growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below mean for your age and gender

C. **If you have short stature associated with Turner syndrome, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. **If you are a child with short stature born small for gestational age, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You had no catch-up growth by age 2 to 4 years
   5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. **If you have short stature or growth failure in children with SHOX deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

F. **If you have adult growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease, surgery (disease of a small area of the brain important for hormone production and body processes), radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the request for treatment of **ANY** of the following?
   - Athletic enhancement
   - Anti-aging purposes
   - Idiopathic short stature

   If yes, do not approve.

   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, continue to #2.

2. Does the patient have **ONE** of the following diagnoses and meet the associated criteria?
   **For pediatric growth hormone deficiency (GHD), renewal requires ALL of the following:**
   - Therapy is prescribed by or in consultation with an endocrinologist
   - The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand or the patient has not completed prepubertal growth)
   - The patient meets ONE of the following:
     - Annual growth velocity of 2 cm or more compared with what was observed from the previous year
     - Annual growth velocity of 1 cm or more compared with what was observed from the previous year in patients who are near the terminal phase of puberty

   *(Renewal criteria continued on next page)*

   **CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

For short stature associated with Turner syndrome, renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For short stature in children born small for gestational age (SGA), renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For short stature or growth failure in children with SHOX deficiency, renewal requires ALL of the following:
- Therapy is prescribed by or in consultation with an endocrinologist
- The patient's epiphyses are NOT closed (as confirmed by radiograph of the wrist and hand)
- Growth velocity of 2 cm or more compared with what was observed from the previous year or patient has not reached 50th percentile for patient's predicted adult height

For adult growth hormone deficiency, renewal requires:
- Therapy is prescribed by or in consultation with an endocrinologist

If yes, approve for 12 months by GPI-14 for all strengths.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Zomacton) requires the following rule(s) be met for renewal:
A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature in children born small for gestational age (SGA)
   4. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   5. Adult growth hormone deficiency

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement   
   2. Anti-aging purposes    
   3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

D. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have short stature or growth failure in children with SHOX deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOMATROPIN - ZOMACTON

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zomacton

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 10/22
Client Approval: 10/22
P&T Approval: 04/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a patient with a diagnosis of short bowel syndrome who meets ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
   - The patient is currently on specialized nutritional support (such as high carbohydrate, low-fat diet, adjusted for individual requirements and preferences)

   If yes, approve for 4 weeks by GPID or GPI-14 for #1 vial per day (max dose not to exceed 8mg per day).

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOMATROPIN (Zorbtive) requires the following rule(s) be met for approval:
A. You have short bowel syndrome (the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. Therapy is prescribed by or in consultation with a gastroenterologist (digestive system doctor)
C. The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
D. You are currently on specialized nutritional support such as high carbohydrate, low-fat diet, adjusted for individual requirements and preferences

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of short bowel syndrome?

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient been on the medication for 4 weeks?

   If yes, do not approve. [**Note:** The patient should only be approved for one 4 weeks fill in a lifetime.]
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

   If no, **approve by GPID or GPI-14 for the remainder of therapy with a maximum of 4 weeks of therapy.** (Please subtract any previous fills; maximum cumulative approval is for 4 weeks.).

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SOMATROPIN (Zorbtive)** requires the following rule(s) be met for renewal:

A. You have short bowel syndrome (the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. You have not been on the requested medication for 4 weeks

Your doctor told us [**INSERT PT SPECIFIC INFO PROVIDED**]. We do not have information showing you [**INSERT UNMET CRITERIA**]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
SOMATROPIN - ZORBTIVE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zorbtive.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 10/22
Client Approval: 10/22
P&T Approval: 04/21
SONIDEGIB

Generic | Brand | HICL | GCN | Medi-Span | Exception/Other
---|---|---|---|---|---
SONIDEGIB PHOSPHATE | ODOMZO | 42369 | | GPI-10 (2137006020) | |

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of locally advanced basal cell carcinoma (BCC) and meet the following criteria?
   - The patient is 18 years of age or older
   - This is a recurrence of BCC after the patient has already had surgery or radiation therapy or the patient is not a candidate for surgery or radiation therapy

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at end of the guideline.

2. Has the patient obtained the following tests prior to initiating therapy?
   - Baseline serum creatinine kinase (CK) level
   - Baseline serum creatinine
   - Pregnancy status of females of reproductive potential

   If yes, **approve for 12 months by HICL or GPI 10 with a quantity limit of #1 per day.**
   If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **SONIDEGIB (Odomzo)** requires the following rule(s) be met for approval:
A. You have locally advanced basal cell carcinoma (BCC: type of skin cancer).
B. You are 18 years of age or older
C. This is a recurrence (disease returns) of basal cell carcinoma after surgery or radiation therapy OR you are not a candidate for surgery or radiation therapy
D. Baseline serum creatine kinase (CK: type of lab test) and serum creatinine levels have been obtained before starting therapy
E. If you are a female of reproductive potential, you must verify your pregnancy status before starting therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
SONIDEGIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Odomzo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/22
Created: 10/15
Client Approval: 12/21
P&T Approval: 01/22

Commercial Effective: 01/01/22
Client Approval: 12/21
P&T Approval: 01/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC)?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of unresectable hepatocellular carcinoma?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, continue to #3.

3. Does the patient have a diagnosis of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment?

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named SORAFENIB (Nexavar) requires the following rule(s) be met for approval:
   A. You have ONE of the following diagnoses:
      1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
      2. Unresectable hepatocellular carcinoma (liver cancer that cannot be removed with surgery)
      3. Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment (thyroid cancer that has returned or spread, is getting worse and is not responding to a type of treatment)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
SORAFENIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Review for Nexavar.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A       Created: 05/11
Commercial Effective: 07/18/22  Client Approval: 06/22       P&T Approval: 02/14
GUIDELINES FOR USE

1. Does the patient have a diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a KRAS G12C-mutation, as determined by an FDA-approved test
   - The patient has received at least one prior systemic therapy

If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   - 120mg: #8 per day.
   - 320mg: #3 per day.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SOTORASIB (Lumakras) requires the following rule(s) be met for approval:
A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has grown outside the organ it started in but has not spread to other parts of the body or lung cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. You have a KRAS G12C-mutation (type of gene mutation), as determined by a Food and Drug Administration (FDA)-approved test
D. You have received at least one prior systemic therapy (treatment that spreads throughout the body through the bloodstream)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
SOTORASIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lumakras.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/17/23
Created: 07/21
Client Approval: 03/23
P&T Approval: 07/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet **ALL** of the following criteria?
   2. The patient is 18 years of age or older
   3. Therapy is prescribed by or in consultation with a nephrologist
   4. The patient’s diagnosis is confirmed by a biopsy
   5. The patient is at risk of rapid disease progression (e.g., urine protein-to-creatinine ratio [UPCR] 1.5 g/g or greater)
   6. The patient has proteinuria of at least 1 g/day
   7. The patient has an eGFR of at least 30 mL/min/1.73 m(2)
   8. The patient had a trial of or contraindication to an ACE inhibitor (e.g., lisinopril, enalapril) or an ARB (e.g., losartan, valsartan) for at least 12 weeks
   9. Filspari will NOT be used concurrently with an ACE inhibitor (e.g., lisinopril, enalapril), an ARB (e.g., losartan, valsartan), an endothelin receptor antagonist (e.g., ambrisentan, bosentan), or aliskiren

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for approval:
A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
D. Your diagnosis is confirmed by a biopsy (removal of cells or tissue for examination)
E. You are at risk of rapid disease progression (such as urine protein-to-creatinine-ratio [UPCR: test that measures the amount of protein in urine] of 1.5 g/g or greater)
F. You have proteinuria (increased levels of protein in the urine) of at least 1 g/day
G. You have an eGFR (a tool for evaluating kidney function) of at least 30 mL/min/1.73 m(2)

*Initial denial text continued on next page*
SPARSENTAN

INITIAL CRITERIA (CONTINUED)

H. You had a trial of or contraindication (harmful for) to an angiotensin converting enzyme inhibitor (ACE-I: such as lisinopril, enalapril) or an angiotensin receptor blocker (ARB: such as losartan, valsartan) for at least 12 weeks

I. Filspari will NOT be used concurrently (at the same time) with ACE-I (such as lisinopril, enalapril), an ARB (such as losartan, valsartan), an endothelin receptor antagonist (such as ambrisentan, bosentan), or aliskiren

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of primary immunoglobulin A nephropathy (IgAN) and meet ONE of the following criteria?
   • The patient has had a reduction in proteinuria
   • The patient has improved, or stable kidney function compared to baseline

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

2. Will Filspari be used concurrently with an ACE inhibitor (e.g., lisinopril, enalapril), an ARB (e.g., losartan, valsartan), an endothelin receptor antagonist (e.g., ambrisentan, bosentan), or aliskiren?

   If yes, do not approve.
   DENIAL TEXT: See the renewal denial text at the end of the guideline.

   If no, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SPARSENTAN (Filspari) requires the following rule(s) be met for renewal:
A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You meet ONE of the following:
   1. You had a reduction in proteinuria (increased levels of protein in the urine)
   2. You have improvement or stable kidney function compared to baseline
C. Filspari will NOT be used concurrently (at the same time) with angiotensin converting enzyme inhibitor (ACE-I: such as lisinopril, enalapril), an angiotensin receptor blocker (ARB: such as losartan, valsartan), an endothelin receptor antagonist (such as ambrisentan, bosentan), or aliskiren

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Filspari.

REFERENCES
## STATIN ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROsvustatin Calcium</td>
<td>CRESTOR, EZALKOR, SPRINKLE, ROsvustatin Calcium</td>
<td>19153</td>
<td>20229, 39996, 38314</td>
<td>GPI-14</td>
<td>(39400060100305) (39400060100310) (39400060106805) (39400060106810)</td>
</tr>
<tr>
<td>Pravastatin SODIUM</td>
<td>PRAVACHOL, PRavastatin SODIUM</td>
<td>06227</td>
<td></td>
<td>GPI-10</td>
<td>(3940006510)</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>ZOCOR, SIMVASTATIN</td>
<td>26531</td>
<td>26532, 26533, 26534</td>
<td>GPI-14</td>
<td>(39400075000310) (39400075000320) (39400075000330) (39400075000340)</td>
</tr>
<tr>
<td>Atorvastatin Calcium</td>
<td>LIPITOR, ATORVASTATIN CALCIUM</td>
<td>43720</td>
<td>43721</td>
<td>GPI-14</td>
<td>(39400010100310) (39400010100320)</td>
</tr>
<tr>
<td>Lovastatin, Lovastatin Extended Release</td>
<td>ALTOPREV, LOvastatin</td>
<td>02793</td>
<td></td>
<td>GPI-10</td>
<td>(3940005000)</td>
</tr>
<tr>
<td>FLUvastatin SODIUM, FLUvastatin Extended Release</td>
<td>LESCOL, FLUvastatin SODIUM, LESCOL XL, FLUvastatin Extended Release</td>
<td>08946</td>
<td></td>
<td>GPI-10</td>
<td>(3940003010)</td>
</tr>
<tr>
<td>Pitavastatin Calcium</td>
<td>LIVALO, PITAVASTATIN CALCIUM</td>
<td>36983</td>
<td></td>
<td>GPI-10</td>
<td>(3940005810)</td>
</tr>
<tr>
<td>Pitavastatin Magnesium</td>
<td>ZYPITAMAG, PITAVASTATIN MAGNESIUM</td>
<td>44422</td>
<td></td>
<td>GPI-10</td>
<td>(3940005830)</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

1. Is the patient requesting a cost share exception for the requested low to moderate-intensity statin **AND** does the plan cover these agents at zero cost share (i.e., the plan follows Affordable Care Act [ACA] recommendations and is linked to MedImpact's Essential Health Benefit Tables)?

   If yes, continue to #2.
   If no, guideline does not apply.

   **CONTINUED ON NEXT PAGE**
2. Does the patient's plan have specific procedures, instructions, and/or policies for cost share exception processes or for multi-source brand agent overrides (DAW1 override)?
   
   If yes, guideline does not apply.
   If no, continue to #3.

3. Is the patient between 40-75 years of age without a history of cardiovascular disease and has NOT used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on the patient’s prescription claims profile or medical records?
   • Aspirin/dipyridamole (Aggrenox)
   • Clopidogrel (Plavix)
   • Dipyridamole
   • Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   • Prasugrel (Effient)
   • Praluent Pen
   • Repatha
   • Ticagrelor (Brilinta)
   • Ticlopidine
   • Vorapaxar sulfate (Zontivity)
   
   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Is the request for a generic agent?
   
   If yes, continue to #7.
   If no, continue to #5.

5. Is the request for ONE of the following?
   • A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   • A multi-source brand (MSB) agent
   
   If yes, continue to #6.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
STATIN ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE (CONTINUED)

6. Does the patient meet ONE of the following criteria?
   • Two preferred medications are medically inappropriate for the patient (alternatively, one if only one agent is available)
   • The patient has tried or has a documented medical contraindication to TWO preferred medications (alternatively, one if only one agent is available)
   • The prescriber provided documentation confirming that the requested drug is considered medically necessary (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

   If yes, continue to #7.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

7. Approve the requested agent for 12 months by GPID or GPI-14 at zero copay with the following quantity limits:
   • Atorvastatin (Lipitor): #1 per day.
   • Fluvastatin (Lescol): #2 per day.
   • Fluvastatin ER (Lescol XL): #1 per day.
   • Lovastatin: #2 per day.
   • Lovastatin ER (Altoprev): no quantity limit.
   • Pitavastatin calcium (Livalo): #1 per day.
   • Pitavastatin magnesium (Zypitamag): #1 per day.
   • Pravastatin (Pravachol): #1 per day.
   • Rosuvastatin (Crestor, Ezallor Sprinkle): #1 per day.
   • Simvastatin (Zocor): #1 per day.

   **APPROVAL TEXT (applicable to multi-source brand agents only):** Although your cost share has been reduced to zero-dollar, you may incur a dispense-as-written (DAW) penalty fee if you choose to fill a brand prescription instead of its generic equivalent.

   **CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **STATIN ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

A. The request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. You are between 40 to 75 years of age without a history of cardiovascular disease (heart disease)

C. You have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:
   1. Aspirin/dipyridamole (Aggrenox)
   2. Clopidogrel (Plavix)
   3. Dipyridamole
   4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   5. Prasugrel (Effient)
   6. Praluent Pen
   7. Repatha
   8. Repatha (Brilinta)
   9. Ticagrelor (Brilinta)
   10. Ticlopidine
   11. Vorapaxar sulfate (Zontivity)

D. **If the request is for a single-source brand or multi-source brand agent, approval also requires** ONE of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (or a trial of one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you, (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
RATIONALE
This guideline applies to plans where the pharmacy benefit allows for coverage of low-to-moderate intensity statins at zero copay. The override criteria allow patient access to all FDA-approved statins at zero copay by waiving the applicable cost-sharing for branded or non-preferred branded statins.

In November 2016, the US Preventive Services Task Force (USPSTF) issued its final recommendations on statin use for the primary prevention of cardiovascular disease (CVD) in adults. CVD is a broad term that includes a number of conditions such as coronary heart disease and cerebrovascular disease, which ultimately manifest as heart attack and stroke, respectively. CVD is the leading cause of morbidity and mortality in the US, accounting for one out of every three deaths among adults.

Based on the well-established benefit of statin therapy in reducing the risk of CVD events and mortality, the USPSTF now recommends that adults without a history of CVD use a low- to moderate-dose statin for the primary prevention of CVD events and mortality when all of the following criteria are met (Grade B recommendation):
(1) Age 40 to 75 years
(2) One or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking)
(3) Calculated 10-year risk of a cardiovascular event of 10% or greater

Under the Affordable Care Act (ACA), plans are required to cover USPSTF preventive recommendations that have an A or B rating.

In light of USPSTF recommendations, MedImpact has created an edit to allow for a zero copay to be approved for all low- to moderate-intensity statins for qualifying members. This edit is not applicable to Medicare Part D formularies.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part D Effective: N/A</th>
<th>Created: 12/17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Effective: 07/01/22</td>
<td>Client Approval: 05/22</td>
</tr>
<tr>
<td></td>
<td>P&amp;T Approval: 04/22</td>
</tr>
</tbody>
</table>

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome and meet ALL of the following criteria?
   - The patient is 6 months of age or older AND weighs 7kg or more
   - Therapy is prescribed by or in consultation with a neurologist
   - The patient is currently being treated with clobazam
   - The patient had a trial of or contraindication to TWO of the following: valproic acid derivatives, clobazam, topiramate

If yes, approve for 12 months by GPID or GPI-14 for the requested drug with the following quantity limits:
- 250mg capsule: #12 per day.
- 500mg capsule: #6 per day.
- 250mg powder packet: #12 per day.
- 500mg powder packet: #6 per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named STIRIPENTOL (Diacomit) requires the following rule(s) be met for approval:
A. You have seizures associated with Dravet syndrome (a rare type of seizure)
B. You are 6 months of age or older AND weighs 7kg or more
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
D. You are currently being treated with clobazam (a type of seizure drug)
E. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivatives, clobazam, topiramate

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
STIRIPENTOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of seizures associated with Dravet syndrome AND meet the following criterion?
   • The patient is currently being treated with clobazam

   If yes, approve for 12 months by GPID or GPI-14 for the requested drug with the following quantity limits:
   • 250mg capsule: #12 per day.
   • 500mg capsule: #6 per day.
   • 250mg powder packet: #12 per day.
   • 500mg powder packet: #6 per day.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named STIRIPENTOL (Diacomit) requires the following rule(s) be met for renewal:
A. You have seizures associated with Dravet syndrome (a rare type of seizure)
B. You are currently being treated with clobazam (type of seizure drug)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Diacomit.

REFERENCES

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced renal cell carcinoma (RCC) AND meet the following criterion?
   - The patient is 18 years of age or older
     
     If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
     If no, continue to #2.

2. Does the patient have a diagnosis of gastrointestinal stromal tumor (GIST) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to imatinib mesylate (Gleevec)
     
     If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
     If no, continue to #3.

3. Does the patient have a diagnosis of unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's tumor is progressive and well-differentiated
     
     If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
     If no, continue to #4.

4. Is the request for adjuvant treatment of renal cell carcinoma and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy
     
     If yes, approve for 12 months by HICL or GPI-10, with a quantity limit of #1 per day.
     If no, do not approve.

DENIAL TEXT:  See denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named SUNITINIB (Sutent) requires the following rule(s) be met for approval:

A. The requested medication is being used for ONE of the following:
   1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   2. Gastrointestinal stromal tumor (GIST: type of growth in the digestive system)
   3. Unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET: type of pancreas cancer)

B. If you have advanced renal cell carcinoma (RCC), approval also requires:
   1. You are 18 years of age or older

C. If you have gastrointestinal stromal tumor (GIST), approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of imatinib mesylate (Gleevec), unless there is a medical reason why you cannot (contraindication)

D. If you have unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET), approval also requires:
   1. You are 18 years of age or older
   2. Your tumor is progressive (getting worse) and well-differentiated

E. If the request is for adjuvant treatment of renal cell carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You are at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of kidney)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sutent.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/11
Commercial Effective: 09/06/21  Client Approval: 08/21  P&T Approval: 01/18

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Benign Prostatic Hyperplasia (BPH)?
   
   If yes, continue to #2.
   If no, continue to #3.

2. Has the patient tried or had a contraindication to at least TWO preferred formulary agents, including ONE agent from EACH of the following classes?
   - 5-alpha-reductase inhibitors: (e.g., finasteride or dutasteride)
   - Alpha blockers: (e.g., doxazosin, terazosin, tamsulosin, or alfuzosin)

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - Cialis 2.5mg OR 5mg: #30 per 30 days.

   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of erectile dysfunction?

   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

4. Is erectile dysfunction a covered benefit?

   If yes, continue to #5.
   If no, guideline does not apply.

5. Has the patient tried generic sildenafil (Viagra)?

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength as follows:
   - Cialis 2.5mg OR 5mg: #30 per 30 days.

   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named TADALAFIL (Cialis) requires the following rule(s) be met for approval:
A. You have benign prostatic hyperplasia (BPH: your prostate is too big causing difficulty urinating) OR erectile dysfunction (difficulty getting/keeping an erection)
B. If you have benign prostatic hyperplasia (BPH), approval also requires:
   1. You previously tried at least two preferred formulary alternatives, including one medication from each of the following classes:
      a. 5-alpha-reductase inhibitors: (such as finasteride or dutasteride)
      b. Alpha blockers: (such as doxazosin, terazosin, tamsulosin, or alfuzosin)
C. If you have erectile dysfunction, approval also requires:
   1. You have previously tried generic sildenafil (Viagra)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Cialis.

REFERENCES
TADALAFIL-ADCIRCA, ALYQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TADALAFIL</td>
<td>ADCIRCA, ALYQ,</td>
<td>26587</td>
<td>GPI-14</td>
<td>(40143080000320)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TADALAFIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])

If yes, continue to #2.
If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #2 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TADALAFIL-ADCIRCA, ALYQ (Adcirca/Alyq) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

(Initial denial text continued on the next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

D. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

E. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL the following criteria?
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   - The patient has shown improvement from baseline in the 6-minute walk distance test OR remains stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, approve for 12 months by G PID or GPI-14 with a quantity limit of #2 per day. If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TADALAFIL-ADCIRCA, ALYQ (Adcirca/Alyq) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
D. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Adcirca/Alyq.

REFERENCES
- Adcirca [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company; September 2020.
TADALAFIL-TADLIQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TADALAFIL</td>
<td>TADLIQ</td>
<td>52585</td>
<td>14</td>
<td>GPID-14 (40143080001820)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   - The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   - The patient is unable to swallow tadalafil tablets

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #10mL per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TADALAFIL-TADLIQ (Tadliq) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

(Initial denial text continued on the next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

D. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

E. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

F. You are unable to swallow tadalafil tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (WHO Group 1) and meet ALL the following criteria?
   • The patient is NOT concurrently or intermittently taking oral erectile dysfunction agents (e.g., Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   • The patient is NOT concurrently taking guanylate cyclase stimulators (e.g., Adempas [riociguat])
   • The patient has shown improvement from baseline in the 6-minute walk distance test OR remains stable from baseline in the 6-minute walk distance test with a stable or improved WHO functional class

If yes, approve for 12 months by GPI or GPI-14 with a quantity limit of #10mL per day. If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TADALAFIL-TADLIQ (Tadliq) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)

B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

D. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tadliq.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a documented diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) as confirmed by ONE of the following?
   - Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mTcPYP/DPD *(Note: Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system)*
   - Biopsy of tissue of affected organ(s) (cardiac and possibly non-cardiac sites) to confirm amyloid presence AND chemical typing to confirm presence of transthyretin (TTR) protein

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with a cardiologist, transthyretin amyloidosis (ATTR) specialist, or medical geneticist
   - The patient has New York Heart Association (NYHA) class I, II, or III heart failure

   If yes, approve for 12 months for both of the following drugs:
   - Vyndaqel (tafamidis meglumine): Approve by HICL or GPI-10 with a quantity limit of #4 per day.
   - Vyndamax (tafamidis): Approve by HICL or GPI-10 with a quantity limit of #1 per day.
   **APPROVAL TEXT:** Renewal requires that the patient has not progressed to New York Heart Association (NYHA) Class IV heart failure.

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TAFAMIDIS (Vyndaqel, Vyndamax) requires the following rule(s) be met for approval:
A. You have cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein) which is confirmed by ONE of the following:
   1. Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mTcPYP/DPD (a type of test that shows your heart absorbs a chemical for imaging) (Note: Strongly positive defined as heart to contralateral lung [H/Cl] ratio of at least 1.5 or grade 2 or greater localization to the heart using the Perugini grade 1-3 scoring system
   2. Biopsy of tissue of affected organ(s) (can be heart or non-heart related organs) to confirm amyloid (type of protein) presence AND chemical typing to confirm presence of transthyretin (TTR) protein
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a cardiologist (heart doctor), transthyretin amyloidosis (ATTR) specialist, or medical geneticist
D. You have New York Heart Association (NYHA) class I, II or III heart failure (classification of heart failure symptoms)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) AND meet the following criterion?
   • The patient has not progressed to New York Heart Association (NYHA) Class IV heart failure

   If yes, approve for 12 months for both of the following drugs:
   • Vyndaqel (tafamidis meglumine): Approve by HICL or GPI-10 with a quantity limit of #4 per day.
   • Vyndamax (tafamidis): Approve by HICL or GPI-10 with a quantity limit of #1 per day.

   If no, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TAFAMIDIS (Vyndaqel, Vyndamax) requires the following rule(s) be met for renewal:

A. You have cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)
B. You have not progressed to (gotten worse to) New York Heart Association (NYHA) Class IV heart failure (classification of heart failure symptoms)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vyndaqel and Vyndamax.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutation (gBRCAm) as confirmed by a FDA-approved test
   • The patient has been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet ONE of the following criteria?
   • The patient does NOT have hormone receptor (HR)-positive breast cancer
   • The patient has hormone receptor (HR)-positive breast cancer AND has received prior treatment with endocrine therapy or be considered inappropriate for endocrine therapy

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Talzenna will be used in combination with Xtandi (enzalutamide)

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUE ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

4. Does the patient meet **ONE** of the following criteria?
   - The patient had a bilateral orchiectomy
   - The patient has a castrate level of testosterone (i.e., less than 50 ng/dL)
   - Talzenna will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (e.g., Lupron-Depot [leuprolide], Zoladex [goserelin], Supprelin [histrelin], Firmagon [degarelix])

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **TALAZOPARIB (TALZENNA)** requires the following rule(s) be met for approval:
A. You have **ONE** of the following diagnoses:
   1. Human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer (cancer that does not have a type of protein and has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)
   2. HRR gene-mutated (abnormal change in the homologous recombination repair gene) metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
B. You are 18 years of age or older
C. **If you have breast cancer, approval also requires:**
   1. You have a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutation (gBRCAm: a type of gene mutation [abnormal change]) as confirmed by a Food and Drug Administration-approved test
   2. You have been treated with chemotherapy in the neoadjuvant (drugs used to treat cancer given before main treatment), adjuvant (add-on to main treatment), or metastatic setting (treating disease that has spread)
   3. If you have hormone receptor (HR)-positive breast cancer, you had additional treatment with endocrine (hormone) therapy or are considered inappropriate for endocrine therapy

*Denial text continued on next page*
GUIDELINES FOR USE (CONTINUED)

D. If you have prostate cancer, approval also requires:
   1. Talzenna will be used in combination with Xtandi (enzalutamide)
   2. You meet ONE of the following:
      a. You had a bilateral orchiectomy (both testicles have been surgically removed)
      b. You have a castrate level of testosterone (your blood testosterone levels are less
         than 50 ng/dL)
      c. Talzenna will be used together with a gonadotropin-releasing hormone (GnRH)
         analog (such as Lupron-Depot [leuprolide], Zoladex [goserelin], Supprelin [histrelin],
         Firmagon [degarelix])

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work
with your doctor to use a different medication or get us more information if it will allow us to
approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for
Talzenna.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A          Created: 02/19
Commercial Effective: 08/01/23  Client Approval: 06/23
                                   P&T Approval: 07/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of plaque psoriasis and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient has psoriasis covering 3% to 20% of body surface area (BSA) (excluding scalp, palms, fingernails, toenails, and soles)
   - The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See initial denial text at the end of the guideline.

2. Has the patient had a trial of or contraindication to TWO of the following (from different categories)?
   - High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
   - Topical vitamin D analog (e.g., calcipotriene cream, calcitriol ointment)
   - Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
   - Topical retinoid (e.g., tazarotene cream/gel)
   - Anthralin

   If yes, approve for 3 months by HICL or GPI-10.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TAPINAROF (Vtama) requires the following rule(s) be met for approval:
   A. You have plaque psoriasis (a type of skin condition)
   B. You are 18 years of age or older
   C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   D. You have psoriasis covering 3% to 20% of body surface area (BSA) (excluding scalp, palms, fingernails, toenails, and soles)

   (Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

E. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene).

F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
   2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
   3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
   4. Topical retinoid (such as tazarotene cream/gel)
   5. Anthralin

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of plaque psoriasis and meet ALL of the following criteria?
   • The patient has achieved or maintained clear or minimal disease
   • The patient is NOT concurrently using other systemic immunomodulating agents (e.g., Stelara, Otezla), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (e.g., calcitriol, tazarotene)

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TAPINAROF (Vtama) requires the following rule(s) be met for renewal:
A. You have plaque psoriasis (a type of skin condition)
B. You have achieved or maintained clear or minimal disease
C. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Vtama.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/15/22
Created: 05/22
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of non-24 hour sleep-wake disorder (N24HSWD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient is light-insensitive or has total blindness
   - The patient had a trial and failure of maximally-tolerated melatonin therapy
   - The requested medication is for the Hetlioz (tasimelteon) capsules

   If yes, **approve the capsule for a lifetime by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and meet the following criterion?
   - The patient had a trial and failure of maximally-tolerated melatonin therapy

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ONE** of the following criteria?
   - The requested medication is for the brand Hetlioz capsules AND the patient is 16 years of age or older
   - The requested medication is for the Hetlioz LQ oral suspension AND the patient is 3 years to 15 years of age

   If yes, **approve the requested medication for a lifetime by GPID or GPI-14 with the following quantity limits:**
   - Brand Hetlioz capsules: #1 per day.
   - Hetlioz LQ oral suspension: #5mL per day.

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TASIMELTEON (Hetlioz, Hetlioz LQ)** requires the following rule(s) be met for approval:

A. You have one of the following:
   1. Non-24 hour sleep-wake disorder (N24HSWD) (type of sleep disorder where your sleep time increasingly gets delayed)
   2. Nighttime sleep disturbances in Smith-Magenis syndrome (SMS) (type of genetic disorder that causes sleeping problems)

B. **If you have non-24 hour sleep-wake disorder, approval also requires:**
   1. You are 18 years of age or older
   2. You are light-insensitive or have total blindness
   3. You have previously tried and failed maximally-tolerated melatonin therapy
   4. You are requesting the capsule

C. **If you have nighttime sleep disturbances in Smith-Magenis syndrome, approval also requires:**
   1. You are requesting brand Hetlioz capsules if you are 16 years of age or older
   2. You are requesting Hetlioz LQ oral suspension if you are 3 to 15 years old
   3. You have previously tried and failed maximally-tolerated melatonin therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, refer to the Prescribing Information and/or Drug Monograph for Hetlioz.

**REFERENCES**
### GUIDELINES FOR USE

1. Does the patient have a diagnosis of onychomycosis (fungal infection) of the toenails?
   - If yes, continue to #2.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient have a diagnosis of diabetes, peripheral vascular disease (PVD), or immunosuppression?
   - If yes, continue to #4.
   - If no, continue to #3.

3. Does the patient have pain surrounding the nail or soft tissue involvement?
   - If yes, continue to #4.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

4. Has the patient previously tried or have a contraindication to oral terbinafine OR oral itraconazole AND ciclopirox topical solution?
   - If yes, continue to #5.
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

5. Are five or less toenails affected?
   - If yes, **approve for 48 weeks by HICL or GPI-10 with a quantity limit of #10mL (1 bottle) per 60 days.**
   - If no, **approve for 48 weeks by HICL or GPI-10 with a quantity limit of #10mL (1 bottle) per 30 days.**

**CONTINUED ON NEXT PAGE**
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TAVABOROLE (Kerydin) requires the following rule(s) be met for approval:
A. You have onychomycosis of the toenails (toenail fungus infection)
B. You have complicating factors such as diabetes, peripheral vascular disease (narrowed blood vessels cause low blood flow), a suppressed immune system, or pain surrounding the nail or soft tissue
C. You have previously tried the following agents, unless there is a medical reason why you cannot (contraindication):
   1. Oral terbinafine OR oral itraconazole
   2. Ciclopirox topical solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Kerydin.

REFERENCES
azzemetostat

1. Does the patient have a diagnosis of metastatic or locally advanced epithelioid sarcoma and meet **ALL** of the following criteria?
   - The patient is 16 years of age or older
   - The patient is not eligible for complete resection
   
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of relapsed or refractory follicular lymphoma **AND** meet the following criterion?
   - The patient is 18 years of age or older
   
   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient meet **ALL** of the following criteria?
   - The tumors are positive for an EZH2 mutation as detected by an FDA-approved test
   - The patient has received at least 2 prior systemic therapies
   
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**
   If no, continue to #4.

4. Does the patient have no satisfactory alternative treatment options?
   
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
DENIAL TEXT:  *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TAZEMETOSTAT (Tazverik) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic or locally advanced (cancer that has spread to other parts of the body or has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma (rare type of soft tissue cancer)
   2. Relapsed or refractory follicular lymphoma (cancer of the white blood cells that has returned or is resistant to previous treatment)

B. If you have metastatic or locally advanced epithelioid sarcoma, approval also requires:
   1. You are 16 years of age or older
   2. You are not eligible for complete resection (surgically removing all of a tissue/organ)

C. If you have relapsed or refractory follicular lymphoma, approval also requires:
   1. You are 18 years or older
   2. You meet ONE of the following:
      a. Your tumors are positive for an EZH2 (type of gene) mutation as detected by a Food and Drug Administration (FDA)-approved test AND you have received at least 2 prior systemic therapies (medication/treatment that spreads throughout your body)
      b. You have no satisfactory alternative treatment options

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tazverik.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a non-myeloid malignancy and meet ALL of the following criteria?
   • The patient is 1 month of age or older
   • Therapy is prescribed by or in consultation with a hematologist or oncologist
   • The patient is receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
   • The patient had a trial of or contraindication to the preferred agent: Nivestym

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TBO-FILGRASTIM (Granix) requires the following rule(s) be met for approval:
A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
B. You are 1 month of age or older
C. Therapy is prescribed by or in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor)
D. You are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
E. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TBO-FILGRASTIM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Granix.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 11/01/22
Created: 10/22
Client Approval: 10/22
P&T Approval: 07/21
TEDUGLUTIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEDUGLUTIDE</td>
<td>GATTEX</td>
<td>39890</td>
<td>GCN</td>
<td>GPI-10 (5253307000)</td>
<td>Exception/Other</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of short bowel syndrome (SBS) and meet ALL of the following criteria?
   - The patient is 1 year of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient is dependent on intravenous parenteral nutrition, defined as requiring parenteral nutrition at least three times per week

   If yes, approve for 6 months by HICL or GPI-10.
   If no, do not approve.

   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named TEDUGLUTIDE (Gattex) requires the following rule(s) be met for approval:
   A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
   B. You are 1 year of age or older
   C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   D. You are dependent on parenteral nutrition (administration of nutrition through a vein), defined as requiring parenteral nutrition at least three times per week

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   **CONTINUED ON NEXT PAGE**
TEDUGLUTIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of short bowel syndrome (SBS) and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient has achieved or maintained a decreased need for parenteral support compared to baseline

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TEDUGLUTIDE (Gattex) requires the following rule(s) be met for renewal:
A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
C. You have achieved or maintained a decreased need for parenteral support (administration of nutrition through a vein) compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Gattex.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of carcinoid syndrome diarrhea and meet **ALL** of the following criteria?
   - The medication will be used in combination with a somatostatin analog (e.g., octreotide)
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with an oncologist or gastroenterologist
   - Documentation that the patient has been receiving or has a contraindication to a stable dose of long-acting somatostatin analog therapy [e.g., Sandostatin LAR (octreotide), Somatuline Depot (lanreotide)] for a minimum of 3 months
   - The patient's diarrhea is inadequately controlled as defined by the presence of at least four bowel movements per day

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #3 per day.**
If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **TELOTRISTAT (Xermelo)** requires the following rule(s) be met for approval:

A. You have carcinoid syndrome diarrhea (diarrhea caused by a type of tumor affecting nerves/hormones)
B. The medication will be used in combination with a somatostatin analog such as octreotide
C. You are 18 years of age or older
D. The medication is being prescribed by or given in consultation with an oncologist (cancer/tumor doctor) or gastroenterologist (digestive system doctor)
E. There is documentation showing that you have been receiving a stable dose of long-acting somatostatin analog therapy such as Sandostatin LAR (octreotide) or Somatuline Depot (lanreotide) for a minimum of 3 months – unless there is a medical reason why you cannot (contraindication)
F. You have diarrhea that is inadequately controlled as defined by the presence of at least four bowel movements per day

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TELOTRISTAT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xermelo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 03/17
Client Approval: 04/20
P&T Approval: 04/17
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have ONE of the following diagnoses?
   - Anaplastic astrocytoma
   - Glioblastoma multiforme
   - Small cell lung cancer (SCLC)

   If yes, approve for 12 months as follows:
   - If the plan covers non-self-administered (NSA) agents, approve by HICL or GPI-10.
   - If the plan does NOT cover NSA agents, approve only Temozolomide PO for all strengths by GPID or GPI-14.

   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic melanoma AND meet the following criterion?
   - Temodar will NOT be used concurrently with an immunosuppressive therapy or a medical therapy for the treatment of melanoma

   If yes, approve for 12 months as follows:
   - If the plan covers non-self-administered (NSA) agents, approve by HICL or GPI-10.
   - If the plan does NOT cover NSA agents, approve only Temozolomide PO for all strengths by GPID or GPI-14.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TEMOZOLOMIDE (Temodar) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Anaplastic astrocytoma (type of brain tumor)
   2. Glioblastoma multiforme (type of tumor affecting brain or spine)
   4. Metastatic melanoma (type of skin cancer)

(Initial denial text continued on next page)
TEMOZOLOMIDE

INITIAL CRITERIA (CONTINUED)

B. If you have metastatic melanoma, approval also requires:
   1. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body’s immune system) or a medical therapy for the treatment of melanoma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

NOTE: For the diagnoses of Anaplastic astrocytoma, Glioblastoma multiforme, or Small cell lung cancer (SCLC), please refer to the Initial Criteria section.

1. Does the patient have a diagnosis of metastatic melanoma AND meet the following criterion?
   • Temodar will NOT be used concurrently with an immunosuppressive therapy or a medical therapy for the treatment of melanoma

If yes, approve for 12 months as follows:
   • If the plan covers non-self-administered (NSA) agents, approve by HICL or GPI-10.
   • If the plan does NOT cover NSA agents, approve only Temozolomide PO for all strengths by GPID or GPI-14.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TEMOZOLOMIDE (Temodar) requires the following rule(s) be met for renewal:
A. You have metastatic melanoma (type of skin cancer)
B. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body’s immune system) or a medical therapy for the treatment of melanoma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.
TEMOZOLOMIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Temodar.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/22
Created: 02/12
Client Approval: 05/22
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of irritable bowel syndrome with constipation (IBS-C) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of the preferred agents: lubiprostone AND Linzess

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TENAPANOR (Ibsrela) requires the following rule(s) be met for approval:
   A. You have irritable bowel syndrome with constipation (IBS-C: a type of bowel disease)
   B. You are 18 years of age or older
   C. You had a trial of the preferred agents: lubiprostone AND Linzess

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ibsrela.

REFERENCES
• Ibsrela [Prescribing Information]. Waltham, MA: Ardelyx, Inc.; April 2022.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Mesenchymal-epithelial transition (MET) exon 14 skipping alterations are present

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TEPOTINIB (Tepmetko) requires the following rule(s) be met for approval:
   A. You have metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has spread to other parts of the body)
   B. You are 18 years of age or older
   C. Mesenchymal-epithelial transition (MET) exon 14 skipping alterations (abnormal change in a gene that makes MET protein) are present

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tepmetko.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease AND meet the following criterion?
   • The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TERIFLUNOMIDE (Aubagio) requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return) and active secondary progressive disease (advanced disease)
B. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Review for Aubagio.

REFERENCES
TERIPARATIDE

1. Is the medication being used for **ONE** of the following diagnoses?
   - Postmenopausal osteoporosis
   - Primary or hypogonadal osteoporosis in a male patient
   - Glucocorticoid-induced osteoporosis

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the patient meet **ONE** of the following criteria?
   - The patient is at high risk for fractures defined as **ONE** of the following:
     - History of osteoporotic (i.e., fragility, low trauma) fracture(s)
     - 2 or more risk factors for fracture (e.g., history of multiple recent low trauma fractures, BMD T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as Synarel [nafarelin])
     - No prior treatment for osteoporosis **AND** FRAX score ≥ 20% for any major fracture **OR** ≥ 3% for hip fracture
   - The patient is unable to use oral therapy (i.e., upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine)
   - The patient had a trial of, intolerance to, or a contraindication to a bisphosphonate (e.g., Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Has the patient received a total of 24 months cumulative treatment with Forteo (teriparatide)?

   If yes, continue to #4.
   If no, **approve the requested drug up to 24 months lifetime cumulative treatment duration by GPID or GPI-14 with the following quantity limits:**
   - Forteo 600mcg/2.4mL: #2.4mL per 28 days.
   - Teriparatide 620mcg/2.48mL: #2.48mL per 28 days.

   **CONTINUED ON NEXT PAGE**
TERIPARATIDE

GUIDELINES FOR USE (CONTINUED)

4. Does the patient remain at or has returned to having a high risk for fracture?

If yes, approve the requested drug up to 12 months by GPID or GPI-14 with the following quantity limits:
- Forteo 600mcg/2.4mL: #2.4mL per 28 days.
- Teriparatide 620mcg/2.48mL: #2.48mL per 28 days.

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TERIPARATIDE (Forteo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Postmenopausal osteoporosis (a type of joint condition)
   2. Primary or hypogonadal (sex organs don’t function properly) osteoporosis in a male patient
   3. Glucocorticoid (steroid)-induced osteoporosis

B. You meet ONE of the following:
   1. You are at high risk for fractures defined as ONE of the following:
      a. History of osteoporotic (i.e., fragility, low trauma) fracture(s)
      b. Two or more risk factors for fracture (such as history of multiple recent low trauma fractures, bone marrow density (BMD) T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as Synarel [nafarelin])
      c. No prior treatment for osteoporosis AND FRAX (test for your risk of fractures) score of at least 20 percent for any major fracture OR at least 3 percent for hip fracture
   2. You are unable to use oral therapy due to reasons such as upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine
   3. You had a trial of, intolerance (side effect), or contraindication (harmful for) to a bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

C. You meet ONE of the following:
   1. You have received a total of 24 months of cumulative treatment with Forteo (teriparatide) AND remain at or have returned to having a high risk for fracture
   2. You have received less than 24 months of cumulative treatment

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TERIPARATIDE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Forteo and Teriparatide.

REFERENCE

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/03
Commercial Effective: 04/17/23  Client Approval: 03/23  P&T Approval: 01/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of HIV with lipodystrophy and meets ALL the following criteria?
   - The patient is 18 years of age or older
   - The requested medication is being used for the reduction of excess abdominal fat
   - The patient is currently receiving treatment with a protease inhibitor (PI), PI combination (i.e., saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI), OR an NRTI combination (i.e., zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)

   If yes, approve for 3 months by HICL or GPI-10 with a quantity limit of #60 vials per month.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TESAMORELIN (Egrifta, Egrifta SV) requires the following rule(s) be met for approval:
   A. You have human immunodeficiency virus (HIV: a type of immune disorder) with lipodystrophy (abnormal distribution of fat in the body)
   B. You are 18 years of age or older
   C. The requested medication is being used for the reduction of excess abdominal fat
   D. You are currently receiving treatment with a protease inhibitor (PI: a type of drug), PI combination (saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI: a type of drug), OR an NRTI combination (zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
TESAMORELIN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Egrifta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 02/11
Client Approval: 03/22
P&T Approval: 02/11
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ONE of the following criteria?
   - The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy
   - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
     - At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
     - Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

   If yes, continue to #2.
   If no, continue to #6.

2. Is the patient 40 years of age or older?

   If yes, continue to #3.
   If no, continue to #4.

3. Has the patient’s prostate specific antigen (PSA) been evaluated for prostate cancer screening?

   If yes, continue to #4.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
TESTOSTERONE

INITIAL CRITERIA (CONTINUED)

4. Is the request for AndroGel 1%, AndroGel 1.62%, Axiron, Testim, or Vogelxo?

   If yes, approve the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:
   - AndroGel (testosterone):
     - 25mg (1%) gel packet: #5 grams per day.
     - 50mg (1%) gel packet: #10 grams per day.
     - 1.25g-1.62% gel packet: #1.25 grams per day.
     - 2.5g-1.62% gel packet: #5 grams per day.
     - 20.25/1.25 gel pump: #5 grams per day.
   - Axiron (testosterone):
     - 30mg/1.5mL sol pump: #6 mL per day.
   - Testim (testosterone):
     - 50mg (1%) gel packet: #10 grams per day.
   - Vogelxo (testosterone):
     - 12.5/1.25g gel pump: #10 grams per day.
     - 50mg (1%) gel tube/packet: #10 grams per day.

   If no, continue to #5.

5. Is the request for Androderm, Fortesta, Natesto, or Striant, AND the patient meets the following criterion?

   - The patient had a trial of or contraindication to TWO lower cost testosterone agents (e.g., testosterone cypionate, intramuscular testosterone enanthate)

   If yes, approve the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:
   - Androderm (2mg/24hr, 4mg/24hr): #1 patch per day.
   - Fortesta (testosterone):
     - 10mg (2%): #4 grams per day.
   - Natesto (5.5/0.122 gel pump): #0.732 grams per day.
   - Striant (30mg): #2 per day.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) AND the patient meets the following criterion?
   • The patient is 16 years of age or older

   If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named TESTOSTERONE requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

C. If the request is for Androderm, Fortesta, Natesto or Striant, you had a trial of or contraindication (harmful for) to TWO lower cost testosterone agents (such as testosterone cypionate, intramuscular [injected into the muscle] testosterone enanthate)

D. **If you have gender dysphoria, approval also requires:**
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
   2. You are 16 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
TESTOSTERONE

RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ALL of the following criteria?
   • The patient has improved symptoms compared to baseline and tolerance to treatment
   • The patient’s serum testosterone level and hematocrit concentration have normalized compared to baseline
   • If the patient is 40 years of age or older, the patient’s prostate specific antigen (PSA) has been evaluated for prostate cancer screening

   If yes, approve the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:
   • AndroGel (testosterone):
     o 25mg (1%) gel packet: #5 grams per day.
     o 50mg (1%) gel packet: #10 grams per day.
     o 1.25g-1.62% gel packet: #1.25 grams per day.
     o 2.5g-1.62% gel packet: #5 grams per day.
     o 20.25/1.25 gel pump: #5 grams per day.
   • Axiron (testosterone):
     o 30mg/1.5mL sol pump: #6 mL per day.
   • Testim (testosterone):
     o 50mg (1%) gel packet: #10 grams per day.
   • Vogelxo (testosterone):
     o 12.5/1.25g gel pump: #10 grams per day.
     o 50mg (1%) gel tube/packet: #10 grams per day.
   • Androderm (2mg/24hr, 4mg/24hr): #1 patch per day.
   • Fortesta (testosterone):
     o 10mg (2%): #4 grams per day.
   • Natesto (5.5/0.122 gel pump): #0.732 grams per day.
   • Striant (30mg): #2 per day.

   If no, continue to #2.

2. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

   If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TESTOSTERONE requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)
B. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
C. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for the related testosterone formulation.

REFERENCES
- Axiron [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.; July 2017.

CONTINUED ON NEXT PAGE
<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/01
Commercial Effective: 08/28/23  Client Approval: 08/23  P&T Approval: 07/22
TESTOSTERONE CYCIONATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE</td>
<td>DEPO-TESTOSTERONE, TESTOSTERONE</td>
<td>01400</td>
<td>GPI-10</td>
<td>(2310003010)</td>
<td>NDC ≠ 76420065001</td>
</tr>
<tr>
<td>CYCIONATE</td>
<td>CYCIONATE</td>
<td></td>
<td></td>
<td></td>
<td>FDB: ROUTE ≠ MISCELL.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MEDISPAN: ROUTE ≠ DOES NOT APPLY.</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ONE of the following criteria?
   The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy
   - The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
     o At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
     o Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

   If yes, continue to #2.
   If no, continue to #4.

2. Is the patient 40 years of age or older?

   If yes, continue to #3.
   If no, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   - 100 mg/mL, 200 mg/mL (10 mL vial): up to #10 mL per 28 days.
   - 200 mg/mL (1 mL vial): up to #10 mL per 30 days.

3. Has the patient’s prostate specific antigen (PSA) been evaluated for prostate cancer screening?

   If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
   - 100 mg/mL, 200 mg/mL (10 mL vial): up to #10 mL per 28 days.
   - 200 mg/mL (1 mL vial): up to #10 mL per 30 days.

   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb) AND the patient meets the following criterion?
   - The patient is 16 years of age or older

   If yes, approve for 12 months by GPID or GPI-14 and override quantity limits.
   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TESTOSTERONE CYPIONATE (Depo-Testosterone) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, approval also requires:
   1. You are 16 years of age or older
   2. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ALL of the following criteria?

- The patient has improved symptoms compared to baseline and tolerance to treatment
- The patient's serum testosterone level and hematocrit concentration have normalized compared to baseline
- If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:

- 100 mg/mL, 200 mg/mL (10 mL vial): up to #10 mL per 28 days.
- 200 mg/mL (1 mL vial): up to #10 mL per 30 days.

If no, continue to #2.

Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIA, or IIB)?

If yes, approve for 12 months by GPID or GPI-14 and override quantity limits.
If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TESTOSTERONE CYPIONATE (Depo-Testosterone) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIA, or IIB) for treatment of gender dysphoria may be approved

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE
C. If you are a male patient with primary or secondary hypogonadism, renewal also requires:

1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Depo-Testosterone.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/23
Commercial Effective: 08/28/23 Client Approval: 08/23 P&T Approval: 07/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ONE of the following criteria?
   • The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy
   • The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
     o At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
     o Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

   If yes, continue to #2.
   If no, continue to #6.

2. Is the patient 40 years of age or older?
   If yes, continue to #3.
   If no, continue to #4.

3. Has the patient's prostate specific antigen (PSA) been evaluated for prostate cancer screening?
   If yes, continue to #4.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

4. Is the request for generic intramuscular testosterone enanthate 200 mg/mL?
   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #5 mL per 28 days.
   If no, continue to #5.

CONTINUED ON NEXT PAGE
TESTOSTERONE ENANTHATE

INITIAL CRITERIA (CONTINUED)

5. Is the request for Xyosted and the patient meets ALL of the following criteria?
   • The patient is 18 years of age or older
   • The requested medication is being used for testosterone replacement therapy

   If yes, approve all strengths for 12 months by GPID or GPI-14 with a quantity limit of #2 mL per 28 days.

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

6. Is the request for generic intramuscular testosterone enanthate 200 mg/mL and the patient meets ONE of the following criteria?
   • The patient is female with a diagnosis of metastatic breast cancer
   • The patient is male with a diagnosis of delayed puberty not secondary to a pathological disorder

   If yes, approve for lifetime by GPID or GPI-14 with a quantity limit of #5 mL per 28 days.

   If no, continue to #7.

7. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, Ila, or Iib) AND the patient meets the following criterion?
   • The patient is 16 years of age or older

   If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TESTOSTERONE ENANTHATE (Xyosted) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Gender dysphoria (you identify yourself as a member of the opposite sex)
   4. Metastatic breast cancer (cancer spreading to other areas of body) in a female

B. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   3. If the request is for Xyosted, approval also requires:
      a. You are 18 years of age or older
      b. The requested medication is being used for testosterone replacement therapy

C. If you are a female with metastatic breast cancer OR you are a male with delayed puberty not secondary to a pathological disorder, only intramuscular (injected into muscle) testosterone enanthate may be approved

D. If you have gender dysphoria, approval also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved
   2. You are 16 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ALL of the following criteria?
   • The patient has improved symptoms compared to baseline and tolerance to treatment
   • The patient’s serum testosterone level and hematocrit concentration have normalized compared to baseline
   • If the patient is 40 years of age or older, the patient’s prostate specific antigen (PSA) has been evaluated for prostate cancer screening

   If yes, approve all strengths of the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:
   • Intramuscular testosterone enanthate: #5 mL per 28 days.
   • Xyosted: #2 mL per 28 days.

   If no, continue to #2.

2. Is the request for generic intramuscular testosterone enanthate 200 mg/mL and the patient meets ONE of the following criteria?
   • The patient is male with a diagnosis of delayed puberty not secondary to a pathological disorder
   • The patient is female with a diagnosis of metastatic breast cancer

   If yes, approve by GPID or GPI-14 for lifetime with a quantity limit of #5 mL per 28 days.
   If no, continue to #3.

3. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

   If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named TESTOSTERONE ENANTHATE (Xyosted) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Metastatic breast cancer (cancer spreading to other areas of body) in a female
   4. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

C. If you are a female with metastatic breast cancer OR you are a male with delayed puberty not secondary to a pathological disorder, only intramuscular (injected into muscle) testosterone enanthate may be approved.

D. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TESTOSTERONE ENANTHATE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for the related testosterone enanthate/Xyosted.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 02/23
Client Approval: 08/23
P&T Approval: 07/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) AND the patient meets the following criterion?
   • The patient is 18 years of age or older
     
     If yes, continue to #2.
     If no, continue to #7.

2. Does the patient meet ONE of the following criteria?
   • The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy
   • The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels:
     o At least two total serum testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
     o Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

     If yes, continue to #3.
     If no, do not approve.
     **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the patient 40 years of age or older?
   
   If yes, continue to #4.
   If no, continue to #5.

4. Has the patient’s prostate specific antigen (PSA) been evaluated for prostate cancer screening?
   
   If yes, continue to #5.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
5. Is the request for Kyzatrex?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   - 100 mg: #2 per day.
   - 150 mg and 200 mg: #4 per day.

   If no, continue to #6.

6. Is the request for Jatenzo or Tlando AND the patient meets the following criterion?
   - The patient had a trial of or contraindication to TWO lower cost testosterone agents (e.g., intramuscular testosterone cypionate, intramuscular testosterone enanthate)

   If yes, approve all strengths of the requested agent for 12 months by GPID or GPI-14 with the following quantity limits:
   - Jatenzo 158 mg and 198 mg: #4 per day.
   - Jatenzo 237 mg: #2 per day.
   - Tlando 112.5 mg: #4 per day.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

7. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIA, or IIB) AND the patient meets the following criterion?
   - The patient is 16 years of age or older

   If yes, approve the requested agent for 12 months by GPID or GPI-14 and override quantity limits.

   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, approval also requires:
   1. You are 16 years of age or older
   2. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. You are 18 years of age or older
   2. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   3. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   4. If the request is for Jatenzo or Tlando, you had a trial of or contraindication to (harmful for) TWO lower cost testosterone agents (such as intramuscular testosterone cypionate, intramuscular testosterone enanthate)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENOWNAL CRITERIA

1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ALL of the following criteria?
   • The patient has improved symptoms compared to baseline and tolerance to treatment
   • The patient's serum testosterone level and hematocrit concentration have normalized compared to baseline
   • If the patient is 40 years of age or older, the patient's prostate specific antigen (PSA) has been evaluated for prostate cancer screening

   If yes, approve all strengths of the requested agent for 12 months by GIPID or GPI-14 with the following quantity limits:
   • Kyzatrex 100 mg: #2 per day.
   • Kyzatrex 150 mg and 200 mg: #4 per day.
   • Jatenzo 158 mg and 198 mg: #4 per day.
   • Jatenzo 237 mg: #2 per day.
   • Tlando 112.5 mg: #4 per day.

   If no, continue to #2.

2. Is the requested agent for gender dysphoria as supported by the compendia (e.g., DrugDex strength of recommendation Class I, IIa, or IIb)?

   If yes, approve the requested agent for 12 months by GIPID or GPI-14 and override quantity limits.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)
B. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

(Renewal denial text continued on next page)
C. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Jatenzo, Kyzatrex, and Tlando.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 02/23
Client Approval: 08/23
P&T Approval: 01/23
GUIDELINES FOR USE

1. Is the request for a tetrabenazine dosage that exceeds 50mg?
   - If yes, continue to #2.
   - If no, continue to #3.

2. Does the patient have a diagnosis of chorea (involuntary movements) associated with Huntington's disease and meets ALL of the following criteria?
   - Therapy is prescribed by or given in consultation with a neurologist
   - The patient has been genotyped for CYP2D6 and is identified as an extensive metabolizer (EM) or intermediate metabolizer (IM) of CYP2D6
   - If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
     - Xenazine 12.5mg: #3 per day
     - Xenazine 25mg: #4 per day
   - If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of chorea (involuntary movements) associated with Huntington's disease and meets ALL of the following criteria?
   - Therapy is prescribed by or given in consultation with a neurologist
   - If yes, approve for 12 months by GPID or GPI-14 with the following quantity limits:
     - Xenazine 12.5mg: #3 per day
     - Xenazine 25mg: #2 per day
   - If no, do not approve.
   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TETRABENAZINE (Xenazine)** requires the following rule(s) be met for approval:
A. You have chorea (involuntary movements) associated with Huntington's disease (type of inherited disease that causes nerve cells in brain to break down over time)
B. The medication has been prescribed or given in consultation with a neurologist (nerve doctor)
C. If your request is for a tetrabenazine dosage that exceeds 50mg, approval also requires:
   1. You have been genotyped for CYP2D6 (type of enzyme) and you are identified as an extensive (EM) or intermediate metabolizer (IM) of CYP2D6.

*(Denial text continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xenazine.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Created: 02/09
Effective: 07/01/20
Client Approval: 04/20
P&T Approval: 11/15
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of cystic fibrosis (CF) and meet ALL of the following criteria?
   • The patient is 6 years of age or older
   • Therapy is prescribed by or given in consultation with a pulmonologist or cystic fibrosis (CF) expert

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See initial denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   • Documentation that the patient is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
   • Documentation that the patient has at least ONE of the following mutations in the CFTR gene:

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>546insCTA</td>
<td></td>
<td>E92K</td>
<td>G576A</td>
<td>L346P</td>
<td>R117G</td>
</tr>
<tr>
<td>711+3A→G</td>
<td></td>
<td>E116K</td>
<td>G576A; R668C</td>
<td>L967S</td>
<td>R117H</td>
</tr>
<tr>
<td>2789+5G→A</td>
<td></td>
<td>E193K</td>
<td>G622D</td>
<td>L997F</td>
<td>R117L</td>
</tr>
<tr>
<td>3272-26A→G</td>
<td></td>
<td>E403D</td>
<td>G970D</td>
<td>L1324P</td>
<td>R117P</td>
</tr>
<tr>
<td>3849+10kbC→T</td>
<td></td>
<td>E588V</td>
<td>G1069R</td>
<td>L1335P</td>
<td>R170H</td>
</tr>
<tr>
<td>A120T</td>
<td></td>
<td>E822K</td>
<td>G1244E</td>
<td>L1480P</td>
<td>R258G</td>
</tr>
<tr>
<td>A234D</td>
<td></td>
<td>E831X</td>
<td>G1249R</td>
<td>M152V</td>
<td>R334L</td>
</tr>
<tr>
<td>A349V</td>
<td></td>
<td>F191V</td>
<td>G1349D</td>
<td>M265R</td>
<td>R334Q</td>
</tr>
<tr>
<td>A455E</td>
<td></td>
<td>F311del</td>
<td>H939R</td>
<td>M952I</td>
<td>R347H</td>
</tr>
<tr>
<td>A554E</td>
<td></td>
<td>F311L</td>
<td>H1054D</td>
<td>M952T</td>
<td>R347L</td>
</tr>
<tr>
<td>A1006E</td>
<td></td>
<td>F508C</td>
<td>H1375P</td>
<td>P5L</td>
<td>R347P</td>
</tr>
<tr>
<td>A1067T</td>
<td></td>
<td>F508C; S1251N</td>
<td>I148T</td>
<td>P67L</td>
<td>R352Q</td>
</tr>
<tr>
<td>D110E</td>
<td></td>
<td>F508del</td>
<td>I175V</td>
<td>P205S</td>
<td>R352W</td>
</tr>
<tr>
<td>D110H</td>
<td></td>
<td>F575Y</td>
<td>I336K</td>
<td>Q98R</td>
<td>R553Q</td>
</tr>
<tr>
<td>D192G</td>
<td></td>
<td>F1016S</td>
<td>I601F</td>
<td>Q237E</td>
<td>R668C</td>
</tr>
<tr>
<td>D443Y</td>
<td></td>
<td>F1052V</td>
<td>I618T</td>
<td>Q237H</td>
<td>R751L</td>
</tr>
<tr>
<td>Mutation</td>
<td>Amino Acid</td>
<td>Amino Acid</td>
<td>Amino Acid</td>
<td>Amino Acid</td>
<td>Amino Acid</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>D443Y; G576A; R668C</td>
<td>F1074L</td>
<td>I807M</td>
<td>Q359R</td>
<td>R792G</td>
<td>V1153E</td>
</tr>
<tr>
<td>D579G</td>
<td>F1099L</td>
<td>I980K</td>
<td>Q1291R</td>
<td>R933G</td>
<td>V1240G</td>
</tr>
<tr>
<td>D614G</td>
<td>G126D</td>
<td>I1027T</td>
<td>R31L</td>
<td>R1066H</td>
<td>V1293G</td>
</tr>
<tr>
<td>D836Y</td>
<td>G178E</td>
<td>I1139V</td>
<td>R74Q</td>
<td>R1070Q</td>
<td>W1282R</td>
</tr>
<tr>
<td>D924N</td>
<td>G178R</td>
<td>I1269N</td>
<td>R74W</td>
<td>R1070W</td>
<td>Y109N</td>
</tr>
<tr>
<td>D979V</td>
<td>G194R</td>
<td>I1366N</td>
<td>R74W; D1270N</td>
<td>R1162L</td>
<td>Y161S</td>
</tr>
<tr>
<td>D1152H</td>
<td>G194V</td>
<td>K1060T</td>
<td>R74W; V201M</td>
<td>R1283M</td>
<td>Y1014C</td>
</tr>
<tr>
<td>D1270N</td>
<td>G314E</td>
<td>L15P</td>
<td>R74W; V201M; D1270N</td>
<td>R1283S</td>
<td>Y1032C</td>
</tr>
<tr>
<td>E56K</td>
<td>G551D</td>
<td>L206W</td>
<td>R75Q</td>
<td>S549N</td>
<td></td>
</tr>
<tr>
<td>E60K</td>
<td>G551S</td>
<td>L320V</td>
<td>R117C</td>
<td>S549R</td>
<td></td>
</tr>
</tbody>
</table>

If yes, **approve for 24 weeks by HICL or GPI-10 with a quantity limit of #2 per day.**

**APPROVAL TEXT:** Renewal requires the patient have shown improvement in clinical status compared to baseline as shown by ONE of the following: i) patient has improved, maintained, or demonstrated less than expected decline in FEV1, ii) patient has improved, maintained, or demonstrated less than expected decline in BMI, or iii) patient has experienced a reduction in rate of pulmonary exacerbations.

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
Our guideline named **TEZACFTOR/IVACAFTOR (Symdeko)** requires the following rule(s) be met for approval:

A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)

B. You are 6 years of age or older

C. Therapy is prescribed by or given in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert

D. You have documentation that you are either homozygous (you have 2 copies of the same gene) for the F508del-CFTR (Cystic fibrosis transmembrane conductance regulator) gene mutation; **OR** you have documentation that you have at least one of the following mutations in the CFTR gene:

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td>711+3A→G</td>
<td>E116K, G576A; R668C, L967S, R117H, S737F</td>
</tr>
<tr>
<td>2789+5G→A</td>
<td>E193K, G622D, L997F, R117L, S912L</td>
</tr>
<tr>
<td>3849+10kbC→T</td>
<td>E588V, G1069R, L1335P, R170H, S977F</td>
</tr>
<tr>
<td>A120T</td>
<td>E822K, G1244E, L1480P, R258G, S1159F</td>
</tr>
<tr>
<td>A234D</td>
<td>E831X, G1249R, M152V, R334L, S1159P</td>
</tr>
<tr>
<td>A349V</td>
<td>F191V, G1349D, M265R, R334Q, S1251N</td>
</tr>
<tr>
<td>A455E</td>
<td>F311del, H939R, M952I, R347H, S1255P</td>
</tr>
<tr>
<td>A554E</td>
<td>F311L, H1054D, M952T, R347L, T338I</td>
</tr>
<tr>
<td>A1006E</td>
<td>F508C, H1375P, P5L, R347P, T1036N</td>
</tr>
<tr>
<td>A1067T</td>
<td>F508C; S1251N, I148T, P67L, R352Q, T1053I</td>
</tr>
<tr>
<td>D110E</td>
<td>F508del, I175V, P205S, R352W, V201M</td>
</tr>
<tr>
<td>D110H</td>
<td>F575Y, I336K, Q98R, R553Q, V232D</td>
</tr>
<tr>
<td>D192G</td>
<td>F1016S, I601F, Q237E, R668C, V562I</td>
</tr>
<tr>
<td>D443Y</td>
<td>F1052V, I618T, Q237H, R751L, V754M</td>
</tr>
<tr>
<td>D443Y; G576A;</td>
<td>F1074L, I807M, Q359R, R792G, V1153E</td>
</tr>
<tr>
<td>R668C</td>
<td>F1099L, I980K, Q1291R, R933G, V1240G</td>
</tr>
</tbody>
</table>

*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*
Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of cystic fibrosis (CF) and improvement in clinical status compared to baseline as shown by ONE of the following?
   - The patient has improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume)
   - The patient has improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
   - The patient has experienced a reduction in rate of pulmonary exacerbations

If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #2 per day.
If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TEZACAFTOR/IVACAFTOR (Symdeko) requires the following rule(s) be met for renewal:
A. You have cystic fibrosis (CF: inherited life-threatening disorder that damages the lungs and digestive system)
B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
   1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
   2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
   3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Symdeko.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 02/01/21
Created: 02/18
Client Approval: 01/21
P&T Approval: 01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of severe asthma and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine
   - The patient is concurrently treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [e.g., salmeterol, formoterol], long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline)
   - Tezspire will NOT be used concurrently with Xolair (omalizumab), Dupixent (dupilumab), or an anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient meet ONE of the following criteria?
   - The patient has experienced at least ONE asthma exacerbation requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months
   - The patient has experienced at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months

   If yes, continue to #4.
   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks?
   • Daytime asthma symptoms more than twice per week
   • Any night waking due to asthma
   • Use of a short-acting inhaled beta2-agonist (SABA) [e.g., albuterol] reliever for symptoms more than twice per week
   • Any activity limitation due to asthma

   If yes, continue to #4.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

4. Does the patient have severe asthma with an eosinophilic phenotype and meet ALL of the following criteria?
   • The patient has a documented blood eosinophil level of at least 150 cells/mcL within the last 12 months
   • The patient had a trial of or contraindication to TWO of the following preferred agents: Fasenra (benralizumab), Nucala (mepolizumab), Dupixent (dupilumab)

   If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1.91mL per 28 days.
   If no, continue to #5.

5. Does the patient have severe oral corticosteroid-dependent asthma AND meet the following criterion?
   • The patient had a trial of or contraindication to the following preferred agent: Dupixent (dupilumab)

   If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1.91mL per 28 days.
   If no, continue to #6.

6. Does the patient have severe allergic asthma AND meet the following criterion?
   • The patient had a trial of or contraindication to the following preferred agent: Xolair (omalizumab)

   If yes, approve for 4 months by HICL or GPI-10 with a quantity limit of #1.91mL per 28 days.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

   **CONTINUED ON NEXT PAGE**
INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TEZEPELUMAB-EKKO (Tezspire) requires the following rule(s) be met for approval:

A. You have severe asthma (a type of lung condition)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a doctor specializing in allergy or pulmonary (lung/breathing) medicine
D. You are being treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometason, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline
E. You meet ONE of the following:
   1. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      a. Daytime asthma symptoms more than twice per week
      b. Any night waking due to asthma
      c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      d. Any activity limitation due to asthma
F. You will NOT use Tezspire concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

G. If you have severe asthma with an eosinophilic phenotype (type of inflammatory asthma), approval also requires:
   1. You have a documented blood eosinophil (a type of white blood cell) level of at least 150 cells/mcL within the last 12 months
   2. You had a trial of or contraindication (harmful for) to TWO of the following: Fasenra (benralizumab), Nucala (mepolizumab), Dupixent (dupilumab)

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
**TEZEPELUMAB-EKKO**

**INITIAL CRITERIA (CONTINUED)**

H. If you have severe oral corticosteroid-dependent asthma, approval also requires:
   1. You had a trial of or contraindication (harmful for) to Dupixent (dupilumab)

I. If you have severe allergic asthma, approval also requires:
   1. You had a trial of or contraindication (harmful for) to Xolair (omalizumab)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RENEWAL CRITERIA**

1. Has the patient shown a clinical response as evidenced by ONE of the following?
   - Reduction in asthma exacerbation from baseline
   - Decreased utilization of rescue medications (e.g., albuterol)
   - Increase in percent predicted FEV1 from pretreatment baseline
   - Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)

   If yes, continue to #2.
   If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - The patient will continue to use an inhaled corticosteroid (ICS) [e.g., triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication (e.g., long-acting inhaled beta2-agonist [e.g., salmeterol, formoterol], long-acting muscarinic antagonist [e.g., aclidinium bromide, ipratropium, tiotropium, umeclidinium], a leukotriene receptor antagonist [e.g., montelukast, zafirlukast, zileuton], theophylline)
   - Tezspire will NOT be used concurrently with Xolair (omalizumab), Dupixent (dupilumab), or an anti-IL5 biologic (e.g., Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1.91mL per 28 days.

   If no, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TEZEPELUMAB-EKKO (Tezspire) requires the following rule(s) be met for renewal:
A. You have shown a clinical response as evidenced by ONE of the following:
   1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   2. Decreased use of rescue medications (such as albuterol)
   3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)
B. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as ipratropium, tiotropium), leukotriene receptor antagonist (such as montelukast,zaflrutukast), or theophylline
C. You will NOT use Tezspire concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tezspire.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 06/01/23
Created: 01/22
Client Approval: 05/23
P&T Approval: 04/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
THALIDOMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>THALIDOMIDE</td>
<td>THALOMID</td>
<td>11465</td>
<td></td>
<td>GPI-10 (9939207000)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of multiple myeloma **AND** meet the following criterion?
   - Thalomid will be used in combination with dexamethasone
     
     If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
     If no, continue to #2.

2. Does the patient have a diagnosis of erythema nodosum leprosum (ENL)?
   
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
   If no, continue to #3.

3. Does the patient have a diagnosis of anemia due to myelodysplastic syndrome **AND** meet the following criterion?
   - The patient has been previously treated for anemia due to myelodysplastic syndrome
     
     If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**
     If no, continue to #4.

4. Does the patient have a diagnosis of Waldenström's macroglobulinemia?
   
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named THALIDOMIDE (Thalomid) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Multiple myeloma (a type of blood cancer)
   2. Erythema nodosum leprosum (ENL: a type of immune condition)
   3. Anemia due to myelodysplastic syndrome (a type of blood condition due to blood cancer)
   4. Waldenström's macroglobulinemia (a type of blood cancer)

B. If you have multiple myeloma, approval also requires:
   1. Thalomid will be used in combination with dexamethasone

C. If you have anemia due to myelodysplastic syndrome, approval also requires:
   1. You have been previously treated for anemia due to myelodysplastic syndrome

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Thalomid.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of relapsed or refractory advanced renal cell carcinoma (RCC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient received two or more prior systemic therapies (e.g., Cabometyx, Keytruda, Opdivo)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #21 per 28 days.
If no, do not approve.
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TIVOZANIB (Fotivda) requires the following rule(s) be met for approval:
A. You have relapsed or refractory advanced renal cell carcinoma (type of kidney cancer that returned or no longer responds to treatment)
B. You are 18 years of age or older
C. You previously received two or more systemic therapies (such as Cabometyx, Keytruda, Opdivo)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Fotivda.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/21
Created: 05/21
Client Approval: 05/21
P&T Approval: 04/21
GUIDELINES FOR USE

1. Does the patient have a diagnosis of cystic fibrosis and meet ALL of the following criteria?
   - The patient is 6 years of age or older
   - The patient has a lung infection with a gram-negative species (such as *Pseudomonas aeruginosa*; *Staphylococcus aureus* is not a gram-negative species)

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

2. Is the request for Bethkis (tobramycin), Tobi (tobramycin) inhalation solution, or Kitabis Pak (tobramycin)?

   If yes, approve the requested agent for 12 months by GPID or GPI-14 as follows:
   - Tobi inhalation solution: #280mL (#56 of 5mL ampules) per 28 days (fill count = 6).
   - Bethkis: #224mL (#56 of 4mL ampules) per 28 days (fill count = 6).
   - Kitabis Pak: #280mL per 28 days (fill count = 6).

   If no, continue to #3.

3. Is the request for Tobi Podhaler and the patient meets ONE of the following criteria?
   - The patient had a trial and failure of or contraindication to ONE generic inhaled tobramycin product
   - The patient is not able to tolerate the prolonged administration of nebulizers

   If yes, Tobi Podhaler for 12 months by GPID or GPI-14 with a quantity limit of #224 capsules per 28 days (fill count = 6).

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **TOBRAMYCIN INHALED** (Bethkis, Tobi, Tobi Podhaler, Kitabis Pak) requires the following rule(s) be met for approval:

A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
B. You are 6 years of age or older
C. You have a lung infection with a gram-negative species (type of bacteria that does not stain a purple color)
D. **If the request is for Tobi Podhaler, approval also requires ONE of the following:**
   1. You had a trial and failure of or contraindication (harmful for) to ONE generic inhaled tobramycin product
   2. You are not able to tolerate the prolonged administration of nebulizers

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Tobi, Tobi Podhaler, Bethkis or Kitabis.

**REFERENCES**

- Tobi [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2018.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 05/12
Commercial Effective: 01/01/22 Client Approval: 11/21 P&T Approval: 10/21
TOCILIZUMAB - SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOCILIZUMAB</td>
<td>ACTEMRA</td>
<td>35486</td>
<td>45082</td>
<td>GPI-14</td>
<td>(6650007000E520)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(6650007000D520)</td>
</tr>
</tbody>
</table>

PAC NOTE: For requests for the IV dosage form of Actemra, please see the Actemra IV PA Guideline.

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   - The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

   If no, continue to #2.

2. Does the patient have a diagnosis of giant cell arteritis (GCA) AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient has a diagnosis of systemic sclerosis (SSc) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
   • Therapy is prescribed by or in consultation with a pulmonologist or rheumatologist
   • The patient does NOT have other etiologies of interstitial lung disease (ILD) [e.g., heart failure/fluid overload, drug-induced lung toxicity (cyclophosphamide, methotrexate, ACE-inhibitors), recurrent aspiration (such as from GERD), pulmonary vascular disease, pulmonary edema, pneumonia, chronic pulmonary thromboembolism, alveolar hemorrhage or ILD caused by another rheumatic disease, such as mixed connective tissue disease (MCTD)]

   If yes, approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

   If no, continue to #4.

4. Does the patient have a diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   • The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-abbm)  
     [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #1.8mL per 28 days.

   If no, continue to #5.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of systemic juvenile idiopathic arthritis (SJIA) and meet ALL of the following criteria?
   - The patient is 2 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist, dermatologist, or immunologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

If yes, approve for 6 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TOCILIZUMAB - SQ (Actemra - SQ) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (a type of joint condition)
   2. Giant cell arteritis (inflammation of blood vessels typically in and around the head)
   3. Systemic sclerosis-associated interstitial lung disease (disorder that causes hardening of lung tissue)
   4. Polyarticular juvenile idiopathic arthritis (a type of joint condition)
   5. Systemic juvenile idiopathic arthritis (a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

C. If you have giant cell arteritis, approval also requires:
   1. You are 18 years of age or older

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:
   1. You are 18 years of age or older
   2. Your diagnosis of systemic sclerosis (SSc) is according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
   3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
   4. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure or fluid overload, drug-induced lung toxicity [cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)], recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease

E. If you have polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

F. If you have systemic juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TOCILIZUMAB - SQ

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   • The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)  
     [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.
   
   If no, continue to #2.

2. Does the patient have a diagnosis of giant cell arteritis (GCA)?

   If yes, approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

   If no, continue to #3.

3. Does the patient have a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) AND meet the following criterion?
   • The patient has experienced a clinical meaningful improvement or maintenance in annual rate of decline

   If yes, approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

   If no, continue to #4.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) and meet ALL of the following criteria?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - The patient had a trial of or contraindication to the preferred agent Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #1.8mL per 28 days.

   If no, continue to #5.

5. Does the patient have a diagnosis of systemic juvenile idiopathic arthritis (SJIA) and meet ONE of the following criteria?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   - The patient has shown maintained or improved systemic inflammatory disease (e.g., fevers, pain, rash, arthritis)

   If yes, approve for 12 months by GPID or GPI-14 for all subcutaneous formulations (syringe and pen injector) with a quantity limit of #3.6mL per 28 days.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TOCILIZUMAB - SQ (Actemra - SQ) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (a type of joint condition)
   2. Giant cell arteritis (inflammation of blood vessels typically in and around the head)
   3. Systemic sclerosis-associated interstitial lung disease (disorder that causes hardening of lung tissue)
   4. Polyarticular juvenile idiopathic arthritis (a type of joint condition)
   5. Systemic juvenile idiopathic arthritis (a type of joint condition)

(Renewal denial text continued on next page)
RENEWAL CRITERIA (CONTINUED)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

C. **If you have polyarticular juvenile idiopathic arthritis, renewal also requires:**
   3. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   4. You had a trial of or contraindication (harmful for) to the preferred medication Humira (adalimumab), Amjevita (adalimumab-atto), or Cyltezo (adalimumab-adbm)

D. **If you have systemic sclerosis-associated interstitial lung disease, renewal also requires:**
   1. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline

E. **If you have Systemic Juvenile Idiopathic Arthritis, renewal also requires ONE of the following:**
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
   2. You have shown maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Actemra.

**REFERENCE**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/28/23
Created: 11/13
Client Approval: 07/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   • The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months for the requested strength by G PID or GPI-14 as follows:
   • 5mg: #2 per day.
   • 11mg: #1 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   • The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

   If yes, approve for 6 months for the requested strength by G PID or GPI-14 as follows:
   • 5mg: #2 per day.
   • 11mg: #1 per day.

   If no, continue to #3.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam, diclofenac, etc.)
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])
   - [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 6 months for the requested strength by GPID or GPI-14 as follows:
   - 5mg: #2 per day.
   - 11mg: #1 per day.

If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])
   - [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 6 months for ALL strengths by GPID or GPI-14 as follows:
   - 5mg and 10mg: #2 per day.
   - 11mg and 22mg: #1 per day.

If no, continue to #5.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of polyarticular course juvenile idiopathic arthritis (pcJIA) and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a rheumatologist
   • The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   • The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])
   [NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

If yes, approve for 6 months for the requested strength by GPID or GPI-14 as follows:
   • 5mg: #2 per day.
   • 1mg/mL: #10mL per day.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TOFACITINIB (Xeljanz, Xeljanz XR) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)
B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

(Initial denial text continued on next page)
C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam, diclofenac)
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

E. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

F. If you have polyarticular course juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

(Initial denial text continued on next page)
NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) or psoriatic arthritis (PsA) AND meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months for the requested strength by GPID or GPI-14 as follows:
   • 5mg: #2 per day.
   • 11mg: #1 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of ankylosing spondylitis (AS) AND meet the following criterion?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

   If yes, approve for 12 months for the requested strength by GPID or GPI-14 as follows:
   • 5mg: #2 per day.
   • 11mg: #1 per day.

   If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

   If yes, approve for 12 months for ALL strengths by GPID or GPI-14 as follows:
   • 5mg and 10mg: #2 per day.
   • 11mg and 22mg: #1 per day.

   If no, continue to #4.

4. Does the patient have a diagnosis of polyarticular course juvenile idiopathic arthritis (pcJIA) and meet the following criterion?
   • The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve for 12 months for the requested strength by GPID or GPI-14 as follows:
   • 5mg: #2 per day.
   • 1mg/mL: #10mL per day.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.
TOFACITINIB

RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TOFACITINIB (Xeljanz, Xeljanz XR) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, psoriatic arthritis, or polyarticular course juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xeljanz/Xeljanz XR.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A        Created: 11/12
Commercial Effective: 08/28/23    Client Approval: 07/23    P&T Approval: 04/22
GUARDIAN -- MEDICATION

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a nephrologist
   • The patient does not have end-stage renal disease (ESRD; including no renal transplantation or dialysis)

   If yes, approve for 6 months for all strengths as follows:
   • 90mg-30mg (GPID or GPI-14): #56 per 28 days.
   • 45mg-15mg (GPID or GPI-14): #56 per 28 days.
   • 60mg-30mg (GPID or GPI-14): #56 per 28 days.
   • 30-15mg (GPID or GPI-14): #56 per 28 days.
   • 15-15mg (GPID or GPI-14): #56 per 28 days.
   • 15mg (NDC 59148-0082-13) [FDB & Medi-Span]: #60 per 30 days.
   • 30 mg (NDC 59148-0083-13) [FDB & Medi-Span]: #30 per 30 days.

   If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TOLVAPTAN (Jynarque) requires the following rule(s) be met for approval:
A. You have autosomal dominant polycystic kidney disease (ADPKD: inherited disorder in which clusters of cysts develop in the kidneys)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (kidney specialist)
D. You do not have end-stage renal disease (ESRD: advanced kidney disease) including no renal transplantation (kidney transplant) or dialysis

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TOLVAPTAN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) AND meet the following criterion?
   - The patient has not progressed to end-stage renal disease (ESRD)

   If yes, approve for 12 months for all strengths as follows:
   - 90mg-30mg (GPIP or GPI-14): #56 per 28 days.
   - 45mg-15mg (GPIP or GPI-14): #56 per 28 days.
   - 60mg-30mg (GPIP or GPI-14): #56 per 28 days.
   - 30-15mg (GPIP or GPI-14): #56 per 28 days.
   - 15-15mg (GPIP or GPI-14): #56 per 28 days.
   - 15mg (NDC 59148-0082-13) [FDB & Medi-Span]: #60 per 30 days.
   - 30 mg (NDC 59148-0083-13) [FDB & Medi-Span]: #30 per 30 days.

   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TOLVAPTAN (Jynarque) requires the following rule(s) be met for renewal:
A. You have autosomal dominant polycystic kidney disease (ADPKD: inherited disorder in which clusters of cysts develop in the kidneys)
B. You have NOT progressed to end-stage renal (kidney) disease (ESRD)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TOLVAPTAN

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Jynarque.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/23
Created: 08/18
Client Approval: 02/23
P&T Approval: 01/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of partial-onset or primary generalized tonic-clonic seizures and meet ALL of the following criteria?
   • Eprontia will be used as initial monotherapy OR adjunctive therapy
   • Therapy is prescribed by or in consultation with a neurologist
   • The patient is unable to take oral tablets or capsules
   • The patient meets ONE of the following:
     • The patient is 2 to 5 years of age AND had a trial of or contraindication to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
     • The patient is 6 years of age or older AND had a trial of or contraindication to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of seizures associated with Lennox-Gastaut syndrome and meet ALL of the following criteria?
   • Eprontia will be used as adjunctive therapy
   • Therapy is prescribed by or in consultation with a neurologist
   • The patient is unable to take oral tablets or capsules
   • The patient meets ONE of the following:
     • The patient is 2 to 5 years of age AND had a trial of or contraindication to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
     • The patient is 6 years of age or older AND had a trial of or contraindication to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day.
   If no, continue to #3.

3. Does the patient have a diagnosis of migraine and meet ALL of the following criteria?
   • The patient is 12 years of age or older
   • Eprontia will be used as preventative treatment of migraines
   • The patient is unable to take oral tablets or capsules
   • The patient had a trial of or contraindication to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #4mL per day.
   If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TOPIRAMATE (Eprontia)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Partial-onset seizures (a type of seizure)
   2. Primary generalized tonic-clonic seizures (a type of seizure)
   3. Seizures associated with Lennox-Gastaut syndrome (a type of seizure disorder in young children)
   4. Migraine

B. You are unable to take oral tablets or capsules

C. **If you have partial-onset seizures or primary generalized tonic-clonic seizures, approval also requires:**
   1. Eprontia will be used as initial monotherapy OR adjunctive therapy (drugs taken together with)
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. You meet ONE of the following:
      a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
      b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

D. **If you have seizures associated with Lennox-Gastaut syndrome, approval also requires:**
   1. Eprontia will be used as adjunctive therapy (drugs taken together with)
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. You meet ONE of the following:
      a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
      b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, or topiramate ER sprinkle

E. **If you have migraines, approval also requires:**
   1. You are 12 years of age or older
   2. Eprontia will be used as preventative treatment of migraines
   3. You had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

(Continued on next page)

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Eprontia.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/22
Commercial Effective: 07/01/22  Client Approval: 05/22  P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic breast cancer and meet ALL of the following criteria?
   • The patient is a postmenopausal female
   • The patient has an estrogen-receptor positive or unknown tumor

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #30 per 30 days.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TOREMIFENE (Fareston) requires the following rule(s) be met for approval:
   A. You have metastatic breast cancer (cancer has spread to other parts of body)
   B. You are a postmenopausal female (already gone through menopause)
   C. You have an estrogen-receptor positive or unknown tumor

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Fareston.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of edema associated with heart failure or renal disease and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient had a trial of or contraindication to TWO generic loop diuretics (e.g., furosemide, bumetanide)

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   • 40mg: #5 per day.
   • 60mg: #3 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TORSEMIDE (Soaanz) requires the following rule(s) be met for approval:
A. You have edema (swelling caused by fluid build-up in the body) associated with heart failure (a type of heart condition) or renal (kidney) disease
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to TWO generic loop diuretics (such as furosemide, bumetanide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Soaanz.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
   • The patient has atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas
   • The patient has TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
   • The patient had a trial of or contraindication to ONE preferred agent: Dupixent (dupilumab), Rinvoq (upadacitinib)
   • Adbry (tralokinumab-LDRM) will NOT be used concurrently with other systemic biologics (e.g., Dupixent [dupilumab]) or any JAK inhibitors (e.g., Cibinqo [abrocitinib], topical Opzelura [ruxolitinib], Rinvoq [upadacitinib]) for the treatment of atopic dermatitis

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient have a trial of or contraindication to TWO of the following?
   • High or super-high potency topical corticosteroid (e.g., triamcinolone acetonide, fluocinonide, clobetasol propionate)
   • Topical calcineurin inhibitor (e.g., tacrolimus, Elidel [pimecrolimus])
   • Topical PDE-4 inhibitor (e.g., Eucrisa [crisaborole])
   • Topical JAK inhibitor (e.g., Opzelura [ruxolitinib])
   • Phototherapy

   If yes, enter two approvals by HICL or GPI-10 for a total of 6 months as follows:
   • FIRST APPROVAL: Approve with an end date of 30 days with a quantity limit of #6mL per 28 days.
   • SECOND APPROVAL: Approve for 5 months (enter a start date of 2 days before the end of the first approval) with a quantity limit of #4mL per 28 days.

   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TRALOKINUMAB-LDRM (Adbry) requires the following rule(s) be met for approval:
A. You have moderate to severe atopic dermatitis (a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
D. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
F. You had a trial of or contraindication (harmful for) to TWO of the following:
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate)
   2. Topical calcineurin inhibitor (such as tacrolimus, Elidel [pimecrolimus])
   3. Topical PDE-4 inhibitor (Phosphodiesterase-4 Inhibitors such as Eucrisa [crisaborole])
   4. Topical JAK inhibitor (Janus kinase inhibitor such as Opzelura [ruxolitinib])
   5. Phototherapy (light therapy)
G. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
H. You will NOT use Adbry (tralokinumab-lrdm) concurrently (at the same time) with other systemic biologics (such as Dupixent [dupilumab]) or any JAK inhibitors (Janus kinase inhibitor such as Cibinqo [abrocitinib], topical Opzelura [ruxolitinib], Rinvoq [upadacitinib]) for the treatment of atopic dermatitis

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet ALL of the following criteria?
   • The patient has shown improvement while on therapy
   • The patient had a trial of or contraindication to ONE preferred agent: Dupixent (dupilumab), Rinvoq (upadacitinib)
   • Adbry (tralokinumab-LDRM) will NOT be used concurrently with other systemic biologics (e.g., Dupixent [dupilumab]) or any JAK inhibitors (e.g., Cibinqo [abrocitinib], topical Opzelura [ruxolitinib], Rinvoq [upadacitinib]) for the treatment of atopic dermatitis

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #4mL per 28 days.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TRALOKINUMAB-LDRM (Adbry) requires the following rule(s) be met for renewal:

   A. You have moderate to severe atopic dermatitis (a type of skin condition)
   B. You have shown improvement while on therapy
   C. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
   D. You will NOT use Adbry (tralokinumab-LDRM) concurrently (at the same time) with other systemic biologics (such as Dupixent [dupilumab]) or any JAK inhibitors (Janus kinase inhibitor such as Cibinqo [abrocitinib], topicalOpzelura [ruxolitinib], Rinvoq [upadacitinib]) for the treatment of atopic dermatitis

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TRALOKINUMAB-LDRM

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Adbry.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 01/22
Client Approval: 05/23
P&T Approval: 04/23
TRAMADOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAMADOL HCL</td>
<td>QDOLO, TRAMADOL HCL</td>
<td></td>
<td>48598</td>
<td>GPI-14 (6510095102005)</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Is the request for the management of pain and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's pain is severe enough to require an opioid analgesic and alternative treatments are inadequate
   - The patient had a trial of or contraindication to generic tramadol IR tablet or a generic tramadol with acetaminophen product
   - The patient is unable to take oral solid formulations of tramadol or tramadol with acetaminophen (e.g., difficulty swallowing)

If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #80mL per day.
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TRAMADOL (Qdolo) requires the following rule(s) be met for approval:
A. The request is for the management of pain
B. You are 18 years of age or older
C. Your pain is severe enough to require an opioid analgesic (type of pain medication) and alternative treatments are inadequate
D. You had a trial of or contraindication (harmful for) to generic tramadol immediate-release (IR) tablet or a generic tramadol with acetaminophen product
E. You are unable to take oral solid formulations of tramadol or tramadol with acetaminophen (such as with difficulty swallowing)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TRAMADOL

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Qdolo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 03/14/22
Created: 02/21
Client Approval: 02/22
P&T Approval: 01/21
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet ALL of the following criteria?
   - The patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test
   - The requested medication will be used as a single agent in a BRAF-inhibitor treatment-naive patient OR in combination with Tafinlar (dabrafenib)

   If yes, continue to #7.
   If no, continue to #2.

2. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) and meet ALL of the following criteria?
   - The patient has a BRAF V600E mutation as detected by an FDA-approved test
   - The requested medication will be used in combination with Tafinlar (dabrafenib)

   If yes, continue to #7.
   If no, continue to #3.

3. Does the patient have a diagnosis of melanoma and meet ALL of the following criteria?
   - The patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test
   - The requested medication will be used as an adjuvant therapy in combination with Tafinlar (dabrafenib)
   - There is involvement of lymph node(s), following complete resection

   If yes, continue to #7.
   If no, continue to #4.

4. Does the patient have a diagnosis of locally advanced or metastatic anaplastic thyroid cancer (ATC) and meet ALL of the following criteria?
   - The patient has a BRAF V600E mutation
   - The requested medication will be used in combination with Tafinlar (dabrafenib)
   - The patient has no satisfactory locoregional treatment options available

   If yes, continue to #7.
   If no, continue to #5.
TRAMETINIB

GUIDELINES FOR USE (CONTINUED)

5. Does the patient have a diagnosis of unresectable or metastatic solid tumor and meet ALL of the following criteria?
   • The patient is 1 year of age or older
   • The patient has a BRAF V600E mutation
   • The requested medication will be used in combination with Tafinlar (dabrafenib)
   • The patient's disease has progressed following prior treatment and has no satisfactory alternative treatment options

   If yes, continue to #7.
   If no, continue to #6.

6. Does the patient have a diagnosis of low-grade glioma (LGG) and meet ALL of the following criteria?
   • The patient is 1 to 17 years of age
   • The patient has a BRAF V600E mutation
   • The requested medication will be used in combination with Tafinlar (dabrafenib)
   • The patient requires systemic therapy

   If yes, continue to #7.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

7. Is the request for the tablet formulation?

   If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:
   • 2mg: #1 per day.
   • 0.5mg: #3 per day.

   If no, continue to #8.

8. Is the request for the oral solution AND the patient meets the following criterion?
   • The patient is unable to swallow Mekinist (trametinib) tablets

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #42mL per day.

   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TRAMETINIB (Mekinist) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)
   2. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
   3. Melanoma (a type of skin cancer)
   4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)
   5. Unresectable or metastatic solid tumor (tumor that cannot be removed by surgery or has spread to other parts of the body)
   6. Low-grade glioma (LGG: a type of brain cancer)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You have a BRAF V600E or V600K mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication will be used as a single agent in a BRAF-inhibitor treatment-naive patient (you have not been previously treated for this cancer) OR in combination with Tafinlar (dabrafenib)

C. If you have metastatic non-small cell lung cancer, approval also requires:
   1. You have a BRAF V600E mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication will be used in combination with Tafinlar (dabrafenib)

D. If you have melanoma, approval also requires:
   1. You have a BRAF V600E or V600K mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication will be used in combination with Tafinlar (dabrafenib)
   3. There is involvement of lymph node(s), following complete resection (surgical removal)

E. If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:
   1. You have a BRAF V600E mutation (abnormal change in gene)
   2. The requested medication will be used in combination with Tafinlar (dabrafenib)
   3. You do not have any satisfactory locoregional treatment options available (treatments that are focused on the affected area)

(Denial text continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

F. **If you have an unresectable or metastatic solid tumor, approval also requires:**
   1. You are 1 year of age or older
   2. You have a BRAF V600E mutation (abnormal change in gene)
   3. The requested medication will be used in combination with Tafinlar (dabrafenib)
   4. Your disease has progressed following prior treatment and have no satisfactory alternative treatment options

G. **If you have low-grade glioma, approval also requires:**
   1. You are 1 to 17 years of age
   2. You have a BRAF V600E mutation (abnormal change in gene)
   3. The requested medication will be used in combination with Tafinlar (dabrafenib)
   4. You require systemic therapy (treatment that targets the entire body)

H. **If the request is for the oral solution, approval also requires:**
   1. You are unable to swallow Mekinist (trametinib) tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Mekinist.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 07/13
Commercial Effective: 10/01/23  Client Approval: 09/23  P&T Approval: 10/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 AND meet the following criterion?
   • Therapy is prescribed by or in consultation with a cardiologist or pulmonologist

     If yes, continue to #2.
     If no, continue to #4.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   • Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   • Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   • Pulmonary vascular resistance (PVR) greater than 2 Wood units (WU)

     If yes, continue to #3.
     If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

3. Has the patient had a trial of or contraindication to TWO of the following agents from different drug classes?
   - Oral endothelin receptor antagonist (e.g., Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   - Oral phosphodiesterase-5 inhibitor (e.g., Revatio [sildenafil], Adcirca [tadalafil])
   - Oral cGMP stimulator (e.g., Adempas [riociguat])
   - IV/SQ prostacyclin (e.g., Flolan [epoprostenol], Remodulin [treprostinil])

   If yes, approve for 12 months by HICL or GPI-14. (NOTE: Enter approval for all of the available HICLs.)
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

4. Does the patient have a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3) AND meet the following criterion?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist

   If yes, continue to #5.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

5. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units (WU)

   If yes, approve for 6 months by HICL or GPI-14. (NOTE: Enter approval for all of the available HICLs.)
   If not, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TREPROSTINIL INHALED (Tyvaso, Tyvaso DPI) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO: Group 1: a way to classify the severity of disease)
B. If you have **PAH (WHO Group 1)**, approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   3. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
      b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
      c. Oral cGMP stimulator (such as Adempas [riociguat])
      d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
TREPROSTINIL INHALED

INITIAL CRITERIA (CONTINUED)

C. If you have PH-ILD (WHO Group 3), approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and meet ONE of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient remains stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class has improved or remained stable

   If yes, approve for 12 months by HICL or GPI-14. (NOTE: Enter approval for all of the available HICLs.)
   If no, continue to #2.

2. Does the patient have a diagnosis of pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3) and meet ONE of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient has a stable 6-minute walk distance test

   If yes, approve for 12 months by HICL or GPI-14. (NOTE: Enter approval for all of the available HICLs.)

   If no, do not approve.

DENIAL TEXT:  See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TREPROSTINIL INHALED (Tyvaso, Tyvaso DPI) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO: Group 1: a way to classify the severity of disease)
B. If you have PAH (WHO Group 1), renewal also requires ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)
C. If you have PH-ILD (WHO Group 3), renewal also requires ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remained stable in the 6-minute walk distance test

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tyvaso or Tyvaso DPI.

REFERENCES
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 AND meet the following criterion?
   • Therapy is prescribed by or in consultation with a cardiologist or pulmonologist

   If yes, continue to #2.
   If no, do not approve
   DENIAL TEXT: See the initial denial text at the end of the guideline

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   • Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   • Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   • Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, continue to #3.
   If no, do not approve
   DENIAL TEXT: See the initial denial text at the end of the guideline

3. Is the request for continuation of Remodulin (treprostinil) therapy from a hospital discharge?

   If yes, approve for 12 months by HICL or GPI-14.
   If no, continue to #4.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. Is the request for a new start of Remodulin (treprostinil) therapy and the patient meets ONE of the following criteria?
   - The patient is intermediate or high risk
   - The patient had a trial of or contraindication to TWO of the following medications from different drug classes:
     - Oral endothelin receptor antagonist (e.g., Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
     - Oral phosphodiesterase-5 inhibitor (e.g., Revatio [sildenafil], Adcirca [tadalafil])
     - Oral cGMP stimulator (e.g., Adempas [riociguat])

If yes, approve for 12 months by HICL or GPI-14.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TREPROSTINIL INJECTABLE (Remodulin) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
D. For new start requests of Remodulin (treprostinil), approval also requires ONE of the following:
   1. You are intermediate or high risk
   2. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
      b. Oral phosphodiesterase-5 inhibitor (such as Revatio [sildenafil], Adcirca [tadalafil])
      c. Oral cGMP stimulator (such as Adempas [riociguat])
E. If you are continuing current therapy from a hospital discharge, there is no additional requirement for approval.

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and meet ONE of the following criteria?
   - The patient has shown improvement from baseline in the 6-minute walk distance test
   - The patient remains stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class have improved or remained stable

   If yes, approve for 12 months by HICL or GPI-14.
   If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TREPROSTINIL INJECTABLE (Remodulin) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
TREPROMINIL INJECTABLE

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Remodulin.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 03/23
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and meet ALL of the following criteria?
   - Therapy is prescribed by or in consultation with a cardiologist or pulmonologist
   - The patient does NOT have severe hepatic impairment

   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?
   - Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   - Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   - Pulmonary vascular resistance (PVR) greater than 2 Wood units

   If yes, continue to #3.
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

3. Is the request for continuation of Orenitram (treprostinil) therapy from a hospital discharge?

   If yes, **approve for 12 months by HICL or GPI-10.**
   If no, continue to #4.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

4. Is the request for a new start of Orenitram (treprostinil) therapy and the patient meets ALL of the following criteria?
   • The patient had a trial of or contraindication to the preferred oral prostanoid: Uptravi (selexipag)
   • The patient had a trial of or contraindication to TWO of the following medications from different drug classes:
     o Oral endothelin receptor antagonist (e.g., Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
     o Oral phosphodiesterase-5 inhibitor (e.g., Revatio [sildenafil], Adcirca [tadalafil])
     o Oral cGMP stimulator (e.g., Adempas [riociguat])
     o IV/SQ prostacyclin (e.g., Flolan [epoprostenol], Remodulin [treprostinil])

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TREPROSTINIL ORAL (Orenitram) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units (WU)
D. You do NOT have severe hepatic (liver) impairment

(Initial denial text continued on next page)
INITIAL CRITERIA (CONTINUED)

E. For new start requests of Orenitram (treprostinil), approval also requires:
   1. You had a trial of or contraindication (harmful for) to the preferred oral prostanoid: Uptravi
   2. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
      b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
      c. Oral cGMP stimulator (such as Adempas [riociguat])
      d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [Treprostinil])
   F. If you are continuing current therapy from a hospital discharge, there is no additional requirement for approval.

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and meet ONE of the following criteria?
   • The patient has shown improvement from baseline in the 6-minute walk distance test
   • The patient remains stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class has improved or remained stable

If yes, approve for 12 months by HICL or GPI-10.
If no, do not approve.
DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TREPROSTINIL ORAL (Orenitram) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Orenitram.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 09/05
Commercial Effective: 07/01/23  Client Approval: 05/23  P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Wilson's disease and meet ALL of the following criteria?
   • Therapy is prescribed by or in consultation with a hepatologist or gastroenterologist
   • The patient has a Leipzig score of 4 or greater
   • The patient is willing to follow a diet avoiding high copper foods (e.g., shellfish, nuts, chocolate, mushrooms, organ meat)
   • The patient has had a trial of or contraindication to penicillamine (Depen, Cuprimine)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TRIENTINE (Syprine, Clovique) requires the following rule(s) be met for approval:
   A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   B. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
   C. You have a Leipzig score (a type of diagnostic score) of 4 or higher
   D. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
   E. You had a trial of or contraindication (harmful for) to penicillamine (Depen, Cuprimine)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of Wilson's disease AND meet the following criterion?
   • The patient has achieved a free serum copper of less than 10 mcg/dL

   If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #8 per day.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **TRIENTINE** (*Syprine, Clovique*) requires the following rules be met for renewal:
   A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   B. You have achieved a free serum copper (amount of copper in your blood) level of less than 10 mcg/dL

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Syprine.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/16
Commercial Effective: 05/08/23  Client Approval: 04/23  P&T Approval: 10/22
TRIENTINE - CUVRIOR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIENTINE TETRAHYDROCHLORIDE</td>
<td>CUVRIOR</td>
<td>45888</td>
<td>GPI-10</td>
<td>45888</td>
<td>10</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of Wilson's disease and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a prior or current Leipzig score of 4 or greater
   - The patient has a non-ceruloplasmin copper (NCC) level between 50 to 150 mcg/L or a 24-hour urinary copper excretion (UCE) of between 100 to 500 mcg/24 hours
   - Therapy is prescribed by or in consultation with a hepatologist or gastroenterologist
   - The patient is willing to maintain a diet that avoids high copper foods (e.g., shellfish, nuts, chocolate, mushrooms, organ meat)
   - The patient had a trial of penicillamine (Depen, Cuprimine) for at least one year prior to starting Cuvrior
   - The patient had a trial of trientine hydrochloride (Syprine)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #10 per day.
If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TRIENTINE - CUVRIOR requires the following rule(s) be met for approval:
A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
B. You are 18 years of age or older
C. You have a prior or current Leipzig score (a type of diagnostic score) of 4 or higher
D. You have a non-ceruloplasmin copper (NCC: a type of test to check copper levels) level between 50 to 150 mcg/L or a 24-hour urinary copper excretion (UCE: a type of test to check copper levels) between 100 to 500 mcg per 24 hours
E. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
F. You are willing to maintain a diet that avoids high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
G. You had a trial of penicillamine (Depen, Cuprimine) for at least one year prior to starting Cuvrior
H. You had a trial of trientine hydrochloride (Syprine)

(Initial denial text continued on the next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of Wilson's disease **AND** meet the following criterion?
   - The patient's copper levels are monitored via non-ceruloplasmin copper (NCC) or 24-hour urinary copper excretion (UCE) laboratory test

   If yes, **approve for lifetime by HICL or GPI-10 with a quantity limit of #10 per day.**
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **TRIENTINE - CUVRIO** requires the following rules be met for renewal:
   
   A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   B. Your body's copper levels are monitored by a non-ceruloplasmin copper (NCC: a type of test to check copper levels) test or 24-hour urinary copper excretion (UCE: a type of test to check copper levels) test

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cuvrior.

REFERENCES

- Cuvrior [Prescribing Information]. Paris, France: Orphalan SA; April 2022.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 04/23
Commercial Effective: 05/08/23  Client Approval: 04/23  P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
TRIFLURIDINE/TIPIRACIL

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic colorectal cancer and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in combination with an anti-VEGF biological therapy [e.g., Zaltrap (ziv-aflibercept), Cyramza (ramucirumab)]
   - Lonsurf will be used as a single agent OR in combination with bevacizumab

   If yes, continue to #2.
   If no, continue to #4.

2. Is the patient’s metastatic colorectal cancer RAS wild-type?

   If yes, continue to #3.
   If no, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
   - 15/6.14mg: #100 per 28 days.
   - 20/8.19mg: #80 per 28 days.

3. Has the patient had previous treatment with an anti-EGFR agent [e.g., Erbitux (cetuximab), Vectibix (panitumumab)]?

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
   - 15/6.14mg: #100 per 28 days.
   - 20/8.19mg: #80 per 28 days.

   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
4. Does the patient have a diagnosis of metastatic gastric or gastroesophageal junction adenocarcinoma and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received previous treatment with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:**
   - 15/6.14mg: #100 per 28 days.
   - 20/8.19mg: #80 per 28 days.

   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **TRIFLURIDINE/TIPIRACIL (Lonsurf)** requires the following rule(s) be met for approval:

A. **You have ONE of the following diagnoses:**
   1. Metastatic colorectal cancer (a type of digestive system cancer that has spread to other parts of the body)
   2. Metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)

B. **If you have metastatic colorectal cancer, approval also requires:**
   1. You are 18 years of age or older
   2. Lonsurf will be used as a single agent OR in combination with bevacizumab
   3. You had previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy (drugs used to treat cancer) in combination with an anti-VEGF biological therapy such as Zaltrap (ziv-afibercept) or Cyramza (ramucirumab)
   4. If your metastatic colorectal cancer is RAS wild-type (a type of gene), you also had a previous treatment with an anti-EGFR agent such as Erbitux (cetuximab), Vectibix (panitumumab)

C. **If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
   1. You are 18 years of age or older
   2. You had previous treatment with at least two prior lines of chemotherapy (drugs used to treat cancer) that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2 (type of gene)/neu-targeted therapy

*(Denial text continued on next page)*

---

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lonsurf.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 10/15
Commercial Effective: 09/01/23  Client Approval: 08/23  P&T Approval: 10/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) and meet ALL of the following criteria?
   - The patient's diagnosis is confirmed by documentation of at least TWO of the following:
     - Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma
     - Low enzyme activity in cultured fibroblasts
     - One or more known pathogenic mutations in CPT2, ACADVL, HADHA, or HADHB
     - The patient is symptomatic (e.g. rhabdomyolysis, cardiomyopathy) for LC-FAOD
     - Therapy is prescribed by or given in consultation with a gastroenterologist or physician specialist in medical genetics/inherited metabolic disorders
     - The patient had a trial of or contraindication to commercial MCT oil (medical food product)

   If yes, approve for 4 months by HICL or GPI-10.
   APPROVAL TEXT: Renewal requires the patient had a positive clinical response (e.g., improved exercise tolerance) or stabilization of clinical status compared to baseline.

   If no, do not approve.
   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TRIHEPTANOIN (Dojolvi) requires the following rule(s) be met for approval:
   A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
   B. Your diagnosis is confirmed by documentation of at least TWO of the following:
      1. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma
      2. Low enzyme activity in cultured fibroblasts
      3. One or more known pathogenic mutations in CPT2, ACADVL, HADHA, or HADHB
   C. You are symptomatic for LC-FAOD (for example you have rhabdomyolysis [break down of muscle tissue] or cardiomyopathy [disease of the heart muscle])
   D. Therapy is prescribed by or given in consultation with a gastroenterologist (digestive tract doctor) or physician specialist in medical genetics/inherited metabolic disorders
   E. You have previously tried commercial MCT oil (a medical food product) unless there is a medical reason you are unable to (contraindication)

   (Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED ON NEXT)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) AND meet the following criterion?
   - The patient had a positive clinical response (e.g. improved exercise tolerance) or stabilization of clinical status compared to baseline

   If yes, approve for 12 months by HICL or GPI-10.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named TRIHEPTANOIN (Dojolvi) requires the following rule(s) be met for renewal:
   - A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
   - B. You had a positive clinical response (such as improved exercise tolerance) or stabilization of clinical status compared to baseline

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Dojolvi.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/21
Created: 10/20
Client Approval: 11/20
P&T Approval: 10/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

1. Does the patient have a diagnosis of Rett syndrome AND meet the following criterion?
   • The patient is 2 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #120mL per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these
   definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named TROFINETIDE (Daybue) requires the following rule(s) be met for approval:
   A. You have Rett syndrome (a type of nervous system disorder)
   B. You are 2 years of age or older

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
   showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
   your doctor to use a different medication or get us more information if it will allow us to approve
   this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Daybue.

REFERENCES
GUIDELINES FOR USE

1. Is the claim rejecting for the following POS message: “Coverage of this product should be provided through medical benefit, available manufacturer programs, or patient assistance programs”?

   If yes, guideline does not apply.
   If no, continue to #2.

2. Does the patient meet ALL of the following criteria?
   - The insulin pump is prescribed by or in consultation with an endocrinologist
   - The patient has completed a comprehensive diabetes education program within the preceding 24 months
   - The patient follows a maintenance program of at least 3 injections of insulin per day and requires frequent self-adjustments of insulin dose for the past 6 months
   - The patient requires glucose self-testing of at least 4 times per day on average in the preceding 2 months
   - The patient has not received an insulin pump within the last 4 years (Exception: pump is malfunctioning, not repairable, and not under warranty)

   If yes, continue to #3.
   If no, do not approve.
   DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

3. Does the patient meet **ONE** of the following criteria while on a multiple daily insulin injection regimen?
   - The patient's glycosylated hemoglobin level (HbA1c) is greater than 7%
   - The patient has a history of recurring hypoglycemia
   - The patient has wide fluctuations in blood glucose before mealtime
   - The patient experiences the dawn phenomenon with fasting blood glucose levels frequently exceeding 200 mg/dL
   - The patient has a history of severe glycemic excursions (i.e., sudden spikes in blood sugar levels)

   If yes, continue to #4.
   If no, do not approve.

**DENIAL TEXT**: See the denial text at the end of the guideline.

4. Is the request for T: Slim X2 OR T: Slim X2 with Basal-IQ **AND** the patient meets the following criterion?
   - The patient is 6 years of age or older

   If yes, **approve for 1 month by NDC with a quantity limit of #1 fill.**
   If no, continue to #5.

5. Is the request for the T: Slim X2 with Control-IQ **AND** the patient meets the following criterion?
   - The patient is 6 years of age or older

   If yes, **approve for 1 month by NDC with a quantity limit of #1 fill.**
   If no, continue to #6.

6. Is the request for MiniMed 670G and the patient meets **ALL** of the following criteria?
   - The patient has a diagnosis of type 1 diabetes mellitus
   - The patient is 7 years of age or older

   If yes, **approve for 1 month by NDC with a quantity limit of #1 fill.**
   If no, continue to #7.

7. Is the request for MiniMed 770G and the patient meets **ALL** of the following criteria?
   - The patient has a diagnosis of type 1 diabetes mellitus
   - The patient is 2 years of age or older

   If yes, **approve for 1 month by NDC with a quantity limit of #1 fill.**
   If no, continue to #8.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

8. Is the request for MiniMed 780G and the patient meets ALL of the following criteria?
   • The patient has a diagnosis of type 1 diabetes mellitus
   • The patient is 7 years of age or older

   If yes, approve for 1 month by NDC with a quantity limit of #1 fill.
   If no, continue to #9.

9. Is the request for MiniMed 630G and the patient meets ALL of the following criteria?
   • The patient has a diagnosis of type 1 diabetes mellitus
   • The patient is 14 years of age or older

   If yes, approve for 1 month by NDC with a quantity limit of #1 fill.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named T: SLIM/MINIMED INSULIN PUMPS requires the following rule(s) be met for approval:
A. The requested insulin pump is prescribed by or in consultation with an endocrinologist (hormone doctor)
B. You have completed a comprehensive diabetes education program within the previous 24 months
C. You follow a maintenance program of at least 3 injections of insulin per day and require frequent self-adjustments of your insulin dose for the past 6 months
D. You require glucose self-testing of at least 4 times per day on average in the previous 2 months
E. You have not received an insulin pump within the last 4 years (Exception: your pump is malfunctioning, not repairable, and not under warranty)
F. You are on a multiple daily insulin injection regimen and meet ONE of the following:
   1. You have a glycosylated hemoglobin level (HbA1c: measure of how well controlled your blood sugar has been over a period of about 3 months) greater than 7 percent
   2. You have a history of recurring hypoglycemia (low blood sugar)
   3. You have wide fluctuations in blood sugar before mealtime
   4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/Dl
   5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)

(Denial text continued on next page)
GUIDELINES FOR USE (CONTINUED)

G. If you are requesting the T: Slim X2 OR T: Slim X2 with Basal-IQ, approval also requires:
   1. You are 6 years of age or older

H. If you are requesting the T: Slim X2 with Control-IQ, approval also requires:
   1. You are 6 years of age or older

I. If you are requesting the MiniMed 670G, approval also requires:
   1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
   2. You are 7 years of age or older

J. If you are requesting the MiniMed 770G, approval also requires:
   1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
   2. You are 2 years of age or older

K. If you are requesting the MiniMed 780G, approval also requires:
   1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
   2. You are 7 years of age or older

L. If you are requesting the MiniMed 630G, approval also requires:
   1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
   2. You are 14 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different product or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
T: SLIM/MINIMED INSULIN PUMPS

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for the related insulin pumps.

REFERENCES
- MiniMed 670G System. Medtronic. Important Safety Information. Available at: https://www.medtronicdiabetes.com/important-safety-information#minimed-670g
- MiniMed 770G System. Medtronic. Important Safety Information. Available at: https://www.medtronicdiabetes.com/important-safety-information#minimed-770g
- MiniMed 780G System. Medtronic. Important Safety Information. Available at: https://www.medtronicdiabetes.com/important-safety-information#minimed-780g
- MiniMed 630G System. Medtronic. Important Safety Information. Available at: https://www.medtronicdiabetes.com/important-safety-information#minimed-630g

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 08/20
Client Approval: 08/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced unresectable or metastatic HER2-positive breast cancer and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received one or more prior anti-HER2-based regimens (i.e., trastuzumab or trastuzumab with pertuzumab) in the metastatic setting
   - The requested medication will be used in combination with trastuzumab and capecitabine

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   - 50mg: #10 per day.
   - 150mg: #4 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient's cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
   - The requested medication will be used in combination with trastuzumab

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   - 50mg: #10 per day.
   - 150mg: #4 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named TUCATINIB (Tukysa) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Advanced unresectable (cannot be removed with surgery) or metastatic (disease that has spread to other parts of the body) human epidermal growth factor receptor 2 (HER2: type of protein)-positive breast cancer
   2. RAS wild-type (a type of gene), HER2-positive unresectable or metastatic colorectal cancer (a type of digestive cancer)

(Denial text continued on next page)
TUCATINIB

GUIDELINES FOR USE (CONTINUED)

B. If you have advanced unresectable or metastatic HER2-positive breast cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have received one or more prior anti-HER2-based treatment (specifically either trastuzumab or trastuzumab with pertuzumab) for metastatic disease
   3. The requested medication will be used in combination with trastuzumab and capecitabine

C. If you have RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (drugs used to treat cancer)
   3. The requested medication will be used in combination with trastuzumab

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tukysa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 02/06/23
Created: 08/20
Client Approval: 01/23
P&T Approval: 04/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for the acute treatment of migraine and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has a trial of or contraindication to ONE triptan (e.g., sumatriptan, rizatriptan)

   If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.

   APPROVAL TEXT: Renewal requires that the request is for acute treatment of migraines and the patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy (Migraine-ACT)) OR the patient has experienced clinical improvement as defined by ONE of the following: 1) ability to function normally within 2 hours of dose, 2) headache pain disappears within 2 hours of dose, or 3) therapy works consistently in majority of migraine attacks.

   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named UBROGEPANT (Ubrelvy) requires the following rule(s) be met for approval:
   A. You are being treated for acute (quick onset) migraine
   B. You are 18 years of age or older
   C. You have previously tried ONE triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Is the request for the acute treatment of migraine and the patient meets ONE of the following criteria?
   - The patient has experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])
   - The patient has experienced clinical improvement as defined by ONE of the following:
     - Ability to function normally within 2 hours of dose
     - Headache pain disappears within 2 hours of dose
     - Therapy works consistently in majority of migraine attacks

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #16 per 30 days.
If no, do not approve.

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named UBROGEPANT (Ubrelvy) requires the following rule(s) be met for approval:
A. You are being treated for acute (quick onset) migraine
B. You meet ONE of the following:
   1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
   2. You have experienced clinical improvement as defined by ONE of the following:
      a. Ability to function normally within 2 hours of dose
      b. Headache pain disappears within 2 hours of dose
      c. Treatment works consistently in majority of migraine attacks

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
UBROGEPANT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ubrelvy.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/21
Created: 01/20
Client Approval: 11/20
P&T Approval: 10/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm], Enbrel [etanercept])

   If yes, **approve 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm], Enbrel [etanercept])

   If yes, **approve 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   If no, continue to #3.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

3. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet ALL of the following criteria?
   - The patient is 12 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist, allergist, or immunologist
   - The patient has at least TWO of the following: intractable pruritus, cracking and oozing/bleeding of affected skin, impaired activities of daily living
   - Rinvoq will NOT be used concurrently with other systemic biologics (e.g., Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) for atopic dermatitis or other JAK inhibitors (e.g., topical Opzelura [ruxolitinib], Xeljanz [tofacitinib]) for any indication

   If yes, continue to #4.
   If no, continue to #6.

4. Does the patient meet ONE of the following criteria?
   - The patient was previously stable on another biologic (e.g., Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) and switching to the requested drug
   - The patient has atopic dermatitis involving at least 10% of body surface area (BSA)
   - The patient has atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas

   If yes, continue to #5.
   If no, do not approve.
   DENIAL TEXT: See initial denial text at the end of the guideline.

5. Does the patient have a trial of or contraindication to ONE of the following?
   - Topical corticosteroid (e.g., hydrocortisone, clobetasol, halobetasol propionate)
   - Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
   - Topical PDE-4 inhibitor [e.g., Eucrisa (crisaborole)]
   - Topical JAK inhibitor [e.g., Opzelura (ruxolitinib)]
   - Phototherapy

   If yes, approve for 6 months by GPID or GPI-14 for all strengths as follows:
   15mg: #1 per day.
   30mg: #1 per day.

   If no, do not approve.
   DENIAL TEXT: See initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

6. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional therapy (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

   If yes, **approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**
   **FIRST APPROVAL:** Approve 45mg for 8 weeks with a quantity limit of #1 per day.
   **SECOND APPROVAL:** Approve 15mg and 30mg for 4 months with a quantity limit of #1 per day. (Please enter start date of 2 days before the end date of the first approval).

   If no, continue to #7.

7. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a gastroenterologist
   - The patient had a trial of or contraindication to ONE conventional agent (e.g., corticosteroids [e.g., budesonide, methylprednisolone], azathioprine, mercaptopurine, methotrexate, mesalamine)
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

   If yes, **approve for a total of 6 months by GPID or GPI-14. Please enter two authorizations as follows:**
   **FIRST APPROVAL:** Approve 45mg for 12 weeks with a quantity limit of #1 per day.
   **SECOND APPROVAL:** Approve 15mg and 30mg for 3 months with a quantity limit of #1 per day. (Please enter start date of 2 days before the end date of the first approval).

   If no, continue to #8.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

8. Does the patient have a diagnosis of ankylosing spondylitis (AS) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm], Enbrel [etanercept])

   If yes, **approve 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**
   
   If no, continue to #9.

9. Does the patient have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist
   - The patient had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (e.g., Cimzia [certolizumab])
   - The patient had a trial of or contraindication to an NSAID (e.g., ibuprofen, naproxen, meloxicam)

   If yes, continue to #10.
   
   If no, do not approve.
   **DENIAL TEXT:** See the initial denial text at the end of the guideline.

10. Does the patient meet **ONE** of the following criteria?
    - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
    - The patient has C-reactive protein (CRP) levels above the upper limit of normal
    - The patient has sacroiliitis on magnetic resonance imaging (MRI)

    If yes, **approve 15mg for 6 months by GPID or GPI-14 with a quantity limit of #1 per day.**

    If no, do not approve.
    **DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named UPADACITINIB (Rinvoq) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: type of joint condition)
   2. Psoriatic arthritis (PsA: type of skin and joint condition)
   3. Moderate to severe atopic dermatitis (a type of skin condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)
   6. Ankylosing spondylitis (AS: a type of joint condition)
   7. Non-radiographic axial spondyloarthritis (NR-axSpA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm], Enbrel [etanercept])

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist or dermatologist (a type of immune system doctor or skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm], Enbrel [etanercept])

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
UPADACITINIB

INITIAL CRITERIA (CONTINUED)

D. If you have moderate to severe atopic dermatitis, approval also requires:
   1. You are 12 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. You have at least TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
   4. You had a trial of or contraindication (harmful for) to ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol, halobetasol propionate), topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus]), topical PDE-4 inhibitor (such as Eucrisa [crisaborole]), topical JAK inhibitor (such as Opzelura [ruxolitinib]), phototherapy (light therapy)
   5. You will NOT use Rinvoq concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) for atopic dermatitis or other Janus kinase (JAK) inhibitors (such as topical Opzelura [ruxolitinib], Xeljanz [tofacitinib]) for any indication
   6. You meet ONE of the following:
      a. You were previously on another biologic (such as Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) and switching to the requested drug
      b. You have atopic dermatitis involving at least 10% of body surface area (BSA)
      c. You have atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)

E. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

F. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm])

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
G. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm], Enbrel [etanercept])

H. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blockers (such as Cimzia [certolizumab])
   4. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug: such as ibuprofen, naproxen, meloxicam)
   5. You meet ONE of the following:
      a. You have previously on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
      b. You have C-reactive protein (CRP: a measure of how much inflammation you have) levels above the upper limit of normal
      c. You have sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: type of imaging lab)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of moderate to severe rheumatoid arthritis (RA) OR psoriatic arthritis (PsA) AND meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, approve 15mg for 12 months by GPIID or GPI-14 with a quantity limit of #1 per day.

   If no, continue to #2.

2. Does the patient have a diagnosis of moderate to severe atopic dermatitis and meet ALL of the following criteria?
   - The patient has shown improvement while on therapy
   - Rinvoq will NOT be used concurrently with other systemic biologics (e.g., Adbruy [tralokinumab-ldrm], Dupixent [dupilumab]) for atopic dermatitis or OTHER JAK inhibitors (e.g., topical Opzelura [ruxolitinib], XELJANZ [TOFACITINIB]) for ANY INDICATION

   If yes, approve for 12 months by GPIID or GPI-14 for all strengths as follows:
     15mg: #1 per day.
     30mg: #1 per day.

   If no, continue to #3.

3. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

   If yes, approve for 12 months by GPIID or GPI-14 for all strengths as follows:
     15mg: #1 per day.
     30mg: #1 per day.

   If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

   If yes, approve for 12 months by GPIID or GPI-14 for all strengths as follows:
     15mg: #1 per day.
     30mg: #1 per day.

   If no, continue to #5.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

5. Does the patient have a diagnosis of ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA) AND meet the following criterion?
   • The patient has experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

If yes, approve 15mg for 12 months by GPID or GPI-14 with a quantity limit of #1 per day. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **UPADACITINIB (Rinvoq)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe atopic dermatitis (a type of skin condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Ankylosing spondylitis (AS: a type of joint condition)
   7. Non-radiographic axial spondyloarthritis (NR-axSpA: a type of joint condition)

B. **If you have moderate to severe rheumatoid arthritis or psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. **If you have moderate to severe atopic dermatitis, renewal also requires:**
   1. You have shown improvement while on therapy
   2. You will NOT use Rinvoq concurrently (at the same time) with other systemic biologics (such as Adbro [tralokinumab-Idrm], Dupixent [dupilumab]) for atopic dermatitis or other Janus kinase (JAK) inhibitors (such as topical Opzelura [ruxolitinib], Xeljanz [tofacitinib]) for any indication

*(Renewal denial text continued on next page)*

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rinvoq.

REFERENCES


<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A        Created: 08/19
Commercial Effective: 10/01/23  Client Approval: 08/23       P&T Approval: 07/23
URIDINE TRIACETATE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a documented diagnosis of hereditary orotic aciduria as confirmed by ALL of the following criteria?
   • Presence of a mutation in the uridine monophosphate synthase (UMPS) gene
   • Patient has an elevated urinary orotic acid level according to an age-specific reference range

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at end of the guideline.

2. Is the medication prescribed by or given in consultation with a prescriber specializing in inherited metabolic diseases?

   If yes, **approve for 6 months by GPID or GPI-10 up to #4 packets per day.**
   **APPROVAL TEXT:** Renewal requires that the patient's age dependent hematologic parameters (e.g., neutrophil count, neutrophil percent, white blood cell count, mean corpuscular volume) have stabilized or improved from baseline while on treatment with uridine triacetate.

   If no, do not approve.
   **INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) be met for approval:
   A. You have hereditary orotic aciduria (HOA: genetic disease where you do not have a type of protein to make a chemical)
   B. Your diagnosis is confirmed by ALL of the following:
      1. Presence of a mutation in the uridine monophosphate synthase (UMPS) gene
      2. Elevated urinary orotic acid levels according to your age-specific reference range
   C. Therapy is prescribed by or given in consultation with a doctor specializing in inherited metabolic diseases (genetic diseases that result in metabolism problems)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED], We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

   CONTINUED ON NEXT PAGE
URIDINE TRIACETATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Has the patient's age dependent hematologic parameters (e.g., neutrophil count, neutrophil percent, white blood cell count, mean corpuscular volume) stabilized or improved from baseline while on treatment with uridine triacetate?

   If yes, approve for 12 months by GPID or GPI-10 up to #4 packets per day.
   If no, do not approve.

   **RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) to be met for renewal:
   A. Your age dependent hematologic parameters (blood lab tests) have stabilized or improved from baseline while on treatment with Xuriden (uridine triacetate).

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xuriden.

REFERENCES

URSODIOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>URSODIOL</td>
<td>RELTONE,</td>
<td>1073</td>
<td>49115</td>
<td>GPI-14</td>
<td>(52100040000112,</td>
</tr>
<tr>
<td></td>
<td>URSODIOL</td>
<td></td>
<td></td>
<td></td>
<td>52100040000130)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

1. Does the patient have a diagnosis of radiolucent, noncalcified gallbladder stones and meet ALL of the following criteria?
   - The patient's gallbladder stones are less than 20 mm in greatest diameter
   - Elective cholecystectomy is planned unless the patient is at increased surgical risk due to systemic disease, advanced age, or idiosyncratic reaction to general anesthesia, OR the patient refuses surgery
   - The patient had a trial of generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet)
   - The patient is unable to take generic ursodiol formulations (300mg capsule, 250mg tablet, or 500mg tablet)

If yes, approve for 12 months by GPID or GPI-14 for the requested strength.
If no, do not approve.

CLINICAL SPECIALIST NOTE: Use for prevention of gallstone formation in obese patients with rapid weight loss is not covered for this medication.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named URSODIOL (Reltone) requires the following rule(s) be met for approval:
E. You have radiolucent, noncalcified gallbladder stones (hardened deposits of bile, that is barely visible on x-ray, in your gallbladder that do not contain calcium)
F. Your gallbladder stones are less than 20 mm in diameter
G. You plan to have elective cholecystectomy (surgery to remove gallbladder) unless you are at increased surgical risk due to systemic (entire body) disease, advanced age, or idiosyncratic reaction (an unexpected adverse reaction) to general anesthesia, OR you refuse surgery
H. You have tried generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet)
I. You are unable to take generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet) formulations

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
URSODIOL

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Reltone.

REFERENCES
- Ursodiol 200 mg & 400 mg Capsules [Prescribing Information]. Las Vegas, NV: Intra-Sana Laboratories LLC; February 2021.

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 02/21
Commercial Effective: 04/01/22  Client Approval: 03/22  P&T Approval: 01/21
**USTEKINUMAB**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>USTEKINUMAB</td>
<td>STELARA</td>
<td>36187</td>
<td></td>
<td>GPI-10 (9025058500)</td>
<td>(5250407000)</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) and meet **ALL** of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a dermatologist
   - The patient had a trial of or contraindication to ONE or more forms of conventional therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (e.g., betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient meet **ONE** of the following criteria?
   - The patient was previously stable on another biologic (e.g., Cimzia [certolizumab], Cosentyx [secukinumab]) and is switching to the requested drug
   - The patient has psoriasis covering 3% or more of body surface area (BSA)
   - The patient has psoriatic lesions affecting the hands, feet, face, or genital area

   If yes, enter **two approvals for a total of 6 months by GPID or GPI-14 as follows:**
   - **FIRST APPROVAL:** Approve for 1 month with a quantity limit of 1mL per 28 days for 1 fill.
   - **SECOND APPROVAL:** Approve for 5 months with a quantity limit of 1mL per 84 days for 2 fills (Start date is 3 weeks AFTER the start date of the first approval).

   If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guidelines.

3. Does the patient have a diagnosis of psoriatic arthritis (PsA) and meet **ALL** of the following criteria?
   - The patient is 6 years of age or older
   - Therapy is prescribed by or in consultation with a rheumatologist or dermatologist
   - The patient had a trial of or contraindication to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

   If yes, continue to #4.
   If no, continue to #5.

**CONTINUED ON NEXT PAGE**
INITIAL CRITERIA (CONTINUED)

4. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?

   If yes, enter two approvals for a total of 6 months by GPID or GPI-14 as follows:
   • FIRST APPROVAL: Approve for 1 month with a quantity limit of 1mL per 28 days for 1 fill.
   • SECOND APPROVAL: Approve for 5 months with a quantity limit of 1mL per 84 days for 2 fills (Start date is 3 weeks AFTER the start date of the first approval).

   If no, enter two approvals for a total of 6 months by GPID or GPI-14 as follows:
   • FIRST APPROVAL: Approve for 1 month with a quantity limit of 0.5mL per 28 days for 1 fill.
   • SECOND APPROVAL: Approve for 5 months with a quantity limit of 0.5mL per 84 days for 2 fills (Start date is 3 weeks AFTER the start date of the first approval).

5. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a gastroenterologist
   • The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (i.e., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, continue to #7.
   If no, continue to #6.

6. Does the patient have a diagnosis of moderate to severe active ulcerative colitis (UC) and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • Therapy is prescribed by or in consultation with a gastroenterologist
   • The patient had a trial of or contraindication to ONE conventional agent, such as corticosteroids (i.e., budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

   If yes, continue to #7.
   If no, do not approve.

DENIAL TEXT: See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

7. Is the prescriber requesting an intravenous infusion induction dose of Stelara 130mg/26mL?

If yes, enter two approvals for a total of 6 months by GPID or GPI-14 as follows:

- **FIRST APPROVAL:** Approve for 2 months by GPID or GPI-14 with a quantity limit of 104mL (130mg/26mL) per 56 days for 1 fill.
- **SECOND APPROVAL:** Approve for 4 months by GPID or GPI-14 with a quantity limit of 1mL (45mg/0.5mL or 90mg/mL) per 56 days for 2 fills (Start date is 7 weeks AFTER the start date of the first approval).

If no, approve for 6 months by GPID or GPI-14 with a quantity limit of 1mL per 56 days for 3 fills.

**INITIAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **USTEKINUMAB (Stelara)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (PsA: a type of skin and joint condition)
   2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   3. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)
   4. Moderate to severe active ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

*(Initial denial text continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor) OR dermatologist (type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. **If you have moderate to severe Crohn’s disease, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

E. **If you have moderate to severe active ulcerative colitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

1. Does the patient have a diagnosis of psoriatic arthritis (PsA) **AND** meet the following criterion?
   - The patient has experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

   If yes, continue to #2.
   If no, continue to #3.

2. Does the patient have coexistent moderate to severe plaque psoriasis (PsO)?

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL per 84 days.**
   If no, **approve for 12 months by GPID or GPI-14 with a quantity limit of 0.5mL per 84 days.**

3. Does the patient have a diagnosis of moderate to severe plaque psoriasis (PsO) **AND** meet the following criterion?
   - The patient has achieved or maintained clear or minimal disease **OR** a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL per 84 days.**
   If no, continue to #4.

4. Does the patient have a diagnosis of moderate to severe Crohn's disease (CD)?

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL per 56 days.**
   If no, continue to #5.

5. Does the patient have a diagnosis of moderate to severe ulcerative colitis (UC)?

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of 1mL per 56 days.**
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **USTEKINUMAB (Stelara)** requires the following rules be met for renewal:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (PsA: a type of skin and joint condition)
   2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. **If you have moderate to severe plaque psoriasis, renewal also requires:**
   1. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Stelara.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 10/09
Client Approval: 05/23
P&T Approval: 04/23
GUIDELINES FOR USE

1. Does the patient have a diagnosis of moderate to severe tardive dyskinesia (TD) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or in consultation with a neurologist, movement disorder specialist, or psychiatrist
   - The patient’s moderate to severe TD has been present for at least 3 months
   - The patient has a prior history of using antipsychotic medications (e.g., aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if patient is 60 years of age or older) as documented in the prescription claims history
   - The patient had a trial of or contraindication to the preferred agent: Austedo (deutetrabenazine)

   If yes, approve for 12 months by GPID or GPI-14 for all strengths as follows:
   40mg, 60mg, 80mg: #1 per day.
   Initiation pack (40mg-80mg): 1 pack (#28) per fill.

   If no, continue to #2.

2. Does the patient have a diagnosis of chorea associated with Huntington’s disease AND meet the following criterion?
   - The patient is 18 years of age or older

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VALBENAZINE (Ingrezza) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Moderate to severe tardive dyskinesia (TD: uncontrolled body movements)
   2. Chorea (involuntary muscle movements) associated with Huntington’s disease (a type of brain disorder)

(Denial text continued on the next page)
GUIDELINES FOR USE (CONTINUED)

B. **If you have moderate to severe tardive dyskinesia, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), movement disorder specialist, or psychiatrist (a type of mental health doctor)
   3. Your moderate to severe tardive dyskinesia have been present for at least 3 months
   4. You have a history of using antipsychotic medications (such as aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history
   5. You had a trial of or contraindication (harmful for) to the preferred medication: Austedo (deutetrabenazine)

C. **If you have chorea associated with Huntington’s disease, approval also requires:**
   1. You are 18 years of age or older

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**
For further information, please refer to the Prescribing Information and/or Drug Monograph for Ingrezza.

**REFERENCES**

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 10/01/23
Created: 04/17
Client Approval: 09/23
P&T Approval: 10/23
GUIDELINES FOR USE

1. Is the patient currently stable on the requested medication?
   
   If yes, approve for 12 months by GPID or GPI-14 as follows:
   - Caprelsa 100mg: #2 per day.
   - Caprelsa 300mg: #1 per day.

   If no, continue to #2.

2. Does the patient have diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease?
   
   If yes, approve for 12 months by GPID or GPI-14 as follows:
   - Caprelsa 100mg: #2 per day.
   - Caprelsa 300mg: #1 per day.

   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline for VANDETANIB (Caprelsa) requires ONE of the following rule(s) be met for approval:
   A. You are currently stable on the requested medication
   B. You have symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease (advanced thyroid cancer that cannot be removed with surgery or has spread in body)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
VANDETANIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Caprelsa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 05/11
Commercial Effective: 04/10/21  Client Approval: 03/21  P&T Approval: 11/13
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

2. Does the patient have a diagnosis of dry eye disease and meet ALL of the following criteria?
   10. The patient is 18 years of age or older
   11. Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
   12. The patient has at least one positive diagnostic test (e.g., tear breakup time, tear film osmolarity, ocular surface staining, Schirmer test, etc.)
   13. The patient had a trial of or contraindication to ONE ocular lubricant (e.g., carboxymethylcellulose [Refresh, Celluvisc, Thera Tears, Genteal, etc.], polyvinyl alcohol [Liqui tears, Refresh Classic, etc.], or wetting agents [Systane, Lacrilube, etc.])
   14. The patient had a trial of or contraindication to BOTH of the following preferred agents: Restasis (cyclosporine) AND Xiidra (lifitegrast)

If yes, approve for 3 months by GPID or GPI-10 with a quantity limit of #8.4 mL per 30 days.
If no, do not approve.
INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VARENICLINE (Tyrvaya) requires the following rule(s) be met for approval:
A. You have dry eye disease
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist or optometrist (types of eye doctor)
D. You have at least one positive diagnostic test (such as tear breakup time, tear film osmolarity, ocular surface staining, Schirmer test)
E. You had a trial of or contraindication to (harmful for) to ONE ocular lubricant (such as carboxymethylcellulose [Refresh, Celluvisc, Thera Tears, Genteal, etc.], polyvinyl alcohol [Liqui tears, Refresh Classic, etc.], or wetting agents [Systane, Lacrilube])
F. You had a trial of or contraindication to (harmful for) BOTH of the following preferred agents: Restasis (cyclosporine) AND Xiidra (lifitegrast)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

2. Does the patient have a diagnosis of dry eye disease AND meet the following criterion?
   • The patient has demonstrated improvement of dry eye disease

   If yes, approve for 12 months by GPID or GPI-10 with a quantity limit of #8.4 mL per 30 days.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named VARENICLINE (Tyrvaya) requires the following rule(s) be met for renewal:
   A. You have dry eye disease
   B. You have demonstrated improvement of dry eye disease

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Tyrvaya.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of unresectable or metastatic melanoma and meet ALL of the following criteria?
   - The patient has a genetic mutation called BRAF V600E as detected by an FDA-approved test
   - Zelboraf will be used alone or in combination with Cotellic (cobimetinib)

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of Erdheim-Chester Disease **AND** meet the following criterion?
   - The patient has a genetic mutation called BRAF V600

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **VEMURAFENIB (Zelboraf)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed with surgery or has spread to other parts of the body)
   2. Erdheim-Chester Disease (a type of multisystem mutation)

B. **If you have unresectable or metastatic melanoma, approval also requires:**
   1. You have a BRAF V600E mutation (a type of gene mutation) as detected by a Food and Drug Administration (FDA)-approved test
   2. Zelboraf will be used alone or in combination with Cotellic (cobimetinib)

C. **If you have Erdheim-Chester Disease, approval also requires:**
   1. You have a BRAF V600 mutation (a type of gene mutation)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
VEMURAFENIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zelboraf.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A  Created: 08/11
Commercial Effective: 07/01/22  Client Approval: 05/22  P&T Approval: 04/22
VENETOCLAX

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>VENETOCLAX</td>
<td>VENCLEXTA</td>
<td>43284</td>
<td></td>
<td>GPI-10 (2147008000)</td>
<td></td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

1. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) **OR** small lymphocytic lymphoma (SLL) and meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**
   - Venclexta Starting pack: #42 (1 pack) per 28 days.
   - Venclexta 10mg: #2 per day.
   - Venclexta 50mg: #1 per day.
   - Venclexta 100mg: #4 per day.

   If no, continue to #2.

2. Does the patient have newly-diagnosed acute myeloid leukemia (AML) and meet **ALL** of the following criteria?
   - The patient is 75 years of age or older, **OR** the patient is 18 years of age or older with comorbidities that preclude the use of intensive induction chemotherapy
   - The requested medication will be used in combination with azacitidine or decitabine

   If yes, **approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:**
   - Venclexta 10mg: #2 per day.
   - Venclexta 50mg: #1 per day.
   - Venclexta 100mg: #4 per day.

   If no, continue to #3.

**CONTINUED ON NEXT PAGE**
GUIDELINES FOR USE (CONTINUED)

3. Does the patient have newly-diagnosed acute myeloid leukemia (AML) and meet ALL of the following criteria?
   - The patient is 75 years of age or older, OR the patient is 18 years of age or older with comorbidities that preclude the use of intensive induction chemotherapy
   - The requested medication will be used in combination with low-dose cytarabine

   If yes, approve for 12 months for the requested strength by GPID or GPI-14 with the following quantity limits:
   - Venclexta 10mg: #2 per day.
   - Venclexta 50mg: #1 per day.
   - Venclexta 100mg: #6 per day.

   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VENETOCLAX (Venclexta) requires that the following rules are met for approval:
A. You have ONE of the following diagnoses:
   1. Chronic lymphocytic leukemia (CLL: type of blood and bone marrow cancer), small lymphocytic lymphoma (SLL: type of immune system cancer)
   2. Newly-diagnosed acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many undeveloped white blood cells)
B. If you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), approval also requires:
   1. You are 18 years of age or older
C. If you have newly-diagnosed acute myeloid leukemia (AML), approval also requires:
   1. You are 75 years of age or older, OR you are 18 years of age or older with comorbidities (additional diseases) that preclude (prevent) the use of intensive induction chemotherapy
   2. The requested medication will be used in combination with azacitidine or decitabine or low-dose cytarabine

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
VENETOCLAX

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Venclexta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 07/01/20
Created: 11/16
Client Approval: 04/20
P&T Approval: 07/19
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of chronic heart failure and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient has an ejection fraction of less than 45%
   - The patient is NOT concurrently taking long-acting nitrates or nitric oxide donors (e.g. isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (e.g. vardenafil, tadalafil)

   If yes, continue to #2.
   If no, do not approve.

   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Does the patient meet ALL of the following criteria?
   - The patient had a trial of or contraindication to ONE of the following preferred SGLT-2 inhibitors: Farxiga, Xigduo XR, Jardiance, Synjardy
   - The patient had a trial of or contraindication to ONE agent from EACH of the following classes:
     o ACE inhibitor (e.g., enalapril, lisinopril), ARB (e.g., valsartan, candesartan), or angiotensin receptor-neprilysin inhibitor [ARNI] (e.g., sacubitril/valsartan)
     o Beta-blocker (bisoprolol, carvedilol, metoprolol succinate)
     o Aldosterone antagonists (spironolactone or eplerenone)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named VERICIGUAT (Verquvo) requires the following rule(s) be met for approval:
   A. You have chronic heart failure
   B. You have an ejection fraction (measurement of how well your heart pumps out blood with each heartbeat) of less than 45%
   C. You are 18 years of age or older

   (Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. You will not be taking Verquvo together with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil, tadalafil)

E. You have previously tried ONE of the following sodium-glucose transporter-2 inhibitors (SGLT-2 inhibitors: class of drugs) unless there is a medical reason why you cannot (contraindication): Farxiga, Xigduo XR, Jardiance, Synjardy

F. You have previously tried ONE agent from EACH of the following classes unless there is a medical reason why you cannot (contraindication):
   1. Angiotensin converting enzyme (ACE) inhibitors (such as enalapril, lisinopril),
      angiotensin II receptor blockers (ARB: such as valsartan, candesartan), or angiotensin receptor-neprilysin inhibitor (ARNI: such as sacubitril/valsartan)
   2. Beta-blocker (bisoprolol, carvedilol, metoprolol succinate)
   3. Aldosterone antagonists (spironolactone or eplerenone)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of chronic heart failure and meet ALL of the following criteria?
   • The patient has an ejection fraction of less than 45%
   • The patient is NOT concurrently taking long-acting nitrates or nitric oxide donors (e.g. isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (e.g. vardenafil, tadalafil)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named VERICIGUAT (Verquvo) requires the following rule(s) be met for renewal:
   A. You have chronic heart failure
   B. You have an ejection fraction (measurement of how well your heart pumps out blood with each heartbeat) of less than 45%

   *(Renewal denial text continued on next page)
VERICIGUAT

RENEWAL CRITERIA (CONTINUED)

C. You will not be taking Verquvo together with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil, tadalafil)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Verquvo.

REFERENCES
GUIDELINES FOR USE

1. Does the patient have a diagnosis of refractory complex partial seizures (CPS) and meet ALL of the following criteria?
   • The patient is 2 years of age or older
   • Therapy is prescribed by or in consultation with a neurologist
   • The requested medication will be used as adjunctive therapy
   • The potential benefits outweigh the risk of vision loss
   • The patient had a trial of or contraindication to THREE antiepileptic medications, at least two of which must be generic (e.g., carbamazepine, divalproex/valproic acid, oxcarbazepine, levetiracetam IR/ER, gabapentin, zonisamide, topiramate, lamotrigine)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, continue to #2.

2. Does the patient have a diagnosis of infantile spasms and meet ALL of the following criteria?
   • The patient is 1 month to 2 years of age
   • Therapy is prescribed by or in consultation with a neurologist
   • The requested medication will be used as monotherapy
   • The potential benefits outweigh the risk of vision loss

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VIGABATRIN (Sabril, Vigadrone) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Refractory complex partial seizures (a type of seizure)
   2. Infantile spasms (a type of seizure disorder in infancy and childhood)

(Denial text continued on the next page)
GUIDELINES FOR USE (CONTINUED)

B. If you have refractory complex partial seizures, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. The requested medication will be used as adjunctive (add-on) therapy
   4. The potential benefits outweigh the risk of vision loss
   5. You had a trial of or contraindication (harmful for) to THREE antiepileptic medications, at least two of which must be generic (seizure drugs such as carbamazepine, divalproex/valproic acid, oxcarbazepine, levetiracetam immediate-release/extended-release, gabapentin, zonisamide, topiramate, lamotrigine)

C. If you have infantile spasms, approval also requires:
   1. You are 1 month to 2 years of age
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. The requested medication will be used as monotherapy (one drug for treatment)
   4. The potential benefits outweigh the risk of vision loss

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Sabril.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 05/22/23
Created: 05/22
Client Approval: 05/23
P&T Approval: 04/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic basal cell carcinoma AND meet the following criterion?
   • The patient is 18 years of age or older
   
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced basal cell carcinoma and meet ALL of the following criteria?
   • The patient is 18 years of age or older
   • The patient’s cancer has recurred following surgery or the patient is not a candidate for surgery or radiation

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
   If no, do not approve.

**DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **VISMODEGIB (Erivedge)** requires the following rule(s) be met for approval:

A. You have metastatic basal cell carcinoma or locally advanced basal cell carcinoma (type of skin cancer that has spread in the body or is advanced but has not spread)
B. You are 18 years of age or older
C. **If you have locally advanced basal cell carcinoma, approval also requires:**
   1. Your cancer has returned after surgery OR you are not a candidate for surgery or radiation

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
VISMODEGIB

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Erivedge.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/22
Created: 02/12
Client Approval: 12/21
P&T Approval: 01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of active lupus nephritis (LN) and meet ALL of the following criteria?
   - The patient is 18 years of age or older
   - Therapy is prescribed by or given in consultation with a rheumatologist or nephrologist
   - The requested medication will be used in combination with a background immunosuppressive therapy regimen (e.g., mycophenolate mofetil, corticosteroids)

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #6 per day.

APPROVAL TEXT: Renewal requires improvement in renal response from baseline laboratory values (eGFR or proteinuria) and/or clinical parameters (e.g., fluid retention, use of rescue drugs, glucocorticoid use).

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VOCLOSPORIN (Lupkynis) requires the following rule(s) be met for approval:
A. You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a rheumatologist (doctor who specializes in conditions that affect the muscles and skeletal system, especially the joints) or nephrologist (doctor who specializes in the kidney)
D. The requested medication will be used in combination with a background immunosuppressive therapy regimen (such as mycophenolate mofetil, corticosteroids)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

1. Does the patient have a diagnosis of active lupus nephritis (LN) AND meet the following criterion?
   • The patient has improvement in renal response from baseline laboratory values (i.e., eGFR or proteinuria) and/or clinical parameters (e.g., fluid retention, use of rescue drugs, glucocorticoid use)

   If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #6 per day.
   If no, do not approve.

   RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named VOCLOSPORIN (Lupkynis) requires the following rule(s) be met for renewal:
   A. You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
   B. You have improvement in renal response from baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]) and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid use)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Lupkynis.

REFERENCES
GUIDELINES FOR USE

1. Is the patient being treated for *Helicobacter pylori* (*H. pylori*) infection and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to a bismuth-based quadruple regimen (i.e., bismuth/tetracycline/metronidazole plus PPI [e.g., omeprazole, lansoprazole])

   If yes, **approve for 30 days by HICL or GPI-10 with a quantity limit of #112 per 14 days for 1 fill.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **VONOPRAZAN (Voquezna)** requires the following rule(s) be met for approval:
   A. You are being treated for *Helicobacter pylori* (*H. pylori*: a type of bacteria) infection
   B. You are 18 years of age or older
   C. You had a trial of or contraindication (harmful for) to a bismuth-based quadruple regimen (bismuth/tetracycline/metronidazole plus proton pump inhibitor [PPI, such as omeprazole, lansoprazole])

   Your doctor told us [**INSERT PT SPECIFIC INFO PROVIDED**]. We do not have information showing you [**INSERT UNMET CRITERIA**]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Voquezna.

REFERENCES
VOSORITIDE

GUIDELINES FOR USE

1. Does the patient have a diagnosis of achondroplasia and meet **ALL** of the following criteria?
   - The patient is 5 years of age or older
   - The patient has open epiphyses

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 vial per day.**
   If no, do not approve.

   **DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

   Our guideline named **VOSORITIDE (Voxzogo)** requires the following rule(s) be met for approval:
   A. You have achondroplasia (a type of bone condition)
   B. You are 5 years of age or older
   C. You have open epiphyses (the end part of a long bone)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Voxzogo.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 04/01/22
Created: 01/22
Client Approval: 02/22
P&T Approval: 01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of sickle cell disease and meet ALL of the following criteria?
   - The patient is 4 years of age or older
   - The patient has a hemoglobin of less than 10.5 g/dL
   - Therapy is prescribed by or in consultation with a hematologist
   - The patient is having symptoms of anemia which are interfering with activities of daily living
   - The patient had a trial of or contraindication to hydroxyurea

   If yes, continue to #2.
   If no, do not approve.
   DENIAL TEXT: See the initial denial text at the end of the guideline.

2. Is the request for the 300 mg tablet for oral suspension AND the patient weighs less than 40 kg?

   If yes, approve 300mg tablets for oral suspension for 6 months by GPID or GPI-14 with a quantity limit of #5 per day.
   If no, continue to #3.

3. Is the request for the 300 mg tablet for oral suspension and the patient meets ALL of the following criteria?
   - The patient weighs 40 kg or more
   - The patient has tried or has a contraindication to Oxbryta 500mg tablets
   - The patient is unable to swallow Oxbryta 500mg tablets

   If yes, approve 300mg tablets for oral suspension for 6 months by GPID or GPI-14 with a quantity limit of #5 per day.

   If no, approve for 6 months by GPID or GPI-14 as follow:
   - 500mg tablets: #3 per day.
   - 300mg tablets: #3 per day.

   CONTINUED ON NEXT PAGE
VOXELOTOR

INITIAL CRITERIA (CONTINUED)

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VOXELOTOR (Oxbryta) requires the following rule(s) be met for approval:
A. You have sickle cell disease (a type of blood disorder)
B. You are 4 years of age or older
C. Your hemoglobin (a type of blood cell) is less than 10.5 g/dL
D. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
E. You are having symptoms of anemia (a type of blood condition) which are interfering with activities of daily living
F. You had a trial of or contraindication (harmful for) to hydroxyurea
G. If the request is for the 300 mg tablets for oral suspension, approval also requires ONE of the following:
   1. You weigh less than 40 kilograms
   2. You weigh 40 kilograms or more and meet ALL of the following:
      a. You have tried or have a contraindication (harmful for) to Oxbryta 500mg tablets
      b. You are unable to swallow Oxbryta 500mg tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of sickle cell disease AND meet the following criterion?
   • The patient has maintained an improvement in symptoms associated with anemia

   If yes, approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:
   • 500mg tablets: #3 per day.
   • 300mg tablets: #3 per day.
   • 300mg tablets for oral suspension: #5 per day.

   If no, do not approve.

DENIAL TEXT: See the renewal denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named VOXELOTOR (Oxbryta) requires the following rule(s) be met for renewal:
A. You have sickle cell disease (a type of blood disorder)
B. You have maintained an improvement in symptoms associated with anemia (a type of blood condition)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Oxbryta.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A Created: 02/20
Commercial Effective: 01/16/23 Client Approval: 01/23 P&T Approval: 01/22
GUIDELINES FOR USE

1. Does the patient have a diagnosis of mantle cell lymphoma (MCL) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received at least ONE prior therapy for mantle cell lymphoma

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, continue to #2.

2. Does the patient have a diagnosis of Waldenstrom's macroglobulinemia (WM) **AND** meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, continue to #3.

3. Does the patient have a diagnosis of relapsed or refractory marginal zone lymphoma (MZL) and meet **ALL** of the following criteria?
   - The patient is 18 years of age or older
   - The patient has received at least ONE anti-CD20-based regimen

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, continue to #4.

4. Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) **AND** meet the following criterion?
   - The patient is 18 years of age or older

   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
   If no, do not approve.
   **DENIAL TEXT:** See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ZANUBRUTINIB (Brukinsa) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Mantle cell lymphoma (MCL: type of white blood cell cancer)
   2. Waldenstrom's macroglobulinemia (WM: type of blood cancer)
   3. Relapsed or refractory marginal zone lymphoma (MZL: a type of blood cancer)
   4. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   5. Small lymphocytic lymphoma (SLL: a type of blood cancer)
B. You are 18 years of age or older
C. If you have Mantle cell lymphoma (MCL), approval also requires:
   1. You have previously received at least ONE prior therapy for mantle cell lymphoma
D. If you have relapsed or refractory marginal zone lymphoma (MZL), approval also requires:
   1. You have received at least ONE anti-CD20-based regimen (a type of blood cancer treatment plan)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Brukinsa.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 02/06/23
Created: 02/20
Client Approval: 01/23
P&T Approval: 01/23
ZAVEGEPANT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th>HICL</th>
<th>GCN</th>
<th>Medi-Span</th>
<th>Exception/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZAVEGEPANT HCL</td>
<td>ZAVZPRET</td>
<td>48771</td>
<td>GCN</td>
<td>GPI-10</td>
<td>(6770109020)</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Is the request for the acute treatment of migraines and the patient meets ALL of the following criteria?
   - The patient is 18 years of age or older
   - The patient had a trial of or contraindication to ONE triptan (e.g., Imitrex [sumatriptan], Maxalt [rizatriptan])
   - The patient had a trial of or contraindication to TWO of the following preferred agents: Reyvow (lasmiditan), Nurtec ODT (rimegepant), Ubrelvy (ubrogepant)
   - The patient is unable to tolerate oral medications

If yes, approve for 6 months by HICL or GPI-10 with a quantity limit of #8 per 30 days. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named ZAVEGEPANT (Zavzpret) requires the following rule(s) be met for approval:
A. The request is for the acute (quick onset) treatment of migraines (a type of headache)
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to ONE triptan (such as Imitrex [sumatriptan], Maxalt [rizatriptan])
D. You had a trial of or contraindication (harmful for) to TWO of the following medications: Reyvow (lasmiditan), Nurtec ODT (rimegepant), Ubrelvy (ubrogepant)
E. You are NOT able to tolerate oral medications

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
ZAVEGEPANT

RENEWAL CRITERIA

1. Is the request for the acute treatment of migraines?
   If yes, continue to #2.
   If no, do not approve.
   **DENIAL TEXT:** See the renewal denial text at the end of the guideline.

2. Has the patient experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (e.g., Migraine Assessment of Current Therapy [Migraine-ACT])?
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per 30 days.**
   If no, continue to #3.

3. Has the patient experienced clinical improvement as defined by **ONE** of the following criteria?
   - Ability to function normally within 2 hours of dose
   - Headache pain disappears within 2 hours of dose
   - Therapy works consistently in majority of migraine attacks
   If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per 30 days.**
   If no, do not approve.

**RENEWAL DENIAL TEXT:** *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.*

Our guideline named **ZAVEGEPANT (Zavzpret)** requires the following rule(s) be met for approval:
A. The request is for the acute (quick onset) treatment of migraines (a type of headache)
B. You meet **ONE** of the following:
   1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
   2. You have experienced clinical improvement as defined by **ONE** of the following:
      a. Ability to function normally within 2 hours of dose
      b. Headache pain disappears within 2 hours of dose
      c. Treatment works consistently in a majority of migraine attacks

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**CONTINUED ON NEXT PAGE**
ZAVEGEPANT

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Zavzpret.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 08/01/23
Created: 06/23
Client Approval: 06/23
P&T Approval: 01/23
ZONISAMIDE

GUIDELINES FOR USE

1. Does the patient have a diagnosis of partial-onset seizures and meet ALL of the following criteria?
   - The patient is 16 years of age or older
   - Zonisade will be used as adjunctive treatment
   - The patient is unable to swallow zonisamide capsules

   If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #30 mL per day.
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these
definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named ZONISAMIDE (Zonisade) requires the following rule(s) be met for approval:
   A. You have partial-onset seizures (a type of seizure)
   B. You are 16 years of age or older
   C. Zonisade will be used as adjunctive (add-on) treatment
   D. You are unable to swallow to zonisamide capsules

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information
   showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with
   your doctor to use a different medication or get us more information if it will allow us to approve
   this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for
Zonisade.

REFERENCES

<table>
<thead>
<tr>
<th>Library</th>
<th>Commercial</th>
<th>NSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Part D Effective: N/A
Commercial Effective: 01/01/23
Created: 11/22
Client Approval: 11/22
P&T Approval: 10/22
<table>
<thead>
<tr>
<th>Category</th>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>BYNFEZIA</td>
<td>872</td>
</tr>
<tr>
<td>C</td>
<td>C1 ESTERASE INHIBITOR (BERINERT)</td>
<td>234</td>
</tr>
<tr>
<td></td>
<td>C1 ESTERASE INHIBITOR (CINRYZE)</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>C1 ESTERASE INHIBITOR (HAEGARDA)</td>
<td>238</td>
</tr>
<tr>
<td></td>
<td>C1 ESTERASE INHIBITOR, RECOMBINANT</td>
<td>240</td>
</tr>
<tr>
<td></td>
<td>CABLIPI</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>CABOMETYX</td>
<td>242</td>
</tr>
<tr>
<td></td>
<td>CAFOTEGAVIR</td>
<td>1049</td>
</tr>
<tr>
<td></td>
<td>CACZANTINIB S-MALATE</td>
<td>242</td>
</tr>
<tr>
<td></td>
<td>CALQUENCE</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>CAMZYGOS</td>
<td>785</td>
</tr>
<tr>
<td></td>
<td>CAPECITABINE</td>
<td>246</td>
</tr>
<tr>
<td></td>
<td>CAPLACIZUMAB-YHDP</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>CAPMATINIB HYDROCHLORIDE</td>
<td>252</td>
</tr>
<tr>
<td></td>
<td>CAPRELSA</td>
<td>1489</td>
</tr>
<tr>
<td></td>
<td>CAPSIACIN 8% PATCH</td>
<td>253</td>
</tr>
<tr>
<td></td>
<td>CARAC</td>
<td>564</td>
</tr>
<tr>
<td></td>
<td>CARAGLU</td>
<td>256</td>
</tr>
<tr>
<td></td>
<td>CARBIDOPA/LEVODOPA</td>
<td>254</td>
</tr>
<tr>
<td></td>
<td>CARBOXYMETHYCELLULOSE-CELLULOSE-CITRIC ACID</td>
<td>255</td>
</tr>
<tr>
<td></td>
<td>CARGUMMEL ACID</td>
<td>256</td>
</tr>
<tr>
<td></td>
<td>CARAINE NF NANOFILTERED (COMMERCIAL, NSA)</td>
<td>642</td>
</tr>
<tr>
<td></td>
<td>CAYSTON</td>
<td>182</td>
</tr>
<tr>
<td></td>
<td>CELECOXIB (ELYXYB)</td>
<td>259</td>
</tr>
<tr>
<td></td>
<td>CENGERMIN-BKBJ</td>
<td>260</td>
</tr>
<tr>
<td></td>
<td>CEOUT SIMPLIITY</td>
<td>262</td>
</tr>
<tr>
<td></td>
<td>CEOUT SIMPLIITY INSERTER</td>
<td>262</td>
</tr>
<tr>
<td></td>
<td>CERITINIB</td>
<td>267</td>
</tr>
<tr>
<td></td>
<td>CERTOLIZUMAB PEGOL</td>
<td>268</td>
</tr>
<tr>
<td></td>
<td>CGM STEP OVERIDE</td>
<td>297</td>
</tr>
<tr>
<td></td>
<td>CHANTIX</td>
<td>1194</td>
</tr>
<tr>
<td></td>
<td>CHENODAL</td>
<td>282</td>
</tr>
<tr>
<td></td>
<td>CHENODIOL</td>
<td>282</td>
</tr>
<tr>
<td></td>
<td>CHOLAM</td>
<td>285</td>
</tr>
<tr>
<td></td>
<td>CHOLIC ACID</td>
<td>285</td>
</tr>
<tr>
<td></td>
<td>CLALIS</td>
<td>1322</td>
</tr>
<tr>
<td></td>
<td>CIBINOQ</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>CIMQIA</td>
<td>268</td>
</tr>
<tr>
<td></td>
<td>CINRYZE</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>CLADRIKINE</td>
<td>287</td>
</tr>
<tr>
<td></td>
<td>CLASCOTERONE</td>
<td>289</td>
</tr>
<tr>
<td></td>
<td>CLEPIQ</td>
<td>213</td>
</tr>
<tr>
<td></td>
<td>CLEOBAM-SYMPAZAN</td>
<td>291</td>
</tr>
<tr>
<td></td>
<td>CLOVIQUE</td>
<td>1447</td>
</tr>
<tr>
<td></td>
<td>COBIMETINIB FUMARATE</td>
<td>293</td>
</tr>
<tr>
<td></td>
<td>COLLAGENASE CLOSTRIDIUM HIST</td>
<td>295</td>
</tr>
<tr>
<td></td>
<td>COMETRIQ</td>
<td>242</td>
</tr>
<tr>
<td></td>
<td>CONJURPI</td>
<td>742</td>
</tr>
<tr>
<td></td>
<td>CONSENSI</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>CONTINUOUS BLOOD GLUCOSE SENSOR (CGM STEP)</td>
<td>297</td>
</tr>
<tr>
<td></td>
<td>CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER</td>
<td>299</td>
</tr>
</tbody>
</table>
CONNUUS BLEOD-GLUCOSE METER/RECEIVER   DEPEXAL                      360
(CONM STEP)                              DESIRUDIN                     372
CONNUUS BLEOD-GLUCOSE RECIPER (CMG      DEUCRACATINIB                  373
STEP)                                     DEUTETRABENAZINE              376
CONTUUS GLOUCSE MONTORS - STAND-ALONE    DEXCOM G4                      299
CONJUUS COTACEPTIVE ZERO COPAY OVERRIDE  DEXCOM G5                      299
CONJUUS COTACEPTIVE, INTRAVAGINAL       DEXCOM G5-G4 SENSOR           299
CONJUUS COTACEPTIVES, IMPLANTABLE       DEXCOM G6                      297
CONJUUS COTACEPTIVES, INJECTABLE        DEXCOM G6 TRASMITTER          297
CONJUUS COTACEPTIVES, INTRAVAGINAL, SYSTEM 305
CONJUUS COTACEPTIVES, ORAL              DEXTROMETHORPHAN HBR/BUPROPION 378
CONJUUS COTACEPTIVES, TRANSDERMAL       DEXTROMETHORPHAN               380
CONTRAVE ER                                118
COPAXONE                                  591
COPERKTRA                                  413
CORTICOTROPIN                              309
COSENTYX                                   1135
COTELIC                                    293
CRESEMBA                                   677
CRESTOR                                    1313
CRIZOTINIB                                  311
CUPRIMINE                                   1007
CUTAQUIG                                   642
CUVITRUI                                   642
CUVROR                                     1449
CYCLOSPORINE (VERKAZIA)                   313
CYLTEZO                                    43
CYSTADANE                                  203
CYSTADROPS                                 315
CYSTARAN                                    315
CYSTEAMINE BITARTRATE                      314
CYSTEAMINE HCL                             315

D
DABIGATRAN ETExILATE MESELAITE             317
DABRAFENIB MESYLAITE                       319
DACLATASVIR DIHYDROCHLORIDE                323
DACOMITINIB                                328
DALKINZA                                   323
DALFAMPRIDINE                              330
DARAPRIM                                   1053
DARBEPOETIN ALFA IN POLYSORBAT             332
DARIDOREXANT HCL                           340
DAROLUTAMIDE                               343
DASATINIB                                   347
DAURISMO                                   589
DAYBUE                                     1456
DECITABINE                                  350
DEFERASIROX                                352
DEFERIPRONE                                356
DEFEROXAMINE                               360
DEFLAZACORT                                362
DELAFLOXACIN                               367
DEPEN                                      1007
DEPO-TESTOSTERONE                          1368
DESCOVY                                    1049

DESEFALAL                              360
DESIURUDIN                                372
DEUCRACATINIB                             373
DEUTETRABENAZINE                          376
DEXCOM G4                                 299
DEXCOM G5                                 299
DEXCOM G5-G4 SENSOR                       299
DEXCOM G6                                 297
DEXCOM G6 TRASMITTER                      297
DEXTROMETHORPHAN HBR/BUPROPION            378
DEXTROMETHORPHAN                          380
DIABETIC SUPPLIES,MISCCELL               262
DIABETIC TEST STRIPS                     381
DIACOMIT                                 1318
DIAPHRAGMS/CERVICAL CAP                305
DIBENZYLIN                                 1019
DICHLOORPHENAMIDE                         383
DICLOFENAC SODIUM (PENNSAID)               387
DICLOFENAC SODIUM (SOLARAZE)              386
DIFFERIN                                 28
DIGOXIN                                   388
DIMETHYL FUMARATE                         389
DIOXIMEF FUMARATE                         391
DJOLVI                                    1454
DONEPEZIL HCL                             392
DOPTETLET                                 176
DORNASE ALFA                              393
D-PENAMINE                                1007
DRIZALMA SPRINKLE                         398
DROXIDOPA                                 395
DULAGLUTIDE                                600
DULOXETINE HCL (DRIZALMA SPRINKLE)        398
DUOPA                                     254
DUPILUMAB                                  400
DUPIXENT                                  400
DURAGESIC                                 528
DURLAZA                                    157
DUVELISIB                                  413

E
EDARAVONE (ORAL)                           414
EDCRIN                                     501
EFINAUNAZOLE                                417
EFLAPEGRASMIN-XNST                        422
EGRIFTA                                   1360
EGRIFTA SV                                1360
ELACESTRANT                               424
ELAGOLIX AND ESTRADIOL AND NORETHINDRONE  435
ELAGOLIX SODIUM                           426
ELAPEGADEMASE-LVLR                        419
ELBASVIR/GRAZOPREVIS                   430
LEXACAFTOR/TEZACAFTOR/IVACAFTOR            438
ELIYARD                                  740
ELMIRON                                   1014
ELTROMBOPAG OLAMINE                       443
ELYXADOLINE                               451
<table>
<thead>
<tr>
<th>G</th>
<th>H</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>GALAFOLD</td>
<td>UNAKANGLUQ</td>
<td>HYDROCORTISONE</td>
</tr>
<tr>
<td>GALCANEZUMAB-GNLM</td>
<td></td>
<td>HYDROMORPHONE HCL</td>
</tr>
<tr>
<td>GAMASTAN S-D (COMMERCIAL, NSA)</td>
<td></td>
<td>HYFTOR</td>
</tr>
<tr>
<td>GAMMAGARD LIQUID (COMMERCIAL, NSA)</td>
<td></td>
<td>HYQVIA (COMMERCIAL, NSA)</td>
</tr>
<tr>
<td>GAMMAGARD S-D (COMMERCIAL, NSA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAMAQUE (COMMERCIAL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAVRETO</td>
<td></td>
<td>IBBRANCE</td>
</tr>
<tr>
<td>GEFITINIB</td>
<td></td>
<td>IBREXAFUNGERP CITRATE</td>
</tr>
<tr>
<td>GENOTROPIN</td>
<td></td>
<td>IBRUTINIB</td>
</tr>
<tr>
<td>GILENYA</td>
<td></td>
<td>IBSRELA</td>
</tr>
<tr>
<td>GILOTRIF</td>
<td></td>
<td>ICATIBANT ACETATE</td>
</tr>
<tr>
<td>GILTEFIBRUMARATE</td>
<td></td>
<td>ICLUSIG</td>
</tr>
<tr>
<td>GIMOTI</td>
<td></td>
<td>IDELALISIB</td>
</tr>
<tr>
<td>GLASDEGB MALEATE</td>
<td></td>
<td>IDHIFA</td>
</tr>
<tr>
<td>GLATIRAMER ACETATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLUTAMINE (L)-GLUTAMINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLYCEROL PHENYL BUTYRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLYCOPYRRIONIUM TOSYLATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOCOVRI</td>
<td></td>
<td>IGG/HYALURONIDASE, RECOMBINANT</td>
</tr>
<tr>
<td>GOLIMUBAB - SQ</td>
<td></td>
<td>(COMMERCIAL, NSA)</td>
</tr>
<tr>
<td>GOLYTELY</td>
<td></td>
<td>ILOPROST TROMETHAMINE</td>
</tr>
<tr>
<td>GR POL-ORC/SW VER/RYE/KENT/TIM</td>
<td></td>
<td>IMATINIB MESYLATE</td>
</tr>
<tr>
<td>GRANIX</td>
<td></td>
<td>IMBRUVICA</td>
</tr>
<tr>
<td>GRASS POLLEN-TIMOTHY, STD</td>
<td></td>
<td>IMCIVREE</td>
</tr>
<tr>
<td>GRASKE</td>
<td></td>
<td>IMMUN GLOB G(IGG)/GLY/IGA OV50</td>
</tr>
<tr>
<td>GUARDIAN 4 GLUCOSE SENSOR</td>
<td></td>
<td>IMMUN GLOB G(IGG)-HIPP/MALTOSE</td>
</tr>
<tr>
<td>GUARDIAN 4 TRANSMITTER</td>
<td></td>
<td>IMMUN GLOB G(IGG)-IFAS/GLYCINE</td>
</tr>
<tr>
<td>GUARDIAN CONNECT TRANSMITTER</td>
<td></td>
<td>IMMUNE GLOB, GAM CAPRYLATE (COMMERCIAL,</td>
</tr>
<tr>
<td>GUARDIAN LINK 3 TRANSMITTER</td>
<td></td>
<td>NSA)</td>
</tr>
<tr>
<td>GUARDIAN SENSOR 3</td>
<td></td>
<td>IMMUNE GLOBULIN (HUMAN)-KLHW</td>
</tr>
<tr>
<td>GUSELKUMAB</td>
<td></td>
<td>IMMUNE GLOBULIN (HUMAN)-SLRA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IMMUNE GLOBULIN / MALTOSE (COMMERCIAL, NSA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IMMUNE GLOBULIN INTRAVENOUS (COMMERCIAL, NSA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IMPAVIDO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INBRJUA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INCRELEX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INDOGIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INDOMETHACIN (SUSPENSION)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INFAGRATINIB PHOSPHATE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INGENOL MEBUTATE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INGREZZA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INHALED INSULIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INLYTA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTOXEREN SODIUM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INOQUI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INREBIC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INSULIN REGULAR, HUMAN (AFREZZA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON ALFA-2B,RECOMB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON BETA-1A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON BETA-1A/ALBUMIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON BETA-1B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON GAMMA-1B,RECOMB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON FOR MS - AVONEX</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON FOR MS - BETASERON</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON FOR MS - EXTAVIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON FOR MS - PLEGIRIDY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTERFERON FOR MS - REBIF</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTRA-UTERINE DEVICES (IUD'S)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>INTRON A</td>
</tr>
</tbody>
</table>

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
PRIVIGEN (COMMERCIAL, NSA) ........................................ 642
PROCIRIT ............................................................... 466
PROCYSBI .............................................................. 314
PROMACTA .............................................................. 443
PULMOZYME ........................................................... 393
PYRIMETHAMINE ....................................................... 1053
PYRUKYND ............................................................. 834
Q
QBREXZA ................................................................. 604
QDOLO ................................................................. 1428
QINLOCK .............................................................. 1092
QSYMIA ................................................................. 118
QUILIPA ................................................................. 164
QUINZEA ............................................................... 253
QUIVIVIQ ................................................................. 340
R
RADICAVA ORS ......................................................... 414
RAGWITEK .............................................................. 74
RALOXIFENE HCL ..................................................... 217
RANOLAZINE ......................................................... 1058
RAVICTI ................................................................. 602
RAYOS ................................................................. 1047
REBIF ................................................................. 672
REBIF REBIDOSE .................................................. 672
REBOTA ................................................................. 516
RECORLEV ............................................................ 749
REGORAFENIB ......................................................... 1060
RELEUKO ............................................................... 542
RELISTOR ............................................................... 806
RELTONIC ............................................................. 1479
RELUGOLIX ........................................................... 1063
RELUGOLIX/ESTRADION/NORETHINDRONE ACETATE ... 1064
RELYVrio .............................................................. 1222
REMODULIN .......................................................... 1439
RETACRIT ............................................................. 478
RETEVMO .............................................................. 1158
RETIN-A MICRO ....................................................... 28
RETIN-A MICRO PUMP ............................................ 28
REVATIO (IV) ............................................................ 1166
REVATIO (SUSPENSION) ........................................... 1170
REVATIO (TABLET) .................................................. 1176
REVCOVI ............................................................... 419
REVlimID .............................................................. 725
REYVOW ............................................................... 708
REZlidhIA .............................................................. 889
REZUROCK ............................................................ 194
RIBOCICLIB SUCINATE ............................................ 1068
RIBOCICLIB SUCINATE / LETRZOLE ......................... 1071
RIFAXIMIN ........................................................... 1073
RILONACEPT ........................................................ 1078
RILUZOLE ............................................................. 1082
RIMEGEPANT SULFATE ............................................. 1084
RINVOQ .............................................................. 1467
ROICIQUIT ............................................................ 1088
RIPRETINIB .......................................................... 1092
RISANKIZUMAB-RZAA ........................................... 1093
RISDIPLAM .......................................................... 1099
RITLICITINIB TOSYLATE .......................................... 1103
ROFLUMILAST ....................................................... 1107
ROLVEDON .......................................................... 422
ROPEGINTERFERON ALFA-2B-NJFT ......................... 1110
ROSUVASTATIN CALCIUM ....................................... 1313
ROZLYTREK .......................................................... 460
RUBRACA ............................................................. 1111
RUCAPARIB CAMSYLATE ....................................... 1111
RUCONEST ........................................................... 240
RUKOBIA .............................................................. 573
RUXOLITINIB PHOSPHATE ....................................... 1114
RUXOLITINIB PHOSPHATE TOPICAL ......................... 1118
RUZURGI .............................................................. 90
RYDAPT ............................................................... 814
RYLAZE ............................................................... 150
RYPLAZIM ........................................................... 1034
S
SABRIL ................................................................. 1501
SACROSIDASE ....................................................... 1123
SAIZEN ............................................................... 1285
SAIZEN-SAIZENPREP .............................................. 1285
SAJAZIR ............................................................... 628
SANDOSTATIN LAR DEPOT ..................................... 866
SANTYL ................................................................. 295
SARGRAMOSTIM ..................................................... 1125
SARILUMAB .......................................................... 1127
SATRALIZUMAB-MWGE .......................................... 1132
SAXENDA ............................................................. 1118
SCEMBLIX ............................................................ 148
SECUKINUMAB ....................................................... 1135
SELEXIPAG .......................................................... 1151
SELINEXOR .......................................................... 1155
SELPERCATINIB .................................................... 1158
SELUMETINIB ........................................................ 1161
SEMAGLUTIDE ....................................................... 118, 600
SEROSTIM ............................................................ 1289
SETMELANOTIDE ACETATE .................................... 1162
SIGNIFOR ............................................................ 968
SILDENAFIL CITRATE (IV)-REVATIO ......................... 1166
SILDENAFIL CITRATE (SUSPENSION)-REVATIO ....... 1170
SILDENAFIL CITRATE (TABLET)-REVATIO ................ 1176
SILIQ ................................................................. 225
SIMEPREVIR ........................................................ 1181
SIMPOI - SQ ........................................................ 605
SIMVASTATIN ......................................................... 1313
SIMVASTATIN 80 ..................................................... 1185
SIMVASTATIN ORAL SUSPENSION ......................... 1186
SINUVA (NSA) ....................................................... 838
SIPONIMOD .......................................................... 1189
SIROLILUS TOPICAL (HYFTOR) ................................ 1192
SIRTURO .............................................................. 189
SKYCLARYS .......................................................... 902

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
SKYRIZI..........................................................1093
SKYTROFA..................................................767
SMOKING CESSATION ZERO COST SHARE OVERRIDE ...........................................1194
SOAANZ ............................................................1423
SOD PHENYL BUTYRAT / TAURURSODIOL ......................................................1222
SOD PHOSPHATE MBAS / SOD PHOS_DI ..........................................................213
SOD PICOSULF / MAG OX / CITRIC AC ..............................................................213
SOD SULF / POT CHLORIDE / MAG SULF ..........................................................213
SODIUM CHLORIDE/NAHCO3/ KCL/PE ...............................................................213
SODIUM OXYBATE (LUMRYZ) ..........................................................................1205
SODIUM OXYBATE (XYREM) ..........................................................................1210
SODIUM PHENYL BUTYRATE ..........................................................................1217
SODIUM, CALCIUM, MAG, POT OXYBATE ......................................................1198
SODIUM, POTASSIUM, MAG SULFATES ..........................................................213
SOFSUBUR ............................................................1224
SOFSUBUR/VELPATASVIR ..........................................................................1234
SOFSUBUR/VELPATASVIR/VOXILAPREVIR ..................................................1238
SOLARAZE ...............................................................386
SOLIFENACIN SUCCINATE ..........................................................................1242
SOLIRAMFETOL ...............................................................1243
SOMATROGON-GHIA ..........................................................................1247
SOMATROPIN ...............................................................1258
SOMATROPIN (GENOTROPIN) ..............................................................1251
SOMATROPIN (NORDITROPIN) ..............................................................1265
SOMATROPIN (NUTROPIN AQ NUSPIN) ..................................................1272
SOMATROPIN (OMNITROPE) ..............................................................1278
SOMATROPIN (SAIZEN) ...............................................................1285
SOMATROPIN (SEROSTIM) ...............................................................1289
SOMATROPIN (ZOMACTON) ...............................................................1294
SOMATROPIN (ZORBTIVE) ..............................................................1301
SONIDEB PHOSPHATE .................................................................1304
SORAFENIB TOSYLATE ..............................................................1306
SOTORASIB ...............................................................1308
SOTYKU .................................................................373
SOVALDI .................................................................1224
SPARSENTAN ...............................................................1310
SPRITAM .................................................................743
SPRYCEL .................................................................347
STATIN ZERO COST SHARE OVERRIDE ..................................................1313
STELARA .................................................................1481
STIMUFEND ...............................................................992
STIRIPENTOL ...............................................................1318
STIVARGA .................................................................1060
STROSIQ .................................................................151
STRIANT .................................................................1362
SUBCUTANEOUS INSULIN PUMP ..........................................................1457
SUBSYS .................................................................526
SUCRAID .................................................................1123
SUFLEA .................................................................213
SUNITINIB MALATE ..............................................................1320
SUNLENCA ...............................................................723
SUNOSI .................................................................1243
SUPREP .................................................................213
SUTAB .................................................................213
SUTENT .................................................................1320
SYLATRON ...............................................................998
SYLATRON 4-PACK ............................................................998
SYDEKO .................................................................1385
SYMPAZAN ...............................................................291
SYNAREL .................................................................843
SYNRIBO .................................................................890
SYPRINE .................................................................1447

T

T: SLIM/MINIMED INSULIN PUMPS ..................................................1457
T:SLIM X2 ..............................................................1457
T:SLIM X2 CONTROL-IQ ..........................................................1457
T:SLIM X2 WITH BASAL-IQ ..........................................................1457
TABRECTA ...............................................................252
TADALAFIL (CIALIS) ..............................................................1322
TADALAFIL-ADCIRCA, ALYQ ..........................................................1324
TADALAFIL-TADLIQ ..............................................................1327
TADLIQ .................................................................1327
TAFAFIDIS ..............................................................1330
TAFAFIDIS MEGLUMINE ..........................................................1330
TAFINLAR .................................................................319
TAGRISSO .................................................................950
TAKHYRO .................................................................701
TALAZOPARIB TOSYLATE ..............................................................1333
TALTZ .................................................................690
TALZENNA ..............................................................1333
TAMOXIFEN CITRATE ..............................................................217
TAPIAROF ..............................................................1336
TARCEVA .................................................................492
TARGETIN .................................................................204
TARPEYO .................................................................231
TASCENSO ODT ..............................................................554
TASIGNA .................................................................849
TASIMELTEON ..............................................................1339
TAVABOROLE ..............................................................1341
TAVALISSE .................................................................570
TAVNEOS .................................................................172
TAZEMETOSTAT ..............................................................1343
TAVRERIK .................................................................1343
TBO-FILGRASTIM ..............................................................1345
TECIFERIL .................................................................389
TECHNIVIE .................................................................903
TEDUGLITIDE ..............................................................1347
TEGSEDI .................................................................660
TELOTRIPTAT ..............................................................1349
TEMODAR ..............................................................1351
TENASONIC ..............................................................1352
TENAPANOR HCL ..............................................................1354
TENOFOVIR DISOPROXIL FUMARATE ..................................................1049
TEPMETKO ..............................................................1355
TEPOTINIB HCL ..............................................................1355
TERIFLUNOMIDE ..............................................................1356
TERIPARATIDE ..............................................................1357
TESAMORELIN ..............................................................1360
TESTIM .................................................................1362
TESTOSTERONE ..............................................................1362
TESTOSTERONE CYPRIONATE ..................................................1368
TESTOSTERONE ENANTHATE ..................................................1372
TESTOSTERONE UNDECAANOATE ..................................................1378

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/15/2023
MEDIMPACT

STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TESTRED .......................................................... 808
TETRABENAZINE .................................................. 1383
TEZACAFTOR/IVACAFTOR ....................................... 1385
TEZEPELUMAB-EKKO (NSA) ................................... 1390
TEZSPIRE (NSA) .................................................. 1390
THALIDOMIDE .................................................... 1395
THALOMID ........................................................ 1395
TIBSOVO ........................................................... 686
TIGLUTIK .......................................................... 1082
TIROSINT .......................................................... 753
TIROSINT-SOL ..................................................... 755
TIRZEPATIDE ....................................................... 600
TIVOZANIB HCL .................................................. 1397
TLANDO ............................................................. 1378
TOBI ................................................................. 1398
TOBI PODHALER .................................................. 1398
TOBRAMYCIN ...................................................... 1398
TOBRAMYCIN IN 0.225% SOD CHLOR ...................... 1398
TOBRAMYCIN INHALED ......................................... 1398
TOBRAMYCIN/NEBULIZER ..................................... 1398
TOCILIZUMAB-SQ .............................................. 1400
TOFACITINIB CITRATE ........................................ 1407
TOLSURA .......................................................... 681
TOLVAPTAN ......................................................... 1415
TOPIRAMATE (EPRONTE) ....................................... 1418
TOREMIFENE CITRATE ......................................... 1422
TORSEMIDE ....................................................... 1423
TRACLEER ........................................................ 207
TRALOKINUMAB-LDRM ....................................... 1424
TRAMADOL HCL .................................................... 1428
TRAMETINIB DIMETHYL SULFOXIDE ..................... 1430
TREMZYA .......................................................... 614
TREPROMINIL ..................................................... 1434
TREPROMINIL DIOLAMINE .................................... 1443
TREPROMINIL DPI ............................................... 1434
TREPROMINIL SODIUM ........................................ 1439
TRETINOIN MICROSPHERES ................................... 28
TRIENTINE HCL .................................................. 1447
TRIENTINE TETRAHYDROCHLORIDE ...................... 1449
TRIFAROTENE ..................................................... 28
TRIFLURIDINE/TIPRACIL HCL ................................ 1451
TRIHaupto ........................................................ 1454
TRIAKIFTA ........................................................ 438
TROFINETIDE ..................................................... 1456
TRULICITY ........................................................ 600
TRUSELTIQ ........................................................ 651
TRUVAZA ........................................................... 1049
TUKATINIB ........................................................ 1462
TUKVYA ............................................................. 1462
TURING ............................................................ 1018
TYKerb ............................................................. 704
TYMLOS ............................................................ 73
TYVAYA ............................................................. 1491
TYVOSO ............................................................ 1434

UBRILGANT ......................................................... 1464
UDENYA ............................................................ 990
UPADACITINIB .................................................... 1467
UPNCEQ ............................................................ 955
UPTRA ............................................................... 1151
URIDINE TRIACETATE ........................................... 1477
URSOLO ............................................................. 1479
USTEGNAB ........................................................ 1481

V

VALBENAZINE TOSYATE ....................................... 1487
VALCHLOR ......................................................... 794
VANDITANIB ...................................................... 1489
VARENICLINE TARTRATE ....................................... 1491
VARENICLINE TARTRATE (CHANTIX) .................... 1194
VECAMY ............................................................ 789
VELTASSA ........................................................ 970
VEMURAFENIB .................................................... 1493
VENCLEXTA ....................................................... 1495
VENETOCLAX ..................................................... 1495
VENTAVIS .......................................................... 631
VEOZA ............................................................... 534
VERICIGUAT ...................................................... 1498
VERKAZIA ........................................................ 313
VEROVO ............................................................. 1498
VERZEKO .......................................................... 14
VESICARE LS ...................................................... 1242
VIBERZI ............................................................. 451
VICTOZA ........................................................... 600
VIKIRI PAK ........................................................ 907
VIKIRI XR .......................................................... 907
VIGABATRIN ....................................................... 1501
VIGADROINE ...................................................... 1501
VIJOICE ............................................................. 82
VIREAD ............................................................. 1049
VISMODEGIB ...................................................... 1503
VITRAKVI ........................................................... 706
VIVIOJA ............................................................. 953
VIZIMPRO .......................................................... 328
VOCLORPORIN .................................................... 1505
VOGELADO ........................................................ 1362
VONJIO .............................................................. 960
VONOPRANZ ................. 1507
VOQUEZA DUAL PAK ........................................ 1507
VOQUEZA TRIPLE PAK ....................................... 1507
VOSV ................................................................. 1238
VOSORITIDE ....................................................... 1508
VOTRIENT ........................................................ 973
VOWST .............................................................. 514
VOXELATOR ....................................................... 1509
VOXZOGO .......................................................... 1508
VTAMA .............................................................. 1336
VUYI ................................................................. 1021
VUMERITY ........................................................ 391
VYLESE ............................................................ 220
VYNDAMAX ......................................................... 1330
VYNDAGEL ......................................................... 1330

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
# STANDARD COMMERCIAL DRUG FORMULARY
## PRIOR AUTHORIZATION GUIDELINES

<table>
<thead>
<tr>
<th>W</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WAKIX</td>
<td>........................................... 1030</td>
</tr>
<tr>
<td>WEED POLLEN-SHORT RAGWEED</td>
<td>........................................... 74</td>
</tr>
<tr>
<td>WEGOVY</td>
<td>........................................... 118</td>
</tr>
<tr>
<td>WELIREG</td>
<td>........................................... 195</td>
</tr>
<tr>
<td>WINLEVI</td>
<td>........................................... 289</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>X</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>XALKORI</td>
<td>........................................... 311</td>
</tr>
<tr>
<td>XELJANZ</td>
<td>........................................... 1407</td>
</tr>
<tr>
<td>XELJANZ XR</td>
<td>........................................... 1407</td>
</tr>
<tr>
<td>XELODA</td>
<td>........................................... 246</td>
</tr>
<tr>
<td>XEMBIFY</td>
<td>........................................... 642</td>
</tr>
<tr>
<td>XENAZINE</td>
<td>........................................... 1383</td>
</tr>
<tr>
<td>XENICAL</td>
<td>........................................... 118</td>
</tr>
<tr>
<td>XENLETA</td>
<td>........................................... 721</td>
</tr>
<tr>
<td>XERMELO</td>
<td>........................................... 1349</td>
</tr>
<tr>
<td>XIFAXAN</td>
<td>........................................... 1073</td>
</tr>
<tr>
<td>XOLAIR</td>
<td>........................................... 895</td>
</tr>
<tr>
<td>XOSPATA</td>
<td>........................................... 588</td>
</tr>
<tr>
<td>XPOVIO</td>
<td>........................................... 1155</td>
</tr>
<tr>
<td>XTANDI</td>
<td>........................................... 462</td>
</tr>
<tr>
<td>XURIDEN</td>
<td>........................................... 1477</td>
</tr>
<tr>
<td>XYOSTED</td>
<td>........................................... 1372</td>
</tr>
<tr>
<td>XYREM</td>
<td>........................................... 1210</td>
</tr>
<tr>
<td>XYWAV</td>
<td>........................................... 1198</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Y</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>YONSAL</td>
<td>........................................... 19</td>
</tr>
<tr>
<td>YOSPRAL</td>
<td>........................................... 159</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Z</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ZANUBRTINIB</td>
<td>........................................... 1512</td>
</tr>
<tr>
<td>ZARXIO</td>
<td>........................................... 545</td>
</tr>
<tr>
<td>ZAVEGEPANT HCL</td>
<td>........................................... 1514</td>
</tr>
<tr>
<td>ZAVESCA</td>
<td>........................................... 823</td>
</tr>
<tr>
<td>ZAVPRTE</td>
<td>........................................... 1514</td>
</tr>
<tr>
<td>ZEJULA</td>
<td>........................................... 857</td>
</tr>
<tr>
<td>ZELBORAF</td>
<td>........................................... 1493</td>
</tr>
<tr>
<td>ZEPATIER</td>
<td>........................................... 430</td>
</tr>
<tr>
<td>ZEPOSIA</td>
<td>........................................... 957</td>
</tr>
<tr>
<td>ZIEXTENZ</td>
<td>........................................... 988</td>
</tr>
<tr>
<td>ZOCOR</td>
<td>........................................... 1313</td>
</tr>
<tr>
<td>ZOCOR-SIMVASTATIN 80</td>
<td>........................................... 1185</td>
</tr>
<tr>
<td>ZOKINVY</td>
<td>........................................... 765</td>
</tr>
<tr>
<td>ZOMACTON</td>
<td>........................................... 1294</td>
</tr>
<tr>
<td>ZONISADE</td>
<td>........................................... 1517</td>
</tr>
<tr>
<td>ZONISAMIDE</td>
<td>........................................... 1517</td>
</tr>
<tr>
<td>ZORBTIVE</td>
<td>........................................... 1301</td>
</tr>
<tr>
<td>ZOYVY</td>
<td>........................................... 1107</td>
</tr>
<tr>
<td>ZTALMY</td>
<td>........................................... 586</td>
</tr>
<tr>
<td>ZYBAN</td>
<td>........................................... 1194</td>
</tr>
<tr>
<td>ZYCLARA</td>
<td>........................................... 640</td>
</tr>
<tr>
<td>ZYDELIG</td>
<td>........................................... 630</td>
</tr>
<tr>
<td>ZYKADIA</td>
<td>........................................... 267</td>
</tr>
<tr>
<td>ZYPITAMAG</td>
<td>........................................... 1313</td>
</tr>
<tr>
<td>ZYTIGA</td>
<td>........................................... 17</td>
</tr>
</tbody>
</table>

---

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.